Number O
of O
glucocorticoid O
receptors O
in I-cell_type
lymphocytes I-cell_type
and O
their O
sensitivity O
to O
hormone O
action O
. O
The O
study O
demonstrated O
a O
decreased O
level O
of O
glucocorticoid O
receptors O
( O
GR I-DNA
) O
in O
peripheral B-cell_type
blood I-cell_type
lymphocytes I-cell_type
from O
hypercholesterolemic O
subjects O
, O
and O
an O
elevated O
level O
in O
patients O
with O
acute O
myocardial O
infarction O
. O
In O
the I-cell_type
lymphocytes I-cell_type
with O
a O
high O
GR B-protein
number O
, O
dexamethasone O
inhibited O
[ O
3H B-protein
] O
-thymidine O
and O
[ O
3H B-protein
] O
-acetate O
incorporation O
into O
DNA O
and O
cholesterol O
, O
respectively O
, O
in O
the O
same O
manner O
as O
in O
the O
control B-cell_type
cells I-cell_type
. O
On O
the O
other O
hand O
, O
a O
decreased O
GR B-protein
number O
resulted O
in O
a O
less O
efficient O
dexamethasone O
inhibition O
of O
the O
incorporation O
of O
labeled O
compounds O
. O
These O
data O
showed O
that O
the O
sensitivity O
of O
lymphocytes O
to O
glucocorticoids O
changed O
only O
with O
a O
decrease O
of O
GR B-cell_type
level O
. O
[ O
1 O
, O
25-Dihydroxyvitamin B-protein
D3 B-protein
receptors O
in I-cell_type
lymphocytes I-cell_type
and O
T- O
and O
B-lymphocyte B-protein
count O
in O
patients O
with O
glomerulonephritis O
] O
Content O
of O
receptors O
to O
hormonal O
form O
of O
vitamin O
D3 I-protein
, O
1.25 B-protein
( O
OH I-DNA
) O
2D3 O
, O
constituted O
27.3 B-protein
fmole/mg I-DNA
of O
protein O
in I-cell_type
lymphocytes I-cell_type
of O
peripheric O
blood I-cell_type
of O
children O
with O
glomerulonephritis O
. O
In O
the O
patients O
concentration O
of O
total O
and O
ionized O
form O
of O
Ca2+ B-cell_type
was O
decreased O
down O
to O
2.04 B-protein
mmole/L O
and O
1.09 B-protein
mmole/L I-protein
, O
respectively O
, O
while O
an O
increase O
in O
parathormone O
( O
PTH I-DNA
) O
by O
36 O
% O
and O
a O
distinct O
decrease O
in O
25 I-cell_line
( O
OH I-DNA
) O
D O
concentration O
( O
lower O
than O
1.25 B-protein
ng/ml I-DNA
) O
was O
found O
in O
blood I-cell_type
; O
content O
of O
cAMP I-RNA
was O
also O
decreased O
in I-cell_type
lymphocytes I-cell_type
by O
33 O
% O
. O
At O
the O
same O
time O
, O
total O
content O
of O
T I-cell_type
lymphocytes I-cell_type
was O
decreased O
1.5-fold B-protein
in O
peripheric O
blood I-cell_type
. I-cell_type
Treatment O
with O
I-hydroxyvitamin B-protein
D3 B-protein
( O
1-1.5 B-protein
mg O
daily O
, O
within O
4 O
weeks O
) O
led O
to O
normalization O
of O
total O
and O
ionized O
form O
of O
Ca2+ O
and I-DNA
of O
25 O
( O
OH I-DNA
) O
D O
, O
but O
did O
not O
affect O
the O
PTH O
content O
in O
blood I-cell_type
. I-cell_type
Concentration I-DNA
of O
the O
receptors O
to O
1.25 B-protein
( O
OH I-DNA
) O
2D3 O
was O
elevated O
up O
to O
39.7 B-protein
fmole/mg O
after O
I I-protein
week O
of O
the O
treatment O
, O
whereas O
it O
was O
decreased O
to O
the O
initial O
level O
24.8 B-protein
fmole/mg O
within O
4 O
weeks O
; O
simultaneous O
alteration O
in O
the O
cAMP I-RNA
content O
was O
observed O
in I-cell_type
lymphocytes I-cell_type
. O
Treatment O
with O
1- B-protein
( O
OH I-DNA
) O
D3 B-protein
normalized O
also O
the O
T I-cell_type
lymphocytes I-cell_type
content O
in O
peripheric O
blood I-cell_type
. I-cell_type
The O
data O
obtained O
suggest O
that O
under O
conditions O
of O
glomerulonephritis O
only O
high O
content O
of O
receptors O
to O
1.25 B-protein
( O
OH I-DNA
) O
2D3 O
in I-cell_type
lymphocytes I-cell_type
enabled O
to O
perform O
the O
cell O
response O
to O
the O
hormone O
effect O
. O
Tumor O
and O
serum O
beta-2-microglobulin B-protein
expression O
in O
women O
with O
breast O
cancer O
. O
To O
investigate O
whether O
the O
tumor O
expression O
of O
beta-2-microglobulin B-protein
( O
beta O
2-M B-protein
) O
could O
serve O
as O
a O
marker O
of O
tumor O
biologic O
behavior O
, O
the O
authors O
studied O
specimens O
of O
breast O
carcinomas O
from O
60 O
consecutive O
female O
patients O
. O
Presence O
of O
beta O
2-M B-protein
was O
analyzed O
by O
immunohistochemistry O
. O
No O
significant O
correlations O
were O
found O
between O
tumor O
beta O
2-M B-protein
expression O
and O
several O
histologic O
attributes O
such O
as O
type I-DNA
, O
histologic O
and O
nuclear B-protein
grades I-protein
, O
mitotic O
index O
, O
necrosis O
, O
vascular O
invasion O
, O
and O
lymphocytic O
infiltration O
. O
Likewise O
, O
beta O
2-M B-protein
was O
not O
associated O
with O
markers O
of O
disease O
extension O
such O
as O
TNM I-protein
, O
( O
UICC I-DNA
, O
classification O
of O
malignant O
tumors O
) O
staging O
and O
axillary O
lymph O
node O
involvement O
or O
with O
estrogen O
, O
progesterone O
, O
and O
glucocorticoid I-DNA
receptor I-protein
levels O
. O
However O
, O
there O
was O
a O
significantly O
positive O
association O
between O
tumor O
beta O
2-M B-protein
expression O
and O
the O
degree O
of O
lymphocytic O
infiltration O
in O
the O
tumor O
tissue O
. O
Beta O
2-M B-protein
serum O
levels O
were O
determined O
by O
an O
enzyme-linked B-protein
immunosorbent O
assay O
in O
samples O
from O
22 O
of O
the O
above O
women O
. O
Although O
some O
of O
the O
highest O
values O
had O
been O
obtained O
in O
women O
with O
larger O
( O
T4 B-protein
) O
primary B-cell_line
tumors I-cell_line
, O
the O
authors O
failed O
to O
detect O
any O
statistical O
relationship O
between O
beta O
2-M B-protein
expression O
in O
the O
tumor O
with O
serum O
levels O
or O
between O
serum O
beta O
2-M B-protein
and O
the O
above O
histologic O
, O
laboratory O
, O
and O
clinical O
factors I-protein
. O
[ O
Preliminary O
observation O
of O
level O
free-form B-DNA
E I-DNA
receptor I-protein
levels O
in O
serum O
of O
normal O
childbearing-aged B-DNA
and O
pregnant O
women O
] O
In O
137 O
cases O
of O
childbearing-aged B-DNA
and O
pregnant O
women O
, O
free O
form O
E I-DNA
receptor I-protein
levels O
( O
sE I-DNA
) O
in O
serum O
were O
measured O
by O
ELISA O
. O
The O
level O
of O
sE B-RNA
was O
significantly O
decreased O
during O
the O
first O
trimester O
, O
slightly O
higher O
in O
the O
second O
trimester O
, O
and O
recovered O
to O
normal O
in O
the O
third O
trimester O
. O
The O
level O
remained O
lower O
in O
29 O
PIH O
women O
but O
appeared O
higher O
in O
overdue O
pregnancies O
as O
compared O
with O
the O
normal O
3rd B-cell_type
trimester O
range O
. O
The O
results O
indicate O
that O
there O
is O
a O
relationship O
between O
a O
change O
in O
T O
cell O
function O
and O
pregnancy O
. O
Kappa O
B-specific B-protein
DNA O
binding O
proteins I-protein
: O
role O
in O
the O
regulation O
of O
human B-DNA
interleukin-2 I-DNA
gene O
expression O
. O
Transcriptional O
activation O
of O
the O
human B-DNA
interleukin-2 B-protein
( O
IL-2 B-protein
) O
gene I-DNA
, O
like O
induction O
of O
the O
IL-2 B-DNA
receptor I-DNA
alpha I-DNA
( I-DNA
IL-2R I-DNA
alpha I-DNA
) I-DNA
gene I-DNA
and O
the O
type O
1 O
human B-DNA
immunodeficiency I-DNA
virus O
( O
HIV-1 B-protein
) O
, O
is O
shown O
to O
be O
modulated O
by O
a O
kappa B-DNA
B-like B-DNA
enhancer B-DNA
element I-DNA
. O
Mutation O
of O
a O
kappa B-DNA
B I-DNA
core O
sequence O
identified O
in O
the O
IL-2 B-DNA
promoter I-DNA
( O
-206 O
to O
-195 B-protein
) O
partially O
inhibits O
both O
mitogen- B-DNA
and O
HTLV-I B-protein
Tax-mediated O
activation O
of O
this O
transcription O
unit O
and O
blocks O
the O
specific O
binding O
of O
two O
inducible O
cellular B-protein
factors I-protein
. O
These O
kappa B-DNA
B-specific B-protein
proteins I-protein
( O
80 O
to O
90 O
and O
50 O
to O
55 O
kilodaltons O
) O
similarly O
interact O
with O
the O
functional O
kappa B-DNA
B I-DNA
enhancer I-DNA
present O
in O
the O
IL-2R B-DNA
alpha I-protein
promoter I-DNA
. O
These O
data O
suggest O
that O
these O
kappa B-DNA
B-specific B-protein
proteins I-protein
have O
a O
role O
in O
the O
coordinate O
regulation O
of O
this O
growth O
factor-growth B-protein
factor I-protein
receptor I-DNA
gene I-DNA
system O
that O
controls O
T O
cell O
proliferation O
. O
Novel O
region O
within O
the O
V O
kappa B-DNA
gene I-DNA
promoter I-DNA
is O
responsible O
for O
tissue O
and O
stage-specific O
expression O
of O
immunoglobulin O
genes I-DNA
in O
human B-DNA
lymphoid I-DNA
neoplasms O
. O
Immunoglobulin O
gene-specific I-DNA
transacting O
factors I-protein
have O
been O
shown O
to O
play O
a O
role O
in O
lymphoid O
tissue-specific O
expression O
of O
immunoglobulin O
genes I-DNA
. O
The O
role O
of O
these O
factors I-protein
in O
B-cell O
differentiation O
and O
stage-specific O
expression O
of O
these O
genes I-DNA
is O
, O
however O
, O
not O
fully O
understood O
. O
We O
have O
used O
a O
model O
of O
human B-cell_type
lymphoid I-DNA
neoplasia O
to O
address O
this O
question O
. O
Different O
fragments O
of O
unrearranged O
human B-DNA
variable I-DNA
region I-DNA
of O
immunoglobulin O
kappa B-DNA
gene I-DNA
( O
V O
kappa B-DNA
) O
were O
used O
for O
cell-free B-DNA
in O
vitro O
transcription I-DNA
and O
DNA O
mobility O
shift O
assays O
. O
Previously O
described O
enhancement O
of O
in O
vitro O
transcription O
that O
was O
only O
seen O
with O
nuclear B-protein
extracts O
derived O
from O
B-cell O
neoplasms O
corresponding O
to O
the O
late O
stages O
of O
B-cell O
differentiation O
was O
shown O
to O
be O
dependent O
on O
the O
actions O
of O
these O
factor I-protein
( O
s O
) O
on O
the O
DNA O
region O
within O
the O
V O
kappa B-DNA
gene I-DNA
promoter I-DNA
. O
This O
region O
is O
located O
within O
the O
920 O
bp O
fragment O
located O
210 O
bp O
upstream O
from O
the O
coding O
region O
and O
this O
fragment O
represents O
a O
possible O
novel O
DNA O
region O
, O
which O
plays O
a O
role O
in O
the O
stage- B-DNA
and O
tissue-specific O
expression O
of O
immunoglobulin O
genes I-DNA
. O
[ O
Determination I-DNA
of O
the O
sensitivity O
to O
glucocorticoids O
in O
vitro O
] O
A O
modified O
method O
for O
the O
determination O
of O
glucocorticoid O
receptors O
in O
human I-cell_type
lymphocytes I-cell_type
is O
suggested O
. O
The O
principal O
distinction O
of O
the O
method O
is O
standardization O
by O
the O
lymphocyte I-cell_line
count O
in O
a O
sample O
( O
1 O
mln O
) O
and O
the O
labeled O
hormone O
concentration O
. O
The O
modification O
saves O
time O
and O
money O
, O
limits O
the O
range O
of O
the O
data O
variations O
, O
and O
makes O
use O
of O
a O
lesser O
volume O
of O
blood I-cell_type
. I-cell_type
Examinations O
of O
70 O
children O
aged O
4 O
to O
15 O
suffering O
from O
the O
nephrotic O
form O
of O
glomerulonephritis O
have O
made O
it O
possible O
to O
distinguish O
two O
groups O
of O
patients O
: O
with O
relatively O
high O
values O
of O
specific O
binding O
X O
= O
6820.1 B-protein
+/- O
530.0 I-cell_line
( O
n O
= O
30 I-cell_line
, O
p O
= O
0.95 I-protein
, O
t O
= O
2.04 B-protein
) O
, O
this O
corresponding O
to O
a O
clinical O
form O
of O
hormone O
-sensitive O
glomerulonephritis I-protein
, O
and O
with O
relatively O
low O
values O
of O
specific O
binding O
X O
= O
1815.2 B-protein
+/- O
302.8 I-cell_line
( O
n O
= O
40 I-cell_line
, O
p O
= O
0.95 I-protein
, O
t O
= O
1.96 B-protein
) O
, O
that O
corresponds O
to O
hormone O
-resistant O
glomerulonephritis O
. O
Dynamic O
studies O
have O
not O
shown O
any O
statistically O
significant O
changes O
in O
the O
specific O
binding O
values O
. O
These O
results O
permit O
regarding O
the O
specific O
binding O
value O
as O
a O
prognostic O
criterion O
in O
the O
assessment O
of O
corticosteroid O
therapy O
; O
this O
allows O
a O
wide O
employment O
of O
the O
described O
method O
in O
practical O
nephrology O
. O
Octamer-binding B-protein
proteins I-protein
from O
B I-DNA
or O
HeLa B-cell_type
cells I-cell_type
stimulate O
transcription I-DNA
of O
the O
immunoglobulin O
heavy-chain B-DNA
promoter I-DNA
in O
vitro O
. O
The O
B-cell O
-type O
specificity O
of O
the O
immunoglobulin O
( O
Ig O
) O
heavy-chain O
and O
light-chain O
promoters O
is O
mediated O
by O
an O
octanucleotide O
( O
OCTA I-DNA
) O
element I-DNA
, O
ATGCAAAT I-protein
, O
that O
is O
also O
a O
functional O
component O
of O
other O
RNA O
polymerase O
II I-protein
promoters I-protein
, O
such O
as O
snRNA I-cell_type
and O
histone I-protein
H2B B-protein
promoters O
. O
Two O
nuclear B-protein
proteins I-protein
that O
bind O
specifically O
and O
with O
high O
affinity O
to O
the O
OCTA O
element I-DNA
have O
been O
identified O
. O
NF-A1 B-protein
is O
present O
in O
a O
variety O
of O
cell O
types I-cell_type
, O
whereas O
the O
presence O
of O
NF-A2 B-protein
is O
essentially O
confined O
to O
B I-DNA
cells I-cell_line
, O
leading O
to O
the O
hypothesis O
that O
NF-A2 B-protein
activates O
cell-type-specific B-protein
transcription I-DNA
of O
the O
Ig O
promoter I-DNA
and O
NF-A1 B-protein
mediates O
the O
other O
responses O
of O
the O
OCTA O
element I-DNA
. O
Extracts O
of O
the O
B-cell O
line O
, O
BJA-B O
, O
contain O
high O
levels O
of O
NF-A2 B-protein
and O
specifically O
transcribe O
Ig O
promoters O
. O
In O
contrast O
, O
extracts O
from O
HeLa B-cell_type
cells I-cell_type
transcribed O
the O
Ig O
promoter I-DNA
poorly O
. O
Surprisingly I-protein
, O
addition O
of O
either O
affinity-enriched B-DNA
NF-A2 B-protein
or O
NF-A1 O
to O
either O
a O
HeLa O
extract O
or O
a O
partially O
purified O
reaction O
system O
specifically O
stimulates O
the O
Ig O
promoter I-DNA
. O
This O
suggests O
that O
the O
constitutive O
OCTA-binding B-protein
factor I-protein
NF-A1 B-protein
can O
activate O
transcription I-DNA
of O
the O
Ig O
promoter I-DNA
and O
that O
B-cell O
-specific B-protein
transcription I-DNA
of O
this O
promoter I-DNA
, O
at O
least O
in O
vitro O
, O
is O
partially O
due O
to O
a O
quantitative O
difference O
in O
the O
amount O
of O
OCTA-binding B-DNA
protein O
. O
Because O
NF-A1 B-protein
can O
stimulate O
Ig O
transcription I-DNA
, O
the O
inability O
of O
this O
factor I-protein
to O
activate O
in O
vivo O
the O
Ig O
promoter O
to O
the O
same O
degree O
as O
the O
snRNA I-RNA
promoters O
probably O
reflects O
a O
difference O
in O
the O
context O
of O
the O
OCTA O
element I-DNA
in O
these O
two O
types I-cell_type
of O
promoters O
. O
Identification O
of O
a O
putative O
regulator O
of O
early B-cell_type
T O
cell O
activation O
genes I-DNA
. O
Molecules O
involved O
in O
the O
antigen I-protein
receptor-dependent O
regulation O
of O
early B-cell_type
T O
cell O
activation O
genes I-DNA
were O
investigated O
with O
the O
use O
of O
functional O
sequences O
of O
the O
T O
cell O
activation-specific B-DNA
enhancer I-DNA
of O
interleukin-2 B-protein
( O
IL-2 B-protein
) O
. O
One O
of O
these O
sequences O
forms O
a O
protein I-protein
complex I-protein
, O
NFAT-1 B-protein
, O
specifically O
with O
nuclear B-protein
extracts O
of O
activated B-cell_type
T B-cell_type
cells I-cell_type
. O
This O
complex I-protein
appeared O
10 O
to O
25 O
minutes O
before O
the O
activation O
of O
the O
IL-2 B-DNA
gene I-DNA
. O
Studies O
with O
inhibitors O
of O
protein O
synthesis O
indicated O
that O
the O
time O
of O
synthesis O
of O
the O
activator O
of O
the O
IL-2 B-DNA
gene I-DNA
in O
Jurkat O
T B-cell_type
cells I-cell_type
corresponds O
to O
the O
time O
of O
appearance O
of O
NFAT-1 B-protein
. O
NFAT-1 B-protein
, O
or O
a O
very O
similar O
protein I-protein
, O
bound O
functional O
sequences O
of O
the O
long I-DNA
terminal I-DNA
repeat I-DNA
( O
LTR I-DNA
) O
of O
the O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
; O
the O
LTR O
of O
this O
virus O
is O
known O
to O
be O
stimulated O
during O
early O
T O
cell O
activation O
. O
The O
binding O
site O
for O
this O
complex I-protein
activated O
a O
linked O
promoter I-DNA
after O
transfection O
into O
antigen I-protein
receptor-activated B-cell_type
T B-cell_type
cells I-cell_type
but O
not O
other O
cell O
types I-cell_type
. O
These O
characteristics O
suggest O
that O
NFAT-1 B-protein
transmits O
signals O
initiated O
at O
the O
T O
cell O
antigen I-DNA
receptor I-protein
. O
Characterization O
of O
thyroid O
hormone O
receptors O
in O
human B-DNA
IM-9 I-cell_type
lymphocytes I-cell_type
. O
Although O
putatively O
identified O
more O
than O
10 O
years O
ago O
, O
thyroid O
hormone O
receptors O
in O
human B-DNA
tissues I-cell_type
remain O
poorly O
characterized O
. O
As O
a O
first O
step O
towards O
understanding O
the O
mechanism O
of O
thyroid O
hormone O
action O
in O
man O
we O
have O
characterized O
T3 B-protein
binding O
sites O
in O
nuclei O
of O
the O
human B-DNA
lymphoblastoid I-cell_type
line O
, O
IM-9 B-protein
cells I-cell_type
. O
In O
whole O
cell O
experiments O
at O
37 O
degrees O
C I-protein
, O
nuclear O
binding O
of O
[ O
125I B-protein
] O
T3 B-protein
was O
saturable O
( O
Kd O
34 O
+/- O
6 O
pmol/l I-DNA
) O
and O
of O
finite O
capacity O
( O
approximately O
equal O
to O
350 O
sites/cell I-DNA
) O
. O
The O
binding O
sites O
were O
extracted O
from O
a O
nuclear B-protein
pellet O
by O
treatment O
with O
0.4 B-protein
mol/l B-DNA
KCl O
and O
sonication O
. O
Separation O
of O
bound O
from O
free O
[ O
125I B-protein
] O
T3 B-protein
in O
the O
extracts O
was O
achieved O
using O
the O
calcium O
phosphate O
matrix I-protein
, O
hydroxyapatite O
at O
a O
concentration O
of O
0.3 B-cell_type
ml O
of O
a O
150 O
g/l O
slurry O
. O
Rectilinear O
Scatchard O
plots O
were O
obtained O
only O
when O
the O
hydroxyapatite O
was O
washed O
with O
a O
buffer O
containing O
0.5 B-protein
% O
Triton O
X-100 B-protein
. O
Under O
these O
conditions O
T3 B-protein
binding O
sites O
in O
the O
nuclear B-protein
extracts O
were O
present O
at O
a O
concentration O
of O
22.4 B-cell_type
+/- O
8.6 B-protein
fmol/mg I-protein
protein O
and O
showed O
an O
affinity O
of O
( O
Kd O
, O
room O
temperature O
) O
140 O
+/- O
10 O
pmol/l I-cell_line
. O
The O
same O
assay O
system O
was O
used O
to O
determine O
the O
hierarchy O
of O
affinities O
for O
a O
range O
of O
natural O
and O
synthetic O
analogues O
. O
Calling O
T3 B-protein
100 O
, O
the O
order O
of O
potencies O
observed O
was O
: O
Triac O
, O
500 O
; O
3 O
, O
5-diiodo-3'-isopropylthyronine O
, O
89 O
; O
T4 I-protein
, O
32 O
; O
3 O
, O
5-dimethyl-3'isopropylthyronine O
2 O
; O
3 O
, O
5-T2 O
, O
0.7 I-cell_line
, O
rT3 O
, O
0.4 B-protein
; O
3'5'-T2 I-protein
, O
less O
than O
0.01 B-protein
. O
These O
results O
suggest O
that O
the O
T3 B-protein
binding O
sites O
present O
in O
human B-DNA
IM-9 B-protein
lymphocyte I-cell_line
nuclei O
and O
extracts O
thereof O
are O
thyroid O
hormone O
receptors O
. O
These B-cell_type
cells I-cell_type
may O
be O
a O
useful O
tool O
to O
increase O
our O
understanding O
of O
human B-cell_type
T3 B-protein
receptors O
Definition O
of O
T-cell O
specific O
DNA-binding B-protein
factors I-protein
that O
interact O
with O
a O
3'-silencer O
in O
the O
CD4+ B-protein
T-cell B-DNA
gene I-DNA
Rpt-1 O
. O
Analysis O
of O
the O
region O
3 O
' O
to O
the O
CD4+ B-protein
T-cell B-DNA
gene I-DNA
Rpt-1 B-protein
( O
encoding O
regulatory O
protein O
T-lymphocyte B-protein
1 O
) O
led O
to O
the O
definition O
of O
a O
silencer O
element I-DNA
that O
inhibits O
heterologous O
gene I-DNA
expression O
in O
certain O
CD4+ B-protein
T-cell B-cell_line
lines I-cell_line
but O
not O
in O
B-cell O
or O
non-lymphoid O
cell O
lines I-cell_line
. O
Functional O
silencer O
activity O
in O
vivo O
was O
associated O
with O
the O
presence O
of O
a O
specific O
silencer-DNA-protein B-protein
complex I-protein
in O
electrophoretic O
mobility O
shift O
assays O
with O
T-cell O
extracts O
. O
Formation O
of O
this O
complex I-protein
was O
selectively O
inhibited O
by O
the O
region O
in O
HIV-1 O
containing O
a O
silencer O
element I-DNA
. O
We O
discuss O
the O
possibility O
that O
DNA-binding B-protein
factors I-protein
may O
coregulate O
HIV-1 O
and O
Rpt-1 B-protein
gene I-DNA
expression O
through O
a O
common O
transcriptional O
silencer O
element I-DNA
. O
Congenital O
immunodeficiencies O
associated O
with O
absence O
of O
HLA B-cell_type
class I-protein
II I-protein
antigens O
on I-cell_type
lymphocytes I-cell_type
result O
from O
distinct O
mutations O
in O
trans-acting B-protein
factors I-protein
. O
Coordinate O
regulation O
of O
HLA B-cell_type
class I-protein
II B-DNA
gene I-DNA
expression O
during O
development O
and O
coinduction O
of O
class I-protein
II I-protein
genes I-DNA
by O
soluble B-protein
factors I-protein
suggests O
that O
common O
trans-acting B-protein
factor I-protein
( O
s O
) O
control O
expression O
of O
these O
genes I-DNA
. O
In O
B-lymphoblastoid O
cell O
lines I-cell_line
derived O
from O
two O
independent O
class B-protein
II-deficient B-protein
bare O
lymphocyte I-cell_line
syndrome O
patients O
, O
we O
observed O
a O
drastic O
decrease O
in O
transcription O
rates O
of O
the O
class I-protein
II I-protein
genes I-DNA
. O
When O
these O
cell O
lines I-cell_line
are O
fused O
, O
class I-protein
II I-protein
genes I-DNA
are O
reexpressed O
, O
indicating O
that O
immunodeficiencies O
in O
bare O
lymphocyte I-cell_line
syndrome O
patients O
are O
the O
result O
of O
two O
distinct O
mutations O
. O
Further O
studies O
show O
that O
genes I-DNA
governing O
the O
expression O
of O
class I-protein
II I-protein
antigens O
fall O
into O
at O
least O
three O
complementation O
groups O
; O
two O
of O
these O
were O
previously O
unidentified O
in O
mutant O
cell O
lines I-cell_line
generated O
in O
vitro O
. O
In O
addition O
, O
we O
report O
the O
identification O
of O
two O
discrete O
complexes O
, O
NFX1.1 I-protein
and O
NFX1.2 I-protein
, O
that O
bind O
to O
the O
DRA O
X O
consensus O
element I-DNA
. O
Though O
the O
mutation O
in O
at O
least O
one O
mutant O
line O
generated O
in O
vitro O
( O
RJ2.2.5 I-DNA
) O
affects O
products O
functioning O
via O
interaction O
with O
the O
X O
box O
, O
clear O
alterations O
in O
either O
NFX1.1 B-protein
or O
NFX1.2 B-protein
are O
not O
found O
in O
any O
of O
the O
mutant O
cell O
lines I-cell_line
. O
In O
vivo O
responsiveness O
to O
glucocorticoid O
correlated O
with O
glucocorticoid I-DNA
receptor I-protein
content O
in O
peripheral B-cell_type
blood I-cell_type
leukocytes I-cell_type
in O
normal O
humans O
. O
Dexamethasone B-cell_type
loading O
tests O
( O
0.1 B-protein
mg O
dexamethasone/kg I-cell_line
, O
iv O
) O
were O
performed O
in O
18 O
normal O
males O
to O
evaluate O
the O
individual O
responsiveness O
to O
glucocorticoid O
. O
There O
were O
inter-individual O
differences O
in O
increase O
in O
peripheral B-cell_type
blood I-cell_type
polymorphonuclear I-cell_type
leukocyte O
count O
, O
decrease O
in O
peripheral B-cell_type
blood I-cell_type
lymphocyte I-cell_line
count O
, O
and O
increase O
in O
plasma O
free O
fatty O
acids O
levels O
after O
dexamethasone O
injection O
. O
In O
addition O
, O
there O
was O
a O
significant O
correlation O
between O
the O
maximum O
increase O
in O
polymorphonuclear O
leukocytes O
and O
the O
maximum O
decrease O
in I-cell_type
lymphocytes I-cell_type
( O
r O
= O
0.7514 I-cell_line
, O
p O
less O
than O
0.0003 B-protein
) O
. O
Simultaneous O
measurements O
of O
glucocorticoid I-DNA
receptor I-protein
content O
by O
whole-cell B-DNA
assay O
revealed O
that O
glucocorticoid I-DNA
receptor I-protein
content O
in O
polymorphonuclear O
leukocytes O
linearly O
correlated O
with O
that O
in O
the O
corresponding I-cell_type
lymphocytes I-cell_type
( O
r O
= O
0.9482 I-cell_line
, O
p O
less O
than O
0.0001 B-protein
) O
. O
There O
were O
also O
significant O
correlations O
between O
the O
maximum O
increase O
in O
polymorphonuclear O
leukocytes O
and O
glucocorticoid I-DNA
receptor I-protein
content O
in O
polymorphonuclear O
leukocytes O
( O
r O
= O
0.7239 I-cell_line
, O
p O
less O
than O
0.0007 B-protein
) O
, O
and O
between O
the O
maximum O
decrease O
in I-cell_type
lymphocytes I-cell_type
and O
glucocorticoid I-DNA
receptor I-protein
content O
in I-cell_type
lymphocytes I-cell_type
( O
r O
= O
0.7703 I-cell_line
, O
p O
less O
than O
0.0002 B-protein
) O
. O
These O
results O
suggest O
that O
individual O
differences O
are O
preserved O
both O
in O
glucocorticoid O
responsiveness O
and O
in O
glucocorticoid I-DNA
receptor I-protein
content O
in O
peripheral B-cell_type
blood I-cell_type
leukocytes I-cell_type
in O
normal O
humans O
. O
Estradiol O
receptors O
in O
the O
cytosol O
of O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
in O
hepatitis O
B I-DNA
virus O
carriers O
treated O
with O
interferon-alpha O
. O
Estradiol O
receptors O
in O
the O
cytosol O
of O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
and O
the O
effects O
of O
interferon-alpha I-cell_line
( O
IFN-alpha I-DNA
) O
on O
estradiol O
receptors O
were O
studied O
in O
asymptomatic O
hepatitis O
B I-DNA
virus O
( O
HBV I-DNA
) O
carriers O
, O
patients O
with O
chronic O
hepatitis O
B I-DNA
and O
normal O
controls O
. O
The O
level O
of O
estradiol O
receptors O
in O
the O
cytosol O
of O
mononuclear B-cell_type
cells I-cell_type
was O
significantly O
lower O
in O
asymptomatic O
HBV O
carriers O
and O
patients O
with O
chronic O
hepatitis O
B I-DNA
, O
compared O
to O
normal O
controls O
. O
This O
low O
level O
of O
cytosol O
estradiol O
receptors O
in O
patients O
with O
chronic O
hepatitis O
B I-DNA
was O
increased O
by O
the O
administration O
of O
IFN-alpha B-protein
. O
In O
addition O
, O
when O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
from O
patients O
with O
chronic O
hepatitis O
B I-DNA
were O
incubated O
with O
IFN-alpha B-protein
in O
vitro O
, O
the O
level O
of O
cytosol O
estradiol O
receptors O
also O
increased O
by O
increasing O
the O
concentration O
of O
IFN-alpha B-protein
. O
We O
previously O
reported O
that O
the O
response O
of O
mononuclear B-cell_type
cells O
to O
estrogen O
is O
impaired O
in O
HBV O
carriers O
, O
and O
our O
present O
results O
suggested O
that O
this O
may O
be O
due O
to O
the O
low O
level O
of O
estradiol O
receptors O
in O
the O
cytosol O
of O
mononuclear B-cell_type
cells I-cell_type
. O
Association O
of O
increased O
lytic O
effector O
cell O
function O
with O
high O
estrogen B-protein
receptor I-protein
levels O
in O
tumor-bearing B-protein
patients O
with O
breast O
cancer O
. O
Tumor-bearing B-protein
patients O
with O
breast O
cancer O
were O
assayed O
for O
their O
natural O
killer O
( O
NK O
) O
cell O
activity O
and O
for O
the O
function O
of O
activated O
cytotoxic O
T-cells I-protein
, O
as O
assessed O
by O
lectin-dependent O
cellular O
cytotoxicity O
( O
LDCC I-DNA
) O
. O
Tumor-bearing B-protein
patients O
with O
breast O
cancer O
had O
a O
significant O
increase O
in O
NK O
activity O
and O
in O
LDCC I-protein
, O
as O
compared O
with O
healthy O
control O
individuals O
. O
Although O
the O
enhanced O
NK O
cell O
activity O
and O
LDCC O
were O
closely O
associated O
with O
high O
levels O
( O
greater O
than O
31 O
fmol/mg I-DNA
) O
of O
estrogen B-protein
receptor I-protein
( O
ER B-protein
) O
content O
in O
the O
primary B-cell_line
tumor I-cell_line
, O
no O
other O
clinical O
or O
histologic O
correlation O
between O
the O
increase O
in O
either O
parameter O
of O
cytotoxic O
effector O
cell O
function O
could O
be O
found O
. O
Thus O
, O
ER B-protein
levels O
greater O
than O
31 O
fmol/mg O
might O
be O
associated O
with O
increased O
cytotoxic O
effector O
cell O
function O
in O
tumor-bearing B-protein
patients O
with O
breast O
cancer O
. O
Properties O
of O
glucocorticoid O
receptors O
in O
Epstein-Barr B-protein
virus-transformed I-cell_type
lymphocytes I-cell_type
from O
patients O
with O
familial O
cortisol O
resistance O
. O
In O
a O
previous O
report O
of O
two O
patients O
with O
familial O
glucocorticoid O
resistance O
due O
to O
reduced O
numbers O
of O
glucocorticoid O
receptors O
( O
GR I-DNA
) O
, O
we O
have O
shown O
decreased O
numbers O
of O
GR B-cell_type
in O
peripheral B-cell_type
mononuclear I-cell_type
cells I-cell_type
and O
cultured O
fibroblasts O
but O
normal O
affinity O
of O
GR B-cell_type
in O
both O
patients O
. O
In O
this O
study O
, O
peripheral I-cell_type
lymphocytes I-cell_type
from O
these O
patients O
, O
one O
patient O
's O
son O
and O
daughter O
, O
and O
normal O
subjects O
were O
transformed O
with O
Epstein-Barr O
virus O
. O
Reduced O
numbers O
and O
normal O
affinity O
of O
GR B-cell_type
were O
found O
in O
the O
Epstein-Barr B-protein
virus-transformed I-cell_type
lymphocytes I-cell_type
from O
both O
patients O
while O
the O
son O
and O
daughter O
had O
normal O
numbers O
and O
affinity O
of O
GR B-cell_type
. O
The O
thermal O
stability O
of O
GR O
and O
thermal O
activation O
of O
cytosolic O
receptors O
in O
both O
patients O
were O
found O
to O
be O
normal O
. O
Although O
the O
percentages O
of O
nuclear B-protein
bound O
GR B-protein
were O
similar O
in O
both O
patients O
and O
normal O
controls O
, O
the O
absolute O
amounts O
of O
nuclear B-protein
bound O
GR I-DNA
of O
the O
patients O
were O
about O
one-half B-DNA
that O
of O
normal O
controls O
. O
These O
abnormal O
properties O
of O
GR B-cell_type
( O
reduced O
numbers O
of O
GR B-protein
) O
were O
preserved O
in O
the O
transformed B-cell_type
cells I-cell_type
from O
the O
patients O
. O
Octamer O
transcription B-protein
factors I-protein
1 O
and O
2 O
each O
bind O
to O
two O
different O
functional O
elements I-DNA
in O
the O
immunoglobulin O
heavy-chain B-DNA
promoter I-DNA
. O
Immunoglobulin O
heavy-chain I-DNA
genes I-DNA
contain O
two O
conserved O
sequence O
elements O
5 O
' O
to O
the O
site I-DNA
of O
transcription O
initiation O
: O
the O
octamer O
ATGCAAAT O
and O
the O
heptamer O
CTCATGA I-protein
. O
Both O
of O
these O
elements I-DNA
are O
required O
for O
normal O
cell-specific B-DNA
promoter I-DNA
function O
. O
The O
present O
study O
demonstrates O
that O
both O
the O
ubiquitous O
and O
lymphoid-cell-specific B-protein
octamer O
transcription B-protein
factors I-protein
( O
OTF-1 O
and O
OTF-2 O
, O
respectively O
) O
interact O
specifically O
with O
each O
of O
the O
two O
conserved O
sequence O
elements I-DNA
, O
forming O
either O
homo- B-DNA
or O
heterodimeric O
complexes O
. O
This O
was O
surprising O
, O
since O
the O
heptamer O
and O
octamer O
sequence O
motifs O
bear O
no O
obvious O
similarity O
to O
each O
other O
. O
Binding O
of O
either O
factor I-protein
to O
the O
octamer O
element I-DNA
occurred O
independently O
. O
However O
, O
OTF O
interaction O
with O
the O
heptamer O
sequence O
appeared O
to O
require O
the O
presence O
of O
an O
intact O
octamer O
motif O
and O
occurred O
with O
a O
spacing O
of O
either O
2 O
or O
14 O
base O
pairs O
between O
the O
two O
elements I-DNA
, O
suggesting O
coordinate O
binding O
resulting O
from O
protein-protein O
interactions O
. O
The O
degeneracy O
in O
sequences O
recognized O
by O
the O
OTFs O
may O
be O
important O
in O
widening O
the O
range O
over O
which O
gene I-DNA
expression O
can O
be O
modulated O
and O
in O
establishing O
cell I-DNA
type O
specificity O
. O
Identification O
of O
a O
novel O
lymphoid O
specific O
octamer O
binding O
protein O
( O
OTF-2B B-protein
) O
by O
proteolytic O
clipping O
bandshift O
assay O
( O
PCBA I-DNA
) O
. O
The O
octamer O
sequence O
ATGCAAAT O
is O
found O
in O
the O
promoters O
of O
immunoglobulin O
( O
Ig O
) O
heavy O
and O
light O
chain I-DNA
genes I-DNA
and O
in O
the O
heavy O
chain B-DNA
enhancer I-DNA
and O
is O
a O
major O
determinant O
of O
the O
cell I-DNA
type O
specific O
expression O
of O
Ig O
genes I-DNA
in O
B I-DNA
cells I-cell_type
. O
An O
apparent O
paradox O
is O
that O
the O
same O
sequence O
serves O
as O
an O
upstream O
promoter I-DNA
or O
enhancer B-DNA
element I-DNA
in O
a O
variety O
of O
housekeeping I-DNA
genes I-DNA
such O
as O
the O
histone I-protein
H2B B-protein
and O
U O
snRNA I-DNA
genes I-DNA
. O
The O
differential O
usage O
of O
this O
regulatory O
sequence O
motif O
is O
thought O
to O
be O
mediated O
by O
different O
species O
of O
octamer O
binding O
proteins I-protein
. O
One O
species O
of O
100 O
kd O
, O
designated O
OTF-1 O
, O
is O
present O
in O
all O
cell O
types I-cell_type
and O
may O
exert O
its O
activating O
function O
only O
when O
it O
can O
interact O
with O
additional O
adjacent O
transcription B-protein
factors I-protein
. O
The O
lymphoid O
cell O
specific O
octamer O
binding O
protein O
of O
60 O
kd O
( O
OTF-2A B-protein
) O
specifically O
stimulates O
Ig O
promoters O
which O
consist O
essentially O
of O
a O
TATA-box B-DNA
and O
an O
octamer O
sequence O
upstream O
of O
it O
. O
Here O
we O
present O
evidence O
for O
yet O
another O
B O
cell O
specific O
octamer O
binding O
protein O
of O
75 O
kd O
( O
OTF-2B B-protein
) O
. O
From O
several O
findings O
, O
including O
the O
absence O
of O
OTF-2B B-protein
( O
but O
not O
OTF-2A B-protein
) O
from O
a O
lymphocyte I-cell_line
line O
that O
can O
not O
respond O
to O
the O
IgH B-DNA
enhancer I-DNA
, O
we O
propose O
a O
role O
of O
the O
novel O
octamer I-protein
factor I-protein
in O
the O
long I-DNA
range O
activation O
by O
the O
IgH B-DNA
enhancer I-DNA
. O
We O
have O
used O
the O
proteolytic O
clipping O
bandshift O
assay O
( O
PCBA I-DNA
) O
technique O
to O
distinguish O
the O
three O
different O
forms O
found O
in O
B I-DNA
cells I-cell_type
. O
This O
analysis O
indicates O
that O
the O
75 O
kd-species O
OTF-2B B-protein
is O
closely O
related O
to O
the O
60 O
kd O
species O
OTF-2A B-protein
. O
Inhibition O
of O
interleukin O
2 O
-induced O
proliferation O
of O
cloned O
murine I-cell_line
T B-cell_type
cells I-cell_type
by O
glucocorticoids O
. O
Possible O
involvement O
of O
an O
inhibitory O
protein O
. O
The O
ability O
of O
glucocorticoids O
to O
inhibit O
interleukin O
2 O
( O
IL I-DNA
2 O
) O
-induced O
T O
cell O
proliferation O
in O
two O
cytotoxic B-cell_type
T O
cell O
( O
CTL I-DNA
) O
clones O
has O
been O
studied O
. O
A O
complete O
inhibition O
of O
DNA O
synthesis O
by O
dexamethasone O
( O
Dx O
) O
could O
be O
observed O
when O
IL B-protein
2-depleted B-DNA
cultures I-cell_line
of O
CTL B-cell_type
were O
either O
incubated O
for O
6 O
h O
with O
the O
hormone O
prior O
to O
the O
addition O
of O
IL B-cell_type
2 O
or O
treated O
simultaneously O
with O
Dx O
and O
a O
low O
concentration O
of O
IL B-cell_type
2 O
. O
No O
significant O
reduction O
in O
the O
number O
and O
affinity O
of O
IL B-cell_type
2 O
receptors O
was O
seen O
after O
6 O
h O
incubation O
with O
Dx O
. O
The O
order O
of O
potency O
observed O
with O
the O
different O
steroids O
indicated O
that O
this O
inhibitory O
effect O
was O
mediated O
through O
binding O
to O
a O
specific O
glucocorticoid I-DNA
receptor I-protein
. O
The O
action O
of O
these O
hormones O
possibly O
involves O
the O
synthesis O
of O
an O
inhibitory O
protein I-protein
( O
s O
) O
, O
since O
the O
presence O
of O
cycloheximide O
during O
the O
incubation O
with O
Dx O
prevented O
the O
inhibition O
of O
DNA O
synthesis O
. O
Furthermore O
, O
supernatant O
from O
Dx-treated O
CTL O
contained O
a O
nondialyzable B-protein
factor I-protein
which O
inhibited O
DNA O
synthesis O
and O
cell O
growth O
of O
CTL B-cell_type
clones O
induced O
by O
IL B-protein
2 O
. O
Blocking O
of O
IL B-cell_type
2 O
synthesis O
and O
IL B-protein
2 I-DNA
receptor I-DNA
formation O
have O
been O
proposed O
as O
one O
of O
the O
major O
mechanisms O
of O
glucocorticoid-induced B-DNA
immunosuppression O
. O
Our O
results O
indicate O
that O
these O
hormones O
may O
also O
affect O
T O
cell O
proliferation O
by O
inhibiting O
IL B-protein
2 O
activity O
. O
Identification O
and O
purification O
of O
a O
human B-DNA
immunoglobulin-enhancer-binding I-cell_type
protein I-protein
( O
NF-kappa B-protein
B I-DNA
) O
that O
activates O
transcription O
from O
a O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
promoter I-DNA
in O
vitro O
. O
The O
enhancer-binding B-protein
factor I-protein
NF-kappa B-protein
B I-protein
, O
which O
is O
found O
only O
in O
cells I-cell_type
that O
transcribe O
immunoglobulin O
light O
chain I-DNA
genes I-DNA
, O
has O
been O
purified O
from O
nuclear B-protein
extracts O
of O
Namalwa B-cell_type
cells I-cell_line
( O
human O
Burkitt I-cell_type
lymphoma B-cell_type
cells I-cell_type
) O
by O
sequence-specific O
DNA O
affinity O
chromatography O
. O
The O
purified O
NF-kappa B-protein
B I-protein
has O
been O
identified O
as O
a O
51-kDa B-protein
polypeptide O
by O
UV-crosslinking B-protein
analysis O
. O
`` O
Footprint O
'' O
and O
methylation-interference B-protein
analyses O
have O
shown O
that O
purified O
NF-kappa B-protein
B I-protein
has O
a O
binding O
activity O
specific O
for O
the O
kappa B-DNA
light O
chain B-DNA
enhancer I-DNA
sequence O
. O
The O
purified B-protein
factor I-protein
activated O
in O
vitro O
transcription I-DNA
of O
the O
human B-DNA
immunodeficiency I-DNA
virus O
type O
I I-protein
promoter I-DNA
by O
binding O
to O
an O
upstream O
NF-kappa B-protein
B-binding B-DNA
site I-DNA
Lymphocyte O
glucocorticoid I-DNA
receptor I-protein
binding O
in O
depression O
: O
normal O
values O
following O
recovery O
. O
The O
number O
of O
glucocorticoid I-DNA
receptor I-DNA
sites I-DNA
in O
lymphocytes I-cell_type
and O
plasma O
cortisol O
concentrations O
were O
measured O
in O
20 O
patients O
who O
had O
recovered O
from O
major O
depressive O
disorder O
and O
20 O
healthy O
control O
subjects O
. O
The O
number O
of O
glucocorticoid I-DNA
receptor I-DNA
sites I-DNA
in O
lymphocytes I-cell_type
from O
the O
recovered O
depressed O
group O
was O
not O
significantly O
different O
from O
that O
of O
the O
control O
group O
. O
Although O
the O
mean O
plasma O
cortisol O
concentration O
in O
recovered O
depressives O
was O
higher O
than O
in O
control O
subjects O
, O
the O
difference O
only O
just O
reached O
significance O
. O
This O
study O
shows O
that O
the O
reduction O
in O
glucocorticoid I-DNA
receptor I-protein
numbers O
which O
occurs O
during O
acute O
depressive O
illness O
does O
not O
persist O
on O
recovery O
and O
is O
, O
therefore O
, O
state-dependent O
. O
Identification O
and O
purification O
of O
a O
human B-DNA
lymphoid-specific I-cell_type
octamer-binding O
protein I-protein
( O
OTF-2 O
) O
that O
activates O
transcription I-DNA
of O
an O
immunoglobulin O
promoter I-DNA
in O
vitro O
. O
The O
octamer O
sequence O
5'-ATGCAAAT O
, O
in O
either O
orientation O
, O
serves O
as O
an O
upstream O
element I-DNA
in O
a O
variety O
of O
promoters O
and O
also O
occurs O
as O
a O
modular B-DNA
enhancer B-DNA
element I-DNA
. O
It O
is O
of O
particular O
interest O
in O
immunoglobulin I-DNA
genes I-DNA
since O
it O
is O
found O
in O
the O
upstream O
regions I-protein
of O
all O
heavy O
and O
light O
chain O
promoters O
and O
in O
the O
heavy O
chain B-DNA
enhancer I-DNA
, O
both O
of O
which O
are O
known O
to O
be O
necessary O
for O
cell-specific I-DNA
expression O
. O
We O
report O
here O
the O
chromatographic O
separation O
of O
ubiquitous O
and O
B I-DNA
cell-specific I-DNA
octamer-binding O
proteins I-protein
. O
The O
B O
cell O
factor I-protein
was O
purified O
to O
homogeneity O
using O
affinity O
chromatography O
and O
consists O
of O
three O
peptides O
of O
62 O
, O
61 O
, O
and O
58.5 B-protein
+/- O
1.5 B-protein
kd O
. O
Each O
of O
the O
polypeptides O
was O
renatured O
after O
SDS-PAGE B-protein
and O
shown O
to O
bind O
to O
the O
octamer O
sequence O
. O
The O
specific O
DNA O
binding O
activity O
of O
the O
pure O
B I-DNA
cell-specific I-protein
factor I-protein
was O
indistinguishable O
from O
that O
of O
the O
affinity-purified B-DNA
ubiquitous O
factor I-protein
. B-protein
This O
B I-DNA
cell-specific I-DNA
octamer-binding B-protein
factor I-protein
, O
in O
pure O
form O
, O
activated O
transcription O
from O
a O
kappa B-DNA
light O
chain B-DNA
promoter I-DNA
in O
vitro O
, O
thus O
demonstrating O
that O
it O
is O
indeed O
a O
B I-DNA
cell-specific I-DNA
transcription B-protein
factor I-protein
for O
this O
gene I-DNA
. O
In O
addition O
to O
the O
ubiquitous O
and O
B I-DNA
cell-specific I-DNA
octamer-binding B-protein
factors I-protein
, O
we O
identified O
several O
additional O
proteins I-protein
, O
one O
of O
which O
is O
B O
cell O
-specific O
, O
that O
interact O
with O
the O
kappa B-DNA
promoter I-DNA
. O
Decreased O
deoxyribonucleic O
acid O
binding O
of O
glucocorticoid-receptor B-protein
complex I-protein
in O
cultured O
skin O
fibroblasts O
from O
a O
patient O
with O
the O
glucocorticoid O
resistance O
syndrome O
. O
A O
patient O
with O
the O
syndrome O
of O
glucocorticoid O
resistance O
was O
studied O
. O
A O
27-yr-old O
woman O
initially O
was O
diagnosed O
as O
having O
Cushing O
's O
disease O
, O
based O
on O
the O
findings O
of O
high O
plasma O
ACTH O
and O
serum O
cortisol O
levels O
, O
increased O
urinary O
cortisol O
secretion O
, O
resistance O
to O
adrenal O
suppression O
with O
dexamethasone O
, O
and O
bilateral O
adrenal O
hyperplasia O
by O
computed O
tomography O
and O
scintigraphy O
of O
the O
adrenal O
glands O
. O
However O
, O
she O
had O
no O
signs O
or O
symptoms O
of O
Cushing O
's O
syndrome O
. O
During O
a O
5-yr O
follow-up I-DNA
, O
no O
clinical O
abnormalities O
developed O
, O
although O
hypercortisolism O
persisted O
. O
End-organ O
resistance O
to O
cortisol O
was O
suspected O
. O
To O
explain O
the O
end-organ B-DNA
resistance O
to O
cortisol O
, O
the O
glucocorticoid O
receptors O
( O
GR I-DNA
) O
in O
peripheral B-cell_type
mononuclear O
leukocytes O
and O
cultured O
skin O
fibroblasts O
from O
a O
forearm O
skin O
biopsy O
were O
characterized O
and O
compared O
with O
the O
results O
of O
similar O
studies O
in O
normal O
subjects O
. O
The O
patient O
's O
GR B-protein
in O
whole O
cell O
assays O
had O
an O
increased O
dissociation O
constant O
( O
Kd O
) O
. O
In O
the O
cytosol O
of O
cultured O
skin O
fibroblasts O
from O
the O
patient O
, O
there O
was O
also O
decreased O
binding O
capacity O
. O
The O
thermal O
stability O
and O
the O
sedimentation O
coefficient O
in O
a O
sucrose O
density O
gradient O
of O
the O
receptors O
in O
the O
cytosol O
of O
cultured O
skin O
fibroblasts O
from O
the O
patient O
and O
normal O
subjects O
were O
similar O
. O
GR I-protein
complex I-protein
activation I-protein
, O
analyzed O
by O
DEAE-cellulose B-protein
chromatography O
, O
was O
decreased O
in O
the O
patient O
. O
DNA O
binding O
of O
the O
GR I-protein
complex I-protein
after O
temperature-induced B-DNA
activation O
was O
lower O
in O
the O
patient O
than O
in O
normal O
subjects O
. O
Nuclear O
translocation O
of O
GR B-cell_type
complexes O
from O
the O
patient O
was O
also O
slightly O
decreased O
. O
These O
results O
suggest O
that O
the O
patient O
's O
glucocorticoid O
resistance O
was O
due O
to O
a O
decrease O
in O
the O
affinity O
of O
the I-DNA
receptor I-protein
for O
glucocorticoids O
and O
a O
decrease O
in O
the O
binding O
of O
the O
GR I-protein
complex I-protein
to O
DNA O
. O
Granulocyte-macrophage B-protein
colony-stimulating B-protein
factor I-protein
. B-protein
Sensitive O
and O
receptor-mediated O
regulation O
by O
1 O
, O
25-dihydroxyvitamin O
D3 B-protein
in O
normal O
human B-cell_type
peripheral B-cell_type
blood I-cell_type
lymphocytes I-cell_type
. O
We O
show O
that O
1 O
, O
25-dihydroxyvitamin O
D3 B-protein
( O
1 O
, O
25 O
[ O
OH B-protein
] O
2D3 B-protein
) O
, O
the O
most O
hormonally O
active O
metabolite O
of O
vitamin O
D3 I-protein
, O
modulates O
sensitively O
and O
specifically O
both O
the O
protein O
and O
messenger O
RNA O
accumulation O
of O
the O
multilineage O
growth I-protein
factor I-protein
granulocyte-macrophage B-protein
colony-stimulating B-protein
factor I-protein
( O
GM-CSF B-protein
) O
. O
The O
regulation O
of O
GM-CSF B-protein
expression O
is O
seen O
in O
both O
normal O
human B-cell_type
mitogen-activated I-cell_line
T I-cell_type
lymphocytes I-cell_type
and O
T I-cell_type
lymphocytes I-cell_type
from O
a O
line O
( O
S-LB1 B-protein
) O
transformed O
with O
human B-cell_type
T I-cell_line
cell O
lymphotropic O
virus O
1 O
( O
HTLV-1 B-protein
) O
. O
In O
contrast O
, O
cells I-cell_type
from O
a O
HTLV-1 B-protein
transformed O
T I-cell_line
lymphocyte I-cell_line
line O
( O
Ab-VDR I-DNA
) O
established O
from O
a O
patient O
with O
vitamin O
D-resistant B-protein
rickets I-DNA
type O
II I-protein
with O
undetectable O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
cellular O
receptors O
are O
resistant O
to O
the O
action O
of O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
. O
Inhibition O
of O
GM-CSF B-protein
expression O
by O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
can O
occur O
independently O
of O
interleukin O
2 O
regulation O
and O
is O
probably O
mediated O
through O
cellular O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
receptors O
. O
We O
conclude O
that O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
may O
be O
important O
in O
the O
physiology O
of O
hematopoiesis O
. O
Altered O
interaction O
between O
triiodothyronine O
and O
its O
nuclear B-protein
receptors O
in O
absence O
of O
cortisol O
: O
a O
proposed O
mechanism O
for O
increased O
thyrotropin O
secretion O
in O
corticosteroid O
deficiency O
states O
. O
Thyroid O
hormones O
occasionally O
appear O
less O
effective O
when O
administered O
alone O
to O
patients O
with O
panhypopituitarism I-protein
, O
and O
manifestations O
suggestive O
of O
hypothyroidism O
have O
been O
reported O
in O
patients O
suffering O
from O
untreated O
Addison O
's O
disease O
. O
In O
the O
latter O
condition O
, O
thyrotropin O
secretion O
is O
increased O
: O
this O
occurs O
already O
after O
as O
little O
as O
2 O
days O
of O
temporary O
withdrawal O
of O
therapy O
with O
substitution O
doses O
of O
corticosteroids O
while O
circulating O
levels O
of O
thyroid O
hormones O
remain O
within O
normal O
limits O
. O
Therefore O
, O
a O
possible O
role O
of O
cortisol O
in O
interaction O
between O
triiodothyronine O
and O
its O
nuclear B-protein
receptors O
was O
examined O
at O
the O
level O
of O
circulating I-cell_type
lymphocytes I-cell_type
obtained O
from O
patients O
with O
primary B-cell_line
or O
secondary O
adrenocortical O
failure O
. O
The O
affinity O
of O
these O
receptors O
was O
found O
to O
be O
decreased O
, O
by O
more O
than O
50 O
% O
on O
average O
, O
in O
the O
absence O
of O
cortisol O
treatments O
. O
This O
change O
was O
promptly O
corrected O
upon O
resumption O
of O
therapy O
. O
The O
number O
of O
binding O
sites O
was O
not O
significantly O
modified O
. O
The O
influence O
of O
cortisol O
on O
thyroid O
hormone O
receptors O
discussed O
here O
might O
account O
for O
the O
clinical O
observations O
mentioned O
above O
. O
Inhibition O
by O
cortisol O
of O
human B-cell_type
natural I-DNA
killer O
( O
NK O
) O
cell O
activity O
. O
The O
effects O
of O
cortisol O
on O
the O
natural O
killer O
( O
NK O
) O
activity O
of O
human B-cell_type
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
( O
PBM I-DNA
) O
cells I-cell_type
were O
studied O
in O
vitro O
using O
a O
direct O
4-h O
51Cr-release B-protein
assay O
and O
K O
562 O
cell O
line O
as O
a O
target I-cell_line
. O
Preincubation B-cell_type
for O
20 O
h O
of O
PBM B-cell_type
cells I-cell_type
drawn O
from O
healthy O
donors O
with O
1 O
X O
10 O
( O
-8 B-protein
) O
to O
1 O
X O
10 O
( O
-5 B-protein
) O
M O
cortisol O
resulted O
in O
a O
significant O
decrease O
of O
NK O
cell O
activity O
. O
The O
magnitude O
of O
the O
suppression O
was O
directly O
related O
to O
the O
steroid O
concentration O
and O
inversely O
related O
to O
the O
number O
of O
effector B-cell_type
cells I-cell_type
. O
Cortisol O
was O
able O
to O
minimize O
the O
enhancement O
of O
NK B-cell_type
cytotoxicity O
obtainable O
in O
the O
presence O
of O
immune O
interferon O
( O
IFN-gamma I-DNA
) O
. O
A O
significantly O
higher O
suppression O
was O
achieved O
after O
sequential O
exposure O
of O
PBM B-cell_type
cells O
to O
cortisol O
and O
equimolar O
levels O
of O
prostaglandin O
E2 B-protein
( O
PgE2 B-DNA
) O
. O
The O
concomitant O
incubation O
with O
theophylline O
and O
isobutyl-methylxanthine B-protein
failed O
to O
enhance O
the O
cortisol-induced I-cell_line
suppression O
, O
whereas O
PgE2-dependent B-protein
inhibition O
significantly O
increased O
after O
exposure O
of O
PBM B-cell_type
cells O
to O
methyl-xanthines O
. O
The O
inhibitory O
effect O
of O
cortisol O
was O
partially O
or O
totally O
prevented O
by O
the O
concomitant O
incubation O
with O
equimolar O
amounts O
of O
11-deoxycortisol O
and O
RU B-protein
486 O
but O
not O
of O
progesterone O
. O
Treatment O
of O
NK B-cell_type
effectors O
with O
a O
monoclonal O
anti-human B-DNA
corticosteroid-binding B-DNA
globulin O
( O
CBG I-DNA
) O
antibody O
produced O
an O
enhancement O
of O
the O
spontaneous O
NK O
activity O
and O
a O
partial O
suppression O
of O
cortisol-mediated B-DNA
effects O
. O
Our O
results O
suggest O
that O
endogenous O
glucocorticoids O
play O
a O
role O
in O
the O
regulation O
of O
NK B-cell_type
cell-mediated I-DNA
cytotoxicity O
. O
Since O
the O
effect O
of O
cortisol O
was O
additive O
to O
that O
of O
PgE2 B-DNA
and O
was O
not O
changed O
by O
phosphodiesterase O
inhibitors O
, O
it O
is O
conceivable O
that O
the O
hormone O
acts O
at O
a O
level O
different O
from O
the O
adenylate O
cyclase O
- O
phosphodiesterase O
system O
. O
Data O
obtained O
with O
the O
use O
of O
antiglucocorticoids O
and O
the O
anti-CBG B-protein
antibody O
are O
compatible O
with O
a O
role O
both O
of O
high-affinity B-cell_type
glucocorticoid O
receptors O
and I-DNA
of O
CBG B-cell_type
in O
mediating O
cortisol O
action O
on O
the O
human B-DNA
NK I-cell_type
cell O
activity O
. O
Interaction O
of O
cell-type-specific O
nuclear B-protein
proteins I-protein
with O
immunoglobulin O
VH B-DNA
promoter I-DNA
region O
sequences O
. O
All O
human B-DNA
and I-DNA
murine I-cell_line
immunoglobulin O
heavy O
chain O
variable O
region O
( O
VH I-DNA
) O
genes I-DNA
contain O
the O
sequence O
ATGCAAAT O
approximately O
70 O
nucleotides O
5 O
' O
from O
the O
site I-DNA
of O
transcription O
initiation O
. O
This O
octanucleotide O
, O
in O
reverse O
orientation O
, O
is O
also O
found O
in O
all O
light O
chain O
variable O
region O
( O
VL I-DNA
) O
genes I-DNA
, O
and O
in O
the O
immunoglobulin O
heavy O
chain O
transcriptional O
enhancer I-DNA
. O
Transfection O
studies O
have O
established O
that O
this O
octamer O
is O
involved O
in O
the O
lymphoid-specific B-DNA
transcription I-DNA
of O
immunoglobulin O
genes I-DNA
. O
Octamer-containing O
fragments O
have O
been O
reported O
to O
bind O
a O
factor I-protein
present O
in O
nuclear B-protein
extracts O
of O
human B-cell_type
cell I-cell_type
lines I-cell_line
; O
however O
, O
identical O
binding O
activity O
was O
detected O
in O
both O
B I-DNA
lymphoid O
and O
non-lymphoid B-cell_type
cells I-cell_type
. O
Here O
we O
establish O
that O
nuclear B-protein
extracts O
from O
distinct O
cell O
types I-cell_type
differ O
in O
their O
ability O
to O
interact O
with O
octamer-containing O
fragments O
. O
We O
have O
also O
detected O
a O
DNA-protein B-protein
interaction O
that O
may O
be O
involved O
in O
the O
cell-type B-DNA
specificity O
of O
immunoglobulin O
expression O
, O
and O
we O
have O
determined O
that O
a O
sequence O
upstream O
of O
the O
octamer O
participates O
in O
an O
interaction O
with O
a O
nuclear B-protein
protein I-protein
( O
s O
) O
. O
Preferential B-protein
transcription I-DNA
of O
HTLV-I B-protein
LTR O
in O
cell-free B-DNA
extracts O
of O
human B-cell_type
T I-cell_type
cells I-cell_type
producing O
HTLV-I B-protein
viral O
proteins I-protein
. O
The O
promoters O
of O
the O
adenovirus O
2 O
major O
late O
gene I-DNA
, O
the O
mouse B-DNA
beta-globin I-DNA
gene I-DNA
, O
the O
mouse B-DNA
immunoglobulin O
VH B-DNA
gene I-DNA
and O
the O
LTR O
of O
the O
human B-DNA
T-lymphotropic I-cell_type
retrovirus O
type O
I I-protein
were O
tested O
for O
their O
transcription O
activities O
in O
cell-free B-DNA
extracts O
of O
four O
cell O
lines I-cell_line
; O
HeLa I-protein
, O
CESS I-protein
( O
Epstein-Barr O
virus-transformed O
human B-DNA
B I-DNA
cell O
line O
) O
, O
MT-1 B-protein
( O
HTLV-I-infected O
human B-cell_type
T I-cell_line
cell O
line O
without O
viral O
protein O
synthesis O
) O
, O
and O
MT-2 B-protein
( O
HTLV-I-infected O
human B-cell_type
T I-cell_line
cell O
line O
producing O
viral O
proteins I-protein
) O
. O
LTR O
was O
preferentially O
transcribed O
in O
the O
extracts O
of O
MT-2 B-protein
although O
the O
other O
three O
genes I-DNA
were O
transcribed O
with O
relatively O
constant O
efficiencies O
in O
different O
extracts O
. O
The O
results O
agree O
well O
with O
the O
previous O
in O
vivo O
studies O
on O
the O
promoter I-DNA
activity O
of O
HTLV-I B-protein
LTR O
. O
Mixing O
of O
HeLa O
and O
MT-2 B-protein
extracts O
revealed O
the O
presence O
of O
a O
LTR-specific B-protein
stimulating O
activity O
in O
MT-2 B-protein
extracts O
. O
A O
nuclear B-protein
factor I-protein
that O
binds O
to O
a O
conserved O
sequence O
motif O
in O
transcriptional O
control O
elements I-DNA
of O
immunoglobulin O
genes I-DNA
. O
Trans-acting B-protein
factors I-protein
that O
mediate O
B-cell O
specific O
transcription I-DNA
of O
immunoglobulin O
genes I-DNA
have O
been O
postulated O
based O
on O
an O
analysis O
of O
the O
expression O
of O
exogenously O
introduced O
immunoglobulin O
gene I-DNA
recombinants O
in O
lymphoid O
and O
non-lymphoid B-cell_type
cells I-cell_type
. O
Two O
B-cell-specific I-DNA
, O
cis-acting B-DNA
transcriptional O
regulatory O
elements I-DNA
have O
been O
identified O
. O
One O
element I-DNA
is O
located O
in O
the O
intron O
between O
the O
variable O
( O
V I-DNA
) O
and O
constant O
( O
C I-DNA
) O
regions I-protein
of O
both O
heavy O
and O
kappa O
light-chain I-DNA
genes I-DNA
and O
acts O
as O
a O
transcriptional O
enhancer I-DNA
. O
The O
second O
element I-DNA
is O
found O
upstream O
of O
both O
heavy O
and O
kappa O
light-chain B-DNA
gene I-DNA
promoters O
. O
This O
element I-DNA
directs O
lymphoid-specific B-DNA
transcription O
even O
in O
the O
presence O
of O
viral O
enhancers O
. O
We O
have O
sought O
nuclear B-protein
factors I-protein
that O
might O
bind O
specifically O
to O
these O
two O
regulatory O
elements I-DNA
by O
application O
of O
a O
modified O
gel O
electrophoresis O
DNA O
binding O
assay O
. O
We O
report O
here O
the O
identification O
of O
a O
human B-DNA
B-cell I-cell_type
nuclear B-protein
factor I-protein
( O
IgNF-A I-DNA
) O
that O
binds O
to O
DNA O
sequences O
in O
the O
upstream O
regions I-protein
of O
both O
the O
mouse B-DNA
heavy O
and O
kappa O
light-chain B-DNA
gene I-DNA
promoters O
and O
also O
to O
the O
mouse B-DNA
heavy-chain B-DNA
gene I-DNA
enhancer I-DNA
. O
This O
sequence-specific B-DNA
binding O
is O
probably O
mediated O
by O
a O
highly O
conserved O
sequence O
motif O
, O
ATTTGCAT I-protein
, O
present O
in O
all O
three O
transcriptional O
elements O
. O
Interestingly B-cell_type
, O
a O
factor I-protein
showing O
similar O
binding O
specificity O
to O
IgNF-A O
is O
also O
present O
in O
human B-DNA
HeLa I-cell_type
cells I-cell_type
. O
The O
new O
world O
primates O
as O
animal O
models O
of O
glucocorticoid O
resistance O
. O
Many O
New O
World O
primate O
species O
have O
greatly O
increased O
plasma O
cortisol O
concentrations O
, O
decreased O
plasma O
cortisol O
binding O
globulin O
capacity O
and O
affinity O
, O
marked O
resistance O
of O
the O
hypothalamic-pituitary-adrenal B-protein
axis O
to O
suppression O
by O
dexamethasone O
, O
and O
no O
biological O
evidence O
of O
glucocorticoid O
excess O
. O
These O
primates O
also O
have O
high O
levels O
of O
circulating O
progesterone O
, O
estrogen O
, O
mineralocorticoid O
, O
androgen O
and O
vitamin O
D O
. O
The O
glucocorticoid O
target I-cell_line
tissues O
that O
have O
been O
examined O
( O
circulating O
mononuclear I-cell_type
lymphocytes I-cell_type
and O
cultured O
skin O
fibroblasts O
) O
have O
normal O
concentrations O
of O
glucocorticoid O
receptors O
with O
decreased O
affinity O
for O
dexamethasone O
. O
Transformation O
of O
B-lymphocytes B-protein
with O
the O
Epstein-Barr O
virus O
leads O
to O
glucocorticoid I-DNA
receptor I-protein
induction O
that O
is O
less O
than O
that O
observed O
with O
cells I-cell_type
from O
Old O
World O
primates O
. O
The I-DNA
receptor I-protein
in O
these I-cell_type
cells I-cell_type
has O
a O
low O
affinity O
for O
dexamethasone O
. O
The O
low O
affinity O
leads O
to O
an O
increased O
loss O
of O
specific O
bound O
ligand O
during O
thermal O
activation O
. O
Meroreceptor O
generation O
is O
normal O
. O
The O
molecular O
weight O
of O
the I-DNA
receptor I-protein
, O
determined O
by O
SDS-PAGE I-protein
, O
is O
similar O
to O
that O
of O
Old O
World O
primates O
( O
approximately O
92 I-cell_line
, O
000 O
) O
and O
the O
activation O
pattern O
per O
se O
, O
examined O
in O
vitro O
by O
heating O
cytosol O
and O
performing O
phosphocellulose O
chromatography O
, O
appears O
similar O
to O
that O
of O
human B-cell_type
controls I-cell_type
. O
The O
ratios O
of O
nuclear O
to O
cytosolic O
hormone-receptor-complexes O
and I-DNA
of O
cytosolic O
activated O
to O
unactivated I-DNA
receptor I-protein
complexes O
in O
intact B-DNA
cells I-cell_type
are O
similar O
to O
Old O
World O
primates O
. O
Results O
from O
mixing O
studies O
do O
not O
support O
the O
hypothesis O
that O
a O
binding O
inhibitor O
( O
s O
) O
or O
a O
deficient O
cytosolic O
positive O
modifier O
( O
s O
) O
of O
binding O
underlies O
the O
findings O
in O
these O
primates O
. O
The O
New O
World O
primates O
, O
unlike O
men O
with O
the O
syndrome O
of O
primary B-cell_line
cortisol I-cell_line
resistance O
, O
have O
compensated O
for O
their O
condition O
with O
intra-adrenal O
and O
mineralocorticoid I-DNA
receptor I-protein
adaptations O
. O
Thus O
, O
unlike O
Old O
World O
primates O
, O
cortisol O
in O
New O
World O
primates O
has O
only O
weak O
sodium-retaining O
potency O
because O
the O
aldosterone I-DNA
receptor I-protein
has O
a O
low O
affinity O
for O
cortisol O
. O
The O
common O
element I-DNA
that O
would O
explain O
the O
apparent O
resistance O
to O
six O
steroid O
hormones O
in O
New O
World O
primates O
Acetylation O
and O
modulation O
of O
erythroid B-cell_type
Kruppel-like B-protein
factor I-protein
( O
EKLF I-DNA
) O
activity O
by O
interaction O
with O
histone I-protein
acetyltransferases O
. O
Erythroid O
Kruppel-like B-protein
factor I-protein
( O
EKLF I-DNA
) O
is O
a O
red O
cell-specific I-DNA
transcriptional O
activator O
that O
is O
crucial O
for O
consolidating O
the O
switch O
to O
high O
levels O
of O
adult O
beta-globin I-DNA
expression O
during O
erythroid B-DNA
ontogeny I-protein
. O
EKLF O
is O
required O
for O
integrity O
of O
the O
chromatin O
structure O
at O
the O
beta-like B-DNA
globin O
locus O
, O
and O
it O
interacts O
with O
a O
positive-acting B-protein
factor I-protein
in O
vivo O
. O
We O
find O
that O
EKLF O
is O
an O
acetylated O
transcription B-protein
factor I-protein
, O
and O
that O
it O
interacts O
in O
vivo O
with O
CBP I-protein
, O
p300 I-protein
, O
and O
P/CAF B-protein
. O
However O
, O
its O
interactions O
with O
these O
histone I-protein
acetyltransferases O
are O
not O
equivalent O
, O
as O
CBP O
and O
p300 I-protein
, O
but O
not O
P/CAF I-protein
, O
utilize O
EKLF O
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans-activation B-DNA
region O
. O
The O
functional O
effects O
of O
these O
interactions O
are O
that O
CBP O
and O
p300 I-protein
, O
but O
not O
P/CAF I-protein
, O
enhance O
EKLF O
's O
transcriptional O
activation O
of O
the O
beta-globin B-DNA
promoter I-DNA
in O
erythroid I-cell_type
cells I-cell_type
. O
These O
results O
establish O
EKLF O
as O
a O
tissue-specific B-protein
transcription B-protein
factor I-protein
that O
undergoes O
post-translational O
acetylation O
and O
suggest O
a O
mechanism O
by O
which O
EKLF O
is O
able O
to O
alter O
chromatin O
structure O
and O
induce O
beta-globin I-DNA
expression O
within O
the O
beta-like B-DNA
globin O
cluster O
. O
Recognition O
of O
herpes O
simplex O
virus O
type O
2 O
tegument O
proteins I-protein
by O
CD4 B-protein
T B-cell_type
cells I-cell_type
infiltrating O
human B-DNA
genital I-DNA
herpes O
lesions O
. O
The O
local O
cellular O
immune O
response O
to O
herpes O
simplex O
virus O
( O
HSV I-DNA
) O
is O
important O
in O
the O
control O
of O
recurrent O
HSV O
infection O
. O
The O
antiviral O
functions O
of O
infiltrating O
CD4-bearing B-cell_type
T B-cell_type
cells I-cell_type
may O
include O
cytotoxicity O
, O
inhibition O
of O
viral O
growth I-protein
, O
lymphokine O
secretion O
, O
and O
support O
of O
humoral O
and O
CD8 B-protein
responses O
. O
The O
antigens O
recognized O
by O
many O
HSV-specific B-protein
CD4 B-protein
T B-cell_type
cells I-cell_type
localizing O
to O
genital O
HSV-2 O
lesions O
are O
unknown O
. O
T B-cell_type
cells I-cell_type
recognizing O
antigens O
encoded O
within O
map O
units O
0.67 I-protein
to O
0.73 I-DNA
of O
HSV B-cell_type
DNA O
are O
frequently O
recovered O
from O
herpetic O
lesions O
. O
Expression O
cloning O
with O
this O
region I-DNA
of O
DNA O
now O
shows O
that O
tegument O
protein O
VP22 I-protein
and O
the O
viral O
dUTPase I-protein
, O
encoded O
by O
genes I-DNA
UL49 B-protein
and O
UL50 I-protein
, O
respectively O
, O
are O
T-cell O
antigens O
. O
Separate O
epitopes I-protein
in O
VP22 B-protein
were O
defined O
for O
T-cell O
clones O
from O
each O
of O
three O
patients O
. O
Reactivity O
with O
the O
tegument O
protein O
encoded O
by O
UL21 B-protein
was O
identified O
for O
an O
additional O
patient O
. O
Three O
new O
epitopes I-protein
were O
identified O
in O
VP16 I-protein
, O
a O
tegument O
protein O
associated O
with O
VP22 B-protein
. O
Some O
tegument-specific B-DNA
CD4 B-protein
T-cell O
clones O
exhibited O
cytotoxic O
activity O
against O
HSV-infected B-protein
cells I-cell_type
. O
These O
results O
suggest O
that O
herpes O
simplex O
tegument O
proteins I-protein
are O
processed O
for O
antigen I-protein
presentation O
in O
vivo O
and O
are O
possible O
candidate O
compounds O
for O
herpes O
simplex O
vaccines O
. O
Fibrinogen O
activates O
NF-kappa B-protein
B I-protein
transcription B-protein
factors I-protein
in O
mononuclear O
phagocytes O
. O
Adhesion O
to O
extracellular O
matrices O
is O
known O
to O
modulate O
leukocyte O
activation O
, O
although O
the O
mechanisms O
are O
not O
fully O
understood O
. O
Mononuclear O
phagocytes O
are O
exposed O
to O
fibrinous O
provisional O
matrix O
throughout O
migration O
into O
inflammatory O
foci O
, O
so O
this O
study O
was O
undertaken O
to O
determine O
whether O
fibrinogen O
triggers O
activation O
of O
NF-kappa B-protein
B I-protein
transcription B-protein
factors I-protein
. O
U937 B-protein
cells I-cell_type
differentiated O
with O
PMA O
in O
nonadherent O
culture O
were O
shown O
to O
express O
two O
fibrinogen-binding O
integrins O
, O
predominately O
CD11b/CD18 I-cell_line
, O
and O
to O
a O
lesser O
extent I-protein
, O
CD11c/CD18 O
. O
Cells O
stimulated O
with O
fibrinogen O
( O
10-100 O
microg/ml I-DNA
) O
/Mn2+ O
( O
50 O
microM B-protein
) O
for O
2 O
h O
were O
examined O
by O
electrophoretic O
mobility O
shift O
assay O
. O
NF-kappa B-protein
B I-protein
activation O
, O
minimal O
in O
unstimulated B-cell_type
cells I-cell_line
, O
was O
substantially O
up-regulated B-DNA
by O
fibrinogen O
. O
Fibrinogen O
also O
caused O
activation O
of O
AP-1 B-protein
, O
but O
not O
SP1 B-protein
or O
cAMP I-RNA
response O
element-binding O
protein I-protein
( O
CREB I-DNA
) O
factors O
. O
Blocking O
mAbs I-protein
against O
CD18 B-protein
and O
CD11b O
abrogated O
fibrinogen O
-induced O
NF-kappa B-protein
B I-protein
activation O
. O
To O
determine O
the O
effects O
on O
transcriptional O
regulation O
, O
U937 B-protein
cells I-cell_type
were O
transfected O
with O
a O
plasmid O
containing O
the O
HIV-1 B-DNA
enhancer I-DNA
( O
bearing O
two O
NF-kappa B-protein
B I-DNA
sites I-DNA
) O
coupled O
to O
a O
chloramphenicol O
acetyltransferase O
( O
CAT I-DNA
) O
reporter O
. O
Cells O
were O
subsequently O
stimulated O
with O
1 O
) O
PMA O
for O
24 O
h O
, O
inducing O
CAT O
activity O
by O
2.6-fold B-protein
, O
2 O
) O
fibrinogen O
/Mn2+ O
for O
2 O
h O
, O
inducing O
CAT O
activity O
by O
3.2-fold B-protein
, O
or O
3 O
) O
costimulation O
with O
fibrinogen O
and O
PMA I-protein
, O
inducing O
5.7-fold B-protein
the O
CAT O
activity O
induced O
by O
PMA O
alone O
. O
We O
conclude O
that O
contact O
with O
fibrinogen-derived B-protein
proteins I-protein
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b/CD18 I-cell_line
, O
resulting O
in O
selective O
activation O
of O
transcriptional O
regulatory O
factors I-protein
, O
including O
NF-kappa B-protein
B I-protein
. O
Peripheral O
blood O
T I-cell_type
cells I-cell_type
and O
monocytes B-cell_type
and O
B O
cell O
lines I-cell_line
derived O
from O
patients O
with O
lupus O
express O
estrogen B-protein
receptor I-protein
transcripts O
similar O
to O
those O
of O
normal B-cell_type
cells I-cell_type
. O
OBJECTIVE O
: O
To O
identify O
and O
characterize O
estrogen B-protein
receptor I-protein
( O
ER B-protein
) O
transcripts O
expressed O
in O
immune B-cell_type
cells I-cell_type
of O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE I-DNA
) O
and O
healthy O
donors O
. O
METHODS I-protein
: O
Peripheral O
blood I-cell_type
monocytes I-cell_type
and O
T B-cell_type
cells I-cell_type
were O
prepared O
from O
patients O
with O
SLE I-protein
( O
n O
= O
6 O
) O
and O
healthy O
donors O
( O
n O
= O
8 O
) O
. O
T B-cell_type
cells I-cell_type
were O
separated O
into O
CD4 B-protein
and O
CD8 B-protein
. O
Some O
monocytes B-cell_type
and O
T B-cell_type
cells I-cell_type
were O
stimulated O
with O
estradiol O
, O
PMA I-protein
, O
and O
ionomycin O
. O
Epstein-Barr B-protein
virus-transformed B-DNA
B O
cell O
lines I-cell_line
( O
n O
= O
7 O
) O
and O
B O
cell O
hybridomas O
( O
n O
= O
2 O
) O
established O
from O
patients O
with O
SLE O
and O
a O
healthy O
individual O
were O
used O
as O
a O
B O
cell O
source O
. O
These B-cell_type
cells I-cell_type
were O
examined O
for O
ER I-RNA
mRNA I-RNA
by O
reverse O
transcription O
nested O
polymerase O
chain O
reaction O
. O
Amplified O
cDNA I-RNA
were O
sequenced O
by O
standard O
methods O
. O
RESULTS I-protein
: O
In O
all B-cell_type
cells I-cell_type
tested O
, O
ER I-RNA
mRNA I-RNA
was O
expressed O
without O
prior O
in O
vitro O
stimulation O
. O
Partial O
sequences O
from O
exons O
1-8 O
were O
nearly O
identical O
to O
the O
published O
sequence O
of O
the O
human O
ER I-RNA
mRNA I-RNA
. O
There O
were O
no O
notable O
differences O
in O
the O
ER I-RNA
transcripts O
between O
patients O
and O
healthy O
controls O
. O
Variant I-DNA
receptor I-protein
transcripts O
lacking O
exon O
5 O
or O
exon O
7 O
, O
which O
encodes O
the O
hormone O
binding I-protein
domain I-protein
, O
were O
identified O
in O
the O
majority O
of O
the B-cell_type
cells I-cell_type
. O
Precise O
deletion O
of O
the O
exons O
suggests O
that O
they O
are O
alternatively O
spliced O
transcripts I-RNA
. O
Whether O
the O
detected O
transcripts I-RNA
are O
translated O
into O
functional I-DNA
receptor I-protein
proteins I-protein
remains O
to O
be O
determined O
. O
In O
vitro O
stimulation O
did O
not O
affect O
ER I-RNA
mRNA I-RNA
expression O
. O
The O
presence O
of O
variants O
did O
not O
correlate O
with O
disease O
activity O
or O
medication O
. O
CONCLUSION I-protein
: O
Monocytes O
, O
T B-cell_type
cells I-cell_type
, O
and O
B I-DNA
cells I-cell_type
in O
patients O
express O
transcripts O
of O
the O
normal O
wild I-DNA
type O
ER B-protein
and O
the O
hormone O
binding I-protein
domain I-protein
variants O
in O
vivo O
. O
DNA O
damaging O
agents O
induce O
expression O
of O
Fas O
ligand O
and O
subsequent O
apoptosis O
in O
T I-cell_type
lymphocytes I-cell_type
via O
the O
activation O
of O
NF-kappa B-protein
B I-protein
and O
AP-1 B-protein
. O
Apoptosis O
induced O
by O
DNA O
damage O
and O
other O
stresses O
can O
proceed O
via O
expression O
of O
Fas O
ligand O
( O
FasL I-DNA
) O
and O
ligation O
of O
its I-DNA
receptor I-protein
, O
Fas O
( O
CD95 B-protein
) O
. O
We O
report O
that O
activation O
of O
the O
two O
transcription B-protein
factors I-protein
NF-kappa B-protein
B I-protein
and O
AP-1 B-protein
is O
crucially O
involved O
in O
FasL O
expression O
induced O
by O
etoposide O
, O
teniposide O
, O
and O
UV B-protein
irradiation O
. O
A O
nondegradable O
mutant O
of O
I I-protein
kappa B-DNA
B I-DNA
blocked O
both O
FasL O
expression O
and O
apoptosis O
induced O
by O
DNA O
damage O
but O
not O
Fas O
ligation O
. O
These O
stimuli O
also O
induced O
the O
stress-activated O
kinase I-protein
pathway O
( O
SAPK/JNK I-DNA
) O
, O
which O
was O
required O
for O
the O
maximal O
induction O
of O
apoptosis O
. O
A O
1.2 B-protein
kb O
FasL B-DNA
promoter I-DNA
responded O
to O
DNA O
damage O
, O
as O
well O
as O
coexpression O
with O
p65 O
Rel O
or O
Fos/Jun O
. O
Mutations O
in O
the O
relevant O
NF-kappa B-protein
B I-protein
and O
AP-1 B-protein
binding O
sites O
eliminated O
these O
responses O
. O
Thus O
, O
activation O
of O
NF-kappa B-protein
B I-protein
and O
AP-1 B-protein
contributes O
to O
stress-induced O
apoptosis O
via O
the O
expression O
of O
FasL B-RNA
. O
A O
small O
, O
nonpeptidyl O
mimic O
of O
granulocyte-colony-stimulating B-protein
factor I-protein
[ O
see O
commetns O
] O
A O
nonpeptidyl O
small O
molecule O
SB B-protein
247464 I-DNA
, O
capable O
of O
activating O
granulocyte-colony-stimulating B-protein
factor I-protein
( O
G-CSF B-protein
) O
signal O
transduction O
pathways O
, O
was O
identified O
in O
a O
high-throughput O
assay O
in O
cultured B-cell_type
cells I-cell_type
. O
Like O
G-CSF I-DNA
, O
SB O
247464 O
induced O
tyrosine I-protein
phosphorylation O
of O
multiple O
signaling O
proteins I-protein
and O
stimulated O
primary B-cell_line
murine I-cell_line
bone I-cell_line
marrow I-cell_line
cells O
to O
form O
granulocytic O
colonies O
in O
vitro O
. O
It O
also O
elevated O
peripheral B-cell_type
blood I-cell_type
neutrophil I-cell_type
counts O
in O
mice O
. O
The O
extracellular I-protein
domain I-protein
of O
the O
murine I-cell_line
G-CSF B-DNA
receptor I-protein
was O
required O
for O
the O
activity O
of O
SB B-cell_type
247464 I-DNA
, O
suggesting O
that O
the O
compound O
acts O
by O
oligomerizing I-DNA
receptor I-protein
chains O
. O
The O
results O
indicate O
that O
a O
small O
molecule O
can O
activate O
a O
receptor I-protein
that O
normally O
binds O
a O
relatively O
large O
protein O
ligand O
. O
Minimal O
residual O
disease O
in O
acute O
myelogenous O
leukemia O
with O
PML/RAR I-DNA
alpha I-DNA
or B-RNA
AML1/ETO I-RNA
mRNA I-RNA
and O
phenotypic O
analysis O
of O
possible B-cell_type
T I-cell_line
and O
natural O
killer B-cell_type
cells I-cell_type
in O
bone I-cell_line
marrow I-cell_line
. O
Here O
we O
studied O
minimal O
residual O
disease O
( O
MRD I-DNA
) O
of O
patients O
with O
acute O
myeloid O
leukemia O
( O
AML I-DNA
) O
who O
have O
PML/RAR I-DNA
alpha I-DNA
or B-RNA
AML1/ETO B-protein
as O
well O
as O
the O
phenotypic O
analysis O
of O
lymphocyte I-cell_line
subsets O
involved O
in O
antitumor O
immunity O
. O
Eight O
patients O
in O
long-term B-DNA
( O
LT B-protein
; O
3 O
to O
15 O
years O
) O
and O
15 O
patients O
in O
short-term B-DNA
( O
ST B-protein
; O
up O
to O
3 O
years O
) O
remission O
were O
studied O
. O
Using O
the O
reverse O
transcription-polymerase B-DNA
chain O
reaction O
( O
RT I-DNA
) O
assay O
, O
the O
limit O
of O
detection O
was O
10 O
( O
-5 B-protein
) O
to O
10 O
( O
-6 B-protein
) O
for O
PML/RAR I-DNA
alpha I-DNA
transcript I-DNA
and O
10 O
( O
-4 B-protein
) O
to O
10 O
( O
-5 B-protein
) O
for O
the O
AML1/ETO B-protein
transcript O
. O
Simultaneously I-protein
, O
T I-cell_line
lymphocyte I-cell_line
subsets O
and O
NK B-cell_type
cells I-cell_type
from O
the O
peripheral B-cell_type
blood I-cell_type
( O
PB I-DNA
) O
and O
bone B-cell_type
marrow I-cell_line
( O
BM I-DNA
) O
were O
investigated O
by O
flow O
cytometric O
analysis O
. O
Four O
of O
the O
eight O
patients O
in O
LT O
and O
7 O
of O
the O
15 O
patients O
in O
ST B-protein
remission O
were O
MRD-positive B-protein
. O
Although O
all O
MRD-positive B-protein
patients O
in O
LT B-protein
remission O
are O
still O
until O
now O
event-free I-DNA
, O
3 O
of O
the O
7 O
MRD-positive B-protein
( O
MRD+ I-DNA
) O
patients O
in O
ST B-protein
remission O
soon O
relapsed O
. O
The O
total O
populations O
of O
CD4 B-protein
+ O
, O
CD8 B-protein
+ O
and O
CD56 B-protein
+ O
[ O
possible O
T-cell O
and O
natural O
killer O
( O
T/NK I-DNA
) O
populations O
] O
in O
the O
BM I-DNA
of O
ST B-cell_type
patients O
and O
MRD+/LT B-protein
patients O
were O
significantly O
( O
p O
< O
.01 B-protein
) O
low O
. O
The O
CD8+ B-protein
CD28+ B-protein
population O
showed O
the O
same O
tendency O
( O
p O
< O
.01-.02 B-protein
) O
. O
The O
T/NK B-protein
subsets O
in O
the O
BM I-DNA
of O
MRD-negative B-protein
( O
MRD- I-DNA
) O
LT I-cell_line
( O
MRD-/LT B-protein
) O
patients O
showed O
similar O
numbers O
of O
cells I-cell_type
as O
normal O
volunteers O
. O
Basically O
, O
the O
total O
percentage O
of O
the O
CD4+ I-protein
, O
CD8+ O
and O
CD56+ O
cell O
populations O
in O
the O
BM B-protein
was O
increased O
and O
in O
the O
following O
order O
: O
MRD-/LT B-protein
patients O
, O
normal O
volunteers O
, O
MRD+/LT B-protein
patients O
and O
MRD+ B-protein
or O
-/ST B-protein
patients O
. O
The O
percentages O
of O
the O
T/NK-cell O
subsets O
in O
the O
PB B-protein
were O
not O
significantly O
different O
among O
these O
groups O
. O
Thus O
, O
the O
difference O
of O
the O
possible O
T/NK-cell O
phenotype O
in O
the O
BM B-protein
may O
strongly O
influence O
clinical O
and O
molecular O
remission O
. O
These O
results O
still O
remain O
to O
be O
confirmed O
by O
further O
studies O
of O
the O
functional O
anti-tumor B-DNA
immunity O
of O
T/NK B-cell_type
cells I-cell_type
of O
AML B-cell_type
in O
remission O
. O
Mycobacterium B-cell_type
tuberculosis O
mannose-capped O
lipoarabinomannan O
can O
induce O
NF-kappaB O
-dependent O
activation O
of O
human B-cell_type
immunodeficiency I-DNA
virus O
type O
1 O
long I-DNA
terminal I-DNA
repeat I-DNA
in O
T B-cell_type
cells I-cell_type
. O
Tuberculosis O
has O
emerged O
as O
an O
epidemic O
, O
extended O
by O
the O
large O
number O
of O
individuals O
infected O
with O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
( O
HIV-1 B-protein
) O
. O
The O
major O
goal O
of O
this O
study O
was O
to O
determine O
whether O
the O
mycobacterial O
cell O
wall O
component O
mannose-capped O
lipoarabinomannan O
( O
ManLAM I-DNA
) O
of O
Mycobacterium B-cell_type
tuberculosis O
( O
M. B-cell_line
tuberculosis O
) O
could O
activate O
transcription I-DNA
of O
HIV-1 O
in O
T B-cell_type
cells I-cell_type
with O
the O
use O
of O
an O
in O
vitro O
cell O
culture O
system O
. O
These O
experiments O
are O
of O
prime O
importance O
considering O
that O
CD4 B-protein
-expressing O
T I-cell_type
lymphocytes I-cell_type
represent O
the O
major O
virus O
reservoir O
in O
the O
peripheral B-cell_type
blood I-cell_type
of O
infected O
individuals O
. O
Using O
the O
1G5 O
cell O
line O
harbouring O
the O
luciferase O
reporter B-DNA
gene I-DNA
under O
the O
control O
of O
the O
HIV-1 O
LTR I-protein
, O
it O
was O
first O
found O
that O
culture O
protein O
filtrates O
( O
CFP I-DNA
) O
from O
M. B-protein
tuberculosis O
or O
purified O
ManLAM O
could O
activate O
HIV-1 O
LTR-dependent I-DNA
gene I-DNA
expression O
unlike O
similarly O
prepared O
CFP O
extracts O
devoid O
of O
ManLAM B-cell_type
. O
The O
implication O
of O
protein B-protein
tyrosine I-protein
kinase I-protein
( O
s O
) O
, O
protein O
kinase I-protein
A O
and/or I-protein
protein O
kinase I-protein
C I-protein
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM-mediated O
activation O
of O
HIV-1 O
LTR-driven B-DNA
gene I-DNA
expression O
using O
herbimycin O
A O
and O
H7 B-protein
. O
It O
was O
also O
determined O
, O
using O
electrophoresis O
mobility O
shift O
assays O
, O
that O
M. B-protein
tuberculosis O
ManLAM O
led O
to O
the O
nuclear B-protein
translocation O
of O
the O
transcription B-protein
factor I-protein
NF-kappaB B-protein
. O
M. B-protein
tuberculosis O
ManLAM O
resulted O
in O
clear O
induction O
of O
the O
luciferase O
gene I-DNA
placed O
under O
the O
control O
of O
the O
wild-type I-DNA
, O
but O
not O
the O
kappaB-mutated I-DNA
, O
HIV-1 O
LTR O
region O
. O
Finally O
, O
the O
ManLAM-mediated O
activation O
of O
HIV-1 O
LTR O
transcription O
was O
found O
to O
be O
independent O
of O
the O
autocrine O
or O
paracrine O
action O
of O
endogenous O
TNF-alpha B-protein
. O
The O
results O
suggest O
that O
M. B-protein
tuberculosis O
can O
upregulate O
HIV-1 O
expression O
in O
T B-cell_type
cells I-cell_type
and O
could O
thus O
have O
the O
potential O
to O
influence O
the O
pathogenesis O
of O
HIV-1 O
infection O
. O
Human O
immunodeficiency O
virus O
type O
1 O
long I-DNA
terminal I-DNA
repeat I-DNA
quasispecies O
differ O
in O
basal O
transcription I-DNA
and O
nuclear B-protein
factor I-protein
recruitment O
in O
human B-DNA
glial I-cell_type
cells I-cell_type
and I-cell_type
lymphocytes I-cell_type
. O
The O
generation O
of O
genomic O
diversity O
during O
the O
course O
of O
infection O
has O
the O
potential O
to O
affect O
all O
aspects O
of O
HIV-1 O
replication O
, O
including O
expression O
of O
the O
proviral O
genome O
. O
To O
gain O
a O
better O
understanding O
of O
the O
impact O
of O
long I-DNA
terminal I-DNA
repeat I-DNA
( O
LTR I-DNA
) O
sequence O
diversity O
on O
LTR-directed B-DNA
gene I-DNA
expression O
in O
cells I-cell_type
of O
the O
central O
nervous O
system O
( O
CNS I-DNA
) O
and O
immune O
system I-protein
, O
we O
amplified O
and O
cloned O
LTRs O
from O
proviral O
DNA O
in O
HIV-1-infected O
peripheral B-cell_type
blood I-cell_type
. I-cell_type
Sequence O
analysis O
of O
nineteen O
LTRs O
cloned O
from O
2 O
adult O
and O
3 O
pediatric O
patients O
revealed O
an O
average O
of O
33 O
nucleotide O
changes O
( O
with O
respect O
to O
the O
sequence O
of O
the O
LAI O
LTR O
) O
within O
the O
455-bp B-protein
U3 B-protein
region O
. O
Transient O
expression O
analyses O
in O
cells I-cell_type
of O
neuroglial O
and O
lymphocytic O
origin O
demonstrated O
that O
some O
of O
these O
LTRs O
had O
activities O
which O
varied O
significantly O
from O
the O
LAI O
LTR O
in O
U-373 B-protein
MG B-cell_type
cells I-cell_line
( O
an O
astrocytoma O
cell O
line O
) O
as O
well O
as O
in O
Jurkat B-cell_type
cells I-cell_line
( O
a O
CD4-positive B-protein
lymphocyte I-cell_line
cell O
line O
) O
. O
While O
LTRs O
which O
demonstrated O
the O
highest O
activities O
in O
U-373 B-protein
MG B-cell_type
cells I-cell_type
also O
yielded O
high O
activities O
in O
Jurkat B-cell_type
cells I-cell_line
, O
the O
LTRs O
were O
generally O
more O
active O
in O
Jurkat B-cell_type
cells I-cell_type
when O
compared O
to O
the O
LAI O
LTR O
. O
Differences O
in O
LTR O
sequence O
also O
resulted O
in O
differences O
in O
transcription B-protein
factor I-protein
recruitment O
to O
cis-acting B-DNA
sites I-DNA
within O
the O
U3 B-protein
region I-DNA
of O
the O
LTR I-protein
, O
as O
demonstrated O
by O
electrophoretic O
mobility O
shift O
assays O
. O
In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription B-protein
factor I-protein
binding O
to O
an O
activating O
transcription B-protein
factor I-protein
/ O
cAMP I-RNA
response O
element I-DNA
binding O
( O
ATF O
/ O
CREB O
) O
binding O
site O
( O
located O
between O
the O
LEF-1 O
and O
distal O
NF-kappaB B-protein
transcription B-protein
factor I-protein
binding O
sites I-DNA
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV-1 O
LTR O
. O
These O
findings O
suggest O
that O
LTR O
sequence O
changes O
can O
significantly O
affect O
basal O
LTR O
function O
and O
transcription B-protein
factor I-protein
recruitment O
, O
which O
may O
, O
in O
turn O
, O
alter O
the O
course O
of O
viral O
replication O
in O
cells I-cell_type
of O
CNS O
and O
immune O
system O
origin O
. O
HMG O
box O
containing O
transcription B-protein
factors I-protein
in O
lymphocyte I-cell_line
differentiation O
. O
The O
identification O
of O
the O
mammalian O
sex-determining B-DNA
gene I-DNA
Sry O
has O
led O
to O
the O
discovery O
of O
a O
large O
family O
of O
related O
( O
' O
HMG O
box O
' O
) O
transcription B-protein
factors I-protein
that O
control O
developmental O
events O
in O
yeast O
, O
C. B-protein
elegans O
, O
Drosophila O
and O
vertebrates O
. O
In O
lymphocyte I-cell_line
differentiation O
, O
several O
HMG O
box O
proteins I-protein
play O
a O
decisive O
role O
. O
Sox-4 B-protein
is O
important O
for O
very O
early O
B-cell O
differentiation O
, O
while O
TCF-1 O
/ O
LEF-1 O
play O
a O
crucial O
role O
in O
early O
thymocyte O
development O
. O
TCF/LEF B-protein
proteins I-protein
have O
recently O
been O
found O
to O
constitute O
a O
downstream O
component O
of O
the O
Wingless/Wnt O
signal O
transduction O
pathway O
. O
In O
flies O
, O
this O
pathway O
controls O
segment O
polarity O
; O
in O
Xenopus O
it O
controls O
the O
definition O
of O
the O
body O
axis O
. O
Deregulation O
of O
the O
pathway O
occurs O
in O
several O
human B-DNA
tumors I-cell_type
. O
These O
insights O
in O
the O
molecular O
events O
that O
are O
involved O
in O
TCF/LEF B-protein
function O
in O
these O
organisms O
may O
eventually O
lead O
to O
the O
understanding O
of O
the O
function O
of O
these O
HMG O
box O
proteins I-protein
in O
lymphoid O
development O
Transcriptional O
regulation O
by O
C/EBP I-DNA
alpha I-DNA
and I-DNA
-beta O
in O
the O
expression O
of O
the O
gene I-DNA
for O
the O
MRP14 B-protein
myeloid O
calcium O
binding O
protein O
. O
Transcriptional O
regulation O
of O
the O
gene I-DNA
for O
the O
myeloid O
calcium O
binding O
protein O
, O
MRP14 I-protein
, O
was O
investigated O
in O
human O
monocytic B-cell_line
leukemia O
cell O
lines I-cell_line
. O
The O
MRP14 B-DNA
gene I-DNA
was O
not O
expressed O
in O
monoblastic O
ML-1 B-protein
cells I-cell_line
, O
promonocytic O
U-937 B-protein
cells I-cell_line
, O
or O
promyelocytic O
HL-60 B-protein
cells I-cell_type
. O
On O
the O
other O
hand O
, O
the O
gene I-DNA
was O
expressed O
in O
monocytic B-cell_line
THP-1 B-DNA
cells I-cell_type
and O
in O
the O
HL-60 B-protein
cells I-cell_type
treated O
with O
1 O
, O
25-dihydroxyvitamin O
D3 B-protein
( O
VD3 B-protein
) O
. O
The O
level O
of O
MRP14 B-protein
in O
VD3-treated B-protein
HL-60 B-protein
cells I-cell_type
was O
two-fold B-DNA
higher O
than O
that O
in O
THP-1 B-DNA
cells I-cell_type
. O
Among O
several O
known O
transcription B-protein
factor I-protein
binding O
motifs O
, O
nuclear O
protein I-protein
( O
s O
) O
of O
VD3-treated B-protein
HL-60 B-protein
cells I-cell_type
and O
THP-1 B-cell_type
cells I-cell_type
bound O
to O
the O
CCAAT/enhancer O
binding O
protein O
( O
C/EBP I-DNA
) O
-binding O
motif O
that O
was O
located O
in O
the O
upstream O
region I-DNA
of O
the O
MRP14 B-DNA
gene I-DNA
( O
-81 B-protein
) O
, O
as O
evidenced O
by O
the O
competitive O
gel O
mobility-shift O
assay O
. O
An O
antibody O
for O
C/EBP I-DNA
alpha I-DNA
super-shifted I-DNA
the O
nucleoprotein O
complex I-protein
in O
THP-1 B-DNA
cells I-cell_type
but O
not O
in O
the O
VD3-treated B-protein
HL-60 B-protein
cells I-cell_line
, O
whereas O
an O
antibody O
for O
C/EBP B-protein
beta O
blocked O
the O
formation O
of O
the O
complex I-protein
with O
the O
nuclear B-protein
factor I-protein
of O
the O
HL-60 B-protein
cells I-cell_type
but O
not O
with O
that O
of O
THP-1 B-cell_type
cells I-cell_type
. O
An O
anti-C/EBP O
delta O
antibody O
had O
no O
effect O
on O
the O
complex I-protein
in O
either O
cell O
. O
Thus O
, O
it O
was O
concluded O
that O
C/EBP I-DNA
alpha I-DNA
and I-DNA
-beta O
were O
able O
to O
bind O
to O
the O
C/EBP B-protein
motif O
, O
and O
that O
C/EBP I-DNA
alpha I-DNA
bound O
to O
the O
motif O
in O
THP-1 B-DNA
cells I-cell_type
and O
C/EBP B-protein
beta O
bound O
to O
that O
in O
the O
VD3-treated B-protein
HL-60 B-protein
cells I-cell_type
. O
Furthermore O
, O
to O
examine O
the O
transcriptional O
activity O
of O
the O
C/EBP B-protein
motif O
, O
we O
transfected O
several O
constructed O
luciferase O
reporter O
DNAs O
into O
HL-60 B-protein
cells I-cell_type
and O
THP-1 B-cell_type
cells I-cell_type
. O
The O
luciferase O
activity O
of O
the O
C/EBP B-protein
motif O
in O
HL-60 B-protein
cells I-cell_type
was O
increased O
by O
VD3 B-protein
treatment O
. O
The O
C/EBP B-protein
motif O
in O
the O
MRP14 B-DNA
gene I-DNA
was O
confirmed O
to O
function O
as O
a O
regulatory O
region O
in O
VD3-treated B-protein
HL-60 B-protein
cells I-cell_type
and O
THP-1 B-cell_type
cells I-cell_type
by O
the O
assay O
. O
Since O
C/EBP B-protein
beta O
was O
also O
detected O
in O
VD3-untreated B-protein
HL-60 B-protein
cells I-cell_type
by O
immunoblotting O
, O
VD3 B-protein
activated O
C/EBP B-protein
beta O
to O
bind O
to O
the O
motif O
, O
probably O
through O
post-translational O
modification O
. O
Patients O
with O
high-risk B-DNA
myelodysplastic O
syndrome O
can O
have O
polyclonal O
or O
clonal O
haemopoiesis O
in O
complete O
haematological O
remission O
. O
The O
clonality O
of O
mature O
peripheral B-cell_type
blood-derived B-protein
myeloid O
and O
lymphoid B-cell_type
cells I-cell_type
and O
bone B-cell_type
marrow I-cell_line
haemopoietic O
progenitors O
from O
18 O
females O
with O
myelodysplasia O
( O
MDS I-DNA
) O
( O
five O
refractory O
anaemia O
, O
RA O
; O
one O
RA B-protein
with O
ringed O
sideroblasts O
, O
RARS O
; O
three O
chronic O
myelomonocytic O
leukaemia O
, O
CMML O
; O
four O
RA B-protein
with O
excess O
of O
blasts O
, O
RAEB O
; O
five O
RAEB O
in O
transformation O
, O
RAEB-t B-protein
) O
was O
studied O
by O
X-chromosome B-protein
inactivation O
analysis O
. O
Using O
the O
human B-DNA
androgen-receptor I-cell_type
( O
HUMARA I-DNA
) O
assay O
, O
we O
analysed O
the O
clonal O
patterns O
of O
highly O
purified O
immature O
CD34+ B-protein
38- O
and O
committed O
CD34+ B-protein
38+ O
marrow-derived I-cell_type
progenitors O
, O
and O
CD16+ B-protein
14- B-protein
granulocytes O
, O
CD14+ O
monocytes B-cell_type
, O
CD3+ B-cell_type
T I-cell_line
and O
CD19+ B-protein
B I-DNA
lymphocytes I-cell_type
from O
peripheral B-cell_type
blood I-cell_type
. I-cell_type
In O
high-risk B-DNA
patients O
( O
RAEB I-DNA
, O
RAEB-t B-protein
) O
, O
clonality O
analysis O
was O
performed O
before O
and O
after O
intensive O
remission-induction B-DNA
treatment O
. O
All O
patients O
, O
except O
one O
with O
RA I-protein
, O
had O
predominance O
of O
a O
single O
clone O
in O
their O
granulocytes O
and O
monocytes B-cell_type
. O
The O
same O
clonal O
pattern O
was O
found O
in O
CD34+ B-protein
progenitor I-cell_type
cells I-cell_type
. O
In O
contrast O
, O
CD3+ B-cell_type
T I-cell_type
lymphocytes I-cell_type
were O
polyclonal O
or O
oligoclonal O
in O
14/18 O
patients O
. O
X-chromosome B-protein
inactivation O
patterns O
of O
CD19+ B-protein
B I-DNA
cells I-cell_type
were O
highly O
concordant O
with O
CD3+ B-cell_type
T B-cell_type
cells I-cell_type
except O
for O
two O
patients O
( O
one O
RA I-protein
, O
one O
CMML O
) O
with O
monoclonal B-protein
B I-DNA
and O
polyclonal O
T I-cell_type
lymphocytes I-cell_type
, O
therefore O
suggesting O
a O
clonal O
mutation O
in O
a O
progenitor O
common O
to O
the O
myeloid O
and O
B-lymphoid B-protein
lineages O
or O
the O
coexistence O
of O
MDS O
and O
a O
B-cell O
disorder O
in O
these O
particular O
patients O
. O
After O
high-dose B-DNA
non-myeloablative B-DNA
chemotherapy O
, O
polyclonal O
haemopoiesis O
was O
reinstalled O
in O
the O
mature O
myeloid B-cell_type
cells I-cell_type
and O
immature O
and O
committed O
marrow I-cell_line
progenitors O
in O
three O
of O
four O
patients O
achieving O
complete O
haematological O
remission O
. O
Therefore O
we O
conclude O
that O
most O
haematological O
remissions O
in O
MDS O
are O
associated O
with O
restoration O
of O
polyclonal O
haemopoiesis O
. O
Prominent O
sex O
steroid O
metabolism O
in O
human I-cell_type
lymphocytes I-cell_type
. O
Steroid O
metabolism O
was O
investigated O
in O
cultured O
human B-DNA
B-lymphoblastoid I-cell_type
cells I-cell_line
( O
B-LCL B-protein
) O
, O
and O
peripheral B-cell_type
blood I-cell_type
T I-cell_type
and O
B I-DNA
cells I-cell_type
. O
Gene O
expression O
was O
examined O
by O
reverse-transcription O
polymerase O
chain O
reaction O
amplification O
( O
RT-PCR B-protein
) O
. O
Appropriate O
sized I-RNA
transcripts I-RNA
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral I-cell_type
lymphocytes I-cell_type
for O
CYP11A I-protein
, O
CYP17 I-protein
, O
HSD11L B-protein
( O
11beta-hydroxysteroid O
dehydrogenase B-protein
I I-protein
) O
, O
HSD17B1 I-protein
( O
17beta-hydroxysteroid O
dehydrogenase I-DNA
type O
I I-DNA
) O
and O
SRD5A1 B-protein
( O
5alpha-reductase B-protein
I I-protein
) O
. O
B-LCL I-DNA
, O
but O
not O
T I-cell_line
and O
B I-DNA
cells I-cell_line
, O
expressed O
CYP11B B-protein
. O
There O
was O
minimal O
expression O
of O
HSD3B1 B-protein
and O
HSD3B2 B-protein
( O
3beta-hydroxysteroid B-protein
dehydrogenase B-protein
I I-protein
and O
II B-protein
) O
in O
B-LCL B-protein
and O
T B-cell_type
cells I-cell_type
. O
Transcripts O
for O
CYP19 B-protein
and O
HSD11K B-protein
were O
not O
detected O
. O
Corresponding B-cell_type
enzymatic O
activity O
was O
detectable O
only O
for O
17-hydroxysteroid B-DNA
dehydrogenase O
and O
5alpha-reductase O
, O
respectively O
producing O
testosterone O
and O
5alpha-dihydrotestosterone B-protein
. O
Steroid O
identities O
were O
confirmed O
by O
gas O
chromatography/mass I-cell_line
spectrometry O
( O
GC/MS B-protein
) O
. O
One O
metabolite O
thought O
to O
be O
deoxycorticosterone O
was O
identified O
by O
GC/MS B-protein
as O
6alpha-hydroxypregnanolone B-protein
. O
It O
was O
concluded O
that O
sex O
hormone O
metabolism O
, O
including O
androgen O
synthesis O
, O
occurs O
in I-cell_type
lymphocytes I-cell_type
, O
and O
may O
modulate O
immune O
response O
. O
Human O
white O
blood I-cell_type
cells I-cell_type
and O
hair O
follicles O
are O
good O
sources O
of O
mRNA I-RNA
for O
the O
pterin O
carbinolamine O
dehydratase/dimerization B-DNA
cofactor O
of O
HNF1 B-protein
for O
mutation O
detection O
. O
Pterin O
carbinolamine O
dehydratase/dimerization B-DNA
cofactor O
of O
HNF1 B-protein
( O
PCD/DCoH I-DNA
) O
is O
a O
protein O
that O
has O
a O
dual O
function O
. O
It O
is O
a O
pterin O
4alpha-carbinolamine B-protein
dehydratase O
that O
is O
involved O
in O
the O
regeneration O
of O
the O
cofactor O
tetrahydrobiopterin O
during O
the O
phenylalanine O
hydroxylase- B-DNA
catalyzed O
hydroxylation O
of O
phenylalanine O
. O
In O
addition O
, O
it O
is O
the O
dimerization O
cofactor O
of O
HNF1 B-protein
that O
is O
able O
to O
activate O
the O
transcriptional O
activity O
of O
HNF1 B-protein
. O
Deficiencies O
in O
the O
gene I-DNA
for O
this O
dual O
functional O
protein O
result O
in O
hyperphenylalaninemia O
. O
Here O
we O
report O
for O
the O
first O
time O
that O
the O
PCD/DCoH I-RNA
mRNA I-RNA
is O
present O
in O
human B-DNA
white I-cell_type
blood I-cell_type
cells I-cell_type
and O
hair O
follicles O
. O
Taking O
advantage O
of O
this O
finding O
, O
a O
sensitive O
, O
rapid O
and O
convenient O
method O
for O
screening O
mutations O
occurring O
in O
the O
coding O
region I-DNA
of O
this O
gene I-DNA
has O
been O
described O
. O
Copyright O
1998 O
Academic O
Press O
. O
Biochemical O
characterization O
of O
the O
NF-Y B-protein
transcription B-protein
factor I-protein
complex I-protein
during O
B I-DNA
lymphocyte I-cell_line
development O
. O
The O
transcription B-protein
factor I-protein
, O
NF-Y I-protein
, O
plays O
a O
critical O
role O
in O
tissue-specific O
major O
histocompatibility I-protein
complex I-protein
class I-protein
II B-DNA
gene I-DNA
transcription O
. I-RNA
In O
this O
report O
the O
biochemical O
properties O
of O
the O
heterotrimeric O
NF-Y B-protein
complex I-protein
have O
been O
characterized O
during O
stage-specific O
B-cell O
development O
, O
and O
in O
several O
class B-protein
II- B-protein
mutant O
B-cell B-cell_line
lines I-cell_line
, O
which O
represent O
distinct O
bare O
lymphocyte I-cell_line
syndrome O
class I-protein
II I-protein
genetic O
complementation O
groups O
. O
The O
NF-Y B-protein
complex I-protein
derived O
from O
class B-protein
II+ B-protein
mature O
B-cells B-protein
bound O
with O
high O
affinity O
to O
anion O
exchangers O
, O
and O
eluted O
as O
an O
intact O
trimeric O
complex I-protein
, O
whereas O
, O
NF-Y B-protein
derived O
from O
class B-protein
II- B-protein
plasma O
B-cells I-protein
, O
and O
from O
bare O
lymphocyte I-cell_line
syndrome O
group O
II O
cell O
lines I-cell_line
, O
RJ2.2.5 I-protein
and O
RM3 B-protein
, O
dissociated O
into O
discrete O
NF-YA B-protein
and O
NF-YB B-protein
: O
C I-protein
subunit O
fractions O
. O
Recombination I-DNA
of O
the O
MPC11 B-protein
plasma O
B-cell O
derived O
NF-Y B-protein
A O
: O
B I-DNA
: O
C I-protein
complex I-protein
with O
the O
low O
molecular O
mass O
protein O
fraction I-protein
, O
NF-Y-associated B-protein
factors I-protein
( O
YAFs O
) O
, O
derived O
from O
mature O
A20 B-protein
B-cell O
nuclei I-protein
, O
conferred O
high O
affinity O
anion O
exchange O
binding O
to O
NF-Y B-protein
as O
an O
intact O
trimeric O
complex I-protein
. O
Recombination I-DNA
of O
the O
native O
NF-YA B-protein
: O
B I-DNA
: O
C I-protein
complex I-protein
with O
the O
transcriptional O
cofactor O
, O
PC4 B-protein
, O
likewise O
conferred O
high O
affinity O
NF-Y B-protein
binding O
to O
anion O
exchangers O
, O
and O
stabilized O
NF-Y B-protein
interaction O
with O
CCAAT-box B-protein
DNA O
motifs O
in O
vitro O
. O
Interaction O
between O
PC4 B-protein
and O
NF-Y B-protein
was O
mapped O
to O
the O
C-terminal B-protein
region I-DNA
of O
PC4 B-protein
, O
and O
the O
subunit O
interaction O
subdomain O
of O
the O
highly O
conserved O
DNA O
binding-subunit O
interaction I-protein
domain I-protein
( O
DBD I-DNA
) O
of O
NF-YA B-protein
. O
These O
results O
suggest O
that O
in O
class B-protein
II+ B-protein
mature O
B-cells B-protein
NF-Y B-protein
is O
associated O
with O
the O
protein O
cofactor I-protein
, O
PC4 B-protein
, O
which O
may O
play O
an O
important O
role O
in O
NF-Y-mediated O
transcriptional O
control O
of O
class I-protein
II I-protein
genes I-DNA
. O
Arrest O
of O
B I-DNA
lymphocyte I-cell_line
terminal I-DNA
differentiation O
by O
CD40 B-protein
signaling O
: O
mechanism O
for O
lack O
of O
antibody-secreting B-cell_type
cells I-cell_type
in O
germinal O
centers O
. O
Despite O
extensive O
research O
, O
the O
role O
of O
CD40 B-protein
signaling O
in O
B O
cell O
terminal O
differentiation O
remains O
controversial O
. O
Here O
we O
show O
that O
CD40 B-protein
engagement O
arrests O
B O
cell O
differentiation O
prior O
to O
plasma O
cell O
formation O
. O
This O
arrest O
is O
manifested O
at O
a O
molecular O
level O
as O
a O
reduction O
in O
mRNA I-RNA
levels O
of O
secretory O
immunoglobulin O
gene I-DNA
products O
such O
as O
mu O
( O
s O
) O
and O
J O
chain O
as O
well O
as O
the O
loss O
of O
the O
transcriptional O
regulator O
BLIMP-1 B-protein
. O
Furthermore O
, O
the O
inhibition O
of O
B O
cell O
differentiation O
by O
CD40 B-protein
engagement O
could O
not O
be O
overcome O
by O
either O
mitogens O
or O
cytokines O
, O
but O
could O
be O
reversed O
by O
antibodies I-protein
that O
interfere O
with O
the O
CD40 B-protein
/ O
gp39 I-protein
interaction O
. O
These O
data O
suggest O
that O
secretory O
immunoglobulin O
is O
not O
produced O
by O
B I-DNA
cells I-cell_type
that O
are O
actively O
engaged O
by O
gp39-expressing O
T B-cell_type
cells I-cell_type
. O
A O
positively O
charged O
alpha-lipoic O
acid O
analogue O
with O
increased O
cellular O
uptake O
and O
more O
potent O
immunomodulatory O
activity O
. O
alpha-Lipoic O
acid O
( O
LA I-DNA
) O
is O
taken O
up O
by O
cells I-cell_type
and O
reduced O
to O
its O
potent O
dithiol O
form O
, O
dihydrolipoate O
( O
DHLA I-DNA
) O
, O
much O
of O
which O
is O
rapidly O
effluxed O
out O
from B-cell_type
cells I-cell_type
. O
To O
improve O
retention O
in O
cells I-cell_line
, O
the O
LA B-protein
molecule O
was O
modified O
to O
confer O
a O
positive O
charge O
at O
physiological O
pH I-RNA
. O
N O
, O
N-dimethyl B-protein
, O
N'-2-amidoethyl-lipoate B-protein
was O
synthesized O
. O
The O
protonated O
form O
of O
the O
new O
molecule O
is O
referred O
to O
as O
LA-Plus O
. O
The O
uptake O
of O
LA-Plus O
by O
human B-DNA
Wurzburg B-cell_type
T B-cell_type
cells I-cell_type
was O
higher O
compared O
to O
that O
of O
LA B-cell_type
. O
Several-fold O
higher O
amounts O
of O
DHLA-Plus O
, O
the O
corresponding O
reduced O
form O
of O
LA-Plus O
, O
were O
detected O
in O
LA-Plus O
treated B-cell_type
cells I-cell_type
compared O
to O
the O
amount O
of O
DHLA O
found O
in O
cells I-cell_type
treated O
with O
LA B-protein
. O
At O
100 O
microM I-protein
, O
LA O
did O
not O
but O
LA-Plus O
inhibited O
H2O2 B-protein
induced O
NF-kappaB O
activation O
and O
NF-kappaB O
directed O
IL-2 B-DNA
receptor I-protein
expression O
. O
Both O
LA O
and O
LA-Plus O
synergised O
with O
selenium O
in O
inhibiting O
H2O2 B-protein
induced O
NF-kappaB O
activation O
. O
At O
150 O
microM I-RNA
LA-Plus O
, O
but O
not O
LA I-protein
, O
inhibited O
TNFalpha O
induced O
NF-kappaB O
activation O
. O
At O
5 O
microM I-RNA
LA-Plus O
, O
but O
not O
LA I-protein
, O
protected O
against O
both O
spontaneous O
and O
etoposide O
induced O
apoptosis O
in O
rat O
thymocytes O
. O
LA-Plus O
is O
thus O
an O
improved O
form O
of O
LA B-cell_type
with O
increased O
therapeutic O
potential O
. O
Copyright O
1998 O
Academic O
Press O
. O
Carrier O
identification O
in O
X-linked B-protein
immunodeficiency O
diseases O
. O
OBJECTIVE O
: O
Carrier O
identification O
in O
X-linked B-protein
immunodeficiency O
disorders O
can O
be O
based O
on O
the O
demonstration O
of O
non-random B-DNA
X O
inactivation O
( O
NRXI I-DNA
) O
in O
affected O
blood O
cell I-cell_type
lineages O
when O
growth O
is O
impaired O
in O
cells I-cell_type
expressing O
the O
abnormal B-DNA
gene I-DNA
. O
We O
examined O
the O
utility O
of O
seeking O
evidence O
of O
NRXI O
to O
test O
the O
carrier O
status O
of O
women O
in O
families O
affected O
by O
X-linked B-protein
severe O
combined O
immunodeficiency O
( O
XSCID I-DNA
) O
and O
X-linked B-protein
hypogammaglobulinaemia O
( O
XLH I-DNA
) O
, O
to O
identify O
as O
carriers O
the O
mothers O
of O
boys O
with O
SCID O
or O
hypogammaglobulinaemia O
whose O
phenotype O
suggested O
X-linkage B-DNA
and O
to O
infer O
X-linkage B-protein
in O
boys O
with O
SCID O
or O
hypogammaglobulinaemia O
whose O
disease O
was O
not O
clearly O
X-linked B-protein
on O
the O
basis O
either O
of O
family O
history O
or O
clinical O
and O
immunological O
characteristics O
. O
METHODOLOGY I-protein
: O
A O
polymerase O
chain O
reaction-based O
method O
was O
used O
to O
amplify O
a O
polymorphic O
CAG O
repeat O
in O
the O
first O
exon O
of O
the O
androgen I-DNA
receptor I-DNA
gene I-DNA
after O
selective O
digestion O
of O
the O
active O
X O
chromosome O
with O
a O
methylation-sensitive O
enzyme I-protein
, O
HpaII O
to O
distinguish O
between O
the O
paternal O
and O
maternal O
alleles O
and O
to O
identify O
their O
methylation O
status O
. O
RESULTS I-protein
: O
Heterozygosity O
was O
found O
in O
24 O
of O
31 O
female O
subjects O
( O
77 O
% O
) O
. O
As O
anticipated O
, O
NRXI O
could O
be O
demonstrated O
in O
all O
lymphoid B-cell_type
cells I-cell_type
studied O
from O
obligate O
carriers O
of O
XSCID O
and O
an O
obligate O
carrier O
of O
XLH B-cell_type
but O
not O
on O
a O
carrier O
of O
X-linked B-protein
immunodeficiency O
with O
hyper-IgM O
. O
The O
finding O
of O
NRXI O
in O
the O
mother O
of O
a O
boy O
with O
a O
SCID O
variant O
showed O
her O
to O
be O
a O
carrier O
of O
XSCID O
and O
establishes O
that O
her O
son O
has O
XSCID I-protein
, O
not O
otherwise O
evident O
from O
available O
data O
. O
CONCLUSIONS I-protein
: O
This O
PCR O
assay O
provides O
a O
rapid O
method O
for O
carrier O
detection O
of O
X-linked B-protein
immunodeficiencies I-protein
, O
and O
has O
allowed O
us O
to O
expand O
the O
phenotype O
of O
XSCID O
Leukocyte-endothelial O
interaction O
is O
augmented O
by O
high O
glucose O
concentrations O
and O
hyperglycemia O
in O
a O
NF-kB-dependent O
fashion O
. O
We O
addressed O
the O
role O
of O
hyperglycemia O
in O
leukocyte-endothelium O
interaction O
under O
flow O
conditions O
by O
exposing O
human B-DNA
umbilical I-cell_type
vein O
endothelial B-cell_type
cells I-cell_type
for O
24 O
h O
to O
normal O
( O
5 O
mM O
) O
, O
high O
concentration O
of O
glucose O
( O
30 O
mM O
) O
, O
advanced O
glycosylation O
end O
product-albumin O
( O
100 O
microg/ml I-DNA
) O
, O
or O
hyperglycemic O
( O
174-316 O
mg/dl I-DNA
) O
sera O
from O
patients O
with O
diabetes O
and O
abnormal O
hemoglobin O
A1c I-cell_line
( O
8.1+/-1.4 B-protein
% O
) O
. O
At O
the O
end O
of O
incubation O
endothelial B-cell_type
cells I-cell_type
were O
perfused O
with O
total O
leukocyte O
suspension O
in O
a O
parallel O
plate O
flow O
chamber O
under O
laminar O
flow O
( O
1.5 B-protein
dyn/cm2 B-protein
) O
. O
Rolling O
and O
adherent B-cell_type
cells I-cell_type
were O
evaluated O
by O
digital O
image O
processing O
. O
Results O
showed O
that O
30 O
mM I-RNA
glucose O
significantly O
( O
P O
< O
0.01 B-protein
) O
increased O
the O
number O
of O
adherent O
leukocytes O
to O
endothelial B-cell_type
cells I-cell_type
in O
respect O
to O
control O
( O
5 O
mM I-RNA
glucose O
; O
151+/-19 O
versus O
33+/-8 O
cells/mm2 B-protein
) O
. O
A O
similar O
response O
was O
induced O
by O
endothelial O
stimulation O
with O
IL-1beta O
, O
here O
used O
as O
positive O
control O
( O
195+/-20 O
cells/mm2 B-protein
) O
. O
The O
number O
of O
rolling B-cell_type
cells I-cell_type
on O
endothelial O
surface I-protein
was O
not O
affected O
by O
high O
glucose O
level O
. O
Stable O
adhesion O
of O
leukocytes O
to O
glucose-treated O
as O
well O
as O
to O
IL-1beta-stimulated B-protein
endothelial B-cell_type
cells I-cell_type
was O
preceded O
by O
short O
interaction O
of O
leukocytes O
with O
the O
endothelial O
surface I-protein
. O
The O
distance O
travelled O
by O
leukocytes O
before O
arrest O
on O
30 O
mM I-RNA
glucose O
, O
or O
on O
IL-1beta-treated O
endothelial B-cell_type
cells I-cell_line
, O
was O
significantly O
( O
P O
< O
0.01 B-protein
) O
higher O
than O
that O
observed O
for O
leukocytes O
adhering O
on O
control O
endothelium O
( O
30 O
mM I-RNA
glucose O
: O
76.7+/-3.5 B-protein
; O
IL1beta O
: O
69.7+/-4 B-protein
versus O
5 O
mM I-RNA
glucose O
: O
21.5+/-5 B-protein
microm O
) O
. O
Functional O
blocking O
of O
E-selectin B-protein
, O
intercellular O
cell O
adhesion O
molecule-1 B-protein
, O
and O
vascular O
cell O
adhesion O
molecule-1 B-protein
on O
endothelial B-cell_type
cells I-cell_type
with O
the O
corresponding O
mouse B-DNA
mAb I-protein
significantly O
inhibited O
glucose-induced O
increase O
in O
leukocyte O
adhesion O
( O
67+/-16 O
, O
83+/-12 O
, O
62+/-8 O
versus O
144+/-21 O
cells/ B-DNA
mm2 B-protein
) O
. O
Confocal O
fluorescence O
microscopy O
studies O
showed O
that O
30 O
mM I-RNA
glucose O
induced O
an O
increase O
in O
endothelial O
surface I-protein
expression O
of O
E-selectin B-protein
, O
intercellular O
cell O
adhesion O
molecule-1 B-protein
, O
and O
vascular O
cell O
adhesion O
molecule-1 B-protein
. O
Electrophoretic O
mobility O
shift O
assay O
of O
nuclear B-protein
extracts O
of O
human B-cell_type
umbilical I-cell_type
vein O
endothelial B-cell_type
cells I-cell_line
( O
HUVEC I-DNA
) O
exposed O
for O
1 O
h O
to O
30 O
mM I-RNA
glucose O
revealed O
an O
intense O
NF-kB O
activation O
. O
Treatment O
of O
HUVEC O
exposed O
to O
high O
glucose O
with O
the O
NF-kB O
inhibitors O
pyrrolidinedithiocarbamate O
( O
100 O
microM B-protein
) O
and O
tosyl-phe-chloromethylketone B-protein
( O
25 O
microM B-protein
) O
significantly O
reduced O
( O
P O
< O
0.05 B-protein
) O
leukocyte O
adhesion O
in O
respect O
to O
HUVEC O
treated O
with O
glucose O
alone O
. O
A O
significant O
( O
P O
< O
0.01 B-protein
) O
inhibitory O
effect O
on O
glucose-induced O
leukocyte O
adhesion O
was O
observed O
after O
blocking O
protein O
kinase I-protein
C I-protein
activity O
with O
staurosporine O
( O
5 O
nM O
) O
. O
When O
HUVEC O
were O
treated O
with O
specific O
antisense O
oligodesoxynucleotides O
against O
PKCalpha O
and O
PKCepsilon O
isoforms O
before O
the O
addition O
of O
30 O
mM I-RNA
glucose O
, O
a O
significant O
( O
P O
< O
0.05 B-protein
) O
reduction O
in O
the O
adhesion O
was O
also O
seen O
. O
Advanced O
glycosylation O
end O
product-albumin O
significantly O
increased O
the O
number O
of O
adhering O
leukocytes O
in O
respect O
to O
native O
albumin O
used O
as O
control O
( O
110+/-16 O
versus O
66+/-7 O
, O
P O
< O
0.01 B-protein
) O
. O
Sera O
from O
diabetic O
patients O
significantly O
( O
P O
< O
0.01 B-protein
) O
enhanced O
leukocyte O
adhesion O
as O
compared O
with O
controls O
, O
despite O
normal O
levels O
of O
IL-1beta O
and O
TNFalpha O
in O
these O
sera O
. O
These O
data O
indicate O
that O
high O
glucose O
concentration O
and O
hyperglycemia O
promote O
leukocyte O
adhesion O
to O
the O
endothelium O
through O
upregulation O
of O
cell O
surface I-protein
expression O
of O
adhesive O
proteins I-protein
, O
possibly O
depending O
on O
NF-kB O
activation O
. O
Ikaros O
in O
hemopoietic O
lineage O
determination O
and O
homeostasis O
. O
Studies O
on O
the O
molecular O
mechanisms O
that O
control O
hemopoietic O
differentiation O
have O
focused O
on O
signaling O
cascades O
and O
nuclear B-protein
effectors O
that O
drive O
this O
complex I-protein
developmental O
system O
in O
a O
regulated O
fashion O
. O
Here O
we O
review O
the O
role O
of O
Ikaros O
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc O
finger O
transcription B-protein
factors I-protein
in O
this O
developmental O
process O
. O
Studies O
on O
an O
Ikaros O
null O
mutation O
have O
revealed O
an O
essential O
role O
for O
this O
factor I-protein
in O
lymphoid O
cell O
fate O
determination O
and O
at O
subsequent O
branch O
points O
of O
the O
T O
cell O
differentiation O
pathway O
. O
Differences O
in O
the O
phenotypes O
of O
a O
null O
and O
a O
dominant O
negative O
( O
DN I-DNA
) O
Ikaros O
mutation O
provide O
insight O
into O
a O
regulatory O
network O
through O
which O
Ikaros O
proteins I-protein
exert O
their O
effects O
in O
development O
. O
In O
addition O
a O
comparative O
analysis O
of O
the O
hemopoietic O
stem O
cell O
and O
precursor O
compartment O
resulting O
from O
the O
two O
Ikaros O
mutations O
reveals O
a O
profound O
yet O
not O
absolute O
requirement O
for O
Ikaros O
Induction O
of O
early O
B O
cell O
factor I-protein
( O
EBF I-DNA
) O
and O
multiple O
B O
lineage I-DNA
genes I-DNA
by O
the O
basic O
helix-loop-helix B-protein
transcription B-protein
factor I-protein
E12 B-protein
. O
The O
transcription B-protein
factors I-protein
encoded O
by O
the O
E2A B-protein
and O
early O
B O
cell O
factor I-protein
( O
EBF I-DNA
) O
genes I-DNA
are O
required O
for O
the O
proper O
development O
of O
B I-DNA
lymphocytes I-cell_type
. O
However O
, O
the O
absence O
of O
B O
lineage I-cell_type
cells I-cell_type
in O
E2A- B-DNA
and O
EBF-deficient B-protein
mice O
has O
made O
it O
difficult O
to O
determine O
the O
function O
or O
relationship O
between O
these O
proteins I-protein
. O
We O
report O
the O
identification O
of O
a O
novel O
model O
system O
in O
which O
the O
role O
of O
E2A B-protein
and O
EBF O
in O
the O
regulation O
of O
multiple O
B O
lineage O
traits O
can O
be O
studied O
. O
We O
found O
that O
the O
conversion O
of O
70Z/3 B-cell_type
pre-B I-cell_type
lymphocytes I-cell_type
to O
cells I-cell_type
with O
a O
macrophage-like O
phenotype O
is O
associated O
with O
the O
loss O
of O
E2A B-protein
and O
EBF O
. O
Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B-protein
protein O
E12 B-protein
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many O
B O
lineage I-DNA
genes I-DNA
, O
including O
EBF I-protein
, O
IL7Ralpha O
, O
lambda5 I-protein
, O
and O
Rag-1 B-protein
, O
and O
the O
ability O
to O
induce O
kappa B-DNA
light O
chain O
in O
response O
to O
mitogen O
. O
Activation O
of O
EBF B-cell_type
may O
be O
one O
of O
the O
critical O
functions O
of O
E12 B-protein
in O
regulating O
the O
B O
lineage O
phenotype O
since O
expression O
of O
EBF B-cell_type
alone O
leads O
to O
the O
activation O
of O
a O
subset O
of O
E12 B-protein
-inducible O
traits O
. O
Our O
data O
demonstrate O
that O
, O
in O
the O
context O
of O
this O
macrophage O
line O
, O
E12 B-protein
induces O
expression O
of O
EBF O
and O
together O
these O
transcription B-protein
factors I-protein
coordinately O
regulate O
numerous O
B I-DNA
lineage-associated I-DNA
genes I-DNA
. O
Activation-induced O
down-regulation O
of O
retinoid I-DNA
receptor I-protein
RXRalpha O
expression O
in O
human B-cell_type
T I-cell_type
lymphocytes I-cell_type
. O
Role O
of O
cell O
cycle O
regulation O
. O
A O
5.4-kilobase I-RNA
mRNA I-RNA
, O
the O
expression O
of O
which O
is O
down-regulated O
after O
treatment O
of O
human B-cell_type
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_line
( O
PBMCs O
) O
with O
various O
T I-cell_line
cell-activating O
agents O
, O
was O
isolated O
using O
an O
mRNA I-RNA
differential O
display O
method O
. O
Nucleotide O
sequence O
analysis O
identified O
the O
5 O
' O
end O
of O
this O
RNA O
as O
human B-DNA
retinoid I-DNA
receptor I-protein
RXRalpha I-RNA
mRNA I-RNA
. O
Here O
, O
we O
report O
the O
nucleotide O
sequence O
of O
3.6 B-cell_type
kilobases O
of O
this O
RNA I-protein
, O
which O
represents O
the O
3 O
' O
end O
of O
RXRalpha I-RNA
mRNA I-RNA
, O
the O
sequence O
of O
which O
has O
not O
been O
previously O
described O
. O
Activated O
PBMCs O
also O
expressed O
lower O
levels O
of O
RXRalpha O
protein I-protein
, O
and O
a O
DNA O
binding O
assay O
showed O
that O
the O
activation-induced O
loss O
of O
RXRalpha I-RNA
mRNA I-RNA
and O
protein O
expression O
correlated O
with O
the O
loss O
of O
DNA O
binding O
activity O
of O
this O
protein O
. O
We O
present O
evidence O
that O
the O
transition O
from O
G0/G1 O
to O
S O
phase O
of O
the O
cell O
cycle O
results O
in O
the O
down-regulation O
of O
RXRalpha O
expression O
and O
that O
cell O
cycle O
inhibitors O
, O
which O
block O
the B-cell_type
cells I-cell_type
in O
G1 B-protein
phase O
, O
prevent O
this O
down-regulation O
. O
The O
decrease O
in O
the O
levels O
of O
RXRalpha I-RNA
mRNA I-RNA
was O
found O
to O
be O
regulated O
at O
the O
post-transcriptional B-DNA
level O
and O
involved O
new O
protein O
synthesis O
. O
These O
observations O
indicate O
that O
the O
levels O
of O
RXRalpha O
expression O
in O
T I-cell_type
lymphocytes I-cell_type
are O
coupled O
to O
cell O
cycle O
progression O
, O
and O
there O
is O
tight O
regulatory O
control O
of O
RXRalpha O
expression O
during O
the O
transition O
from O
G0/G1 O
to O
S O
phase O
of O
the O
cell O
cycle O
. O
Epidemiology O
and O
pathogenesis O
of O
AIDS-related B-DNA
lymphomas O
. O
Among O
patients O
with O
congenital O
and O
acquired O
immunodeficiencies I-protein
, O
non-Hodgkin O
's O
lymphoma O
( O
NHLs O
) O
are O
the O
most O
common O
tumors O
of O
the O
immune O
system O
. O
In O
the O
setting O
of O
human B-cell_type
immunodeficiency I-DNA
virus O
( O
HIV O
) O
infection O
, O
as O
many O
as O
10 O
% O
to O
20 O
% O
of O
people O
ultimately O
developed O
NHLs O
. O
These O
tumors O
are O
clinically O
aggressive O
, O
frequently O
involve O
extranodal I-DNA
sites I-DNA
, O
and O
often O
exhibit O
unique O
features O
that O
distinguish O
them O
from O
NHL O
arising O
in O
individuals O
with O
other O
forms O
of O
immunosuppression O
. O
Important O
in O
the O
development O
of O
HIV-associated B-protein
NHL O
are O
cytokines O
and O
other O
factors I-protein
that O
induce O
B-cell O
proliferation O
and O
increase O
the O
likelihood O
of O
mutations O
of O
c-myc I-DNA
, O
bcl-6 O
, O
and O
other O
tumor-suppressor I-DNA
genes I-DNA
with O
carcinogenic O
potential O
. O
Specific O
forms O
of O
HIV-associated B-protein
NHL O
are O
linked O
to O
expression O
of O
Epstein-Barr O
virus O
( O
EBV I-DNA
) O
-latent O
proteins I-protein
; O
the O
newly O
described O
DNA O
virus O
, O
Karposi O
's O
sarcoma-associated O
herpesvirus/human B-DNA
herpesvirus-8 B-protein
( O
KSHV/HHV-8 B-protein
) O
; O
and O
perhaps O
HIV O
. O
Elucidation O
of O
the O
factors I-protein
that O
contribute O
to O
the O
high O
incidence O
of O
NHL B-cell_type
among O
patients O
infected O
with O
HIV O
provides O
insights O
into O
important O
elements I-DNA
of O
lymphomagenesis O
. O
Matrix O
metalloproteinase O
expression O
in O
human B-DNA
breast I-cell_type
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin O
D O
, O
type O
IV I-DNA
collagen O
, O
laminin O
, O
fibronectin O
, O
EGFR I-protein
, O
c-erbB-2 O
oncoprotein O
, O
p53 I-protein
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O
Matrix O
metalloproteinase O
s O
( O
MMPs O
) O
are O
a O
group O
of O
enzymes O
thought O
to O
be O
responsible O
for O
both O
normal O
connective O
tissue O
matrix O
remodelling O
and O
accelerated O
breakdown O
associated O
with O
tumour O
development O
. O
The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix O
metalloproteinase O
3 O
( O
MMP-3 O
, O
stromelysin-1 B-protein
) O
in O
correlation O
with O
the O
expression O
of O
Basement O
Membrane O
( O
BM I-DNA
) O
antigen I-protein
( O
type I-DNA
IV I-DNA
collagen O
, O
laminin O
) O
, O
fibronectin O
, O
cathepsin O
D O
, O
p53 I-protein
, O
c-erbB-2 O
, O
proliferative O
activity O
( O
Ki-67 I-DNA
, O
PCNA O
) O
, O
steroid I-DNA
receptor I-protein
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O
This O
study O
was O
performed O
on O
a O
series O
of O
frozen O
and O
paraffin O
sections O
from O
84 O
breast O
cancer O
specimens O
by O
immunohistochemistry O
using O
the O
monoclonal O
antibody O
MMP-3 O
( O
Ab-1 B-protein
) O
. O
Stromelysin-1 B-protein
( O
ST1 B-protein
) O
was O
observed O
in O
about O
10 O
% O
of O
epithelial B-cell_type
cells I-cell_type
in O
the O
control O
groups O
( O
cases O
of O
fibrocystic O
and O
benign O
proliferative O
breast O
disease O
) O
, O
while O
expression O
( O
> O
10 O
% O
of O
expression O
) O
was O
detected O
in O
89.7 B-protein
% O
of O
tumours O
. O
The O
expression O
of O
ST1 B-protein
in O
carcinoma B-cell_type
cells I-cell_type
was O
strongly O
associated O
with O
its O
presence O
in O
the O
stroma O
( O
p O
< O
0.001 B-protein
) O
. O
A O
significantly O
positive O
correlation O
was O
found O
between O
ST1 B-protein
expression O
, O
and O
p53 O
tumour O
suppressor O
gene I-DNA
product O
( O
p O
= O
0.004 B-protein
) O
, O
and O
a O
relationship O
with O
c-erbB-2 B-protein
protein O
and O
progesterone I-DNA
receptor I-protein
status O
was O
also O
indicated O
. O
These O
findings O
suggest O
that O
ST1 B-protein
expression O
in O
breast O
cancer O
tissue O
is O
irrespective O
of O
the O
expression O
of O
the O
extracellular O
matrix O
component O
, O
the O
proteolytic O
enzyme O
cathepsin O
D O
and O
the O
growth O
fraction O
of O
the O
tumour I-protein
, O
and O
that O
it O
could O
be O
a O
potential O
new O
prognostic O
marker O
in O
breast O
cancer O
. O
Use O
of O
transfected B-cell_line
liver I-cell_type
cells O
to O
evaluate O
potential O
mechanisms O
of O
alcohol-induced O
liver O
injury O
[ O
see O
comments O
] O
There O
is O
increased O
activity O
of O
the O
proinflammatory O
cytokine O
, O
tumor O
necrosis B-protein
factor I-protein
( O
TNF I-DNA
) O
in O
alcoholic O
liver O
disease O
( O
ALD I-DNA
) O
. O
Hepatic O
neutrophil O
infiltration O
is O
a O
principal O
injurious O
manifestation O
of O
ALD B-cell_type
. O
TNF O
can O
induce O
cellular O
oxidative O
injury O
directly O
, O
and O
indirectly O
by O
inducing O
neutrophil O
chemotactic O
factor I-protein
( O
IL-8 B-protein
) O
production O
by O
hepatocytes O
. O
IL-8 B-protein
activates O
and O
chemotactically O
attracts O
neutrophils O
to O
the O
liver O
where O
they O
release O
oxidizing O
substances O
. O
Patients O
with O
ALD O
also O
have O
decreased O
protective O
factors I-protein
for O
cellular O
oxidative O
injury O
. O
Manganous O
superoxide O
dismutase O
( O
MnSOD I-DNA
) O
is O
an O
antioxidant O
protective I-protein
factor I-protein
. B-protein
The O
objectives O
of O
these O
studies O
were O
to O
investigate O
mechanisms O
for O
induction O
of O
an O
injurious B-protein
factor I-protein
( O
IL-8 B-protein
) O
and O
a O
protective I-protein
factor I-protein
( O
MnSOD I-DNA
) O
in O
the O
HepG2 B-DNA
human B-DNA
hepatoma O
cell O
line O
. O
In O
the O
first O
set O
of O
experiments O
, O
IL-8 B-DNA
gene I-DNA
reporter O
constructs O
were O
used O
to O
transiently O
transfect O
a O
derivative O
( O
MVh2E1-9 B-protein
) O
of O
the O
HepG2 O
cell O
line O
which O
expresses O
P-4502E1 B-protein
and O
metabolizes O
ethanol O
. O
Inactivation O
of O
the O
NF-kappaB O
and O
3'NF-IL-6 B-protein
DNA O
binding O
sites O
decreased O
IL-8 B-DNA
gene I-DNA
transcriptional O
activation O
in O
response O
to O
TNF O
while O
inactivation O
of O
the O
5'NF-IL-6 B-protein
binding O
site O
increased O
IL-8 B-DNA
gene I-DNA
transcriptional O
activity O
in O
response O
to O
TNF O
. O
This O
system O
may O
be O
useful O
to O
assess O
the O
effects O
of O
ethanol O
on O
TNF O
-induced O
hepatocyte O
IL-8 B-protein
production O
. O
In O
the O
second O
set O
of O
experiments O
, O
HepG2 B-DNA
cells I-cell_type
were O
cultured O
in O
25 O
to O
100 O
mmol O
concentrations O
of O
ethanol O
. O
Both O
TNF O
and O
ethanol O
increased O
HepG2 O
cell O
MnSOD I-cell_type
activity O
in O
short-term B-DNA
( O
72 O
hr O
) O
cultures I-cell_line
with O
ethanol O
. O
However O
, O
after O
long-term B-DNA
( O
10 O
weeks O
) O
culture O
with O
ethanol O
, O
there O
was O
no O
induction O
of O
MnSOD B-cell_type
by O
ethanol O
and O
there O
was O
a O
diminished O
induction O
of O
MnSOD B-cell_type
in O
response O
to O
TNF O
. O
Further O
studies O
are O
needed O
to O
assess O
the O
effect O
of O
this O
diminished O
induction O
of O
MnSOD B-cell_type
with O
chronic O
ethanol O
culture O
on O
HepG2 O
cell O
susceptibility O
to O
TNF O
cytotoxicity O
. O
We O
conclude O
that O
transfected O
liver O
cell O
lines I-cell_line
can O
be O
used O
to O
evaluate O
mechanisms O
for O
increased O
injurious B-protein
factors I-protein
and O
decreased O
protective O
factors I-protein
in O
alcoholic O
liver O
injury O
. O
Tissue B-protein
factor I-protein
transcription O
driven O
by O
Egr-1 B-protein
is O
a O
critical O
mechanism O
of O
murine I-cell_line
pulmonary O
fibrin O
deposition O
in O
hypoxia O
. O
Local O
hypoxemia O
and O
stasis O
trigger O
thrombosis O
. O
We O
have O
demonstrated O
previously O
that O
in O
a O
murine I-cell_line
model O
of O
normobaric O
hypoxia O
pulmonary O
fibrin O
deposition O
is O
a O
result O
of O
expression O
of O
tissue B-protein
factor I-protein
, O
especially O
in O
oxygen-deprived O
mononuclear O
phagocytes O
( O
MPs O
) O
. O
We O
now O
show O
that O
transcription B-protein
factor I-protein
early-growth-response B-DNA
gene I-DNA
product O
( O
Egr-1 B-protein
) O
is O
rapidly O
activated O
in O
hypoxia O
, O
both O
in O
vitro O
and O
in O
vivo O
, O
and O
is O
responsible O
for O
transcription I-DNA
and O
expression O
of O
tissue B-protein
factor I-protein
in O
hypoxic O
lung O
. O
MPs O
and O
HeLa B-cell_type
cells I-cell_type
subjected O
to O
hypoxia O
( O
pO2 O
approximately O
13 O
torr O
) O
had O
increased O
levels O
of O
tissue B-protein
factor I-protein
transcripts O
( O
approximately O
18-fold B-protein
) O
and O
an O
increased O
rate O
of O
transcription O
( O
approximately O
15-fold B-protein
) O
, O
based O
on O
nuclear B-protein
run-on O
analysis O
. O
Gel-shift O
analysis O
of O
nuclear B-protein
extracts O
from O
hypoxic O
MPs O
and O
HeLa B-cell_type
cells I-cell_type
demonstrated O
increased O
DNA-binding B-protein
activity O
at O
the O
serum O
response O
region O
( O
SRR O
; O
-111/+14 B-protein
bp O
) O
of O
the O
tissue I-protein
factor I-protein
promoter I-DNA
at O
Egr-1 B-protein
motifs O
. O
Using O
32P-labeled O
Egr O
consensus O
oligonucleotide O
, O
we O
observed O
induction O
of O
DNA-binding B-protein
activity O
in O
nuclear B-protein
extracts O
from O
hypoxic O
lung O
and O
HeLa B-cell_type
cells I-cell_type
because O
of O
activation O
of O
Egr-1 B-protein
, O
by O
means O
of O
supershift O
analysis O
. O
Transient O
transfection O
of O
HeLa B-cell_type
cells I-cell_type
with O
chimeric O
plasmids O
containing O
wild-type B-DNA
or O
mutant O
SRR O
from O
the O
tissue I-protein
factor I-protein
promoter I-DNA
showed O
that O
intact O
Sp1 B-protein
sites I-DNA
are O
necessary O
for O
basal B-DNA
promoter I-DNA
activity O
, O
whereas O
the O
integrity O
of O
Egr-1 B-protein
sites I-DNA
was O
required O
for O
hypoxia-enhanced O
expression O
. O
A O
central O
role O
for O
Egr-1 B-protein
in O
hypoxia-mediated O
tissue I-protein
factor I-protein
expression O
was O
confirmed O
by O
experiments O
with O
homozygous O
Egr-1 B-protein
null O
mice O
; O
wild-type B-DNA
mice O
subjected O
to O
oxygen O
deprivation O
expressed O
tissue I-protein
factor I-protein
and O
showed O
fibrin O
deposition O
, O
but O
hypoxic O
homozygous O
Egr-1 B-protein
null O
mice O
displayed O
neither O
tissue I-protein
factor I-protein
nor O
fibrin O
. O
These O
data O
delineate O
a O
novel O
biology O
for O
hypoxia-induced O
fibrin O
deposition O
, O
in O
which O
oxygen O
deprivation-induced B-DNA
activation O
of O
Egr-1 B-protein
, O
resulting O
in O
expression O
of O
tissue B-protein
factor I-protein
, O
has O
an O
unexpected O
and O
central O
role O
. O
Kinetics O
of O
cytokine O
and O
NFAT I-DNA
gene I-DNA
expression O
in O
human B-DNA
interleukin-2-dependent I-cell_type
T I-cell_line
lymphoblasts O
stimulated O
via O
T-cell B-DNA
receptor I-protein
. O
T B-cell_type
cells I-cell_type
respond O
to O
mitogenic O
or O
antigenic O
stimulation O
by O
proliferation O
and O
by O
turning O
on O
cytokine B-DNA
gene I-DNA
expression O
. O
Here O
we O
have O
analysed O
the O
kinetics O
and O
nature O
of O
cytokine O
production O
in O
human O
peripheral B-cell_type
blood-derived B-cell_type
T I-cell_line
lymphoblasts O
stimulated O
with O
anti-CD3 B-protein
antibodies I-protein
or O
Lens O
culinaris O
lectin O
( O
LCL I-DNA
) O
. O
T B-cell_type
cells I-cell_type
were O
purified O
from O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_line
( O
PBMC I-DNA
) O
and O
primarily O
activated O
with O
anti-CD3 B-protein
antibodies I-protein
and O
cultured O
in O
the O
presence O
of O
interleukin-2 B-protein
( O
IL-2 B-protein
) O
. O
Anti-CD3-restimulated O
T B-cell_type
cells I-cell_type
( O
mainly O
CD8+ B-protein
) O
produced O
IL-2 B-protein
, O
interferon-gamma I-cell_line
( O
IFN-gamma I-DNA
) O
and O
tumour O
necrosis O
factor-alpha B-DNA
( O
TNF-alpha I-DNA
) O
and O
low O
levels O
of O
IL-4 B-protein
and O
IL-10 I-RNA
transcripts O
and O
proteins I-protein
. O
No O
IL-6 B-DNA
gene I-DNA
expression O
was O
observed O
. O
In O
LCL-stimulated B-protein
cells I-cell_type
the O
cytokine O
production O
pattern O
was O
very O
similar O
. O
Steady-state I-RNA
mRNA I-RNA
levels O
of O
IL-2 B-protein
, O
IL-10 O
and O
IFN-gamma B-protein
peaked O
at O
3 O
hr O
after O
anti-CD3 B-protein
stimulation O
and O
declined O
rapidly O
thereafter O
. O
The O
kinetics O
of O
TNF-alpha I-RNA
mRNA I-RNA
expression O
was O
faster I-protein
, O
being O
at O
its O
peak O
level O
1 O
hr O
after O
stimulation O
. O
Anti-CD3-stimulated B-protein
IL-2 B-DNA
gene I-DNA
expression O
was O
down-regulated O
by O
protein O
synthesis O
inhibitor O
, O
whereas O
IL-10 B-protein
, O
IFN-gamma O
and O
TNF-alpha I-DNA
genes I-DNA
were O
readily O
induced O
independent O
of O
ongoing O
protein O
synthesis O
. O
T-cell B-DNA
receptor I-protein
stimulation O
also O
induced O
a O
very O
rapid O
expression O
of O
c-jun I-DNA
, O
c-fos O
and O
NFATc1 I-cell_line
( O
NFATc I-DNA
) O
genes I-DNA
, O
the O
gene I-DNA
products O
of O
which O
are O
involved O
in O
cytokine B-DNA
gene I-DNA
expression O
. O
In O
conclusion O
, O
the O
cytokines O
synthesized O
by O
IL-2-dependent B-DNA
T B-cell_type
cells I-cell_type
were O
predominantly O
IL-2 B-protein
, O
IFN-gamma O
and O
TNF-alpha B-protein
. O
An O
animal O
model O
to O
study O
local O
oxidation O
of O
LDL O
and O
its O
biological O
effects O
in O
the O
arterial O
wall O
. O
Oxidized O
LDL I-protein
( O
oxLDL I-DNA
) O
is O
present O
in O
atherosclerotic O
lesions O
and O
is O
believed O
to O
play O
a O
key O
role O
in O
atherogenesis O
. O
Mainly O
on O
the O
basis O
of O
cell O
culture O
studies O
, O
oxLDL O
has O
been O
shown O
to O
produce O
many O
biological O
effects O
that O
influence O
the O
atherosclerotic O
process O
. O
To O
study O
LDL O
oxidation O
in O
vivo O
, O
we O
have O
established O
a O
model O
in O
which O
Sprague-Dawley B-protein
rats O
are O
given O
a O
single O
injection O
of O
unmodified O
human B-DNA
LDL I-cell_type
( O
> O
or O
= O
4 O
mg/kg B-DNA
body O
weight O
) O
. O
Within O
6 O
hours O
, O
an O
accumulation O
of O
apolipoprotein O
B I-DNA
and O
epitopes B-protein
present O
on O
oxLDL I-RNA
are O
detected O
in O
the O
arterial O
endothelium O
and O
media O
. O
The O
presence O
of O
oxLDL B-cell_type
is O
associated O
with O
activation O
of O
the O
transcription B-protein
factor I-protein
nuclear B-protein
factor-kappaB B-protein
in O
the O
endothelium O
as O
well O
as O
endothelial O
expression O
of O
intercellular O
adhesion O
molecule-1 B-protein
. O
Injection O
of O
LDL B-cell_type
enriched O
with O
the O
antioxidant O
probucol O
resulted O
in O
arterial O
accumulation O
of O
apolipoprotein O
B I-DNA
, O
but O
the O
expression O
of O
oxLDL-specific B-protein
epitopes I-protein
was O
reduced O
at O
24 O
hours O
. O
Thus O
, O
this O
simple O
model O
has O
the O
potential O
to O
analyze O
the O
mechanisms O
behind O
and O
biological O
effects O
of O
LDL B-cell_type
oxidation O
in O
vivo O
. O
Molecular O
mechanisms O
of O
promoter I-DNA
regulation O
of O
the O
gp34 B-DNA
gene I-DNA
that O
is O
trans-activated O
by O
an O
oncoprotein O
Tax O
of O
human B-cell_type
T I-cell_line
cell O
leukemia O
virus O
type O
I I-protein
. O
We O
investigated O
the O
molecular O
mechanism O
of O
transcriptional O
activation O
of O
the O
gp34 B-DNA
gene I-DNA
by O
the O
Tax O
oncoprotein O
of O
human B-cell_type
T I-cell_line
cell O
leukemia O
virus O
type O
I I-protein
( O
HTLV-I B-protein
) O
. O
gp34 I-protein
is O
a O
type O
II I-protein
transmembrane O
molecule O
belonging O
to O
the O
tumor O
necrosis B-protein
factor I-protein
family O
and O
is O
constitutively O
expressed O
on O
HTLV-I-producing B-cell_line
cells I-cell_type
but O
not O
normal O
resting B-cell_type
T B-cell_type
cells I-cell_type
. O
The O
transcriptional O
regulatory O
region I-DNA
of O
the O
gp34 B-DNA
gene I-DNA
was O
activated O
by O
HTLV-I B-protein
Tax O
in O
the O
human B-cell_type
T I-cell_line
cell O
line O
Jurkat O
, O
in O
which O
endogenous O
gp34 I-protein
is O
induced O
by O
Tax O
. O
Sequence O
analysis O
demonstrated O
that O
two O
NF-kappaB-like O
elements I-DNA
( O
1 O
and O
2 O
) O
were O
present O
in O
the O
regulatory O
region O
. O
Both O
NF-kappaB-like O
elements I-DNA
were O
able O
to O
bind O
to O
NF-kappaB O
or O
its O
related O
factor I-protein
( O
s O
) O
in O
a O
Tax O
-dependent O
manner O
. O
Chloramphenicol O
acetyltransferase O
assays O
indicated O
that O
NF-kappaB-like B-DNA
element I-DNA
1 O
was O
Tax O
-responsive O
, O
although O
the O
activity O
was O
lower O
than O
that O
the O
native O
promoter I-DNA
. O
NF-kappaB O
-like B-DNA
element I-DNA
2 O
elevated O
promoter I-DNA
activity O
when O
combined O
with O
NF-kappaB-like B-DNA
element I-DNA
1 O
, O
indicating O
cooperative O
function O
of O
the O
elements I-DNA
for O
maximum O
promoter I-DNA
function O
. O
Unlike O
typical O
NF-kappaB B-DNA
elements I-DNA
, O
the O
NF-kappaB-like O
elements I-DNA
in O
gp34 I-protein
were O
not O
activated O
by O
treatment O
of O
Jurkat B-cell_type
cells I-cell_type
with O
phorbol O
ester O
despite O
induction O
of O
the O
NF-kappaB O
-like O
binding O
activity O
. O
Chloramphenicol O
acetyltransferase O
reporter O
assays O
using O
the O
region O
upstream O
of O
the O
NF-kappaB-like O
elements I-DNA
identified O
an O
upstream O
region O
that O
reduced O
transcription O
from O
cognate O
and O
noncognate O
core O
promoters O
in O
a O
Tax-independent O
manner O
. O
Our O
results O
imply O
complex I-protein
regulation O
of O
expression O
of O
the O
gp34 B-DNA
gene I-DNA
and O
suggest O
implication O
of O
gp34 B-cell_type
in O
proliferation O
of O
HTLV-I B-protein
infected O
T B-cell_type
cells I-cell_type
. O
beta-Amyloid B-protein
fibrils O
activate O
parallel O
mitogen-activated B-DNA
protein O
kinase I-protein
pathways O
in O
microglia O
and O
THP1 B-protein
monocytes B-cell_type
. O
The O
senile O
plaques O
of O
Alzheimer O
's O
disease O
are O
foci O
of O
local O
inflammatory O
responses O
, O
as O
evidenced O
by O
the O
presence O
of O
acute O
phase O
proteins I-protein
and O
oxidative O
damage O
. O
Fibrillar O
forms O
of O
beta-amyloid B-cell_type
( O
Abeta I-DNA
) O
, O
which O
are O
the O
primary B-cell_line
constituents O
of O
senile O
plaques O
, O
have O
been O
shown O
to O
activate B-protein
tyrosine I-protein
kinase-dependent O
signal O
transduction O
cascades O
, O
resulting O
in O
inflammatory O
responses O
in O
microglia O
. O
However O
, O
the O
downstream O
signaling O
pathways O
mediating O
Abeta O
-induced O
inflammatory O
events O
are O
not O
well O
characterized O
. O
We O
report O
that O
exposure O
of O
primary B-cell_line
rat I-cell_line
microglia O
and O
human B-cell_type
THP1 I-cell_type
monocytes B-cell_type
to O
fibrillar O
Abeta O
results O
in O
the O
tyrosine I-protein
kinase I-protein
-dependent O
activation O
of O
two O
parallel O
signal O
transduction O
cascades O
involving O
members O
of O
the O
mitogen-activated B-DNA
protein O
kinase I-protein
( O
MAPK I-DNA
) O
superfamily O
. O
Abeta O
stimulated O
the O
rapid O
, O
transient O
activation O
of O
extracellular O
signal-regulated O
kinase I-protein
1 O
( O
ERK1 B-protein
) O
and O
ERK2 B-protein
in O
microglia O
and O
ERK2 B-protein
in O
THP1 B-protein
monocytes B-cell_type
. O
A O
second O
superfamily O
member I-protein
, O
p38 O
MAPK I-protein
, O
was O
also O
activated O
with O
similar O
kinetics O
. O
Scavenger I-DNA
receptor I-protein
and I-DNA
receptor I-protein
for O
advanced O
glycated O
end O
products O
( O
RAGE I-DNA
) O
ligands O
failed O
to O
activate O
ERK O
and O
p38 O
MAPK O
in O
the O
absence O
of O
significant O
increases O
in O
protein B-protein
tyrosine I-protein
phosphorylation O
, O
demonstrating O
that O
scavenger O
receptors O
and O
RAGE O
are O
not O
linked O
to O
these O
pathways O
. O
Importantly O
, O
the O
stress-activated O
protein I-protein
kinases I-protein
( O
SAPKs O
) O
were O
not O
significantly O
activated O
in O
response O
to O
Abeta O
. O
Downstream O
effectors O
of O
the O
MAPK O
signal O
transduction O
cascades O
include O
MAPKAP I-protein
kinases I-protein
, O
such O
as O
RSK1 B-protein
and O
RSK2 I-protein
, O
as O
well O
as O
transcription B-protein
factors I-protein
. O
Exposure O
of O
microglia O
and O
THP1 B-protein
monocytes B-cell_type
to O
Abeta O
resulted O
in O
the O
activation O
of O
RSK1 B-protein
and O
RSK2 B-protein
and O
phosphorylation O
of O
cAMP O
response O
element-binding O
protein O
at O
Ser133 I-cell_line
, O
providing O
a O
mechanism O
for O
Abeta O
-induced O
changes O
in O
gene I-DNA
expression O
Regulation O
of O
cellular O
retinoic O
acid O
binding O
protein O
( O
CRABP O
II B-protein
) O
during O
human B-DNA
monocyte I-DNA
differentiation O
in O
vitro O
. O
Cellular O
retinoic O
acid O
binding O
proteins I-protein
( O
CRABP I-DNA
) O
are O
low O
molecular O
weight O
proteins I-protein
whose O
precise O
function O
remains O
unknown O
. O
They O
bind O
retinoids O
and O
may O
thereby O
modulate O
the O
intracellular O
steady-state B-DNA
concentration O
of O
retinoids O
. O
Whereas O
CRABP B-protein
I I-protein
is O
ubiquitously O
expressed O
, O
CRABP I-protein
II I-protein
is O
mainly O
detected O
in O
various O
cell O
types I-cell_type
of O
the O
skin O
. O
By O
representative O
difference O
analysis O
we O
found O
that O
CRABP I-protein
II I-protein
is O
also O
strongly O
expressed O
in O
human B-DNA
monocyte-derived I-cell_line
macrophages O
( O
MAC I-DNA
) O
but O
not O
in O
freshly O
isolated O
monocytes B-cell_type
( O
MO I-DNA
) O
. O
The O
CRABP I-protein
II I-RNA
mRNA I-RNA
was O
gradually O
upregulated O
during O
differentiation O
from O
MO O
to O
MAC O
in O
the O
presence O
of O
2 O
% O
serum O
. O
Adherence O
, O
which O
is O
important O
for O
MO B-protein
differentiation O
, O
induced O
CRABP I-protein
II I-protein
expression O
, O
but O
the O
addition O
of O
10 O
( O
-7 B-protein
) O
M O
retinoic O
acid O
inhibited O
the O
upregulation O
of O
CRABP I-protein
II I-protein
expression O
during O
MO/MAC B-protein
differentiation O
. O
As O
MO B-protein
can O
differentiate O
along O
the O
classical O
pathway O
not O
only O
to O
MAC O
but O
also O
to O
dendritic B-cell_type
cells I-cell_type
we O
analyzed O
the O
expression O
of O
CRABP I-protein
II I-protein
in O
MO-derived B-protein
dendritic B-cell_type
cells I-cell_type
cultured O
with O
10 O
% O
FCS I-protein
, O
IL-4 B-protein
, O
and O
GM-CSF B-protein
. O
In O
contrast O
to O
MAC I-protein
, O
MO-derived O
dendritic B-cell_type
cells I-cell_type
showed O
an O
extremely O
low O
expression O
of O
CRABP I-protein
II I-protein
. O
From O
these O
results O
we O
conclude O
( O
1 O
) O
that O
the O
availability O
and O
the O
metabolism O
of O
retinoids O
may O
be O
different O
in O
MAC O
compared O
to O
MO O
and O
dendritic B-cell_type
cells I-cell_type
and O
( O
2 O
) O
that O
this O
may O
influence O
differentiation O
and O
activation O
of O
those B-cell_type
cells I-cell_type
. O
Transcription B-protein
factor I-protein
B-cell-specific B-protein
activator O
protein I-protein
( O
BSAP I-DNA
) O
is O
differentially O
expressed O
in O
B I-DNA
cells I-cell_type
and O
in O
subsets O
of O
B-cell O
lymphomas O
. O
The O
paired O
box O
containing O
gene I-DNA
PAX-5 O
encodes O
the O
transcription B-protein
factor I-protein
BSAP B-protein
( O
B-cell-specific O
activator O
protein O
) O
, O
which O
plays O
a O
key O
role O
in O
B-lymphocyte B-protein
development O
. O
Despite O
its O
known O
involvement O
in O
a O
rare O
subtype O
of O
non-Hodgkin O
's O
lymphoma O
( O
NHL I-DNA
) O
, O
a O
detailed O
examination O
of O
BSAP O
expression O
in O
NHL O
has O
not O
been O
previously O
reported O
. O
In O
this O
study O
, O
we O
analyzed O
normal O
and O
malignant O
lymphoid O
tissues O
and O
cell O
lines I-cell_line
, O
including O
102 O
cases O
of O
B-cell O
NHL I-protein
, O
23 O
cases O
of O
T- O
and O
null-cell O
NHL I-protein
, O
and O
18 O
cases O
of O
Hodgkin O
's O
disease O
. O
Normal O
lymphoid O
tissues O
showed O
strong O
nuclear B-protein
BSAP I-protein
expression O
in O
mantle O
zone O
B I-DNA
cells I-cell_line
, O
less O
intense O
reactivity O
in O
follicular O
center O
B I-DNA
cells I-cell_line
, O
and O
no O
expression O
in O
cells I-cell_type
of O
the O
T-cell-rich O
zones O
. O
Monocytoid O
B I-DNA
cells I-cell_type
showed O
weak O
expression O
, O
whereas O
plasma B-cell_type
cells I-cell_type
and O
extrafollicular O
large O
transformed O
B I-DNA
cells I-cell_type
were O
negative O
. O
Of O
the O
102 O
B-cell O
NHLs O
, O
83 O
( O
81 O
% O
) O
demonstrated O
BSAP O
expression O
. O
All O
of O
the O
13 O
( O
100 O
% O
) O
B-cell O
chronic O
lymphocytic O
leukemias O
( O
B-CLLs B-protein
) O
, O
21 O
of O
( O
100 O
% O
) O
mantle O
cells I-cell_line
( O
MCLs O
) O
, O
and O
20 I-DNA
of O
21 O
( O
95 O
% O
) O
follicular O
lymphomas O
( O
FLs O
) O
were O
positive O
. O
Moderate O
staining O
intensities O
were O
found O
in O
most O
B-CLL B-protein
and O
FL B-protein
cases O
, O
whereas O
most O
MCLs O
showed O
strong O
reactions O
, O
paralleling O
the O
strong O
reactivity O
of O
nonmalignant O
mantle B-cell_type
cells I-cell_type
. O
Eight O
of O
12 O
( O
67 O
% O
) O
marginal O
zone O
lymphoma O
cases O
showed O
negative O
or O
low O
BSAP O
levels O
, O
and O
17 O
of O
24 O
( O
71 O
% O
) O
large O
B-cell O
lymphomas O
displayed O
moderate O
to O
strong O
expression O
. O
None O
of O
the O
23 O
T- O
and O
null-cell O
lymphomas O
reacted O
with O
the O
BSAP O
antisera O
, O
whereas O
in O
Hodgkin O
's O
disease O
, O
2 O
of O
4 O
( O
50 O
% O
) O
nodular O
lymphocytic O
predominance O
and O
5 O
of O
14 O
( O
36 O
% O
) O
classical O
cases O
showed O
weak O
nuclear B-protein
or O
nucleolar O
BSAP O
reactions O
in O
a O
fraction O
of O
the O
tumor I-cell_type
cells I-cell_type
. O
Western O
blot O
analysis O
showed O
a O
52-kD B-protein
BSAP O
band O
in O
B-cell B-cell_line
lines I-cell_line
, O
but O
not O
in O
non-B-cell O
or O
plasma O
cell O
lines I-cell_line
. O
We O
conclude O
that O
BSAP O
expression O
is O
largely O
restricted O
to O
lymphomas O
of O
B-cell O
lineage I-cell_type
and O
that O
BSAP O
expression O
varies O
in O
B-cell O
subsets O
and O
subtypes O
of O
B-cell O
NHL O
. O
The O
high O
levels O
of O
BSAP I-protein
, O
especially O
those O
found O
in O
large-cell B-DNA
lymphomas O
and O
in O
some O
follicular O
lymphomas O
, O
may O
be O
a O
consequence O
of O
deregulated O
gene I-DNA
expression O
and O
suggest O
a O
possible O
involvement O
of O
PAX-5 O
in O
certain O
B-cell O
malignancies O
. O
This O
is O
a O
US B-protein
government O
work O
. O
There O
are O
no O
restrictions O
on O
its O
use O
. O
Mitogen O
and O
growth O
factor-induced I-cell_type
activation O
of O
a O
STAT-like B-protein
molecule O
in O
channel O
catfish O
lymphoid B-cell_type
cells I-cell_type
. O
This O
article O
describes O
the O
identification O
of O
a O
putative O
STAT B-protein
molecule O
in O
the O
channel O
catfish O
( O
Ictalurus O
punctatus O
) O
, O
the O
first O
report O
of O
such O
a O
molecule O
in O
a O
'lower O
' O
vertebrate O
. O
A O
monoclonal O
antibody O
against O
human B-DNA
STAT6 I-cell_type
recognizes O
an O
approximately O
100 O
kDa I-protein
molecule O
that O
becomes O
activated O
and O
translocates O
to O
the O
nucleus O
upon O
both O
growth I-protein
factor I-protein
and O
mitogen O
stimulation O
of O
catfish O
leukocytes O
. O
This O
presumed O
catfish O
STAT B-protein
binds O
the O
mammalian O
interferon-gamma O
activation O
site I-DNA
, O
a O
known O
motif O
of O
mammalian O
STAT B-protein
binding O
, O
as O
shown O
by O
electromobility O
shift O
assays O
. O
Purification O
of O
the O
proteins I-protein
present O
in O
these O
DNA O
complexes O
confirms O
that O
the O
catfish O
reactive O
molecule O
binds O
to O
the O
interferon-gamma O
activation O
site O
sequence O
. O
These O
results O
suggest O
that O
STAT B-protein
molecules I-protein
have O
been O
highly O
conserved O
in O
vertebrate O
evolution O
. O
Isolation O
and O
analysis O
of O
a O
T O
cell O
clone O
variant O
exhibiting O
constitutively O
phosphorylated O
Ser133 B-protein
cAMP I-RNA
response O
element-binding O
protein O
. O
In O
driving O
T O
cell O
proliferation O
, O
IL-2 B-protein
stimulates O
a O
new O
program O
of O
gene I-DNA
expression O
that O
includes O
proliferating O
cell O
nuclear B-protein
antigen I-protein
( O
PCNA I-DNA
) O
, O
a O
requisite O
processivity B-protein
factor I-protein
for O
DNA O
polymerase O
delta O
. O
PCNA B-protein
transcription O
is O
regulated O
in O
part O
through O
tandem O
CRE O
sequences O
in O
the O
promoter I-DNA
and O
CRE O
binding O
proteins I-protein
; O
IL-2 B-protein
stimulates O
CREB O
phosphorylation O
in O
the O
resting O
cloned O
T I-cell_line
lymphocyte I-cell_line
, O
L2 B-protein
. O
After O
culturing O
L2 B-protein
cells I-cell_type
for O
greater O
than O
91 O
days O
, O
we O
consistently O
isolate O
a O
stable O
variant O
that O
exhibits O
constitutive O
CREB O
phosphorylation O
. O
L2 I-protein
and O
L2 B-protein
variant B-cell_type
cells I-cell_type
were O
tested O
for O
IL-2 B-protein
responsiveness O
and O
rapamycin O
sensitivity O
with O
respect O
to O
specific O
kinase I-protein
activity O
, O
PCNA O
expression O
and O
proliferation O
. O
In O
L2 B-protein
cells I-cell_line
, O
IL-2 B-protein
stimulated O
and O
rapamycin O
inhibited O
the O
following O
: O
cAMP-independent O
CREB I-protein
kinase I-protein
activity O
, O
PCNA O
expression O
and O
proliferation O
. O
In O
L2 B-protein
variant B-cell_type
cells I-cell_line
, O
CREB I-protein
kinase I-protein
activity O
was O
constitutively O
high O
; O
IL-2 B-protein
stimulated O
and O
rapamycin O
blocked O
PCNA O
expression O
and O
proliferation O
. O
These O
results O
indicate O
that O
IL-2 B-protein
induces O
a O
rapamycin-sensitive I-DNA
, O
cAMP-independent O
CREB I-protein
kinase I-protein
activity O
in O
L2 B-protein
cells I-cell_type
. O
However O
, O
phosphorylation O
of O
CREB O
alone O
is O
not O
sufficient O
to O
drive O
PCNA O
expression O
and O
L2 O
cell O
proliferation O
in O
the O
absence O
of O
IL-2 B-protein
. O
Serotonin O
derivative O
, O
N- O
( O
p-coumaroyl I-DNA
) O
serotonin O
, O
inhibits O
the O
production O
of O
TNF-alpha B-RNA
, O
IL-1alpha O
, O
IL-1beta O
, O
and O
IL-6 B-protein
by O
endotoxin-stimulated O
human B-cell_type
blood I-cell_type
monocytes I-cell_type
. O
We O
have O
reported O
that O
N- B-protein
( O
p-coumaroyl I-DNA
) O
serotonin O
( O
CS I-DNA
) O
and O
its O
derivatives O
with O
antioxidative O
activity O
are O
present O
in O
safflower O
seeds O
. O
As O
reactive O
oxygen O
species O
( O
ROS I-DNA
) O
are O
implicated O
in O
the O
signaling O
of O
lipopolysaccharide I-protein
( O
LPS I-DNA
) O
, O
we O
examined O
whether O
CS B-protein
has O
a O
suppressive O
effect O
on O
inflammatory O
cytokine O
generation O
from O
human B-DNA
monocyte I-DNA
s O
in O
vitro O
. O
CS B-protein
at O
50-200 O
microM I-RNA
reduced O
tumor O
necrosis B-protein
factor I-protein
( O
TNF I-DNA
) O
, O
interleukin-1 B-protein
( O
IL-1 B-protein
) O
, O
and O
IL-6 B-protein
activities O
in O
the O
culture O
supernatants O
from O
LPS-stimulated O
human B-cell_type
blood I-cell_type
monocytes I-cell_type
without O
cytotoxicity O
. O
ELISA O
assay O
revealed O
that O
the O
production O
of O
TNF-alpha B-RNA
, O
IL-1alpha O
, O
IL-1beta O
, O
and O
IL-6 B-protein
was O
inhibited O
by O
CS B-protein
. O
Northern O
blot O
analysis O
showed O
that O
LPS-induced B-protein
expression O
of O
these O
cytokine O
mRNA I-RNA
in O
monocytes B-cell_type
was O
suppressed O
by O
CS B-protein
. O
NF-kappaB O
activation O
was O
also O
inhibited O
by O
CS B-protein
. O
These O
findings O
indicate O
that O
CS B-protein
has O
a O
suppressive O
effect O
on O
proinflammatory O
cytokine O
production O
from O
monocytes B-cell_type
, O
and O
this O
effect O
is O
based O
in O
part O
on O
the O
suppression O
of O
cytokine O
mRNA I-RNA
expression O
through O
inhibition O
of O
NF-kappaB O
activation O
. O
Elevated O
expression O
of O
differentiation O
inhibitory O
factor I-protein
nm23 I-RNA
mRNA I-RNA
in O
monoblastic O
crisis O
of O
a O
patient O
with O
chronic O
myelogenous O
leukemia O
. O
Differentiation O
inhibitory O
factor I-protein
nm23 B-DNA
gene I-DNA
has O
been O
found O
to O
be O
expressed O
in O
high O
quantities O
in O
acute O
myelogenous O
leukemia O
( O
AML I-DNA
) O
, O
especially O
in O
acute O
monocytic B-cell_line
leukemia O
( O
AML-M5 B-protein
) O
and O
is O
suggested O
as O
a O
new O
prognostic I-protein
factor I-protein
in O
AML-M5 B-protein
. O
We O
report O
an O
example O
of O
elevated O
expression O
of O
nm23 I-RNA
mRNA I-RNA
in O
a O
patient O
with O
chronic O
myelogenous O
leukemia O
( O
CML I-DNA
) O
who O
developed O
monoblastic O
crisis O
. O
Relative O
levels O
of O
nm23-H1 O
and O
-H2 I-RNA
mRNA I-RNA
extracted O
from O
the O
patient O
's O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
and O
bone B-cell_type
marrow I-cell_line
mononuclear B-cell_type
cells I-cell_type
were O
measured O
by O
quantitative O
reverse O
transcriptase O
polymerase O
chain O
reaction O
. O
The O
level O
of O
nm23-H1 I-RNA
mRNA I-RNA
in O
CML B-cell_type
cells I-cell_type
at O
the O
chronic O
phase O
was O
as O
high O
as O
that O
in O
bone I-cell_line
marrow I-cell_line
cells I-cell_type
from O
healthy O
volunteers O
. O
The O
mRNA I-RNA
level O
of O
nm23-H2 B-protein
was O
slightly O
below O
the O
normal O
level O
. O
At O
blastic O
crisis O
, O
however O
, O
expression O
of O
both O
nm23-H1 O
and O
-H2 I-RNA
mRNA I-RNA
was O
elevated O
to O
about O
three O
to O
nine O
times O
of O
that O
at O
the O
chronic O
phase O
. O
Proliferated O
blastic B-cell_type
cells I-cell_type
were O
positive O
for O
non-specific B-DNA
esterase O
, O
and O
the O
serum O
lysozyme O
level O
was O
elevated O
and O
diagnosed O
as O
monoblastic O
crisis O
. O
The O
patient O
received O
combined O
chemotherapy O
but O
response O
was O
partial O
. O
These O
findings O
are O
compatible O
with O
our O
previous O
report O
that O
nm23 B-DNA
gene I-DNA
is O
overexpressed O
in O
monocytic B-cell_line
leukemia O
. O
Increased O
transcription O
decreases O
the O
spontaneous O
mutation O
rate O
at O
the O
thymidine O
kinase I-protein
locus O
in O
human B-cell_type
cells I-cell_type
. O
Transcription B-cell_type
increases O
DNA O
repair O
efficiency O
and O
modulates O
the O
distribution O
of O
certain O
types I-cell_type
of O
DNA O
damage O
. O
Furthermore O
, O
increased O
transcription O
level O
stimulates O
spontaneous O
mutation O
rate O
in O
yeast O
. O
We O
explored O
whether O
transcription O
level O
affects O
spontaneous O
mutation O
rate O
in O
human B-cell_type
cells I-cell_type
. O
We O
first O
developed O
two O
thymidine O
kinase I-protein
( O
tk O
) O
inducible O
human O
cell I-cell_type
lines I-cell_line
using O
the O
Gal4-Estrogen I-DNA
receptor I-protein
system O
. O
In O
our O
TK6i-G3 O
and O
G9 B-protein
tk O
heterozygous O
cell O
lines I-cell_line
, O
the O
active O
tk O
allele O
is O
linked O
to O
an O
inducible B-DNA
promoter I-DNA
element I-DNA
. O
Tk I-RNA
mRNA I-RNA
is O
induced O
following O
treatment O
with O
estrogen O
. O
Spontaneous O
mutation O
rate O
was O
significantly O
decreased O
in O
human O
cell I-cell_type
lines I-cell_line
after O
induction O
in O
contrast O
to O
the O
report O
in O
yeast O
. O
Thus O
, O
humans O
may O
have O
evolved O
different O
or O
additional O
mechanisms O
to O
deal O
with O
transcription O
related O
spontaneous O
mutagenesis O
. O
Copyright O
1998 O
Elsevier O
Science O
B.V B-protein
. O
All O
rights O
reserved O
. O
Mutation O
of O
BCL-6 B-DNA
gene I-DNA
in O
normal O
B I-DNA
cells I-cell_type
by O
the O
process O
of O
somatic O
hypermutation O
of O
Ig O
genes I-DNA
. O
Immunoglobulin O
( O
Ig O
) O
genes I-DNA
are O
hypermutated O
in O
B I-DNA
lymphocytes I-cell_type
that O
are O
the O
precursors O
to O
memory O
B I-DNA
cells I-cell_type
. O
The O
mutations O
are O
linked O
to O
transcription O
initiation I-protein
, O
but O
non-Ig B-protein
promoters O
are O
permissible O
for O
the O
mutation O
process O
; O
thus O
, O
other O
genes I-DNA
expressed O
in O
mutating O
B I-DNA
cells I-cell_type
may O
also O
be O
subject O
to O
somatic O
hypermutation O
. O
Significant O
mutations O
were O
not O
observed O
in O
c-MYC I-DNA
, O
S14 I-protein
, O
or O
alpha-fetoprotein B-DNA
( O
AFP I-DNA
) O
genes I-DNA
, O
but O
BCL-6 O
was O
highly O
mutated O
in O
a O
large O
proportion O
of O
memory O
B I-DNA
cells I-DNA
of O
normal O
individuals O
. O
The O
mutation O
pattern O
was O
similar O
to O
that O
of O
Ig O
genes I-DNA
. O
CD28-mediated B-protein
activation O
in O
CD45RA+ I-protein
and O
CD45RO+ B-cell_type
T B-cell_type
cells I-cell_type
: O
enhanced O
levels O
of O
reactive O
oxygen O
intermediates O
and O
c-Rel O
nuclear B-protein
translocation O
in O
CD45RA+ B-cell_type
cells I-cell_type
. O
We O
have O
analyzed O
the O
effect O
of O
complete B-cell_type
T O
cell O
activation O
( O
anti-CD3 B-protein
plus O
anti-CD28 B-protein
) O
on O
the O
activation O
of O
NF-kappaB O
in O
CD45RA+ I-protein
( O
naive O
) O
and O
CD45RO+ B-protein
( O
memory/effector I-DNA
) O
T B-cell_type
cells I-cell_type
. O
Long O
exposure O
( O
24 O
h O
) O
induced O
stronger O
NF-kappaB O
DNA O
binding O
in O
CD45RA+ B-cell_type
cells I-cell_type
than O
in O
CD45RO+ B-cell_type
cells I-cell_type
. O
Analysis O
of O
the O
nuclear B-protein
c-Rel O
protein O
indicated O
that O
after O
anti-CD3+anti-CD28 O
stimulation O
the O
level O
of O
c-Rel O
was O
higher O
in O
CD45RA+ B-cell_type
cells I-cell_type
. O
Analysis O
of O
the O
cytoplasmic O
inhibitor O
IkappaBalpha O
indicated O
that O
anti-CD3+anti-CD28 O
stimulation O
induced O
a O
long-lasting B-DNA
degradation O
in O
CD45RA+ B-cell_type
cells I-cell_type
but O
in O
CD45RO+ B-cell_type
cells I-cell_type
the O
degradation O
process O
was O
more O
rapid O
. O
Because O
the O
CD28 B-protein
costimulus O
is O
known O
to O
induce O
the O
production O
of O
reactive O
oxygen O
intermediates O
( O
ROIs O
) O
, O
the O
intracellular O
ROI O
levels O
in O
CD45RA+ I-protein
and O
CD45RO+ B-cell_type
cells I-cell_type
were O
compared O
by O
flow O
cytometry O
. O
ROIs O
were O
produced O
in O
both O
cell O
types I-cell_type
, O
but O
more O
strongly O
in O
CD45RA+ B-cell_type
cells I-cell_type
. O
The O
data O
presented O
in O
this O
study O
further O
emphasize O
the O
differences O
between O
CD45RA+ I-protein
and O
CD45RO+ B-cell_type
T I-cell_type
lymphocytes I-cell_type
in O
ROI-dependent B-protein
signaling O
pathways O
. O
Non-Hodgkin O
's O
lymphoma O
involving O
bilateral O
breasts O
[ O
see O
comments O
] O
We O
describe O
here O
two O
cases O
of O
diffuse O
large O
cell I-DNA
type O
non-Hodgkin I-DNA
's O
lymphoma O
affecting O
the O
bilateral O
breasts O
. O
The O
contralateral O
tumor O
in O
one O
case O
appeared O
17 O
months O
after O
the O
first O
mastectomy O
, O
whereas O
the O
bilateral O
tumors O
occurred O
concurrently O
in O
the O
other O
patient O
who O
was O
pregnant O
and O
showed O
widespread O
dissemination O
at O
initial O
presentation O
. O
Lymphoma B-cell_type
cells I-cell_type
from O
both O
cases O
showed O
the O
mature O
B-cell O
immunophenotype O
and O
had O
rearrangements O
of O
the O
BCL6 B-DNA
gene I-DNA
. O
Both O
patients O
developed O
progressive O
disease O
despite O
chemo-radiotherapy B-DNA
and O
died O
of O
leukemic O
manifestations O
. O
There O
were O
no O
apparent O
pathological O
features O
of O
lymphomas O
of O
mucosa-associated B-DNA
lymphoid O
tissue O
origin O
Biochemical O
characterization O
of O
MIP-1 O
alpha I-DNA
nuclear B-protein
protein O
. O
A O
family O
of O
hematopoietic B-cell_type
specific O
transcription B-protein
factors I-protein
, O
MIP-1 O
alpha I-DNA
nuclear B-protein
protein I-protein
( O
MNP I-DNA
) O
family O
, O
has O
recently O
been O
identified O
. O
They O
are O
intimately O
involved O
in O
regulating O
the O
transcription I-DNA
of O
the O
huMIP-1 I-DNA
alpha I-DNA
gene I-DNA
in O
monocytes B-cell_type
, O
T-cells O
, O
and O
transformed O
B-cells B-protein
. O
One O
member O
of O
the O
family O
( O
MNP-1 O
) O
is O
essential O
for O
promoter I-DNA
activity O
in O
monocytes B-cell_type
and O
B-cells I-DNA
, O
while O
another O
( O
MNP-2 O
) O
is O
required O
for O
full O
promotor O
activity O
in O
T-cells B-protein
. O
A O
third O
member O
of O
the O
family O
( O
MNP-3 O
) O
is O
expressed O
in O
PMA O
induced O
HL60 B-protein
cells I-cell_type
and O
probably O
has O
a O
role O
in O
monocyte O
differentiation O
. O
In O
this O
communication O
we O
demonstrate O
by O
two O
techniques O
that O
MNP-1 O
and O
MNP-2 O
are O
distinct O
but O
related O
factors I-protein
, O
and O
we O
present O
further O
evidence O
to O
show O
that O
MNP-1 O
acts O
as O
a O
heterodimer O
. O
Bcl-3 B-protein
expression O
and O
nuclear B-protein
translocation O
are O
induced O
by O
granulocyte-macrophage B-DNA
colony-stimulating B-protein
factor I-protein
and O
erythropoietin O
in O
proliferating O
human O
erythroid I-cell_type
precursors I-cell_line
. O
Bcl-3 B-protein
is O
a O
proto-oncogene O
involved O
in O
the O
chromosomal O
translocation O
t O
( O
14 O
; O
19 O
) O
found O
in O
some O
patients O
with O
chronic O
lymphocytic O
leukemia O
. O
It O
shares O
structural O
similarities O
with O
and O
is O
a O
member O
of O
the O
IkappaB O
family O
of O
proteins I-protein
. O
In O
this O
report I-protein
, O
involvement O
of O
Bcl-3 B-protein
in O
hematopoietic B-cell_type
growth O
factor-stimulated O
erythroid B-DNA
proliferation O
and O
differentiation O
was O
examined O
. O
In O
TF-1 B-protein
cells I-cell_line
, O
an O
erythroleukemia O
cell O
line O
, O
granulocyte-macrophage O
colony-stimulating B-protein
factor I-protein
( O
GM-CSF B-protein
) O
and O
erythropoietin O
( O
Epo O
) O
greatly O
enhanced O
Bcl-3 B-protein
expression O
at O
both O
the O
protein O
and O
mRNA I-RNA
levels O
in O
association O
with O
stimulation O
of O
proliferation O
. O
Bcl-3 B-protein
protein O
was O
also O
highly O
expressed O
in O
early O
burst-forming B-protein
unit-erythroid B-protein
( O
BFU-E B-protein
) O
-derived O
erythroid B-DNA
precursors I-cell_line
( O
day O
7 O
) O
and O
decreased O
during O
maturation O
( O
days O
10 O
and O
14 O
) O
, O
suggesting O
that O
Bcl-3 B-protein
is O
involved O
in O
normal O
erythroid B-DNA
proliferation O
. O
In O
these O
hematopoietic B-cell_type
cells I-cell_type
, O
Bcl-3 B-protein
was O
hyperphosphorylated O
. O
GM-CSF B-protein
and O
Epo O
modulated O
the O
subcellular O
localization O
of O
Bcl-3 B-protein
. O
Upon O
stimulation O
of O
TF-1 B-protein
cells I-cell_type
with O
GM-CSF B-protein
or O
Epo O
, O
the O
nuclear B-protein
translocation O
of O
Bcl-3 B-protein
was O
dramatically O
enhanced O
. O
Overexpression O
of O
Bcl-3 B-protein
in O
TF-1 B-protein
cells I-cell_type
by O
transient O
transfection O
along O
with O
the O
NF-kappaB B-protein
factors I-protein
p50 O
or O
p52 O
resulted O
in O
significant O
induction O
of O
an O
human B-DNA
immunodeficiency I-DNA
virus-type B-DNA
1 O
( O
HIV-1 B-protein
) O
kappaB-TATA-luceriferase O
reporter O
plasmid O
, O
demonstrating O
that O
Bcl-3 B-protein
has O
a O
positive O
role O
in O
transactivation O
of O
kappaB-containing I-DNA
genes I-DNA
in O
erythroid I-cell_type
cells I-cell_type
. O
Stimulation O
with O
GM-CSF B-protein
enhanced O
c-myb I-RNA
mRNA I-RNA
expression O
in O
these I-cell_type
cells I-cell_type
. O
Bcl-3 B-protein
in O
nuclear B-protein
extracts O
of O
TF-1 B-protein
cells I-cell_type
bound O
to O
a O
kappaB B-DNA
enhancer I-DNA
in O
the O
c-myb B-DNA
promoter I-DNA
together O
with O
NF-kappaB2/p52 O
and O
this O
binding O
activity O
was O
enhanced O
by O
GM-CSF B-protein
stimulation O
. O
Furthermore O
, O
cotransfection O
of O
Bcl-3 B-protein
with O
p52 O
or O
p50 O
in O
TF-1 B-protein
cells I-cell_type
resulted O
in O
significant O
activation O
of O
a O
c-myb B-DNA
kappaB-TATA-luceriferase B-protein
reporter O
plasmid O
. O
These O
findings O
suggest O
that O
Bcl-3 B-protein
may O
participate O
in O
the O
transcriptional O
regulation O
of O
certain O
kappaB-containing I-DNA
genes I-DNA
involved O
in O
hematopoiesis O
, O
including O
c-myb B-DNA
. O
Copyright O
1998 O
by O
The O
American O
Society O
of O
Hematology O
. O
5-Lipoxygenase B-protein
compartmentalization O
in O
granulocytic B-cell_type
cells I-cell_type
is O
modulated O
by O
an O
internal O
bipartite O
nuclear B-protein
localizing O
sequence O
and O
nuclear B-protein
factor I-protein
kappa B-DNA
B I-DNA
complex I-protein
formation O
. O
A O
region O
of O
basic O
amino O
acids O
spanning O
residues O
639-656 O
in O
the O
human B-DNA
5-lipoxygenase B-protein
sequence O
resembles O
a O
consensus O
bipartite O
nuclear B-protein
localizing O
sequence O
. O
A O
synthetic O
peptide O
consisting O
of O
the O
Kaposi O
fibroblast O
growth I-protein
factor I-protein
signal O
sequence O
fused O
to O
the O
5-lipoxygenase639-656 O
bipartite O
nuclear B-protein
localizing O
sequence O
has O
a O
prominent O
inhibitory O
effect O
on O
5-lipoxygenase B-protein
catalysis O
in O
granulocytic O
HL-60 B-protein
cells I-cell_type
activated O
by O
calcium O
ionophor O
A23187 B-protein
. O
Recombinant O
5-lipoxygenase B-protein
was O
not O
affected O
by O
the O
peptide O
. O
The O
peptide O
also O
inhibited O
redistribution O
of O
5-lipoxygenase B-protein
from O
the O
cytosol O
to O
the O
nuclear B-protein
membrane O
of O
HL-60 B-protein
cells I-cell_type
stimulated O
by O
A23187 B-protein
. O
5-Lipoxygenase B-protein
protein O
was O
detected O
in O
nuclear B-protein
factor I-protein
kappaB B-protein
( O
NF-kappaB I-DNA
) O
p65 O
subunit O
immunoprecipitate O
fractions O
prepared O
from O
HL-60 O
cell O
lysates O
. O
The O
amount O
of O
5-lipoxygenase B-protein
protein O
coimmunoprecipitated O
by O
NF-kappaB O
antiserum O
was O
increased O
following O
A23187 B-protein
stimulation O
. O
In O
cells I-cell_type
treated O
with O
agents O
that O
block O
5-lipoxygenase B-protein
translocation O
to O
the O
nucleus O
, O
5-lipoxygenase B-protein
protein O
appearing O
in O
the O
NF-kappaB O
immunoprecipitate O
was O
diminished O
. O
Our O
results O
implicate O
an O
internal O
bipartite O
nuclear B-protein
localizing O
sequence O
as O
a O
regulatory I-protein
domain I-protein
that O
modulates O
5-lipoxygenase B-protein
redistribution O
and O
catalysis O
in O
granulocytic B-cell_type
cells I-cell_type
. O
Additionally I-protein
, O
our O
results O
suggest O
that O
molecular O
determinants O
which O
govern O
5-lipoxygenase B-protein
and O
NF-kappaB O
redistribution O
to O
the O
nucleus O
may O
be O
coordinately O
controlled O
in O
granulocytic B-cell_type
cells I-cell_type
. O
Copyright O
1998 O
Academic O
Press O
. O
Inhibition O
of O
CD28/CD3-mediated B-protein
costimulation O
of O
naive O
and O
memory O
human B-cell_type
T I-cell_type
lymphocytes I-cell_type
by O
intracellular O
incorporation O
of O
polyclonal O
antibodies I-protein
specific O
for O
the O
activator O
protein-1 B-protein
transcriptional O
complex I-protein
. O
A O
number O
of O
indirect O
methods O
have O
been O
utilized O
in O
demonstrating O
activator O
protein-1 B-protein
transcription B-protein
factor I-protein
function O
in O
IL-2 B-DNA
promoter I-DNA
activity O
. O
However O
, O
there O
has O
been O
no O
direct O
demonstration O
that O
activator O
protein-1 B-protein
is O
involved O
in O
CD28-dependent B-protein
costimulation O
of O
IL-2 B-DNA
gene I-DNA
transcription O
in O
freshly O
isolated O
naive O
and O
memory O
human B-cell_type
T I-cell_type
lymphocytes I-cell_type
. O
To O
address O
this O
issue O
, O
the O
method O
of O
scrape O
loading O
was O
applied O
to O
purified O
peripheral B-cell_type
blood I-cell_type
T I-cell_type
lymphocytes I-cell_type
. O
Since O
scrape O
loading O
relies O
on O
adherent B-cell_type
cells I-cell_line
, O
peripheral B-cell_type
blood I-cell_type
human B-cell_type
T I-cell_line
( O
PB-T B-protein
) O
cells I-cell_type
were O
immobilized O
on O
the O
nonspecific O
cell O
attachment O
factor I-protein
poly-L-lysine B-protein
. O
Cells O
scraped O
off O
poly-L-lysine B-protein
in O
the O
presence O
of O
Ig O
FITC O
efficiently O
incorporated O
Ig O
, O
with O
relatively O
uniform O
fluorescence O
. O
T B-cell_type
cells I-cell_type
retained O
their O
physical O
parameters O
as O
measured O
by O
forward O
and O
side O
light O
scatter O
, O
and O
functional O
activity O
as O
measured O
by O
costimulation O
of O
proliferation O
and O
IL-2 B-protein
production O
after O
being O
scraped O
off O
this O
substrate O
. O
CD28/CD3-costimulated O
T B-cell_type
cells I-cell_type
produced O
intracellular O
IL-2 B-protein
from O
all O
subsets O
measured O
( O
CD4+ I-DNA
, O
CD4- O
, O
CD45RO+ I-protein
, O
and O
CD45RO- B-protein
) O
. O
IL-2 B-protein
production O
and O
intracellular O
accumulation O
in O
nonscraped O
PB-T B-protein
cells I-cell_type
activated O
with O
CD28/CD3 B-protein
coligation O
were O
skewed O
favoring O
CD45RO+ I-protein
and O
CD4+ B-protein
subsets O
, O
as O
was O
IL-2 B-protein
production O
in O
scraped O
PB-T B-protein
cells I-cell_type
. O
The O
intracellular O
incorporation O
of O
Abs O
specific O
for O
c-Fos O
and O
c-Jun O
family O
members O
by O
scrape O
loading O
inhibited O
the O
production O
and O
intracellular O
accumulation O
of O
IL-2 B-protein
within O
6 O
h O
of O
costimulation O
with O
PMA/ionomycin I-DNA
, O
or O
costimulation O
by O
CD28 B-protein
and O
CD3 B-protein
ligation O
. O
Scrape O
loading O
thus O
provides O
an O
efficient O
mechanism O
for O
intracellular O
incorporation O
of O
macromolecules O
, O
and O
the O
first O
direct O
evidence O
that O
c-Fos O
and O
c-Jun O
are O
involved O
in O
transcription I-DNA
of O
the O
IL-2 B-DNA
gene I-DNA
within O
its O
correct O
chromosomal O
context O
, O
in O
resting O
human B-cell_type
T I-cell_line
lymphocyte I-cell_line
subpopulations O
. O
Differential O
expression O
of O
Nur77 B-cell_type
family O
members O
in O
human B-DNA
T-lymphotropic I-DNA
virus O
type O
1-infected B-DNA
cells I-cell_type
: O
transactivation O
of O
the O
TR3/nur77 B-DNA
gene I-DNA
by O
Tax O
protein O
. O
We O
analyzed O
the O
differential O
expression O
and O
regulation O
of O
three O
members O
of O
the O
Nur77 B-protein
transcription B-protein
factor I-protein
family O
by O
the O
human B-DNA
T-lymphotropic I-DNA
virus O
type O
1 O
( O
HTLV-1 B-protein
) O
Tax O
protein O
. O
We O
have O
demonstrated O
that O
in O
both O
HTLV-1-infected B-protein
cells I-cell_type
and O
Tax-expressing O
JPX-9 B-DNA
cells I-cell_line
, O
TR3/nur77 O
is O
highly O
expressed O
, O
whereas O
neither O
NOR-1 O
nor O
NOT O
expression O
is O
detectable O
. O
Transient O
transfection O
analysis O
further O
confirmed O
the O
Tax O
transactivation O
of O
the O
TR3/nur77 B-DNA
promoter I-DNA
but O
not O
the O
NOR-1 B-DNA
promoter I-DNA
in O
different O
cell O
types I-cell_type
. O
Furthermore O
, O
expression O
of O
a O
luciferase O
reporter B-DNA
gene I-DNA
driven O
by O
the O
NGFI-B B-protein
( O
rat O
homolog O
of O
TR3/Nur77 B-protein
) O
response O
element I-DNA
( O
NBRE I-DNA
) O
provided O
evidence O
that O
Tax O
-mediated O
transactivation O
resulted O
in O
the O
induction O
of O
a O
functional O
protein O
. O
Cotransfection O
assays O
with O
the O
TR3/nur77 B-DNA
promoter I-DNA
sequence O
or O
the O
NBRE O
binding O
motif O
together O
with O
a O
series O
of O
Tax O
mutants O
have O
shown O
that O
Tax O
-induced O
TR3/nur77 O
expression O
is O
mediated O
by O
CREB/ATF-related B-protein
transcription B-protein
factors I-protein
. O
Negative O
regulation O
of O
the O
heat O
shock O
transcriptional O
response O
by O
HSBP1 B-protein
. O
In O
response O
to O
stress O
, O
heat O
shock O
factor I-protein
1 O
( O
HSF1 B-protein
) O
acquires O
rapid O
DNA O
binding O
and O
transient O
transcriptional O
activity O
while O
undergoing O
conformational O
transition O
from O
an O
inert O
non-DNA-binding O
monomer O
to O
active O
functional O
trimers O
. O
Attenuation O
of O
the O
inducible O
transcriptional O
response O
occurs O
during O
heat O
shock O
or O
upon O
recovery O
at O
non-stress B-DNA
conditions O
and O
involves O
dissociation O
of O
the O
HSF1 B-protein
trimer O
and O
loss O
of O
activity O
. O
We O
have O
used O
the O
hydrophobic O
repeats O
of O
the O
HSF1 B-protein
trimerization I-protein
domain I-protein
in O
the O
yeast O
two-hybrid B-DNA
protein O
interaction O
assay O
to O
identify O
heat O
shock O
factor I-protein
binding O
protein O
1 O
( O
HSBP1 B-protein
) O
, O
a O
novel O
, O
conserved O
, O
76-amino-acid O
protein O
that O
contains O
two O
extended O
arrays O
of O
hydrophobic O
repeats O
that O
interact O
with O
the O
HSF1 B-protein
heptad O
repeats O
. O
HSBP1 B-protein
is O
nuclear-localized B-DNA
and O
interacts O
in O
vivo O
with O
the O
active O
trimeric O
state O
of O
HSF1 B-protein
that O
appears O
during O
heat O
shock O
. O
During O
attenuation O
of O
HSF1 O
to O
the O
inert O
monomer O
, O
HSBP1 B-protein
associates O
with O
Hsp70 O
. O
HSBP1 B-protein
negatively O
affects O
HSF1 B-protein
DNA-binding B-protein
activity O
, O
and O
overexpression O
of O
HSBP1 B-protein
in O
mammalian B-cell_type
cells I-cell_type
represses O
the O
transactivation O
activity O
of O
HSF1 B-protein
. O
To O
establish O
a O
biological O
role O
for O
HSBP1 I-protein
, O
the O
homologous O
Caenorhabditis O
elegans O
protein O
was O
overexpressed O
in O
body O
wall O
muscle B-cell_type
cells I-cell_type
and O
was O
shown O
to O
block O
activation O
of O
the O
heat O
shock O
response O
from O
a O
heat O
shock O
promoter-reporter B-DNA
construct O
. O
Alteration O
in O
the O
level O
of O
HSBP1 B-protein
expression O
in O
C. B-protein
elegans O
has O
severe O
effects O
on O
survival O
of O
the O
animals O
after O
thermal O
and O
chemical O
stress O
, O
consistent O
with O
a O
role O
for O
HSBP1 B-protein
as O
a O
negative O
regulator O
of O
the O
heat O
shock O
response O
. O
Long-range O
transcriptional O
regulation O
of O
cytokine B-DNA
gene I-DNA
expression O
. O
Most O
studies O
on O
the O
control O
of O
cytokine B-DNA
gene I-DNA
expression O
have O
involved O
the O
functional O
analysis O
of O
proximal O
promoters O
. O
Recent O
work O
has O
identified O
distal O
elements I-DNA
that O
mediate O
long-range B-DNA
cytokine B-DNA
gene I-DNA
regulation O
and O
has O
implicated O
chromatin O
reorganization O
in O
regulation O
of O
cytokine B-DNA
gene I-DNA
loci O
. O
These O
studies O
have O
begun O
to O
elucidate O
the O
basis O
for O
cell-specificity O
and O
high-level B-protein
expression O
of O
cytokine I-DNA
genes I-DNA
. O
A O
signaling O
complex I-protein
of O
Ca2+-calmodulin-dependent B-protein
protein O
kinase I-protein
IV O
and O
protein O
phosphatase O
2A B-protein
[ O
see O
comments O
] O
Stimulation O
of O
T I-cell_type
lymphocytes I-cell_type
results O
in O
a O
rapid O
increase O
in O
intracellular O
calcium O
concentration O
( O
[ O
Ca2+ O
] O
i O
) O
that O
parallels O
the O
activation O
of O
Ca2+-calmodulin-dependent B-protein
protein O
kinase I-protein
IV I-protein
( O
CaMKIV I-DNA
) O
, O
a O
nuclear B-protein
enzyme O
that O
can O
phosphorylate O
and O
activate O
the O
cyclic O
adenosine O
monophosphate O
( O
cAMP I-DNA
) O
response O
element-binding O
protein I-protein
( O
CREB I-DNA
) O
. O
However O
, O
inactivation O
of O
CaMKIV B-cell_type
occurs O
despite O
the O
sustained O
increase O
in O
[ O
Ca2+ O
] O
i O
that O
is O
required O
for O
T O
cell O
activation O
. O
A O
stable O
and O
stoichiometric O
complex I-protein
of O
CaMKIV B-cell_type
with O
protein O
serine-threonine O
phosphatase O
2A B-protein
( O
PP2A B-protein
) O
was O
identified O
in O
which O
PP2A B-protein
dephosphorylates O
CaMKIV I-cell_type
and O
functions O
as O
a O
negative O
regulator O
of O
CaMKIV B-cell_type
signaling O
. O
In O
Jurkat O
T B-cell_type
cells I-cell_type
, O
inhibition O
of O
PP2A B-protein
activity O
by O
small O
t O
antigen I-protein
enhanced O
activation O
of O
CREB O
-mediated O
transcription O
by O
CaMKIV O
. O
These O
findings O
reveal O
an O
intracellular O
signaling O
mechanism O
whereby O
a O
protein O
serine-threonine O
kinase I-protein
( O
CaMKIV I-DNA
) O
is O
regulated O
by O
a O
tightly O
associated O
protein O
serine-threonine O
phosphatase O
( O
PP2A B-protein
) O
. O
Hypoxia O
down-regulates O
MCP-1 O
expression O
: O
implications O
for O
macrophage O
distribution O
in O
tumors O
. O
Monocyte O
chemoattractant O
protein O
1 O
( O
MCP-1 O
) O
is O
likely O
to O
contribute O
to O
the O
macrophage O
infiltrate O
in O
human B-DNA
ovarian I-DNA
carcinomas O
. O
Although O
MCP-1 O
is O
predominantly O
expressed O
by O
the O
tumor O
parenchyma O
, O
macrophages O
accumulate O
at O
highest O
density O
in O
necrotic O
regions I-protein
, O
which O
are O
associated O
with O
low O
oxygen O
tensions O
. O
Tumor O
necrosis B-protein
factor I-protein
alpha I-DNA
( O
TNF-alpha I-DNA
) O
can O
stimulate O
MCP-1 O
production O
and O
is O
also O
present O
within O
ovarian O
carcinomas O
. O
We O
have O
investigated O
the O
effect O
of O
hypoxia O
both O
on O
MCP-1 O
expression O
in O
ovarian O
cancer O
cell O
lines I-cell_line
and O
monocyte O
migration O
. O
Hypoxia O
down-regulated O
TNF-alpha-induced O
MCP-1 I-RNA
mRNA I-RNA
and O
protein O
production O
by O
ovarian O
cancer B-cell_type
cells I-cell_type
. O
The O
effect O
was O
mimicked O
by O
cobalt O
chloride O
and O
desferrioxamine O
, O
consistent O
with O
a O
specific O
oxygen-sensing I-cell_type
mechanism O
. O
Unlike O
antioxidants O
, O
hypoxia O
did O
not O
inhibit O
nuclear B-protein
factor I-protein
KB B-protein
mobilization O
. O
Monocyte O
migration O
in O
response O
to O
MCP-1 O
was O
also O
diminished O
under O
hypoxic O
conditions O
. O
Down-regulation O
of O
MCP-1 O
expression O
and O
the O
inhibition O
of O
monocyte O
migration O
are O
independent O
effects O
of O
hypoxia O
that O
may O
contribute O
to O
the O
distribution O
of O
macrophages O
within O
ovarian O
tumors O
. O
Activation O
of O
nuclear B-protein
factor I-protein
kappa B-DNA
B I-DNA
inflammatory O
bowel O
disease O
[ O
see O
comments O
] O
BACKGROUND I-protein
: O
Expression O
of O
pro-inflammatory O
cytokines O
is O
increased O
in O
the O
intestinal O
lamina O
propria O
of O
patients O
with O
inflammatory O
bowel O
disease O
( O
IBD I-DNA
) O
. O
Nuclear I-protein
factor I-protein
kappa B-DNA
B I-DNA
( O
NF O
kappa B-DNA
B I-DNA
) O
controls O
transcription I-DNA
of O
inflammation I-DNA
genes I-DNA
. O
On O
activation O
, O
NF O
kappa B-DNA
B I-DNA
is O
rapidly O
released O
from O
its O
cytoplasmic O
inhibitor O
( O
I O
kappa B-DNA
B I-DNA
) O
, O
transmigrates O
into O
the O
nucleus O
, O
and O
binds O
to O
DNA O
response O
elements I-DNA
in O
gene I-DNA
promoter I-DNA
regions I-protein
. O
AIMS O
: O
To O
investigate O
whether O
increased O
activation O
of O
NF O
kappa B-DNA
B I-DNA
is O
important O
in O
IBD O
and O
may O
be O
down-regulated O
by O
anti-inflammatory B-DNA
treatment O
. O
METHODS I-protein
: O
Activation O
of O
NF O
kappa B-DNA
B I-DNA
was O
determined O
by O
western O
blot O
assessment O
and O
electrophoretic O
mobility O
shift O
assay O
in O
nuclear B-protein
extracts O
of O
colonic O
biopsy O
samples O
as O
well O
as O
lamina O
propria O
mononuclear B-cell_type
cells I-cell_type
. O
RESULTS I-protein
: O
Nuclear O
levels O
of O
NF O
kappa B-DNA
B I-DNA
p65 O
are O
increased O
in O
lamina O
propria O
biopsy O
specimens O
from O
patients O
with O
Crohn O
's O
disease O
in O
comparison O
with O
patients O
with O
ulcerative O
colitis O
and O
controls O
. O
Increased O
activation O
of O
NF O
kappa B-DNA
B I-DNA
was O
detected O
in O
lamina O
propria O
mononuclear B-cell_type
cells I-cell_type
from O
patients O
with O
active O
IBD O
. O
Corticosteroids O
strongly O
inhibit O
intestinal O
NF O
kappa B-DNA
B I-DNA
activation O
in O
IBD O
in O
vivo O
and O
in O
vitro O
by O
stabilising O
the O
cytosolic O
inhibitor O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
against I-DNA
activation O
induced O
degradation O
. O
CONCLUSIONS I-protein
: O
In O
both O
IBDs O
, O
but O
particularly O
Crohn O
's O
disease O
, O
increased O
activation O
of O
NF O
kappa B-DNA
B I-DNA
may O
be O
involved O
in O
the O
regulation O
of O
the O
inflammatory O
response O
. O
Inhibition O
of O
NF O
kappa B-DNA
B I-DNA
activation O
may O
represent O
a O
mechanism O
by O
which O
steroids O
exert O
an O
anti-inflammatory B-DNA
effect O
in O
IBD O
Insufficient O
glycemic O
control O
increases O
nuclear B-protein
factor-kappa B-DNA
B I-DNA
binding O
activity O
in O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
isolated O
from O
patients O
with I-DNA
type O
1 O
diabetes O
. O
OBJECTIVE O
: O
The O
redox-sensitive B-protein
transcription B-protein
factor I-protein
nuclear B-protein
factor-kappa B-DNA
B I-DNA
( O
NF-kappa B-protein
B I-DNA
) O
is O
believed O
to O
contribute O
to O
late O
diabetic O
complications O
. O
It O
is O
unknown O
whether O
NF-kappa B-protein
B I-protein
is O
influenced O
by O
glycemic O
control O
. O
RESEARCH O
DESIGN I-protein
AND O
METHODS I-protein
: O
To O
determine O
whether O
NF-kappa B-protein
B I-protein
is O
activated O
in O
patients O
with O
insufficient O
glycemic O
control O
( O
HbA1c O
> O
10 O
% O
) O
, O
we O
developed O
a O
tissue O
culture-independent B-DNA
electrophoretic O
mobility O
shift O
assay O
( O
EMSA I-DNA
) O
-based O
semiquantitative O
detection O
system O
that O
allowed O
us O
to O
determine O
NF-kappa B-protein
B I-protein
activation O
in O
ex O
vivo-isolated O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_line
( O
PBMCs O
) O
. O
We O
included O
43 O
patients O
with I-DNA
type O
1 O
diabetes O
in O
this O
cross-sectional O
study O
. O
10 O
of O
those O
received O
the O
antioxidant O
thioctic O
acid O
( O
600 O
mg/day I-cell_line
p.o. I-DNA
) O
for O
2 O
weeks O
. O
RESULTS I-protein
: O
Monocytes O
of O
patients O
with O
HbA1c O
levels O
> O
10 O
% O
demonstrated O
significantly O
higher O
NF-kappa B-protein
B I-protein
binding O
activity O
in O
an O
EMSA O
and O
a O
stronger O
NF-kappa B-protein
B I-protein
staining O
in O
immunohistochemistry O
than O
monocytes B-cell_type
of O
patients O
with O
HbA1c O
levels O
of O
6-8 O
% O
. O
The O
increase O
in O
NF-kappa B-protein
B I-protein
activation O
correlated O
with O
an O
increase O
in O
plasmatic O
markers O
of O
lipid O
peroxidation O
. O
Treatment O
with O
the O
antioxidant O
thioctic O
acid O
decreased O
NF-kappa B-protein
B I-protein
binding O
activity O
. O
CONCLUSIONS I-protein
: O
Hyperglycemia B-cell_type
induces O
activation O
of O
the O
transcription B-protein
factor I-protein
NF-kappa B-protein
B I-protein
in O
ex O
vivo-isolated I-DNA
PBMCs O
of O
patients O
with I-DNA
type O
1 O
diabetes O
. O
NF-kappa B-protein
B I-protein
activation O
is O
at O
least O
partially O
dependent O
on O
oxidative O
stress O
, O
since O
the O
antioxidant O
thioctic O
acid O
significantly O
lowered O
the O
extent O
of O
NF-kappa B-protein
B I-protein
binding O
activity O
. O
Synergistic O
activation O
of O
MAP B-cell_type
kinase I-protein
( O
ERK1/2 B-protein
) O
by O
erythropoietin O
and O
stem O
cell O
factor I-protein
is O
essential O
for O
expanded O
erythropoiesis O
. O
Stem O
cell O
factor I-protein
( O
SCF I-DNA
) O
and O
erythropoietin O
( O
EPO I-DNA
) O
work O
synergistically O
to O
support O
erythropoiesis O
, O
but O
the O
mechanism O
for O
this O
synergism O
is O
unknown O
. O
By O
using O
purified O
human O
erythroid I-cell_type
colony-forming I-cell_type
cells I-cell_line
( O
ECFC I-DNA
) O
, O
we O
have O
found O
that O
SCF O
and O
EPO O
synergistically O
activate O
MAP I-protein
kinase I-protein
( O
MAPK I-DNA
, O
ERK1/2 B-protein
) O
, O
which O
correlates O
with O
the O
cell O
growth O
and O
thus O
may O
be O
responsible O
for O
the O
synergistic O
effects O
. O
Treatment O
of O
the B-cell_type
cells I-cell_type
with O
PD98059 I-protein
and O
wortmannin O
, O
inhibitors O
of O
MEK O
and O
PI-3 B-protein
kinase I-protein
, O
respectively O
, O
inhibited O
the O
synergistic O
activation O
of O
MAPK O
and O
also O
the O
cell O
growth O
, O
further O
supporting O
this O
conclusion O
. O
Wortmannin O
only O
inhibits O
MAPK O
activation O
induced O
by O
EPO O
but O
not O
that O
by O
SCF I-protein
, O
suggesting O
that O
SCF O
and O
EPO O
may O
activate O
MAPK O
through O
different O
pathways O
, O
which O
would O
facilitate O
synergy O
. O
Furthermore O
, O
EPO I-protein
, O
but O
not O
SCF I-protein
, O
led O
to O
activation O
of O
STAT5 I-protein
, O
whereas O
SCF O
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO O
-induced O
STAT5 B-protein
activation O
, O
suggesting O
that O
STAT5 B-protein
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF O
and O
EPO O
. O
Together O
, O
the O
data O
suggest O
that O
synergistic O
activation O
of O
MAPK O
by O
SCF O
and O
EPO O
is O
essential O
for O
expanded O
erythropoiesis O
. O
Copyright O
1998 O
by O
The O
American O
Society O
of O
Hematology O
. O
The O
molecular O
and O
phenotypic O
profile O
of O
primary B-cell_line
central I-cell_line
nervous O
system O
lymphoma O
identifies O
distinct O
categories O
of O
the O
disease O
and O
is O
consistent O
with O
histogenetic O
derivation O
from O
germinal O
center-related B-DNA
B I-DNA
cells I-cell_type
. O
Primary O
central O
nervous O
system O
lymphoma O
( O
PCNSL I-DNA
) O
is O
a O
major O
cause O
of O
morbidity O
and O
mortality O
among O
human B-DNA
immunodeficiency I-DNA
virus O
( O
HIV O
) O
-infected O
individuals O
. O
The O
precise O
histogenetic O
derivation O
and O
the O
molecular O
pathogenesis O
of O
PCNSL O
is O
poorly O
understood O
. O
In O
an O
attempt O
to O
clarify O
the O
histogenesis O
and O
pathogenesis O
of O
these O
lymphomas O
, O
49 O
PCNSL I-protein
( O
26 O
acquired O
immunodeficiency O
syndrome O
[ O
AIDS O
] O
-related O
and O
23 O
AIDS-unrelated B-protein
) O
were O
analyzed O
for O
multiple O
biologic O
markers O
, O
which O
are O
known O
to O
bear O
histogenetic O
and O
pathogenetic O
significance O
for O
mature O
B-cell O
neoplasms O
. O
PCNSL O
associated O
frequently O
( O
50.0 I-DNA
% O
) O
with O
mutations O
of O
BCL-6 O
5 O
' O
noncoding O
regions I-protein
, O
which O
are O
regarded O
as O
a O
marker O
of O
B-cell O
transition O
through O
the O
germinal O
center O
( O
GC I-DNA
) O
. O
Expression O
of O
BCL-6 O
protein I-protein
, O
which O
is O
restricted O
to O
GC B-protein
B I-DNA
cells I-cell_type
throughout O
physiologic O
B-cell O
maturation O
, O
was O
detected O
in O
100 O
% O
AIDS-unrelated B-protein
PCNSL O
and O
in O
56.2 B-protein
% O
AIDS-related B-DNA
cases O
. O
Notably O
, O
among O
AIDS-related B-DNA
PCNSL I-protein
, O
expression O
of O
BCL-6 O
was O
mutually O
exclusive O
with O
expression O
of O
Epstein-Barr O
virus O
( O
EBV I-DNA
) O
-encoded O
latent O
membrane O
protein I-protein
( O
LMP I-DNA
) O
-1 O
and I-DNA
, O
with O
few O
exceptions O
, O
also O
of O
BCL-2 O
. O
All O
but O
one O
PCNSL O
expressed O
hMSH2 I-cell_line
, O
which O
among O
mature O
B I-DNA
cells I-cell_type
selectively O
stains O
GC B-protein
B I-DNA
cells I-cell_type
. O
These O
data O
suggest O
that O
PCNSL O
may O
be O
frequently O
related O
to O
GC B-protein
B I-DNA
cells I-cell_type
and O
may O
be O
segregated O
into O
two O
major O
biologic O
categories O
based O
on O
the O
expression O
pattern O
of O
BCL-6 O
, O
LMP-1 O
, O
and O
BCL-2 O
. O
BCL-6 O
( O
+ O
) O
/ O
LMP-1 O
( O
- O
) O
/ O
BCL-2 O
( O
- O
) O
PCNSL O
occur O
both O
in O
the O
presence O
and O
in O
the O
absence O
of O
HIV O
infection O
and O
consistently O
display O
a O
large O
noncleaved O
cell O
morphology O
. O
Conversely O
, O
BCL-6 O
( O
- O
) O
/ O
LMP-1 O
( O
+ O
) O
/ O
BCL-2 O
( O
+ O
) O
PCNSL O
are O
restricted O
to O
HIV-infected B-protein
hosts O
and O
are O
represented O
by O
lymphomas O
with O
immunoblastic O
features O
. O
These O
data O
are O
relevant O
for O
the O
pathogenesis O
and O
histogenesis O
of O
PCNSL O
and O
may O
be O
helpful O
to O
segregate O
distinct O
biologic O
and O
prognostic O
categories O
of O
these O
lymphomas O
. O
Copyright O
1998 O
by O
The O
American O
Society O
of O
Hematology O
. O
Antioxidant O
regulation O
of O
phorbol O
ester-induced B-protein
adhesion O
of O
human B-cell_type
Jurkat I-cell_type
T-cells O
to O
endothelial B-cell_type
cells I-cell_type
. O
Regulation O
of O
adhesion O
molecule O
expression O
and O
function O
by O
reactive O
oxygen O
species O
via O
specific O
redox O
sensitive O
mechanisms O
have O
been O
reported O
. O
The O
effects O
of O
clinically O
safe O
antioxidants O
in O
the O
regulation O
of O
adhesion O
molecule O
expression O
in O
human B-DNA
endothelial I-cell_type
cells I-cell_line
( O
ECV I-DNA
) O
, O
and O
adherence O
of O
human B-cell_type
Jurkat I-cell_line
T B-cell_type
cells O
to O
ECV B-cell_type
cells I-cell_type
were O
investigated O
. O
The O
thiol O
antioxidant O
, O
alpha-lipoate I-DNA
, O
at O
clinically O
relevant O
doses O
down-regulated O
phorbol O
12-myristate B-protein
13-acetate B-protein
( O
PMA I-DNA
) O
-induced O
adhesion O
molecule O
expression O
and O
cell-cell O
adhesion O
. O
Inhibition O
of O
PMA-induced B-protein
ICAM-1 B-protein
and O
VCAM-1 B-protein
expression O
as O
well O
as O
PMA-induced B-protein
adhesion O
of O
Jurkat O
T-cells O
to O
ECV B-cell_type
cells I-cell_type
by O
alpha-lipoate B-protein
was O
dose O
dependent O
( O
50-250 O
microM B-protein
) O
. O
The O
effect O
was O
significant O
for O
ICAM-1 B-protein
( O
p O
< O
.01 B-protein
) O
and O
VCAM-1 B-protein
( O
p O
< O
.01 B-protein
) O
expression O
in O
cells I-cell_type
pretreated O
with O
100 O
microM I-RNA
alpha-lipoate B-protein
compared O
to O
PMA-activated B-protein
untreated B-cell_type
cells I-cell_type
. O
Inhibition O
of O
PMA-induced B-protein
adhesion O
molecule O
expression O
and O
cell-cell O
adhesion O
was O
more O
pronounced O
when O
a O
combination O
of O
antioxidants O
, O
alpha-lipoate O
and O
alpha-tocopherol I-DNA
, O
were O
used O
compared O
to O
the O
use O
of O
either O
of O
these O
antioxidant O
alone O
. O
The O
regulation O
of O
adhesion O
molecule O
expression O
and O
function O
by O
low O
concentration O
of O
antioxidants O
investigated O
does O
not O
appear O
to O
be O
NF-kappaB O
regulated O
or O
transcription O
dependent O
because O
no O
change O
in O
the O
mRNA I-RNA
response O
was O
observed O
. O
Protein O
kinase I-protein
C I-protein
( O
PKC I-DNA
) O
has O
been O
suggested O
to O
regulate O
PMA-induced B-protein
adhesion O
molecule O
expression O
by O
post-transcriptional B-DNA
stabilization O
of O
adhesion O
molecule O
mRNA I-RNA
. O
Alpha-lipoate B-protein
pretreatment O
did O
not O
influence O
the O
response O
of O
PKC B-cell_type
activity O
to O
PMA O
. O
Oxidants O
are O
known O
to O
be O
involved O
in O
the O
regulation O
of O
cell O
adhesion O
processes O
. O
Treatment O
of O
ECV B-cell_type
cells I-cell_type
with O
PMA O
induced O
generation O
of O
intracellular O
oxidants O
. O
Alpha-lipoate B-protein
( O
100 O
or O
250 O
microM B-protein
) O
treatment O
decreased O
PMA-induced B-protein
generation O
of O
intracellular O
oxidants O
. O
The O
inhibitory O
effect O
of O
low O
concentration O
of O
alpha-lipaote B-cell_type
alone O
or O
in O
combination O
with O
alpha-tocopherol O
on O
agonist-induced O
adhesion O
processes O
observed O
in O
this O
study O
may O
be O
of O
potential O
therapeutic O
value O
. O
Binding O
of O
human B-cell_type
immunodeficiency I-DNA
virus O
type O
1 O
to O
CD4 B-protein
and O
CXCR4 B-protein
receptors O
differentially O
regulates O
expression O
of O
inflammatory I-DNA
genes I-DNA
and O
activates O
the O
MEK O
/ERK I-protein
signaling O
pathway O
. O
We O
have O
previously O
shown O
that O
binding O
of O
human B-cell_type
immunodeficiency I-DNA
virus O
type O
1 O
( O
HIV-1 B-protein
) O
virions O
to O
CD4 B-protein
receptors O
stimulates O
association O
of O
Lck O
with O
Raf-1 B-protein
and O
results O
in O
the O
activation O
of O
Raf-1 B-protein
kinase I-protein
in O
a O
Ras-independent O
manner O
. O
In O
the O
present O
study O
, O
we O
demonstrate O
that O
HIV-1 O
envelope O
glycoproteins O
of O
both O
T-cell-tropic O
and O
macrophagetropic O
strains O
rapidly O
activate O
the O
ERK/mitogen-activated O
protein I-protein
( O
MAP I-DNA
) O
kinase O
pathway O
and O
the O
binding O
of O
nuclear B-protein
transcription B-protein
factors I-protein
( O
AP-1 B-protein
, O
NF-kappaB O
, O
and O
C/EBP B-protein
) O
and O
stimulate O
expression O
of O
cytokine O
and O
chemokine I-DNA
genes I-DNA
. O
The O
activation O
of O
this O
signaling O
pathway O
requires O
functional O
CD4 B-protein
receptors O
and O
is O
independent O
of O
binding O
to O
CXCR4 B-protein
. O
Binding O
of O
the O
natural O
ligand O
stromal O
cell-derived B-protein
factor I-protein
1 O
( O
SDF-1 O
) O
to O
CXCR4 I-protein
, O
which O
inhibits O
entry O
of O
T-cell-tropic B-protein
HIV-1 O
, O
activates O
also O
the O
ERK/ I-protein
MAP I-protein
kinase I-protein
pathway O
. O
However O
, O
SDF-1 O
did O
not O
affect O
the O
CD4-mediated B-protein
expression O
of O
cytokine O
and O
chemokine I-DNA
genes I-DNA
. O
These O
results O
provide O
firm O
molecular O
evidence O
that O
binding O
of O
HIV-1 O
envelope O
glycoproteins O
to O
CD4 B-protein
receptor I-protein
initiates O
a O
signaling O
pathway O
( O
s O
) O
independent O
of O
the O
binding O
to O
the O
chemokine I-DNA
receptor I-protein
that O
leads O
to O
the O
aberrant O
expression O
of O
inflammatory I-DNA
genes I-DNA
and O
may O
contribute O
significantly O
to O
HIV-1 O
replication O
as O
well O
as O
to O
deregulation O
of O
the O
immune O
system O
. O
Antigen I-DNA
receptor I-protein
signaling O
induces O
MAP O
kinase-mediated O
phosphorylation O
and O
degradation O
of O
the O
BCL-6 B-DNA
transcription B-protein
factor I-protein
. B-protein
The O
bcl-6 B-protein
proto-oncogene O
encodes O
a O
POZ/zinc B-protein
finger O
transcriptional O
repressor O
expressed O
in O
germinal O
center O
( O
GC I-DNA
) O
B I-DNA
and O
T B-cell_type
cells I-cell_type
and O
required O
for O
GC B-protein
formation O
and O
antibody O
affinity O
maturation O
. O
Deregulation O
of O
bcl-6 B-protein
expression O
by O
chromosomal O
rearrangements O
and O
point O
mutations O
of O
the O
bcl-6 B-DNA
promoter I-DNA
region O
are O
implicated O
in O
the O
pathogenesis O
of O
B-cell O
lymphoma O
. O
The O
signals O
regulating O
bcl-6 B-protein
expression O
are O
not O
known O
. O
Here O
we O
show O
that O
antigen I-DNA
receptor I-protein
activation O
leads O
to O
BCL-6 O
phosphorylation O
by O
mitogen-activated B-DNA
protein O
kinase I-protein
( O
MAPK I-DNA
) O
. O
Phosphorylation I-protein
, O
in O
turn O
, O
targets I-cell_line
BCL-6 O
for O
rapid O
degradation O
by O
the O
ubiquitin O
/ O
proteasome O
pathway O
. O
These O
findings O
indicate O
that O
BCL-6 O
expression O
is O
directly O
controlled O
by O
the O
antigen I-DNA
receptor I-protein
via O
MAPK O
activation O
. O
This O
signaling O
pathway O
may O
be O
crucial O
for O
the O
control O
of O
B-cell O
differentiation O
and O
antibody O
response O
and O
has O
implications O
for O
the O
regulation O
of O
other O
POZ/zinc B-protein
finger O
transcription B-protein
factors I-protein
in O
other O
tissues O
. O
Glucocorticoid O
receptors O
are O
differentially O
expressed O
in O
the B-cell_type
cells I-cell_type
and O
tissues O
of O
the O
immune O
system O
. O
Cytosolic O
glucocorticoid I-DNA
receptor I-protein
( O
GR I-DNA
) O
binding O
studies O
on O
immune O
tissues O
demonstrate O
that O
the O
thymus O
exhibits O
three O
to O
four O
times O
higher O
levels O
of O
GR I-protein
protein O
than O
the O
spleen O
. O
High O
levels O
of O
GR B-cell_type
are O
consistent O
with O
the O
exquisite O
sensitivity O
of O
the O
thymus O
to O
glucocorticoid O
exposure O
. O
Nevertheless I-protein
, O
whole O
cell O
binding O
studies O
reveal O
similar O
levels O
of O
GR B-cell_type
in O
immature O
thymic B-cell_line
T I-cell_type
lymphocytes I-cell_type
and O
more O
mature I-protein
, O
splenic O
T I-cell_type
lymphocytes I-cell_type
. O
Moreover O
, O
whole O
cell O
binding O
techniques O
indicate O
that O
neutrophils O
( O
which O
represent O
roughly O
30 O
% O
of O
splenic O
leukocytes O
) O
exhibit O
higher O
GR B-protein
than O
both O
T I-cell_line
and O
B I-DNA
lymphocytes I-cell_type
, O
further O
contradicting O
results O
from O
cytosolic O
binding O
studies O
. O
To O
address O
these O
inconsistencies O
, O
GR I-protein
protein O
was O
assessed O
in O
immune B-cell_type
cells I-cell_type
and O
tissues O
using O
cytosolic O
radioligand O
binding O
. O
Western O
blot O
analysis O
, O
and O
immunocytochemistry O
. O
Consistent O
with O
previous O
cytosolic I-DNA
receptor I-protein
binding O
studies O
on O
immune O
tissue O
homogenates O
, O
thymic B-cell_line
T B-cell_type
cells I-cell_type
were O
found O
to O
have O
higher O
levels O
of O
GR B-cell_type
than O
T B-cell_type
cells I-cell_type
isolated O
from O
the O
spleen O
. O
In O
addition O
, O
neutrophils O
were O
found O
to O
have O
fewer O
GR B-protein
than I-cell_type
lymphocytes I-cell_type
and O
monocytes B-cell_type
. O
These O
results O
indicate O
a O
meaningful O
relationship O
between I-DNA
receptor I-protein
expression O
and O
known O
sensitivity O
to O
glucocorticoids O
. O
Functional O
replacement O
of O
the O
mouse B-DNA
E2A B-DNA
gene I-DNA
with O
a O
human B-DNA
HEB I-cell_type
cDNA I-RNA
. O
The O
mammalian O
E2A B-protein
, O
HEB I-protein
, O
and O
E2-2 I-DNA
genes I-DNA
encode O
a O
unique O
class O
of O
basic O
helix-loop-helix I-cell_line
( O
bHLH I-DNA
) O
transcription B-protein
factors I-protein
that O
are O
evolutionarily O
conserved O
and O
essential O
for O
embryonic B-cell_type
and O
postnatal O
development O
. O
While O
the O
structural O
and O
functional O
similarities O
among O
the O
gene I-DNA
products O
are O
well O
demonstrated O
, O
it O
is O
not O
clear O
why O
deletion O
of O
E2A B-protein
, O
but O
not O
HEB O
or O
E2-2 I-protein
, O
leads O
to O
a O
complete O
arrest O
in O
B-lymphocyte B-protein
development O
. O
To O
understand O
the O
molecular O
basis O
of O
the O
functional O
specificity O
between O
E2A B-protein
and O
HEB O
/ O
E2-2 B-protein
in O
mammalian O
development O
, O
we O
generated O
and O
tested O
a O
panel O
of O
E2A B-protein
knockin O
mutations O
including O
subtle O
mutations O
in O
the O
E12 B-protein
and O
E47 B-protein
exons O
and O
substitution O
of O
both O
E12 B-protein
and O
E47 B-protein
exons O
with O
a O
human B-DNA
HEB I-cell_type
cDNA I-RNA
. O
We O
find O
that O
the O
alternatively O
spliced O
E12 B-protein
and O
E47 B-protein
bHLH I-RNA
proteins I-protein
of O
the O
E2A B-DNA
gene I-DNA
play O
similar O
and O
additive O
roles O
in O
supporting O
B I-DNA
lymphopoiesis O
. O
Further O
, O
we O
find O
that O
HEB O
driven O
by O
the O
endogenous O
E2A B-DNA
promoter I-DNA
can O
functionally O
replace O
E2A B-protein
in O
supporting O
B-cell O
commitment O
and O
differentiation O
toward O
completion O
. O
Finally O
, O
the O
postnatal O
lethality O
associated O
with O
E2A B-protein
disruption O
is O
fully O
rescued O
by O
the O
addition O
of O
HEB B-cell_type
. O
This O
study O
suggests O
that O
the O
functional O
divergence O
among O
E12 I-protein
, O
E47 I-protein
, O
and O
HEB O
in O
different O
cell O
types I-cell_type
is O
partially O
defined O
by O
the O
context O
of O
gene I-DNA
expression O
. O
Biased O
dependency O
of O
CD80 B-protein
versus O
CD86 B-protein
in O
the O
induction O
of O
transcription B-protein
factors I-protein
regulating O
the O
human O
IL-2 B-DNA
promoter I-DNA
. O
In O
addition O
to O
the O
signals O
obtained O
by O
ligation O
of O
the O
TCR I-protein
, O
T B-cell_type
cells I-cell_type
need O
additional O
, O
co-stimulatory O
signals O
to O
be O
activated O
. O
One O
such O
co-stimulatory O
signal O
is O
delivered O
when O
CD28 B-protein
on O
T B-cell_type
cells I-cell_type
binds O
to O
CD80 B-protein
or O
CD86 B-protein
on O
antigen-presenting B-cell_type
cells I-cell_line
( O
APC I-DNA
) O
. O
In O
the O
present O
study O
, O
we O
analyzed O
the O
ability O
of O
CD80 B-protein
and O
CD86 O
to O
co-stimulate O
human B-cell_type
T I-cell_type
cells I-cell_type
activated O
by O
superantigen O
. O
Using O
the O
Raji O
B O
cell O
lymphoma O
, O
which O
express O
similar O
levels O
of O
CD80 B-protein
and O
CD86 I-protein
, O
it O
was O
found O
that O
T O
cell O
proliferation O
was O
mainly O
co-stimulated B-protein
by O
CD80 B-protein
. O
To O
further O
characterize O
the O
consequences O
of O
this O
biased O
co-stimulatory O
dependency O
, O
we O
employed O
a O
well-defined B-DNA
system O
of O
transfected B-cell_line
CHO B-cell_type
cells I-cell_type
expressing O
human B-DNA
MHC I-protein
class I-protein
II I-protein
together O
with O
CD80 I-protein
, O
CD86 B-protein
or O
CD80 B-protein
and O
CD86 B-protein
. O
Proliferation I-DNA
of O
freshly O
prepared O
CD4+ B-cell_type
T B-cell_type
cells I-cell_type
required O
the O
presence O
of O
either O
CD80 B-protein
or O
CD86 B-protein
. O
However O
, O
IL-2 B-protein
production O
reached O
only O
suboptimal O
levels O
in O
the O
presence O
of O
CD86 B-protein
but O
optimal O
levels O
with O
CD80 B-protein
. O
To O
analyze O
IL-2 B-protein
transcriptional O
activity O
in O
CD80 B-protein
and O
CD86 B-protein
co-stimulated B-cell_type
T B-cell_type
cells I-cell_type
we O
used O
Jurkat O
T B-cell_type
cells I-cell_type
transfected O
with O
luciferase O
reporter B-DNA
gene I-DNA
constructs O
. O
CD80 B-protein
induced O
higher O
levels O
of O
IL-2 B-DNA
promoter I-DNA
-enhancer O
activity O
compared O
to O
CD86 B-protein
. O
Furthermore O
, O
the O
activity O
of O
transcription B-protein
factors I-protein
regulating O
the O
IL-2 B-protein
promoter-enhancer B-DNA
region O
including O
activation O
protein-1 B-protein
, O
CD28 B-protein
response O
element I-DNA
and O
nuclear B-protein
factor I-protein
kappaB B-protein
were O
4-8 O
times O
higher O
after O
CD80 B-protein
compared O
to O
CD86 B-protein
ligation O
. O
Our O
results O
suggest O
that O
the O
eventual O
appearance O
of O
CD80 B-protein
on O
recently O
activated O
CD86+ B-protein
APC O
is O
important O
for O
the O
superinduction O
of O
IL-2 B-protein
production O
and O
to O
support O
vigorous O
T O
cell O
proliferation O
. O
Duplication O
of O
the O
DR3 B-protein
gene I-DNA
on O
human B-DNA
chromosome I-cell_type
1p36 O
and O
its O
deletion O
in O
human B-DNA
neuroblastoma I-DNA
. O
The O
human B-DNA
DR3 B-protein
gene I-DNA
, O
whose O
product O
is O
also O
known O
as O
Wsl-1/APO-3/TRAMP/LARD I-cell_line
, O
encodes O
a O
tumor O
necrosis O
factor-related B-DNA
receptor I-protein
that O
is O
expressed O
primarily O
on O
the O
surface I-protein
of O
thymocytes O
and I-cell_type
lymphocytes I-cell_type
. O
DR3 B-protein
is O
capable O
of O
inducing O
both O
NF-kappa B-protein
B I-protein
activation O
and O
apoptosis O
when O
overexpressed O
in O
mammalian B-cell_type
cells I-cell_line
, O
although O
its O
ligand O
has O
not O
yet O
been O
identified O
. O
We O
report O
here O
that O
the O
DR3 B-protein
gene I-DNA
locus O
is O
tandemly O
duplicated O
on O
human B-DNA
chromosome I-cell_type
band O
1p36.2-p36.3 B-DNA
and O
that O
these O
genes I-DNA
are O
hemizygously O
deleted O
and/or I-cell_line
translocated O
to O
another O
chromosome O
in O
neuroblastoma O
( O
NB I-DNA
) O
cell O
lines I-cell_line
with O
amplified O
MYCN O
. O
Duplication O
of O
at O
least O
a O
portion O
of O
the O
DR3 B-protein
gene I-DNA
, O
including O
the O
extracellular O
and O
transmembrane O
regions I-protein
but O
not O
the O
cytoplasmic I-protein
domain I-protein
, O
was O
demonstrated O
by O
both O
fluorescence O
in O
situ O
hybridization O
and O
genomic O
Southern O
blotting O
. O
In O
most O
NB O
cell O
lines I-cell_line
, O
both O
the O
DR3 B-protein
and O
the O
DR3L B-protein
sequences O
are O
simultaneously O
deleted O
and/or I-cell_line
translocated O
to O
another O
chromosome O
. O
Finally O
, O
DR3/ O
Wsl-1 B-protein
protein O
expression O
is O
quite O
variable O
among O
these O
NB O
cell O
lines I-cell_line
, O
with O
very O
low O
or O
undetectable O
levels O
in O
7 O
of O
17 O
NB O
cell O
lines I-cell_line
Differential O
protection O
of O
normal O
and O
malignant O
human B-DNA
myeloid I-DNA
progenitors O
( O
CFU-GM B-protein
) O
from O
Ara-C O
toxicity O
using O
cycloheximide O
. O
Cycloheximide B-cell_type
, O
a O
reversible O
protein O
synthesis O
inhibitor O
, O
is O
thought O
to O
block O
DNA O
replication O
in O
normal O
cells I-cell_type
by O
preventing O
synthesis O
of O
a O
labile O
protein O
. O
In O
animal O
systems O
, O
cycloheximide O
protects O
normal O
cells I-cell_type
from O
cytotoxic O
S-phase B-protein
specific O
agents O
, O
such O
as O
cytosine O
arabinoside O
( O
Ara-C I-DNA
) O
. O
Malignant B-cell_type
cells I-cell_type
appear O
not O
to O
be O
susceptible O
to O
cycloheximide-induced O
cycle O
arrest O
and I-DNA
, O
subsequently O
, O
may O
not O
be O
protected O
from O
Ara-C O
cytotoxicity O
. O
The O
effect O
of O
cycloheximide O
on O
granulocyte/macrophage B-DNA
progenitors O
( O
CFU-GM B-protein
) O
after O
in O
vitro O
Ara-C O
exposure O
was O
examined O
using O
normal O
human B-cell_type
bone I-cell_line
marrow I-cell_line
, O
malignant O
progenitors O
from O
patients O
with O
chronic O
myelogenous O
leukemia O
( O
CML I-DNA
) O
, O
and O
clonogenic B-cell_type
cells I-cell_type
from O
the O
human B-DNA
acute I-cell_type
nonlymphocytic O
leukemia O
cell O
lines I-cell_line
HL-60 O
and O
KG-1 B-protein
. O
Mononuclear O
or O
clonogenic B-cell_type
cells I-cell_type
were O
incubated O
for O
one O
hour O
with O
cycloheximide O
, O
followed O
by O
the O
addition O
, O
for O
three O
or O
17 O
hours O
, O
of O
Ara-C O
before O
being O
plated O
in O
a O
methylcellulose O
culture O
system O
. O
CFU-GM B-protein
survival O
was O
significantly O
increase O
if O
normal O
cells I-cell_type
were O
treated O
with O
cycloheximide O
before O
Ara-C O
exposure O
. O
Similar O
cycloheximide O
pretreatment O
of O
CML B-cell_type
progenitors O
and O
clonogenic O
HL-60 B-protein
and O
KG-1 B-protein
cells I-cell_type
failed O
to O
protect O
CFU-GM B-protein
from O
Ara-C-induced B-protein
cytotoxicity O
. O
Primary O
cortisol O
resistance O
accompanied O
by O
a O
reduction O
in O
glucocorticoid O
receptors O
in O
two O
members O
of O
the O
same O
family O
. O
This O
report O
describes O
studies O
of O
a O
man O
suspected O
of O
having O
primary B-cell_line
cortisol I-cell_line
resistance O
. O
This O
conclusion O
is O
based O
on O
his O
high O
plasma O
cortisol O
levels O
and O
high O
24-h O
urinary O
17-hydroxycorticosteroid B-DNA
and O
cortisol O
excretion O
, O
plus O
the O
fact O
that O
he O
had O
no O
manifestations O
of O
Cushing O
's O
syndrome O
. O
Among O
family O
members O
tested I-protein
, O
his O
mother O
also O
had O
hypercortisolemia O
. O
Both O
mother O
and O
son O
had O
high O
levels O
of O
unbound O
plasma O
cortisol O
, O
but O
their O
plasma O
ACTH O
concentrations O
were O
within O
the O
normal O
range O
. O
Both O
were O
partially O
resistant O
to O
dexamethasone O
adrenal O
suppression O
, O
and O
both O
had O
mild O
hypertension O
without O
hypokalemia O
. O
To O
study O
this O
apparent O
end-organ B-DNA
resistance O
to O
cortisol O
, O
we O
examined O
the O
glucocorticoid O
receptors O
in O
peripheral B-cell_type
mononuclear I-cell_type
cells I-cell_type
. O
Using O
whole O
cell O
assays O
, O
glucocorticoid O
receptors O
in O
both O
patients O
were O
found O
to O
have O
reduced O
total O
binding O
capacity O
. O
We O
conclude O
that O
these O
two O
patients O
, O
members O
of O
the O
same O
family I-protein
, O
have O
primary B-cell_line
cortisol I-cell_line
resistance O
accompanied O
by O
a O
reduced O
number O
of O
glucocorticoid O
receptors O
. O
[ O
Glucocorticoid O
receptors O
and O
response O
to O
polychemotherapy O
in O
acute O
lymphatic O
leukemia O
] O
Glucocorticoid I-DNA
receptor I-protein
( O
GR I-DNA
) O
levels O
were O
quantified O
in O
leukemic O
blasts O
from O
peripheral B-cell_type
blood I-cell_type
of O
86 O
patients O
with O
acute O
lymphoblastic O
leukemia O
. O
The O
subsequent O
achievement O
of O
complete O
remission O
after O
combination O
chemotherapy O
was O
correlated O
with O
high I-DNA
receptor I-protein
levels O
. O
Forty-seven O
of O
50 O
patients O
with O
leukemic B-cell_type
cells I-cell_type
containing O
more O
than O
6 O
, O
000 I-DNA
receptor I-DNA
sites I-DNA
and O
22 I-DNA
of O
36 O
patients O
with O
cells I-cell_type
containing O
less O
than O
6 O
, O
000 I-DNA
receptor I-DNA
sites I-DNA
achieved O
remission O
. O
The O
study O
of O
glucocorticoid O
receptors O
in O
leukemic B-cell_type
cells I-cell_type
may O
predict O
response O
to O
combination O
chemotherapy O
in O
patients O
with O
acute O
lymphoblastic O
leukemia O
. O
Specific O
uptake O
of O
1 O
, O
25-dihydroxycholecalciferol O
by O
human B-DNA
chronic I-DNA
myeloid O
leukemia B-cell_type
cells I-cell_type
. O
We O
have O
examined O
mononuclear O
cell O
preparations O
from O
patients O
with O
chronic O
myeloid O
leukemia O
[ O
CML O
] O
for O
binding O
of O
and O
response O
to O
1 O
, O
25-dihydroxycholecalciferol O
[ O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
] O
. O
Whole B-cell_type
cells I-cell_type
specifically O
took O
up O
[ O
3H B-protein
] O
-1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
with O
high O
affinity O
( O
Kd O
3.6 B-protein
X O
10 O
( O
-11 B-protein
) O
M O
) O
and O
low O
capacity O
. O
Subcellular O
fractionation O
of O
labeled B-cell_type
cells I-cell_type
showed O
that O
binding O
was O
restricted O
to O
cytosols O
and O
nuclei O
. O
Sucrose O
gradient O
centrifugation O
of O
cells I-cell_type
preincubated O
with O
[ O
3H B-protein
] O
-1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
revealed O
a O
single O
3.6S B-protein
peak O
which O
was O
totally O
displaced O
with O
100-fold O
excess O
nonradioactive O
hormone O
. O
However O
, O
we O
were O
unable O
to O
demonstrate O
specific O
binding O
of O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
by O
postlabeling O
standard O
cytosol O
preparations O
. O
In O
addition O
, O
cytosols O
prepared O
from O
a O
mixture O
of O
CML B-cell_type
cells I-cell_type
and O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
receptor-positive B-DNA
T47D B-protein
( O
human O
breast I-cell_type
cancer O
) O
cells I-cell_type
had O
less O
than O
10 O
% O
of O
the O
binding O
measured O
in O
T47D B-protein
cytosol O
alone O
. O
However O
, O
the O
levels O
of O
binding O
in O
T47D B-protein
cytosols O
were O
not O
reduced O
if O
the O
receptors O
were O
occupied O
with O
[ O
3H B-protein
] O
-1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
prior O
to O
the O
addition O
of O
the O
CML O
cytosols O
. O
Thus O
, O
CML B-cell_type
cells I-cell_type
appear O
to O
contain O
both O
the I-DNA
receptor I-protein
for O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
and O
an O
unknown O
substance O
which O
prevents O
its O
detection O
following O
the O
preparation O
of O
cytosol O
. O
Cells O
from O
patients O
with O
CML O
in O
the O
chronic O
phase O
specifically O
bound O
more O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
[ O
18.0 B-protein
+/- O
3.2 I-cell_line
( O
S.E. I-DNA
) O
fmol/10 O
( O
7 O
) O
cells I-cell_type
] O
than O
did O
those O
in O
acute O
myeloid O
transformation O
[ O
7.2 B-protein
+/- O
1.5 B-protein
] O
or O
than O
did B-cell_type
cells I-cell_type
from O
patients O
with O
acute O
myeloid O
leukemia O
[ O
2.6 B-protein
+/- O
0.8 B-protein
] O
. O
Only B-cell_type
cells I-cell_type
from O
the O
first O
group O
of O
patients O
responded O
to O
the O
addition O
of O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
by O
differentiating O
along O
the O
monocyte-macrophage B-DNA
pathway O
. O
We O
conclude O
that O
the O
differentiation-induction B-DNA
effect O
of O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
is O
likely O
to O
depend O
on O
adequate O
levels O
of B-DNA
receptor I-protein
and O
that O
intact B-DNA
cells I-cell_type
rather O
than O
cytosol O
preparations O
should O
be O
studied O
before B-cell_type
cells I-cell_type
of O
a O
particular O
tissue O
are O
designated O
as B-DNA
receptor I-protein
negative O
. O
Effect O
of O
cell O
cycle O
position O
on O
dexamethasone O
binding O
by O
mouse B-DNA
and O
human B-cell_type
lymphoid O
cell O
lines I-cell_line
: O
correlation O
between O
an O
increase O
in O
dexamethasone O
binding O
during O
S O
phase O
and O
dexamethasone O
sensitivity O
. O
We O
determined O
the O
effect O
of O
cell O
cycle O
position O
on O
the O
amount O
of O
dexamethasone O
that O
was O
specifically O
bound O
by O
mouse B-DNA
and O
human B-cell_type
lymphoid O
cell O
lines I-cell_line
. O
Cell B-cell_line
lines I-cell_line
that O
were O
either O
sensitive O
or O
resistant O
to O
growth O
inhibition O
by O
dexamethasone O
were O
compared O
. O
Exponentially B-cell_type
growing B-cell_type
cells I-cell_type
were O
separated O
by O
centrifugal O
elutriation O
into O
fractions O
that O
corresponded O
to O
different O
positions O
in O
the O
cell O
cycle O
. O
The O
cell O
cycle O
phase O
distribution O
of O
each O
fraction O
was O
estimated O
by O
flow O
cytometry O
and O
autoradiography O
. O
The O
amount O
of O
dexamethasone O
bound O
per O
cell O
in O
each O
fraction O
was O
measured O
by O
a O
whole O
cell O
binding O
assay O
. O
In O
three O
dexamethasone-sensitive O
cell O
lines I-cell_line
( O
two O
mouse B-DNA
and O
one O
human O
) O
, O
we O
found O
that O
the O
amount O
of O
dexamethasone O
bound O
per O
cell O
increased O
2-4-fold B-protein
between O
G1 B-protein
phase O
and O
S O
phase O
, O
and O
then O
decreased O
during O
G2/M B-protein
phase O
. O
Results O
were O
the O
same O
when O
the O
amount O
of O
dexamethasone O
bound O
per O
milligram O
of O
cell O
protein O
was O
measured O
. O
Binding O
affinity O
was O
the O
same O
during O
G1 B-protein
phase O
and O
S O
phase O
, O
but O
the O
proportion O
of O
bound O
dexamethasone O
that O
translocated O
to O
the O
nucleus O
was O
greater O
during O
S O
phase O
. O
In O
contrast O
, O
we O
found O
that O
the O
amount O
of O
dexamethasone O
bound O
per O
cell O
by O
three O
dexamethasone-resistant O
cell O
lines I-cell_line
( O
two O
mouse B-DNA
and O
one O
human O
) O
did O
not O
increase O
during O
S O
phase O
. O
Our O
results O
indicate O
that O
cell O
cycle O
changes O
in O
dexamethasone O
binding O
are O
not O
simply O
related O
to O
changes O
in O
cell O
protein O
or O
cell O
volume O
during O
the O
cell O
cycle O
. O
An O
increase O
in O
dexamethasone O
binding O
during O
S O
phase O
may O
be O
required O
for O
dexamethasone O
to O
inhibit O
cell O
growth O
, O
and O
a O
failure O
of O
dexamethasone O
binding O
to O
increase O
during O
S O
phase O
might O
represent O
a O
new O
mechanism O
of O
dexamethasone O
resistance O
in O
lymphoid B-cell_type
cells I-cell_type
. O
Presence O
and O
steroid O
inducibility O
of O
glutamine O
synthetase O
in O
human B-DNA
leukemic I-cell_type
cells I-cell_type
. O
Glutamine O
synthetase O
( O
EC B-protein
6.3.1.2 B-protein
; O
GS B-protein
) O
is O
present O
in O
lymphoblasts O
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL I-DNA
) O
as O
well O
as O
in O
normal O
peripheral B-cell_type
blood I-cell_type
lymphocytes I-cell_type
. O
In O
16 O
out O
of O
20 O
ALL O
patients O
studied O
exposure O
of O
the B-cell_type
cells O
to O
physiological O
concentrations O
of O
dexamethasone O
in O
vitro O
increased O
enzyme O
activity O
above O
the O
control O
levels O
. O
The O
increase O
was O
specific O
for O
glucocorticoid I-DNA
receptor I-protein
ligands O
. O
A O
direct O
correlation O
was O
found O
between O
the O
magnitude O
of O
glucocorticoid-mediated B-DNA
increase O
of O
GS B-cell_type
activity O
and O
the O
cellular O
levels O
of O
specific O
glucocorticoid O
receptors O
assayed O
in O
the O
same O
cell O
specimen O
. O
Moreover O
, O
the O
basal O
levels O
of O
the O
enzyme O
measured O
in O
cells I-cell_type
prior O
to O
exposure O
to O
dexamethasone O
correlated O
negatively O
with I-DNA
receptor I-protein
density O
. O
It O
is O
suggested O
that O
the O
presence O
of O
steroid-inducible B-DNA
GS B-protein
in O
ALL B-cell_type
cells I-cell_type
may O
prove O
to O
be O
a O
marker O
for O
functional I-DNA
receptor I-DNA
sites I-DNA
. O
Binding O
of O
progestins O
to O
the O
glucocorticoid I-DNA
receptor I-protein
. O
Correlation O
to O
their O
glucocorticoid-like B-DNA
effects O
on O
in O
vitro O
functions O
of O
human B-cell_type
mononuclear I-cell_type
leukocytes O
. O
A O
number O
of O
physiological O
and O
synthetic O
progestins O
were O
tested O
for O
their O
ability O
to O
compete O
with O
[ O
3H B-protein
] O
dexamethasone O
for O
the O
binding O
to O
the O
glucocorticoid I-DNA
receptor I-DNA
of O
human B-cell_type
mononuclear I-cell_type
leukocytes O
and O
their O
ability O
to O
elicit O
glucocorticoid-like B-DNA
effects O
on O
the O
same B-cell_type
cells I-cell_type
. O
As O
compared O
to O
the O
reference O
compound O
dexamethasone O
( O
relative I-DNA
receptor I-protein
binding O
affinity O
defined O
as O
100 O
% O
) O
, O
two O
potent O
synthetic O
progestins O
with O
a O
pregnane-type B-protein
structure O
, O
megestrol O
acetate O
and O
medroxyprogesterone O
acetate O
, O
were O
found O
to O
display O
a O
considerable O
binding O
affinity O
towards O
the I-DNA
receptor I-protein
( O
46 O
and O
42 O
% O
, O
respectively O
) O
. O
The O
relative O
binding O
affinity O
of O
the O
naturally O
occurring O
ligand I-protein
, O
cortisol O
, O
to O
the O
receptor I-protein
was O
clearly O
lower O
( O
25 O
% O
) O
. O
The O
effective O
binding O
of O
medroxyprogesterone B-RNA
acetate O
to O
the O
glucocorticoid I-DNA
receptor I-protein
was O
confirmed O
by O
direct O
binding O
studies O
utilizing O
a O
tritiated O
derivative O
of O
this O
steroid O
. O
No O
evidence O
for O
the O
existence O
of O
a O
specific O
progesterone I-DNA
receptor I-protein
in O
human B-DNA
mononuclear I-cell_type
leukocytes O
was O
obtained O
as O
judged O
by O
the O
results O
of O
competition O
experiments O
where O
a O
progesterone O
receptor-specific B-DNA
ligand O
[ O
3H B-protein
] O
Org O
2058 O
was O
used O
. O
Medroxyprogesterone O
acetate O
and O
megestrol O
acetate O
also O
induced O
glucocorticoid-like B-DNA
effects O
on O
the O
lymphocyte I-cell_line
functions O
. O
These O
included O
inhibition O
of O
the O
proliferative O
responses O
to O
the O
T-cell O
mitogens O
concanavalin O
A O
and O
phytohaemagglutinin O
and O
an O
enhanced O
accumulation O
of O
immunoglobulin O
secreting B-cell_type
cells I-cell_type
in O
pokeweed O
mitogen-stimulated O
cultures I-cell_line
. O
The O
progestin O
effect O
appears O
to O
be O
mediated O
through O
a O
radiosensitive O
( O
suppressor O
) O
subpopulation O
of O
T I-cell_type
lymphocytes I-cell_type
. O
In O
contrast O
, O
the O
synthetic O
progestins O
related O
structurally O
to O
19-nortestosterone O
, O
norethisterone O
and O
d-norgestrel I-DNA
, O
were O
virtually O
devoid O
of O
binding O
affinity O
towards O
the O
glucocorticoid I-DNA
receptor I-protein
nor O
did O
they O
measurably O
influence O
the O
in O
vitro O
lymphocyte I-cell_line
functions O
. O
These O
studies O
demonstrate O
that O
certain O
progestins O
in O
common O
clinical O
use O
probably O
possess O
inherent O
glucocorticoid O
activity O
and O
suggest O
that O
side O
effects O
attributable O
to O
this O
character O
( O
e.g. I-DNA
suppression O
of O
the O
pituitary-adrenal B-DNA
axis O
) O
might O
be O
expected O
when O
these O
compounds O
are O
used O
in O
pharmacological O
doses O
. O
Metabolic O
and O
ultrastructural O
aspects O
of O
the O
in O
vitro O
lysis O
of O
chronic O
lymphocytic O
leukemia B-cell_type
cells I-cell_type
by O
glucocorticoids O
. O
Human O
chronic O
lymphocytic O
leukemia O
( O
CLL I-DNA
) O
cells I-cell_type
like O
prothymocytes O
and O
immunoactivated O
T-lymphocytes B-protein
are O
readily O
lysed O
in O
vitro O
by O
pharmacological O
concentrations O
of O
glucocorticoids O
such O
as O
cortisol O
, O
whereas O
peripheral B-cell_type
blood I-cell_type
lymphocytes I-cell_type
and O
thymocytes O
are O
unaffected O
by O
the O
hormone O
. O
In O
this O
study O
, O
metabolic O
and O
ultrastructural O
aspects O
of O
the O
cortisol-induced I-cell_line
killing O
process O
of O
CLL B-cell_type
cells I-cell_type
are O
recorded O
. O
In O
vitro O
lysis O
was O
found O
to O
be O
temperature O
dependent O
and O
was O
detected O
only O
after O
6 O
to O
8 O
hr O
incubation O
with O
cortisol O
by O
means O
of O
the O
trypan O
blue O
exclusion O
test O
. O
However O
, O
30 O
min O
of O
incubation O
with O
cortisol O
at O
either O
37 O
degrees O
or O
4 O
degrees O
followed O
by O
the O
removal O
of O
the O
hormone O
was O
still O
sufficient O
to O
induce O
the O
lytic O
process O
. O
Ultrastructural O
studies O
demonstrated O
sequential O
changes O
in O
the O
cytoplasm O
, O
including O
swelling O
of O
mitochondria O
and O
cytoplasmic O
decompartmentalization I-protein
, O
followed O
by O
loss O
of O
surface I-protein
microvilli O
with O
the O
appearance O
of O
`` O
holes O
'' O
in O
the O
cell O
membrane O
, O
and O
subsequent O
condensation O
of O
nuclear B-protein
chromatin O
. O
The O
large O
holes O
in O
the O
membrane O
appearing O
after O
6 O
hr O
of O
incubation O
with O
the O
hormone O
may O
be O
the O
cause O
for O
the O
penetration O
of O
the O
viable O
stain O
into O
the O
dead B-cell_type
cells I-cell_line
, O
as O
seen O
by O
light O
microscopy O
. O
Addition O
of O
metabolic O
inhibitors O
including O
actinomycin O
D O
, O
puromycin O
, O
and O
cycloheximide O
following O
administration O
of O
cortisol O
resulted O
in O
inhibition O
of O
the O
cell O
lysis O
. O
An O
excess O
of O
an O
antagonist O
such O
as O
cortexolone O
was O
found O
to O
inhibit O
the O
cortisol-induced I-cell_line
cytolysis O
of O
the O
CLL B-cell_type
cells I-cell_type
. O
It O
is O
suggested O
that O
the O
glucocorticoid-induced B-DNA
lysis O
of O
human B-cell_type
CLL I-cell_type
cells I-cell_type
is O
similar O
to O
the O
phenomenon O
observed O
in O
rat O
or O
murine I-cell_type
lymphocytes I-cell_type
and O
is O
mediated O
by O
interaction O
of O
the O
steroid O
molecule O
with O
the O
cytoplasmic I-DNA
receptor I-protein
. O
The O
resulting O
complex I-protein
appears O
to O
activate O
specific O
gene I-DNA
( O
s O
) O
the O
products O
of O
which O
eventually O
cause O
cytolysis O
. O
Glucocorticoid O
receptors O
in O
lymphoid O
tumors O
. O
There O
is O
a O
range O
of O
levels O
of O
glucocorticoid I-DNA
receptor I-protein
numbers O
seen O
in O
the O
various O
subclasses O
of O
acute O
lymphatic O
leukemia O
( O
ALL I-DNA
) O
. O
This O
variability O
can O
not O
be O
explained O
by O
the O
known O
correlation O
between O
active O
cell O
proliferation O
and O
an O
increase O
in O
the O
number O
of O
receptors O
, O
since O
the O
tumors O
with O
the O
highest O
growth O
fraction O
( O
i.e. I-DNA
, O
Burkitt O
's O
lymphoma O
and O
T-cell O
leukemia O
) O
tend O
to O
have O
lower O
average I-DNA
receptor I-protein
numbers O
than O
do O
tumors O
with O
lower O
growth O
fractions O
such O
as O
common O
ALL O
. O
All O
clinical O
specimens O
from O
patients O
with O
lymphatic O
leukemia O
have O
some O
measurable O
level O
of O
glucocorticoid O
receptors O
; O
therefore O
, O
the O
resistance O
seen O
in O
vivo O
can O
not O
be O
explained O
by O
the O
lack O
of O
receptors O
. O
However O
, O
there O
has O
been O
a O
positive O
correlation O
, O
in O
our O
hands O
, O
with I-DNA
receptor I-protein
level O
and O
prognosis O
. O
On O
the O
basis O
of O
in O
vitro O
models O
, O
it O
is O
proposed O
that O
perhaps O
the O
high I-DNA
receptor I-protein
cell O
lines I-cell_line
( O
i.e. I-DNA
, O
common O
ALL O
of O
childhood O
) O
have O
relative O
stability O
of O
their O
genetic O
material O
making O
glucocorticoid-resistant B-DNA
mutations O
less O
likely O
to O
occur O
in O
patients O
with O
these I-cell_type
cells I-cell_type
than O
in O
low-receptor O
cell O
lines I-cell_line
( O
i.e. I-DNA
, O
T-cell O
leukemia O
) O
. O
This O
greater O
genetic O
variability O
in O
the O
low-receptor B-cell_line
lines I-cell_line
could O
account O
for O
the O
earlier O
emergence O
of O
clinical O
glucocorticoid O
resistance O
in O
these O
patients O
. O
[ O
Tumor O
histology O
and O
steroid O
receptors O
in O
breast O
carcinoma O
] O
In O
Specimens O
of O
115 O
patients O
with O
breast O
cancer O
4 O
tumorparameters O
( O
tumorsize I-DNA
, O
tumorboder O
, O
nucleargrade O
, O
lymphocytic O
stromal O
reaction O
) O
3 O
features O
of O
regional O
lymphnodes O
( O
sinushistiocytosis O
, O
T-cellreaction O
, O
lymphnode O
metastases O
) O
and O
estrogen O
and O
progesteron O
receptors O
were O
determined O
. O
A O
strong O
sinushistiocytosis O
and O
T-cellreaction B-protein
could O
be O
verified O
mainly O
in O
metastases O
in O
free O
lymphnodes O
. O
The O
steroid I-DNA
receptor I-protein
content O
does O
not O
correlate O
with O
histological O
parameters O
Aldosterone-receptor B-protein
deficiency O
in O
pseudohypoaldosteronism O
. O
Pseudohypoaldosteronism I-protein
, O
a O
syndrome O
characterized O
by O
salt O
wasting O
and O
failure O
to O
thrive O
, O
usually O
presents O
in O
infancy O
as O
high O
urinary O
levels O
of O
sodium O
despite O
hyponatremia O
, O
hyperkalemia O
, O
hyperreninemia O
, O
and O
elevated O
aldosterone O
levels O
. O
We O
have O
investigated O
this O
syndrome O
for O
the O
possibility O
of O
abnormal O
Type O
I I-protein
or O
`` O
mineralocorticoid-like B-DNA
'' O
receptors O
, O
which O
have O
intrinsic O
steroid O
specificity O
indistinguishable O
from O
that O
of O
renal O
mineralocorticoid O
receptors O
and O
are O
found O
in O
many O
tissues O
and I-DNA
cells I-cell_line
, O
including O
mononuclear O
leukocytes O
. O
We O
have O
studied O
three O
patients O
with O
pseudohypoaldosteronism O
: O
the O
28-year-old O
index O
case O
in O
Melbourne O
( O
Patient O
1 O
) O
and O
two O
siblings O
in O
Munich O
, O
eight O
and O
two O
years O
of O
age O
( O
Patients O
2 O
and O
3 O
) O
; O
clinically O
, O
Patient O
3 O
had O
a O
less O
severe O
case O
than O
his O
sister O
. O
Percoll-separated O
control O
monocytes B-cell_type
bound O
[ O
3H B-protein
] O
aldosterone O
with O
high O
affinity O
( O
Kd O
approximately O
3 O
nM O
) O
and O
limited O
capacity O
( O
150 O
to O
600 O
sites I-DNA
per O
cell O
) O
. O
On O
repeated O
examination O
, O
no O
[ O
3H B-protein
] O
aldosterone O
binding O
was O
found O
in O
monocytes B-cell_type
from O
Patients O
1 O
and O
2 O
; O
in O
Patient O
3 O
, O
the O
levels O
were O
62 I-DNA
sites I-DNA
per O
cell O
, O
more O
than O
2 O
S.D. I-DNA
below O
those O
of O
the O
control O
. O
Levels O
in O
the O
parents O
of O
the O
Munich O
patients O
( O
first O
cousins O
) O
were O
normal O
. O
It O
appears O
that O
pseudohypoaldosteronism O
is O
caused O
by O
a O
Type O
I I-DNA
receptor I-protein
defect O
, O
that O
the O
defect O
may O
be O
complete O
or O
partial O
, O
that O
transmission O
may O
be O
autosomal O
recessive O
, O
and O
that O
the O
study O
of O
patients O
with O
pseudohypoaldosteronism O
may O
indicate O
physiologic O
roles O
for O
Type O
I I-protein
receptors O
in O
nonepithelial O
tissues O
. O
Glucocorticoid O
inhibition O
of O
urokinase-like O
plasminogen O
activators O
in O
cultured O
human B-DNA
lymphoblasts I-cell_type
. O
Two O
human B-DNA
lymphoblast O
cell O
lines I-cell_line
, O
LICR-LON-HMy2 B-protein
( O
HMy2 I-DNA
cells I-cell_type
) O
and O
GM4672A B-cell_type
cells I-cell_line
, O
are O
moderately O
growth O
inhibited O
by O
dexamethasone O
( O
1 O
, O
4-pregnadien-9-fluoro-16 B-protein
alpha-methyl-11 B-protein
beta O
, O
17 O
alpha I-DNA
, O
21-triol-3 O
, O
20-dione B-protein
) O
( O
Dex O
) O
. O
Both O
cell O
types I-cell_type
secrete O
a O
urokinase O
( O
UK I-DNA
) O
-like O
plasminogen O
activator O
( O
PA I-DNA
) O
. O
Treatment O
of O
both O
HMy2 O
and O
GM4672A B-cell_type
cells I-cell_type
with O
Dex O
for O
1-4 O
days O
inhibits O
extracellular O
PA B-protein
activity O
in O
a O
concentration-dependent B-DNA
manner O
, O
being O
half-maximal B-DNA
at O
approximately O
1 O
X O
10 O
( O
-9 B-protein
) O
M O
. O
Inhibition O
of O
PA B-cell_type
in O
both O
cell O
types I-cell_type
is O
specific O
for O
active O
glucocorticoids O
, O
and O
this O
specificity O
parallels O
the O
ability O
of O
various O
steroids O
to O
bind O
to O
glucocorticoid O
receptors O
. O
HMy2 O
cell O
PA I-cell_type
is O
fully O
suppressible O
by O
Dex O
, O
whereas O
up O
to O
one O
third O
of O
the O
activator O
expressed O
by O
GM4672A B-cell_type
cells I-cell_type
is O
resistant O
to O
glucocorticoid O
inhibition O
. O
Mixing O
experiments O
using O
a O
UK B-protein
standard O
and O
conditioned O
media O
from O
Dex-treated B-protein
cells I-cell_type
suggest O
an O
absence O
of O
glucocorticoid-inducible B-DNA
inhibitors O
to O
UK B-protein
or O
plasmin O
in O
both O
cell O
types I-cell_type
. O
However O
, O
conditioned O
media O
from O
Dex-treated B-protein
GM4672A B-cell_type
cells I-cell_type
inhibits O
a O
portion O
of O
the O
homologous O
cellular O
activator O
in O
conditioned O
media O
from O
control O
GM4672A B-cell_type
cells I-cell_type
. O
Thus O
, O
low O
levels O
of O
glucocorticoid-inducible B-DNA
inhibitors O
may O
contribute O
to O
, O
but O
can O
not O
fully O
account O
for O
, O
Dex O
inhibition O
of O
GM4672A B-protein
PA B-protein
activity O
. O
Glucocorticoid-inducible B-protein
inhibitors O
in O
HMy2 B-cell_type
cells I-cell_type
are O
either O
totally O
absent O
or O
are O
present O
at O
undetectable O
levels O
. O
Thus O
, O
regulation O
of O
UK-like B-protein
PAs O
in O
HMy2 O
and O
GM4672A B-cell_type
cells I-cell_type
differs O
with O
respect O
to O
the O
extent O
to O
which O
glucocorticoids O
inhibit O
constitutively O
expressed O
activator O
levels O
, O
as O
well O
as O
the O
possible O
contribution O
of O
glucocorticoid-inducible B-DNA
inhibitors O
to O
the O
regulatory O
process O
in O
GM4672A B-cell_type
cells I-cell_type
. O
Characterization O
of O
aldosterone O
binding O
sites O
in O
circulating O
human B-DNA
mononuclear I-cell_type
leukocytes O
. O
Aldosterone O
binding O
sites O
in O
human B-DNA
mononuclear I-cell_type
leukocytes O
were O
characterized O
after O
separation O
of O
cells I-cell_type
from O
blood I-cell_type
by O
a O
Percoll O
gradient O
. O
After O
washing O
and O
resuspension O
in O
RPMI-1640 B-protein
medium I-protein
, O
cells I-cell_type
were O
incubated O
at O
37 O
degrees O
C I-protein
for O
1 O
h O
with O
different O
concentrations O
of O
[ O
3H B-protein
] O
aldosterone O
plus O
a O
100-fold O
concentration O
of O
RU-26988 B-protein
( O
11 I-DNA
alpha I-DNA
, O
17 O
alpha-dihydroxy-17 O
beta-propynylandrost-1 I-cell_line
, O
4 O
, O
6-trien-3-one B-protein
) O
, O
with O
or O
without O
an O
excess O
of O
unlabeled O
aldosterone O
. O
Aldosterone O
binds O
to O
a O
single O
class O
of O
receptors O
with O
an O
affinity O
of O
2.7 B-cell_type
+/- O
0.5 B-protein
nM I-cell_line
( O
means O
+/- O
SD I-protein
, O
n O
= O
14 O
) O
and O
a O
capacity O
of O
290 O
+/- O
108 O
sites/cell I-cell_line
( O
n O
= O
14 O
) O
. O
The O
specificity O
data O
show O
a O
hierarchy O
of O
affinity O
of O
desoxycorticosterone B-RNA
= O
corticosterone O
= O
aldosterone O
greater O
than O
hydrocortisone O
greater O
than O
dexamethasone O
. O
The O
results O
indicate O
that O
mononuclear O
leukocytes O
could O
be O
useful O
for O
studying O
the O
physiological O
significance O
of O
these O
mineralocorticoid O
receptors O
and O
their O
regulation O
in O
humans O
. O
Mineralocorticoid O
and O
glucocorticoid O
receptors O
in O
circulating O
mononuclear O
leukocytes O
of O
patients O
with O
primary B-cell_line
hyperaldosteronism I-cell_line
. O
Mineralocorticoid O
and O
glucocorticoid O
receptors O
were O
measured O
in O
circulating O
mononuclear O
leukocytes O
in O
5 O
patients O
affected O
by O
Conn O
's O
syndrome O
( O
3 O
cases O
of O
bilateral O
adrenal O
hyperplasia O
and O
2 O
cases O
of O
adenoma O
plus O
unilateral O
hyperplasia O
) O
. O
The O
number O
of O
the O
binding O
sites O
per O
cell O
resulted O
significantly O
lower O
( O
189 O
+/- O
114 O
, O
mean O
+/- O
SD B-protein
) O
, O
as O
compared O
with O
the O
normal O
controls O
( O
298 O
+/- O
105 O
) O
. O
The O
affinity O
of O
aldosterone O
for O
the I-DNA
receptor I-protein
was O
found O
to O
be O
not O
different O
than O
that O
of O
healthy O
control O
subjects O
. O
The O
capacity O
and O
the O
affinity O
of O
dexamethasone O
for O
glucocorticoid O
receptors O
ranged O
in O
the O
normal O
values O
. O
These O
data O
suggest O
a O
possible O
down-regulation O
of O
mineralocorticoid O
receptors O
in O
humans O
. O
Short-term O
and O
long-term O
effects O
of O
estrogen O
on O
lymphoid O
tissues O
and O
lymphoid B-cell_type
cells I-cell_type
with O
some O
remarks O
on O
the O
significance O
for O
carcinogenesis O
. O
Estrogens O
have O
long I-DNA
been O
thought O
to O
play O
a O
role O
in O
regulating O
the O
immune O
system O
. O
The O
difference O
in O
some O
types I-cell_type
of O
immune O
responses O
between O
males O
and O
females O
is O
well-known B-DNA
, O
as O
is O
the O
pronounced O
thymic B-cell_line
involution O
induced O
by O
exogenous O
estrogens O
. O
Estrogens O
stimulate O
some O
aspects O
of O
macrophage O
activity O
and I-DNA
, O
depending O
on O
dose O
and O
mitogen O
, O
inhibit O
or O
stimulate O
lymphocyte I-cell_line
proliferative O
response O
in O
vitro O
. O
Another O
example O
is O
the O
estrogen O
effect O
on O
the O
delayed I-DNA
type O
hypersensitivity I-DNA
response O
. O
A O
broad O
review O
is O
given O
of O
such O
estrogen O
effects O
on O
lymphoid O
tissue O
and O
immune O
response O
. O
Most O
of O
the O
studies O
published O
so O
far O
are O
phenomenological O
. O
However O
, O
the O
recent O
description O
of O
estrogen O
receptors O
in O
the O
thymus O
and O
in O
some O
lymphocyte I-cell_line
subpopulations O
, O
as O
well O
as O
a O
deeper O
understanding O
of O
regulating B-protein
factors I-protein
in O
the O
immune O
system I-protein
, O
open O
the O
possibility O
of O
a O
more O
detailed O
understanding O
of O
the O
estrogen O
mechanism O
of O
interference O
. O
Estrogen O
effects O
in O
adults O
are O
reversible O
. O
After O
treating O
neonatal O
mice O
with O
the O
synthetic O
estrogen O
diethylstilbestrol I-protein
( O
DES I-DNA
) O
, O
disturbances O
are O
induced O
in O
lymphocyte I-cell_line
populations O
and O
lymphocyte I-cell_line
functions O
which O
are O
permanent O
and O
irreversible O
. O
Lymphocytes O
from O
adult O
, O
neonatally O
DES-treated B-protein
female O
mice O
have O
a O
reduced O
mitogen O
response O
to O
ConA O
and O
LPS O
( O
T O
and O
B O
cell O
mitogen O
) O
and O
the O
delayed I-DNA
type O
hypersensitivity I-DNA
response O
is O
depressed O
. O
A O
detailed O
analysis O
demonstrated O
a O
decreased B-cell_type
T I-cell_line
helper O
cell O
population O
. O
The O
activity O
of O
Natural O
Killer B-cell_type
cells I-cell_type
is O
permanently O
reduced O
and O
this O
functional O
impairment O
is O
related O
to O
a O
decreased O
number O
of O
these B-cell_type
cells I-cell_line
, O
in O
turn O
determined O
at O
the O
bone I-cell_line
marrow I-cell_line
level O
. O
The O
same O
animals O
have O
an O
increased O
sensitivity O
to O
chemical O
carcinogens O
( O
methylcholanthrene O
) O
and O
they O
spontaneously O
develop O
epithelial O
changes O
in O
the O
uterine O
cervix O
which O
morphologically O
are O
similar O
to O
adenocarcinoma O
. O
The O
association O
between O
estrogen-associated B-DNA
malignancy O
and O
estrogen O
effects O
in O
lymphocyte I-cell_line
functions O
deserves O
further O
study O
. O
Drugs O
affecting O
the O
hormonal O
receptors O
of O
normal O
and O
leukaemic O
peripheral B-cell_type
leucocytes O
. O
The O
authors O
investigated O
the O
behaviour O
of O
steroid O
hormone O
uptake O
in O
leukaemic B-cell_type
cells I-cell_line
( O
CML I-DNA
, O
CLL I-protein
, O
AML I-protein
, O
ALL O
) O
, O
in O
basal O
conditions O
and O
after O
incubation O
with O
drugs O
which O
modify O
the O
cellular O
concentration O
of O
cAMP I-protein
, O
PGE O
and O
PGF O
. O
The O
results O
demonstrated O
the O
presence O
in O
leukaemic B-cell_type
cells I-cell_type
of O
an O
alteration O
in O
the O
incorporation O
of O
steroid O
hormones O
. O
This O
alteration O
was O
scarcely O
modified O
by O
incubation O
with O
theophylline O
, O
which O
increases O
cellular O
concentration O
of O
cAMP I-RNA
. O
On O
the O
other O
hand O
, O
it O
was O
moderately O
counteracted O
by O
thioproline O
and O
was O
evidently O
inhibited O
by O
flurbiprofen O
, O
which O
also O
reduced O
cellular O
concentrations O
of O
prostaglandins O
, O
particularly O
PGE2 I-protein
, O
with O
the O
exception O
of O
PGF2 B-protein
which O
showed O
a O
poor O
response O
. O
Differences O
were O
observed O
in O
the O
behavior O
of O
hormonal O
uptake O
of O
CML I-protein
, O
in O
contrast O
to O
that O
of O
AML I-protein
, O
CLL O
and O
ALL O
peripheral B-cell_type
leucocytes O
. O
Human O
breast O
cancer O
and O
impaired O
NK O
cell O
function O
. O
Recent O
advances O
in O
tumor O
immunology O
have O
led O
to O
the O
discovery O
of O
a O
new O
lymphoid O
cell O
with O
unique O
antitumor O
activity O
. O
Natural O
killer O
( O
NK O
) O
cells I-cell_type
form O
an O
antitumor O
surveillance O
system O
and O
appear O
to O
be O
vital O
in O
preventing O
tumor O
growth O
and O
metastasis O
in O
animal O
models O
. O
We O
studied O
NK O
activity O
in O
patients O
with O
benign O
and O
malignant O
breast O
disease O
, O
using O
a O
chromium-51 B-protein
release O
microtiter O
cytotoxicity O
assay O
with O
K562 B-protein
cells I-cell_type
as O
targets I-cell_line
. O
Compared O
with O
benign O
controls O
, O
patients O
with O
malignancies O
had O
significantly O
depressed O
NK O
-mediated O
lysis O
( O
P O
less O
than O
0.01 B-protein
) O
. O
Furthermore O
, O
lysis O
in O
those O
with O
advanced O
disease O
( O
stages O
II I-protein
, O
III I-protein
, O
and O
IV B-protein
) O
was O
significantly O
less O
than O
in O
those O
with O
limited O
disease O
( O
stage O
I I-protein
) O
( O
P O
less O
than O
0.01 B-protein
) O
. O
NK O
activity O
was O
not O
correlated O
to O
estrogen O
or O
progesterone I-DNA
receptor I-protein
states O
. O
Positive O
correlation O
of O
a O
depressed O
natural O
killer O
activity O
with O
the O
extent O
of O
tumor O
spread O
supports O
the O
concept O
of O
an O
NK O
cell O
immune O
surveillance O
system O
in O
breast O
cancer O
and O
emphasizes O
its O
importance O
in O
this O
malignancy O
. O
Immunosuppressive O
effect O
of O
serum O
progesterone O
during O
pregnancy O
depends O
on O
the O
progesterone O
binding O
capacity O
of O
the I-cell_type
lymphocytes I-cell_type
. O
Cytotoxic O
activity O
and O
progesterone O
binding O
capacity O
of O
the I-cell_type
lymphocytes I-cell_type
, O
together O
with O
serum O
progesterone O
concentrations O
, O
were O
determined O
in O
women O
with O
normal O
pregnancy O
or O
with O
a O
clinical O
diagnosis O
of O
threatened O
abortion O
or O
threatened O
premature O
labour O
. O
The I-cell_type
lymphocytes I-cell_type
of O
women O
with O
threatened O
abortion O
or O
threatened O
premature O
labour O
showed O
significantly O
higher O
cytotoxic O
activity O
( O
P O
less O
than O
0.001 B-protein
) O
and O
significantly O
lower O
progesterone O
binding O
capacity O
( O
P O
less O
than O
0.001 B-protein
) O
than O
did I-cell_type
lymphocytes I-cell_type
obtained O
from O
the O
healthy O
pregnant O
women O
. O
Significant O
inverse O
correlation O
was O
found O
between O
progesterone O
binding O
capacity O
and O
cytotoxic O
activity O
of O
the I-cell_type
lymphocytes I-cell_type
( O
P O
less O
than O
0.001 B-protein
) O
, O
but O
the O
progesterone O
concentration O
of O
the O
pregnancy O
serum O
appeared O
to O
have O
no O
influence O
on O
the O
other O
two O
parameters O
. O
The O
findings O
indicate O
that O
intact O
progesterone O
binding O
capacity O
of O
the I-cell_type
lymphocytes I-cell_type
is O
an O
essential B-protein
factor I-protein
for O
the O
manifestation O
of O
the O
blocking O
effect O
exerted O
by O
pregnancy O
serum O
on O
lymphocyte I-cell_line
cytotoxicity O
in O
vitro O
. O
Serum O
sex O
steroid O
and O
peptide O
hormone O
concentrations O
, O
and O
endometrial O
estrogen O
and O
progestin I-DNA
receptor I-protein
levels O
during O
administration O
of O
human B-cell_type
leukocyte I-cell_type
interferon O
. O
Five O
normally O
cycling O
healthy O
women O
were O
given O
daily O
subcutaneous O
injections O
of O
human B-cell_type
leukocyte I-cell_type
interferon O
( O
3 O
X O
10 O
( O
6 O
) O
units/day I-DNA
) O
from O
the O
3rd O
through O
23rd O
day O
of O
the O
menstrual O
cycle O
, O
and O
serum O
steroid O
and O
peptide O
hormone O
concentrations O
monitored O
at O
3-day B-DNA
intervals O
during O
the O
treatment O
and O
the O
preceding O
control O
cycle O
. O
Concentrations O
of O
cytosol O
and O
nuclear B-protein
estrogen O
receptors O
( O
ERC O
and O
ERN I-protein
, O
respectively O
) O
and O
progestin O
receptors O
( O
PRC O
and O
PRN O
) O
were O
also O
measured O
from O
endometrial O
biopsies O
taken O
on O
the O
24th O
day O
of O
the O
control O
and O
treatment O
cycle O
. O
In O
addition O
, O
an O
extensive O
monitoring O
of O
clinical O
chemical O
and O
hematological O
tests O
from O
the O
blood I-cell_type
samples I-cell_type
were O
performed O
. O
Serum O
estradiol O
and O
progesterone O
concentrations O
were O
significantly O
decreased O
during O
the O
treatment O
cycle O
, O
suggesting O
that O
interferon O
interacts O
in O
vivo O
with O
the O
function O
of O
both O
FSH O
and O
LH B-protein
. O
No O
significant O
changes O
were O
observed O
in O
the O
serum O
peptide O
hormone O
concentrations O
measured O
( O
FSH I-DNA
, O
LH I-protein
, O
prolactin O
, O
insulin O
, O
growth O
hormone O
and O
TSH O
) O
; O
neither O
were O
the O
levels O
of O
endometrial O
ERC I-protein
, O
ERN I-protein
, O
PRC O
and O
PRN O
affected O
by O
interferon O
administration O
. O
As O
expected O
, O
interferon O
administration O
resulted O
in O
decreased O
leukocyte O
counts O
. O
Moreover O
, O
an O
increasing O
tendency O
in O
the O
activities O
of O
serum O
alkaline O
phosphatase O
and O
gamma-glutamyltransferase B-protein
during O
the O
interferon O
therapy O
shows O
that O
interferon O
may O
slightly O
interfere O
with O
the O
liver O
function O
. O
These O
results O
suggest O
that O
one O
of O
the O
mechanisms O
by O
which O
interferon O
treatment O
may O
affect O
the O
growth O
of O
hormone-dependent B-DNA
neoplasms O
could O
be O
the O
interaction O
with O
production O
and/or I-cell_line
function O
of O
circulating O
hormonal O
compounds O
. O
[ O
Glucocorticoid I-DNA
receptor I-protein
level O
in O
the O
blood I-cell_type
leukocytes I-cell_type
in O
different O
acute O
diseases O
] O
Content O
of O
glucocorticoid O
receptors O
in O
cytosol O
of O
blood I-cell_type
leukocytes I-cell_type
, O
concentration O
of O
cortisol O
and O
amount O
of O
leukocytes O
in O
blood I-cell_type
were I-cell_type
studied O
in O
20 O
patients O
with O
acute O
impairments O
within O
the O
second O
day O
of O
the O
disease O
. O
Content O
of O
receptors O
in O
cytosol O
of O
blood I-cell_type
leukocytes I-cell_type
was O
studied O
using O
3H-triamcinolone O
acetonide O
. O
Distinct O
increase O
in O
amount O
of O
the O
leukocyte O
glucocorticoid O
receptors O
was O
found O
in O
patients O
with O
poisoning O
by O
dichlorethane O
and O
hypnotic O
drugs O
under O
conditions O
of O
acute O
myocardial O
infarction O
. O
In O
acute O
pancreatitis O
content O
of O
the O
leukocyte O
receptors O
was O
not O
altered O
as O
compared O
with O
controls O
. O
Concentration I-DNA
of O
endogenous O
cortisol O
was O
increased O
in O
blood I-cell_type
of O
all O
the O
patients O
, O
except O
of O
the O
cases O
of O
acetate O
intoxication O
. O
Reverse O
correlation O
was O
observed O
between O
concentration O
of O
cortisol O
in O
blood I-cell_type
and I-cell_type
content O
of O
glucocorticoid O
receptors O
in O
leukocytes O
. O
But O
in O
the O
patients O
with O
acute O
pancreatitis O
the O
decrease O
in O
content O
of O
leukocyte O
glucocorticoid O
receptors O
was O
not O
observed O
although O
there O
was O
an O
increase O
in O
cortisol O
concentration O
in O
blood I-cell_type
. I-cell_type
The O
role O
of O
glucocorticoid O
receptors O
in O
immunological O
processes O
under O
conditions O
of O
purulent O
complications O
and O
possibility O
to O
regulate O
the O
metabolism O
in O
leukocytes O
Therapeutic O
concentrations O
of O
glucocorticoids O
suppress O
the O
antimicrobial O
activity O
of O
human B-cell_type
macrophages I-cell_type
without O
impairing O
their O
responsiveness O
to O
gamma O
interferon O
. O
By O
exposing O
human B-DNA
blood-derived I-DNA
macrophages O
and O
alveolar O
macrophages O
in O
vitro O
to O
dexamethasone O
, O
we O
showed O
in O
these O
studies O
that O
glucocorticoids O
markedly O
suppress O
the O
antimicrobial O
activity O
of O
macrophages O
but O
not O
macrophage O
activation O
by O
lymphokines O
. O
As O
little O
as O
2.5 B-protein
X O
10 O
( O
-8 B-protein
) O
mol/liter I-DNA
of O
dexamethasone O
prevented O
macrophages O
from O
inhibiting O
germination O
of O
Aspergillus O
spores O
or O
from O
eliminating O
ingested O
bacteria O
such O
as O
Listeria O
, O
Nocardia O
, O
or O
Salmonella O
. O
Damage O
to O
macrophage O
function O
was O
inhibited O
by O
progesterone O
and O
appeared O
to O
be O
receptor-mediated B-DNA
. O
In O
accordance O
with O
in O
vivo O
observations O
, O
dexamethasone O
required O
24-36 O
h O
to O
suppress O
antimicrobial O
activity O
. O
While O
glucocorticoids O
interfered O
with O
base-line B-DNA
activity O
of O
macrophages O
, O
dexamethasone O
concentrations O
comparable O
to O
drug O
levels O
in O
patients O
had O
no O
effect O
on O
macrophage O
activation O
. O
Proliferating I-cell_type
lymphocytes I-cell_type
and O
gamma-interferon O
thus O
increased O
the O
antimicrobial O
activity O
of O
phagocytes O
exposed O
to O
glucocorticoids O
over O
that O
of O
control B-cell_type
cells I-cell_type
. O
Macrophage O
activation O
and O
correction O
of O
the O
dexamethasone O
effect O
by O
gamma-interferon I-DNA
, O
however O
, O
was O
dependent O
on O
the O
pathogen O
. O
The O
lymphokine O
enhanced O
the O
antimicrobial O
activity O
of O
dexamethasone-treated O
macrophages O
against O
Listeria O
and O
Salmonella O
but O
not O
against O
Aspergillus O
or O
Nocardia O
. O
Dexamethasone-induced O
damage O
to O
the O
antimicrobial O
activity O
of O
human B-cell_type
macrophages I-cell_type
in O
vitro O
parallels O
observations O
that O
glucocorticoids O
render O
laboratory O
animals O
susceptible O
to O
listeriosis O
and O
aspergillosis O
by O
damaging O
resident O
macrophages O
. O
Suppression O
of O
macrophage O
antimicrobial O
activity O
should O
thus O
be O
considered O
when O
treating O
patients O
with O
glucocorticoids O
; O
its O
prevention O
by O
gamma-interferon O
might O
be O
beneficial O
for O
some O
but O
not O
all O
pathogens O
. O
Interleukin O
2 I-DNA
receptor I-protein
( O
Tac O
antigen I-protein
) O
expression O
in O
HTLV-I-associated O
adult O
T-cell O
leukemia O
. O
Interleukin-2 B-protein
( O
IL-2 B-protein
) O
is O
a O
lymphokine O
synthesized O
by O
some O
T-cells B-protein
following O
activation O
. O
Resting O
T-cells B-protein
do O
not O
express O
IL-2 B-protein
receptors O
, O
but O
receptors O
are O
rapidly O
expressed O
on O
T-cells B-protein
following O
interaction O
of O
antigens O
, O
mitogens O
, O
or O
monoclonal B-protein
antibodies I-protein
with O
the O
antigen-specific O
T-cell B-DNA
receptor I-protein
complex I-protein
. O
Using O
anti-Tac I-DNA
, O
a O
monoclonal O
antibody O
that O
recognizes O
the O
IL-2 B-DNA
receptor I-protein
, O
the I-DNA
receptor I-protein
has O
been O
purified O
and O
shown O
to O
be O
a O
Mr O
33 I-cell_line
, O
000 O
peptide O
that O
is O
posttranslationally O
glycosylated O
to O
a O
Mr O
55 I-cell_line
, O
000 O
mature O
form O
. O
Normal O
resting O
T-cells O
and O
most O
leukemic O
T-cell O
populations O
do O
not O
express O
IL-2 B-protein
receptors O
; O
however O
, O
the O
leukemic B-cell_type
cells I-cell_type
of O
the O
11 O
patients O
examined O
who O
had O
human O
T-cell O
lymphotropic O
virus-associated O
adult O
T-cell O
leukemia O
expressed O
the O
Tac O
antigen I-protein
. O
In O
human O
T-cell O
lymphotropic O
virus-I O
infected I-cell_type
cells I-cell_line
, O
the O
Mr O
42 I-cell_line
, O
000 O
long I-DNA
open O
reading O
frame O
protein O
encoded O
in O
part O
by O
the O
pX B-DNA
region I-DNA
of O
this O
virus O
may O
act O
as O
a O
transacting O
transcriptional O
activator O
that O
induces O
IL-2 B-DNA
receptor I-DNA
gene I-DNA
transcription I-DNA
, O
thus O
providing O
an O
explanation O
for O
the O
constant O
association O
of O
IL-2 B-DNA
receptor I-protein
expression O
with O
adult O
T-cell O
lymphotropic O
virus-I O
infection O
of O
lymphoid B-cell_type
cells I-cell_type
. O
The O
constant O
expression O
of O
large O
numbers O
of O
IL-2 B-protein
receptors O
which O
may O
be O
aberrant O
may O
play O
a O
role O
in O
the O
uncontrolled O
growth O
of O
adult O
T-cell O
leukemia B-cell_type
cells I-cell_type
. O
Two O
patients O
with O
Tac-positive O
adult O
T-cell O
leukemia O
have O
been O
treated O
with O
the O
anti-Tac B-protein
. O
One O
of O
the O
patients O
had O
6- O
and O
3-mo O
remissions O
of O
his O
leukemia O
following O
two O
courses O
of O
therapy O
with O
this O
monoclonal O
antibody O
directed O
toward O
this O
growth I-protein
factor I-protein
receptor I-protein
. O
Lymphocyte O
glucocorticoid I-DNA
receptor I-protein
binding O
in O
depressed O
patients O
with O
hypercortisolemia O
. O
Despite O
elevated O
levels O
of O
serum O
and O
urinary O
cortisol O
, O
patients O
with O
depressive O
illness O
manifest O
none O
of O
the O
clinical O
stigmata O
of O
glucocorticoid O
excess O
. O
This O
hypercortisolemia O
in O
the O
absence O
of O
clinical O
effects O
suggests O
a O
state O
of O
hormone O
resistance O
and O
could O
be O
mediated O
by O
alterations O
in O
the O
glucocorticoid I-DNA
receptor I-protein
. O
Earlier O
studies O
have O
shown O
that O
small O
doses O
of O
glucocorticoids O
cause O
a O
decrease O
in O
glucocorticoid I-DNA
receptor I-protein
binding O
in O
normal O
human I-cell_type
lymphocytes I-cell_type
. O
White B-cell_type
cells I-cell_type
from O
depressed O
patients O
with O
significant O
hypercortisolemia O
would O
be O
expected O
to O
show O
a O
similar O
change O
in B-DNA
receptor I-protein
concentration O
if O
peripheral B-cell_type
tissues O
are O
adequately O
exposed O
to O
and O
sensitive O
to O
the O
hormone O
. O
In O
this O
study O
we O
compared O
the O
binding O
of O
[ O
3H B-protein
] O
dexamethasone O
to I-cell_type
lymphocytes I-cell_type
from O
normal O
subjects O
and O
depressed O
patients O
with O
hypercortisolemia O
. O
Lymphocytes O
from O
normal O
subjects O
had O
a O
mean I-DNA
receptor I-protein
concentration I-DNA
of O
10.2 B-cell_type
+/- O
0.66 B-protein
fm/10 B-protein
( O
6 O
) O
cells I-cell_line
( O
S.E.M. I-DNA
) O
and O
a O
dissociation O
constant O
of O
4.8 B-cell_type
+/- O
0.47 B-protein
nM I-RNA
. O
Lymphocytes O
from O
depressed O
patients O
with O
abnormal O
0800 O
h O
serum O
cortisol O
after O
dexamethasone O
had O
a O
mean I-DNA
receptor I-protein
concentration I-DNA
of O
8.8 B-cell_type
+/- O
0.75 B-protein
fm/10 B-protein
( O
6 O
) O
cells I-cell_line
, O
which O
was O
not O
significantly O
different O
from O
that O
in I-cell_type
lymphocytes I-cell_type
from O
normal O
subjects O
or O
from O
depressed O
subjects O
with O
normal O
post-dexamethasone O
cortisol O
levels O
( O
9.4 B-protein
+/- O
0.95 B-protein
fm/10 B-protein
( O
6 O
) O
cells O
) O
. O
Lymphocytes O
from O
depressed O
patients O
with O
elevated O
urinary O
free O
cortisol O
excretion O
( O
UFC I-DNA
) O
also O
had O
normal I-DNA
receptor I-protein
concentration O
and O
binding O
affinity O
for O
dexamethasone O
. O
The O
lack O
of O
a O
change O
in O
lymphocyte I-cell_line
glucocorticoid I-DNA
receptor I-protein
concentration O
in O
the O
presence O
of O
cortisol O
excess O
suggests O
the O
possibility O
that O
hypercortisolemia O
in O
depressive O
illness O
represents O
a O
state O
of O
peripheral B-cell_type
glucocorticoid O
resistance O
. O
Structure O
and O
regulation O
of O
the O
glucocorticoid O
hormone I-DNA
receptor I-protein
. O
The O
glucocorticoid I-DNA
receptor I-protein
is O
an O
intracellular O
protein O
which O
possesses O
three O
distinct O
domains O
, O
one O
that O
binds O
agonist O
and O
antagonist O
steroids O
, O
one O
that O
binds O
DNA O
, O
and O
one O
that O
binds O
anti-receptor B-protein
antibodies I-protein
and O
is O
required O
for O
glucocorticoid O
modulation O
of O
gene I-DNA
expression O
. O
In O
intact B-DNA
cells I-cell_line
, O
receptor I-protein
number O
, O
affinity O
and O
activity O
can O
change O
in O
response O
to O
factors O
that O
bind O
to O
the O
receptor I-protein
, O
or O
that O
act O
indirectly O
through O
ill-defined O
mechanisms O
which O
may O
include O
resumption O
or O
arrest O
of O
cell O
cycling O
and O
variations O
in O
intracellular O
calcium O
ion O
concentrations O
. O
Some O
of O
these O
factors I-protein
appear O
to O
exert O
their O
effect O
by O
controlling O
critical I-DNA
receptor I-protein
properties O
such O
as O
ATP-dependent B-protein
phosphorylation O
, O
integrity O
of O
thiol O
groups O
, O
and O
exposure O
of O
key O
amino O
acid O
residues O
. O
Glucocorticoid O
agonists O
promote O
the O
'transformation O
' O
of O
the I-DNA
receptor I-protein
into O
the O
DNA-binding B-protein
state O
, O
which O
is O
competent O
for O
modulating O
gene I-DNA
expression O
. O
Glucocorticoid O
antagonists O
are O
steroids O
that O
interact O
with O
the I-DNA
receptor I-protein
but O
either O
fail O
to O
produce O
a O
stable O
complex I-protein
or O
produce O
a O
stable O
but O
inefficient O
complex I-protein
. O
Although O
substituent O
groups O
that O
confer O
agonist O
or O
antagonist O
activity O
to O
the O
steroid O
have O
been O
identified O
, O
the O
molecular O
determinants O
of O
this O
difference O
at O
the I-DNA
receptor I-protein
level O
remain O
unknown O
. O
Most O
in O
vitro O
and O
in O
vivo O
data O
on B-DNA
receptor I-protein
regulation O
can O
be O
accommodated O
by O
postulating O
the O
existence O
of O
an O
intracellular O
cycle O
that O
involves O
five O
states O
of O
the I-DNA
receptor I-protein
. O
The O
active O
free I-DNA
receptor I-protein
is O
phosphorylated O
, O
reduced O
, O
and O
presumably O
oligomeric O
( O
state O
A O
) O
. O
Following O
binding O
of O
an O
agonist O
( O
state O
B I-DNA
) O
, O
it O
can O
become O
transformed O
by O
dissociation O
into O
its O
subunits O
and O
dephosphorylation O
( O
state O
C I-protein
) O
. O
The O
transformed I-DNA
receptor I-protein
then O
interacts O
with O
chromatin O
( O
state O
D O
) O
. O
Dissociation O
of O
the O
steroid O
and O
oxidation O
of B-DNA
receptor I-protein
thiol O
group O
( O
s O
) O
lead O
to O
the O
inactive I-DNA
receptor I-protein
form O
( O
state O
E O
) O
. O
Reduction O
and O
rephosphorylation O
of O
the I-DNA
receptor I-protein
enable O
it O
to O
bind O
steroids O
again O
so O
that O
the O
cycle O
is O
closed O
. O
Thermodynamics O
of O
steroid O
binding O
to O
the O
human B-DNA
glucocorticoid I-DNA
receptor I-protein
. O
The O
thermodynamics O
of O
the O
interaction O
of O
glucocorticoids O
with O
their I-DNA
receptor I-protein
were O
studied O
in O
cytosol O
from O
human B-DNA
lymphoblastoid I-cell_type
cells I-cell_type
. O
The O
rate O
and O
affinity O
constants O
of O
dexamethasone O
and O
cortisol O
between O
0 O
degree O
and O
25 O
degrees O
C I-protein
were O
calculated O
by O
curve-fitting B-protein
from O
time-course B-DNA
and O
equilibrium O
kinetics O
. O
The O
data O
were O
consistent O
with O
a O
simple O
reversible O
bimolecular O
interaction O
. O
Arrhenius O
and O
Va O
n't O
Hoff O
plots O
were O
curvilinear O
for O
both O
steroids O
. O
At O
equilibrium O
, O
the O
solution O
for O
the O
equation O
delta O
G O
= O
delta O
H O
- O
T I-cell_line
X O
delta O
S O
( O
eqn. I-DNA
1 O
) O
was O
( O
in O
kJ I-RNA
X O
mol-1 B-protein
) O
-47 O
= O
36 O
- O
83 I-cell_line
( O
dexamethasone I-DNA
) O
and O
-42 B-protein
= O
-9 O
- O
33 I-cell_line
( O
cortisol I-DNA
) O
at O
0 O
degree O
C I-protein
. O
Enthalpy O
and O
entropy O
changes O
decreased O
quasi-linearly O
with O
temperature O
such O
that O
, O
at O
25 O
degrees O
C I-protein
, O
the O
respective O
values O
were O
-50 B-protein
= O
-75 B-protein
+ O
25 O
and O
-43 B-protein
= O
-48 B-protein
+ O
5 O
. O
Thus O
, O
for O
both O
steroids O
, O
the O
interaction O
was O
entropy-driven O
at O
low O
temperature O
and O
became O
entirely O
enthalpy-driven O
at O
20 O
degrees O
C I-protein
. O
Thermodynamic B-cell_type
values O
for O
the O
transition O
state O
were O
calculated O
from O
the O
rate O
constants O
. O
For O
the O
forward O
reaction O
, O
eqn. B-DNA
( O
1 O
) O
gave O
45 O
= O
84 O
- O
39 I-cell_line
( O
dexamethasone I-DNA
) O
and O
46 O
= O
60 O
- O
14 O
( O
cortisol I-DNA
) O
at O
0 O
degree O
C I-protein
, O
and O
44 O
= O
24 O
+ O
20 I-cell_line
( O
dexamethasone I-DNA
) O
and O
46 O
= O
28 O
+ O
18 O
( O
cortisol I-DNA
) O
at O
25 O
degrees O
C I-protein
. O
These O
data O
fit O
quite O
well O
with O
a O
two-step B-DNA
model O
[ O
Ross O
& O
Subramanian O
( O
1981 I-DNA
) O
Biochemistry O
20 I-cell_line
, O
3096-3102 O
] O
proposed O
for O
ligand-protein I-cell_type
interactions O
, O
which O
involves O
a O
partial O
immobilization O
of O
the O
reacting O
species O
governed O
by O
hydrophobic O
forces O
, O
followed O
by O
stabilization O
of O
the O
complex I-protein
by O
short-range O
interactions O
. O
On O
the O
basis O
of O
this O
model O
, O
an O
analysis O
of O
the O
transition-state O
thermodynamics O
led O
to O
the O
conclusion O
that O
no O
more O
than O
half O
of O
the O
steroid O
molecular O
area O
is O
engaged O
in O
the O
binding O
process O
. O
Cell O
cycle-related B-protein
changes O
in O
number O
of O
T-lymphocyte B-protein
receptors O
for O
glucocorticoids O
and O
insulin O
. O
Enriched O
human O
peripheral B-cell_type
T-lymphocytes B-protein
were O
stimulated O
with O
PHA O
and O
examined O
for O
variations O
in O
insulin O
and O
glucocorticoid O
( O
dexamethasone I-DNA
) O
receptor I-protein
numbers O
during O
the O
early O
phases O
of O
the O
cell O
cycle O
. O
Cells O
in O
G0 I-protein
, O
G1a O
and O
G1b O
phases O
, O
where O
the O
G1a O
- O
G1b O
transition O
is O
an O
Interleukin O
2 O
dependent O
event O
, O
were O
quantitated O
by O
flow O
cytometry O
. O
Few O
but O
significant O
numbers O
of O
glucocorticoid O
receptors O
( O
2700/cell I-DNA
) O
and O
no O
insulin O
receptors O
( O
-1/cell B-protein
) O
were O
found O
in O
the O
resting O
( O
G0 B-protein
) O
phase O
. O
As B-cell_line
cells I-cell_type
entered O
the O
G1a O
phase O
the O
specific O
binding O
of O
dexamethasone O
increased O
and I-DNA
of O
insulin O
took O
place O
. O
Although O
the O
specific O
binding O
further O
increased O
as O
T-cells B-protein
entered O
the O
G1b O
phase O
( O
as O
measured O
at O
44 O
h O
of O
incubation O
and O
using O
hydroxyurea-treated B-cell_type
cells I-cell_type
) O
, O
the O
major O
changes O
in O
the O
specific O
binding O
of O
dexamethasone O
took O
place O
during O
the O
period O
16 O
- O
20 O
h O
after O
stimulation O
. O
Based O
on O
these O
findings O
, O
it O
is O
concluded O
that O
both I-DNA
receptor I-protein
types O
( O
cell O
membrane O
and O
cytoplasmic O
receptors O
) O
are O
being O
formed O
and O
increased O
at O
G1 B-protein
phase O
prior O
to O
cell O
proliferation O
, O
indicating O
the O
importance O
of O
G1 B-protein
phase O
in O
immunoregulation O
. O
Glucocorticoid O
receptors O
and O
cortico-sensitivity B-protein
in O
a O
human B-DNA
clonal I-cell_type
monocytic B-cell_line
cell O
line O
, O
CM-SM B-protein
. O
CM-SM B-protein
is O
a O
clonal O
line O
of O
human B-cell_type
precursor I-cell_type
mononuclear O
phagocytes O
inducible O
to O
macrophage O
differentiation O
in O
response O
to O
the O
tumor B-DNA
promoter I-DNA
phorbol O
ester O
12-O-tetradecanoyl-phorbol-13-acetate B-protein
( O
TPA I-DNA
) O
. O
Untreated O
CM-SM B-protein
cells I-cell_type
contain O
single O
class I-protein
, O
high-affinity I-DNA
( O
KD B-protein
= O
4.0 B-protein
X O
10 O
( O
-9 B-protein
) O
M O
) O
glucocorticoid-specific I-DNA
receptor I-DNA
sites I-DNA
( O
approximately O
60 I-cell_line
, O
000 O
per O
cell O
) O
, O
as O
measured O
by O
a O
whole O
cell O
assay O
, O
at O
37 O
degrees O
C I-protein
, O
using O
[ O
3H B-protein
] O
triamcinolone O
acetonide O
( O
TA I-DNA
) O
. O
Exposure O
of O
CM-SM B-protein
to O
dexamethasone O
( O
DEX I-DNA
) O
produced O
a O
progressive O
, O
dose- B-DNA
and O
time-related O
series O
of O
changes O
in O
CM-SM O
cell O
growth O
, O
saturation O
density O
, O
morphology O
, O
and O
functional O
properties O
, O
with O
half-maximal B-DNA
effects O
at O
about O
10 O
( O
-9 B-protein
) O
M O
for O
DEX O
. O
TA-receptor B-protein
sites I-DNA
rapidly O
decreased O
( O
about O
70 O
% O
) O
after O
DEX O
treatment O
, O
without O
any O
apparent O
change O
in O
steroid O
specificity O
and O
affinity O
. O
After O
5 O
days O
in O
culture O
with O
a O
saturating O
concentration O
( O
3.6 B-protein
X O
10 O
( O
-8 B-protein
) O
M O
) O
of O
hormone O
, O
the O
cells I-cell_type
reached O
a O
saturation O
density O
of O
about O
9.0 B-protein
X O
10 O
( O
6 O
) O
viable O
cells/ml I-cell_line
( O
about O
4.0 B-protein
X O
10 O
( O
6 O
) O
viable O
cells/ml O
in O
the O
controls O
) O
, O
while O
the O
modal O
volume O
of O
the O
resulting O
cell O
population O
was O
approximately O
60 O
% O
, O
as O
compared O
to O
the O
volume O
of O
untreated B-cell_type
cells I-cell_type
. O
DEX-treated B-cell_line
cells I-cell_type
appeared O
less O
differentiated O
than O
controls O
, O
as O
assessed O
by O
combined O
morphologic O
, O
antigenic O
, O
and O
cytoenzymatic O
analyses O
. O
DEX O
almost O
completely O
inhibited O
TPA O
activation O
of O
the O
following O
macrophage O
functions O
: O
adherency O
to O
the O
culture O
plate O
, O
expression O
of O
lysosomal O
enzymes O
, O
Fc O
and O
C3 B-protein
receptors O
, O
and O
stimulation O
of O
phagocytosis O
. O
After O
removal O
of O
DEX I-protein
, O
the O
cells I-cell_line
, O
within O
a O
few O
passages O
, O
returned O
to O
a O
state O
apparently O
identical O
to O
the O
untreated O
controls O
and O
could O
be O
induced O
to O
macrophage O
differentiation O
in O
response O
to O
TPA O
. O
Acute O
lymphoblastic O
leukemia O
in O
children O
: O
current O
status O
, O
controversies O
, O
and O
future O
perspective O
. O
Disease-free O
survival O
( O
DFS I-DNA
) O
in O
childhood O
ALL O
is O
60 O
% O
, O
and O
survival O
in O
good O
, O
average O
, O
and O
poor O
prognostic O
groups O
defined O
by O
initial O
WBC O
and O
age O
is O
90 I-cell_line
, O
60 O
, O
and O
45 O
% O
, O
respectively O
. O
Additional O
immunological O
, O
morphological O
, O
biochemical O
, O
cytokinetic O
, O
and O
cytogenetic O
factors I-protein
have O
been O
identified O
, O
illustrating O
the O
heterogeneity O
of O
ALL O
and O
its O
derivation O
from O
malignant O
clones O
at O
various O
stages O
of O
differentiation O
and O
with O
varying O
rates O
of O
proliferation O
. O
Of O
biologic O
importance O
, O
these O
factors I-protein
may O
refine O
further O
the O
characteristic O
features O
of O
clinically-determined O
prognostic O
groups O
. O
Multivariate O
analysis O
of O
large O
prospective O
trials O
with O
homogeneous O
therapy O
will O
be O
required O
to O
determine O
the O
independent O
prognostic O
importance O
of O
these O
factors I-protein
. O
Current O
treatment O
strategies O
in O
ALL O
include O
( O
1 O
) O
tailoring O
therapy O
and O
its O
intensity O
to O
prognostic O
groups O
; O
( O
2 O
) O
multiple-drug O
combinations O
in O
induction O
; O
( O
3 O
) O
early O
use O
of O
intrathecal O
( O
IT I-DNA
) O
methotrexate O
( O
MTX I-DNA
) O
; O
( O
4 O
) O
CNS O
prophylaxis O
with O
IT B-protein
MTX O
alone O
in O
good O
prognosis O
patients O
and O
combined O
cranial O
radiation O
( O
CXRT I-DNA
) O
, O
1800 O
rads O
plus O
IT B-protein
MTX I-protein
, O
in O
average O
and O
poor O
prognosis O
patients O
. O
Current O
studies O
show O
a O
CNS O
relapse O
rate O
of O
5 O
% O
in O
all O
prognostic O
groups O
. O
Late O
neuropsychological O
defects O
caused O
by O
cranial O
XRT O
and O
IT B-protein
MTX O
have O
prompted O
programs O
designed O
to O
reduce O
the O
potential O
late O
toxicity O
of O
CNS B-cell_type
prophylaxis O
. O
More O
pronounced O
in O
younger O
children O
, O
these O
abnormalities O
include O
decreased O
IQ I-protein
, O
visual-motor O
incoordination O
, O
poor O
performance O
in O
mathematics O
, O
and O
memory O
dysfunction O
. O
Until O
1980 I-DNA
, O
more O
intensive O
induction O
, O
consolidation O
, O
and O
maintenance O
therapy O
had O
failed O
to O
prolong O
DFS O
in O
children O
with O
a O
poor O
prognosis O
. O
In O
West O
Germany O
( O
Berlin-Frankfurt-Muenster I-DNA
protocol O
) O
a O
70 O
to O
75 O
% O
DFS O
is O
seen O
in O
all O
patients O
regardless O
of O
initial O
WBC I-protein
, O
suggesting O
that O
effective O
therapy O
will O
override O
prognostic O
factors I-protein
. O
Ultra-high-dose O
MTX I-protein
, O
without O
cranial O
radiation O
, O
is O
also O
showing O
promise O
in O
poor O
prognosis O
patients O
. O
Other O
issues O
include O
the O
optimal O
duration O
of O
therapy O
, O
the O
role O
of O
testicular O
biopsies O
, O
and O
prophylactic O
testicular O
radiation O
. O
Recent O
studies O
suggest O
that O
prognostic O
factors I-protein
lose O
their O
significance O
after O
2 O
years O
of O
continuous O
complete O
remission O
and O
that O
2 O
years O
of O
maintenance O
therapy O
is O
adequate O
. O
Bilateral O
open-wedge B-DNA
testicular O
biopsies O
have O
identified O
occult O
testicular O
disease O
in O
8 O
to O
10 O
% O
of O
males O
. O
A O
unified O
approach O
to O
children O
with O
leukemia/lymphoma I-protein
, O
a O
group O
with O
a O
particularly O
poor O
prognosis O
, O
utilizing O
NHL-type B-protein
therapy O
may O
be O
more O
effective O
than O
conventional O
ALL O
therapy O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O
Glucocorticoid I-DNA
receptor I-protein
and O
in O
vitro O
sensitivity O
to O
steroid O
hormones O
in O
human B-DNA
lymphoproliferative I-cell_type
diseases O
and O
myeloid O
leukemia O
. O
The O
glucocorticoid I-DNA
receptor I-protein
( O
GR I-DNA
) O
quantitation O
by O
a O
whole-cell B-DNA
assay O
and/or I-cell_line
cytosol O
technique O
and O
the O
in O
vitro O
sensitivity O
to O
steroids O
have O
been O
assessed O
in O
peripheral B-cell_type
blood I-cell_type
cells I-cell_type
from O
normal O
donors O
and O
patients O
with O
chronic O
lymphatic O
leukemia O
( O
CLL I-DNA
) O
, O
acute O
lymphoblastic O
leukemia O
( O
ALL I-DNA
) O
, O
lymphosarcoma O
cell O
leukemia O
( O
LSCL I-DNA
) O
, O
acute O
nonlymphatic O
leukemia O
( O
ANLL I-DNA
) O
, O
and O
chronic O
myeloid O
leukemia O
( O
CML I-DNA
) O
. O
Within O
the O
lymphoproliferative O
diseases O
, O
ALL B-cell_type
cells I-cell_type
exhibited O
the O
highest O
GR B-protein
concentration O
( O
regardless O
of O
the O
method O
used O
) O
and O
the O
highest O
in O
vitro O
inhibition O
of O
spontaneous O
[ O
3H B-protein
] O
thymidine O
( O
[ O
3H B-protein
] O
TdR O
) O
uptake O
by O
glucocorticoids O
. O
A O
significant O
relationship O
between O
GR B-protein
concentration O
( O
whole-cell I-DNA
assay O
) O
and O
in O
vitro O
sensitivity O
to O
dexamethasone O
was O
also O
found O
. O
On O
the O
contrary O
, O
CLL B-cell_type
cells I-cell_type
presented O
the O
highest O
sensitivity O
to O
glucocorticoids O
in O
PHA-stimulated O
cell O
cultures I-cell_line
. O
Cells O
from O
the O
only O
two O
ALL O
patients O
who O
did O
not O
undergo O
a O
remission O
after O
glucocorticoid-inclusive B-DNA
chemotherapy O
had O
both O
the O
lowest O
in O
vitro O
sensitivity O
to O
dexamethasone O
and O
the O
lowest O
GR B-protein
concentration O
with O
whole-cell B-DNA
assay O
. O
Concerning O
myeloid O
leukemia O
, O
ANLL O
patients O
had O
GR B-protein
concentrations O
slightly O
higher O
than O
those O
found O
in O
the O
ALL O
group O
but O
exhibited O
the O
lowest O
degree O
of O
inhibition O
of O
spontaneous O
[ O
3H B-protein
] O
TdR O
uptake O
by O
dexamethasone O
( O
stimulatory O
effects O
occurred O
in O
some O
cases O
) O
. O
CML B-cell_type
cells I-cell_type
exhibited O
an O
inhibition O
degree O
by O
in O
vitro O
glucocorticoids O
significantly O
higher O
than O
that O
of O
ANLL B-cell_type
cells I-cell_type
but O
not O
different O
from O
that O
of O
lymphoproliferative B-RNA
diseases O
. O
No O
clear O
relationship O
among O
GR B-protein
pattern O
, O
in O
vitro O
cell O
sensitivity O
to O
glucocorticoids O
, O
and O
clinicohematologic O
parameters O
was O
observed O
in O
myeloid O
leukemia-bearing I-cell_line
patients O
. O
Glucocorticoid O
receptors O
and O
in O
vitro O
corticosensitivity O
of O
peanut-positive O
and O
peanut-negative O
human B-DNA
thymocyte I-cell_type
subpopulations O
. O
In O
6 O
human B-DNA
thymus I-cell_type
glands O
, O
the O
immature O
subset O
of O
thymocytes O
was O
separated O
from O
the O
more O
mature O
one O
, O
by O
differential O
peanut O
lectin O
agglutination O
. O
These O
2 O
cell O
subpopulations O
were O
analyzed O
for O
glucocorticoid I-DNA
receptor I-protein
content O
by O
using O
a O
whole O
cell O
assay O
, O
with O
( O
3H B-protein
) O
-triamcinolone O
acetonide O
as O
tracer O
. O
The O
unagglutinated O
thymocytes O
( O
peanut O
negative O
) O
contained O
about O
2 O
times O
more I-DNA
receptor I-DNA
sites I-DNA
per O
cell O
than O
agglutinated O
( O
peanut O
positive O
) O
ones O
( O
7650 I-DNA
+/- O
1550 O
S.D. I-protein
verus O
3195 O
+/- O
896 O
S.D. B-protein
) O
. O
The O
affinity O
for O
steroid O
was O
similar O
in O
both O
cell O
subsets O
, O
as O
was O
the O
stereospecificity O
for O
glucocorticoids O
, O
the O
time-course I-DNA
of O
steroid-receptor O
association O
, O
and O
cytoplasmic O
to O
nuclear B-protein
translocation O
. O
Despite O
the O
greater O
number O
of O
glucocorticoid I-DNA
receptor I-DNA
sites I-DNA
, O
the O
peanut-negative O
thymocyte O
subpopulation O
did O
not O
differ O
from O
the O
peanut-positive O
one O
in O
its O
sensitivity O
to O
the O
inhibitory O
effects O
of O
triamcinolone O
acetonide O
, O
as O
determined O
by O
measurements O
of O
the O
incorporation O
of O
radiolabeled O
precursors I-cell_line
of O
protein O
and O
DNA O
. O
Moreover O
, O
the O
peanut-negative O
subset O
appeared O
more O
resistant O
in O
vitro O
to O
the O
steroid-induced O
cell O
lysis O
as O
compared O
to O
the O
peanut-positive O
one O
. O
Thus O
, O
our O
data O
suggest O
that O
glucocorticoid I-DNA
receptor I-protein
density O
and O
corticosensitivity O
are O
not O
directly O
correlated O
and O
that O
the O
number O
of O
glucocorticoid I-DNA
receptor I-DNA
sites I-DNA
may O
be O
dependent O
on O
the O
degree O
of O
immunologic O
maturation O
Defective O
binding O
and O
function O
of O
1 O
, O
25-dihydroxyvitamin O
D3 B-protein
receptors O
in O
peripheral B-cell_type
mononuclear I-cell_type
cells I-cell_type
of O
patients O
with O
end-organ B-DNA
resistance O
to O
1 O
, O
25-dihydroxyvitamin O
D O
. O
Lectin-induced O
DNA O
synthesis O
by O
peripheral B-cell_type
mononuclear I-cell_type
cells I-cell_type
from O
17 O
normal O
donors O
was O
inhibited O
( O
40-60 O
% O
) O
by O
1 O
, O
25-dihydroxyvitamin O
D3 B-protein
( O
1 O
, O
25 O
[ O
OH B-protein
] O
2D3 B-protein
) O
at O
physiological O
concentrations O
( O
10 O
( O
-10 B-protein
) O
-10 O
( O
-9 B-protein
) O
M O
) O
. O
The I-cell_type
lymphocytes I-cell_type
acquire O
specific O
receptors O
for O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
upon O
activation O
by O
the O
lectins O
. O
This O
process O
precedes O
the O
inhibitory O
effect O
of O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
. O
We O
studied I-cell_type
lymphocytes I-cell_type
from O
six O
patients O
from O
four O
different O
kindreds O
with O
the O
syndrome O
of O
hereditary O
end-organ B-DNA
resistance O
to O
1 O
, O
25 O
( O
OH I-DNA
) O
2D O
( O
the O
so-called B-DNA
vitamin O
D-dependent B-protein
rickets I-DNA
type O
II I-DNA
) O
. O
In O
five O
patients O
( O
three O
kindreds O
) O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
did O
not O
acquire O
receptors O
for O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
upon O
phytohemagglutinin-induced B-DNA
activation O
. O
Moreover O
, O
in O
contrast O
to O
normal I-cell_type
lymphocytes I-cell_type
, O
the O
mitogenic O
stimulation O
of O
these O
patients O
' O
lymphocytes I-cell_type
by O
phytohemagglutinin O
and O
concanavalin O
A O
was O
not O
inhibited O
by O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
. O
Activated I-cell_type
lymphocytes I-cell_type
of O
the O
sixth O
patient O
from O
a O
fourth O
kindred O
exhibited O
normal O
binding O
of O
[ O
3H B-protein
] O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
but O
the O
hormone O
failed O
to O
inhibit O
the O
mitogenic O
stimulation O
. O
A O
similar O
pattern O
of O
the O
vitamin O
D O
effector O
system O
was O
previously O
observed O
in O
fibroblasts O
cultured O
from O
skin O
biopsies O
of O
the O
same O
group O
of O
patients O
. O
The O
conclusions O
from O
these O
findings O
are O
: O
( O
a O
) O
the O
inhibition O
of O
mitogenic O
stimulation O
by O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
is O
mediated O
by O
specific O
functional O
receptors O
to O
the O
hormone O
; O
and O
( O
b O
) O
the O
receptors O
for O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
in O
mononuclear B-cell_type
cells I-cell_type
are O
probably O
controlled O
genetically O
by O
the O
same O
mechanisms O
as O
the O
effector O
system O
in O
well-characterized O
target I-cell_line
organs O
of O
the O
hormone O
, O
such O
as O
intestine O
and O
kidney O
. O
Glucocorticoid O
receptors O
of O
mononuclear O
leukocytes O
from O
myasthenia O
gravis O
patients O
. O
The O
present O
study O
was O
performed O
to O
analyse O
glucocorticoid I-DNA
receptor I-protein
( O
GR I-DNA
) O
binding O
in O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
leukocytes O
( O
MNL I-DNA
) O
from O
39 O
myasthenia O
gravis O
( O
MG I-DNA
) O
patients O
( O
unoperated O
patients O
( O
n O
= O
13 O
) O
, O
thymectomized O
patients O
( O
n O
= O
14 O
) O
and O
patients O
receiving O
glucocorticoids O
: O
thymectomized O
( O
n O
= O
11 O
) O
and O
unoperated O
( O
n O
= O
6 O
] O
. O
A O
whole O
cell O
binding O
assay O
with O
3 O
( O
H I-DNA
) O
dexamethasone O
was O
used O
. O
GR B-protein
mean O
values O
were O
significantly O
higher O
in O
the O
MNL O
of O
MG B-cell_type
patients O
( O
thymectomized O
or O
not O
) O
not O
receiving O
glucocorticoid O
than O
in O
the O
MNL O
of O
healthy O
donors O
. O
Affinity O
was O
within O
the O
normal O
range O
. O
Sex O
, O
age O
or O
clinical O
forms O
of O
illness O
did O
not O
influence O
the O
results O
. O
In O
patients O
receiving O
prednisone O
( O
Pd O
) O
the O
GR B-protein
values O
were O
significantly O
lower O
than O
in O
MG B-protein
patients O
without O
Pd O
therapy O
, O
independent O
of O
Pd O
dose O
or O
time O
of O
administration O
. O
No O
differences O
in B-DNA
receptor I-protein
binding O
between O
normal O
subjects O
and O
MG B-protein
patients O
receiving O
Pd O
have O
been O
found O
. O
Immunological B-cell_type
interference O
of O
high O
dose O
corticosteroids O
. O
High-dose O
corticosteroids O
( O
HDC I-DNA
) O
will O
influence O
cellular O
as O
well O
as O
humoral O
participants O
of O
the O
immune O
response O
. O
The O
lymphoid O
tissue O
will O
decrease O
in O
size O
and O
weight O
after O
prolonged O
treatment O
with O
HDC O
. O
Lymphocyte O
functions O
will O
be O
impaired O
. O
Reduced O
synthesis O
of O
B- B-protein
as O
well O
as O
T-lymphocytes B-protein
will O
be O
seen O
. O
The O
inhibitory O
effect O
on O
B-cell O
function O
can O
be O
observed O
both O
as O
decreased O
serum O
levels O
of O
immunoglobulins O
and O
as O
impaired O
binding O
of O
antibodies I-protein
and O
complement O
to O
the O
cellular O
surface I-protein
. O
Reduced O
T-cell O
function O
indicated O
by O
impaired O
stimulation O
by O
PHA O
and O
porkweed O
as O
well O
as O
by O
impaired O
lymphokinin O
effects O
on O
leukocyte O
migration O
inhibition O
has O
been O
reported O
. O
Reduced O
lymphocyte I-cell_line
adherence O
to O
antigen I-protein
and O
suppressed O
lymphocyte I-cell_line
reaction O
have O
also O
been O
observed O
. O
Humoral B-protein
factors I-protein
involved O
in O
chemotaxis O
, O
opsonisation O
, O
phagocytosis O
, O
vascular O
permeability O
leading O
to O
leakage O
of O
fluid O
and I-DNA
cells I-cell_type
and O
factors I-protein
involved O
in O
lysis O
of O
antigens O
are O
impaired O
. O
This O
can O
be O
explained O
partly O
by O
the O
observed O
reduced O
complement O
activation O
via O
the O
alternative O
as O
well O
as O
the O
classical O
pathway O
in O
association O
with O
HDC O
therapy O
. O
Acute O
processes O
with O
increased O
vascular O
permeability O
and O
accumulation O
of O
leukocytes O
as O
impairing B-protein
factors I-protein
could O
be O
influenced O
beneficially O
by O
HDC O
therapy O
. O
This O
positive O
effect O
can O
be O
seen O
in O
treatment O
of O
septic O
shock O
or O
rejection O
of O
a O
transplant O
. O
However O
, O
if O
sepsis O
or O
rejection O
is O
not O
rapidly O
reversed O
, O
complications O
such O
as O
multisystem O
organ O
failure O
and O
bacteremia O
are O
prone O
to O
appear O
. O
Identification O
of O
human B-cell_type
leukemic I-DNA
glucocorticoid O
receptors O
using O
affinity O
labeling O
and O
anti-human B-protein
glucocorticoid I-DNA
receptor I-protein
antibodies O
. O
Antisera O
raised O
against O
human B-DNA
lymphoid I-DNA
glucocorticoid O
receptors O
were O
used O
in O
combination O
with O
the O
glucocorticoid I-DNA
receptor I-protein
affinity O
label O
[ O
3H B-protein
] O
dexamethasone O
21-mesylate O
[ O
( O
3H B-protein
] O
DM B-protein
) O
to O
identify O
the O
glucocorticoid O
receptors O
of O
the O
human B-DNA
B-lymphoblastoid I-DNA
cell O
line O
IM-9 B-protein
and O
the O
human O
T-cell O
leukemic O
cell O
line O
CEM-C7 B-protein
. O
Antisera O
were O
obtained O
following O
immunization O
of O
New O
Zealand O
White O
rabbits O
with O
[ O
3H B-protein
] O
triamcinolone O
acetonide O
[ O
( O
3H B-protein
] O
TA B-protein
) O
-glucocorticoid I-DNA
receptor I-protein
complexes O
partially O
purified O
by O
two-stage B-DNA
DNA-cellulose B-protein
chromatography O
. O
The O
presence O
of O
anti-human B-DNA
glucocorticoid I-DNA
receptor I-protein
antibodies O
was O
verified O
by O
: O
( O
a O
) O
adsorption O
of O
[ O
3H B-protein
] O
TA-receptor-antibody B-protein
complexes O
to O
Protein O
A O
; O
( O
b O
) O
a O
shift O
to O
higher O
apparent O
molecular O
weight O
in O
the O
elution O
position O
from O
Sephacryl O
S300 B-protein
of O
[ O
3H B-protein
] O
TA-receptor B-protein
complexes O
incubated O
with O
immune O
serum O
; O
and O
( O
c O
) O
the O
ability O
of O
immune O
serum O
to O
displace O
[ O
3H B-protein
] O
TA-receptor B-protein
complexes O
on O
sucrose O
gradients O
. O
These O
antibodies I-protein
also O
recognized O
rat O
liver O
and O
murine I-cell_line
S49 O
cell O
glucocorticoid O
receptors O
. O
Sodium O
dodecyl O
sulfate-polyacrylamide B-DNA
gel O
electrophoresis O
of O
[ O
3H B-protein
] O
DM-labeled B-protein
IM-9 B-protein
cytosol O
identified O
a O
major O
competable O
band O
with O
a O
molecular O
weight O
of O
approximately O
90 I-cell_line
, O
000 O
, O
three O
minor O
competable O
components O
with O
molecular O
weights O
of O
approximately O
78 I-cell_line
, O
000 O
, O
approximately O
51 I-cell_line
, O
000 O
, O
and O
approximately O
38 I-cell_line
, O
500 O
, O
and O
at O
least O
21 O
other O
noncompetable O
components O
. O
Following O
immunoprecipitation I-DNA
of O
[ O
3H B-protein
] O
DM-labeled B-protein
cytosol O
with O
immune O
serum O
, O
only O
the O
Mr O
90 I-cell_line
, O
000 O
and O
78 I-DNA
, O
000 O
components O
were O
seen O
. O
Sodium O
dodecyl O
sulfate-polyacrylamide B-DNA
gel O
electrophoresis O
of O
[ O
3H B-protein
] O
DM-labeled B-protein
CEM-C7 B-protein
cytosol O
revealed O
a O
larger O
number O
of O
[ O
3H B-protein
] O
DM-labeled B-protein
components O
. O
However O
, O
after O
immunoprecipitation I-DNA
of O
[ O
3H B-protein
] O
DM-labeled B-protein
CEM-C7 B-protein
cytosol O
, O
a O
predominant O
competable O
component O
with O
a O
molecular O
weight O
of O
90 O
, O
000 O
was O
easily O
identified O
. O
This O
component O
was O
markedly O
diminished O
when O
cytosols O
from O
the O
glucocorticoid O
receptor-deficient O
cell O
line O
ICR-27 B-protein
were O
used O
. O
Thus O
, O
the O
combination O
of O
affinity O
labeling O
and O
anti-human B-protein
glucocorticoid I-DNA
receptor I-protein
antibodies O
is O
capable O
of O
providing O
direct O
physical O
identification O
of O
human B-cell_type
lymphoid I-DNA
glucocorticoid O
receptors O
. O
Effect O
of O
thymosin O
on O
glucocorticoid I-DNA
receptor I-protein
activity O
and O
glucocorticoid O
sensitivity O
of O
human B-cell_type
thymocytes I-cell_type
. O
Incubation O
with O
thymosin O
fraction O
5 O
, O
( O
TMS O
F5 B-protein
at O
300 O
micrograms/ml I-DNA
) O
a O
partially O
purified O
thymic B-cell_line
factor I-protein
, O
reduced O
the O
steroid O
binding O
activity O
of O
human B-cell_type
infant I-cell_type
thymocytes O
from O
9.6 B-protein
+/- O
2.1 B-protein
fmole/ml O
to O
5.0 B-protein
+/- O
2.0 B-protein
fmole/ml O
. O
The O
glucocorticoid I-DNA
receptor I-protein
activity O
in O
normal O
infant O
thymocytes O
was O
found O
to O
be O
2 O
, O
146 O
+/- O
726 O
( O
s.d. I-DNA
) O
sites I-DNA
per O
cell O
with O
dissociation O
constant O
of O
1.4 B-cell_type
+/- O
0.6 B-protein
X O
10 O
( O
-8 B-protein
) O
M O
. O
TMS O
F5 B-protein
also O
increased O
the O
resistance O
of O
human B-cell_type
thymocytes O
to O
the O
cytolytic O
effect O
of O
dexamethasone O
( O
2.5 B-protein
X O
10 O
( O
-8 B-protein
) O
M O
) O
to O
168.6 B-protein
+/- O
30.2 B-protein
% O
of O
control O
( O
P O
less O
than O
0.01 B-protein
) O
. O
In O
animals O
, O
medullary O
and O
peripheral B-cell_type
blood I-cell_type
T I-cell_type
cells I-cell_type
are O
more O
resistant O
to O
glucocorticoids O
than O
immature O
thymic B-cell_line
T B-cell_type
cells I-cell_type
. O
The O
results O
show O
that O
thymosin O
can O
induce O
changes O
consistent O
with O
differentiation O
in O
human B-DNA
thymocytes I-cell_type
. O
These O
in O
vitro O
results O
are O
consistent O
with O
a O
physiological O
role O
of O
thymosin O
in O
intrathymic O
T O
cell O
maturation O
in O
man O
. O
Incubation O
of O
a O
human B-DNA
malignant I-cell_type
thymus O
derived O
T O
cell O
line O
( O
MOLT O
3 O
) O
with O
TMS O
F5 B-protein
also O
resulted O
in O
a O
significant O
reduction O
of O
the O
number O
of O
steroid O
binding O
sites O
to O
44.2 B-protein
+/- O
15.3 B-protein
% O
of O
control O
( O
P O
less O
than O
0.05 B-protein
) O
, O
but O
TMS O
F5 B-protein
did O
not O
significantly O
reduce O
the O
glucocorticoid O
sensitivity O
of O
MOLT O
3 O
cells I-cell_type
. O
Specific O
high-affinity I-DNA
receptors O
for O
1 O
, O
25-dihydroxyvitamin O
D3 B-protein
in O
human O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
: O
presence O
in O
monocytes B-cell_type
and O
induction O
in O
T I-cell_type
lymphocytes I-cell_type
following O
activation O
. O
Human O
peripheral B-cell_type
blood I-cell_type
monocytes I-cell_type
have O
high O
affinity O
binding O
sites O
for O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
( O
Kd O
0.14 B-protein
nM I-cell_line
, O
sedimentation O
coefficient O
3.7S B-protein
) O
. O
Resting O
human O
peripheral B-cell_type
blood I-cell_type
T I-cell_type
lymphocytes I-cell_type
, O
however O
, O
do O
not O
have O
a O
demonstrable O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 I-DNA
receptor I-protein
. O
After O
activation O
with O
phytohemagglutinin O
the O
T B-cell_type
cells I-cell_type
exhibit O
the I-DNA
receptor I-protein
within O
24 O
h O
, O
and O
this O
expression O
is O
blocked O
by O
cycloheximide O
. O
The I-DNA
receptor I-protein
in O
activated B-cell_type
T I-cell_type
lymphocytes I-cell_type
has O
a O
sedimentation O
coefficient O
of O
3.7S B-DNA
and O
a O
high O
affinity O
( O
Kd O
0.10 B-protein
nM O
) O
for O
the O
ligand O
. O
Effects O
of O
chronic O
glucocorticoid O
excess O
in O
man O
on O
insulin O
binding O
to O
circulating B-cell_type
cells I-cell_type
: O
differences O
between O
endogenous O
and O
exogenous O
hypercorticism O
. O
We O
measured O
[ O
125I B-protein
] O
insulin O
binding O
to O
circulating O
monocytes B-cell_type
or O
erythrocytes B-cell_type
from O
16 O
patients O
with O
chronic O
glucocorticoid O
excess O
, O
9 O
chronically O
treated O
with O
prednisone O
and O
7 O
with O
adrenocortical O
hyperfunction O
. O
With O
monocytes B-cell_type
, O
[ O
125I B-protein
] O
insulin O
binding O
was O
iincreased O
in O
all O
patients O
. O
Analysis O
of O
binding O
data O
indicated O
that O
increased O
binding O
in O
patients O
treated O
with O
prednisone O
was O
due O
to O
an O
ncrease O
in B-DNA
receptor I-protein
concentration I-DNA
, O
whereas O
in O
patients O
with O
adrenocortical O
hyperfunction O
, O
it O
was O
due O
to O
an O
increase O
in B-DNA
receptor I-protein
affinity O
. O
With O
erythrocytes B-cell_type
from O
patients O
with O
adrenocortical O
hyperfunction O
there O
was O
an O
increase O
in B-DNA
receptor I-protein
affinity O
and O
a O
decrease O
in B-DNA
receptor I-protein
concentration I-DNA
, O
so O
that O
the O
binding O
of O
[ O
125I B-protein
] O
insulin O
was O
normal O
. O
The O
disparity O
of O
results O
between O
endogenous O
and O
exogenous O
hypercorticism O
, O
between O
the O
two O
cell O
types I-cell_type
, O
and O
between O
the O
present O
studies O
and O
previous O
studies O
suggest O
that O
the O
effects O
of O
glucocorticoid O
excess O
on O
the O
insulin I-DNA
receptor I-protein
are O
extremely O
complex I-protein
and O
wide-ranging O
and O
that O
in O
this O
condition O
, O
extrapolations O
in O
humans O
from O
data O
with O
circulating B-cell_type
cells O
to O
liver O
and O
muscle O
may O
not O
be O
appropriate O
. O
Reduced O
level O
of O
cellular O
glucocorticoid O
receptors O
in O
patients O
with O
anorexia O
nervosa O
. O
Specific O
glucocorticoid O
receptors O
were O
measured O
in O
circulating O
mononuclear O
leukocytes O
from O
12 O
patients O
with O
anorexia O
nervosa O
and O
21 O
healthy O
control O
subjects O
. O
Cells O
from O
patients O
were O
found O
to O
contain O
a O
significantly O
( O
p O
less O
than O
0.01 B-protein
) O
lower O
level O
of O
glucocorticoid I-DNA
receptor I-protein
( O
3830 I-DNA
+/- O
210 O
sites/cell I-protein
, O
mean O
+/- O
SE B-protein
) O
than O
those O
from O
controls O
( O
4930 I-DNA
+/- O
250 O
sites/cell I-DNA
) O
. O
A O
partial O
glucocorticoid I-DNA
receptor I-protein
defect O
may O
well O
explain O
the O
abnormal O
cortisol O
metabolism O
and O
glucocorticoid O
resistance O
commonly O
found O
in O
patients O
with O
anorexia O
nervosa O
. O
Regulation O
of O
the O
glucocorticoid I-DNA
receptor I-protein
in O
human I-cell_type
lymphocytes I-cell_type
. O
The O
presence O
of O
a O
glucocorticoid I-DNA
receptor I-protein
in O
human I-cell_type
lymphocytes I-cell_type
is O
well O
established O
, O
but O
factors I-protein
affecting O
its O
regulation O
have O
not O
been O
described O
. O
Using O
a O
competitive O
binding O
whole O
cell O
assay O
, O
we O
have O
examined O
the O
binding O
of O
[ O
3H B-protein
] O
-dexamethasone O
at O
24 O
and O
37 O
degrees O
C I-protein
in O
untreated O
normal O
subjects O
and O
in O
healthy O
subjects O
taking O
various O
glucocorticoid O
preparations O
. O
At O
24 O
degrees O
C I-protein
normal O
human I-cell_type
lymphocytes I-cell_type
had O
6000 O
binding O
sites/cell O
and O
a O
dissociation O
constant O
of O
4 O
x O
10 O
( O
-9 B-protein
) O
M O
. O
The O
administration O
of O
1 O
mg O
of O
dexamethasone O
, O
5 O
mg O
of O
prednisone O
, O
and O
37.5 B-protein
mg O
of O
cortisone O
acetate O
resulted O
in O
a O
30 O
% O
decrease O
in O
binding O
sites O
after O
1 O
week O
with O
no O
change O
in O
binding O
affinity O
. O
No O
changes O
in O
the O
number O
of O
binding O
sites O
was O
noted O
before O
1 O
week O
and O
the O
diminished O
number O
persisted O
for O
1 O
week O
after O
discontinuation O
of O
glucocorticoid O
treatment O
. O
Lymphocytes O
from O
hospitalized O
patients O
taking O
40-60 O
mg O
of O
dexamethasone O
daily O
demonstrated O
the O
same O
change O
in O
number O
of O
binding O
sites O
that O
was O
seen O
in O
normal O
subjects O
taking O
1 O
mg O
of O
dexamethasone O
. O
When O
binding O
assays O
were O
carried O
out O
at O
physiologic O
temperature O
there O
was O
the O
same O
decrease O
in O
number O
of O
binding O
sites O
after O
dexamethasone O
administration O
, O
and O
in O
addition O
, O
there O
was O
a O
two-fold B-DNA
increase O
in O
binding O
affinity O
. O
Glucocorticoid O
administration O
results O
in O
a O
time-dependent O
decrease O
in O
the O
number O
of O
lymphocyte I-cell_line
glucocorticoid O
binding O
sites O
that O
is O
independent O
of O
the O
type I-DNA
of O
glucocorticoid O
administered O
. O
This O
is O
the O
first O
in O
vivo O
demonstration O
that O
glucocorticoids O
modulate O
their O
own O
receptors O
in O
man O
. O
Immunoglobulin O
localization O
in O
benign O
and O
malignant O
lesions O
of O
the O
human B-DNA
mammary I-DNA
gland O
. O
Using O
direct O
imunofluorescence I-protein
, O
lesions O
from O
266 O
human B-DNA
breast I-cell_type
specimens O
were O
studied O
for O
the O
presence O
of O
IgA B-cell_type
, O
IgM O
, O
or O
IgG O
localization O
. O
The O
lesions O
included O
benign O
elements I-DNA
from O
66 O
subcutaneous O
mastectomy O
specimens O
in O
which O
the O
absence O
of O
simultaneous O
breast O
malignancy O
was O
documented O
, O
primary B-cell_line
breast I-cell_line
carcinomas O
from O
153 O
mastectomy O
specimens O
, O
and O
47 O
biopsies O
containing O
metastatic O
breast O
cancer O
. O
A O
statistically O
significant O
association O
of O
IgA O
and O
IgM O
with O
benign O
lesions O
was O
contrasted O
to O
the O
association O
of O
IgG B-cell_type
with O
malignant O
lesions O
. O
In O
both O
primary B-cell_line
and O
metastatic O
lesions O
, O
IgG O
localization O
was O
associated O
with O
estrogen-receptor-poor O
primary B-cell_line
cancers I-cell_line
as O
compared O
with O
estrogen-receptor-rich O
primary B-cell_line
cancers I-cell_line
. O
Among O
primary B-cell_line
breast I-cell_line
cancer O
patients O
, O
IgG O
localization O
in O
the O
tumor O
correlated O
with O
relative O
lymphopenia O
. O
A O
shorter O
disease-free B-DNA
interval O
was O
noted O
in O
association O
with O
IgG O
localization O
among O
the O
metastatic O
breast O
lesions O
. O
No O
statistically O
significant O
association O
between O
stage O
of O
disease O
and O
immunoglobulin O
presence O
was O
demonstrable O
. O
Moderate-to-severe O
intraductal O
epithelial O
hyperplasias O
were O
more O
often O
associated O
with O
immunoglobulin O
G O
localization O
that O
were O
other O
benign O
lesions O
Correlation O
of O
steroid O
receptors O
with O
histologic O
differentiation O
in O
mammary O
carcinoma O
. O
A O
Singapore O
experience O
. O
Cancer O
of O
the O
breast O
is O
the O
most O
common O
tumor O
in O
females O
in O
Singapore O
, O
with O
the O
rate O
of O
20.7 B-cell_type
per O
100 O
, O
000 O
per O
year O
( O
1977 I-DNA
estimate O
) O
, O
which O
is O
predicted O
to O
increase O
to O
29.8 B-protein
per O
100 O
, O
000 O
women O
per O
year O
by O
1995 O
. O
A O
detailed O
histopathologic O
review O
of O
50 O
primary B-cell_line
breast I-cell_line
cancer O
tumors O
analyzed O
for O
estrogen B-protein
receptor I-protein
( O
ER B-protein
) O
level O
was O
carried O
out O
and O
a O
variety O
of O
morphologic O
features O
correlated O
with O
ER B-protein
results O
to O
identify O
any O
factors I-protein
that O
will O
improve O
the O
management O
and O
prognosis O
for O
breast O
cancer O
. O
Cytosol O
was O
incubated O
with O
3H-estradiol B-protein
in O
the O
presence O
and O
absence O
of O
cold O
diethylstilbestrol I-protein
, O
and O
bound O
and O
free O
hormone O
were O
separated O
by O
Dextran-coated O
charcoal O
method O
. O
Tumors O
binding O
more O
than O
5 O
fmol/mg O
cytosol O
protein O
were O
classified O
as O
ER B-protein
-positive O
. O
Progesterone I-DNA
receptor I-protein
( O
PR I-DNA
) O
level O
was O
analyzed O
in O
some O
specimens O
with O
the O
use O
of O
a O
similar O
method O
. O
Most O
of O
the O
patients O
were O
Chinese O
( O
90 O
% O
) O
. O
Three O
patients O
were O
Malays O
, O
one O
was O
Indian O
, O
and O
one O
was O
European O
in O
this O
series O
. O
Results O
indicated O
that O
there O
was O
strong O
correlation O
between O
ER B-protein
level O
, O
age O
, O
and O
histologic O
grade O
of O
the O
tumors O
. O
No O
correlation O
existed O
between O
absence O
or O
presence O
of O
lymph O
node O
metastases O
and O
ER B-protein
. O
Although O
there O
was O
a O
trend O
for O
ER B-protein
-positive O
tumors O
to O
have O
a O
low-grade B-DNA
lymphocytic O
infiltration O
, O
the O
difference O
was O
not O
statistically O
significant O
. O
Mononuclear B-cell_type
cells I-cell_type
infiltrating O
human B-DNA
mammary I-DNA
carcinomas O
: O
immunohistochemical O
analysis O
with O
monoclonal B-protein
antibodies I-protein
. O
Breast O
carcinomas O
were O
examined O
by O
the O
immunoperoxidase O
technique O
using O
antisera O
specific O
for O
lymphocyte I-cell_line
subsets O
, O
monocytes B-cell_type
, O
NK B-cell_type
cells I-cell_type
and O
major O
histocompatibility I-protein
antigens O
( O
HLA-A I-DNA
, O
-B O
, O
-C O
; O
Ia-like B-protein
) O
. O
Sixty-four O
per O
cent O
of O
the O
patients O
had O
a O
moderate O
or O
strong O
mononuclear O
cell O
infiltration O
, O
77 O
% O
of O
the O
patients O
without O
mononuclear O
cell O
infiltration O
had O
receptors O
for O
estrogens O
as O
compared O
to O
51 O
% O
of O
the O
patients O
with O
infiltration O
. O
The O
majority O
of O
the O
infiltrating O
mononuclear B-cell_type
cells I-cell_type
were O
T B-cell_type
cells I-cell_type
; O
generally O
the O
OKT8 B-protein
cells I-cell_type
were O
predominant O
. O
The O
Leu O
3A/OKT8 O
cell O
ratio O
was O
not O
related O
to O
histological I-DNA
type I-DNA
, O
tumor O
size O
, O
age O
of O
the O
patient O
or O
presence O
of O
metastases O
. O
Some O
of O
the O
T B-cell_type
cells I-cell_type
had O
the O
Ia O
antigen I-protein
and O
were O
thus O
probably O
activated O
. O
The O
B I-DNA
cells I-cell_type
were O
either O
absent O
or O
less O
numerous O
than O
the O
T B-cell_type
cells I-cell_type
. O
There O
was O
no O
relation O
between O
their O
distribution O
and O
the O
various O
parameters O
studied O
. O
A O
few O
monocytes B-cell_type
were O
heterogeneous O
according O
to O
their O
markers O
( O
OKM B-protein
I I-protein
and O
acid O
phosphatase O
) O
. O
In O
6 O
cases O
only O
there O
was O
a O
strong O
infiltration O
of O
mononuclear B-cell_type
cells I-cell_type
positive O
for O
acid O
phosphatase O
. O
The O
number O
of O
the O
natural O
killer B-cell_type
cells I-cell_type
was O
also O
low O
. O
Only O
a O
few O
mononuclear O
infiltrating B-cell_type
cells I-cell_type
had O
receptors O
for O
transferrin O
. O
There O
was O
a O
positive O
correlation O
between O
the O
inflammatory O
infiltration O
and O
the O
presence O
of O
HLA B-cell_type
class-I O
antigens O
on O
tumor O
cell O
s O
. O
Some O
of O
the O
antisera O
specific O
for O
lymphocyte I-cell_line
subsets O
also O
stained O
the O
breast O
carcinoma B-cell_type
cells I-cell_type
. O
The O
great O
variations O
in O
the O
subsets O
of O
mononuclear B-cell_type
cells I-cell_type
in O
breast O
carcinomas O
may O
correspond O
to O
various O
systems O
of O
defense O
against O
neoplasm O
. O
A O
case O
of O
male O
pseudohermaphroditism O
with O
normal O
androgen I-DNA
receptor I-protein
binding O
and O
47 I-DNA
, O
XYY O
karyotype O
. O
A O
case O
of O
male O
pseudohermaphroditism O
with O
47 I-cell_line
, O
XYY O
karyotype O
in O
blood I-cell_type
and I-cell_type
cutaneous O
fibroblasts O
is O
described O
. O
The O
plasma O
testosterone O
response O
to O
HCG O
stimulation O
was O
slightly O
below O
the O
normal O
range O
on O
two O
occasions O
suggesting O
a O
deficit O
of O
gonadal O
function O
. O
A O
study O
of O
the O
receptors O
for O
dihydrotestosterone O
in O
fibroblasts O
of O
genital O
and O
nongenital O
skin O
showed O
a O
normal O
concentration O
of O
receptors O
in O
genital O
skin O
; O
5-alpha-reductase B-DNA
activity O
in O
fibroblasts O
of O
the O
genital O
skin O
was O
low O
, O
but O
the O
plasma O
relationship O
testosterone/dihydrotestosterone B-DNA
under O
HCG O
stimulation O
was O
normal O
. O
The O
diagnostic O
possibility O
of O
a O
complete O
testicular O
feminization O
syndrome O
with O
normal O
receptors O
for O
dihydrotestosterone O
is O
commented O
on O
. O
1 O
, O
25-Dihydroxyvitamin B-protein
D3 B-protein
inhibits O
antigen-induced O
T O
cell O
activation O
. O
The O
proliferative O
response O
of O
murine I-cell_line
spleen O
and O
thymus B-cell_type
cells O
to O
antigen I-protein
but O
not O
to O
lectin O
was O
inhibited O
by O
the O
active O
metabolite O
of O
vitamin O
D3 I-protein
, O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
. O
To O
directly O
examine O
the O
effect O
of O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
on O
T O
cell O
activation O
in O
the O
absence O
of O
other O
complicating O
interactions O
, O
we O
utilized O
a O
panel O
of O
cloned O
Ia-restricted B-cell_type
T O
cell O
hybridomas O
that O
secrete O
IL B-protein
2 O
on O
activation O
by O
cloned O
Ia-bearing O
stimulator B-cell_type
cells I-cell_line
( O
TA3 B-protein
) O
or O
when O
stimulated O
by O
mitogen O
. O
Physiologic O
concentrations O
of O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
( O
0.01 B-protein
to O
0.1 B-protein
nm O
) O
inhibited O
the O
antigen-induced O
secretion O
of O
IL B-cell_type
2 O
by O
several O
of O
these O
T O
cell O
hybridomas O
. O
This O
inhibition O
was O
dependent O
on O
the O
concentration O
of O
the O
free O
hormone O
and O
could O
be O
overcome O
by O
increasing O
the O
number O
of O
Ia-bearing O
stimulator B-cell_type
cells I-cell_type
used O
. O
Pretreatment O
of O
the O
T I-cell_line
hybridoma O
but O
not O
the O
TA3 B-protein
stimulator O
cell O
with O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
resulted O
in O
inhibition O
of O
activation O
. O
These O
results O
are O
consistent O
with O
the O
finding O
that O
specific O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
receptors O
are O
present O
on O
the O
T O
cell O
hybridomas O
but O
are O
lacking O
in O
TA3 B-protein
cells I-cell_type
. O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
failed I-protein
, O
however O
, O
to O
inhibit O
the O
activation O
of O
the O
T O
cell O
hybridomas O
by O
lectin O
or O
by O
an O
anti-Thy-1 B-protein
antibody O
. O
These O
findings O
suggest O
that O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
may O
be O
interfering O
with O
early O
events O
of O
antigen-induced B-cell_type
T O
cell O
activation O
, O
perhaps O
by O
hindering B-cell_type
T O
cell O
recognition O
of O
the O
relevant O
antigen I-protein
on O
stimulator O
cell O
surfaces O
. O
This O
system O
should O
prove O
useful O
in O
studying O
the O
molecular O
mechanisms O
by O
which O
1 O
, O
25- O
( O
OH I-DNA
) O
2D3 O
acts O
to O
inhibit O
T O
cell O
activation O
and O
subsequent O
IL B-protein
2 O
production O
. O
Glucocorticoid O
receptors O
and O
steroid O
sensitivity O
in O
normal O
and O
neoplastic O
human B-DNA
lymphoid I-DNA
tissues O
: O
a O
review O
. O
The O
determination O
of O
estrogen O
and O
progesterone O
receptors O
in O
breast O
cancer O
has O
been O
shown O
to O
be O
useful O
in O
predicting O
the O
response O
to O
endocrine O
therapy O
. O
Given O
their O
well-known B-DNA
inhibitory O
effects O
on O
lymphoid O
tissue I-protein
, O
glucocorticoids O
have O
been O
used O
widely O
in O
the O
treatment O
of O
leukemia O
. O
Given O
these O
facts O
, O
over O
the O
last O
10 O
years O
, O
several O
investigators O
have O
measured O
the O
number O
of O
glucocorticoid O
receptors O
in O
normal O
and O
neoplastic O
lymphoid O
tissue O
to O
see O
whether O
their O
number O
correlated O
with O
glucocorticoid O
responsiveness O
in O
vitro O
or O
in O
vivo O
. O
No O
clear O
correlation O
could O
be O
established O
between O
the O
level O
of O
glucocorticoid I-DNA
receptor I-protein
and O
the O
in O
vitro O
action O
of O
steroids O
in O
normal O
and O
neoplastic O
lymphoid O
tissue O
. O
In O
contrast O
, O
attempts O
to O
correlate O
glucocorticoid I-DNA
receptor I-protein
levels O
in O
acute O
lymphocytic O
leukemia O
to O
in O
vivo O
steroid O
responsiveness O
and O
immunological I-DNA
type O
using O
the O
whole-cell-binding O
assay O
for I-DNA
receptor I-protein
determination O
and O
selecting O
the O
patients O
according O
to O
age O
and O
immunological O
criteria O
have O
been O
more O
successful O
. O
[ O
Glucocorticoid O
receptors O
in O
normal O
human I-cell_type
lymphocytes I-cell_type
] O
Glucocorticoid O
( O
GC I-DNA
) O
receptors O
were O
studied O
in O
intact I-cell_type
lymphocytes I-cell_type
from O
11 O
donors O
. O
GC O
binding O
parameters O
were O
found O
to O
be O
highly O
reproducible O
in O
repeated O
experiments O
with I-cell_type
lymphocytes I-cell_type
. O
It O
was O
shown O
that O
GC B-protein
receptors O
in O
donors O
' O
lymphocytes I-cell_type
could O
be O
distributed O
into O
two O
different O
classes O
similarly O
to O
the O
pattern O
seen O
in O
skin O
fibroblasts O
. O
Human I-cell_type
lymphocytes I-cell_type
are O
an O
adequate O
object O
for O
studying O
genetically O
determined O
variability O
of O
GC B-cell_type
receptors O
and O
its O
clinical O
importance O
. O
Specific O
estrogen O
binding O
sites O
in O
human B-DNA
lymphoid I-cell_type
cells I-cell_type
and O
thymic B-cell_line
cells I-cell_type
. O
The O
binding O
of O
estrogen O
in O
preparations O
of O
human B-cell_type
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_line
, O
as O
well O
as O
by O
splenic O
and O
thymic B-cell_line
cells I-cell_type
is O
demonstrated O
by O
three O
different O
approaches O
( O
Dextran-coated O
charcoal O
method I-protein
, O
whole O
cell O
assay O
, O
and O
gel O
filtration O
on O
a O
sepharose O
4B B-protein
column O
) O
. O
Scatchard O
's O
analysis O
of O
[ O
3H B-protein
] O
-moxestrol O
( O
R2858 B-protein
) O
and O
[ O
3H B-protein
] O
-estradiol O
binding O
proves O
the O
existence O
of O
a O
single O
class O
of B-DNA
receptor I-DNA
sites I-DNA
having O
a O
dissociation O
constant O
of O
0.18-2.4 B-protein
X O
10 O
( O
-9 B-protein
) O
M O
. O
Physicochemical O
properties O
of O
the O
binder I-protein
, O
including O
binding O
capacity O
and O
steroid O
specificity O
, O
are O
quite O
similar O
to O
those O
reported O
for O
the O
thymus O
of O
small O
mammalian O
species O
or O
human B-DNA
thymoma I-DNA
. O
Administration O
of O
fibroblast O
interferon O
to O
patients O
with O
advanced O
breast O
cancer O
: O
possible O
effects O
on O
skin O
metastasis O
and O
on O
hormone O
receptors O
. O
Eleven O
patients O
with O
metastasized O
breast O
cancer O
received O
8 O
intramuscular O
injections O
of O
6 O
x O
10 O
( O
6 O
) O
units O
of O
human B-cell_type
fibroblast I-cell_type
interferon O
over O
a O
period O
of O
40 O
days O
. O
The O
injections O
did O
not O
cause O
local O
irritation O
or O
inflammation O
. O
Fever O
occurred O
in O
only O
1 O
of O
the O
11 O
patients O
. O
Although O
several O
types I-cell_type
of O
metastases O
were O
monitored O
, O
only O
skin O
nodules O
consistently O
( O
10 O
out O
of O
11 O
patients O
) O
exhibited O
changes O
that O
were O
suggestive O
of O
a O
therapeutic O
effect O
of O
the O
treatment O
regimen O
: O
either O
a O
simple O
decrease O
in O
size O
of O
some O
nodules O
or O
central O
necrosis O
accompanied O
by O
an O
inflammatory O
reaction O
. O
NK-activity O
of O
peripheral B-cell_type
blood I-cell_type
leukocytes I-cell_type
was O
significantly O
increased O
after O
administration O
of O
the O
first O
dose O
; O
the O
effect O
of O
subsequent O
injections O
was O
less O
clear O
. O
Receptors O
for O
estrogens O
and O
progestogens O
were O
increased O
in O
the O
tumor O
biopsies O
of O
2 O
out O
of O
2 O
and I-DNA
5 O
out O
of O
6 O
patients O
tested O
respectively O
. O
Decreased O
glucocorticoid I-DNA
receptor I-protein
binding O
in O
adrenal O
insufficiency O
. O
To O
examine O
the O
effect O
of O
glucocorticoid O
deficiency O
on O
the O
glucocorticoid I-DNA
receptor I-protein
, O
we O
examine O
the O
binding O
of O
[ O
3H B-protein
] O
dexamethasone O
to I-cell_type
lymphocytes I-cell_type
in O
normal O
subjects O
and O
patients O
with O
adrenal O
insufficiency O
before O
and O
after O
glucocorticoid O
replacement O
therapy O
. O
Using O
a O
whole O
cell O
competitive O
binding O
assay O
, O
normal O
human I-cell_type
lymphocytes I-cell_type
had O
5977 O
+/- O
1487 O
( O
mean O
+/- O
SD B-protein
) O
binding O
sites/cell O
and O
a O
dissociation O
constant O
of O
10 O
+/- O
2 O
nM I-RNA
. O
Lymphocytes O
from O
patients O
with O
untreated O
adrenal O
insufficiency O
had O
fewer O
binding O
sites O
( O
3364 I-DNA
+/-322 B-protein
) O
and O
a O
2-fold B-protein
increase O
in O
binding O
affinity O
( O
5.4 B-protein
+/- O
0.9 B-protein
mM O
) O
. O
The O
administration O
of O
conventional O
replacement O
doses O
of O
cortisone O
acetate O
for O
6 O
months O
caused O
no O
change O
in B-DNA
receptor I-protein
number O
, O
but O
was O
associated O
with O
a O
decrease O
in O
binding O
affinity O
toward O
normal O
. O
After B-DNA
long I-DNA
term O
glucocorticoid O
replacement O
therapy O
, O
binding O
parameters O
were O
similar O
to O
those O
in O
patients O
before O
treatment O
. O
The O
physiological O
implications O
of O
the O
decreased I-DNA
receptor I-protein
number O
and O
increased O
binding O
affinity O
in O
adrenal O
insufficiency O
remain O
to O
be O
elucidated O
. O
Glucocorticoid I-DNA
receptor I-protein
concentrations O
and I-DNA
terminal I-DNA
transferase O
activity O
as O
indicators O
of O
prognosis O
in O
acute O
non-lymphocytic B-protein
leukaemia O
. O
Activity O
of O
terminal O
deoxynucleotidyl O
transferase O
( O
TdT I-DNA
) O
, O
adenosine O
deaminase O
, O
and O
5'nucleotidase B-protein
and O
the O
cellular O
concentration O
of O
glucocorticoid O
( O
dexamethasone I-DNA
) O
receptor I-protein
were O
determined O
in O
25 O
patients O
with O
acute O
non-lymphocytic B-protein
leukaemia O
. O
All O
patients O
were O
treated O
according O
to O
a O
common O
protocol O
. O
Increased O
activity O
of O
TdT B-cell_type
( O
greater O
than O
0.1 B-protein
unit/microgram O
DNA O
) O
was O
found O
in O
11 O
patients O
. O
This O
group O
of O
patients O
was O
shown O
to O
have O
higher O
remission O
and O
survival O
rates O
( O
p O
= O
0.06 B-protein
) O
compared O
with O
patients O
with O
low O
activity O
of O
TdT B-cell_type
. O
The O
glucocorticoid I-DNA
receptor I-protein
concentration I-DNA
of O
the O
leukaemic O
blast I-cell_type
cells I-cell_type
ranged O
from O
0 O
to O
0.94 B-protein
fmol/microgram O
DNA O
. O
Thirteen O
patients O
had O
blast I-cell_type
cells I-cell_type
with O
a O
glucocorticoid I-DNA
receptor I-protein
concentration O
over O
0.22 B-protein
fmol/microgram O
DNA O
. O
These O
patients O
had O
significantly O
increased O
remission O
and O
survival O
rates O
( O
p O
= O
0.006 B-protein
) O
compared O
with O
those O
with O
a O
low I-DNA
receptor I-protein
concentration O
. O
This O
finding O
can O
not O
be O
explained O
by O
a O
difference O
in O
sensitivity O
to O
glucocorticoids O
since O
these O
were O
not O
used O
as O
therapeutic O
agents O
. O
Adenosine O
deaminase O
and O
5'nucleotidase B-protein
activities O
both O
varied O
within O
two O
orders O
of O
magnitude O
. O
No O
correlation O
could O
be O
found O
between O
activities O
of O
these O
enzymes O
and O
remission O
or O
survival O
rate O
. O
These O
results O
show O
that O
measurements O
of O
TdT B-cell_type
activity O
and O
the O
glucocorticoid I-DNA
receptor I-protein
concentration O
yield O
valuable O
prognostic O
information O
in O
acute O
non-lymphocytic B-protein
leukaemia O
[ O
3H B-protein
] O
cortivazol O
: O
a O
unique O
high O
affinity O
ligand O
for O
the O
glucocorticoid I-DNA
receptor I-protein
. O
Cortivazol O
( O
CVZ I-DNA
) O
and O
deacylcortivazol O
( O
DAC I-DNA
) O
are O
pyrazolosteroids O
with O
potent O
glucocorticoid O
activity O
. O
In O
previous O
work O
we O
showed O
that O
DAC O
is O
40-fold O
more O
potent O
than O
dexamethasone O
( O
DEX I-DNA
) O
in O
lysing O
leukemic O
lymphoblasts O
. O
To O
assess O
the O
interaction O
between O
these O
atypical O
steroids O
and O
the O
glucocorticoid I-DNA
receptor I-protein
, O
we O
examined O
the O
binding O
of O
[ O
3H B-protein
] O
CVZ O
to O
cytosol O
from O
glucocorticoid-sensitive B-DNA
and O
-resistant O
variants O
of O
the O
human B-DNA
leukemic O
cell O
line O
CEM O
C7 B-protein
. O
In O
glucocorticoid-sensitive B-cell_type
cells I-cell_type
[ O
3H B-protein
] O
CVZ O
causes O
a O
2-fold B-protein
induction O
of O
glutamine O
synthetase O
and O
binds O
to O
a O
protein O
in O
the O
4.6 B-protein
S O
region I-DNA
of O
high O
salt O
sucrose O
gradients O
. O
On O
DEAE-cellulose B-protein
chromatography O
, O
[ O
3H B-protein
] O
CVZ-receptor B-protein
complexes O
show O
a O
shift O
from O
high O
( O
0.25 I-DNA
M O
KP B-protein
) O
to O
low O
salt O
( O
0.09 I-DNA
M O
KP B-protein
) O
eluting O
forms O
upon O
activation O
. O
CVZ O
competes O
for O
a O
97 I-cell_line
, O
000-dalton O
protein O
labeled O
by O
[ O
3H B-protein
] O
dexamethasone O
mesylate O
. O
Scatchard O
analysis O
of O
the O
binding O
of O
[ O
3H B-protein
] O
CVZ O
in O
glucocorticoid-sensitive B-cell_type
cells I-cell_type
revealed O
a O
curvilinear O
plot O
which O
resolved O
into O
high O
( O
0.4 B-protein
nM O
) O
and O
low O
( O
11 O
nM O
) O
affinity O
components O
. O
The I-DNA
receptor I-protein
concentration I-DNA
of O
the O
low O
affinity I-DNA
site I-DNA
( O
0.30 I-DNA
pmol/mg I-protein
protein O
) O
was O
approximately O
twice O
that O
of O
the O
high O
affinity I-DNA
site I-DNA
( O
0.14 I-DNA
pmol/mg I-protein
protein O
) O
. O
Dissociation O
experiments O
with O
dilution O
and/or I-cell_line
excess O
unlabeled O
CVZ O
supported O
the O
presence O
of O
independent B-RNA
sites I-DNA
. O
In O
contrast O
, O
the O
binding O
of O
[ O
3H B-protein
] O
DEX O
to O
C7 B-protein
cytosol O
revealed O
a O
single O
class O
of O
binding O
sites O
( O
Kd O
= O
1.9 B-protein
nM I-RNA
; O
receptor I-protein
concentration I-DNA
, O
0.46 B-protein
pmol/mg I-protein
protein O
) O
. O
Examination O
of O
the O
binding O
of O
[ O
3H B-protein
] O
CVZ O
using O
10 O
( O
-5 B-protein
) O
M O
DEX O
as O
the O
competing O
ligand O
showed O
that O
DEX O
binds O
only O
to O
the O
low O
affinity I-DNA
site I-DNA
detected O
by O
[ O
3H B-protein
] O
CVZ O
. O
In O
cytosol O
from O
a O
glucocorticoid-resistant O
cell O
line O
with O
virtually O
no O
[ O
3H B-protein
] O
DEX O
binding O
, O
[ O
3H B-protein
] O
CVZ O
detected O
a O
single O
high O
affinity O
binding O
site O
that O
was O
similar O
in O
dissociation O
constant O
( O
0.8 B-protein
nM O
) O
and I-DNA
receptor I-protein
concentration O
( O
0.13 I-DNA
pmol/mg I-protein
protein O
) O
to O
the O
high O
affinity I-DNA
site I-DNA
detected O
in O
the O
glucocorticoid-sensitive O
cell O
line O
C7 B-protein
. O
A O
controlled O
pore O
glass O
bead O
assay O
for O
the O
measurement O
of O
cytoplasmic O
and O
nuclear B-protein
glucocorticoid O
receptors O
. O
An O
assay O
for O
the O
quantitation O
of O
cytoplasmic O
and O
nuclear B-protein
glucocorticoid O
receptors O
in O
lymphoid O
tissue O
has O
been O
developed O
using O
controlled O
pore O
glass O
( O
CPG I-DNA
) O
beads O
. O
Soluble I-DNA
receptor I-protein
-- O
3H-steroid B-protein
complex I-protein
( O
cytosol O
or O
nuclear B-protein
extract O
) O
is O
adsorbed O
quantitatively O
within O
the O
crevasses O
of O
porous O
glass O
beads O
. O
Excess O
labeled O
steroid O
as O
well O
as O
most O
non-specifically O
bound O
steroid O
is O
easily O
washed O
away O
, O
leaving O
the O
hormone-receptor O
complex I-protein
retained O
by O
the O
beads O
. O
Bound O
3H-steroid B-protein
is O
eluted O
with O
ethanol O
and O
measured O
for O
radioactivity O
. O
This O
procedure O
which O
is O
simple I-protein
, O
rapid O
, O
and O
highly O
reproducible O
is O
carried O
out O
using O
frozen O
samples O
( O
stable O
for O
many O
months O
) O
containing O
as O
few O
as O
1 O
X O
10 O
( O
7 O
) O
cells I-cell_type
. O
A O
comparison O
of O
the O
CPG O
assay O
to O
dextran O
coated O
charcoal O
and O
a O
whole O
cell O
assay O
demonstrates O
that O
CPG O
and O
dextran O
coated O
charcoal O
give O
equivalent O
measurements O
of O
cytosolic I-DNA
receptor I-protein
concentration I-DNA
, O
while O
the O
CPG O
and O
whole O
cell O
assays O
provide O
equivalent O
values O
for O
total I-DNA
receptor I-protein
content O
. O
Plasmacytoid O
blast O
crisis O
in O
B-cell O
chronic O
lymphocytic O
leukemia O
: O
effect O
of O
estradiol O
on O
growth O
and O
differentiation O
in O
vitro O
. O
Evolution O
of O
a O
case O
of O
chronic O
lymphocytic O
leukemia O
( O
CLL I-DNA
) O
into O
blast O
crisis O
was O
found O
to O
be O
characterized O
by O
three O
unusual O
features O
( O
1 O
) O
the O
phenotype O
of O
the O
emerging O
blast I-cell_type
cells I-cell_type
was O
that O
of O
pre-plasmacytoid B-cell_type
cells I-cell_type
as O
shown O
by O
plasma O
cell O
morphology O
and O
an O
immunological O
phenotype O
corresponding O
partially O
with O
CLL- B-protein
or O
intermediate O
B-cells I-protein
, O
partially O
with O
plasma B-cell_type
cells I-cell_line
( O
terminal I-DNA
transferase O
- O
, O
common O
acute O
lymphocytic O
leukemia O
antigen I-protein
- O
, O
Ia+ O
, O
surface I-protein
immunoglobulin O
heavy O
chains O
- O
, O
surface I-protein
kappa B-DNA
light O
chains O
+ O
, O
intracytoplasmic O
immunoglobulin O
A+ O
and O
G+ I-protein
, O
BA-1+ O
, O
polyclonal O
gammaglobulin O
production O
) O
; O
( O
2 O
) O
cytogenetic O
analysis O
of O
spontaneous O
metaphases O
revealed O
that O
in O
addition O
to O
the O
typical O
CLL O
abnormality O
, O
trisomy O
12 O
, O
in O
all O
of O
the B-cell_type
cells I-cell_line
, O
an O
additional O
translocation O
between O
chromosomes O
14 O
and O
17 O
was O
present O
in O
40 O
% O
with O
a O
presumptive O
breakpoint O
on O
chromosome O
14 O
( O
q12-3 B-protein
) O
never O
described O
before O
( O
commonly O
q32 B-protein
) O
and O
( O
3 O
) O
the O
progression O
of O
the O
disease O
was O
associated O
with O
a O
striking O
increase O
in O
the O
expression O
by O
the O
transformed B-cell_type
cells I-cell_type
of O
specific O
binding O
sites O
for O
estradiol O
( O
E2 B-protein
) O
due O
to O
an O
actual O
increase O
in O
total O
cellular I-DNA
receptor I-protein
proteins I-protein
and O
not O
to O
a O
change O
in B-DNA
receptor I-protein
affinity O
for O
E2 B-protein
. O
The O
functional O
status O
of O
the O
steroid O
receptors O
was O
confirmed O
by O
nuclear B-protein
transfer O
of O
the O
cytoplasmic O
hormone-receptor O
complex I-protein
upon O
temperature O
activation O
. O
Since O
the O
rise O
in O
E2-receptor B-protein
display O
paralleled O
a O
large O
increase O
in O
the O
proliferative O
activity O
of O
the B-cell_type
cells I-cell_type
as O
well O
as O
a O
change O
in O
their O
maturation O
status O
the O
question O
was O
raised O
as O
to O
whether O
the O
E2-receptor B-protein
should O
be O
considered O
as O
a O
physiological O
marker O
of O
growth O
rate O
or O
of O
cellular O
differentiation O
. O
Exposure O
of O
the O
patient O
's O
blast I-cell_type
cells O
to O
E2 B-protein
in O
vitro O
resulted O
in O
cessation O
of O
cell O
growth O
following O
at O
least O
one O
mitosis O
after O
addition O
of O
the O
inducer O
as O
seen O
from O
the O
replacement O
of O
the O
large O
blasts O
by O
small O
CLL-like B-protein
cells I-cell_type
without O
definite O
signs O
of O
alteration O
of O
the O
differentiation O
status O
. O
This O
suggests O
the O
association O
of O
E2-receptor B-protein
expression O
with O
control O
of O
growth O
rather O
than O
cell O
maturation O
. O
Multiple O
forms O
and O
fragments O
of O
cytosolic O
glucocorticoid O
receptors O
from O
human B-DNA
leukemic I-cell_type
cells I-cell_type
and O
normal I-cell_type
lymphocytes I-cell_type
. O
Therapy O
with O
glucocorticoids O
is O
generally O
more O
effective O
in O
acute O
lymphoblastic O
leukemia O
than O
in O
other O
types I-cell_type
of O
human B-cell_type
leukemia I-DNA
. O
Previous O
studies O
, O
however O
, O
have O
not O
revealed O
any O
consistent O
relationship O
between O
clinical O
responsiveness O
and O
the O
cellular O
or O
cytosolic O
concentration O
of O
glucocorticoid-binding I-DNA
sites I-DNA
. O
The O
objectives O
of O
this O
study O
were O
to O
determine O
whether O
there O
are O
intrinsic O
structural O
differences O
among O
the O
glucocorticoid O
receptors O
in O
various O
types I-cell_type
of O
leukemic B-cell_type
cells I-cell_type
and O
normal I-cell_type
lymphocytes I-cell_type
and O
to O
investigate O
the O
role O
of O
endogenous O
peptidases O
in B-DNA
receptor I-protein
degradation O
. O
Cytosols O
were O
prepared O
from O
fresh O
or O
rapidly O
frozen O
leukocytes O
from O
6 O
healthy O
adults O
and O
35 O
high-risk B-DNA
leukemia O
patients O
( O
median O
white O
blood O
cell I-cell_type
count O
, O
150 O
, O
000 O
cells/microliter I-cell_line
; O
median O
age O
, O
13 O
years O
) O
. O
Receptors O
were O
labeled O
with O
[ O
3H B-protein
] O
triamcinolone O
acetonide O
and O
quantitated O
by O
charcoal-dextran I-cell_line
treatment O
or O
Sephadex O
LH-20 B-protein
chromatography O
. O
Mean O
and O
median O
cytosolic I-DNA
receptor I-protein
concentrations O
in O
12 O
acute O
lymphoblastic O
leukemia O
specimens O
lacking O
the O
standard O
B-cell O
or O
T-cell O
markers O
( O
`` O
null B-cell_type
cells I-cell_type
'' O
) O
were O
approximately O
4-fold B-protein
higher O
than O
in O
23 O
other O
leukemic O
cell O
specimens O
. O
No O
other O
consistent O
differences O
in B-DNA
receptor I-protein
content O
were O
observed O
. O
Agarose O
filtration O
and O
ultracentrifugation O
in O
hypotonic O
buffers O
containing O
20 O
mM I-RNA
Na2MoO4 O
revealed O
complexes O
of O
similar O
size O
and O
shape O
in O
all O
clinical O
specimens O
tested O
and O
two O
established O
leukemic O
cell O
lines I-cell_line
. O
They O
had O
Stokes O
radii O
( O
Rs O
) O
of O
8.1 B-cell_type
+/- O
0.5 I-cell_line
( O
S.D. I-DNA
) O
nm O
( O
n O
= O
50 O
) O
, O
sedimentation O
coefficients O
of O
9.5 B-cell_type
+/- O
0.3S B-protein
( O
n O
= O
40 O
) O
, O
molecular O
weights O
of O
approximately O
330 O
, O
000 O
, O
and O
axial O
ratios O
( O
a/b I-DNA
) O
of O
approximately O
12 O
. O
In O
hypertonic O
, O
molybdate-free O
buffer I-protein
, O
these O
oligomeric O
complexes O
were O
dissociated O
into O
subunits O
with O
Rs O
of O
5.9 B-cell_type
+/- O
0.3 B-protein
nm O
( O
n O
= O
12 O
) O
and O
a/b I-DNA
of O
11 O
to O
12 O
, O
as O
observed O
previously O
for O
other O
receptors O
. O
Fragmentation I-DNA
of O
the O
oligomer O
and O
the O
subunit O
was O
evident O
in O
some O
cytosols O
. O
High O
activities O
of O
peptidases O
of O
various O
specificities O
were O
detected O
in O
leukemic O
cell O
cytosols O
, O
as O
in O
other O
cytosols O
, O
by O
fluorometric O
assays O
with O
derivatives O
of O
7-amino-4-methylcoumarin B-protein
. O
Receptor O
cleavage O
by O
these O
and O
other O
endogenous O
enzymes O
may O
account O
for O
previous O
observations O
of O
`` O
abnormal O
'' O
receptors O
in O
cytosols O
from O
some O
leukemic O
specimens O
. O
We O
conclude O
that O
intrinsic O
structural O
defects O
in O
the O
receptors O
are O
unlikely O
explanations O
for O
the O
unresponsiveness O
of O
some O
types I-cell_type
of O
leukemia O
to O
steroid O
therapy O
. O
Glucocorticoid I-DNA
receptor I-protein
number O
and O
intracellular O
water O
space O
. O
In O
order O
to O
elucidate O
the O
relationship O
between O
cell O
water O
content O
and O
number O
of O
glucocorticoid O
receptors O
, O
eleven O
normal O
and O
malignant O
lymphoid O
or O
myelomonocytic O
cell O
types I-cell_type
originating O
from O
mouse I-DNA
, O
rat O
and O
man O
were O
investigated O
. O
The O
cellular O
water O
space O
was O
measured O
with O
3H2O I-protein
, O
and O
glucocorticoid I-DNA
receptor I-protein
number O
was O
measured O
in O
a O
whole-cell B-DNA
binding O
assay O
with O
[ O
3H B-protein
] O
dexamethasone O
at O
30 O
and O
37 O
degrees O
C I-protein
. O
The O
intracellular O
water O
phase O
concentration O
of O
glucocorticoid O
receptors O
( O
around O
40 O
nmol/l O
cell O
water O
) O
, O
and O
the O
dependence O
of B-DNA
receptor I-protein
affinity O
on O
temperature O
were O
similar O
in O
normal O
and O
malignant O
rodent O
and O
human B-cell_type
cells I-cell_type
. O
It O
is O
concluded O
that O
comparisons O
of O
glucocorticoid I-DNA
receptor I-protein
levels O
are O
best O
made O
on O
the O
basis O
of O
intracellular I-DNA
receptor I-protein
concentrations O
. O
Covalent O
labeling O
of O
rat O
thymocyte O
and O
human B-cell_type
lymphoid I-DNA
glucocorticoid I-DNA
receptor I-protein
. O
Lymphoid B-cell_type
cells I-cell_type
contain O
specific O
receptors O
for O
glucocorticoids O
. O
We O
have O
used O
[ O
3H B-protein
] O
dexamethasone-21-mesylate O
to O
label O
covalently O
glucocorticoid O
receptors O
in O
rat O
thymic I-cell_type
lymphocytes I-cell_type
and O
in O
neoplastic O
cells I-cell_type
obtained O
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
and O
malignant O
lymphoma O
. O
The O
covalently O
labeled O
glucocorticoid O
receptors O
were O
identified O
by O
polyacrylamide O
gel O
electrophoresis O
( O
in O
the O
presence O
of O
0.1 B-cell_type
% O
sodium O
dodecyl O
sulfate O
) O
. O
In O
cytosolic O
fractions O
prepared O
from O
rat O
thymic I-cell_type
lymphocytes I-cell_type
, O
[ O
3H B-protein
] O
-dexamethasone-21-mesylate B-protein
labels O
a O
protein I-protein
( O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
) O
which O
was O
identified O
as O
the O
glucocorticoid I-DNA
receptor I-protein
by O
the O
following O
criteria O
: O
( O
a O
) O
labeling O
of O
this O
moiety O
is O
inhibited O
by O
treatment O
with O
a O
100-fold O
molar O
excess O
of O
glucocorticoids O
, O
such O
as O
dexamethasone O
and O
triamcinolone O
acetonide O
; O
and O
( O
b O
) O
the O
covalently O
labeled O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
protein O
is O
activated O
( O
by O
heating O
at O
20 O
degrees O
for O
30 O
min O
) O
to O
a O
form O
that O
binds O
to O
DNA-cellulose B-protein
. O
When O
intact O
thymocytes O
are O
treated O
with O
[ O
3H B-protein
] O
dexamethasone-21-mesylate I-cell_line
, O
an O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
moiety O
is O
also O
labeled O
covalently O
. O
Approximately B-cell_type
35 O
% O
of O
the O
glucocorticoid O
receptors O
can O
be O
labeled O
covalently O
when O
intact O
thymocytes O
are O
treated O
with O
100 O
nM I-RNA
[ O
3H B-protein
] O
dexamethasone-21-mesylate B-protein
for O
30 O
min O
at O
4 O
degrees O
. O
Neoplastic B-cell_type
cells I-cell_type
from O
acute O
lymphoblastic O
leukemia O
and O
malignant O
lymphoma O
were O
treated O
with O
[ O
3H B-protein
] O
dexamethasone-21-mesylate B-protein
. O
In O
all O
samples O
, O
an O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
moiety O
was O
labeled O
covalently O
; O
labeling O
was O
inhibited O
by O
excess O
glucocorticoid O
. O
Smaller O
moieties O
were O
also O
identified O
by O
competition O
experiments O
; O
these O
may O
represent O
proteolytic O
fragments O
of O
the O
Mr O
approximately O
equal O
to O
95 O
, O
000 I-DNA
receptor I-protein
. O
Thus O
, O
in O
rat O
and O
human B-cell_type
lymphoid I-cell_type
cells I-cell_line
, O
[ O
3H B-protein
] O
dexamethasone-21-mesylate B-protein
can O
be O
used O
to O
label O
covalently O
the O
glucocorticoid I-DNA
receptor I-protein
. O
The O
association O
of O
cytosol O
oestrogen O
and O
progesterone O
receptors O
with O
histological O
features O
of O
breast O
cancer O
and O
early O
recurrence O
of O
disease O
. O
Two O
hundred O
and O
eighty-eight O
primary B-cell_line
breast I-cell_line
tumours O
were O
examined O
for O
the O
presence O
or O
absence O
of O
oestrogen O
( O
REc O
) O
and O
progesterone O
( O
RPc O
) O
receptors O
. O
Analysis O
has O
shown O
a O
relative O
interdependence O
between O
the O
steroid I-DNA
receptor I-protein
status O
of O
primary B-cell_line
breast I-cell_line
cancer O
and O
other O
prognostic O
variables O
such O
as O
histological O
grade O
, O
lymphocytic O
infiltration O
and O
tumour O
elastosis O
. O
There O
were O
significant O
associations O
between O
epithelial O
cellularity O
, O
stromal O
fibrosis O
and O
the O
value O
of O
REc O
in O
those O
tumours O
in O
which O
the I-DNA
receptor I-protein
was O
present O
. O
Cellularity O
and O
fibrosis O
were O
unrelated O
to O
the O
presence O
or O
absence O
of O
oestrogen I-DNA
receptor I-protein
. O
By O
contrast O
, O
neither O
the O
presence O
or O
absence O
nor O
the O
value O
of O
RPc O
could O
be O
related O
to O
cellularity O
or O
fibrosis O
. O
The O
value O
of O
REc O
and O
RPc O
analysis O
as O
an O
indicator O
of O
prognosis O
was O
examined O
in O
a O
sub-group I-DNA
of O
175 O
patients O
receiving O
no O
additional O
treatment O
following O
mastectomy O
. O
Overall O
relapse-free B-DNA
survival O
( O
RFS I-DNA
) O
was O
no O
different O
for O
those O
patients O
with O
receptors O
compared O
to O
those O
without O
them O
( O
REc O
P O
= O
0.11 I-protein
, O
RPc O
P O
= O
0.7 B-protein
) O
. O
There O
was O
no O
difference O
in O
RFS O
of B-DNA
receptor I-protein
positive O
and O
negative O
tumours O
when O
the O
axillary O
node O
status O
was O
taken O
into O
account O
. O
Clinical O
implications O
of O
glucocorticoid O
receptors O
in O
human B-DNA
leukemia I-DNA
. O
Normal O
lymphoid B-cell_type
cells I-cell_type
contain O
glucocorticoid I-DNA
receptor I-protein
. O
A O
variety O
of O
stimuli O
that O
activate O
these I-cell_type
cells I-cell_type
also O
induce O
increases O
in B-DNA
receptor I-protein
concentration O
. O
Similar O
glucocorticoid O
receptors O
can O
be O
detected O
in O
lymphoid B-cell_type
cells I-cell_type
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL I-DNA
) O
. O
Absence O
of O
the O
glucocorticoid I-DNA
receptor I-protein
( O
usually O
found O
in O
treated O
patients O
) O
predicts O
lack O
of O
glucocorticoid O
responsiveness O
. O
Furthermore O
, O
in O
our O
hands O
, O
glucocorticoid I-DNA
receptor I-protein
levels O
correlate O
with O
the O
duration O
of O
complete O
remission O
in O
ALL I-protein
( O
though O
not O
in O
other O
forms O
of O
leukemia O
) O
. O
This O
association O
is O
independent O
of O
cell O
type O
, O
age O
, O
sex O
, O
or O
initial O
leukocyte O
count O
. O
The O
level O
of B-DNA
receptor I-protein
shows O
a O
negative O
correlation O
with O
increasing O
aggressiveness O
of O
the O
tumor O
( O
null-cell I-DNA
leukemia O
greater O
than O
T-cell O
leukemia O
greater O
than O
Burkitt O
's O
lymphoma O
) O
. O
Corticosteroid-mediated B-protein
immunoregulation O
in O
man O
. O
Glucocorticoids O
have O
profound O
and O
complex I-protein
effects O
on O
the O
human B-DNA
immune I-cell_type
response O
. O
However O
, O
the O
precise O
mechanisms O
of O
the O
corticosteroid-induced B-DNA
immunoregulation O
in O
man O
have O
not O
been O
precisely O
defined O
. O
Intracytoplasmic O
corticosteroid-specific B-DNA
receptors O
appear O
to O
be O
an O
important O
common O
pathway O
for O
steroid-induced O
changes O
, O
but O
variations O
of B-DNA
receptor I-protein
parameters O
do O
not O
account O
for O
the O
multifaceted O
effects O
on O
the O
immune O
system O
. O
Human O
circulating O
mononuclear B-cell_type
cells I-cell_type
redistribute O
out O
of O
the O
intravascular O
compartment O
following O
treatment O
with O
corticosteroids O
. O
Although O
certain O
components O
at O
this O
redistribution O
phenomenon O
have O
been O
well-characterized I-protein
, O
the O
importance O
of O
this O
compartmental O
cellular O
shift O
with O
respect O
to O
the O
mechanisms O
of O
corticosteroid-induced B-DNA
immunoregulation O
are O
less O
well-defined B-DNA
. O
Recent O
observations O
that O
activated I-cell_type
lymphocytes I-cell_type
may O
be O
sensitive O
to O
the O
lytic O
effects O
of O
glucocorticoids O
suggest O
that O
under O
certain O
situations O
the O
elimination O
of O
selected O
subsets O
of O
cells I-cell_type
may O
be O
a O
relevant O
mechanism O
of O
corticosteroid-mediated B-DNA
immunoregulation O
in O
man O
. O
Corticosteroid-mediated B-protein
effects O
on O
monocyte O
function O
may O
be O
an O
important O
mechanism O
of O
drug-induced B-cell_type
immunoregulation O
in O
monocyte-dependent O
responses O
. O
In O
some O
experimental O
conditions O
, O
corticosteroids O
inhibit O
Interleukin O
1 O
production O
by O
monocytes B-cell_type
. O
The O
immunoregulatory O
effects O
of O
corticosteroids O
on O
lymphocyte I-cell_line
immune O
responses O
are O
complex I-protein
. O
In O
vitro O
corticosteroids O
appear O
to O
selectively O
affect O
early O
immunoregulatory O
events O
as O
opposed O
to O
altering O
an O
established O
response O
. O
Multiple I-DNA
sites I-DNA
of O
steroid-induced O
modulations O
of O
human B-cell_type
B I-DNA
cell O
responses O
have O
been O
defined O
. O
Human O
lymphoid O
cell O
lines I-cell_line
and O
glucocorticoids O
: O
II I-protein
. O
Whole O
cell O
and O
cytoplasmic O
binding O
properties O
of O
lymphoblastoid O
, O
leukaemia O
and O
lymphoma O
lines I-cell_line
. O
The O
glucocorticoid O
binding O
properties O
of O
18 O
human B-DNA
lymphoid O
cell O
lines I-cell_line
( O
HLCL I-DNA
) O
have O
been O
investigated O
. O
The O
specificity O
of O
steroid O
binding O
was O
confirmed O
with O
various O
glucocorticoid O
agonists O
and O
antagonists O
. O
A O
gradation O
in O
whole O
cell O
and O
cytoplasmic O
glucocorticoid O
binding O
capacity O
was O
observed O
in O
the O
different O
cell O
line O
types I-cell_type
: O
lymphoblastoid O
greater O
than O
lymphoma O
greater O
than O
leukaemia O
. O
The O
cytoplasmic O
receptors O
of O
leukaemia O
and O
lymphoblastoid O
lines I-cell_line
appeared O
to O
contain O
both O
proteinaceous O
and O
phospholipid O
components O
. O
Cytoplasmic O
steroid-receptor O
complexes O
exhibited O
a O
wide O
range O
of O
sedimentation O
coefficients O
( O
8.5-11.3S B-protein
) O
in O
low O
ionic O
strength O
buffer O
but O
there O
was O
no O
correlation O
with O
cell O
line I-DNA
type O
or O
glucocorticoid O
sensitivity O
. O
Activation O
of O
these O
complexes O
by O
heat O
( O
37 O
degrees O
C I-protein
) O
or O
exposure O
to O
high O
ionic O
strength O
buffer O
( O
0.3 B-protein
M O
NaCl I-DNA
) O
induced O
nuclear B-protein
binding O
of O
steroid O
but O
only O
complexes O
in O
high O
ionic O
strength O
buffer O
manifested O
changes O
in O
sedimentation O
coefficient O
. O
No O
correlation O
was O
observed O
between O
the O
level O
or O
nature O
of O
glucocorticoid O
binding O
and O
the O
cytolethal O
or O
cytostatic O
responsiveness O
of O
HLCL O
to O
glucocorticoid O
treatment O
in O
vitro O
. O
The O
resistance O
to O
cytolethal O
effects O
can O
not O
be O
ascribed O
to O
a O
failure O
of O
cells O
to O
take O
up O
and O
bind O
steroid O
or O
to O
significant O
differences O
in O
the O
molecular O
species O
of O
cytoplasmic O
receptors O
present O
. O
The O
molecular O
mechanisms O
by O
which O
glucocorticoids O
achieve O
cytolethal O
responses O
in O
human B-DNA
lymphoid I-cell_type
cells I-cell_type
CD28 B-protein
-mediated O
activation O
in O
CD45RA+ I-protein
and O
CD45RO+ B-cell_type
T B-cell_type
cells I-cell_type
: O
enhanced O
levels O
of O
reactive O
oxygen O
intermediates O
and O
c-Rel O
nuclear B-protein
translocation O
in O
CD45RA+ B-cell_type
cells I-cell_type
. O
We O
have O
analyzed O
the O
effect O
of O
complete B-cell_type
T O
cell O
activation O
( O
anti-CD3 B-protein
plus O
anti-CD28 B-protein
) O
on O
the O
activation O
of O
NF-kappaB O
in O
CD45RA+ I-protein
( O
naive O
) O
and O
CD45RO+ B-protein
( O
memory/effector I-DNA
) O
T B-cell_type
cells I-cell_type
. O
Long O
exposure O
( O
24 O
h O
) O
induced O
stronger O
NF-kappaB O
DNA O
binding O
in O
CD45RA+ B-cell_type
cells I-cell_type
than O
in O
CD45RO+ B-cell_type
cells I-cell_type
. O
Analysis O
of O
the O
nuclear B-protein
c-Rel O
protein O
indicated O
that O
after O
anti-CD3+anti-CD28 O
stimulation O
the O
level O
of O
c-Rel O
was O
higher O
in O
CD45RA+ B-cell_type
cells I-cell_type
. O
Analysis O
of O
the O
cytoplasmic O
inhibitor O
IkappaBalpha O
indicated O
that O
anti-CD3+anti-CD28 O
stimulation O
induced O
a O
long-lasting B-DNA
degradation O
in O
CD45RA+ B-cell_type
cells I-cell_type
but O
in O
CD45RO+ B-cell_type
cells I-cell_type
the O
degradation O
process O
was O
more O
rapid O
. O
Because O
the O
CD28 B-protein
costimulus O
is O
known O
to O
induce O
the O
production O
of O
reactive O
oxygen O
intermediates O
( O
ROIs O
) O
, O
the O
intracellular O
ROI O
levels O
in O
CD45RA+ I-protein
and O
CD45RO+ B-cell_type
cells I-cell_type
were O
compared O
by O
flow O
cytometry O
. O
ROIs O
were O
produced O
in O
both O
cell O
types I-cell_type
, O
but O
more O
strongly O
in O
CD45RA+ B-cell_type
cells I-cell_type
. O
The O
data O
presented O
in O
this O
study O
further O
emphasize O
the O
differences O
between O
CD45RA+ I-protein
and O
CD45RO+ B-cell_type
T I-cell_type
lymphocytes I-cell_type
in O
ROI-dependent B-protein
signaling O
pathways O
. O
Ikaros O
in O
hemopoietic O
lineage O
determination O
and O
homeostasis O
. O
Studies O
on O
the O
molecular O
mechanisms O
that O
control O
hemopoietic O
differentiation O
have O
focused O
on O
signaling O
cascades O
and O
nuclear B-protein
effectors O
that O
drive O
this O
complex I-protein
developmental O
system O
in O
a O
regulated O
fashion O
. O
Here O
we O
review O
the O
role O
of O
Ikaros O
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc O
finger O
transcription B-protein
factors I-protein
in O
this O
developmental O
process O
. O
Studies O
on O
an O
Ikaros O
null O
mutation O
have O
revealed O
an O
essential O
role O
for O
this O
factor I-protein
in O
lymphoid O
cell O
fate O
determination O
and O
at O
subsequent O
branch O
points O
of O
the O
T O
cell O
differentiation O
pathway O
. O
Differences O
in O
the O
phenotypes O
of O
a O
null O
and O
a O
dominant O
negative O
( O
DN I-DNA
) O
Ikaros O
mutation O
provide O
insight O
into O
a O
regulatory O
network O
through O
which O
Ikaros O
proteins I-protein
exert O
their O
effects O
in O
development O
. O
In O
addition O
a O
comparative O
analysis O
of O
the O
hemopoietic O
stem O
cell O
and O
precursor O
compartment O
resulting O
from O
the O
two O
Ikaros O
mutations O
reveals O
a O
profound O
yet O
not O
absolute O
requirement O
for O
Ikaros O
in O
the O
production O
and O
differentiation O
of O
these O
populations O
. O
Overexpression O
of O
p65 O
and O
c-Jun O
substitutes O
for O
B7-1 B-protein
costimulation O
by O
targeting O
the O
CD28RE B-protein
within O
the O
IL-2 B-DNA
promoter I-DNA
. O
The O
role O
of O
Rel O
and O
activation O
protein-1 B-protein
( O
AP-1 B-protein
) O
in O
IL-2 B-DNA
promoter I-DNA
activity O
in O
B7-1- B-DNA
and O
leukocyte O
function-associated B-DNA
Ag-3 B-protein
( O
LFA. I-DNA
3 O
) O
-costimulated O
T B-cell_type
cells I-cell_type
has O
been O
evaluated O
. O
We O
demonstrate O
that O
overexpression O
of O
c-Jun O
but O
not O
c-Fos O
increases O
IL-2 B-DNA
promoter I-DNA
activity O
in O
both O
B7-1- B-DNA
and O
LFA-3-costimulated B-protein
Jurkat O
T B-cell_type
cells I-cell_type
. O
Cotransfection O
of O
both O
c-Jun B-DNA
and O
c-Fos O
substitutes O
for O
B7-1 B-protein
costimulation O
in O
driving O
an O
activation O
protein-1 B-protein
response O
element I-DNA
but O
not O
for O
the O
IL-2 B-DNA
promoter I-DNA
. O
Overexpression O
of O
Rel B-protein
proteins I-protein
demonstrated O
that O
p65-expressing B-protein
Jurkat B-cell_type
cells I-cell_type
transcribed O
equally O
well O
a O
nuclear B-protein
factor I-protein
kappabeta O
reporter O
construct O
when O
costimulated O
with O
B7-1 B-protein
or O
LFA-3 O
, O
but O
transcription I-DNA
of O
IL-2 B-DNA
promoter I-DNA
or O
CD28 B-protein
response O
element I-DNA
( O
CD28RE B-protein
) O
-driven O
reporters O
was O
superior O
in O
B7-1-costimulated B-DNA
cells I-cell_type
. O
Combined O
expression O
of O
c-Jun O
and O
p65 O
induced O
vigorous O
transcription I-DNA
of O
IL-2 B-protein
promoter- B-DNA
and O
CD28RE-driven B-protein
reporter O
constructs O
in O
both O
LFA-3- B-protein
and O
B7-1-costimulated B-protein
Jurkat B-cell_type
cells I-cell_type
. O
Mutating O
the O
CD28RE B-protein
but O
not O
the O
upstream O
nuclear B-protein
factor I-protein
kappabeta-binding B-DNA
site I-DNA
in O
the O
IL-2 B-DNA
promoter I-DNA
reduced O
B7-1 B-protein
-driven B-protein
transcription O
> O
90 O
% O
. O
The O
results O
implicates O
a O
major O
role O
of O
the O
CD28RE B-protein
in O
the O
integration O
of O
p65 B-cell_type
/ O
c-Jun O
-mediated O
transcription O
within O
the O
IL-2 B-DNA
promoter I-DNA
. O
We O
suggest O
that O
the O
transition O
from O
an O
autocrine O
LFA-3 O
-driven O
immune O
response O
to O
a O
B7 B-protein
-- O
induced O
paracrine O
immune O
response O
involves O
the O
activation O
of O
c-Jun O
and O
p65 I-protein
, O
which O
target I-cell_line
the O
CD28RE B-DNA
region I-DNA
of O
the O
IL-2 B-DNA
promoter I-DNA
. O
Defects O
in O
actin-cap B-DNA
formation O
in O
Vav-deficient B-protein
mice O
implicate O
an O
actin O
requirement O
for O
lymphocyte I-cell_line
signal O
transduction O
. O
BACKGROUND I-protein
: O
Antigen-receptor O
interactions O
on I-cell_type
lymphocytes I-cell_type
result O
in O
local O
clustering O
of O
actin O
, O
receptors O
and O
signaling O
molecules I-protein
into O
an O
asymmetric O
membrane O
structure O
termed O
a O
cap O
. O
Although O
actin O
polymerization O
is O
known O
to O
be O
required O
, O
the O
mechanisms O
underlying O
cap O
formation O
are O
unclear O
. O
We O
have O
studied O
the O
events O
underlying O
cap O
formation O
using O
mice O
bearing O
a O
null O
mutation O
in O
vav O
( O
vav O
-/- O
) O
, O
a O
gene I-DNA
that O
encodes O
a O
guanine-nucleotide O
exchange B-protein
factor I-protein
for O
the O
GTPase O
Rac O
. O
RESULTS I-protein
: O
Lymphocytes O
from O
vav O
-/- O
mice O
failed O
to O
form O
T-cell B-DNA
receptor I-protein
caps O
following O
activation O
and O
had O
a O
defective O
actin O
cytoskeleton O
. O
The O
vav-/- B-cell_type
T B-cell_type
cells I-cell_type
were O
deficient O
in O
interleukin-2 B-protein
( O
IL-2 B-protein
) O
production O
and O
proliferation O
, O
and O
the O
peak O
of O
Ca2+ B-cell_type
mobilization O
was O
reduced O
although O
of O
normal O
duration O
. O
Activation O
of O
Jun O
N-terminal B-protein
kinase I-protein
or O
stress-activated O
kinase I-protein
( O
JNK O
or O
SAPK O
) O
and O
mitogen-activated O
protein O
kinase I-protein
( O
MAPK I-DNA
) O
and O
the O
induction O
of O
the O
transcription B-protein
factor I-protein
NF-ATc1 B-protein
and O
egr-1 I-DNA
genes I-DNA
was O
normal O
. O
Despite O
the O
reduced O
Ca2+ O
mobilization O
, O
translocation O
of O
cytoplasmic O
NF-ATc O
to O
the O
nucleus O
was O
normal O
, O
reflecting O
that O
the O
lower O
levels O
of O
Ca2+ B-cell_type
in O
vav-/- B-DNA
cells I-cell_type
were O
still O
sufficient O
to O
activate O
calcineurin O
. O
Treatment O
of O
lymphocytes I-cell_type
with O
cytochalasin O
D O
, O
which O
blocks O
actin O
polymerization O
, O
inhibited O
cap O
formation O
and O
produced O
defects O
in O
signaling O
and O
IL-2 B-protein
transcriptional O
induction O
in O
response O
to O
antigen-receptor O
signaling O
that O
were O
nearly O
identical O
to O
those O
seen O
in O
vav-/- B-DNA
cells I-cell_type
. O
In O
transfection O
studies O
, O
either O
constitutively O
active O
Vav O
or O
Rac O
could O
complement O
constitutively O
active O
calcineurin O
to O
activate O
NF-AT-dependent B-protein
transcription O
. I-RNA
CONCLUSIONS I-protein
: O
These O
results O
indicate O
that O
Vav O
is O
required O
for O
cap O
formation O
in I-cell_type
lymphocytes I-cell_type
. O
Furthermore O
, O
the O
correlation O
between O
cap O
formation O
, O
IL-2 B-protein
production O
and O
proliferation O
supports O
the O
hypothesis O
that O
an O
actin-dependent O
pathway O
is O
a O
source O
of O
specialized O
growth O
regulatory O
signals O
. O
CD14 B-protein
-dependent O
activation O
of O
human B-cell_type
endothelial I-cell_type
cells I-cell_type
by O
Bacteroides O
fragilis O
outer O
membrane O
. O
We O
studied O
the O
capacity O
of O
isolated O
Bacteriodes O
fragilis O
outer O
membrane O
, O
B. B-protein
fragilis O
NCTC9343 B-protein
lipopolysaccharide I-protein
( O
LPS O
; O
endotoxin O
) O
, O
and O
B. B-protein
fragilis O
NCTC9343 B-protein
capsular O
polysaccharides O
to O
activate O
human B-DNA
umbilical I-cell_type
vein O
endothelial O
cell O
( O
HUVEC I-DNA
) O
monolayers O
. O
To O
assess O
HUVEC O
activation O
, O
E-selectin B-protein
expression O
was O
measured O
by O
enzyme-linked B-protein
immunosorbent O
assay O
( O
ELISA I-DNA
) O
, O
Northern O
blot O
analysis O
for O
E-selectin-specific I-RNA
mRNA I-RNA
, O
and O
electrophoretic O
gel O
mobility O
shift O
assay O
( O
EMSA I-DNA
) O
for O
NF-kappa B-protein
B I-protein
, O
a O
transcription B-protein
factor I-protein
necessary O
for O
E-selectin B-DNA
gene I-DNA
activation O
. O
Exposure O
of O
HUVECs O
to O
B. B-protein
fragilis O
outer O
membrane O
fractions O
, O
separated O
from O
other O
components O
of O
the O
B. B-protein
fragilis O
cell O
wall O
by O
isopycnic O
, O
sucrose O
gradient O
centrifugation O
, O
significantly O
increased O
surface I-protein
expression O
of O
E-selectin B-protein
and O
induced O
functional O
endothelial O
cell O
-dependent O
leukocyte O
adhesion O
. O
B. B-protein
fragilis O
outer O
membranes O
induced O
translocation O
of O
NF-kappa B-protein
B I-protein
to O
HUVEC O
nuclei O
and O
accumulation O
of O
E-selectin I-RNA
mRNA I-RNA
in O
HUVEC O
cytoplasm O
. O
E-selectin B-protein
expression O
induced O
by O
B. B-protein
fragilis O
outer O
membranes O
was O
not O
blocked O
by O
polymixin O
B I-DNA
. O
In O
contrast O
, O
E-selectin B-protein
expression O
induced O
by O
outer O
membrane O
fractions O
purified O
from O
E. B-protein
coli O
was O
competitively O
inhibited O
by O
polymixin O
B I-DNA
. O
Neither O
purified O
B. B-protein
fragilis O
LPS I-protein
, O
a O
prominent O
constituent O
of O
the O
outer O
membrane O
, O
nor O
purified O
B. B-protein
fragilis O
capsular O
polysaccharides O
induced O
HUVEC O
activation O
. O
Two O
different O
monoclonal B-protein
antibodies I-protein
directed O
against O
human B-DNA
CD14 B-protein
completely O
inhibited O
B. B-protein
fragilis O
outer O
membrane-induced I-cell_line
NF-kappa B-protein
B I-protein
activation O
, O
E-selectin B-protein
transcription I-DNA
, O
and O
E-selectin B-protein
surface I-protein
expression O
. O
We O
conclude O
that O
the O
outer O
membrane O
component O
of O
the O
B. B-protein
fragilis O
cell O
wall O
contains O
a O
proinflammatory B-protein
factor I-protein
( O
s O
) O
, O
that O
is O
not O
LPS I-protein
, O
which O
induces O
human B-DNA
endothelial O
cell O
activation O
by O
a O
soluble O
CD14 B-protein
-dependent O
mechanism O
. O
NF-kappaB O
protects O
HIV-1-infected B-protein
myeloid B-cell_type
cells I-cell_type
from O
apoptosis O
. O
HIV-1 O
infection O
of O
primary B-cell_line
monocytic B-cell_line
cells I-cell_type
and O
myeloid O
cell O
lines I-cell_line
results O
in O
sustained O
NF-kappaB O
activation O
. O
Recently O
, O
NF-kappaB O
induction O
has O
been O
shown O
to O
play O
a O
role O
in O
protecting B-cell_type
cells I-cell_type
from O
programmed O
cell O
death O
. O
In O
the O
present O
study O
, O
we O
sought O
to O
investigate O
whether O
constitutive O
NF-kappaB O
activity O
in O
chronically O
HIV-1-infected B-protein
promonocytic O
U937 B-protein
( O
U9-IIIB B-protein
) O
and O
myeloblastic O
PLB-985 B-protein
( O
PLB-IIIB B-protein
) O
cells I-cell_type
affects O
apoptotic O
signaling O
. O
TNFalpha O
and O
cycloheximide O
caused O
infected I-cell_type
cells O
to O
undergo O
apoptosis O
more O
rapidly O
than O
parental O
U937 B-protein
and O
PLB-985 B-protein
cells I-cell_type
. O
Inhibition O
of O
TNFalpha O
-induced O
NF-kappaB O
activation O
using O
the O
antioxidant O
N-acetylcysteine B-protein
( O
NAC I-DNA
) O
resulted O
in O
increased O
apoptosis O
in O
both O
U937 B-protein
and O
U9-IIIB B-protein
cells I-cell_line
, O
while O
preactivation O
of O
NF-kappaB O
with O
the O
non-apoptotic B-protein
inducer O
IL-1beta B-protein
caused O
a O
relative O
decrease O
in O
apoptosis O
. O
Inhibition O
of O
constitutive O
NF-kappaB O
activity O
in O
U9-IIIB B-DNA
and O
PLB-IIIB B-protein
cells I-cell_type
also O
induced O
apoptosis O
, O
suggesting O
that O
NF-kappaB O
protects B-cell_type
cells I-cell_type
from O
a O
persistent O
apoptotic O
signal O
. O
TNFalpha O
plus O
NAC O
treatment O
resulted O
in O
a O
marked O
decrease O
in O
Bcl-2 B-protein
protein O
levels O
in O
HIV-1-infected B-protein
cells I-cell_line
, O
coupled O
with O
an O
increase O
in O
Bax O
protein O
compared O
to O
uninfected O
cells I-cell_line
, O
suggesting O
that O
the O
difference O
in O
susceptibility O
to O
TNFalpha O
-induced O
apoptosis O
may O
relate O
to O
the O
differences O
in O
relative O
levels O
of O
Bcl-2 B-protein
and O
Bax O
. O
The O
protective O
role O
of O
NF-kappaB O
in O
blocking O
TNFalpha- O
and O
HIV-1-induced B-protein
apoptosis O
was O
supported O
by O
studies O
in O
Jurkat O
T B-cell_type
cells I-cell_type
engineered O
to O
express O
IkappaB I-DNA
alpha I-DNA
repressor I-DNA
mutants O
( O
TD-IkappaB I-DNA
) O
under O
the O
control O
of O
a O
tetracycline-responsive B-DNA
promoter I-DNA
. O
Cells O
underwent O
apoptosis O
in O
response O
to O
TNFalpha O
only O
when O
NF-kappaB O
activation O
was O
inhibited O
by O
TD-IkappaB O
expression O
. O
As O
was O
observed O
for O
the O
U9-IIIB B-protein
cells I-cell_line
, O
TNFalpha O
treatment O
also O
induced O
a O
marked O
decrease O
in O
Bcl-2 B-protein
protein O
levels O
in O
TD-IkappaB O
expressing B-cell_type
cells I-cell_type
. O
These O
experiments O
demonstrate O
that O
apoptotic O
signaling O
is O
perturbed O
in O
HIV-1-infected B-protein
U9-IIIB B-protein
cells I-cell_type
and O
indicate O
that O
NF-kappaB O
activation O
may O
play O
an O
additional O
protective O
role O
against O
HIV-1-induced B-protein
apoptosis O
in O
myeloid B-cell_type
cells I-cell_type
. O
Human O
normal O
peripheral B-cell_type
blood I-cell_type
B-lymphocytes I-cell_type
are O
deficient O
in O
DNA-dependent B-protein
protein O
kinase I-protein
activity O
due O
to O
the O
expression O
of O
a O
variant O
form O
of O
the O
Ku86 I-protein
protein O
. O
The O
heterodimeric O
Ku O
protein I-protein
, O
which O
comprises O
a O
86 O
kDa I-protein
( O
Ku86 I-DNA
) O
amd O
a O
70 O
kDa I-protein
( O
Ku70 I-DNA
) O
subunits O
, O
is O
an O
abundant O
nuclear B-protein
DNA-binding I-protein
protein O
which O
binds O
in O
vitro O
to O
DNA O
termini O
without O
sequence O
specificity O
. O
Ku O
is O
the O
DNA-targeting B-protein
component O
of O
the O
large O
catalytic O
sub-unit I-DNA
of O
the O
DNA-dependent B-protein
protein O
kinase I-protein
complex I-protein
( O
DNA-PK B-protein
[ O
CS B-protein
] O
) O
, O
that O
plays O
a O
critical O
role O
in O
mammalian O
double-strand B-protein
break O
repair O
and O
lymphoid O
V O
( O
D I-DNA
) O
J O
recombination O
. O
By O
using O
electrophoretic O
mobility O
shift O
assays O
, O
we O
demonstrated O
that O
in O
addition O
to O
the O
major O
Ku O
x O
DNA O
complex O
usually O
detected O
in O
cell O
line O
extracts O
, O
a O
second O
complex I-protein
with O
faster O
electrophoretic O
mobility O
was O
observed O
in O
normal O
peripheral B-cell_type
blood I-cell_type
lymphocytes I-cell_type
( O
PBL I-DNA
) O
extracts O
. O
The O
presence O
of O
this O
faster O
migrating O
complex I-protein
was O
restricted O
to O
B I-DNA
cells I-cell_type
among O
the O
circulating O
lymphocyte I-cell_line
population O
. O
Western O
blot O
analysis O
revealed O
that O
B I-DNA
cells I-cell_type
express O
a O
variant O
form O
of O
the O
Ku86 I-protein
protein O
with O
an O
apparent O
molecular O
weight O
of O
69 O
kDa I-protein
, O
and O
not O
the O
86 O
kDa- O
full-length O
protein O
. O
Although O
the O
heterodimer O
Ku70/variant-Ku86 B-DNA
binds O
to O
DNA-ends O
, O
this O
altered O
form O
of O
the O
Ku O
heterodimer O
has O
a O
decreased O
ability O
to O
recruit O
the O
catalytic O
component O
of O
the O
complex I-protein
, O
DNA-PK B-protein
( O
CS I-DNA
) O
, O
which O
contributes O
to O
an O
absence O
of O
detectable O
DNA-PK B-protein
activity O
in O
B I-DNA
cells I-cell_type
. O
These O
data O
provide O
a O
molecular O
basis O
for O
the O
increased O
sensitivity O
of O
B I-DNA
cells O
to O
ionizing O
radiation O
and O
identify O
a O
new O
mechanism O
of O
regulation O
of O
DNA-PK B-protein
activity O
that O
operates O
in O
vivo O
. O
Co-stimulation O
of O
human B-cell_type
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
with O
IL-2 B-protein
and O
anti-CD3 B-protein
monoclonal B-protein
antibodies I-protein
induces O
phosphorylation O
of O
CREB O
. O
Phosphorylation O
of O
the O
cAMP-response B-protein
element I-DNA
binding O
protein O
CREB I-protein
within O
1 O
h O
of O
CD2 B-protein
but O
not O
CD3 B-protein
cross-linking I-DNA
of O
human B-cell_type
PBMC I-DNA
was O
recently O
demonstrated O
. O
The O
absence O
of O
P-CREB B-protein
following O
CD3 B-protein
cross-linking B-protein
was O
unexpected O
, O
as O
other O
laboratories O
reported O
increased O
phosphorylation O
of O
CREB O
following O
CD3 B-protein
cross-linking I-DNA
of O
the O
Jurkat O
lymphocyte I-cell_line
cell O
line O
. O
Due O
to O
Jurkat O
T-cells B-protein
being O
IL-2-independent I-cell_line
, O
it O
was O
postulated O
that O
IL-2 B-protein
might O
provide O
a O
necessary O
co-stimulus O
for O
phosphorylation O
of O
CREB O
in O
primary B-cell_line
lymphocytes I-cell_type
. O
Therefore O
, O
P-CREB B-protein
was O
evaluated O
following O
co-stimulation I-DNA
of O
human B-cell_type
PBMC I-DNA
through O
the O
IL-2 B-protein
and O
CD2 B-protein
or O
CD3 B-protein
receptors O
. O
IL-2 B-protein
did O
not O
further O
augment O
phosphorylation O
of O
CREB O
following O
CD2 B-protein
cross-linking B-protein
. O
However O
, O
while O
neither O
IL-2 B-protein
nor O
CD3 B-protein
cross-linking B-protein
alone O
induced O
P-CREB I-protein
, O
a O
4.5-fold B-protein
increase O
in O
phosphorylation O
of O
CREB O
within O
1 O
h O
of O
IL-2/CD3 B-protein
co-stimulation O
was O
observed O
. O
Phosphorylation O
was O
not O
associated O
with O
the O
induction O
of O
cAMP I-protein
, O
and O
inhibition O
of O
PKA B-cell_type
signaling O
had O
no O
effect O
on O
P-CREB B-protein
. O
Consistent O
with O
signal O
transduction O
through O
p56lck B-protein
or O
p59fyn B-protein
, O
inhibition O
of O
PTK B-cell_type
signaling O
reduced O
phosphorylation O
50 O
% O
. O
Interestingly B-cell_type
, O
inhibiting O
PKC O
signaling O
with O
calphostin O
C I-protein
further O
increased O
P-CREB B-protein
levels O
3-fold B-protein
over O
that O
observed O
in O
IL-2/CD3 B-protein
co-stimulated B-cell_type
cells I-cell_type
not O
pretreated O
with O
a O
PKC O
inhibitor O
. O
In O
contrast O
to O
previous O
studies O
performed O
in O
the O
absence O
of O
exogenous O
IL-2 B-protein
, O
no O
increase O
in O
binding O
of O
CREB O
to O
a O
32P-labeled O
oligonucleotide O
probe O
was O
observed O
by O
electrophoretic O
mobility O
shift O
assay O
. O
These O
data O
suggest O
that O
the O
IL-2 B-protein
and O
CD3 B-protein
signaling O
pathways O
provide O
a O
necessary O
and O
co-operative O
stimulus O
promoting O
phosphorylation O
of O
CREB O
following I-DNA
receptor I-protein
cross-linking I-DNA
. O
HIV-1 O
infection O
induces O
a O
selective O
reduction O
in O
STAT5 B-protein
protein O
expression O
. O
HIV-1 O
infection O
is O
accompanied O
by O
qualitative O
and O
quantitative O
defects O
in O
CD4+ B-cell_type
T I-cell_type
lymphocytes I-cell_type
. O
Loss O
of O
immune O
function O
in O
HIV O
patients O
is O
usually O
associated O
with O
a O
profound O
dysregulation O
of O
cytokine O
production O
. O
To O
investigate O
whether O
cytokine O
signaling O
defects O
occur O
during O
HIV O
infection O
, O
PHA O
blasts O
from O
healthy O
human B-DNA
donors I-cell_type
were O
infected O
with O
two O
strains O
of O
HIV-1 O
and O
screened O
for O
the O
expression O
of O
STAT B-protein
proteins I-protein
used O
in O
cytokine O
signaling O
. O
A O
selective O
decrease O
in O
STAT5B B-protein
was O
seen O
8 O
days O
after O
infection O
with O
the O
BZ167 B-protein
dual-tropic O
HIV O
isolate O
, O
but O
not O
with O
the O
Ba-L I-DNA
, O
M-tropic B-protein
strain O
. O
Based O
on O
these O
findings O
, O
purified O
T B-cell_type
cells I-cell_type
from O
HIV-infected B-protein
patients O
in O
different O
stages O
of O
disease O
were O
also O
tested O
for O
STAT B-protein
expression O
; O
decreases O
in O
STAT5A I-protein
, O
STAT5B I-protein
, O
and O
STAT1alpha B-protein
were O
observed O
in O
all O
patients O
. O
The O
reduction O
in O
STATs O
seen O
in O
vivo O
and O
in O
vitro O
after O
HIV O
infection O
may O
contribute O
to O
the O
loss O
of O
T O
cell O
function O
in O
HIV O
disease O
. O
Transcription B-protein
factors I-protein
that O
regulate O
monocyte O
/ O
macrophage O
differentiation O
. O
Although O
all O
the B-cell_type
cells I-cell_type
in O
an O
organism O
contain O
the O
same O
genetic O
information O
, O
differences O
in O
the O
cell O
phenotype O
arise O
from O
the O
expression O
of O
lineage-specific I-DNA
genes I-DNA
. O
During O
myelopoiesis O
, O
external O
differentiating O
signals O
regulate O
the O
expression O
of O
a O
set O
of O
transcription B-protein
factors I-protein
. O
The O
combined O
action O
of O
these O
transcription B-protein
factors I-protein
subsequently O
determines O
the O
expression O
of O
myeloid-specific I-DNA
genes I-DNA
and O
the O
generation O
of O
monocytes B-cell_type
and O
macrophages O
. O
In O
particular O
, O
the O
transcription B-protein
factor I-protein
PU.1 B-protein
has O
a O
critical O
role O
in O
this O
process O
. O
We O
review O
the O
contribution O
of O
several O
transcription B-protein
factors I-protein
to O
the O
control O
of O
macrophage O
development O
Transcription B-protein
factor I-protein
LKLF O
is O
sufficient O
to O
program O
T O
cell O
quiescence O
via O
a O
c-Myc O
-- O
dependent O
pathway O
. O
T I-cell_type
lymphocytes I-cell_type
circulate O
in O
a O
quiescent O
state O
until O
they O
encounter O
cognate O
antigen I-protein
bound O
to O
the O
surface I-protein
of O
an O
antigen-presenting B-cell_type
cell O
. O
The O
molecular O
pathways O
that O
regulate O
T O
cell O
quiescence O
remain O
largely O
unknown O
. O
Here O
we O
show O
that O
forced O
expression O
of O
the O
lung O
Kruppel-like B-protein
transcription B-protein
factor I-protein
( O
LKLF I-DNA
) O
in O
Jurkat O
T B-cell_type
cells I-cell_type
is O
sufficient O
to O
program O
a O
quiescent O
phenotype O
characterized O
by O
decreased O
proliferation O
, O
reduced O
cell O
size O
and O
protein O
synthesis O
and O
decreased O
surface I-protein
expression O
of O
activation O
markers O
. O
Conversely O
, O
LKLF-deficient O
peripheral B-cell_type
T B-cell_type
cells I-cell_type
produced O
by O
gene I-DNA
targeting O
showed O
increased O
proliferation O
, O
increased O
cell O
size O
and O
enhanced O
expression O
of O
surface I-protein
activation O
markers O
in O
vivo O
. O
LKLF O
appeared O
to O
function O
, O
at O
least O
in O
part O
, O
by O
decreasing O
expression O
of O
the O
proto-oncogene O
encoding O
c-Myc O
. O
Forced O
expression O
of O
LKLF O
was O
associated O
with O
markedly O
decreased O
c-Myc O
expression O
. O
In O
addition O
, O
many O
effects O
of O
LKLF O
expression O
were O
mimicked O
by O
expression O
of O
the O
dominant-negative B-DNA
MadMyc I-protein
protein O
and O
rescued O
by O
overexpression O
of O
c-Myc O
. O
Thus O
, O
LKLF O
is O
both O
necessary O
and O
sufficient O
to O
program O
quiescence O
in O
T B-cell_type
cells I-cell_type
and O
functions O
, O
in O
part O
, O
by O
negatively O
regulating O
a O
c-Myc O
-- O
dependent O
pathway O
. O
HTLV-1 B-protein
p12 I-cell_line
( O
I I-DNA
) O
protein O
enhances O
STAT5 B-protein
activation O
and O
decreases O
the O
interleukin-2 B-protein
requirement O
for O
proliferation O
of O
primary B-cell_line
human I-cell_line
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
. O
The O
p12 I-cell_line
( O
I I-DNA
) O
protein O
, O
encoded O
by O
the O
pX I-RNA
open O
reading O
frame O
I I-protein
of O
the O
human B-DNA
T-lymphotropic I-DNA
virus O
type O
1 O
( O
HTLV-1 B-protein
) O
, O
is O
a O
hydrophobic O
protein O
that O
localizes O
to O
the O
endoplasmic O
reticulum O
and O
the O
Golgi O
. O
Although O
p12 I-cell_line
( O
I I-DNA
) O
contains O
4 O
minimal O
proline-rich I-DNA
, O
src O
homology O
3-binding O
motifs O
( O
PXXP I-DNA
) O
, O
a O
characteristic O
commonly O
found O
in O
proteins I-protein
involved O
in O
signaling O
pathways O
, O
it O
has O
not O
been O
known O
whether O
p12 I-cell_line
( O
I I-DNA
) O
has O
a O
role O
in O
modulating O
intracellular O
signaling O
pathways O
. O
This O
study O
demonstrated O
that O
p12 I-cell_line
( O
I I-DNA
) O
binds O
to O
the O
cytoplasmic I-protein
domain I-protein
of O
the O
interleukin-2 I-DNA
receptor I-protein
( O
IL-2R B-protein
) O
beta O
chain O
that O
is O
involved O
in O
the O
recruitment O
of O
the O
Jak1 O
and O
Jak3 O
kinases I-protein
. B-protein
As O
a O
result O
of O
this O
interaction O
, O
p12 O
( O
I I-DNA
) O
increases O
signal O
transducers O
and O
activators O
of O
transcription O
5 O
( O
STAT5 B-protein
) O
DNA O
binding O
and O
transcriptional O
activity O
and O
this O
effect O
depends O
on O
the O
presence O
of O
both O
IL-2R B-DNA
beta I-protein
and O
gamma O
( O
c O
) O
chains O
and O
Jak3 O
. O
Transduction O
of O
primary B-cell_line
human I-cell_line
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_line
( O
PBMCs O
) O
with O
a O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1-based B-DNA
retroviral O
vector O
expressing O
p12 I-cell_line
( O
I I-DNA
) O
also O
resulted O
in O
increased O
STAT5 B-protein
phosphorylation O
and O
DNA O
binding O
. O
However O
, O
p12 O
( O
I I-DNA
) O
could O
increase O
proliferation O
of O
human B-cell_type
PBMCs I-cell_type
only O
after O
stimulation O
of O
T-cell O
receptors O
by O
treatment O
of O
cells I-cell_type
with O
low O
concentrations O
of O
alphaCD3 B-cell_type
and O
alphaCD28 B-protein
antibodies I-protein
. O
In O
addition O
, O
the O
proliferative O
advantage O
of O
p12 B-cell_type
( O
I I-DNA
) O
-transduced O
PBMCs O
was O
evident O
mainly O
at O
low O
concentrations O
of O
IL-2 B-protein
. O
Together O
, O
these O
data O
indicate O
that O
p12 I-cell_line
( O
I I-DNA
) O
may O
confer O
a O
proliferative O
advantage O
on O
HTLV-1-infected B-protein
cells I-cell_type
in O
the O
presence O
of O
suboptimal O
antigen I-protein
stimulation O
and O
that O
this O
event O
may O
account O
for O
the O
clonal O
proliferation O
of O
infected O
T B-cell_type
cells I-cell_type
in O
vivo O
. O
( O
Blood. I-DNA
2001 O
; O
98 O
: O
823-829 O
) O
Single O
dose O
intranasal O
administration O
of O
retinal O
autoantigen O
generates O
a O
rapid O
accumulation O
and O
cell O
activation O
in O
draining O
lymph O
node O
and O
spleen O
: O
implications O
for O
tolerance O
therapy O
. O
BACKGROUND/AIMS B-protein
: O
A O
single O
intranasal O
delivery O
of O
retinal O
autoantigen O
suppresses O
effectively O
experimental O
autoimmune O
uveoretinitis O
( O
EAU I-DNA
) O
. O
To O
further O
unravel O
underlying O
mechanisms O
the O
authors O
wished O
to O
determine O
, O
firstly O
, O
the O
kinetics O
of O
antigen I-protein
delivery O
and I-DNA
, O
secondly O
, O
the O
early O
cellular O
responses O
involved O
in O
the O
initial O
stages O
of O
nasal O
mucosal O
tolerance O
induction O
. O
METHODS I-protein
: O
Flow O
cytometry O
, O
cell O
proliferation O
assays O
, O
and O
microscopy O
were O
used O
to O
track O
antigen I-protein
following O
a O
single O
, O
intranasal O
dose O
of O
Alexa-488 B-protein
labelled O
retinal O
antigen I-protein
. O
RESULTS I-protein
: O
A O
rapid O
accumulation O
of O
antigen I-protein
within O
both O
superficial O
cervical O
lymph O
nodes O
( O
SCLN I-DNA
) O
and O
spleen O
was O
observed O
after O
30 O
minutes O
. O
Significant O
proliferative O
responses O
to O
IRBP O
were O
elicited O
by O
48 O
hours O
indicating O
that O
systemic O
priming O
of O
naive B-cell_type
T B-cell_type
cells O
to O
retinal O
antigen I-protein
had O
occurred O
. O
Cell O
activation O
was O
further O
confirmed O
by O
immunoprecipitation O
studies O
, O
which O
demonstrated O
phosphorylation O
of O
STAT4 B-protein
but O
not O
STAT6 B-protein
in O
both O
lymph O
nodes O
and O
spleen O
. O
However O
, O
at O
24 O
hours O
, O
STAT4 B-protein
heterodimerisation O
with O
STAT B-protein
3 O
was O
only O
observed O
in O
spleen O
. O
CONCLUSIONS I-protein
: O
The O
results O
provide O
novel O
evidence O
that O
following O
a O
single O
intranasal O
application O
rapid O
transfer O
of O
antigen I-protein
occurs O
. O
Resulting B-cell_type
T O
cell O
proliferation O
develops O
consequent O
to O
differential O
cell O
signalling O
in O
SCLN O
and O
spleen O
. O
Further O
understanding O
of O
these O
underlying O
cellular O
mechanisms O
, O
in O
particular O
as O
is O
inferred O
by O
the O
results O
the O
contribution O
of O
local O
versus O
systemic O
tolerance O
induction O
, O
may O
assist O
in O
strategies O
to O
clinically O
apply O
mucosal O
tolerance O
therapy O
successfully O
. O
Regulation O
of O
interleukin O
( O
IL I-DNA
) O
-18 B-DNA
receptor I-DNA
alpha I-DNA
chain I-DNA
expression O
on O
CD4 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
during O
T I-cell_line
helper O
( O
Th O
) O
1/Th2 O
differentiation O
. O
Critical O
downregulatory O
role O
of O
IL-4 B-protein
. O
Interleukin O
( O
IL I-DNA
) O
-18 O
has O
been O
well O
characterized O
as O
a O
costimulatory B-protein
factor I-protein
for O
the O
induction O
of O
IL-12-mediated B-protein
interferon O
( O
IFN I-DNA
) O
-gamma O
production O
by O
T I-cell_line
helper O
( O
Th O
) O
1 O
cells I-cell_line
, O
but O
also O
can O
induce O
IL-4 B-protein
production O
and O
thus O
facilitate O
the O
differentiation O
of O
Th2 B-cell_type
cells I-cell_type
. O
To O
determine O
the O
mechanisms O
by O
which O
IL-18 B-protein
might O
regulate O
these O
diametrically O
distinct O
immune O
responses O
, O
we O
have O
analyzed O
the O
role O
of O
cytokines O
in O
the O
regulation O
of O
IL-18 B-DNA
receptor I-DNA
alpha I-DNA
chain I-DNA
( O
IL-18Ralpha B-protein
) O
expression O
. O
The O
majority O
of O
peripheral B-cell_type
CD4 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
constitutively O
expressed O
the O
IL-18Ralpha O
. O
Upon O
antigen I-protein
stimulation O
in O
the O
presence O
of O
IL-12 B-protein
, O
marked O
enhancement O
of O
IL-18Ralpha O
expression O
was O
observed O
. O
IL-12 B-protein
-mediated O
upregulation O
of O
IL-18Ralpha O
required O
IFN-gamma B-protein
. O
Activated O
CD4 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
that O
expressed O
low O
levels O
of O
IL-18Ralpha O
could O
produce O
IFN-gamma B-protein
when O
stimulated O
with O
the O
combination O
of O
IL-12 B-protein
and O
IL-18 B-protein
, O
while O
CD4 B-protein
( O
+ O
) O
cells I-cell_type
which O
expressed O
high O
levels O
of O
IL-18Ralpha O
could O
respond O
to O
IL-18 B-protein
alone O
. O
In O
contrast O
, O
T O
cell O
stimulation O
in O
the O
presence O
of O
IL-4 B-protein
resulted O
in O
a O
downregulation O
of O
IL-18Ralpha O
expression O
. O
Both O
IL-4 B-protein
( O
-/ O
) O
- O
and O
signal O
transducer O
and O
activator O
of O
transcription O
( O
Stat O
) O
6 O
( O
-/ O
) O
- O
T B-cell_type
cells I-cell_type
expressed O
higher O
levels O
of O
IL-18Ralpha O
after O
TCR O
stimulation O
. O
Furthermore O
, O
activated O
T B-cell_type
cells I-cell_type
from O
Stat6 I-cell_line
( O
-/ O
) O
- O
mice O
produced O
more O
IFN-gamma B-protein
in O
response O
to O
IL-18 B-protein
than O
wild-type B-DNA
controls O
. O
Thus O
, O
positive/negative O
regulation O
of O
the O
IL-18Ralpha O
by O
the O
major O
inductive O
cytokines O
( O
IL-12 B-protein
and O
IL-4 B-protein
) O
determines O
the O
capacity O
of O
IL-18 O
to O
polarize O
an O
immune O
response O
. O
Glucocorticoid-regulated B-protein
transcription B-protein
factors I-protein
. O
Glucocorticoids O
are O
the O
most O
effective O
antiinflammatory O
drugs O
used O
in O
the O
treatment O
of O
asthma O
. O
They O
act O
by O
binding O
to O
a O
specific I-DNA
receptor I-protein
( O
GR I-DNA
) O
that O
, O
upon O
activation O
, O
translocates O
to O
the O
nucleus O
and O
either O
increases O
( O
transactivates O
) O
or O
decreases O
( O
transrepresses O
) O
gene I-DNA
expression O
. O
Inhibition O
of O
pro-inflammatory B-protein
transcription B-protein
factors I-protein
such O
as O
activator O
protein I-protein
( O
AP I-DNA
) O
-1 O
, O
signal O
transducers O
and O
activators O
of O
transcription O
( O
STATs O
) O
, O
nuclear B-protein
factor I-protein
of O
activated B-cell_type
T B-cell_type
cells I-cell_type
( O
NFAT I-DNA
) O
and O
nuclear B-protein
factor I-protein
( O
NF I-DNA
) O
-kappa O
B I-DNA
is O
thought O
to O
be O
a O
major O
action O
of O
glucocorticoids O
. O
Acetylation O
of O
histones O
allows O
unwinding O
of O
the O
local O
DNA O
structure O
and O
enables O
RNA O
polymerase O
II I-protein
to O
enhance O
gene I-DNA
transcription O
. I-RNA
Histone O
acetylation O
is O
regulated O
by O
a O
balance O
between O
the O
activity O
of O
histone I-protein
acetyltransferases I-protein
( O
HATs O
) O
and O
histone I-protein
deacetylases O
( O
HDACs O
) O
. O
GR B-protein
acts O
as O
a O
direct O
inhibitor O
of O
NF-kappa B-protein
B-induced B-protein
HAT O
activity O
and O
also O
by O
recruiting O
HDAC2 O
to O
the O
NF-kappa B-protein
B/HAT I-protein
complex I-protein
. O
A O
sub-group O
of O
patients O
with O
glucocorticoid-insensitive B-DNA
asthma O
have O
an O
inability O
to O
induce O
histone I-protein
acetylation O
in O
response O
to O
dexamethasone O
suggesting O
reduced O
expression O
of O
a O
GR-specific B-protein
HAT O
. O
This O
suggests O
that O
pharmacological O
manipulation O
of O
specific O
histone I-protein
acetylation O
status O
is O
a O
potentially O
useful O
approach O
for O
the O
treatment O
of O
inflammatory O
diseases O
. O
Identification O
of O
the O
precise O
mechanism O
by O
which O
activated O
GR B-protein
recruits O
HDAC2 B-protein
may O
reveal O
new O
targets I-cell_line
for O
the O
development O
of O
drugs O
that O
may O
dissociate O
the O
antiinflammatory O
actions O
of O
glucocorticoids O
from O
their O
side O
effects O
that O
are O
largely O
due O
to O
gene I-DNA
induction O
. O
Copyright O
Academic O
Press O
. O
Differential O
ultraviolet-B-induced O
immunomodulation O
in O
XPA I-protein
, O
XPC I-protein
, O
and O
CSB O
DNA O
repair-deficient O
mice O
. O
Ultraviolet O
B I-DNA
irradiation O
has O
serious O
consequences O
for O
cellular O
immunity O
and O
can O
suppress O
the O
rejection O
of O
skin O
tumors O
and O
the O
resistance O
to O
infectious O
diseases O
. O
DNA O
damage O
plays O
a O
crucial O
role O
in O
these O
immunomodulatory O
effects O
of O
ultraviolet O
B I-DNA
, O
as O
impaired O
repair O
of O
ultraviolet-B-induced O
DNA O
damage O
has O
been O
shown O
to O
cause O
suppression O
of O
cellular O
immunity O
. O
Ultraviolet-B-induced O
DNA O
damage O
is O
repaired O
by O
the O
nucleotide O
excision O
repair O
mechanism O
very O
efficiently O
. O
Nucleotide O
excision O
repair O
comprises O
two O
subpathways O
: O
transcription-coupled O
and O
global O
genome O
repair O
. O
In O
this O
study O
the O
immunologic O
consequences O
of O
specific O
nucleotide O
excision O
repair O
defects O
in O
three O
mouse B-DNA
models O
, O
XPA I-protein
, O
XPC I-protein
, O
and O
CSB O
mutant O
mice O
, O
were O
investigated O
. O
XPA O
mice O
carry O
a O
total O
nucleotide O
excision O
repair O
defect I-protein
, O
whereas O
XPC O
and O
CSB O
mice O
only O
lack O
global O
genome O
and O
transcription-coupled O
nucleotide O
excision O
repair I-protein
, O
respectively O
. O
Our O
data O
demonstrate O
that O
cellular O
immune O
parameters O
in O
XPA I-protein
, O
XPC I-protein
, O
and O
CSB O
mice O
are O
normal O
compared O
with O
their O
wild-type B-DNA
( O
control O
) O
littermates O
. O
This O
may O
indicate O
that O
the O
reported O
altered O
cellular O
responses O
in O
xeroderma O
pigmentosum O
patients O
are O
not O
constitutive O
but O
could O
be O
due O
to O
external B-protein
factors I-protein
, O
such O
as O
ultraviolet O
B I-DNA
. O
Upon O
exposure O
to O
ultraviolet O
B I-DNA
, O
only O
XPA O
mice O
are O
very O
sensitive O
to O
ultraviolet-B-induced O
inhibition O
of O
Th1-mediated B-protein
contact O
hypersensitivity O
responses O
and O
interferon-gamma O
production O
in O
skin O
draining O
lymph O
nodes O
. O
Lipopolysaccharide-stimulated B-protein
tumor O
necrosis B-protein
factor I-protein
alpha I-DNA
and I-DNA
interleukin-10 B-protein
production O
are O
significantly O
augmented O
in O
both O
XPA O
and O
CSB O
mice O
after O
ultraviolet O
B I-DNA
exposure O
. O
Lymph O
node O
cell O
numbers O
were O
increased O
very O
significantly O
in O
XPA I-protein
, O
mildly O
increased O
in O
CSB I-protein
, O
and O
not O
in O
XPC O
mice O
. O
In O
general O
XPC O
mice O
do O
not O
exhibit O
any O
indication O
of O
enhanced O
ultraviolet O
B I-DNA
susceptibility O
with O
regard O
to O
the O
immune O
parameters O
analyzed O
. O
These O
data O
suggest O
that O
both O
global O
genome O
repair O
and O
transcription-coupled O
repair O
are O
needed O
to O
prevent O
immunomodulation O
by O
ultraviolet O
B I-DNA
, O
whereas O
transcription-coupled O
repair O
is O
the O
major O
DNA O
repair O
subpathway O
of O
nucleotide O
excision O
repair O
that O
prevents O
the O
acute O
ultraviolet-B-induced O
effects O
such O
as O
erythema O
. O
Biomechanical B-cell_type
strain O
induces O
class B-protein
a O
scavenger I-DNA
receptor I-protein
expression O
in O
human B-DNA
monocyte/macrophages I-cell_type
and O
THP-1 B-cell_type
cells I-cell_type
: O
a O
potential O
mechanism O
of O
increased O
atherosclerosis O
in O
hypertension O
. O
BACKGROUND I-protein
: O
Although O
hypertension O
is O
an O
important O
risk I-protein
factor I-protein
for O
the O
development O
of O
atherosclerosis O
, O
the O
mechanisms O
for O
this O
interaction O
are O
incompletely O
described O
. O
Previous O
studies O
have O
suggested O
that O
biomechanical O
strain O
regulates O
macrophage O
phenotype O
. O
We O
tested O
the O
hypothesis O
that O
biomechanical O
strain O
can O
induce O
expression O
of O
the O
class B-protein
A O
scavenger I-DNA
receptor I-protein
( O
SRA I-DNA
) O
, O
an O
important O
lipoprotein I-DNA
receptor I-protein
in O
atherogenesis O
. O
METHODS I-protein
AND O
RESULTS I-protein
: O
Human O
monocyte/macrophages I-cell_line
or O
THP-1 B-DNA
cells I-cell_type
were O
cultured O
in O
a O
device O
that O
imposes O
uniform O
biaxial O
cyclic O
1-Hz B-protein
strains O
of O
0 O
% O
, O
1 O
% O
, O
2 O
% O
, O
or O
3 O
% O
, O
and O
SRA O
expression O
was O
analyzed O
. O
Mechanical O
strains O
induced O
SRA I-RNA
mRNA I-RNA
( O
3.5+/-0.6-fold B-protein
at O
3 O
% O
strain O
for O
48 O
hours O
, O
P O
< O
0.01 B-protein
) O
and O
SRA I-protein
protein O
in O
THP-1 B-DNA
cells I-cell_type
in O
an O
amplitude-dependent B-DNA
manner O
. O
This O
induction O
was O
accompanied O
by O
augmented O
expression O
of O
the O
class B-protein
B I-DNA
scavenger I-DNA
receptor I-protein
CD36 B-protein
( O
2.8+/-0.3-fold I-DNA
, O
P O
< O
0.001 B-protein
) O
but O
not O
by O
increased O
peroxisome O
proliferator-activated B-DNA
receptor-gamma O
expression O
. O
To O
evaluate O
this O
effect O
in O
vivo O
, O
apolipoprotein O
E O
( O
-/- O
) O
mice O
were O
randomly O
assigned O
to O
receive O
standard O
chow O
, O
a O
high-cholesterol O
diet O
, O
or O
a O
high-cholesterol O
diet O
with O
hypertension O
induced O
by O
angiotensin O
II I-protein
infusion O
for O
8 O
weeks O
. O
Immunohistochemistry O
revealed O
that O
among O
macrophages O
in O
atherosclerotic O
lesions O
of O
the O
aorta O
, O
the O
proportion O
of O
macrophages O
with O
SRA O
expression O
was O
highest O
in O
hypertensive O
animals O
on O
a O
high-cholesterol O
diet O
( O
43.9+/-0.7 B-protein
% O
, O
versus O
12.0+/-2.0 B-protein
% O
for O
normotensive O
animals O
on O
a O
high-cholesterol O
diet O
and O
4.7+/-4.7 B-protein
% O
for O
animals O
on O
standard O
chow O
; O
P O
< O
0.001 B-protein
) O
. O
CONCLUSIONS I-protein
: O
Biomechanical B-cell_type
strain O
induces O
SRA O
expression O
by O
monocyte/macrophages I-protein
, O
suggesting O
a O
novel O
mechanism O
for O
promotion O
of O
atherosclerosis O
in O
hypertensive O
patients O
. O
High O
glucose O
induces O
MCP-1 O
expression O
partly O
via O
tyrosine I-protein
kinase-AP-1 O
pathway O
in O
peritoneal O
mesothelial B-cell_type
cells I-cell_type
. O
BACKGROUND I-protein
: O
High O
glucose O
in O
peritoneal O
dialysis O
solutions O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
peritoneal O
fibrosis O
in O
chronic O
ambulatory O
peritoneal O
dialysis O
( O
CAPD I-DNA
) O
patients O
. O
However O
, O
the O
mechanisms O
are O
not O
very O
clear O
. O
Peritoneal O
macrophages O
seem O
to O
participate O
in O
the O
process O
of O
peritoneal O
fibrosis O
and O
monocyte O
chemoattractant O
protein-1 B-protein
( O
MCP-1 O
) O
plays O
a O
key O
role O
in O
the O
recruitment O
of O
monocytes B-cell_type
toward O
the O
peritoneal O
cavity O
. O
However O
, O
little O
is O
known O
about O
the O
effect O
of O
high O
glucose O
on O
MCP-1 O
expression O
and O
its O
signal O
transduction O
pathway O
in O
human B-DNA
peritoneal I-cell_type
mesothelial B-cell_type
cells I-cell_type
. O
METHODS I-protein
: O
Mesothelial B-cell_type
cells I-cell_type
were O
cultured O
with O
glucose O
( O
5 O
to O
100 O
mmol/L B-protein
) O
or O
mannitol O
chronically O
for O
up O
to O
seven O
days O
. O
MCP-1 O
expression O
of O
mRNA I-RNA
and O
protein O
was O
measured O
by O
Northern O
blot O
analysis O
and O
enzyme-linked B-protein
immunosorbent O
assay O
( O
ELISA I-DNA
) O
. O
Chemotactic O
activity O
of O
high-glucose-conditioned B-RNA
culture O
supernatant O
was O
measured O
by O
chemotactic O
assay O
. O
To O
examine O
the O
roles O
of O
the O
transcription B-protein
factors I-protein
activator O
protein-1 B-protein
( O
AP-1 B-protein
) O
and O
nuclear B-protein
factor-kappaB B-protein
( O
NF-kappaB I-DNA
) O
, O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA I-DNA
) O
was O
performed O
. O
RESULTS I-protein
: O
Glucose O
induced O
MCP-1 I-RNA
mRNA I-RNA
expression O
in O
a O
time- B-DNA
and O
dose-dependent O
manner O
. O
MCP-1 O
protein O
in O
cell O
culture O
supernant O
was O
also O
increased O
. O
Equivalent O
concentrations O
of O
mannitol O
had O
no O
significant O
effect O
. O
High-glucose-conditioned B-protein
supernatant O
possessed O
an O
increased O
chemotactic O
activity O
for O
monocytes B-cell_type
, O
which O
was O
neutralized O
by O
anti-MCP-1 B-protein
antibody O
. O
EMSA O
revealed O
that O
glucose O
increased O
the O
AP-1 B-protein
binding O
activity O
in O
a O
time- B-DNA
and O
dose-dependent O
manner O
, O
but O
not O
NF-kappaB O
. O
Curcumin O
, O
an O
inhibitor O
of O
AP-1 B-protein
, O
dose-dependently O
suppressed O
the O
induction O
of O
MCP-1 I-RNA
mRNA I-RNA
by O
high O
glucose O
. O
Tyrosine O
kinase I-protein
inhibitors O
such O
as O
genistein O
( O
12.5 B-protein
to O
50 O
micromol/L I-DNA
) O
and O
herbimycin O
A O
( O
0.1 B-protein
to O
1 O
micromol/L I-DNA
) O
inhibited O
the O
high-glucose-induced B-protein
MCP-1 I-RNA
mRNA I-RNA
expression O
in O
a O
dose-dependent O
manner O
, O
and O
also O
suppressed O
the O
high-glucose-induced B-protein
AP-1 B-protein
binding O
activity O
. O
CONCLUSIONS I-protein
: O
: O
High O
glucose O
induced O
mesothelial O
MCP-1 O
expression O
partly O
via O
the O
tyrosine I-protein
kinase- B-DNA
AP-1 B-protein
pathway O
. O
Signal O
thresholds O
and O
modular O
synergy O
during O
expression O
of O
costimulatory O
molecules I-protein
in O
B I-DNA
lymphocytes I-cell_type
. O
We O
analyzed O
intracellular O
pathways O
modulating O
surface I-protein
densities O
of O
CD80 B-protein
and O
CD86 B-protein
in O
B I-DNA
cells I-cell_type
activated O
through O
ligation O
of O
the O
Ag B-DNA
receptor I-protein
, O
and O
the O
adhesion O
molecule O
CD54 B-protein
. O
Whereas O
B O
cell O
Ag B-DNA
receptor I-protein
( O
BCR I-DNA
) O
cross-linking O
alone O
stimulated O
increased O
expression O
of O
CD86 I-protein
, O
up-regulation I-DNA
of O
CD80 B-protein
required O
dual O
stimulation O
with O
anti-IgM O
and O
anti-CD54 B-protein
. O
The O
principal O
downstream O
component O
contributed O
by O
BCR O
signaling O
, O
toward O
both O
CD80 B-protein
and O
CD86 B-protein
induction O
, O
was O
the O
elevated O
concentration O
of O
free O
cytoplasmic O
Ca O
( O
2+ O
) O
, O
recruited O
by O
way O
of O
capacitative O
influx O
. O
This O
alone O
was O
sufficient O
to O
generate O
an O
increase O
in O
CD86 B-protein
levels O
. O
However O
, O
CD80 B-protein
enhancement O
required O
the O
concerted O
action O
of O
both O
intracellular O
Ca O
( O
2+ O
) O
concentration O
and O
CD54-initiated B-protein
pathways O
. O
The O
nexus O
between O
anti-IgM O
and O
anti-CD54 B-protein
stimulation O
, O
in O
the O
context O
of O
CD80 B-protein
regulation O
, O
was O
identified O
to O
involve O
a O
self-propagating O
process O
of O
sequential O
synergy O
. O
The O
first O
step O
involved O
amplified O
accumulation O
of O
intracellular O
cAMP I-protein
, O
as O
a O
result O
of O
cross-talk B-DNA
between O
BCR O
-mobilized O
Ca O
( O
2+ O
) O
and O
CD54-derived B-protein
signals O
. O
This O
then O
facilitated O
a O
second O
synergistic O
interaction O
between O
Ca O
( O
2+ O
) O
and O
cAMP I-DNA
, O
culminating O
in O
CD80 B-protein
expression O
. O
Our O
findings O
of O
distinct O
signal O
transducer O
requirements O
, O
with O
the O
added O
consequences O
of O
cross-talk O
, O
offers O
an O
explanation O
for O
variable O
modulation O
of O
costimulatory O
molecule O
expression O
in O
response O
to O
diverse O
physiological O
stimuli O
. O
Importantly O
, O
these O
results O
also O
reveal O
how O
concentration O
threshold O
barriers O
for O
recruitment O
of O
individual O
second O
messengers O
can O
be O
overcome O
by O
constructive O
convergence O
of O
signaling O
modules O
. O
The O
role O
of O
Epstein-Barr O
virus O
in O
neoplastic O
transformation O
. O
In O
this O
review O
, O
we O
focus O
on O
new O
data O
from O
basic O
, O
translational O
and O
clinical O
research O
relating O
to O
the O
Epstein-Barr O
virus O
( O
EBV I-DNA
) O
. O
Beside O
its O
well-known B-DNA
tropism O
for O
B I-DNA
lymphocytes I-cell_type
and O
epithelial B-cell_type
cells I-cell_line
, O
EBV O
also O
infects O
T I-cell_type
lymphocytes I-cell_type
, O
monocytes B-cell_type
and O
granulocytes O
. O
After O
primary B-cell_line
infection I-cell_line
, O
EBV O
persists O
throughout O
the O
life O
span O
in O
resting O
memory O
B I-DNA
cells I-cell_line
, O
from O
where O
it O
is O
reactivated O
upon O
breakdown O
of O
cellular O
immunity O
. O
In O
the O
process O
of O
neoplastic O
transformation O
, O
the O
EBV-encoded B-protein
latent O
membrane O
protein O
1 O
( O
LMP1 B-protein
) O
oncogene O
represents O
the O
major O
driving O
force O
. O
LMP1 B-protein
acts O
like O
a O
constitutively O
activated I-DNA
receptor I-DNA
of O
the O
tumor O
necrosis B-protein
factor I-protein
receptor I-protein
family O
and O
allows O
the O
amplification O
or O
bypassing O
of O
physiological O
regulatory O
signals O
through O
direct O
and O
indirect O
interactions O
with O
proteins I-protein
of O
the O
tumor O
necrosis B-protein
factor I-protein
receptor-associated B-protein
factor I-protein
( O
TRAF I-DNA
) O
family O
. O
TRAF2 B-protein
-mediated O
NF-kappaB O
activation O
, O
AP-1 B-protein
induction O
and O
JAK3 B-protein
/ O
STAT B-protein
activation O
may O
result O
in O
sustained O
proliferation O
leading O
to O
lymphoma O
. O
The O
ability O
of O
LMP1 O
to O
suppress O
germinal O
center O
formation O
and O
its O
capacity O
to O
mediate O
its O
own O
transcriptional O
activation O
shed O
new O
light O
on O
the O
pathogenesis O
of O
EBV-associated B-protein
latency I-DNA
type O
II I-protein
lymphoproliferations I-protein
like O
Hodgkin O
's O
disease O
and O
angioimmunoblastic O
lymphadenopathy O
. O
The O
carboxy O
terminus O
of O
LMP1 B-protein
is O
also O
a O
reliable O
marker O
for O
individual O
EBV O
strain O
identification O
and O
thus O
offers O
new O
possibilities O
in O
tracing O
the O
molecular O
events O
leading O
to O
posttransplant O
lymphoproliferative O
disorders O
( O
PTLDs O
) O
. O
Cytotoxic B-cell_type
T I-cell_type
lymphocytes I-cell_type
directed O
against O
well-characterized O
epitopes I-protein
of O
EBV B-cell_type
latency I-DNA
genes I-DNA
represent O
an O
already O
successful O
and O
promising O
therapeutic O
approach O
to O
EBV-associated B-protein
lymphomas O
, O
in O
particular O
PTLDs O
Interferon-alpha O
drives O
T I-cell_line
cell-mediated O
immunopathology O
in O
the O
intestine O
. O
The O
ability O
of O
interferon O
( O
IFN I-DNA
) O
-alpha O
to O
induce O
autoimmunity O
and O
exacerbate O
Th1 O
diseases O
is O
well O
known O
. O
We O
have O
recently O
described O
enhanced O
expression O
of O
IFN-alpha B-protein
in O
the O
mucosa O
of O
patients O
with O
celiac O
disease O
( O
CD I-DNA
) O
, O
a O
gluten-sensitive O
Th1-mediated B-protein
enteropathy O
, O
characterized O
by O
villous O
atrophy O
and O
crypt O
cell O
hyperplasia O
. O
Previous O
studies O
from O
this O
laboratory O
have O
shown O
that O
T O
cell O
activation O
in O
explant O
cultures I-cell_line
of O
human B-cell_type
fetal I-cell_type
gut O
can O
also O
result O
in O
villous O
atrophy O
and O
crypt O
cell O
hyperplasia O
. O
We O
have O
, O
therefore O
, O
examined O
changes O
that O
take O
place O
in O
explant O
cultures I-cell_line
of O
human B-cell_type
fetal I-cell_type
gut O
after O
activation O
of O
T B-cell_type
cells I-cell_type
with O
anti-CD3 B-protein
and/or I-cell_line
IFN-alpha B-protein
. O
We O
show O
that O
activation O
of O
T B-cell_type
cells I-cell_type
with O
anti-CD3 B-protein
alone O
elicits O
a O
small O
IFN-gamma B-DNA
and O
TNF-alpha B-protein
response O
with O
no O
tissue O
injury O
. O
Similarly O
, O
no O
changes O
are O
seen O
in O
explants O
cultured O
with O
IFN-alpha B-protein
alone O
. O
However O
, O
addition O
of O
IFN-alpha B-protein
with O
anti-CD3 B-protein
results O
in O
enhanced O
Th1 O
response O
and O
crypt O
cell O
hyperplasia O
. O
This O
is O
associated O
with O
enhanced O
phosphorylation O
of O
STAT1 I-protein
, O
STAT3 I-protein
, O
and O
Fyn O
, O
a O
Src O
homology B-protein
tyrosine I-protein
kinase I-protein
, O
which O
interacts O
with O
both O
TCR O
and O
IFN-alpha O
signal O
components O
. O
Together O
these O
data O
indicate O
that O
IFN-alpha B-protein
can O
facilitate O
activation O
of O
Th1-reactive B-cell_type
cells I-cell_type
in O
the O
gut O
and O
drive O
immunopathology O
. O
Suppression O
of O
tumor O
necrosis B-protein
factor I-protein
alpha I-DNA
production I-DNA
by O
cAMP I-RNA
in O
human O
monocytes B-cell_type
: O
dissociation O
with O
mRNA I-RNA
level O
and O
independent O
of O
interleukin-10 B-protein
. O
BACKGROUND I-protein
: O
Elevation O
of O
cellular O
cAMP I-RNA
inhibits O
lipopolysaccharide I-protein
( O
LPS I-DNA
) O
-stimulated O
tumor O
necrosis B-protein
factor I-protein
alpha I-DNA
( O
TNF-alpha I-DNA
) O
production O
and O
increases O
the O
expression O
of O
interleukin O
( O
IL I-DNA
) O
-10 O
in O
mononuclear B-cell_type
cells I-cell_type
. O
TNF-alpha B-DNA
gene I-DNA
expression O
obligates O
activation O
of O
the O
transcription B-protein
factor I-protein
nuclear B-protein
factor I-protein
kappaB B-protein
( O
NF-kappaB I-DNA
) O
. O
Exogenous O
IL-10 B-protein
inhibits O
NF-kappaB O
in O
monocytes B-cell_type
and O
thus O
attenuates O
TNF-alpha B-protein
production O
. O
We O
examined O
the O
role O
of O
endogenous O
IL-10 B-protein
in O
the O
regulation O
of O
NF-kappaB O
activation O
and O
TNF-alpha B-protein
production O
in O
human O
monocytes B-cell_type
by O
cAMP I-RNA
. O
METHODS I-protein
: O
Human O
monocytes B-cell_type
were O
stimulated O
with O
Escherichia O
coli O
LPS I-protein
( O
100 O
ng/ml I-DNA
) O
with O
and O
without O
forskolin O
( O
FSK I-DNA
, O
50 O
microM B-protein
) O
or O
dibutyryl O
cyclic O
AMP I-protein
( O
dbcAMP I-DNA
, O
100 O
microM B-protein
) O
. O
Cytokine O
( O
TNF-alpha I-DNA
and O
IL-10 B-protein
) O
release O
was O
measured O
by O
immunoassay O
. O
TNF-alpha I-RNA
mRNA I-RNA
was O
measured O
by O
reverse O
transcription O
polymerase O
chain O
reaction O
, O
and O
NF-kappaB O
DNA O
binding O
activity O
was O
assessed O
by O
gel O
mobility O
shift O
assay O
. O
RESULTS I-protein
: O
cAMP-elevating B-protein
agents O
inhibited O
LPS-stimulated B-protein
TNF-alpha B-protein
release O
( O
0.77 I-DNA
+/- O
0.13 B-protein
ng/10 B-protein
( O
6 O
) O
cells I-cell_type
in O
LPS O
+ O
dbcAMP I-cell_type
and O
0.68 B-protein
+/- O
0.19 B-protein
ng/10 B-protein
( O
6 O
) O
cells I-cell_type
in O
LPS O
+ O
FSK I-protein
, O
both O
P O
< O
0.05 B-protein
vs O
1.61 B-protein
+/- O
0.34 B-protein
ng/10 B-protein
( O
6 O
) O
cells I-cell_type
in O
LPS O
alone O
) O
. O
Conversely O
, O
cAMP I-RNA
enhanced O
LPS-stimulated B-protein
IL-10 B-protein
release O
( O
100 O
+/- O
21.5 B-protein
pg/10 B-protein
( O
6 O
) O
cells I-cell_type
in O
LPS O
+ O
dbcAMP I-cell_type
and O
110 O
+/- O
25.2 B-protein
pg/10 B-protein
( O
6 O
) O
cells I-cell_type
in O
LPS O
+ O
FSK I-protein
, O
both O
P O
< O
0.05 B-protein
vs O
53.3 B-protein
+/- O
12.8 B-protein
pg/10 B-protein
( O
6 O
) O
cells I-cell_type
in O
LPS O
alone O
) O
. O
Neither O
TNF-alpha I-RNA
mRNA I-RNA
expression O
nor O
NF-kappaB O
activation O
stimulated O
by O
LPS O
was O
inhibited O
by O
the O
cAMP-elevating B-protein
agents O
. O
Neutralization O
of O
IL-10 B-protein
with O
a O
specific O
antibody O
did O
not O
attenuate O
the O
effect O
of O
cAMP-elevating B-protein
agents O
on O
TNF-alpha B-protein
production O
. O
CONCLUSION I-protein
: O
The O
results O
indicate O
that O
cAMP I-RNA
inhibits O
LPS-stimulated B-protein
TNF-alpha B-protein
production O
through O
a O
posttranscriptional O
mechanism O
that O
is O
independent O
of O
endogenous O
IL-10 B-protein
. O
Copyright O
2001 O
Academic O
Press O
. O
Activation O
of O
the O
p21 I-cell_line
( O
CIP1/WAF1 I-DNA
) O
promoter I-DNA
by O
bone I-cell_line
morphogenetic O
protein-2 B-protein
in O
mouse B-DNA
B O
lineage I-cell_type
cells I-cell_type
. O
BMPs O
exert O
a O
negative O
growth O
effect O
on O
various O
types I-cell_type
of O
cells I-cell_type
. O
We O
have O
previously O
reported O
that O
BMP-2 O
inhibited O
the O
growth O
of O
HS-72 B-protein
mouse B-DNA
hybridoma B-cell_type
cells I-cell_type
by O
inducing O
p21 I-cell_line
( O
CIP1/WAF1 I-DNA
) O
expression O
. O
In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP-2 O
activated O
the O
mouse B-DNA
p21 I-cell_line
( O
CIP1/WAF1 I-DNA
) O
promoter I-DNA
in O
HS-72 B-protein
cells I-cell_line
, O
and O
that O
a O
29-base O
pair O
( O
b O
) O
region I-DNA
of O
the O
promoter I-DNA
( O
-1928/-1900 O
relative O
to O
the O
TATA O
box O
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP-2 O
as O
well O
as O
expression O
of O
Smad1 B-cell_type
, O
Smad4 O
, O
and O
constitutively O
active O
mutants O
of O
BMP B-cell_type
type O
I I-protein
receptors O
. O
Furthermore O
, O
an O
oligonucleotide O
containing O
the O
29-b B-DNA
region O
was O
found O
to O
be O
associated O
with O
Smad4 I-cell_type
and O
phosphorylated O
Smad1 O
in O
the O
nuclear B-protein
extract O
of O
BMP-2 O
-stimulated O
HS-72 B-protein
cells I-cell_type
. O
These O
results O
suggested O
that O
BMP-2 O
might O
activate O
p21 I-cell_line
( O
CIP1/WAF1 I-DNA
) O
transcription O
by O
inducing O
a O
binding O
of O
Smad4 O
and O
Smad1 O
to O
the O
29-b B-DNA
region O
in O
HS-72 B-protein
cells I-cell_type
. O
Dendritic O
cell O
development O
from O
common O
myeloid O
progenitors O
. O
Dendritic B-cell_type
cells I-cell_line
( O
DCs O
) O
are O
professional O
antigen-presenting B-cell_type
cells I-cell_type
which O
both O
initiate O
adaptive O
immune O
responses O
and O
control O
tolerance O
to O
self-antigens O
. O
It O
has O
been O
suggested O
that O
these O
different O
effects O
on O
responder B-cell_type
cells I-cell_type
depend O
on O
subsets O
of O
DCs O
arising O
from O
either O
myeloid O
or O
lymphoid O
hematopoietic B-cell_type
origins O
. O
In O
this O
model O
, O
CD8 B-protein
alpha+ B-DNA
Mac-1- B-protein
DCs O
are O
supposed O
to O
be O
of O
lymphoid O
while O
CD8 B-protein
alpha- B-DNA
Mac-1+ B-protein
DCs O
are O
supposed O
to O
be O
of O
myeloid O
origin O
. O
Here O
we O
summarize O
our O
findings O
that O
both O
CD8 B-protein
alpha+ B-DNA
and O
CD8 B-protein
alpha- B-DNA
DCs O
can O
arise O
from O
clonogenic O
common O
myeloid O
progenitors O
( O
CMPs O
) O
in O
both O
thymus O
and O
spleen O
. O
Therefore O
CD8 B-protein
alpha I-DNA
expression O
DCs O
does O
not O
indicate O
a O
lymphoid O
origin O
and O
differences O
among O
CD8 B-protein
alpha+ B-DNA
and O
CD8 B-protein
alpha- B-DNA
DCs O
might O
rather O
reflect O
maturation O
status O
than O
ontogeny O
. O
On O
the O
basis O
of O
transplantation O
studies O
, O
it O
seems O
likely O
that O
most O
of O
the O
DCs O
in O
secondary O
lymphoid O
organs O
and O
a O
substantial O
fraction O
of O
thymic B-cell_line
DCs O
are O
myeloid-derived O
. O
Macrophage O
stimulation O
with O
Murabutide O
, O
an O
HIV-suppressive B-protein
muramyl O
peptide O
derivative O
, O
selectively O
activates O
extracellular O
signal-regulated O
kinases I-protein
1 O
and O
2 O
, O
C/EBPbeta O
and O
STAT1 B-protein
: O
role O
of O
CD14 B-protein
and O
Toll-like O
receptors O
2 O
and I-DNA
4 O
. O
The O
smallest O
unit O
of O
bacterial O
peptidoglycans O
known O
to O
be O
endowed O
with O
biological O
activities O
is O
muramyl O
dipeptide O
( O
MDP I-DNA
) O
. O
A O
clinically O
acceptable O
synthetic O
derivative O
of O
MDP I-protein
, O
namely O
murabutide O
( O
MB I-DNA
) O
, O
has O
been O
found O
to O
present O
interesting O
pharmacological O
properties O
and O
to O
suppress O
HIV-1 O
replication O
in O
monocyte-derived I-cell_line
macrophages O
( O
MDM I-DNA
) O
. O
We O
have O
addressed O
the O
signaling O
events O
activated O
in O
MDM O
following O
stimulation O
with O
either O
MB B-protein
or O
the O
potent O
immunostimulant O
LPS O
. O
We O
also O
examined O
whether O
signaling O
by O
muramyl O
peptides O
involves O
the O
use O
of O
cell O
surface I-protein
receptors I-protein
, O
including O
CD14 B-protein
and O
Toll-like I-DNA
receptor I-protein
2 O
( O
TLR2 B-protein
) O
or O
TLR4 B-protein
that O
are O
known O
to O
be O
signal-transducing O
receptors O
for O
other O
bacterial O
cell O
wall O
components O
. O
We O
demonstrate O
that O
, O
unlike O
LPS I-protein
, O
the O
safe O
immunomodulator O
MB B-protein
selectively O
activates O
extracellular O
signal-regulated O
kinases I-protein
( O
Erk O
) O
1/2 O
, O
in O
the O
absence O
of O
detectable O
Jun O
N-terminal B-protein
kinase I-protein
( O
JNK I-DNA
) O
or O
p38 O
mitogen-activated B-protein
kinase I-protein
activation O
. O
Furthermore O
, O
STAT1 B-protein
activation O
but O
weak O
or O
no O
activation O
of O
STAT3 B-protein
or O
STAT5 B-protein
respectively O
, O
could O
be O
detected O
in O
MB-stimulated B-protein
MDM O
. O
Using O
MonoMac6 B-cell_type
cells I-cell_line
, O
we O
observed O
high O
C/EBPbeta O
and O
AP-1 B-protein
but O
weaker O
and O
transient O
NF-kappaB O
activation O
by O
MB B-protein
. O
Moreover O
, O
the O
truncated O
form O
of O
C/EBPbeta B-cell_type
, O
known O
to O
repress O
HIV-1 B-protein
transcription I-DNA
, O
was O
detected O
in O
extracts O
from O
MB-treated B-protein
THP-1 B-DNA
cells I-cell_type
. O
Surprisingly I-protein
, O
neither O
MB B-protein
nor O
MDP O
were O
able O
to O
transduce O
signals O
via O
CD14 B-protein
and O
TLR2 B-protein
or O
4 O
. O
These O
findings O
present O
major O
differences O
in O
the O
early O
cell O
activation O
process O
between O
LPS O
and O
muramyl O
peptides O
, O
and O
strongly O
argue O
for O
the O
implication O
of O
co-receptors B-cell_type
other O
than O
TLR2 B-protein
and O
TLR4 B-protein
in O
mediating O
the O
signaling O
events O
induced O
by O
defined O
subunits O
of O
bacterial O
peptidoglycans O
. O
Nuclear O
peroxisome O
proliferator-activated B-DNA
receptors O
alpha I-DNA
and I-DNA
gamma O
have O
opposing O
effects O
on O
monocyte O
chemotaxis O
in O
endometriosis O
. O
The O
peroxisome O
proliferator-activated B-DNA
receptors O
( O
PPARs O
) O
alpha I-DNA
and I-DNA
gamma O
are O
nuclear B-protein
receptors O
that O
play O
important O
roles O
in O
inflammatory O
diseases O
like O
ulcerative O
colitis O
and O
arthritis O
. O
In O
this O
study O
, O
we O
examined O
the O
possible O
role O
of O
PPARs O
in O
macrophage O
attraction O
into O
the O
peritoneal O
cavity O
of O
patients O
with O
endometriosis O
. O
We O
identified O
PPAR-alpha B-DNA
and O
-gamma O
messenger O
RNA O
by O
RT-PCR B-protein
and O
protein O
by O
immunoblotting O
of O
lysates O
of O
peritoneal O
macrophages O
and O
monocytic B-cell_line
U937 B-protein
cells I-cell_type
. O
Using O
immunocytochemistry I-protein
, O
we O
localized O
PPAR-alpha B-DNA
and O
-gamma O
within O
the O
nuclei O
of O
both O
cell O
types I-cell_type
. O
Monocyte O
chemotactic O
activity O
of O
peritoneal O
fluid O
from O
patients O
with O
endometriosis O
was O
quantified O
in O
Boyden O
chambers O
. O
Migration O
of O
U937 B-cell_type
cells I-cell_type
was O
increased O
by O
WY B-protein
14643 O
and O
reduced O
by O
rosiglitazone O
. O
Peritoneal O
fluid O
from O
patients O
with O
endometriosis O
activated O
U937 B-protein
cells I-cell_type
transiently O
transfected O
with O
a O
PPAR-alpha/GAL4 B-protein
luciferase O
reporter O
. O
By O
contrast O
, O
peritoneal O
fluid O
did O
not O
cause O
significant O
activation O
of O
PPAR-gamma/GAL4 B-protein
constructs O
. O
The O
U937 B-protein
cells I-cell_type
transiently O
transfected O
with O
a O
PPAR O
response O
element I-DNA
luciferase O
reporter O
showed O
disease O
stage-dependent O
up-regulation B-protein
when O
treated O
with O
peritoneal O
fluid O
from O
patients O
with O
endometriosis O
. O
Treatment O
with O
peritoneal O
fluid O
from O
healthy O
controls O
down-regulated O
PPAR O
response O
element I-DNA
transactivation O
. O
We O
conclude O
that O
peritoneal O
fluid O
of O
endometriosis O
patients O
contains O
activators O
of O
PPAR-alpha B-protein
that O
stimulate O
macrophage O
chemotaxis O
. O
Inhibitors O
of O
PPAR-alpha B-protein
or O
activators O
of O
PPAR-gamma B-protein
could O
be O
developed O
for O
the O
treatment O
of O
inflammation O
associated O
with O
endometriosis O
. O
Long-term-impaired O
expression O
of O
nuclear B-protein
factor-kappa B-DNA
B I-DNA
and O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
in O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
of O
trauma O
patients O
. O
Nuclear I-protein
factor I-protein
( O
NF I-DNA
) O
-kappa O
B I-DNA
expression O
and O
dimer O
characteristics O
were O
studied O
in O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_line
( O
PBMCs O
) O
of O
major-trauma B-cell_type
patients O
and O
healthy O
controls O
. O
Analysis O
of O
PBMCs O
on O
days O
1 O
, O
3 O
, O
5 O
, O
and O
10 O
after O
trauma O
revealed O
that O
expression O
of O
both O
p65p50 B-protein
heterodimers O
and O
p50p50 B-protein
homodimers O
was O
significantly O
reduced O
compared O
with O
that O
in O
controls O
. O
In O
vitro O
lipopolysaccharide I-protein
( O
LPS I-DNA
) O
stimulation O
of O
PBMCs O
induced O
NF-kappa B-protein
B I-protein
translocation O
. O
However O
, O
throughout O
the O
survey I-protein
, O
p65p50 O
activation O
remained O
significantly O
lower O
in O
trauma O
patients O
than O
in O
controls O
. O
After O
LPS O
stimulation O
in O
vitro O
, O
the O
p65p50/p50p50 B-protein
ratio O
was O
significantly O
lower O
in O
PBMCs O
from O
trauma O
patients O
than O
from O
healthy O
controls O
. O
The O
ex O
vivo O
expression O
of O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
was O
higher O
in O
PBMCs O
of O
controls O
than O
of O
trauma O
patients O
. O
LPS O
did O
not O
induce O
I I-protein
kappa B-DNA
B I-DNA
expression O
in O
PBMCs O
from O
trauma O
patients O
, O
but O
strong O
induction O
was O
obtained O
with O
staphylococci O
, O
suggesting O
that O
this O
defect O
is O
not O
universal O
and O
depends O
on O
the O
nature O
of O
the O
activating O
signal O
. O
Although O
no O
direct O
correlation O
was O
found O
between O
levels O
of O
interleukin-10 B-protein
or O
transforming O
growth O
factor-beta B-DNA
and O
NF-kappa B-protein
B I-protein
, O
these O
immunosuppressive O
cytokines O
were O
significantly O
elevated O
in O
trauma O
patients O
by O
10 O
days O
after O
admission O
. O
The O
long-term B-DNA
low-basal B-DNA
and O
LPS-induced O
nuclear B-protein
translocation O
of O
NF-kappa B-protein
B I-protein
recalled O
long-term B-DNA
immunoparalysis O
observed O
in O
patients O
with O
severe O
inflammatory O
stress O
such O
as O
trauma O
. O
Hepatic O
ischemia-reperfusion B-DNA
injury O
. O
BACKGROUND I-protein
: O
The O
morbidity O
associated O
with O
liver O
transplantation O
and O
major O
hepatic O
resections O
is O
partly O
a O
result O
of O
ischemia-reperfusion B-DNA
injury O
. O
DATA O
SOURCES I-protein
: O
The O
entire O
world O
literature O
on O
the O
subject O
was O
searched O
via O
Medline O
. O
Keywords O
included O
reperfusion O
injury I-protein
, O
transplantation O
, O
liver O
resection O
, O
nitric O
oxide O
, O
endothelin O
, O
cytokines O
, O
Kupffer B-cell_type
cells I-cell_line
, O
ischemic/ischaemic O
preconditioning O
, O
and O
nuclear B-protein
factor-kappa B-DNA
B I-DNA
. O
CONCLUSIONS I-protein
: O
An O
imbalance O
between O
endothelin O
and O
nitric O
oxide O
levels O
results O
in O
failure O
of O
the O
hepatic O
microcirculation O
at O
the O
onset O
of O
reperfusion O
. O
Activation O
of O
nuclear B-protein
factor-kappa B-DNA
B I-DNA
in O
the O
liver O
promotes O
proinflammatory O
cytokine O
and O
adhesion O
molecule O
synthesis O
. O
These O
result O
in O
oxygen-derived I-cell_type
free O
radical O
production O
and O
neutrophil O
recruitment O
, O
further O
contributing O
to O
cellular O
injury O
. O
Various O
therapeutic O
modalities O
acting O
on O
the O
above O
mediators O
have O
been O
successfully O
used O
to O
attenuate O
reperfusion O
injury O
in O
animal O
models O
of O
hepatic O
transplantation O
and O
resection O
. O
Application O
of O
the O
knowledge O
gained O
from O
animal O
models O
of O
hepatic O
ischemia-reperfusion O
to O
the O
clinical O
setting O
will O
improve O
the O
outcome O
of O
hepatic O
surgery O
. O
Down-regulation O
of O
IL-12 B-protein
p40 B-DNA
gene I-DNA
in O
Plasmodium O
berghei-infected O
mice O
. O
We O
analyzed O
the O
mechanism O
that O
causes O
suppression O
of O
IL-12 B-protein
p40 B-DNA
gene I-DNA
induction O
during O
Plasmodium O
berghei O
infection O
. O
Although O
IL-12 B-protein
together O
with O
IFN-gamma B-protein
plays O
an O
important O
role O
in O
protection O
against O
pathogenic O
infection O
, O
the O
IL-12 B-protein
p70 I-protein
protein O
production O
of O
infected O
macrophages O
is O
lower O
than O
that O
by O
the O
uninfected O
macrophages O
. O
We O
showed O
in O
the O
present O
study O
that O
the O
induction O
of O
IL-12 B-protein
p40 B-DNA
gene I-DNA
but O
not O
IL-12 B-protein
p35 B-DNA
gene I-DNA
in O
macrophages O
of O
P. B-RNA
berghei-infected O
mice O
was O
profoundly O
inhibited O
. O
The O
inhibition O
was O
induced O
by O
interaction O
with O
macrophages O
that O
had O
contacted O
with O
P. B-protein
berghei-infected O
erythrocytes B-cell_type
and O
was O
mediated O
by O
a O
soluble I-protein
factor I-protein
, O
IL-10 B-protein
. O
There O
was O
comparable O
activation O
of O
NF-kappaB O
in O
uninfected O
and O
infected I-cell_type
cells I-cell_type
. O
The O
induction O
of O
IFN-regulatory B-protein
factor-1 B-DNA
gene I-DNA
was O
comparable O
in O
transcription O
level O
in O
uninfected O
and O
infected I-cell_type
cells I-cell_line
, O
while O
the O
unidentified O
complex I-protein
formation O
of O
IFN-regulatory B-protein
factor-1 B-protein
was O
observed O
in O
infected I-cell_type
cells I-cell_type
. O
Therefore O
, O
the O
inhibition O
of O
the O
IL-12 B-protein
p40 B-DNA
gene I-DNA
induction O
appeared O
to O
be O
regulated O
at O
transcriptional O
regulation O
level O
of O
the O
gene I-DNA
. O
The O
Friend O
of O
GATA B-protein
proteins I-protein
U-shaped O
, O
FOG-1 O
, O
and O
FOG-2 O
function O
as O
negative O
regulators O
of O
blood O
, O
heart O
, O
and O
eye O
development O
in O
Drosophila O
. O
Friend O
of O
GATA I-protein
( O
FOG I-DNA
) O
proteins I-protein
regulate O
GATA O
factor-activated B-DNA
gene I-DNA
transcription O
. I-RNA
During O
vertebrate O
hematopoiesis O
, O
FOG O
and O
GATA B-protein
proteins I-protein
cooperate O
to O
promote O
erythrocyte O
and O
megakaryocyte O
differentiation O
. O
The O
Drosophila O
FOG O
homologue O
U-shaped B-protein
( O
Ush O
) O
is O
expressed O
similarly O
in O
the O
blood O
cell I-cell_type
anlage O
during O
embryogenesis O
. O
During O
hematopoiesis O
, O
the O
acute O
myeloid O
leukemia O
1 O
homologue O
Lozenge O
and O
Glial B-cell_type
cells I-cell_type
missing O
are O
required O
for O
the O
production O
of O
crystal B-cell_type
cells I-cell_type
and O
plasmatocytes O
, O
respectively O
. O
However O
, O
additional O
factors I-protein
have O
been O
predicted O
to O
control O
crystal O
cell O
proliferation O
. O
In O
this O
report I-protein
, O
we O
show O
that O
Ush O
is O
expressed O
in O
hemocyte O
precursors I-cell_line
and O
plasmatocytes O
throughout O
embryogenesis O
and O
larval O
development O
, O
and O
the O
GATA I-protein
factor I-protein
Serpent O
is O
essential O
for O
Ush O
embryonic B-cell_type
expression O
. O
Furthermore O
, O
loss O
of O
ush O
function O
results O
in O
an O
overproduction O
of O
crystal B-cell_type
cells I-cell_line
, O
whereas O
forced O
expression O
of O
Ush O
reduces O
this O
cell O
population O
. O
Murine O
FOG-1 O
and O
FOG-2 O
also O
can O
repress O
crystal O
cell O
production O
, O
but O
a O
mutant O
version O
of O
FOG-2 O
lacking O
a O
conserved O
motif O
that O
binds O
the O
corepressor O
C-terminal B-protein
binding O
protein O
fails O
to O
affect O
the O
cell O
lineage I-cell_type
. O
The O
GATA I-protein
factor I-protein
Pannier O
( O
Pnr O
) O
is O
required O
for O
eye O
and O
heart O
development O
in O
Drosophila O
. O
When O
Ush O
, O
FOG-1 O
, O
FOG-2 O
, O
or O
mutant O
FOG-2 O
is O
coexpressed O
with O
Pnr O
during O
these O
developmental O
processes O
, O
severe O
eye O
and O
heart O
phenotypes O
result I-protein
, O
consistent O
with O
a O
conserved O
negative O
regulation O
of O
Pnr O
function O
. O
These O
results O
indicate O
that O
the O
fly O
and O
mouse O
FOG O
proteins I-protein
function O
similarly O
in O
three O
distinct O
cellular O
contexts O
in O
Drosophila O
, O
but O
may O
use O
different O
mechanisms O
to O
regulate O
genetic O
events O
in O
blood I-cell_type
vs O
. O
cardial O
or O
eye O
cell O
lineages O
The O
RING O
finger O
protein O
Siah-1 B-protein
regulates O
the O
level O
of O
the O
transcriptional O
coactivator O
OBF-1 O
. O
The O
transcriptional O
coactivator O
OBF-1 O
, O
which O
interacts O
with O
Oct-1 B-protein
and O
Oct-2 B-protein
and O
the O
octamer O
site O
DNA O
, O
has O
been O
shown O
to O
be O
critical O
for O
development O
of O
a O
normal O
immune O
response O
and O
the O
formation O
of O
germinal O
centers O
in O
secondary O
lymphoid O
organs O
. O
Here O
we O
have O
identified O
the O
RING O
finger O
protein O
Siah-1 B-protein
as O
a O
protein O
interacting O
specifically O
with O
OBF-1 O
. O
This O
interaction O
is O
mediated O
by O
the O
C-terminal B-protein
part O
of O
Siah-1 B-protein
and O
by O
residues O
in O
the O
N-terminus B-protein
of O
OBF-1 O
, O
partly O
distinct O
from O
the O
residues O
required O
for O
formation O
of O
a O
complex I-protein
with O
the O
Oct O
POU O
domains O
and O
the O
DNA O
. O
Interaction O
between O
Siah-1 B-protein
and O
OBF-1 O
leads O
to O
downregulation O
of O
OBF-1 O
protein O
level O
but O
not O
mRNA I-RNA
, O
and O
to O
a O
corresponding O
reduction O
in O
octamer O
site-dependent B-protein
transcription O
activation O
. O
Inhibition O
of O
the O
ubiquitin-proteasome B-DNA
pathway O
in O
B I-DNA
cells I-cell_type
leads O
to O
elevated O
levels O
of O
OBF-1 O
protein O
. O
Furthermore O
, O
in O
immunized O
mice O
, O
OBF-1 O
protein O
amounts O
are O
dramatically O
increased O
in O
primary B-cell_line
activated I-cell_line
B I-DNA
cells I-cell_line
, O
without O
concomitant O
increase O
in O
OBF-1 I-RNA
mRNA I-RNA
. O
These O
data O
suggest O
that O
Siah-1 B-protein
is O
part O
of O
a O
novel O
regulatory O
loop O
controlling O
the O
level O
of O
OBF-1 O
protein O
in O
B I-DNA
cells I-cell_type
. O
The O
beta-catenin B-DNA
-- O
TCF-1 O
pathway O
ensures O
CD4 B-protein
( O
+ O
) O
CD8 B-protein
( O
+ O
) O
thymocyte O
survival O
. O
The O
association O
of O
trans-acting B-cell_type
T O
cell O
factors I-protein
( O
TCFs O
) O
or O
lymphoid B-DNA
enhancer I-DNA
factor I-protein
1 O
( O
LEF-1 O
) O
with O
their O
coactivator O
beta-catenin B-DNA
mediates O
transient O
transcriptional O
responses O
to O
extracellular O
Wnt O
signals O
. O
We O
show O
here O
that O
T O
cell O
maturation O
depends O
on O
the O
presence O
of O
the O
beta-catenin B-DNA
-- O
binding I-protein
domain I-protein
in O
TCF-1 O
. O
This I-protein
domain I-protein
is O
necessary O
to O
mediate O
the O
survival O
of O
immature O
CD4 B-protein
( O
+ O
) O
CD8 B-protein
( O
+ O
) O
double-positive O
( O
DP I-DNA
) O
thymocytes O
. O
Accelerated O
spontaneous O
thymocyte O
death O
in O
the O
absence O
of O
TCF-1 O
correlates O
with O
aberrantly O
low O
expression O
of O
the O
anti-apoptotic O
protein O
Bcl-x O
( O
L I-DNA
) O
. O
Increasing O
anti-apoptotic O
effectors O
in O
thymocytes O
by O
the O
use O
of O
a O
Bcl-2 B-protein
transgene O
rescued O
TCF-1-deficient B-protein
DP B-protein
thymocytes O
from O
apoptosis O
. O
Thus O
, O
TCF-1 O
, O
upon O
association O
with O
beta-catenin I-DNA
, O
transiently O
ensures O
the O
survival O
of O
immature B-cell_type
T B-cell_type
cells I-cell_type
, O
which O
enables O
them O
to O
generate O
and O
edit O
T O
cell I-DNA
receptor I-protein
( O
TCR I-DNA
) O
alpha O
chains I-protein
and O
attempt O
TCR O
-mediated O
positive O
selection O
. O
TRAIL/Apo2L O
ligand O
selectively O
induces O
apoptosis O
and O
overcomes O
drug O
resistance O
in O
multiple O
myeloma O
: O
therapeutic O
applications O
. O
Multiple O
myeloma O
( O
MM I-DNA
) O
remains O
incurable O
and O
novel O
treatments O
are O
urgently O
needed O
. O
Preclinical O
in O
vitro O
and O
in O
vivo O
evaluations O
were O
performed O
to O
assess O
the O
potential O
therapeutic O
applications O
of O
human B-cell_type
recombinant I-cell_type
tumor O
necrosis B-protein
factor I-protein
( O
TNF I-DNA
) O
-related O
apoptosis-inducing O
ligand/Apo2 O
ligand O
( O
TRAIL/Apo2L B-cell_line
) O
in O
MM B-protein
. O
TRAIL/Apo2L O
potently O
induced O
apoptosis O
of O
MM B-cell_type
cells I-cell_type
from O
patients O
and O
the O
majority O
of O
MM O
cell O
lines I-cell_line
, O
including B-cell_type
cells I-cell_type
sensitive O
or O
resistant O
to O
dexamethasone O
( O
Dex O
) O
, O
doxorubicin O
( O
Dox O
) O
, O
melphalan O
, O
and O
mitoxantrone O
. O
TRAIL/Apo2L O
also O
overcame O
the O
survival O
effect O
of O
interleukin O
6 O
on O
MM B-cell_type
cells I-cell_type
and O
did O
not O
affect O
the O
survival O
of O
peripheral B-cell_type
blood I-cell_type
and I-cell_type
bone B-cell_type
marrow I-cell_line
mononuclear B-cell_type
cells I-cell_type
and O
purified O
B I-DNA
cells I-cell_type
from O
healthy O
donors O
. O
The O
status O
of O
the O
TRAIL O
receptors O
( O
assessed O
by O
immunoblotting O
and O
flow O
cytometry O
) O
could O
not O
predict O
TRAIL O
sensitivity O
of O
MM B-cell_type
cells I-cell_type
. O
The O
anti-MM O
activity O
of O
TRAIL/Apo2L B-cell_type
was O
confirmed O
in O
nu/xid/bg O
mice O
xenografted O
with O
human B-DNA
MM I-cell_type
cells I-cell_type
; O
TRAIL I-protein
( O
500 O
microg O
intraperitoneally O
daily O
for O
14 O
days O
) O
was O
well O
tolerated O
and O
significantly O
suppressed O
the O
growth O
of O
plasmacytomas O
. O
Dox O
up-regulated B-DNA
the O
expression O
of O
the O
TRAIL I-DNA
receptor I-protein
death I-DNA
receptor I-protein
5 O
( O
DR5 B-protein
) O
and O
synergistically O
enhanced O
the O
effect O
of O
TRAIL O
not O
only O
against O
MM B-cell_type
cells I-cell_type
sensitive O
to O
, O
but O
also O
against O
those O
resistant O
to O
, O
Dex- O
or O
Dox-induced B-protein
apoptosis O
. O
Nuclear I-protein
factor I-protein
( O
NF I-DNA
) O
-kappaB O
inhibitors O
, O
such O
as O
SN50 B-protein
( O
a O
cell-permeable O
inhibitor O
of O
the O
nuclear B-protein
translocation O
and O
transcriptional O
activity O
of O
NF-kappaB B-protein
) O
or O
the O
proteasome O
inhibitor O
PS-341 B-protein
, O
enhanced O
the O
proapoptotic O
activity O
of O
TRAIL/Apo2L B-cell_type
against O
TRAIL-sensitive B-protein
MM B-cell_type
cells I-cell_line
, O
whereas O
SN50 B-protein
reversed O
the O
TRAIL O
resistance O
of O
ARH-77 B-protein
and O
IM-9 B-protein
MM B-cell_type
cells I-cell_type
. O
Importantly O
, O
normal O
B I-DNA
lymphocytes I-cell_type
were O
not O
sensitized O
to O
TRAIL O
by O
either O
Dox O
, O
SN50 I-protein
, O
or O
PS-341 B-protein
. O
These O
preclinical O
studies O
suggest O
that O
TRAIL/Apo2L O
can O
overcome O
conventional O
drug O
resistance O
and O
provide O
the O
basis O
for O
clinical O
trials O
of O
TRAIL O
-based O
treatment O
regimens O
to O
improve O
outcome O
in O
patients O
with O
MM B-protein
. O
( O
Blood. I-DNA
2001 O
; O
98 O
: O
795-804 O
) O
CD28 B-protein
costimulation O
is O
required O
not O
only O
to O
induce O
IL-12 B-DNA
receptor I-protein
but O
also O
to O
render O
janus O
kinases/STAT4 B-protein
responsive O
to O
IL-12 B-protein
stimulation O
in O
TCR-triggered B-cell_type
T B-cell_type
cells I-cell_type
. O
The O
activation O
of O
resting B-cell_type
T B-cell_type
cells I-cell_type
for O
the O
acquisition O
of O
various O
functions O
depends O
on O
whether O
CD28 B-protein
costimulatory O
signals O
are O
provided O
upon O
T O
cell I-DNA
receptor I-protein
stimulation O
. O
Here O
, O
we O
investigated O
how O
CD28 B-protein
costimulation O
functions O
to O
allow O
TCR O
-triggered O
resting O
T B-cell_type
cells O
to O
acquire O
IL-12 B-protein
responsiveness O
. O
When O
T B-cell_type
cells I-cell_type
are O
stimulated O
with O
low O
doses O
of O
anti-CD3 B-protein
mAb I-protein
, O
CD28 B-protein
costimulation O
was O
required O
for O
the O
optimal O
levels O
of O
IL-12 B-DNA
receptor I-protein
( O
IL-12R B-protein
) O
expression O
. O
However O
, O
stimulation O
of O
T B-cell_type
cells I-cell_type
with O
high O
doses O
of O
anti-CD3 B-protein
alone O
induced O
comparable O
levels O
of O
IL-12R B-protein
expression O
to O
those O
induced O
upon O
CD28 B-protein
costimulation O
. O
Nevertheless I-protein
, O
there O
was O
a O
substantial O
difference O
in O
IL-12 B-protein
responsiveness O
between O
these O
two O
groups O
of O
T B-cell_type
cells I-cell_type
: O
compared O
to O
anti-CD28-costimulated B-protein
T B-cell_type
cells I-cell_type
, O
T B-cell_type
cells I-cell_type
that O
were O
not O
costimulated O
with O
anti-CD28 B-protein
exhibited O
decreased O
levels O
of O
Janus O
kinases I-protein
( O
JAK I-DNA
) O
JAK2/TYK2 O
and O
STAT4 B-protein
phosphorylation O
and O
IFN-y B-protein
production O
following O
IL-12 B-protein
stimulation O
. O
Importantly O
, O
STAT6 B-protein
phosphorylation O
following O
IL-4 B-protein
stimulation O
was O
not O
decreased O
in O
anti-CD28-uncostimulated B-cell_type
T B-cell_type
cells I-cell_type
. O
These O
resutls O
indicate O
that O
CD28 B-protein
costimulation O
not O
only O
contributes O
to O
up-regulating O
IL-12R B-protein
expression O
but O
is O
also O
required O
to O
render O
JAKs/STAT4 O
responsive O
to O
IL-12 B-protein
stimulation O
. O
Constitutively O
activated O
Akt-1 B-protein
is O
vital O
for O
the O
survival O
of O
human B-cell_type
monocyte-differentiated I-cell_type
macrophages O
. O
Role O
of O
Mcl-1 B-protein
, O
independent O
of O
nuclear B-protein
factor I-protein
( O
NF I-DNA
) O
-kappaB O
, O
Bad O
, O
or O
caspase O
activation O
. O
Recent O
data O
from O
mice O
deficient O
for O
phosphatase O
and O
tensin O
homologue O
deleted O
from O
chromosome O
10 O
or O
src O
homology O
2 O
domain-containing I-DNA
5 O
' O
inositol O
phosphatase O
, O
phosphatases O
that O
negatively O
regulate O
the O
phosphatidylinositol O
3-kinase B-protein
( O
PI3K B-protein
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K B-protein
pathway O
for O
macro-phage O
survival O
. O
Here O
, O
we O
focused O
on O
the O
role O
of O
the O
PI3K-regulated B-protein
serine/threonine O
kinase I-protein
Akt-1 B-protein
in O
modulating O
macrophage O
survival O
. O
Akt-1 B-protein
was O
constitutively O
activated O
in O
human B-DNA
macrophages I-cell_type
and O
addition O
of O
the O
PI3K B-protein
inhibitor O
, O
LY294002 I-protein
, O
suppressed O
the O
activation O
of O
Akt-1 B-protein
and O
induced O
cell O
death O
. O
Furthermore O
, O
suppression O
of O
Akt-1 B-protein
by O
inhibition O
of O
PI3K B-protein
or O
a O
dominant O
negative O
( O
DN I-DNA
) O
Akt-1 O
resulted O
in O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
activation O
of O
caspases-9 B-protein
and O
-3 O
, O
and O
DNA O
fragmentation O
. O
The O
effects O
of O
PI3K B-protein
inhibition O
were O
reversed O
by O
the O
ectopic O
expression O
of O
constitutively O
activated O
Akt-1 B-protein
or O
Bcl-x B-protein
( O
L I-DNA
) O
. O
Inhibition O
of O
PI3K B-protein
/Akt-1 B-protein
pathway O
either O
by O
LY294002 B-protein
or O
DN B-protein
Akt-1 B-protein
had O
no O
effect O
on O
the O
constitutive O
or O
inducible O
activation O
of O
nuclear B-protein
factor I-protein
( O
NF I-DNA
) O
-kappaB O
in O
human B-DNA
macrophages I-cell_type
. O
However O
, O
after O
inhibition O
of O
the O
PI3K B-protein
/ O
Akt-1 B-protein
pathway O
, O
a O
marked O
decrease O
in O
the O
expression O
of O
the O
antiapoptotic O
molecule O
Mcl-1 B-protein
, O
but O
not O
other O
Bcl-2 B-protein
family O
members O
was O
observed O
, O
and O
Mcl-1 B-protein
rescued O
macrophages O
from O
LY294002-induced O
cell O
death O
. O
Further O
, O
inhibition O
of O
Mcl-1 B-protein
by O
antisense O
oligonucleotides O
, O
also O
resulted O
in O
macrophage O
apoptosis O
. O
Thus O
, O
our O
findings O
demonstrate O
that O
the O
constitutive O
activation O
of O
Akt-1 B-protein
regulates O
macrophage O
survival O
through O
Mcl-1 B-protein
, O
which O
is O
independent O
of O
caspases O
, O
NF-kappaB O
, O
or O
Bad O
. O
GRbeta O
expression O
in O
nasal O
polyp O
inflammatory B-cell_type
cells I-cell_type
and O
its O
relationship O
to O
the O
anti-inflammatory B-DNA
effects O
of O
intranasal O
fluticasone O
. O
BACKGROUND I-protein
: O
Nasal O
polyposis O
disease O
is O
an O
inflammatory O
disorder O
with O
intense O
eosinophilic O
infiltration O
of O
respiratory O
mucosa O
that O
is O
often O
difficult O
to O
control O
with O
topical O
steroids O
. O
Recent O
evidence O
suggests O
that O
overexpression O
of O
the O
glucocorticoid I-DNA
receptor I-protein
splice O
variant O
GRbeta O
in O
inflammatory B-cell_type
cells I-cell_type
might O
contribute O
to O
steroid O
insensitivity O
in O
diseases O
such O
as O
asthma O
. O
OBJECTIVE O
: O
The O
purposes O
of O
this O
investigation O
were O
to O
determine O
whether O
nasal O
polyp O
( O
NP I-DNA
) O
inflammatory B-cell_type
cells I-cell_type
overexpress O
GRbeta O
and O
to O
examine O
whether O
GRbeta O
overexpression O
is O
associated O
with O
insensitivity O
to O
the O
potent O
topical O
steroid O
fluticasone O
propionate O
( O
FP I-DNA
) O
. O
METHODS I-protein
: O
Biopsies O
were O
obtained O
from O
10 O
subjects O
with O
NPs O
before O
and O
4 O
weeks O
after O
treatment O
with O
intranasal O
FP B-protein
. O
Middle O
turbinates O
biopsies O
from O
6 O
healthy O
, O
nonallergic O
subjects O
served O
as O
normal O
controls O
. O
Biopsies O
were O
immunostained O
for O
inflammatory O
cell O
markers O
as O
well O
as O
GRbeta O
and O
probed O
for O
various O
cytokine O
mRNA I-RNA
. O
The O
anti-inflammatory O
response O
to O
FP B-protein
was O
examined O
in O
relation O
to O
pretreatment O
levels O
of O
GRbeta O
expression O
. O
RESULTS I-protein
: O
The O
total O
numbers O
of O
inflammatory B-cell_type
cells I-cell_type
were O
increased O
in O
NPs O
. O
The O
percentage O
of O
inflammatory B-cell_type
cells I-cell_type
expressing O
GRbeta O
was O
also O
increased O
( O
40.5 I-DNA
% O
+/- O
19.2 B-protein
% O
vs O
16.1 B-protein
% O
+/- O
4.0 B-protein
% O
, O
P O
=.009 B-protein
) O
. O
GRbeta O
expression O
in O
NPs O
was O
almost O
exclusive O
to O
T I-cell_type
lymphocytes I-cell_type
, O
eosinophils O
, O
and O
macrophages O
. O
An O
inverse O
correlation O
was O
observed O
between O
the O
baseline O
inflammatory O
cell O
GRbeta O
expression O
and O
the O
reduction O
after O
FP B-protein
treatment O
in O
EG2-positive B-protein
eosinophils O
, O
CD4-positive O
T I-cell_type
lymphocytes I-cell_type
, O
endothelial O
VCAM-1 B-protein
expression O
, O
and O
IL-4 B-protein
mRNA-positive B-cell_type
cells I-cell_type
. O
NPs O
that O
were O
`` O
FP-insensitive B-protein
'' O
in O
terms O
of O
suppression O
of O
eosinophil O
numbers O
( O
major O
basic O
protein O
-positive O
) O
had O
a O
significantly O
greater O
percentage O
of O
GRbeta-positive O
inflammatory B-cell_type
cells I-cell_line
, O
a O
higher O
ratio O
of O
GRbeta-positive/GRalpha-positive B-cell_type
cells I-cell_line
, O
and O
increased O
numbers O
of O
GRbeta-positive O
eosinophils O
and O
macrophages O
in O
comparison O
with O
those O
that O
were O
`` O
FP-sensitive. B-protein
'' O
`` O
FP-insensitive B-protein
'' O
NPs O
also O
demonstrated O
a O
higher O
percentage O
of O
IL-5-positive B-protein
inflammatory B-cell_type
cells I-cell_type
expressing O
GRbeta O
before O
and O
after O
FP B-protein
treatment O
. O
CONCLUSION I-protein
: O
GRbeta O
expression O
appears O
to O
be O
a O
marker O
of O
steroid O
insensitivity O
in O
NPs O
. O
Expression O
of O
GRbeta O
by O
NP B-protein
inflammatory B-cell_type
cells I-cell_line
, O
particularly O
T B-cell_type
cells I-cell_type
and O
eosinophils O
, O
might O
render O
them O
resistant O
to O
suppression O
by O
topical O
steroids O
and O
thereby O
contribute O
to O
persistent O
NP B-protein
inflammation O
. O
Transcriptional O
regulation O
of O
galectin-10 B-protein
( O
eosinophil O
Charcot-Leyden B-protein
crystal O
protein O
) O
: O
a O
GC B-protein
box O
( O
-44 O
to O
-50 B-protein
) O
controls O
butyric O
acid O
induction O
of O
gene I-DNA
expression O
. O
Galectin-10 B-protein
( O
gal-10 I-DNA
, O
also O
known O
as O
Charcot-Leyden B-protein
crystal O
protein O
) O
is O
a O
member O
of O
the O
galectin O
family O
of O
beta-galactoside O
binding O
proteins I-protein
that O
is O
expressed O
uniquely O
in O
eosinophilic O
and O
basophilic O
leukocytes O
. O
To O
gain O
a O
better O
understanding O
of O
galectin B-DNA
gene I-DNA
expression O
, O
we O
present O
an O
analysis O
of O
the O
transcriptional O
regulation O
of O
the O
gene I-DNA
encoding O
gal-10 B-protein
. O
Analysis O
of O
the O
minimal O
promoter I-DNA
revealed O
nine O
consensus-binding I-DNA
sites I-DNA
for O
transcription B-protein
factors I-protein
, O
including O
several O
that O
are O
also O
found O
in O
the O
minimal O
promoters O
of O
galectins O
-1 O
, O
-2 O
, O
and O
-3 O
. O
The O
decrease O
in O
gal-10 B-DNA
promoter I-DNA
activity O
after O
disruption O
of O
either O
the O
GC B-protein
box O
( O
-44 O
to O
-50 B-protein
) O
or O
the O
Oct O
site I-DNA
( O
-255 O
to O
-261 B-protein
) O
suggests O
that O
these O
sites I-DNA
, O
along O
with O
the O
previously O
characterized O
GATA O
and O
EoTF I-DNA
sites I-DNA
, O
are O
necessary O
for O
full O
promoter I-DNA
activity O
. O
By O
supershift O
analysis O
, O
we O
demonstrate O
binding O
of O
the O
transcription B-protein
factors I-protein
Sp1 O
and O
Oct1 O
to O
the O
consensus O
GC B-protein
box O
and O
the O
Oct O
site I-DNA
, O
respectively O
. O
Similar O
to O
gal-1 O
, O
gal-10 B-protein
expression O
is O
induced O
by O
butyric O
acid O
, O
an O
effect O
that O
is O
lost O
upon O
ablation O
of O
the O
GC B-protein
box O
. O
Additionally I-protein
, O
we O
demonstrate O
AML3 B-protein
binding O
to O
the O
consensus O
AML I-DNA
site I-DNA
and O
YY1 B-protein
binding O
to O
the O
Inr O
sequence O
, O
both O
elements I-DNA
functioning O
as O
silencers O
in O
the O
gal-10 B-DNA
promoter I-DNA
. O
Tumour-stromal O
interactions O
. O
Role O
of O
the O
stroma O
in O
mammary O
development O
. O
Mammary O
development O
depends O
on O
branching O
morphogenesis O
, O
namely O
the O
bifurcation O
and O
extension O
of O
ductal O
growth O
points O
( O
end O
buds O
) O
and O
secretory O
lobules O
into O
a O
more O
or O
less O
fatty O
stroma O
. O
Because O
breast O
carcinomas O
are O
overwhelmingly O
ductal O
in O
origin I-protein
, O
this O
review O
focuses O
on O
stromal O
influences O
guiding O
postnatal O
ductal O
development O
and O
there O
is O
only O
the O
briefest O
account O
of O
the O
role O
of O
embryonic B-cell_type
stroma O
( O
mesenchyme O
) O
. O
The O
stroma O
as O
the O
necessary O
target I-cell_line
for O
endocrine O
mammogens O
and O
the O
source O
of O
stimulatory O
growth B-protein
factors I-protein
is O
described O
and O
the O
importance O
of O
mammary O
epithelium-induced O
modifications O
of O
the O
periductal O
stroma O
is O
emphasized O
. O
Evidence O
is O
presented O
that O
if O
they O
are O
to O
grow O
, O
end O
buds O
must O
condition O
proximal O
fatty O
stroma O
by O
recruiting O
white O
blood I-cell_type
cells I-cell_type
as O
well O
as O
inducing O
stromal O
cell O
division O
and I-DNA
, O
possibly O
, O
estrogen O
receptors O
. O
The O
induction O
of O
a O
fibrous O
stromal O
tunic O
around O
the O
end O
bud O
is O
described O
and O
its O
likely O
role O
as O
a O
complex I-protein
ductal O
morphogen O
is O
discussed O
; O
a O
possible O
role O
in O
growth O
inhibition O
is O
also O
considered O
. O
Although O
the O
signals O
governing O
fibrotic O
induction O
, O
ductal O
morphogenesis O
, O
and O
growth O
inhibition O
are O
unknown O
, O
a O
role O
for O
transforming O
growth O
factor-beta B-DNA
is O
highly O
likely O
and O
is O
discussed O
. O
Finally O
, O
a O
need O
for O
new O
conceptual O
and O
experimental O
approaches O
to O
understanding O
stromal-epithelial O
signaling O
is O
discussed O
. O
Adipophilin O
is O
a O
sensitive O
marker O
for O
lipid O
loading O
in O
human B-cell_type
blood I-cell_type
monocytes I-cell_type
. O
Adipophilin O
, O
a O
marker O
of O
lipid O
accumulation O
initially O
described O
in O
adipocytes O
, O
was O
recently O
shown O
to O
be O
induced O
in O
macrophage O
foam B-cell_type
cells I-cell_type
. O
We O
found O
that O
even O
freshly O
isolated O
blood I-cell_type
monocytes I-cell_type
express O
adipophilin O
and O
that O
the O
amount O
of O
adipophilin O
protein O
is O
variable O
in O
monocytes B-cell_type
from O
different O
healthy O
individuals O
. O
However O
, O
the O
physiological O
expression O
of O
adipophilin O
does O
not O
correlate O
with O
the O
levels O
of O
free O
fatty O
acids O
, O
cholesterylesters O
or O
free O
cholesterol O
. O
Enzymatically B-cell_type
modified O
low-density O
lipoprotein O
( O
E-LDL B-protein
) O
induces O
rapid O
foam O
cell O
formation O
in O
monocytes B-cell_type
and O
upregulates O
adipophilin I-RNA
mRNA I-RNA
and O
protein O
within O
2 O
h O
of O
incubation O
. O
This O
rapid O
induction O
of O
adipophilin O
is O
accompanied O
by O
a O
significant O
increase O
of O
free O
fatty O
acids O
in O
monocytes B-cell_type
incubated O
with O
E-LDL B-protein
. O
Adipophilin O
facilitates O
the O
uptake O
of O
free O
fatty O
acids O
, O
and O
here O
we O
demonstrate O
that O
free O
fatty O
acids O
increase O
is O
related O
to O
the O
early O
upregulation O
of O
adipophilin O
expression O
in O
blood I-cell_type
monocytes I-cell_type
. O
Fatty O
acids O
are O
ligands O
for O
peroxisome O
proliferator-activated B-DNA
receptor-gamma B-protein
( O
PPARgamma I-DNA
) O
, O
and O
the O
upregulation O
of O
adipophilin O
mRNA I-RNA
by O
PPARgamma O
agonists O
like O
15d-PGJ B-protein
( O
2 O
) O
and O
ciglitazone O
indicates O
that O
PPARgamma O
may O
mediate O
the O
induction O
of O
adipophilin O
expression O
in O
human B-cell_type
blood I-cell_type
monocytes I-cell_type
. O
Constitutive O
expression O
of O
MHC I-protein
class I-protein
II I-protein
genes I-DNA
in O
melanoma O
cell O
lines I-cell_line
results O
from O
the O
transcription I-DNA
of O
class I-protein
II I-protein
transactivator O
abnormally O
initiated O
from O
its O
B I-DNA
cell-specific I-DNA
promoter I-DNA
. O
In O
melanoma O
cell O
lines I-cell_line
, O
two O
different O
patterns O
of O
MHC I-protein
class I-protein
II I-protein
expression O
have O
been O
described O
, O
either O
an O
IFN O
gamma-inducible O
expression O
of O
HLA-DR B-protein
and O
HLA-DP I-DNA
, O
with O
a O
faint O
or O
null O
expression O
of O
HLA-DQ B-protein
, O
resembling O
that O
described O
for O
melanocytes O
, O
or O
a O
constitutive O
expression O
, O
i.e. I-protein
, O
IFN-gamma O
independent O
, O
of O
all O
three O
HLA-D B-protein
isotypes O
. O
As O
this O
latter O
phenotype O
has O
been O
associated O
with O
a O
more O
rapid O
progression O
of O
melanoma O
tumors O
, O
we O
have O
analyzed O
in O
different O
melanoma O
cell O
lines I-cell_line
the O
molecular O
mechanisms O
leading O
to O
this O
abnormal O
pattern O
of O
MHC I-protein
class I-protein
II I-protein
expression O
. O
In O
agreement O
with O
the O
evidence O
of O
a O
coordinate O
transcription I-DNA
of O
the O
HLA-D I-DNA
genes I-DNA
in O
these O
cell O
lines I-cell_line
, O
we O
have O
shown O
the O
constitutive O
expression O
of O
CIITA B-cell_type
( O
class B-protein
II I-protein
transactivator O
) O
transcripts O
, O
CIITA O
being O
known O
as O
the O
master O
switch O
of O
MHC I-protein
class I-protein
II I-protein
expression O
. O
Unexpectedly I-protein
, O
these O
transcripts I-RNA
initiate O
from O
promoter I-DNA
III O
of O
the O
CIITA B-DNA
gene I-DNA
, O
a O
promoter I-DNA
that O
is O
mainly O
used O
constitutively O
in O
B I-DNA
lymphocytes I-cell_type
. O
This O
expression O
was O
further O
shown O
to O
occur O
through O
factor I-protein
( O
s O
) O
acting O
on O
the O
enhancer I-DNA
located O
upstream O
of O
CIITA B-DNA
promoter I-DNA
III I-protein
, O
which O
was O
previously O
described O
in O
epithelioid B-cell_type
cells I-cell_type
as O
an O
IFN-gamma-response O
sequence O
. O
The O
hypothesis O
of O
a O
general O
abnormality O
of O
the O
IFN-gamma B-protein
transduction O
pathway O
was O
dismissed O
. O
Constitutive B-protein
transcription I-DNA
of O
CIITA O
from O
promoter I-DNA
III O
having O
been O
observed O
in O
unrelated O
melanoma O
cell O
lines I-cell_line
, O
we O
propose O
the O
hypothesis O
that O
this O
phenomenon O
might O
not O
be O
a O
random O
event O
, O
but O
could O
be O
linked O
to O
the O
neoplasic O
state O
of O
the O
melanoma B-cell_type
cells I-cell_type
Caspase O
-mediated O
calcineurin O
activation O
contributes O
to O
IL-2 B-protein
release O
during O
T O
cell O
activation O
. O
Calcineurin O
, O
a O
Ca O
( O
2+ O
) O
/calmodulin-dependent O
Ser/Thr O
phosphatase O
( O
protein O
phosphatase O
2B B-protein
) O
, O
plays O
a O
critical O
role O
in O
IL-2 B-protein
production O
during O
T O
cell O
activation O
. O
It O
has O
been O
previously O
reported O
that O
IL-2 B-protein
release O
in O
activated O
Jurkat O
T I-cell_line
requires O
caspase-like B-DNA
activity O
( O
Posmantur O
et O
al. I-cell_line
( O
1998 I-DNA
) O
Exp. I-DNA
Cell. B-DNA
Res. B-DNA
244 O
, O
302-309 O
) O
. O
We O
report O
here O
that O
the O
60-kDa B-protein
catalytic O
subunit O
of O
calcineurin O
A O
( O
Cn O
A O
) O
was O
partially O
cleaved O
to O
a O
45-kDa B-protein
form O
in O
phytohemagglutinin O
A O
( O
PHA I-DNA
) O
or O
phorbol O
ester O
+ O
ionomycin O
( O
P O
+ O
I I-protein
) O
-activated O
Jurkat B-cell_type
cells I-cell_type
. O
In O
parallel O
, O
proteolytic O
activation O
of O
upstream O
caspases O
( O
caspase-8 B-protein
and O
-9 B-protein
) O
as O
well O
as O
effector O
caspase-3 B-protein
was O
also O
observed O
. O
Cn O
A O
cleavage O
was O
caspase O
mediated O
, O
since O
it O
was O
inhibitable O
by O
pan-caspase O
inhibitor O
Cbz-Asp-CH B-protein
( O
2 O
) O
OC I-cell_line
( O
O I-DNA
) O
-2 O
, O
6-dichlorobenzene O
( O
Z-D-DCB I-DNA
) O
. O
Cn O
A O
cleavage O
was O
also O
observed O
when O
purified O
calcineurin O
was O
digested O
in O
vitro O
with O
caspase-3 B-protein
. O
Truncated O
Cn O
A O
was O
associated O
with O
enhanced O
phosphatase O
activity O
and O
reduced O
calmodulin O
sensitivity O
. O
Furthermore O
, O
in O
PHA O
or O
P O
+ O
I-activated B-protein
Jurkat B-cell_type
cells I-cell_line
, O
dephosphorylation O
of O
calcineurin O
substrate O
NFATc O
( O
a O
transcription B-protein
factor I-protein
known O
to O
be O
involved O
in O
transactivation O
of O
the O
IL-2 B-DNA
gene I-DNA
) O
, O
was O
also O
suppressed O
by O
Z-D-DCB B-protein
. O
Taken O
together O
, O
our O
results O
suggest O
that O
caspase-mediated O
cleavage O
of O
Cn O
A O
contributes O
to O
IL-2 B-protein
production O
during O
T O
cell O
activation O
. O
Copyright O
2001 O
Academic O
Press O
. O
Maturation O
of O
human B-cell_type
dendritic I-cell_type
cells I-cell_type
as O
sulfasalazine O
target I-cell_line
. O
AIM O
: O
Sulfasalazine B-cell_type
, O
a O
nonsteroidal O
anti-inflammatory B-DNA
drug O
, O
is O
effective O
in O
treating O
some O
autoimmune O
diseases O
, O
but O
its O
mechanism O
of O
action O
is O
unclear O
. O
To O
determine O
whether O
dendritic B-cell_type
cells I-cell_type
could O
be O
a O
possible O
target I-cell_line
of O
the O
drug O
, O
we O
studied O
the O
effects O
of O
sulfasalazine O
and O
its O
metabolites I-protein
, O
aminosalicylate O
and O
sulfapyridine I-DNA
, O
on O
in O
vitro O
maturation O
( O
terminal I-DNA
differentiation O
) O
of O
human B-cell_type
myeloid I-DNA
dendritic B-cell_type
cells I-cell_type
. O
METHODS I-protein
: O
We O
prepared O
immature O
dendritic B-cell_type
cells I-cell_type
by O
incubating O
CD14-positive B-protein
cells I-cell_type
in O
the O
presence O
of O
granulocyte- B-DNA
macrophage O
colony-stimulating B-protein
factor I-protein
and O
interleukin O
( O
IL I-DNA
) O
-4 O
. O
The B-cell_type
cells I-cell_type
were O
matured O
by O
addition O
of O
tumor O
necrosis B-protein
factor I-protein
( O
TNF I-DNA
) O
-a O
, O
IL-1 B-protein
beta O
, O
and O
prostaglandin O
E2 B-protein
in O
the O
presence O
of O
sulfasalazine O
or O
its O
metabolites I-protein
-- O
aminosalicylate O
and O
sulfapyridine I-DNA
, O
or O
their O
combinations O
. O
We O
quantified O
the O
effect O
of O
drugs O
on O
the O
dendritic O
cell O
characteristics O
, O
such O
as O
stimulation O
of O
autologous O
and O
allogeneic O
pan-T O
cell O
proliferation O
, O
surface I-protein
marker O
phenotype O
, O
IL-12 B-protein
p40 O
subunit O
secretion O
, O
and O
activation O
of O
nuclear B-protein
transcription B-protein
factor I-protein
( O
NF I-DNA
) O
-kappa O
B I-DNA
. O
RESULTS I-protein
: O
Dendritic B-cell_type
cells I-cell_type
treated O
with O
sulfasalazine O
( O
1.25 I-DNA
micromol/L O
or O
2.5 B-protein
micromol/L I-DNA
) O
could O
not O
stimulate O
T B-cell_type
cells I-cell_type
( O
p O
< O
0.028 I-cell_line
, O
two-sided O
paired O
t-test B-protein
) O
. O
In O
distinction O
to O
drug-free O
maturing O
dendritic B-cell_type
cells I-cell_line
, O
2.5 B-protein
micromol/L O
sulfasalazine O
upregulated O
the O
levels O
of O
CD14 B-protein
and O
CD68 B-protein
and O
downregulated O
the O
levels O
of O
CD40 I-protein
, O
CD80 I-protein
, O
and O
CD83 B-protein
( O
for O
all O
CD B-protein
markers O
, O
p O
< O
0.03 B-protein
for O
difference O
between O
measurements O
in O
the O
absence O
and O
the O
presence O
of O
sulfasalazine O
) O
. O
From O
concentration-dependent B-DNA
changes O
in O
CD83 B-protein
expression O
, O
we O
found O
an O
apparent O
ID50 B-protein
> O
> O
1.5 B-protein
micromol/L O
sulfasalazine O
. O
The O
apparent O
ID50 B-protein
value O
for O
aminosalicylate-inhibited B-DNA
maturation O
was O
4 O
micromol/L O
. O
Sulfapyridine B-cell_type
had O
no O
effect O
. O
At O
1.25 B-protein
micromol/L I-protein
, O
sulfasalazine O
largely O
inhibited O
NF-kB O
activation O
in O
dendritic B-cell_type
cells I-cell_type
. O
CONCLUSION I-protein
: O
Maturing O
human B-DNA
dendritic I-cell_type
cells I-cell_type
are O
hundred-fold B-DNA
more O
sensitive O
to O
sulfasalazine O
than O
T B-cell_type
cells I-cell_type
and O
NK B-cell_type
cells I-cell_type
and O
the O
most O
sensitive O
human B-cell_type
cells I-cell_type
described O
so O
far O
. O
Thus O
, O
dendritic O
cell O
maturation O
is O
an O
important O
target I-cell_line
of O
sulfasalazine O
. O
Because O
of O
the O
role O
of O
dendritic B-cell_type
cells I-cell_type
in O
( O
auto O
) O
immunity O
, O
inhibition O
of O
their O
maturation O
might O
provide O
a O
target I-cell_line
for O
further O
optimization O
of O
sulfasalazine O
therapy O
. O
Defective O
function O
of O
the O
proteasome O
in O
autoimmunity O
: O
involvement O
of O
impaired O
NF-kappaB O
activation O
. O
Type O
1 O
diabetes O
( O
also O
known O
as O
insulin-dependent B-DNA
diabetes O
mellitus O
or O
juvenile-onset O
diabetes O
) O
is O
usually O
caused O
by O
T I-cell_line
cell-mediated O
autoimmunity O
, O
with O
a O
prediabetic O
state O
characterized O
by O
the O
production O
of O
autoantibodies O
specific O
for O
proteins I-protein
expressed O
by O
pancreatic O
beta B-cell_type
cells I-cell_type
. O
The O
nonobese O
patient O
with O
diabetes O
( O
NOD I-DNA
) O
mouse O
is O
a O
spontaneous O
model O
of O
type O
1 O
diabetes O
with O
a O
strong O
genetic O
component O
that O
maps O
to O
the O
major O
histocompatibility I-protein
complex I-protein
( O
MHC I-DNA
) O
region I-DNA
of O
the O
genome O
. O
A O
specific O
proteasome O
defect O
has O
been O
identified O
in O
NOD O
mouse B-DNA
in O
select O
lymphocytic O
and O
monocytic B-cell_line
lineages O
that O
results O
from O
down-regulation O
of O
expression O
of O
the O
proteasome O
subunit O
LMP2 I-protein
, O
which O
is O
encoded O
by O
a O
gene I-DNA
in O
the O
MHC I-protein
genomic O
region O
. O
This O
defect O
prevents O
the O
proteolytic O
processing O
required O
for O
the O
production O
and O
activation O
of O
the O
transcription B-protein
factor I-protein
nuclear B-protein
factor-kappaB B-protein
( O
NF-kappaB I-DNA
) O
, O
which O
plays O
important O
roles O
in O
immune O
and O
inflammatory O
responses O
, O
as O
well O
as O
increases O
the O
susceptibility O
of O
the O
affected B-cell_type
cells O
to O
apoptosis O
induced O
by O
tumor O
necrosis O
factor-alpha B-DNA
( O
TNF-alpha I-DNA
) O
. O
The O
novel O
role O
of O
the O
proteasome O
in O
dysfunction O
in O
autoimmunity O
is O
presented O
and O
documented O
to O
be O
both O
tissue O
and O
developmental O
stage O
specific O
. O
We O
propose O
a O
role O
of O
the O
proteasome O
as O
a O
step O
in O
disease O
pathogenesis O
and O
tissue O
targeting O
. O
Down-regulation O
of O
TDT B-protein
transcription O
in O
CD4 B-protein
( O
+ O
) O
CD8 B-protein
( O
+ O
) O
thymocytes O
by O
Ikaros O
proteins I-protein
in O
direct O
competition O
with O
an O
Ets O
activator O
. O
Ikaros O
is O
a O
unique O
regulator O
of O
lymphopoiesis O
that O
associates O
with O
pericentromeric O
heterochromatin O
and O
has O
been O
implicated O
in O
heritable B-DNA
gene I-DNA
inactivation O
. O
Binding O
and O
competition O
experiments O
demonstrate O
that O
Ikaros O
dimers O
compete O
with O
an O
Ets O
activator O
for O
occupancy O
of O
the O
lymphocyte-specific B-DNA
TdT B-DNA
promoter I-DNA
. O
Mutations O
that O
selectively O
disrupt O
Ikaros O
binding O
to O
an O
integrated O
TdT B-DNA
promoter I-DNA
had O
no O
effect O
on O
promoter I-DNA
function O
in O
a O
CD4 B-protein
( O
+ O
) O
CD8 B-protein
( O
+ O
) O
thymocyte O
line O
. O
However O
, O
these O
mutations O
abolished O
down-regulation O
on O
differentiation O
, O
providing O
evidence O
that O
Ikaros O
plays O
a O
direct O
role O
in O
repression O
. O
Reduced O
access O
to O
restriction O
enzyme O
cleavage O
suggested O
that O
chromatin O
alterations O
accompany O
down-regulation O
. O
The O
Ikaros-dependent O
down-regulation O
event O
and O
the O
observed O
chromatin O
alterations O
appear O
to O
precede O
pericentromeric O
repositioning O
. O
Current O
models O
propose O
that O
the O
functions O
of O
Ikaros O
should O
be O
disrupted O
by O
a O
small O
isoform O
that O
retains O
the O
dimerization I-protein
domain I-protein
and O
lacks O
the O
DNA-binding I-protein
domain I-protein
. O
Surprisingly I-protein
, O
in O
the O
CD4 B-protein
( O
+ O
) O
CD8 B-protein
( O
+ O
) O
thymocyte O
line O
, O
overexpression O
of O
a O
small O
Ikaros O
isoform O
had O
no O
effect O
on O
differentiation O
or O
on O
the O
pericentromeric O
targeting O
and O
DNA-binding B-protein
properties O
of O
Ikaros O
. O
Rather O
, O
the O
small O
isoform O
assembled O
into O
multimeric O
complexes O
with O
DNA-bound B-protein
Ikaros O
at O
the O
pericentromeric O
foci O
. O
The O
capacity O
for O
in O
vivo O
multimer O
formation O
suggests O
that O
interactions O
between O
Ikaros O
dimers O
bound O
to O
the O
TdT B-DNA
promoter I-DNA
and O
those O
bound O
to O
pericentromeric O
repeat O
sequences O
may O
contribute O
to O
the O
pericentromeric O
repositioning O
of O
the O
inactive B-DNA
gene I-DNA
. O
Type O
I I-protein
interferons O
and O
IL-12 B-protein
: O
convergence O
and O
cross-regulation O
among O
mediators O
of O
cellular O
immunity O
. O
Therapeutic O
use O
of O
type O
I I-protein
IFN I-protein
( O
IFN-alpha/beta I-DNA
) O
has O
become O
common O
. O
Many O
of O
the O
diverse O
diseases O
targeted O
are O
marked O
by O
pathogenetic O
abnormalities O
in O
cell-mediated I-DNA
immunity O
( O
CMI I-DNA
) O
, O
these O
cellular O
immune O
responses O
either O
causing O
injury O
to O
the O
host O
, O
lacking O
sufficient O
vigor O
for O
virus O
or O
tumor O
clearance O
, O
or O
both O
. O
In O
general O
, O
therapeutic O
efficacy O
is O
limited O
. O
It O
is O
thus O
notable O
that O
the O
pleiotropic O
effects O
of O
type O
I I-protein
IFN O
on O
CMI O
remain O
poorly O
understood O
. O
We O
characterized O
the O
effects O
of O
type O
I I-protein
IFN O
on O
the O
production O
of O
IL-12 B-protein
, O
the O
central O
immunoregulatory O
cytokine O
of O
the O
CD4 B-protein
( O
+ O
) O
T O
cell O
arm O
of O
CMI B-cell_type
. O
We O
show O
that I-DNA
type O
I I-protein
IFN O
are O
potent O
inhibitors O
of O
IL-12 B-protein
production O
by O
human B-DNA
monocytes/macrophages I-cell_type
. O
The O
underlying O
mechanism O
involves O
transcriptional O
inhibition O
of O
the O
IL-12p40 B-DNA
gene I-DNA
, O
marked O
by O
down-regulation O
of O
PU.1 B-protein
binding O
activity O
at O
the O
upstream O
Ets O
site I-DNA
of O
the O
IL-12p40 B-DNA
promoter I-DNA
. O
Type O
I I-protein
IFN O
have O
previously O
been O
shown O
to O
be O
able O
to O
substitute O
for O
IL-12 B-protein
in O
driving O
IFN-gamma B-protein
production O
from O
T I-cell_line
and O
NK B-cell_type
cells I-cell_type
. O
The O
ability O
of O
IFN-alpha/beta O
to O
suppress O
IL-12 B-protein
production O
while O
up-regulating B-protein
IFN-gamma B-protein
production O
suggests O
a O
possible O
mechanistic O
basis O
for O
the O
difficulties O
of O
employing O
these O
cytokines O
in O
diseases O
involving O
abnormalities O
of O
CMI B-cell_type
. O
Nuclear O
factor-kappaB B-protein
suppressive O
and O
inhibitor-kappaB O
stimulatory O
effects O
of O
troglitazone O
in O
obese O
patients O
with I-DNA
type O
2 O
diabetes O
: O
evidence O
of O
an O
antiinflammatory O
action O
? O
It O
has O
been O
shown O
recently O
that O
troglitazone O
exerts O
an O
anti-inflammatory B-DNA
effect O
, O
in O
vitro O
, O
and O
in O
experimental O
animals O
. O
To O
test O
these O
properties O
in O
humans O
, O
we O
investigated O
the O
effect O
of O
troglitazone O
on O
the O
proinflammatory O
transcription B-protein
factor I-protein
nuclear B-protein
factor-kappaB O
and O
its O
inhibitory O
protein O
IkappaB I-protein
in O
mononuclear B-cell_type
cells I-cell_line
( O
MNC I-DNA
) O
and O
plasma O
soluble O
intracellular O
adhesion O
molecule-1 B-protein
, O
monocyte O
chemoattractant O
protein-1 B-protein
, O
plasminogen O
activator O
inhibitor-1 O
, O
and O
C-reactive B-protein
protein O
. O
We O
also O
examined O
the O
effect O
of O
troglitazone O
on O
reactive O
oxygen O
species O
generation O
, O
p47 O
( O
phox O
) O
subunit O
expression O
, O
9-hydroxyoctadecadienoic O
acid O
( O
9-HODE B-protein
) O
, O
13-HODE O
, O
o-tyrosine O
, O
and O
m-tyrosine O
in O
obese O
patients O
with I-DNA
type O
2 O
diabetes O
. O
Seven O
obese O
patients O
with I-DNA
type O
2 O
diabetes O
were O
treated O
with O
troglitazone O
( O
400 O
mg/day I-DNA
) O
for O
4 O
weeks O
. O
Blood O
samples O
were O
obtained O
at O
weekly O
intervals O
. O
Nuclear O
factor-kappaB O
binding O
activity O
in O
MNC O
nuclear B-protein
extracts O
was O
significantly O
inhibited O
after O
troglitazone O
treatment O
at O
week O
1 O
and O
continued O
to O
be O
inhibited O
up O
to O
week O
4 O
. O
On O
the O
other O
hand O
, O
IkappaB I-protein
protein O
levels O
increased O
significantly O
after O
troglitazone O
treatment O
at O
week O
1 O
, O
and O
this O
increase O
persisted O
throughout O
the O
study O
. O
Plasma O
monocyte O
chemoattractant O
protein-1 B-protein
and O
soluble O
intracellular O
adhesion O
molecule-1 B-protein
concentrations O
did O
not O
decrease O
significantly O
after O
troglitazone O
treatment O
, O
although O
there O
was O
a O
trend O
toward O
inhibition O
. O
Reactive O
oxygen O
species O
generation O
by O
polymorphonuclear B-cell_type
cells I-cell_type
and O
MNC I-protein
, O
p47 O
( O
phox O
) O
subunit O
protein O
quantities O
, O
plasminogen O
activator O
inhibitor-1 O
, O
and O
C-reactive B-protein
protein O
levels O
decreased O
significantly O
after O
troglitazone O
intake O
. O
13-HODE/linoleic O
acid O
and O
9-HODE/linoleic O
acid O
ratios O
also O
decreased O
after O
troglitazone O
intake O
. O
However O
, O
o-tyrosine/phenylalanine O
and O
m-tyrosine/phenylalanine B-protein
ratios O
did O
not O
change O
significantly O
. O
These O
data O
show O
that O
troglitazone O
has O
profound O
antiinflammatory O
effects O
in O
addition O
to O
antioxidant O
effects O
in O
obese I-DNA
type O
2 O
diabetics O
; O
these O
effects O
may O
be O
relevant O
to O
the O
recently O
described O
beneficial O
antiatherosclerotic O
effects O
of O
troglitazone O
at O
the O
vascular O
level O
. O
OX40 B-protein
stimulation O
by O
gp34/OX40 O
ligand O
enhances O
productive O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
infection O
. O
OX40 B-protein
is O
a O
member O
of O
the O
tumor O
necrosis B-protein
factor I-protein
( O
TNF I-DNA
) O
receptor I-protein
superfamily O
and O
known O
to O
be O
an O
important O
costimulatory O
molecule O
expressed O
on O
activated B-cell_type
T B-cell_type
cells I-cell_type
. O
To O
investigate O
the O
role O
of O
costimulation O
of O
OX40 B-protein
in O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
( O
HIV-1 B-protein
) O
infection O
by O
its O
natural O
ligand I-protein
, O
gp34 I-protein
, O
the O
OX40-transfected B-protein
ACH-2 O
cell O
line O
, O
ACH-2/OX40 O
, O
chronically O
infected O
with O
HIV-1 O
, O
was O
cocultured O
with O
paraformaldehyde O
( O
PFA I-DNA
) O
-fixed O
gp34-transfected O
mouse O
cell O
line O
, O
SV-T2/gp34 O
. O
The O
results O
showed O
that O
HIV-1 O
production O
was O
strongly O
induced O
. O
This O
was O
followed O
by O
apparent O
apoptosis O
, O
and O
both O
processes O
were O
specifically O
inhibited O
by O
the O
gp34 I-protein
-specific O
neutralizing O
monoclonal O
antibody O
5A8 B-protein
. O
Endogenous O
TNF I-DNA
alpha I-DNA
( O
TNF-alpha I-DNA
) O
and O
TNF-beta B-protein
production O
were O
not O
involved O
in O
the O
enhanced O
HIV-1 O
production O
. O
Furthermore O
, O
enhanced O
HIV-1 B-protein
transcription O
in O
gp34 I-protein
-stimulated O
ACH-2/OX40 B-protein
cells I-cell_type
was O
dependent O
on O
the O
kappa B-DNA
B I-DNA
site I-DNA
of O
the O
HIV-1 B-DNA
long I-DNA
terminal I-DNA
repeat I-DNA
, O
and O
the O
OX40-gp34 B-protein
interaction O
activated O
NF-kappa B-protein
B I-protein
consisting O
of O
p50 O
and O
p65 O
subunits O
. O
When O
primary B-cell_line
activated I-cell_line
CD4 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
acutely O
infected O
with O
HIV-1 B-protein
( O
NL4-3 B-protein
) O
( O
CXCR4-using B-protein
T-cell-line-tropic B-protein
) O
were O
cocultured O
with O
PFA-fixed B-protein
gp34 I-protein
( O
+ O
) O
human O
T-cell O
leukemia O
virus O
type O
1-bearing B-DNA
MT-2 B-protein
cells I-cell_type
or O
SV-T2/gp34 B-protein
cells I-cell_line
, O
HIV-1 O
production O
was O
also O
markedly O
enhanced O
. O
The O
enhancement O
was O
again O
significantly O
inhibited O
by O
5A8 B-protein
. O
The O
present O
study O
first O
shows O
that O
OX40-gp34 B-protein
interaction O
stimulates O
HIV-1 O
expression O
and O
suggests O
that O
OX40 B-protein
triggering O
by O
gp34 I-protein
may O
play O
an O
important O
role O
in O
enhancing O
HIV-1 O
production O
in O
both O
acutely O
and O
latently O
infected O
CD4 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
in O
vivo O
. O
Troglitazone I-protein
, O
a O
PPARgamma O
ligand I-protein
, O
inhibits O
osteopontin B-DNA
gene I-DNA
expression O
in O
human B-DNA
monocytes/macrophage I-cell_type
THP-1 B-DNA
cells I-cell_type
. O
Peroxizome O
proliferator-activated B-DNA
receptor-gamma B-protein
( O
PPARgamma I-DNA
) O
is O
a O
member O
of O
the O
nuclear I-DNA
receptor I-protein
family O
of O
transcription B-protein
factors I-protein
that O
regulate O
adipocyte O
differentiation O
. O
Recent O
studies O
indicate O
that O
liganded O
PPARgamma O
not O
only O
promotes O
differentiation O
but O
also O
inhibits O
the O
activation O
of O
macrophages O
. O
Osteopontin O
, O
a O
component O
of O
extracellular O
matrix I-protein
, O
is O
synthesized O
by O
macrophages O
in O
atherosclerotic O
plaques O
. O
In O
this O
study O
, O
we O
examined O
whether O
PPARgamma O
ligand O
regulates O
osteopontin B-DNA
gene I-DNA
expression O
in O
THP-1 B-DNA
cells I-cell_line
, O
a O
cell O
line O
derived O
from O
human O
monocytic B-cell_line
leukemia B-cell_type
cells I-cell_type
which O
can O
differentiate O
to O
macrophage O
upon O
stimulation O
with O
phorbol O
ester O
PMA O
. O
Northern O
blot O
analysis O
showed O
that O
osteopontin O
expression O
is O
markedly O
induced O
in O
response O
to O
PMA O
. O
Troglitazone I-protein
, O
a O
PPARgamma O
ligand I-protein
, O
dramatically O
attenuated O
the O
PMA-induced B-protein
osteopontin O
expression O
. O
Transient O
transfection O
assays O
of O
the O
human B-DNA
osteopontin I-cell_type
promoter/luciferase B-DNA
construct O
which O
contains O
a O
5'-flanking B-DNA
region O
between O
-1500 B-DNA
and O
+87 O
relative O
to O
the O
transcription O
start I-DNA
site I-DNA
demonstrate O
that O
either O
treatment O
with O
troglitazone O
or O
cotransfection O
of O
PPARgamma B-cell_type
expression O
vector O
inhibits O
osteopontin O
promoter I-DNA
activity O
. O
These O
data O
indicate O
that O
troglitazone O
reduces O
osteopontin B-DNA
gene I-DNA
expression O
at O
transcriptional O
level O
through O
PPARgamma O
activation O
, O
and O
suggest O
the O
role O
of O
troglitazone O
in O
inhibiting O
the O
ability O
of O
macrophages O
to O
produce O
extracellular O
matrix I-protein
, O
which O
is O
particularly O
relevant O
to O
atherosclerotic O
plaque O
formation O
. O
Transcription B-protein
factor I-protein
NF-kappa B-protein
B I-protein
regulates O
Ig O
lambda O
light O
chain B-DNA
gene I-DNA
rearrangement O
. O
The O
tissue- B-DNA
and O
stage-specific O
assembly O
of O
Ig O
and O
TCR I-DNA
genes I-DNA
is O
mediated O
by O
a O
common O
V O
( O
D I-DNA
) O
J O
recombinase O
complex I-protein
in O
precursor I-cell_type
lymphocytes I-cell_type
. O
Directed O
alterations O
in O
the O
accessibility O
of O
V O
, O
D O
, O
and O
J I-DNA
gene I-DNA
segments O
target I-cell_line
the O
recombinase O
to O
specific O
Ag B-DNA
receptor I-protein
loci O
. O
Accessibility B-cell_type
within O
a O
given O
locus O
is O
regulated O
by O
the O
functional O
interaction O
of O
transcription B-protein
factors I-protein
with O
cognate B-DNA
enhancer B-DNA
elements I-DNA
and O
correlates O
with O
the O
transcriptional O
activity O
of O
unrearranged B-DNA
gene I-DNA
segments O
. O
As O
demonstrated O
in O
our O
prior O
studies O
, O
rearrangement O
of O
the O
Igkappa O
locus O
is O
regulated O
by O
the O
inducible O
transcription B-protein
factor I-protein
NF-kappaB B-protein
. O
In O
contrast O
to O
the O
Igkappa O
locus O
, O
known O
transcriptional O
control O
elements I-DNA
in O
the O
Iglambda O
locus O
lack O
functional O
NF-kappaB O
binding O
sites O
. O
Consistent O
with O
this O
observation O
, O
the O
expression O
of O
assembled O
Iglambda I-DNA
genes I-DNA
in O
mature O
B I-DNA
cells I-cell_type
has O
been O
shown O
to O
be O
NF-kappaB O
independent O
. O
Nonetheless O
, O
we O
now O
show O
that O
specific O
repression O
of O
NF-kappaB O
inhibits O
germline O
transcription I-DNA
and O
recombination I-DNA
of O
Iglambda B-DNA
gene I-DNA
segments O
in O
precursor O
B I-DNA
cells I-cell_type
. O
Molecular O
analyses O
indicate O
that O
the O
block O
in O
NF-kappaB O
impairs O
Iglambda O
rearrangement O
at O
the O
level O
of O
recombinase O
accessibility O
. O
In O
contrast O
, O
the O
activities O
of O
known O
Iglambda O
promoter I-DNA
and I-DNA
enhancer I-DNA
elements I-DNA
are O
unaffected O
in O
the O
same O
cellular O
background O
. O
These O
findings O
expand O
the O
range O
of O
NF-kappaB O
action O
in O
precursor O
B I-DNA
cells I-cell_type
beyond O
Igkappa O
to O
include O
the O
control O
of O
recombinational O
accessibility O
at O
both O
L O
chain O
loci O
. O
Moreover O
, O
our O
results O
strongly O
suggest O
the O
existence O
of O
a O
novel O
Iglambda O
regulatory O
element I-DNA
that O
is O
either O
directly O
or O
indirectly O
activated O
by O
NF-kappaB O
during O
the O
early O
stages O
of O
B O
cell O
development O
. O
Transcription B-protein
factor I-protein
STAT5A B-protein
is O
a O
substrate O
of O
Bruton O
's B-protein
tyrosine I-protein
kinase I-protein
in O
B I-DNA
cells I-cell_type
. O
STAT5A B-protein
is O
a O
molecular O
regulator O
of O
proliferation O
, O
differentiation O
, O
and O
apoptosis O
in O
lymphohematopoietic B-cell_type
cells I-cell_type
. O
Here O
we O
show O
that O
STAT5A B-protein
can O
serve O
as O
a O
functional O
substrate O
of O
Bruton O
's B-protein
tyrosine I-protein
kinase I-protein
( O
BTK I-DNA
) O
. O
Purified O
recombinant O
BTK O
was O
capable O
of O
directly O
binding O
purified O
recombinant O
STAT5A B-protein
with O
high O
affinity O
( O
K O
( O
d O
) O
= O
44 O
nm O
) O
, O
as O
determined O
by O
surface I-protein
plasmon O
resonance O
using O
a O
BIAcore O
biosensor O
system O
. O
BTK O
was O
also O
capable O
of O
tyrosine-phosphorylating B-DNA
ectopically O
expressed O
recombinant O
STAT5A B-protein
on O
Tyr O
( O
694 O
) O
both O
in O
vitro O
and O
in O
vivo O
in O
a O
Janus O
kinase I-protein
3 O
-independent O
fashion O
. O
BTK O
phosphorylated O
the O
Y665F I-protein
, O
Y668F I-protein
, O
and O
Y682F I-DNA
, O
Y683F B-protein
mutants O
but O
not O
the O
Y694F B-protein
mutant O
of O
STAT5A B-protein
. O
STAT5A B-protein
mutations O
in O
the O
Src O
homology O
2 O
( O
SH2 B-protein
) O
and O
SH3 B-protein
domains O
did O
not O
alter O
the O
BTK O
-mediated B-protein
tyrosine I-protein
phosphorylation O
. O
Recombinant O
BTK O
proteins I-protein
with O
mutant O
pleckstrin O
homology O
, O
SH2 B-protein
, O
or O
SH3 B-protein
domains O
were O
capable O
of O
phosphorylating O
STAT5A I-protein
, O
whereas O
recombinant O
BTK O
proteins I-protein
with O
SH1/kinase I-protein
domain I-protein
mutations O
were O
not O
. O
In O
pull-down B-DNA
experiments O
, O
only O
full-length O
BTK O
and O
its O
SH1/kinase I-protein
domain I-protein
( O
but O
not O
the O
pleckstrin O
homology O
, O
SH2 B-protein
, O
or O
SH3 B-protein
domains O
) O
were O
capable O
of O
binding O
STAT5A B-protein
. O
Ectopically O
expressed O
BTK I-protein
kinase I-protein
domain I-protein
was O
capable O
of O
tyrosine-phosphorylating B-DNA
STAT5A B-protein
both O
in O
vitro O
and O
in O
vivo O
. O
BTK O
-mediated B-protein
tyrosine I-protein
phosphorylation O
of O
ectopically O
expressed O
wild I-DNA
type O
( O
but O
not O
Tyr O
( O
694 O
) O
mutant O
) O
STAT5A B-protein
enhanced O
its O
DNA O
binding O
activity O
. O
In O
BTK O
-competent O
chicken O
B I-DNA
cells I-cell_line
, O
anti-IgM-stimulated B-protein
tyrosine I-protein
phosphorylation O
of O
STAT5 B-protein
protein O
was O
prevented O
by O
pretreatment O
with O
the O
BTK O
inhibitor O
LFM-A13 B-protein
but O
not O
by O
pretreatment O
with O
the O
JAK3 B-protein
inhibitor O
HI-P131 B-protein
. O
B O
cell O
antigen I-DNA
receptor I-protein
ligation O
resulted O
in O
enhanced B-protein
tyrosine I-protein
phosphorylation O
of O
STAT5 B-protein
in O
BTK O
-deficient O
chicken O
B I-DNA
cells I-cell_type
reconstituted O
with O
wild I-DNA
type O
human B-DNA
BTK I-cell_type
but O
not O
in O
BTK O
-deficient O
chicken O
B I-DNA
cells I-cell_type
reconstituted O
with O
kinase-inactive O
mutant O
BTK O
. O
Similarly O
, O
anti-IgM O
stimulation O
resulted O
in O
enhanced B-protein
tyrosine I-protein
phosphorylation O
of O
STAT5A B-protein
in O
BTK O
-competent B-DNA
B I-DNA
cells I-cell_type
from O
wild I-DNA
type O
mice O
but O
not O
in O
BTK O
-deficient B-DNA
B I-DNA
cells I-cell_type
from O
XID O
mice O
. O
In O
contrast O
to O
B I-DNA
cells I-cell_type
from O
XID O
mice O
, O
B I-DNA
cells I-cell_type
from O
JAK3 B-protein
knockout O
mice O
showed O
a O
normal O
STAT5A B-protein
phosphorylation O
response O
to O
anti-IgM O
stimulation O
. O
These O
findings O
provide O
unprecedented O
experimental O
evidence O
that O
BTK O
plays O
a O
nonredundant O
and O
pivotal O
role O
in O
B O
cell O
antigen I-protein
receptor-mediated O
STAT5A B-protein
activation O
in O
B I-DNA
cells I-cell_type
Role O
of O
T-bet B-protein
in O
commitment O
of O
TH1 B-cell_type
cells I-cell_type
before O
IL-12 B-protein
-dependent O
selection O
. O
How O
cytokines O
control O
differentiation O
of O
helper B-cell_type
T I-cell_line
( O
TH I-DNA
) O
cells I-cell_type
is O
controversial O
. O
We O
show O
that O
T-bet I-DNA
, O
without O
apparent O
assistance O
from O
interleukin O
12 O
( O
IL-12 B-protein
) O
/ O
STAT4 I-protein
, O
specifies O
TH1 B-protein
effector O
fate O
by O
targeting O
chromatin O
remodeling O
to O
individual O
interferon-gamma I-cell_line
( O
IFN-gamma I-DNA
) O
alleles O
and O
by O
inducing O
IL-12 B-DNA
receptor I-protein
beta2 O
expression O
. O
Subsequently I-protein
, O
it O
appears O
that O
IL-12 B-protein
/ O
STAT4 B-protein
serves O
two O
essential O
functions O
in O
the O
development O
of O
TH1 B-cell_type
cells I-cell_type
: O
as O
growth O
signal O
, O
inducing O
survival O
and O
cell O
division O
; O
and O
as O
trans-activator I-DNA
, O
prolonging O
IFN-gamma B-protein
synthesis O
through O
a O
genetic O
interaction O
with O
the O
coactivator O
, O
CREB-binding B-DNA
protein O
. O
These O
results O
suggest O
that O
a O
cytokine O
does O
not O
simply O
induce O
TH B-protein
fate O
choice O
but O
instead O
may O
act O
as O
an O
essential O
secondary O
stimulus O
that O
mediates O
selective O
survival O
of O
a O
lineage O
. O
Stat6 O
is O
necessary O
and O
sufficient O
for O
IL-4 B-protein
's O
role O
in O
Th2 O
differentiation O
and O
cell O
expansion O
. O
IL-4 B-protein
plays O
a O
critical O
role O
in O
the O
differentiation O
of O
T I-cell_line
CR-stimulated B-protein
naive O
CD4 B-protein
T B-cell_type
cells O
to O
the O
Th2 O
phenotype O
. O
In O
response O
to O
IL-4 B-protein
, O
the O
IL-4R B-protein
activates O
a O
set O
of O
phosphotyrosine O
binding O
domain-containing O
proteins I-protein
, O
including O
insulin I-DNA
receptor I-protein
substrate O
1/2 O
, O
Shc B-protein
, O
and O
IL-4R B-protein
interacting O
protein I-protein
, O
as O
well O
as O
Stat6 O
. O
Stat6 O
has O
been O
shown O
to O
be O
required O
for O
Th2 O
differentiation O
. O
To O
determine O
the O
roles O
of O
the O
phosphotyrosine O
binding O
adaptors O
in O
Th2 O
differentiation O
, O
we O
prepared O
a O
retrovirus O
containing O
a O
mutant O
of O
the O
human B-DNA
( O
h O
) O
IL-4R B-protein
alpha-chain O
, O
Y497F I-protein
, O
which O
is O
unable O
to O
recruit O
these O
adaptors O
. O
The O
mutant O
hIL-4Ralpha O
, O
as O
well O
as O
the O
wild-type B-DNA
( O
WT I-DNA
) O
hIL-4Ralpha O
, O
was O
introduced O
into O
naive O
CD4 B-protein
T B-cell_type
cells I-cell_type
. O
Upon O
hIL-4 B-protein
stimulation O
, O
Y497F B-protein
worked O
as O
well O
as O
the O
WT B-protein
hIL-4Ralpha O
in O
driving O
Th2 O
differentiation O
, O
as O
measured O
by O
Gata3 O
up-regulation O
and O
IL-4 B-protein
production O
. O
Furthermore O
, O
IL-4-driven O
cell O
expansion O
was O
also O
normal O
in O
the B-cell_type
cells I-cell_type
infected O
with O
Y497F I-protein
, O
although B-cell_type
cells I-cell_type
infected O
with O
Y497F B-protein
were O
not O
capable O
of O
phosphorylating O
insulin I-DNA
receptor I-protein
substrate O
2 O
. O
These O
results O
suggest O
that O
the O
signal O
pathway O
mediated O
by O
Y497 B-protein
is O
dispensable O
for O
both O
IL-4 B-protein
-driven O
Th2 O
differentiation O
and O
cell O
expansion O
. O
Both O
WT O
and O
Y497F B-protein
hIL-4Ralpha O
lose O
the O
ability O
to O
drive O
Th2 O
differentiation O
and O
cell O
expansion O
in O
Stat6-knockout B-protein
CD4 B-protein
T B-cell_type
cells I-cell_type
. O
A O
constitutively O
activated O
form O
of O
Stat6 B-cell_type
introduced O
into O
CD4 B-protein
T B-cell_type
cells I-cell_type
resulted O
in O
both O
Th2 O
differentiation O
and O
enhanced O
cell O
expansion O
. O
Thus O
, O
activated O
Stat6 O
is O
necessary O
and O
sufficient O
to O
mediate O
both O
IL-4 B-protein
-driven O
Th2 O
differentiation O
and O
cell O
expansion O
in O
CD4 B-protein
T B-cell_type
cells I-cell_type
. O
The O
effect O
of O
HIV-1 O
regulatory O
proteins I-protein
on O
cellular I-DNA
genes I-DNA
: O
derepression O
of O
the O
IL-2 B-DNA
promoter I-DNA
by O
Tat O
. O
In O
HIV-infected B-protein
individuals O
dysregulation O
of O
the O
immune O
system O
is O
characterized O
by O
severe O
disorders O
of O
the O
cytokine O
network O
. O
Increase O
secretion O
of O
IL-2 B-protein
, O
the O
major O
T O
cell O
growth O
and O
differentiation O
cytokine O
, O
may O
play O
a O
decisive O
role O
in O
sensitization O
of O
T B-cell_type
cells I-cell_type
for O
activation O
induced O
apoptosis O
and O
indirect O
death O
of O
activated B-cell_type
T B-cell_type
cells I-cell_type
through O
augmented O
virus O
replication O
. O
We O
investigated O
the O
cause O
of O
enhanced O
IL-2 B-protein
secretion O
and O
found O
that O
the O
HIV O
Tat O
induces O
this O
effect O
. O
We O
demonstrate O
that O
increased O
IL-2 B-protein
secretion O
is O
due O
to O
Tat O
-enhanced O
IL-2 B-DNA
promoter I-DNA
activation O
. O
Tat O
derepresses O
and O
activates O
the O
distal O
AP-1 B-protein
site I-DNA
( O
position O
-185 O
to O
-177 B-protein
) O
in O
the O
IL-2 B-DNA
promoter I-DNA
. O
In O
nonstimulated B-cell_type
T B-cell_type
cells I-cell_type
a O
repressor O
complex I-protein
containing O
NF-IL6 I-protein
, O
JunB I-protein
, O
c-Fos O
and O
Fra-1 B-protein
is O
formed O
on O
the O
AP-1 B-protein
( O
IL-2/d B-protein
) O
site O
and O
represses O
IL-2 B-DNA
promoter I-DNA
activity O
. O
After O
T O
cell O
activation O
, O
a O
heterodimeric O
activator O
containing O
p65 O
and O
c-Jun O
binds O
to O
the O
AP-1 B-protein
( O
IL-2/d B-protein
) O
site O
. O
HIV O
Tat O
enhances O
activation O
of O
NF-kappaB O
and O
consequently O
, O
activates O
the O
AP-1 B-protein
( O
IL-2/d B-protein
) O
site O
. O
Our O
data O
provide O
evidence O
for O
a O
novel O
mechanism O
by O
which O
HIV O
Tat O
dysregulates O
IL-2 B-protein
production O
and O
therefore O
may O
contribute O
to O
the O
HIV-1 O
infection O
in O
a O
way O
yet O
to O
be O
clarified O
. O
Transforming O
growth O
factor-beta1 B-protein
interferes O
with O
thrombopoietin-induced O
signal O
transduction O
in O
megakaryoblastic O
and O
erythroleukemic B-cell_type
cells I-cell_type
. O
OBJECTIVE O
: O
Thrombopoietin O
( O
TPO I-DNA
) O
and O
transforming O
growth O
factor-beta B-DNA
( O
1 O
) O
( O
TGF-beta B-protein
( O
1 O
) O
) O
have O
been O
shown O
to O
exert O
opposite O
effects O
on O
proliferation O
and O
megakaryocytic O
differentiation O
of O
hematopoietic B-cell_type
cells I-cell_type
. O
To O
determine O
whether O
TGF-beta B-protein
( O
1 O
) O
interferes O
directly O
with O
TPO O
-induced O
signal O
transduction O
in O
hematopoietic B-cell_type
cells I-cell_type
, O
we O
compared O
the O
regulatory O
effects O
in O
the O
TPO O
-responsive O
cell O
lines I-cell_line
Mo-7e O
and O
HEL O
. O
MATERIALS O
AND O
METHODS I-protein
: O
The B-cell_type
cells I-cell_type
were O
stimulated O
by O
100 O
ng/mL O
TPO O
and/or I-cell_line
100 O
ng/mL O
TGF-beta1 O
and O
analyzed O
for O
proliferation O
( O
3H B-protein
thymidine O
incorporation O
) O
, O
viability O
( O
trypan O
blue O
exclusion O
) O
, O
and O
protein O
expression O
and O
phosphorylation O
( O
Western O
blot O
) O
. O
RESULTS I-protein
: O
TPO O
enhanced O
the O
proliferation O
of O
Mo-7e B-cell_type
cells I-cell_type
as O
determined O
by O
3H-thymidine B-protein
incorporation O
, O
whereas O
TGF-beta1 B-protein
suppressed O
baseline O
cell O
growth O
and O
antagonized O
the O
proliferative O
effect O
of O
TPO B-cell_type
. O
TPO O
-induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen-activated B-DNA
protein O
kinase I-protein
( O
MAPK I-DNA
) O
pathway O
( O
PD098059 B-protein
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK O
extracellular O
signal-regulated O
kinases I-protein
( O
ERK I-DNA
) O
ERK1 O
and O
ERK2 I-protein
, O
and O
AG490 I-protein
, O
an O
inhibitor O
of O
Janus O
kinase-2 B-protein
, O
which O
completely O
blocked O
TPO O
-induced O
proliferation O
. O
As O
demonstrated O
by O
Western O
blotting O
, O
TGF-beta1 O
reduced O
the O
TPO O
-stimulated O
ERK1 B-protein
/ O
ERK2 B-protein
and O
STAT5 B-protein
phosphorylation O
in O
Mo-7e B-DNA
and O
HEL B-cell_type
cells I-cell_type
. O
This O
effect O
was O
completely O
reversed O
by O
preincubation O
with O
a O
tyrosine I-protein
phosphatase O
inhibitor O
( O
Na3VO4 I-DNA
) O
, O
which O
suggests O
that O
TGF-beta1 B-protein
activated O
a O
phosphatase O
. O
Although O
STAT3 B-protein
also O
was O
activated O
by O
TPO I-protein
, O
STAT3 B-protein
activation O
remained O
unaltered O
by O
TGF-beta1 B-protein
. O
CONCLUSION I-protein
: O
Taken O
together O
, O
these O
data O
suggest O
that O
TGF-beta1 B-protein
modulates O
TPO O
-mediated O
effects O
on O
megakaryocytic O
proliferation O
by O
interfering O
with O
TPO O
-induced O
signal O
transduction O
, O
particularly O
by O
reducing O
the O
activities O
of O
MAPK O
ERK1/ERK2 O
and O
STAT5 B-protein
. O
Invariant O
chain O
induces O
B O
cell O
maturation O
by O
activating O
a O
TAF I-protein
( O
II I-DNA
) O
105-NF-kappaB O
-dependent B-protein
transcription O
program O
. O
Early O
stages O
of O
B O
cell O
development O
occur O
in O
the O
bone I-cell_line
marrow I-cell_line
, O
resulting O
in O
formation O
of O
immature O
B I-DNA
cells I-cell_type
. O
From O
there O
these O
immature B-cell_type
cells I-cell_type
migrate O
to O
the O
spleen O
where O
they O
differentiate O
to O
mature B-cell_type
cells I-cell_type
. O
This O
final O
maturation O
step O
is O
crucial O
for O
the O
B I-DNA
cells O
to O
become O
responsive O
to O
antigens O
and O
to O
participate O
in O
the O
immune O
response O
. O
Recently O
, O
invariant O
chain O
( O
Ii O
) O
, O
a O
major O
histocompatibility I-protein
complex I-protein
class I-protein
II I-protein
chaperone I-protein
, O
as O
well O
as O
the O
transcription B-protein
factors I-protein
c-Rel O
and O
p65/RelA I-DNA
, O
were O
found O
to O
play O
a O
role O
in O
the O
final O
antigen-independent B-DNA
differentiation O
stage O
of O
B I-DNA
cells I-cell_type
in O
the O
spleen O
. O
In O
this O
study O
, O
we O
investigated O
a O
possible O
link O
between O
Ii O
-dependent B-DNA
B O
cell O
maturation O
and O
the O
NF-kappaB O
pathway O
. O
Our O
studies O
indicate O
that O
Ii O
-induced B-DNA
B O
cell O
maturation O
involves O
activation O
of O
transcription O
mediated O
by O
the O
NF-kappaB O
p65/RelA B-protein
homodimer O
and O
requires O
the O
B I-DNA
cell-enriched I-DNA
coactivator O
TBP-associated B-protein
factor I-protein
( O
II I-DNA
) O
105 O
. O
Androgens O
indirectly O
accelerate O
thymocyte O
apoptosis O
. O
Apoptotic O
processes O
, O
or O
the O
disturbance O
of O
the O
natural O
regulation O
of O
these O
processes O
, O
may O
be O
involved O
in O
the O
pathogenesis O
of O
autoimmune O
diseases O
( O
AID I-DNA
) O
. O
Women O
are O
, O
in O
general O
, O
more O
susceptible O
than O
men O
to O
develop O
AID O
like O
rheumatoid O
arthritis O
. O
Androgens O
and O
glucocorticoids O
, O
in O
contrast O
to O
oestrogens O
, O
have O
favourable O
effects O
in O
AID O
models O
as O
well O
as O
in O
human B-DNA
AID I-cell_type
. O
It O
is O
known O
that O
glucocorticoids O
( O
GC I-DNA
) O
, O
used O
for O
treatment O
of O
AID I-protein
, O
increase O
apoptosis O
in O
the O
thymus O
resulting O
in O
decreased O
numbers O
of O
CD4+ B-protein
CD8+ B-protein
thymocytes O
. O
It O
was O
asked O
whether O
androgens O
, O
in O
contrast O
to O
oestrogens O
, O
exert O
their O
favourable O
effects O
in O
the O
treatment O
of O
AID B-cell_type
by O
a O
mechanism O
comparable O
to O
that O
described O
for O
GC B-protein
by O
eliminating O
the O
apoptosis O
prone O
CD4+ B-protein
CD8+ B-protein
population O
in O
the O
thymus O
. O
Although O
both O
androgens O
and O
oestrogens O
proved O
thymolytic O
, O
a O
significantly O
decreased O
percentage O
of O
CD4+ B-protein
CD8+ B-protein
thymocytes O
was O
observed O
by O
flow O
cytometry O
after O
treatment O
of O
mice O
with O
the O
androgen O
methyltestosterone I-protein
, O
but O
not O
with O
the O
oestrogen O
ethinylestradiol O
. O
To O
investigate O
whether O
the O
observed O
thymolytic O
effects O
were O
due O
to O
the O
presence O
of O
hormone O
receptors O
on O
thymocytes O
, O
cells I-cell_type
were O
isolated O
from O
the O
thymus O
and O
incubated O
with O
androgens O
or O
oestrogens O
to O
measure O
apoptosis O
. O
Several O
techniques O
were O
used O
to O
determine O
thymocyte O
apoptosis O
in O
vitro O
, O
but O
no O
enhanced O
apoptotic O
signal O
was O
observed O
. O
Using O
the O
very O
sensitive O
TUNEL O
assay O
, O
no O
direct O
effect O
of O
androgens O
on O
thymocytes O
in O
vitro O
could O
be O
observed O
. O
This O
is O
in O
sharp O
contrast O
to O
the O
high O
signal O
observed O
with O
GC B-protein
. O
Therefore O
, O
upon O
in O
vivo O
androgen O
treatment O
, O
other O
cells I-cell_type
containing O
androgen O
receptors O
than O
thymocytes O
are O
probably O
involved O
in O
inducing O
the O
increase O
in O
thymic B-cell_line
apoptosis O
. O
To O
study O
the O
role O
of O
the O
androgen I-DNA
receptor I-protein
on O
thymocyte O
apoptosis O
, O
androgen I-DNA
receptor I-protein
mutant O
( O
Tfm/Y I-DNA
) O
mice O
were O
treated O
with O
androgens O
. O
No O
alterations O
of O
thymocyte O
subpopulations O
were O
seen O
, O
suggesting O
that O
changes O
in O
the O
percentage O
of O
CD4+ B-protein
CD8+ B-protein
thymocytes O
after O
administration O
of O
androgens O
depend O
on O
the O
presence O
of O
functional O
androgen O
receptors O
. O
Thus O
, O
it O
is O
concluded O
that O
androgens O
indirectly O
accelerate O
thymocyte O
apoptosis O
in O
vivo O
. O
Inhibition O
of O
the O
transcription B-protein
factors I-protein
AP-1 O
and O
NF-kappaB O
in O
CD4 B-protein
T B-cell_type
cells I-cell_type
by O
peroxisome O
proliferator-activated B-DNA
receptor I-protein
gamma O
ligands O
. O
The O
peroxisome O
proliferator-activated B-DNA
receptor I-protein
gamma O
( O
PPARgamma I-DNA
) O
, O
a O
member O
of O
the O
nuclear B-protein
hormone I-DNA
receptor I-protein
superfamily O
, O
is O
essential O
for O
adipocyte O
differentiation O
and O
glucose O
homeostasis O
. O
PPARgamma O
has O
been O
found O
recently O
to O
regulate O
macrophage O
activation O
in O
response O
to O
mitogens O
and O
inflammation O
. O
Our O
study O
shows O
PPARgamma O
to O
be O
preferentially O
expressed O
in O
the O
nuclei O
of O
resting B-cell_type
T B-cell_type
cells I-cell_type
and O
to O
increase O
upon O
activation O
of O
T B-cell_type
cells I-cell_type
by O
either O
anti-CD3 B-protein
and O
anti-CD28 B-protein
or O
phorbol O
myristyl O
acetate O
( O
PMA I-DNA
) O
. O
We O
also O
found O
the O
PPARgamma O
ligand O
ciglitizone O
to O
attenuate O
the O
activation O
of O
T B-cell_type
cells I-cell_type
by O
inhibiting O
cytokine B-DNA
gene I-DNA
expression O
and O
anti-CD3 B-protein
and O
anti-CD28 B-protein
or O
PMA-induced B-protein
proliferative O
responses O
. O
Inhibition O
of O
both O
the O
proliferative O
response O
and O
inflammatory O
cytokine O
expression O
in O
CD4 B-protein
T B-cell_type
cells I-cell_type
was O
correlated O
with O
suppression O
of O
the O
activated O
transcription B-protein
factors I-protein
AP1 O
and O
NF-kappaB O
. O
PPARgamma O
ligands O
also O
strongly O
inhibited O
SEA-induced B-protein
Vbeta3 B-cell_type
T O
cell O
activation O
in O
vivo O
. O
These O
results O
, O
together O
with O
previous O
findings O
of O
the O
inhibitory O
effect O
of O
PPARgamma B-cell_type
ligands O
on O
activated O
macrophages O
, O
provide O
clear O
evidence O
for O
PPARgamma O
as O
a O
negative O
regulator O
of O
the O
inflammatory O
activation O
of O
both O
macrophage O
and O
T B-cell_type
cells I-cell_type
. O
PPARgamma O
may O
thus O
be O
a O
potential O
therapeutic O
target I-cell_line
for O
the O
treatment O
of O
autoimmunity O
. O
A O
prominent O
role O
for O
activator O
protein-1 B-protein
in O
the O
transcription I-DNA
of O
the O
human B-DNA
2B4 I-cell_type
( O
CD244 B-protein
) O
gene I-DNA
in O
NK B-cell_type
cells I-cell_type
. O
The O
cell O
surface I-protein
glycoprotein O
2B4 B-protein
( O
CD244 B-protein
) O
of O
the O
Ig O
superfamily O
is O
involved O
in O
the O
regulation O
of O
NK B-cell_type
and O
T I-cell_line
lymphocyte I-cell_line
functions O
. O
We O
have O
recently O
identified O
CD48 B-protein
as O
the O
high O
affinity O
counterreceptor O
for O
2B4 B-protein
in O
both O
mice O
and O
humans O
. O
The O
cytoplasmic I-protein
domain I-protein
of O
2B4 B-cell_type
associates O
with O
src O
homology O
2 O
domain-containing O
protein O
or O
signaling O
lymphocyte I-cell_line
activation O
molecule-associated B-DNA
protein I-protein
, O
whose O
mutation O
is O
the O
underlying O
genetic O
defect O
in O
the O
X-linked B-protein
lymphoproliferative O
syndrome O
. O
In O
this O
study O
, O
we O
report O
the O
molecular O
cloning O
and O
characterization O
of O
the O
human B-DNA
2B4 I-cell_type
( O
h2B4 I-DNA
) O
promoter I-DNA
. O
Through O
primer O
extension O
analysis O
, O
we O
found O
that O
the O
transcription I-DNA
of O
the O
h2B4 B-DNA
gene I-DNA
initiates O
at O
multiple O
start I-DNA
sites I-DNA
. O
We O
isolated O
h2B4 O
genomic O
clones O
and O
PCR O
amplified O
the O
5 O
' O
untranslated O
region O
containing O
the O
promoter I-DNA
elements O
. O
We O
have O
identified O
a O
functional O
AP-1 B-protein
site I-DNA
that O
lies O
between O
( O
-106 O
to O
-100 B-protein
) O
through O
transient O
transfection O
analysis O
in O
YT B-cell_type
cells I-cell_line
, O
a O
human B-DNA
NK I-cell_type
cell O
line O
. O
EMSAs O
with O
Abs O
specific O
for O
various O
protein B-protein
factors I-protein
of O
the O
AP-1 B-protein
family O
revealed O
that O
multiple O
members O
of O
the O
Jun O
family O
are O
involved O
in O
the O
regulation O
of O
the O
h2B4 B-DNA
gene I-DNA
. O
Mutation O
of O
the O
AP-1 B-protein
site I-DNA
not O
only O
abolishes O
protein/DNA O
interactions O
but O
also O
promoter I-DNA
activity O
. O
These O
results O
demonstrate O
a O
significant O
role O
for O
AP-1 B-protein
in O
the O
transcriptional O
regulation O
of O
the O
h2B4 B-DNA
gene I-DNA
. O
Functional O
correction O
of O
FA-C B-protein
cells I-cell_type
with O
FANCC O
suppresses O
the O
expression O
of O
interferon O
gamma-inducible I-DNA
genes I-DNA
. O
Because O
hematopoietic B-cell_type
cells I-cell_type
derived O
from O
Fanconi O
anemia O
( O
FA I-DNA
) O
patients O
of O
the O
C-complementation B-DNA
group O
( O
FA-C B-protein
) O
are O
hypersensitive O
to O
the O
inhibitory O
effects O
of O
interferon O
gamma O
( O
IFNgamma I-DNA
) O
, O
the O
products O
of O
certain O
IFNgamma-inducible I-DNA
genes I-DNA
known O
to O
influence O
hematopoietic B-cell_type
cell O
survival O
were O
quantified O
. O
High O
constitutive O
expression O
of O
the O
IFNgamma-inducible I-DNA
genes I-DNA
, O
IFN-stimulated B-DNA
gene I-DNA
factor O
3 O
gamma O
subunit O
( O
ISGF3gamma I-DNA
) O
, O
IFN O
regulatory O
factor-1 B-protein
( O
IRF-1 O
) O
, O
and O
the O
cyclin-dependent O
kinase I-protein
inhibitor O
p21 I-cell_line
( O
WAF1 B-protein
) O
was O
found O
in O
FANCC O
mutant O
B I-DNA
lymphoblasts O
, O
low-density O
bone I-cell_line
marrow I-cell_line
cells I-cell_line
, O
and O
murine I-cell_line
embryonic B-cell_type
fibroblasts O
. O
Paradoxically B-cell_type
, O
these O
cells I-cell_type
do O
not O
activate O
signal O
transducer O
and O
activator O
of O
transcription O
( O
STAT B-protein
) O
1 O
properly O
. O
In O
an O
attempt O
to O
clarify O
mechanisms O
by O
which O
FA-C B-protein
cells I-cell_type
overexpress O
IFNgamma-inducible I-DNA
genes I-DNA
in O
the O
face O
of O
defective O
STAT1 B-protein
phosphorylation O
, O
it O
was O
reasoned O
that O
decreased O
levels O
of O
activated O
STAT1 B-protein
might O
result O
in O
reduced O
expression O
of O
a O
hematopoietic B-cell_type
IFNgamma-responsive O
protein O
that O
normally O
modulates O
expression O
of O
other O
IFNgamma-responsive I-DNA
genes I-DNA
. O
Levels O
of O
the O
IFNgamma O
-inducible B-protein
factor I-protein
IFN O
consensus O
sequence O
binding O
protein O
( O
ICSBP I-DNA
) O
, O
a O
negative O
trans-acting B-DNA
regulator O
of O
some O
IFNgamma-inducible I-DNA
genes I-DNA
, O
were O
quantified O
. O
ICSBP O
levels O
were O
reduced O
in O
FA-C B-protein
B I-DNA
lymphoblasts O
and O
MEFs O
. O
However O
, O
enforced O
expression O
of O
ICSBP O
failed O
to O
down-regulate O
IRF-1 O
, O
ISGF3gamma O
, O
and O
p21 B-protein
( O
WAF1 B-protein
) O
. O
Thus O
, O
the O
FANCC I-protein
protein O
functions O
to O
modulate O
expression O
of O
a O
family O
of O
genes I-DNA
that O
in O
normal O
cells I-cell_type
are O
inducible O
only O
by O
specific O
environmental O
cues O
for O
apoptosis O
or O
mitogenic O
inhibition O
, O
but O
it O
does O
so O
independently O
of O
the O
classic O
IFN-STAT1 B-protein
pathway O
and O
is O
not O
the O
direct O
result O
of O
reduced O
ICSBP O
expression O
. O
A O
genetic O
investigation O
of O
E2A B-protein
function O
in O
lymphocyte I-cell_line
development O
. O
Lymphocytes O
are O
derived O
from O
hematopoietic B-cell_type
stem I-cell_type
cells I-cell_line
( O
HSC I-DNA
) O
following O
a O
series O
of O
regulated O
differentiation O
events O
. O
Multipotent O
HSCs O
become O
committed O
to O
the O
B O
cell O
lineage I-cell_type
in O
bone I-cell_line
marrow I-cell_line
and O
the O
T O
cell O
lineage I-cell_type
in O
the O
thymus O
after O
receiving O
appropriate O
signals O
from O
the O
corresponding O
microenvironment O
. O
These O
committed O
lymphoid B-cell_type
cells I-cell_type
must O
then O
undergo O
V O
( O
D I-DNA
) O
J O
recombination O
at O
the O
immunoglobulin O
gene I-DNA
or O
T O
cell I-DNA
receptor I-DNA
gene I-DNA
locus O
resulting O
in O
clonal O
production O
of O
functional O
B I-DNA
or O
T I-cell_type
lymphocytes I-cell_type
, O
respectively O
. O
Lymphocyte O
commitment O
and O
differentiation O
are O
accompanied O
by O
programmed O
gene I-DNA
expression O
or O
repression O
events O
which O
are O
driven O
by O
lineage I-cell_type
and O
stage O
specific O
transcription B-protein
factors I-protein
. O
The O
basic-helix-loop-helix B-protein
( O
bHLH I-DNA
) O
transcription B-protein
factors I-protein
encoded O
by O
the O
E2A B-DNA
gene I-DNA
are O
involved O
in O
several O
differentiation O
events O
during O
B I-DNA
and O
T O
cell O
development O
, O
including O
lineage O
commitment O
, O
initiation O
of O
V O
( O
D I-DNA
) O
J O
recombination O
, O
and O
antigen I-DNA
receptor I-protein
mediated O
proliferation O
and O
differentiation O
. O
Several O
recent O
reviews O
have O
provided O
a O
comprehensive O
discussion O
of O
biochemical O
, O
cellular O
, O
and O
genetic O
research O
on O
E2A B-protein
function O
in O
lymphocyte I-cell_line
development O
( O
1 O
, O
2 O
) O
. O
Here O
, O
we O
only O
discuss O
some O
of O
the O
genetic O
approaches O
our O
laboratory O
( O
except O
where O
it O
is O
noted O
) O
has O
undertaken O
to O
investigate O
the O
molecular O
pathways O
mediated O
by O
E2A B-protein
transcription B-protein
factors I-protein
in O
lymphocyte I-cell_line
development O
D609 B-protein
inhibits O
ionizing O
radiation-induced B-DNA
oxidative O
damage O
by O
acting O
as O
a O
potent O
antioxidant O
. O
Tricyclodecan-9-yl-xanthogenate B-protein
( O
D609 B-protein
) O
has O
been O
extensively O
studied O
in O
biological O
systems O
and O
exhibits O
a O
variety O
of O
biological O
functions O
, O
including O
antiviral O
, O
antitumor O
, O
and O
anti-inflammatory O
activities O
. O
Most O
of O
these O
activities O
have O
been O
largely O
attributed O
to O
the O
inhibitory O
effect O
of O
D609 B-protein
on O
phosphatidylcholine-specific B-DNA
phospholipase B-protein
C I-protein
. O
However O
, O
as O
a O
xanthate O
derivative O
, O
D609 B-protein
is O
a O
strong O
electrolyte O
and O
readily O
dissociates O
to O
xanthate O
anions O
and O
cations O
of O
alkali O
metals O
in O
solution O
. O
Xanthate O
anions O
and O
protonated O
xanthic O
acid O
contain O
a O
free O
thiol O
moiety O
and O
are O
highly O
reductive O
. O
This O
implies O
that O
D609 B-protein
and O
other O
xanthate O
derivatives O
may O
function O
as O
potent O
antioxidants O
. O
Indeed O
, O
we O
found O
that O
D609 B-protein
inhibited O
the O
Fenton O
reaction-induced I-cell_line
oxidation O
of O
dihydrorhodamine O
123 O
in O
a O
dose-dependent O
manner O
similar O
to O
that O
of O
pyrrolidinedithiocarbamate B-RNA
, O
a O
well O
known O
antioxidant O
. O
In O
addition O
, O
D609 B-protein
inhibited O
the O
formation O
of O
the O
alpha-phenyl-tert-butylnitrone-free B-protein
radical O
spin O
adducts O
and O
lipid O
peroxidation O
of O
synaptosomal O
membranes O
by O
the O
Fenton O
reagents O
. O
Furthermore O
, O
preincubation O
of O
lymphocytes I-cell_type
with O
D609 B-protein
resulted O
in O
a O
significant O
diminution O
of O
ionizing O
radiation O
( O
IR I-DNA
) O
-induced O
1 O
) O
production O
of O
reactive O
oxygen O
species O
; O
2 O
) O
decrease O
in O
intracellular O
reduced O
glutathione O
; O
3 O
) O
oxidative O
damage O
to O
proteins I-protein
and O
lipids O
; O
and O
4 O
) O
activation O
of O
nuclear B-protein
factor-kappaB B-protein
. O
Moreover O
, O
when O
D609 B-protein
( O
50 O
mg/kg B-DNA
i.v. I-DNA
) O
was O
administered O
to O
mice O
10 O
min O
prior O
to O
total O
body O
IR I-cell_line
( O
6.5 I-DNA
and O
8.5 B-protein
Gy O
) O
, O
it O
protected O
the O
mice O
from O
IR-induced B-protein
lethality O
. O
Thus O
, O
these O
results O
indicate O
that O
D609 B-protein
is O
a O
potent O
antioxidant O
and O
has O
the O
ability O
to O
inhibit O
IR-induced B-protein
cellular O
oxidative O
stress O
. O
Inhibition O
of O
AP-1 B-protein
by O
the O
glucocorticoid-inducible B-DNA
protein O
GILZ I-protein
. O
The O
immunosuppressive O
effects O
of O
glucocorticoids O
arise O
largely O
by O
inhibition O
of O
cytokine B-DNA
gene I-DNA
expression O
, O
which O
has O
been O
ascribed O
to O
interference O
between O
the O
glucocorticoid I-DNA
receptor I-protein
and I-DNA
transcription B-protein
factors I-protein
such O
as O
AP-1 B-protein
and O
NF-kappa B-protein
B I-protein
as O
well O
as O
by O
competition O
for O
common O
coactivators O
. O
Here O
we O
show O
that O
glucocorticoid-induced B-DNA
inhibition O
of O
interleukin-2 B-protein
mRNA I-RNA
expression O
in O
activated O
normal O
T B-cell_type
cells I-cell_type
required O
new O
protein O
synthesis O
, O
suggesting O
that O
this O
phenomenon O
is O
secondary O
to O
expression O
of O
glucocorticoid-regulated I-DNA
genes I-DNA
. O
One O
of O
the O
most O
prominent O
glucocorticoid-induced I-DNA
genes I-DNA
is O
glucocorticoid-induced B-DNA
leucine O
zipper O
( O
GILZ I-DNA
) O
, O
which O
has O
been O
reported O
to O
inhibit O
activation-induced O
up-regulation I-DNA
of O
Fas O
ligand O
( O
FasL I-DNA
) O
mRNA I-RNA
. O
Indeed O
, O
transient O
expression O
of O
GILZ O
in O
Jurkat O
T B-cell_type
cells I-cell_type
blocked O
induction O
of O
a O
reporter O
construct O
driven O
by O
the O
FasL B-DNA
promoter I-DNA
. O
This O
could O
be O
accounted O
for O
by O
GILZ O
-mediated O
inhibition O
of O
Egr-2 B-protein
and O
Egr-3 B-protein
, O
NFAT/AP-1 B-protein
-inducible B-protein
transcription B-protein
factors I-protein
that O
bind O
a O
regulatory O
element I-DNA
in O
the O
FasL B-DNA
promoter I-DNA
and O
up-regulate O
FasL O
expression O
. O
GILZ O
also O
potently O
inhibited O
AP-1-driven B-DNA
and O
IL-2 B-protein
promoter-driven O
reporter O
constructs O
, O
and O
recombinant O
GILZ O
specifically O
interacted O
with O
c-Fos O
and O
c-Jun O
in O
vitro O
and O
inhibited O
the O
binding O
of O
active O
AP-1 O
to O
its O
target I-cell_line
DNA O
. O
Whereas O
homodimerization O
of O
GILZ O
required O
the O
presence O
of O
its O
leucine O
zipper I-protein
, O
the O
interaction O
with O
c-Fos O
and O
c-Jun O
occurred O
through O
the O
N-terminal B-protein
60-amino O
acid O
region I-DNA
of O
GILZ O
. O
Thus O
, O
GILZ O
represents O
a O
glucocorticoid-induced B-DNA
gene I-DNA
product O
that O
can O
inhibit O
a O
variety O
of O
activation-induced O
events O
, O
at O
least O
in O
part O
by O
direct O
interference O
with O
AP-1 B-protein
, O
and O
is O
therefore O
a O
candidate O
for O
a O
mediator O
of O
glucocorticoid-induced B-DNA
immunosuppression O
. O
Pharmacokinetic O
differences O
between O
a O
T I-cell_line
cell-tolerizing O
and O
a O
T I-cell_line
cell-activating O
peptide O
. O
Vaccination O
with O
a O
peptide O
representing O
a O
CTL O
epitope O
from O
the O
human B-DNA
papillomavirus I-cell_type
( O
HPV I-DNA
) O
16 O
E7 I-protein
protein O
induces O
a O
specific O
CTL O
response O
that O
prevents O
the O
outgrowth O
of O
HPV16 B-protein
E7-expressing B-protein
tumors O
. O
In O
contrast O
, O
vaccination O
with O
a O
peptide O
encoding O
an O
adenovirus O
type O
5 O
( O
Ad5 B-protein
) O
E1A B-protein
CTL O
epitope O
results O
in O
CTL O
tolerance O
and O
enhanced O
growth O
of O
an O
Ad5 O
E1A-expressing B-protein
tumor O
. O
It O
is O
unclear O
why O
these O
peptides O
induce O
such O
opposite O
effects O
. O
To O
determine O
whether O
a O
difference O
in O
pharmacokinetics O
can O
explain O
the O
functional O
contrasts O
, O
tritiated O
Ad5 O
E1A B-protein
and O
HPV16 B-protein
E7 B-protein
peptides O
were O
injected O
into O
mice O
. O
Results O
show O
that O
the O
tolerizing O
peptide O
spread O
through O
the O
body O
16 O
times O
faster O
than O
the O
activating O
peptide O
and O
was O
cleared O
at O
least O
2 O
times O
faster O
. O
The O
HPV16 B-protein
E7 B-protein
peptide O
kinetics O
correlated O
with O
the O
kinetics O
of O
HPV16 B-protein
E7 B-protein
-specific O
CTL O
induction O
. O
In O
contrast O
, O
Ad5 O
E1A B-protein
peptide O
injection O
resulted O
in O
physical O
deletion O
of O
preexisting O
Ad5 O
E1A B-protein
-specific O
CTLs O
within O
24 O
h O
after O
injection O
. O
This O
tolerization O
occurred O
at O
the O
time O
when O
the O
peptide O
reached O
its O
maximum O
peptide O
concentration O
in O
the O
organs O
. O
These O
data O
suggest O
that O
ubiquitous O
expression O
of O
the O
tolerizing O
Ad5 O
E1A B-protein
peptide O
within O
a O
short O
period O
of O
time O
causes O
activation-induced O
cell O
death O
of O
Ad5 B-cell_type
E1A B-protein
-specific O
CTLs O
. O
Therefore O
, O
information O
on O
the O
pharmacokinetics O
of O
peptides O
is O
vital O
for O
the O
safety O
and O
efficacy O
of O
peptide-based B-cell_type
vaccines O
. O
Smad3 I-cell_type
and O
Smad4 O
mediate O
transforming O
growth O
factor-beta1 B-protein
-induced O
IgA O
expression O
in O
murine I-cell_line
B I-DNA
lymphocytes I-cell_type
. O
Transforming O
growth I-protein
factor I-protein
( O
TGF I-DNA
) O
-beta1 O
is O
well O
established O
as O
a O
critical O
IgA O
isotype O
switching B-protein
factor I-protein
and O
Smad O
molecules I-protein
have O
been O
reported O
to O
act O
as O
transducers O
and O
transcriptional O
factors I-protein
in O
the O
expression O
of O
TGF-beta1 B-protein
-targeted I-DNA
genes I-DNA
. O
We O
examined O
the O
involvement O
of O
Smad O
proteins I-protein
in O
TGF-beta1 B-protein
-induced O
IgA O
expression O
. O
First O
, O
we O
found O
that O
TGF-beta1 B-protein
significantly O
increases O
endogenous O
germ-line B-DNA
( O
GL I-DNA
) O
alpha I-RNA
transcripts I-RNA
by O
LPS-stimulated B-protein
CH12.LX.4933 B-protein
( O
mu O
( O
+ O
) O
) O
B I-DNA
lymphoma O
cells I-cell_type
. O
To O
investigate O
its O
signaling O
mechanisms O
, O
the O
lymphoma O
cell O
line O
was O
transfected O
with O
pFL3 O
that O
contains O
the O
TGF-beta-responsive B-DNA
element I-DNA
of O
the O
GLalpha B-DNA
promoter I-DNA
, O
and O
stimulated O
with O
TGF-beta1 B-protein
. O
Similar O
to O
endogenous O
GLalpha I-RNA
transcripts I-RNA
, O
TGF-beta1 O
induces O
GLalpha B-DNA
promoter I-DNA
activity O
and O
overexpression O
of O
Smad3 B-cell_type
markedly O
enhances O
the O
promoter I-DNA
activity O
. O
This O
activity O
is O
further O
augmented O
by O
cotransfected O
Smad4 O
. O
On O
the O
other O
hand O
, O
Smad7 O
substantially O
abrogates O
the O
synergistic O
effect O
of O
Smad3/4 B-cell_type
on O
GLalpha B-DNA
promoter I-DNA
activity O
. O
In O
addition O
, O
overexpression O
of O
Smad3/4 B-cell_type
enhances O
TGF-beta1 B-protein
-induced O
endogenous O
GLalpha I-RNA
transcripts I-RNA
in O
normal O
spleen O
B O
cell O
s O
. O
Finally O
, O
in O
the O
presence O
of O
TGF-beta1 O
, O
overexpression O
of O
Smad3/4 B-cell_type
selectively O
increases O
both O
surface I-protein
IgA O
expression O
and O
IgA O
production O
. O
The O
results O
from O
the O
present O
study O
indicate O
that O
Smad3 I-cell_line
, O
Smad4 O
, O
and O
Smad7 I-DNA
, O
at O
least O
in O
part O
, O
serve O
as O
mediators O
linking O
TGF-beta1 O
to O
transcriptional O
regulation O
of O
IgA B-cell_type
switching O
related O
gene I-DNA
and O
regulation O
of O
IgA B-cell_type
class B-protein
switching O
. O
The O
translesion O
DNA O
polymerase O
zeta O
plays O
a O
major O
role O
in O
Ig O
and O
bcl-6 B-protein
somatic O
hypermutation O
. O
Ig O
somatic O
mutations O
would O
be O
introduced O
by O
a O
polymerase O
( O
pol O
) O
while O
repairing O
DNA O
outside O
main O
DNA O
replication O
. O
We O
show O
that O
human B-DNA
B I-DNA
cells I-cell_type
constitutively O
express O
the O
translesion O
pol O
zeta O
, O
which O
effectively O
extends O
DNA O
past O
mismatched O
bases O
( O
mispair O
extender O
) O
, O
and O
pol O
eta O
, O
which O
bypasses O
DNA O
lesions O
in O
an O
error-free B-DNA
fashion O
. O
Upon O
B O
cell I-DNA
receptor I-protein
( O
BCR I-DNA
) O
engagement O
and O
coculture O
with O
activated O
CD4+ B-cell_type
T B-cell_type
cells I-cell_type
, O
these I-cell_type
lymphocytes I-cell_type
upregulated O
pol O
zeta O
, O
downregulated O
pol O
eta O
, O
and O
mutated O
the O
Ig O
and O
bcl-6 I-DNA
genes I-DNA
. O
Inhibition O
of O
the O
pol O
zeta O
REV3 B-protein
catalytic O
subunit O
by O
specific O
phosphorothioate-modified B-DNA
oligonucleotides O
impaired O
Ig O
and O
bcl-6 B-protein
hypermutation O
and O
UV B-protein
damage-induced O
DNA O
mutagenesis O
, O
without O
affecting O
cell O
cycle O
or O
viability O
. O
Thus O
, O
pol O
zeta O
plays O
a O
critical O
role O
in O
Ig O
and O
bcl-6 B-protein
hypermutation O
, O
perhaps O
facilitated O
by O
the O
downregulation O
of O
pol O
eta O
. O
Molecular O
mechanism O
of O
cell O
cycle O
progression O
induced O
by O
the O
oncogene O
product O
Tax O
of O
human B-cell_type
T-cell O
leukemia O
virus O
type O
I I-protein
. O
The O
trans-activator O
protein O
Tax O
of O
human B-cell_type
T-cell O
leukemia O
virus O
type O
I I-protein
( O
HTLV-I B-protein
) O
plays O
an O
important O
role O
in O
the O
development O
of O
adult O
T-cell O
leukemia O
through O
, O
at O
least O
in O
part O
, O
its O
ability O
to O
stimulate O
cell O
growth O
. O
We O
previously O
reported O
that O
Tax O
induced O
cell O
cycle O
progression O
from O
G0/G1 B-protein
phase O
to O
S O
and O
G2/M B-protein
phases O
in O
human O
T-cell O
line O
Kit O
225 B-cell_type
cells I-cell_type
. O
To O
elucidate O
molecular O
mechanism O
of O
Tax O
-induced O
cell O
cycle O
progression O
, O
we O
systematically O
examined O
the O
effects O
of O
Tax O
on O
biochemical O
events O
associated O
with O
cell O
cycle O
progression O
. O
Introduction O
of O
Tax O
into O
resting O
Kit O
225 B-cell_type
cells I-cell_type
induced O
activation O
of O
the O
G1/S B-protein
transition O
regulation O
cascade O
consisting O
of O
activation O
of O
cyclin O
dependent O
kinase I-protein
2 O
( O
CDK2 B-protein
) O
and O
CDK4 I-protein
, O
phosphorylation O
of O
the O
Rb O
family O
proteins I-protein
and O
an O
increase O
in O
free O
E2F B-protein
. O
The O
kinase I-protein
activation O
was O
found O
to O
result O
from O
Tax O
-induced O
expression O
of O
genes I-DNA
for O
cell O
cycle O
regulatory O
molecules I-protein
including O
cyclin O
D2 I-protein
, O
cyclin O
E O
, O
E2F1 I-protein
, O
CDK2 I-protein
, O
CDK4 O
and O
CDK6 I-protein
, O
and O
Tax O
-induced O
reduction O
of O
CDK B-cell_type
inhibitors O
p19 I-cell_line
( O
INK4d I-DNA
) O
and O
p27 B-protein
( O
Kip1 I-DNA
) O
. O
These O
modulations O
by O
Tax O
always O
paralleled O
the O
ability O
of O
Tax O
to O
activate O
the O
NF-kappaB B-protein
transcription O
pathway O
. O
These O
results O
indicate O
the O
important O
role O
of O
Tax O
-mediated O
trans-activation I-DNA
of O
the O
genes I-DNA
for O
cell O
cycle O
regulatory O
molecules I-protein
in O
Tax O
-induced O
cell O
cycle O
progression O
. O
Cot B-protein
kinase I-protein
induces O
cyclooxygenase-2 B-protein
expression O
in O
T B-cell_type
cells I-cell_type
through O
activation O
of O
the O
nuclear B-protein
factor I-protein
of O
activated B-cell_type
T B-cell_type
cells I-cell_type
. O
Cyclooxygenase-2 B-protein
( O
COX-2 O
) O
is O
induced O
in O
human B-cell_type
T I-cell_type
lymphocytes I-cell_type
upon O
T O
cell I-DNA
receptor I-protein
triggering O
. O
Here O
we O
report O
that O
Cot B-protein
kinase I-protein
, O
a O
mitogen-activated B-DNA
protein O
kinase I-protein
kinase I-protein
kinase I-protein
involved O
in O
T O
cell O
activation O
, O
up-regulates O
COX-2 B-DNA
gene I-DNA
expression O
in O
Jurkat O
T B-cell_type
cells I-cell_type
. O
Induction O
of O
COX-2 B-DNA
promoter I-DNA
activity O
by O
Cot B-protein
kinase I-protein
occurred O
mainly O
through O
activation O
of O
the O
nuclear B-protein
factor I-protein
of O
activated B-cell_type
T B-cell_type
cells I-cell_type
( O
NFAT I-DNA
) O
. O
Mutation O
of O
the O
distal O
( O
-105/-97 B-protein
) O
and O
proximal O
( O
-76/-61 B-protein
) O
NFAT O
response O
elements I-DNA
in O
the O
COX-2 B-DNA
promoter I-DNA
abolished O
the O
activation O
induced O
by O
Cot B-protein
kinase I-protein
. O
Even O
more O
, O
coexpression O
of O
a O
dominant O
negative O
version O
of O
NFAT O
inhibited O
Cot B-protein
kinase I-protein
-mediated O
COX-2 B-DNA
promoter I-DNA
activation O
, O
whereas O
cotransfection O
of O
a O
constitutively O
active O
version O
of O
the O
calcium-dependent B-DNA
phosphatase O
calcineurin O
synergizes O
with O
Cot B-protein
kinase I-protein
in O
the O
up-regulation I-DNA
of O
COX-2 B-DNA
promoter I-DNA
-driven O
transcription O
. I-RNA
Strikingly O
, O
Cot O
kinase I-protein
increased O
transactivation O
mediated O
by O
a O
GAL4-NFAT B-protein
fusion O
protein O
containing O
the O
N-terminal B-protein
transactivation I-protein
domain I-protein
of O
NFATp O
. O
In O
contrast O
to O
phorbol O
ester O
plus O
calcium O
ionophore O
A23187 I-protein
, O
Cot O
kinase I-protein
increases O
both O
COX-2 B-DNA
promoter I-DNA
activity O
and O
NFAT O
-mediated O
transactivation O
in O
a O
cyclosporin O
A-independent B-protein
manner O
. O
These O
data O
indicate O
that O
Cot B-protein
kinase I-protein
up-regulates O
COX-2 B-DNA
promoter I-DNA
-driven O
transcription O
through O
the O
NFAT O
response O
elements I-DNA
, O
being O
the O
Cot B-protein
kinase I-protein
-induced O
NFAT O
-dependent O
transactivation O
presumably O
implicated O
in O
this O
up-regulation B-protein
. O
Positive O
and O
negative O
roles O
of O
the O
trans-acting B-cell_type
T O
cell O
factor-1 B-protein
for O
the O
acquisition O
of O
distinct O
Ly-49 B-protein
MHC I-protein
class B-protein
I I-protein
receptors O
by O
NK B-cell_type
cells I-cell_type
. O
Members O
of O
the O
Ly-49 B-DNA
gene I-DNA
family O
code O
for O
class B-protein
I I-protein
MHC-specific B-protein
receptors O
that O
regulate O
NK O
cell O
function O
. O
Due O
to O
a O
combinatorial O
distribution O
of O
Ly-49 B-protein
receptors O
, O
NK B-cell_type
cells I-cell_type
display O
considerable O
clonal O
heterogeneity O
. O
The O
acquisition O
of O
one O
Ly-49 B-DNA
receptor I-protein
, O
Ly-49A O
is O
strictly O
dependent O
on O
the O
transcriptional O
trans-acting B-protein
factor I-protein
T I-cell_line
cell-specific I-DNA
factor-1 B-protein
( O
TCF-1 O
) O
. O
Indeed O
, O
TCF-1 O
binds O
to O
two O
sites I-DNA
in O
the O
Ly-49a B-DNA
promoter I-DNA
and O
regulates O
its O
activity O
, O
suggesting O
that O
the O
Ly-49a B-DNA
gene I-DNA
is O
a O
direct O
TCF-1 O
target I-cell_line
. O
TCF-1 O
deficiency O
resulted O
in O
the O
altered O
usage O
of O
additional O
Ly-49 B-protein
receptors O
. O
We O
show O
in O
this O
study O
, O
using O
TCF-1 O
beta O
( O
2 O
) O
-microglobulin O
double-deficient O
mice O
, O
that O
these O
repertoire O
alterations O
are O
not O
due O
to O
Ly-49/MHC O
class B-protein
I I-protein
interactions O
. O
Our O
findings O
rather O
suggest O
a O
TCF-1 O
-dependent O
, O
cell O
autonomous O
effect O
on O
the O
acquisition O
of O
multiple O
Ly-49 B-protein
receptors O
. O
Besides O
reduced I-DNA
receptor I-protein
usage O
( O
Ly-49A O
and O
D O
) O
, O
we O
also O
observed O
no O
effect O
( O
Ly-49C B-protein
) O
and O
significantly O
expanded O
( O
Ly-49G O
and O
I I-protein
) O
receptor I-protein
usage O
in O
the O
absence O
of O
TCF-1 O
. O
These O
effects O
did O
not O
in O
all O
cases O
correlate O
with O
the O
presence O
of O
TCF O
binding O
sites O
in O
the O
respective O
proximal B-DNA
promoter I-DNA
. O
Therefore O
, O
besides O
TCF-1 O
binding O
to O
the O
proximal B-DNA
promoter I-DNA
, O
Ly-49 B-protein
acquisition O
may O
also O
be O
regulated O
by O
TCF-1 O
binding O
to O
more O
distant O
cis-acting B-DNA
elements I-DNA
and/or O
by O
regulating O
the O
expression O
of O
additional O
trans-acting B-protein
factors I-protein
. O
Consistent O
with O
the O
observed O
differential O
, O
positive O
or O
negative O
role O
of O
TCF-1 O
for O
Ly-49 B-DNA
receptor I-protein
acquisition O
, O
reporter O
gene I-DNA
assays O
revealed O
the O
presence O
of O
an O
inducing O
as O
well O
as O
a O
repressing O
TCF I-DNA
site I-DNA
in O
certain O
proximal O
Ly-49 B-protein
promoters O
. O
These O
findings O
reveal O
an O
important O
role O
of O
TCF-1 O
for O
the O
formation O
of O
the O
NK O
cell I-DNA
receptor I-protein
repertoire O
. O
Ligation O
of O
CD11b O
and O
CD11c O
beta O
( O
2 O
) O
integrins O
by O
antibodies I-protein
or O
soluble O
CD23 B-protein
induces O
macrophage O
inflammatory O
protein O
1alpha I-cell_line
( O
MIP-1alpha B-protein
) O
and O
MIP-1beta B-protein
production O
in O
primary B-cell_line
human I-cell_line
monocytes B-cell_type
through O
a O
pathway O
dependent O
on O
nuclear B-protein
factor-kappaB B-protein
. O
Chemokines O
and O
adhesion O
molecules I-protein
such O
as O
integrins O
play O
a O
major O
part O
in O
the O
trafficking O
, O
extravasation O
, O
and O
recruitment O
of O
leukocytes O
to O
inflammatory O
sites I-DNA
. O
This O
study O
investigated O
the O
effects O
of O
beta O
( O
2 O
) O
integrin O
engagement O
on O
chemokine O
production O
by O
freshly O
isolated O
human O
monocytes B-cell_type
. O
We O
found O
that O
ligation O
of O
CD11b B-cell_type
or O
CD11c O
but O
not O
CD11a I-DNA
alpha I-DNA
chains I-DNA
of O
beta O
( O
2 O
) O
integrins O
by O
antibodies I-protein
or O
soluble O
CD23 B-protein
( O
sCD23 I-DNA
) O
fusion O
proteins I-protein
rapidly O
induced O
transcription I-DNA
and O
secretion O
of O
interleukin O
8 O
, O
macrophage O
inflammatory O
protein I-protein
( O
MIP I-DNA
) O
1alpha O
, O
and O
MIP-1beta B-protein
. O
Because O
the O
promoters O
of O
these O
chemokine I-DNA
genes I-DNA
contain O
kappaB O
binding O
sites I-DNA
, O
we O
assessed O
the O
possible O
role O
of O
nuclear B-protein
factor-kappaB B-protein
( O
NF-kappaB I-DNA
) O
in O
controlling O
induction O
of O
the O
genes I-DNA
through O
beta O
( O
2 O
) O
integrin O
engagement O
. O
Electrophoretic O
mobility O
shift O
assays O
showed O
that O
sCD23 O
or O
antibodies I-protein
to O
CD11b O
or O
to O
CD11c O
up-regulated B-DNA
DNA-binding B-protein
activity O
of O
NF-kappaB O
. O
Activation O
of O
NF-kappaB O
was O
accompanied O
by O
degradation O
of O
its O
cytosolic O
inhibitor O
IkappaB-alpha B-protein
. O
Blockade O
of O
depletion O
of O
IkappaB-alpha B-protein
by O
proteasome O
inhibitors O
( O
proteasome O
inhibitor O
I I-protein
or O
acetyl-leucinyl-leucinyl-norleucinal B-protein
) O
led O
to O
concomitant O
inhibition O
of O
NF-kappaB O
DNA-binding B-protein
activity O
and O
expression O
of O
MIP-1alpha B-DNA
and O
MIP-1beta B-protein
messenger O
RNA O
induced O
by O
beta O
( O
2 O
) O
integrin O
ligation O
. O
These O
results O
suggest O
that O
triggering O
of O
CD11b B-cell_type
or O
CD11c O
beta O
( O
2 O
) O
integrin O
on O
primary B-cell_line
human I-cell_line
monocytes B-cell_type
provides O
activation O
signals O
leading O
to O
nuclear B-protein
translocation O
of O
NF-kappaB O
and O
subsequent O
secretion O
of O
MIP-1alpha B-DNA
and O
MIP-1beta B-protein
that O
may O
have O
an O
important O
role O
in O
recruitment O
of O
other O
inflammatory B-cell_type
cells I-cell_type
during O
initiation O
of O
an O
inflammatory O
response O
Synergistic O
transcriptional O
activation O
of O
human B-cell_type
Acyl-coenzyme I-DNA
A O
: O
cholesterol O
acyltransterase-1 B-DNA
gene I-DNA
by O
interferon-gamma O
and O
all-trans-retinoic O
acid O
THP-1 B-DNA
cells I-cell_type
. O
Acyl-coenzyme B-protein
A O
: O
cholesterol O
acyltransferase O
( O
ACAT I-DNA
) O
is O
an O
intracellular O
enzyme O
involved O
in O
cellular O
cholesterol O
homeostasis O
and O
in O
atherosclerotic O
foam O
cell O
formation O
. O
Human O
ACAT-1 B-DNA
gene I-DNA
contains O
two O
promoters O
( O
P1 B-protein
and O
P7 B-protein
) O
, O
each O
located O
in O
a O
different O
chromosome O
( O
1 O
and O
7 O
) O
( O
Li O
, O
B. B-protein
L. I-protein
, O
Li O
, O
X. B-protein
L. I-protein
, O
Duan O
, O
Z. B-protein
J. I-protein
, O
Lee O
, O
O. I-protein
, O
Lin O
, O
S. I-protein
, O
Ma O
, O
Z. B-protein
M. I-protein
, O
Chang O
, O
C. B-protein
C. I-protein
, O
Yang O
, O
X. B-protein
Y. I-protein
, O
Park O
, O
J. B-protein
P. I-protein
, O
Mohandas O
, O
T. B-protein
K. I-protein
, O
Noll O
, O
W. I-protein
, O
Chan O
, O
L. I-protein
, O
and O
Chang O
, O
T. B-protein
Y. I-cell_line
( O
1999 I-DNA
) O
J. B-protein
Biol O
Chem. B-DNA
274 O
, O
11060-11071 O
) O
. O
Interferon-gamma O
( O
IFN-gamma I-DNA
) O
, O
a O
cytokine O
that O
exerts O
many O
pro-atherosclerotic B-DNA
effects O
in O
vivo O
, O
causes O
up-regulation I-DNA
of O
ACAT-1 I-RNA
mRNA I-RNA
in O
human B-cell_type
blood I-cell_type
monocyte-derived I-cell_type
macrophages O
and O
macrophage-like B-cell_type
cells I-cell_type
but O
not O
in O
other O
cell O
types I-cell_type
. O
To O
examine O
the O
molecular O
nature O
of O
this O
observation O
, O
we O
identified O
within O
the O
ACAT-1 B-protein
P1 B-DNA
promoter I-DNA
a O
159-base O
pair O
core O
region O
. O
This O
region O
contains O
4 O
Sp1 O
elements I-DNA
and O
an O
IFN-gamma B-protein
activated O
sequence O
( O
GAS I-DNA
) O
that O
overlaps O
with O
the O
second O
Sp1 O
element I-DNA
. O
In O
the O
monocytic B-cell_line
cell O
line O
THP-1 O
cell O
, O
the O
combination O
of O
IFN-gamma B-DNA
and O
all-trans-retinoic O
acid O
( O
a O
known O
differentiation O
agent O
) O
enhances O
the O
ACAT-1 B-protein
P1 B-DNA
promoter I-DNA
but O
not O
the O
P7 B-DNA
promoter I-DNA
. O
Additional O
experiments O
showed O
that O
all-trans-retinoic O
acid O
causes O
large O
induction O
of O
the O
transcription B-protein
factor I-protein
STAT1 B-protein
, O
while O
IFN-gamma B-protein
causes O
activation O
of O
STAT1 B-protein
such O
that O
it O
binds O
to O
the O
GAS/Sp1 B-DNA
site I-DNA
in O
the O
ACAT-1 B-protein
P1 B-DNA
promoter I-DNA
. O
Our O
work O
provides O
a O
molecular O
mechanism O
to O
account O
for O
the O
effect O
of O
IFN-gamma B-protein
in O
causing O
transcriptional O
activation O
of O
ACAT-1 B-protein
in O
macrophage-like B-cell_type
cells I-cell_type
. O
Inhaled O
nitric O
oxide O
down-regulates O
intrapulmonary O
nitric O
oxide O
production O
in O
lipopolysaccharide-induced B-DNA
acute O
lung O
injury O
. O
OBJECTIVE O
: O
To O
examine O
whether O
inhaled O
nitric O
oxide O
( O
NO I-DNA
) O
affected O
the O
intrapulmonary O
production O
of O
NO I-protein
, O
reactive O
oxygen O
species O
, O
and O
nuclear B-protein
factor-kappaB B-protein
in O
a O
lipopolysaccharide I-protein
( O
LPS I-DNA
) O
-induced O
model O
of O
acute O
lung O
injury O
. O
DESIGN I-protein
: O
Prospective O
, O
randomized O
, O
laboratory O
study O
. O
SETTING I-protein
: O
Experimental O
laboratory O
at O
a O
biomedical O
institute O
. O
SUBJECTS O
: O
Twenty O
male O
rabbits O
weighing O
2.5-3.5 B-protein
kg O
. O
INTERVENTIONS I-protein
: O
Saline O
or O
LPS I-protein
( O
5 O
mg/kg I-DNA
of O
body O
weight O
) O
was O
administered O
intravenously O
with O
or O
without O
NO B-protein
inhalation O
( O
10 O
ppm O
) O
in O
each O
group O
of O
five O
rabbits O
. O
MEASUREMENTS I-protein
AND O
MAIN O
RESULTS I-protein
: O
LPS O
increased O
the O
lung O
leak O
index O
, O
the O
neutrophils O
and O
NO B-protein
levels O
in O
bronchoalveolar O
lavage O
fluid O
, O
and O
NO B-protein
levels O
produced O
by O
resting O
and O
stimulated O
alveolar O
macrophages O
. O
Inhaled O
NO B-protein
decreased O
the O
lung O
leak O
index O
, O
the O
neutrophils O
and O
NO B-protein
levels O
as O
measured O
by O
nitrite O
levels O
in O
the O
lavage O
fluid O
, O
and O
NO B-protein
produced O
by O
the O
resting O
and O
stimulated O
alveolar O
macrophages O
. O
Inhaled O
NO B-protein
also O
blocked O
the O
activities O
of O
reactive O
oxygen O
species O
and O
nuclear B-protein
factor-kappaB O
binding O
to O
DNA O
in O
lavage B-cell_type
cells I-cell_type
and O
in O
alveolar O
macrophages O
. O
CONCLUSION I-protein
: O
Inhaled O
NO B-protein
attenuates O
LPS-induced B-protein
acute O
lung O
injury I-protein
, O
possibly O
by O
decreasing O
NO B-protein
production O
in O
the O
lungs O
. O
The O
mechanism O
of O
reducing O
NO B-protein
production O
resulting O
from O
inhaled O
NO B-protein
may O
involve O
, O
in O
part O
, O
the O
activities O
of O
reactive O
oxygen O
species O
and/or O
nuclear B-protein
factor-kappaB B-protein
. O
Treatment O
of O
allergic O
airway O
inflammation O
and O
hyperresponsiveness O
by O
antisense-induced B-DNA
local O
blockade O
of O
GATA-3 B-protein
expression O
. O
Recent O
studies O
in O
transgenic O
mice O
have O
revealed O
that O
expression O
of O
a O
dominant O
negative O
form O
of O
the O
transcription B-protein
factor I-protein
GATA-3 B-protein
in O
T B-cell_type
cells I-cell_type
can O
prevent O
T I-cell_line
helper O
cell I-DNA
type O
2 O
( O
Th2 B-protein
) O
-mediated O
allergic O
airway O
inflammation O
in O
mice O
. O
However O
, O
it O
remains O
unclear O
whether O
GATA-3 B-protein
plays O
a O
role O
in O
the O
effector O
phase O
of O
allergic O
airway O
inflammation O
and O
whether O
antagonizing O
the O
expression O
and/or I-cell_line
function O
of O
GATA-3 B-protein
can O
be O
used O
for O
the O
therapy O
of O
allergic O
airway O
inflammation O
and O
hyperresponsiveness O
. O
Here O
, O
we O
analyzed O
the O
effects O
of O
locally O
antagonizing O
GATA-3 B-protein
function O
in O
a O
murine I-cell_line
model O
of O
asthma O
. O
We O
could O
suppress O
GATA-3 B-protein
expression O
in O
interleukin O
( O
IL I-DNA
) O
-4 O
-producing O
T B-cell_type
cells I-cell_type
in O
vitro O
and O
in O
vivo O
by O
an O
antisense O
phosphorothioate O
oligonucleotide O
overlapping O
the O
translation O
start I-DNA
site I-DNA
of O
GATA-3 B-protein
, O
whereas O
nonsense O
control O
oligonucleotides O
were O
virtually O
inactive O
. O
In O
a O
murine I-cell_line
model O
of O
asthma O
associated O
with O
allergic O
pulmonary O
inflammation O
and O
hyperresponsiveness O
in O
ovalbumin O
( O
OVA I-DNA
) O
-sensitized O
mice O
, O
local O
intranasal O
administration O
of O
fluorescein O
isothiocyanate-labeled B-DNA
GATA-3 B-protein
antisense O
oligonucleotides O
led O
to O
DNA O
uptake O
in O
lung B-cell_type
cells I-cell_type
associated O
with O
a O
reduction O
of O
intracellular O
GATA-3 B-protein
expression O
. O
Such O
intrapulmonary O
blockade O
of O
GATA-3 B-protein
expression O
caused O
an O
abrogation O
of O
signs O
of O
lung O
inflammation O
including O
infiltration O
of O
eosinophils O
and O
Th2 O
cytokine O
production O
. O
Furthermore O
, O
treatment O
with O
antisense O
but O
not O
nonsense O
oligonucleotides O
induced O
a O
significant O
reduction O
of O
airway O
hyperresponsiveness O
in O
OVA-sensitized B-protein
mice O
to O
levels O
comparable O
to O
saline-treated O
control O
mice O
, O
as O
assessed O
by O
both O
enhanced O
pause O
( O
PenH I-DNA
) O
responses O
and O
pulmonary O
resistance O
determined O
by O
body O
plethysmography O
. O
These O
data O
indicate O
a O
critical O
role O
for O
GATA-3 B-protein
in O
the O
effector O
phase O
of O
a O
murine I-cell_line
asthma O
model O
and O
suggest O
that O
local O
delivery O
of O
GATA-3 B-protein
antisense O
oligonucleotides O
may O
be O
a O
novel O
approach O
for O
the O
treatment O
of O
airway O
hyperresponsiveness O
such O
as O
in O
asthma O
. O
This O
approach O
has O
the O
potential O
advantage O
of O
suppressing O
the O
expression O
of O
various O
proinflammatory O
Th2 O
cytokines O
simultaneously O
rather O
than O
suppressing O
the O
activity O
of O
a O
single O
cytokine O
. O
T I-cell_line
helper-cell B-DNA
phenotype O
regulates O
atherosclerosis O
in O
mice O
under O
conditions O
of O
mild O
hypercholesterolemia O
. O
BACKGROUND I-protein
: O
T B-cell_type
cells I-cell_type
are O
implicated O
in O
atherosclerosis O
, O
but O
little O
is O
known O
about O
the O
genetic O
control O
or O
molecular O
pathways O
, O
especially O
under O
conditions O
of O
mild O
hypercholesterolemia O
. O
METHODS I-protein
AND O
RESULTS I-protein
: O
BALB/c B-protein
mice O
, O
making O
a O
CD4+ B-protein
Th2 I-cell_line
( O
IL-4+ B-protein
) O
cell O
response O
, O
express O
both O
MHC I-protein
class I-protein
II I-protein
antigens I-protein
( O
IA B-protein
( O
d O
) O
, O
IE I-cell_line
( O
d O
) O
) O
and O
are O
atherosclerosis-resistant B-DNA
. O
C57Bl/6 O
mice O
produce O
a O
CD4+ B-protein
Th1 I-cell_line
( O
interferon O
[ O
IFN O
] O
gamma+ B-DNA
) O
response O
, O
express O
IA I-cell_line
( O
b O
) O
but O
no O
IE I-protein
, O
and O
are O
atherosclerosis-prone O
. O
To O
evaluate O
T I-cell_line
helper-cell B-DNA
phenotype O
in O
fatty O
streak O
formation O
, O
wild-type O
C57Bl/6 O
mice O
( O
IA B-protein
( O
b O
) O
+IE- B-protein
) O
and O
transgenic O
mice O
, O
either O
AB I-cell_line
( O
o O
) O
, O
IA I-cell_line
( O
b O
) O
-IE- O
; O
ABEalpha I-protein
, O
IA-IE B-protein
( O
k O
) O
+ O
; O
or O
BL B-protein
: O
TG B-protein
: O
Ealpha O
, O
IA I-cell_line
( O
b O
) O
+IE O
( O
k O
) O
+ O
, O
were O
fed O
a O
high-cholesterol O
diet O
for O
16 O
weeks O
and O
evaluated O
histomorphometrically O
for O
aortic O
lesions O
. O
Lesion O
size O
in O
AB I-cell_line
( O
o O
) O
, O
ABEalpha O
, O
and O
BL B-protein
: O
TG B-protein
: O
Ealpha O
strains O
was O
decreased O
by O
54 O
% O
, O
79 O
% O
, O
and O
82 O
% O
, O
respectively O
, O
compared O
with O
wild-type I-DNA
, O
correlating O
with O
decreased O
Th1 O
and O
increased O
Th2 O
expression O
and O
suggesting O
that O
T I-cell_line
helper-cell B-DNA
phenotype O
is O
important O
in O
fatty O
lesion O
development O
. O
Decreasing O
Th1 B-cell_type
cells I-cell_type
by O
antibodies I-protein
( O
alpha-CD4 B-protein
) O
or O
cytokines O
( O
IL-4 B-protein
) O
also O
caused O
> O
/=80 O
% O
reductions O
in O
lesion O
size O
. O
Immunohistology O
revealed O
IFN-gamma I-DNA
, O
but O
not O
IL-4 B-protein
, O
colocalized O
with O
activated O
macrophages O
. O
Confirming O
these O
findings O
in O
a O
different O
mouse B-DNA
strain I-protein
, O
BALB/c O
Stat O
6 O
knockout O
mice O
( O
Th2 O
cell-deficient B-protein
) O
developed O
aortic O
lesions O
comparable O
to O
C57Bl/6 O
mice O
on O
the O
same O
diet O
. O
CONCLUSIONS I-protein
: O
In O
mildly O
hypercholesterolemic O
C57Bl/6 O
mice O
, O
presence O
of O
IA B-cell_type
( O
b O
) O
and O
absence O
of O
IE B-cell_type
regulated O
CD4+ B-cell_type
T I-cell_line
helper-cell B-DNA
phenotype O
; O
fatty O
lesions O
were O
proportional O
to O
IFNgamma+ O
Th1 B-cell_type
cells I-cell_type
in O
both O
C57Bl/6 O
and O
BALB/c B-protein
strains O
. O
IFN-gamma B-protein
may O
participate O
through O
macrophage O
activation O
, O
whereas O
IL-4 B-protein
may O
act O
to O
limit O
Th1-cell B-protein
response O
. O
Requirement O
for O
p38 O
and O
p44/p42 O
mitogen-activated B-DNA
protein I-protein
kinases I-protein
in O
RAGE O
-mediated O
nuclear B-protein
factor-kappaB O
transcriptional O
activation O
and O
cytokine O
secretion O
. O
Advanced O
glycation O
end O
product O
( O
AGE I-DNA
) O
activation O
of O
the O
signal-transducing B-DNA
receptor I-protein
for O
AGE I-protein
( O
RAGE I-DNA
) O
has O
been O
linked O
to O
a O
proinflammatory O
phenotypic O
change O
within B-cell_type
cells I-cell_type
. O
However O
, O
the O
precise O
intracellular O
signaling O
pathways O
involved O
have O
not O
been O
elucidated O
. O
We O
demonstrate O
here O
that O
human B-DNA
serum I-cell_type
albumin O
modified O
with O
N O
( O
varepsilon O
) O
- O
( O
carboxymethyl I-DNA
) O
lysine O
( O
CML I-DNA
) O
, O
a O
major O
AGE O
adduct O
that O
progressively O
accumulates O
with O
aging O
, O
diabetes O
, O
and O
renal O
failure O
, O
induced O
nuclear B-protein
factor I-protein
( O
NF I-DNA
) O
-kappaB O
-driven O
reporter B-DNA
gene I-DNA
expression O
in O
human O
monocytic B-cell_line
THP-1 B-DNA
cells I-cell_type
. O
The O
NF-kappaB O
response O
was O
blocked O
with O
a O
synthetic O
peptide O
corresponding O
to O
the O
putative O
ligand-binding I-protein
domain I-protein
of O
RAGE I-protein
, O
with O
anti- B-DNA
RAGE O
antiserum O
, O
and O
by O
coexpression O
of O
truncated O
receptors O
lacking O
the O
intracellular I-protein
domain I-protein
. O
Signal O
transduction O
from O
RAGE O
to O
NF-kappaB O
involved O
the O
generation O
of O
reactive O
oxygen O
species O
, O
since O
reporter B-DNA
gene I-DNA
expression O
was O
blocked O
with O
the O
antioxidant O
N-acetyl-L-cysteine B-protein
. O
CML-modified B-protein
albumin O
produced O
rapid O
transient O
activation O
of O
tyrosine I-protein
phosphorylation O
, O
extracellular O
signal-regulated O
kinase I-protein
1 O
and O
2 O
, O
and O
p38 O
mitogen-activated B-DNA
protein O
kinase I-protein
( O
MAPK I-DNA
) O
, O
but O
not O
c-Jun O
NH I-cell_line
( O
2 O
) O
-terminal O
kinase I-protein
. O
RAGE O
-mediated O
NF-kappaB O
activation O
was O
suppressed O
by O
the O
selective O
p38 O
MAPK O
inhibitor O
SB203580 B-protein
and O
by O
coexpression O
of O
a O
kinase-dead B-DNA
p38 O
dominant-negative B-DNA
mutant O
. O
Activation O
of O
NF-kappaB O
by O
CML-modified B-protein
albumin O
increased O
secretion O
of O
proinflammatory O
cytokines O
( O
tumor O
necrosis O
factor-alpha I-DNA
, O
interleukin-1beta O
, O
and O
monocyte O
chemoattractant O
protein-1 B-protein
) O
severalfold O
, O
and O
inhibition O
of O
p38 B-cell_type
MAPK O
blocked O
these O
increases O
. O
These O
results O
indicate O
that O
p38 O
MAPK O
activation O
mediates O
RAGE O
-induced O
NF-kappaB O
-dependent O
secretion O
of O
proinflammatory O
cytokines O
and O
suggest O
that O
accelerated O
inflammation O
may O
be O
a O
consequence O
of O
cellular O
activation O
induced O
by O
this I-DNA
receptor I-protein
. O
Antigen-receptor O
cross-linking O
and O
lipopolysaccharide O
trigger O
distinct O
phosphoinositide O
3-kinase B-protein
-dependent O
pathways O
to O
NF-kappa B-protein
B I-protein
activation O
in O
primary B-cell_line
B I-DNA
cells I-cell_type
. O
The O
NF-kappaB/Rel B-protein
transcription B-protein
factors I-protein
play O
an O
important O
role O
in O
the O
expression O
of O
genes I-DNA
involved O
in O
B O
cell O
development O
, O
differentiation O
and O
function O
. O
Nuclear O
NF-kappaB O
is O
induced O
in O
B I-DNA
cells I-cell_type
by O
engagement O
of O
either O
the O
BCR O
or O
CD40 B-protein
or O
by O
stimulation O
with O
lipopolysaccharide I-protein
( O
LPS I-DNA
) O
. O
Despite O
the O
importance O
of O
NF-kappaB O
to O
B O
cell O
function O
, O
little O
is O
known O
about O
the O
signaling O
pathways O
leading O
to O
NF-kappaB O
activation O
. O
In O
this O
report O
we O
address O
the O
role O
of O
phosphoinositide O
3'-kinase B-protein
( O
PI B-protein
3-kinase B-protein
) O
in O
BCR O
- O
and O
LPS-induced B-protein
NF-kappaB O
activation O
using O
populations O
of O
primary B-cell_line
murine I-cell_line
resting O
B I-DNA
cells I-cell_type
. O
Using O
the O
specific O
pharmacological O
inhibitors O
of O
PI B-cell_type
3-kinase O
, O
Wortmannin O
and O
LY294002 I-protein
, O
we O
demonstrate O
that O
PI B-protein
3-kinase B-protein
activity O
is O
vital O
for O
BCR O
-induced O
NF-kappaB O
DNA-binding B-protein
activity O
. O
Furthermore O
, O
we O
show O
that O
this O
is O
achieved O
via O
protein O
kinase I-protein
C I-protein
-dependent O
degradation O
of O
IkappaBalpha B-cell_type
. O
Similar O
analyses O
reveal O
that O
PI B-protein
3-kinase B-protein
is O
also O
critical O
in O
triggering O
NF-kappaB O
DNA-binding B-protein
activity O
and O
IkappaBalpha B-cell_type
degradation O
following O
LPS O
stimulation O
. O
Interestingly B-cell_type
, O
a O
PKC O
inhibitor O
which O
blocked O
the O
BCR O
-induced O
IkappaBalpha O
degradation O
had O
no O
effect O
on O
the O
degradation O
of O
IkappaBalpha B-cell_type
after O
LPS O
stimulation O
. O
Taken O
together O
, O
our O
results O
indicate O
the O
involvement O
of O
PI B-cell_type
3-kinase B-protein
in O
at O
least O
two O
distinct O
signaling O
pathways O
leading O
to O
activation O
of O
NF-kappaB O
in O
B I-DNA
cells I-cell_type
. O
Tetramer-guided O
epitope O
mapping O
: O
rapid O
identification O
and O
characterization O
of O
immunodominant O
CD4+ B-cell_type
T O
cell O
epitopes I-protein
from O
complex I-protein
antigens O
. O
T O
cell O
responses O
to O
Ags O
involve O
recognition O
of O
selected O
peptide O
epitopes I-protein
contained O
within O
the O
antigenic O
protein O
. O
In O
this O
report I-protein
, O
we O
describe O
a O
new O
approach O
for O
direct O
identification O
of O
CD4+ B-cell_type
T O
cell O
epitopes I-protein
of O
complex I-protein
Ags O
that O
uses O
human B-DNA
class I-protein
II I-protein
tetramers O
to O
identify O
reactive B-cell_type
cells I-cell_type
. O
With O
a O
panel O
of O
60 O
overlapping O
peptides O
covering O
the O
entire O
sequence O
of O
the O
VP16 B-protein
protein I-protein
, O
a O
major O
Ag O
for O
HSV-2 O
, O
we O
generated O
a O
panel O
of O
class I-protein
II I-protein
MHC I-protein
tetramers O
loaded O
with O
peptide O
pools O
that O
were O
used O
to O
stain O
peripheral I-cell_type
lymphocytes I-cell_type
of O
an O
HSV-2 O
infected O
individual O
. O
With O
this O
approach O
, O
we O
identified O
four O
new O
DRA1*0101/DRB1*0401- B-protein
and O
two O
DRA1*0101/DRB1*0404-restricted I-cell_line
, O
VP16-specific B-protein
epitopes I-protein
. O
By O
using O
tetramers O
to O
sort O
individual B-cell_type
cells I-cell_line
, O
we O
easily O
obtained O
a O
large O
number O
of O
clones O
specific O
to O
these O
epitopes I-protein
. O
Although O
DRA1*0101/DRB1*0401 I-protein
and O
DRA1*0101/DRB1*0404 B-protein
are O
structurally O
very O
similar O
, O
nonoverlapping O
VP16 B-protein
epitopes I-protein
were O
identified O
, O
illustrating O
high O
selectivity O
of O
individual O
allele O
polymorphisms O
within O
common O
MHC I-protein
variants O
. O
This O
rapid O
approach O
to O
detecting O
CD4+ B-cell_type
T O
cell O
epitopes I-protein
from O
complex I-protein
Ags O
can O
be O
applied O
to O
any O
known O
Ag O
that O
gives O
a O
T O
cell O
response O
. O
Localized O
pancreatic O
NF-kappaB O
activation O
and O
inflammatory O
response O
in O
taurocholate-induced B-DNA
pancreatitis O
. O
Transcription B-protein
factor I-protein
nuclear B-protein
factor-kappaB B-protein
( O
NF-kappaB I-DNA
) O
is O
activated O
in O
cerulein O
pancreatitis O
and O
mediates O
cytokine O
expression O
. O
The O
role O
of O
transcription B-protein
factor I-protein
activation O
in O
other O
models O
of O
pancreatitis O
has O
not O
been O
established O
. O
Here O
we O
report O
upregulation O
of O
NF-kappaB O
and O
inflammatory O
molecules I-protein
, O
and O
their O
correlation O
with O
local O
pancreatic O
injury I-protein
, O
in O
a O
model O
of O
severe O
pancreatitis O
. O
Rats O
received O
intraductal O
infusion O
of O
taurocholate O
or O
saline I-protein
, O
and O
the O
pancreatic O
head O
and O
tail O
were O
analyzed O
separately O
. O
NF-kappaB O
and O
activator O
protein-1 B-protein
( O
AP-1 B-protein
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA I-RNA
expression O
of O
interleukin-6 B-protein
, O
tumor O
necrosis O
factor-alpha I-DNA
, O
KC I-protein
, O
monocyte O
chemoattractant O
protein-1 B-protein
, O
and O
inducible O
nitric O
oxide O
synthase O
was O
assessed O
by O
semiquantitative O
RT-PCR B-protein
. O
Morphological B-cell_type
damage O
and O
trypsin O
activation O
were O
much O
greater O
in O
the O
pancreatic O
head O
than O
tail O
, O
in O
parallel O
with O
a O
stronger O
activation O
of O
NF-kappaB O
and O
cytokine O
mRNA I-RNA
. O
Saline O
infusion O
mildly O
affected O
these O
parameters O
. O
AP-1 B-protein
was O
strongly O
activated O
in O
both O
pancreatic O
segments O
after O
either O
taurocholate O
or O
saline O
infusion O
. O
NF-kappaB O
inhibition O
with O
N-acetylcysteine B-protein
ameliorated O
the O
local O
inflammatory O
response O
. O
Correlation O
between O
localized O
NF-kappaB O
activation O
, O
cytokine O
upregulation O
, O
and O
tissue O
damage O
suggests O
a O
key O
role O
for O
NF-kappaB O
in O
the O
development O
of O
the O
inflammatory O
response O
of O
acute O
pancreatitis O
. O
CD45 B-protein
tyrosine I-protein
phosphatase O
controls O
common O
gamma-chain O
cytokine O
-mediated O
STAT B-protein
and O
extracellular O
signal-related B-protein
kinase I-protein
phosphorylation O
in O
activated O
human B-DNA
lymphoblasts I-cell_type
: O
inhibition O
of O
proliferation O
without O
induction O
of O
apoptosis O
. O
The O
objective O
of O
this O
study O
was O
to O
test O
whether O
CD45 B-protein
signals O
can O
influence O
signaling O
processes O
in O
activated O
human B-DNA
lymphoblasts I-cell_type
. O
To O
this O
end O
, O
we O
generated O
lymphoblasts O
which O
proliferate O
in O
response O
to O
common O
gamma-chain O
cytokines O
, O
but O
readily O
undergo O
apoptosis O
after O
cytokine O
withdrawal O
. O
In O
experiments O
with O
the O
CD45R0 B-protein
mAb I-protein
UCHL-1 B-protein
, O
but O
not O
control O
CD45 B-protein
mAbs I-protein
, O
we O
found O
significant O
inhibition O
of O
proliferation O
. O
Interestingly B-cell_type
, O
the O
pan-CD45 B-protein
mAb I-protein
GAP8.3 I-protein
, O
which O
is O
most O
effective O
in O
inhibition O
of O
OKT-3-mediated B-protein
proliferation O
in O
quiescent I-cell_type
lymphocytes I-cell_type
, O
was O
ineffective O
in O
lymphoblasts O
. O
Addition O
of O
CD3 B-protein
mAb I-protein
OKT-3 O
had O
no O
influence O
on O
IL-2-mediated B-protein
proliferation O
( O
with O
or O
without O
UCHL-1 B-protein
) O
. O
In O
contrast O
, O
after O
addition O
of O
OKT-3 O
to O
IL-4 B-protein
- O
and O
IL-7 B-protein
-stimulated O
proliferation O
assays O
, O
UCHL-1 B-protein
signals O
could O
not O
significantly O
alter O
cellular O
proliferation O
. O
We O
did O
not O
find O
induction O
of O
apoptosis O
following O
CD45R0 B-protein
signaling O
. O
In O
Western O
blots O
using O
mAbs I-protein
detecting O
phosphorylated O
STAT-3 B-protein
, O
STAT-5 B-protein
, O
STAT-6 B-protein
, O
or O
extracellular O
signal-related B-protein
kinase I-protein
1/2 O
, O
we O
found O
that O
CD45R0 B-protein
signaling O
could O
effectively O
diminish O
phosphorylation O
of O
these O
intracellular O
signaling O
components O
. O
Using O
RT-PCR I-protein
, O
we O
found O
that O
CD45R0 B-protein
signaling O
inhibited O
IL-2 B-protein
mRNA I-RNA
production O
without O
major O
influence O
on O
IL-13 B-protein
, O
IL-5 B-protein
, O
or O
IFN-gamma I-RNA
mRNA I-RNA
levels O
. O
Costimulation B-cell_type
with O
OKT-3 O
and O
IL-2 B-protein
optimally O
induced O
secretion O
of O
IFN-gamma B-RNA
, O
TNF-alpha I-DNA
, O
and O
IL-5 B-protein
, O
which O
was O
not O
decreased O
by O
CD45 B-protein
signals O
. O
In O
conclusion O
, O
we O
illustrate O
that O
CD45R0 B-protein
signals O
control O
early O
cytokine O
receptor-associated B-DNA
signaling O
processes O
and O
mRNA I-RNA
and O
DNA O
synthesis O
in O
activated O
human B-DNA
lymphoblasts I-cell_type
. O
Furthermore O
, O
we O
show O
the O
existence O
of O
CD45 B-protein
epitopes I-protein
( O
GAP8.3 B-protein
) O
, O
which O
are O
active O
and O
critical O
for O
signaling O
in O
quiescent I-cell_type
lymphocytes I-cell_type
, O
but O
are O
nonfunctional O
in O
activated O
human B-DNA
lymphoblasts I-cell_type
. O
Pax5 O
determines O
the O
identity O
of O
B I-DNA
cells I-cell_type
from O
the O
beginning O
to O
the O
end O
of O
B-lymphopoiesis B-protein
. O
Despite O
being O
one O
of O
the O
most O
intensively O
studied O
cell O
types I-cell_type
, O
the O
molecular O
basis O
of O
B O
cell O
specification O
is O
largely O
unknown O
. O
The O
Pax5 B-DNA
gene I-DNA
encoding O
the O
transcription B-protein
factor I-protein
BSAP O
is O
required O
for O
progression O
of O
B-lymphopoiesis B-protein
beyond O
the O
pro-B O
cell O
stage O
. O
Pax5-deficient B-protein
pro-B B-cell_line
cells I-cell_type
are O
, O
however O
, O
not O
yet O
committed O
to O
the O
B-lymphoid B-protein
lineage O
, O
but O
instead O
have O
a O
broad O
lymphomyeloid O
developmental O
potential O
. O
Pax5 O
appears O
to O
mediate O
B-lineage B-protein
commitment O
by O
repressing O
the O
transcription I-DNA
of O
non-B-lymphoid I-DNA
genes I-DNA
and O
by O
simultaneously O
activating O
the O
expression O
of O
B-lineage-specific I-DNA
genes I-DNA
. O
Pax5 O
thus O
functions O
both O
as O
a O
transcriptional O
repressor O
and O
activator O
, O
depending O
on O
its O
interactions O
with O
corepressors O
of O
the O
Groucho O
protein O
family O
or O
with O
positive O
regulators O
such O
as O
the O
TATA-binding B-DNA
protein O
. O
Once O
committed O
to O
the O
B-lineage I-DNA
, O
B I-DNA
cells I-cell_type
require O
Pax5 O
function O
to O
maintain O
their O
B-lymphoid B-protein
identity O
throughout O
B O
cell O
development O
Partners O
in O
transcription O
: O
NFAT O
and O
AP-1 B-protein
. O
Combinatorial B-cell_type
regulation O
is O
a O
powerful O
mechanism O
that O
enables O
tight O
control O
of O
gene I-DNA
expression O
, O
via O
integration O
of O
multiple O
signaling O
pathways O
that O
induce O
different O
transcription B-protein
factors I-protein
required O
for O
enhanceosome O
assembly O
. O
The O
four O
calcium-regulated B-DNA
transcription B-protein
factors I-protein
of O
the O
NFAT O
family O
act O
synergistically O
with O
AP-1 B-protein
( O
Fos/Jun I-DNA
) O
proteins I-protein
on O
composite O
DNA O
elements O
which O
contain O
adjacent O
NFAT O
and O
AP-1 B-protein
binding O
sites I-DNA
, O
where O
they O
form O
highly O
stable O
ternary O
complexes O
to O
regulate O
the O
expression O
of O
diverse O
inducible I-DNA
genes I-DNA
. O
Concomitant O
induction O
of O
NFAT O
and O
AP-1 B-protein
requires O
concerted O
activation O
of O
two O
different O
signaling O
pathways O
: O
calcium/calcineurin I-protein
, O
which O
promotes O
NFAT O
dephosphorylation I-protein
, O
nuclear O
translocation O
and O
activation O
; O
and O
protein O
kinase I-protein
C I-protein
( O
PKC I-DNA
) O
/Ras O
, O
which O
promotes O
the O
synthesis O
, O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Fos O
and O
Jun O
families O
of O
transcription B-protein
factors I-protein
. O
A O
fifth O
member O
of O
the O
NFAT O
family I-protein
, O
NFAT5 I-protein
, O
controls O
the O
cellular O
response O
to O
osmotic O
stress O
, O
by O
a O
mechanism O
that O
requires O
dimer O
formation O
and O
is O
independent O
of O
calcineurin O
or O
of O
interaction O
with O
AP-1 B-protein
. O
Pharmacological O
interference O
with O
theNFAT I-RNA
: O
AP-1 B-protein
interaction O
may O
be O
useful O
in O
selective O
manipulation O
of O
the O
immune O
response O
. O
Balanced O
activation O
of O
NFAT O
and O
AP-1 B-protein
is O
known O
to O
be O
required O
for O
productive O
immune O
responses O
, O
but O
the O
role O
of O
NFAT O
: O
AP-1 B-protein
interactions O
in O
other O
cell O
types I-cell_type
and O
biological O
processes O
remains O
to O
be O
understood O
. O
Cytokine O
production O
by O
Vgamma O
( O
+ O
) O
-T-cell O
subsets O
is O
an O
important O
factor I-protein
determining O
CD4 B-protein
( O
+ O
) O
-Th-cell O
phenotype O
and O
susceptibility O
of O
BALB/c B-cell_type
mice O
to O
coxsackievirus O
B3-induced B-protein
myocarditis O
. O
Two O
coxsackievirus O
B3 B-protein
( O
CVB3 B-protein
) O
variants O
( O
H3 B-protein
and O
H310A1 B-protein
) O
differ O
by O
a O
single O
amino O
acid O
mutation O
in O
the O
VP2 B-protein
capsid O
protein O
. O
H3 B-protein
induces O
severe O
myocarditis O
in O
BALB/c B-protein
mice O
, O
but O
H310A1 B-protein
is O
amyocarditic O
. O
Infection O
with O
H3 I-protein
, O
but O
not O
H310A1 I-protein
, O
preferentially O
activates O
Vgamma4 O
Vdelta4 B-cell_type
cells I-cell_line
, O
which O
are O
strongly O
positive O
for O
gamma O
interferon O
( O
IFN-gamma I-DNA
) O
, O
whereas O
Vgamma1 O
Vdelta4 B-cell_type
cells I-cell_type
are O
increased O
in O
both O
H3 I-protein
and O
H310A1 B-protein
virus-infected O
animals O
. O
Depletion O
of O
Vgamma1 B-cell_type
( O
+ O
) O
cells I-cell_type
using O
monoclonal O
anti-Vgamma1 B-protein
antibody O
enhanced O
myocarditis O
and O
CD4 B-protein
( O
+ O
) O
- O
, O
IFN-gamma B-protein
( O
+ O
) O
-cell O
responses O
in O
both O
H3- B-protein
and O
H310A1-infected B-protein
mice O
yet O
decreased O
the O
CD4 B-protein
( O
+ O
) O
- O
, O
IL-4 B-protein
( O
+ O
) O
-cell O
response O
. O
Depleting O
Vgamma4 I-cell_line
( O
+ O
) O
cells I-cell_type
suppressed O
myocarditis O
and O
reduced O
CD4 B-protein
( O
+ O
) O
IFN-gamma O
( O
+ O
) O
cells I-cell_type
but O
increased O
CD4 B-protein
( O
+ O
) O
IL-4 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
. O
The O
role O
of O
cytokine O
production O
by O
Vgamma1 I-cell_line
( O
+ O
) O
and O
Vgamma4 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
was O
investigated O
by O
adoptively O
transferring O
these I-cell_type
cells I-cell_type
isolated O
from O
H3-infected B-protein
BALB/c B-protein
Stat4 O
knockout O
( O
Stat4ko I-DNA
) O
( O
defective O
in O
IFN-gamma B-protein
expression O
) O
or O
BALB/c B-protein
Stat6ko I-cell_line
( O
defective O
in O
IL-4 B-protein
expression O
) O
mice O
into O
H3 B-protein
virus-infected O
wild-type B-DNA
BALB/c B-protein
recipients O
. O
Vgamma4 O
and O
Vgamma1 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
from O
Stat4ko O
mice O
expressed O
IL-4 B-protein
but O
no O
or O
minimal O
IFN-gamma I-DNA
, O
whereas O
these O
cell O
populations O
derived O
from O
Stat6ko O
mice O
expressed O
IFN-gamma B-protein
but O
no O
IL-4 B-protein
. O
Stat4ko O
Vgamma1 I-cell_line
( O
+ O
) O
cells I-cell_line
( O
IL-4 B-protein
( O
+ O
) O
) O
suppress O
myocarditis O
. O
Stat6ko O
Vgamma1 I-cell_line
( O
+ O
) O
cells I-cell_line
( O
IFN-gamma B-protein
( O
+ O
) O
) O
were O
not O
inhibitory O
. O
Stat6ko O
Vgamma4 I-cell_line
( O
+ O
) O
cells I-cell_line
( O
IFN-gamma B-protein
( O
+ O
) O
) O
significantly O
enhanced O
myocarditis O
. O
Stat4ko O
Vgamma4 I-cell_line
( O
+ O
) O
cells I-cell_line
( O
IL-4 B-protein
( O
+ O
) O
) O
neither O
inhibited O
nor O
enhanced O
disease O
. O
These O
results O
show O
that O
distinct O
gammadelta-T-cell O
subsets O
control O
myocarditis O
susceptibility O
and O
bias O
the O
CD4 B-protein
( O
+ O
) O
-Th-cell O
response O
. O
The O
cytokines O
produced O
by O
the O
Vgamma O
subpopulation O
have O
a O
significant O
influence O
on O
the O
CD4 B-protein
( O
+ O
) O
-Th-cell O
phenotype O
. O
Plasmin O
-induced O
expression O
of O
cytokines O
and O
tissue B-protein
factor I-protein
in O
human O
monocytes B-cell_type
involves O
AP-1 B-protein
and O
IKKbeta O
-mediated O
NF-kappaB O
activation O
. O
It O
was O
previously O
shown O
that O
plasmin O
activates O
human O
peripheral I-cell_type
monocytes B-cell_type
in O
terms O
of O
lipid O
mediator O
release O
and O
chemotactic O
migration O
. O
Here O
it O
is O
demonstrated O
that O
plasmin O
induces O
proinflammatory O
cytokine O
release O
and O
tissue B-protein
factor I-protein
( O
TF I-DNA
) O
expression O
by O
monocytes B-cell_type
. O
Plasmin O
0.043 B-DNA
to O
1.43 B-protein
CTA O
U/mL I-protein
, O
but O
not O
active O
site-blocked B-DNA
plasmin O
, O
triggered O
concentration-dependent B-DNA
expression O
of O
mRNA I-RNA
for O
interleukin-1alpha B-protein
( O
IL-1alpha B-protein
) O
, O
IL-1beta O
, O
tumor O
necrosis O
factor-alpha B-DNA
( O
TNF-alpha I-DNA
) O
, O
and O
TF B-protein
with O
maximum O
responses O
after O
4 O
hours O
. O
Plasmin O
-mediated I-RNA
mRNA I-RNA
expression O
was O
inhibited O
in O
a O
concentration-dependent B-DNA
manner O
by O
the O
lysine O
analogue O
trans-4- B-protein
( O
aminomethyl O
) O
cyclohexane-1-carboxylic O
acid O
( O
t-AMCA I-DNA
) O
. O
Increases O
in O
mRNA I-RNA
levels O
were O
followed O
by O
concentration- B-DNA
and O
time-dependent O
release O
of O
IL-1alpha O
, O
IL-1beta O
and O
TNF-alpha O
and O
by O
TF B-protein
expression O
on O
monocyte O
surfaces O
. O
Neither O
cytokines O
nor O
TF B-protein
could O
be O
detected O
when O
monocytes B-cell_type
were O
preincubated O
with O
actinomycin O
D O
or O
cycloheximide O
. O
Electrophoretic O
mobility O
shift O
assays O
indicated O
plasmin O
-induced O
activation O
of O
NF-kappaB O
; O
DNA-binding B-protein
complexes O
were O
composed O
of O
p50 B-cell_type
, O
p65 I-protein
, O
and O
c-Rel I-DNA
, O
as O
shown O
by O
supershift O
experiments O
. O
Nuclear O
translocation O
of O
NF-kappaB/Rel B-protein
proteins I-protein
coincided O
with O
IkappaBalpha O
degradation O
. O
At O
variance O
with O
endotoxic O
lipopolysaccharide I-protein
, O
plasmin O
elicited O
the O
rapid O
degradation O
of O
another O
cytoplasmic O
NF-kappaB O
inhibitor O
, O
p105 O
. O
Proteolysis O
of O
NF-kappaB O
inhibitors O
was O
apparently O
due O
to O
transient O
activation O
of O
IkappaB B-cell_type
kinase I-protein
( O
IKK I-DNA
) O
beta O
that O
reached O
maximum O
activity O
at O
1 O
hour O
after O
plasmin O
stimulation O
. O
In O
addition O
, O
AP-1 B-protein
binding O
was O
increased O
in O
plasmin O
-treated O
monocytes B-cell_type
, O
with O
most O
complexes O
composed O
of O
JunD I-protein
, O
c-Fos O
, O
and O
FosB O
. O
These O
findings O
further O
substantiate O
the O
role O
of O
plasmin O
as O
a O
proinflammatory O
activator O
of O
human B-cell_type
monocytes I-cell_type
and O
reveal O
an O
important O
new O
link O
between O
the O
plasminogen-plasmin B-DNA
system O
and O
inflammation O
. O
( O
Blood. I-DNA
2001 O
; O
97 O
: O
3941-3950 O
) O
STAT3 B-protein
is O
constitutively O
active O
in O
some O
patients O
with O
Polycythemia O
rubra O
vera O
. O
OBJECTIVE O
: O
Polycythemia O
vera O
is O
a O
clonal O
stem O
cell O
disorder O
characterized O
by O
hyperproliferation O
of O
the O
erythroid B-DNA
, O
myeloid O
, O
and O
megakaryocytic O
lineages O
. O
While O
it O
has O
been O
shown O
that O
progenitor I-cell_type
cells I-cell_type
of O
P. B-RNA
vera O
patients O
are O
hypersensitive O
to O
several O
growth B-protein
factors I-protein
including O
erythropoietin O
, O
insulin-like O
growth O
factor-1 B-protein
, O
thrombopoietin O
, O
interleukin-3 B-protein
, O
and O
granulocyte/monocyte B-cell_type
colony-stimulating B-protein
factor I-protein
, O
the O
molecular O
pathogenesis O
of O
this O
disease O
remains O
unknown O
. O
Growth B-protein
factor I-protein
hypersensitivity O
could O
be O
mediated O
by O
changes O
in O
signal O
transduction O
pathways O
. O
We O
therefore O
investigated O
a O
common O
downstream O
effector O
of O
cytokines O
, O
the O
signal O
transducers O
and O
activators O
of O
transcription O
( O
STATs O
) O
. O
A O
constitutive O
activation O
of O
STAT B-protein
factors I-protein
could O
explain O
the O
increased O
proliferation O
of O
P. B-RNA
vera B-cell_type
cells I-cell_type
even O
in O
the O
absence O
of O
growth B-protein
factor I-protein
stimulation O
. O
METHODS I-protein
: O
Peripheral O
granulocytes O
from O
patients O
with O
P. B-protein
vera O
and O
from O
healthy O
volunteers O
were O
assayed O
for O
STAT1 I-protein
, O
3 O
, O
and O
5 O
DNA O
binding O
by O
electrophoretic O
mobility O
shift O
assay O
. O
RESULTS I-protein
: O
Four O
of O
14 O
P. B-protein
vera O
patients O
analyzed O
showed O
constitutive O
STAT3 B-protein
DNA O
binding O
in O
unstimulated O
peripheral B-cell_type
granulocytes O
, O
while O
none O
of O
the O
17 O
healthy O
volunteers O
tested O
did O
. O
None O
of O
the O
subjects O
showed O
constitutive O
STAT1 B-protein
or O
STAT5 B-protein
activity O
. O
Western O
blotting O
demonstrated O
that O
, O
in O
the O
three O
patients O
, O
STAT3 B-protein
is O
constitutively O
phosphorylated O
on O
Tyr O
705 O
, O
whereas O
it O
is O
unphosphorylated O
in O
the O
other O
patients O
and O
in O
controls O
. O
Interestingly B-cell_type
, O
constitutive O
STAT3 B-protein
activity O
did O
not O
correlate O
with O
the O
duration O
of O
disease O
or O
the O
treatment O
regimen O
. O
It O
was O
observed O
in O
a O
recently O
diagnosed O
patient O
and O
in O
two O
patients O
treated O
only O
with O
phlebotomy O
. O
CONCLUSION I-protein
: O
Our O
data O
suggest O
that O
constitutive O
phosphorylation O
and O
activation O
of O
STAT3 B-protein
is O
not O
a O
secondary O
event O
induced O
by O
mutagenizing O
agents O
or O
by O
prolonged O
hyperproliferation O
of O
hematopoietic B-cell_type
cells I-cell_type
, O
but O
rather O
represents O
a O
primary B-cell_line
molecular I-cell_line
aberration O
. O
Constitutively O
active O
STAT3 B-protein
may O
contribute O
to O
the O
growth I-protein
factor I-protein
hypersensitivity O
of O
P. B-RNA
vera B-cell_type
cells I-cell_type
. O
Identification O
of O
phosphorylation O
sites I-DNA
for O
Bruton O
's B-protein
tyrosine I-protein
kinase I-protein
within O
the O
transcriptional O
regulator O
BAP/TFII-I B-protein
. O
Bruton O
's B-protein
tyrosine I-protein
kinase I-protein
( O
Btk O
) O
, O
a O
member O
of O
the O
Tec O
family O
of O
cytosolic O
kinases I-protein
, O
is O
essential O
for O
B O
cell O
development O
and O
function O
. O
BAP/TFII-I I-protein
, O
a O
protein O
implicated O
in O
transcriptional O
regulation O
, O
is O
associated O
with O
Btk O
in O
B I-DNA
cells I-cell_type
and O
is O
transiently O
phosphorylated O
on O
tyrosine I-protein
following O
B O
cell I-DNA
receptor I-protein
engagement O
. O
BAP/TFII-I B-protein
is O
a O
substrate O
for O
Btk O
in O
vitro O
and O
is O
hyperphosphorylated O
on O
tyrosine I-protein
upon O
coexpression O
with O
Btk O
in O
mammalian B-cell_type
cells I-cell_type
. O
In O
an O
effort O
to O
understand O
the O
physiologic O
consequences O
of O
BAP/TFII-I B-protein
tyrosine I-protein
phosphorylation O
following O
B O
cell I-DNA
receptor I-protein
stimulation O
, O
site-directed O
mutagenesis O
and O
phosphopeptide O
mapping O
were O
used O
to O
locate O
the O
predominant O
sites I-DNA
of O
BAP/TFII-I B-protein
phosphorylation O
by O
Btk O
in O
vitro O
. O
These O
residues O
, O
Tyr248 I-cell_line
, O
Tyr357 I-cell_line
, O
and O
Tyr462 I-cell_line
, O
were O
also O
found O
to O
be O
the O
major B-DNA
sites I-DNA
for O
Btk O
-dependent O
phosphorylation O
of O
BAP/TFII-I B-protein
in O
vivo O
. O
Residues O
Tyr357 I-cell_type
and O
Tyr462 B-protein
are O
contained O
within O
the O
loop O
regions I-protein
of O
adjacent O
helix-loop-helix-like O
repeats O
within O
BAP/TFII-I B-protein
. O
Mutation O
of O
either O
Tyr248 I-cell_line
, O
Tyr357 I-cell_line
, O
or O
Tyr462 O
to O
phenylalanine O
reduced O
transcription O
from O
a O
c-fos B-DNA
promoter I-DNA
relative O
to O
wild-type O
BAP/TFII-I B-protein
in O
transfected O
COS-7 B-DNA
cells I-cell_line
, O
consistent O
with O
the O
interpretation O
that O
phosphorylation O
at O
these O
sites I-DNA
contributes O
to O
transcriptional O
activation O
. O
Phosphorylation O
of O
BAP/TFII-I B-protein
by O
Btk O
may O
link O
engagement O
of O
receptors O
such O
as O
surface I-protein
immunoglobulin O
to O
modulation O
of O
gene I-DNA
expression O
. O
Expression O
of O
interferon O
consensus O
sequence O
binding O
protein O
induces O
potent O
immunity O
against O
BCR/ABL-induced O
leukemia O
. O
Mice O
deficient O
in O
the O
interferon O
consensus O
sequence O
binding O
protein O
( O
ICSBP I-DNA
) O
develop O
a O
disease O
resembling O
chronic O
myeloid O
leukemia O
( O
CML I-DNA
) O
, O
which O
in O
humans O
is O
caused O
by O
the O
BCR/ABL B-protein
oncoprotein O
. O
Interferon-alpha O
( O
IFN-alpha I-DNA
) O
induces O
ICSBP O
expression O
and O
is O
an O
effective O
therapy O
for O
CML O
. O
This O
study O
examined O
whether O
enforced O
expression O
of O
ICSBP O
might O
antagonize O
BCR/ABL-induced O
leukemia O
; O
results O
demonstrated O
that O
ICSBP-modified B-protein
cells I-cell_type
generated O
a O
protective O
CD8 B-protein
( O
+ O
) O
cytotoxic O
T-cell O
response O
against O
BCR/ABL-transformed B-protein
BaF3 B-DNA
cells I-cell_type
in O
a O
murine I-cell_line
leukemia O
model O
. O
ICSBP O
expression O
represents O
a O
novel O
means O
of O
stimulating O
a O
host O
immune O
response O
to O
BCR/ABL B-protein
( O
+ O
) O
leukemia B-cell_type
cells I-cell_type
and O
a O
potential O
strategy O
for O
immunotherapy O
of O
CML B-cell_type
. O
( O
Blood. I-DNA
2001 O
; O
97 O
: O
3491-3497 O
) O
A O
transcriptional O
block O
in O
the O
IL-2 B-DNA
promoter I-DNA
at O
the O
-150 B-protein
AP-1 B-protein
site I-DNA
in O
effector O
CD8+ B-cell_type
T B-cell_type
cells I-cell_type
. O
Both O
CD4+ B-DNA
and O
CD8+ B-cell_type
T B-cell_type
cells I-cell_type
that O
produce O
IL-2 B-protein
in O
response O
to O
Ag O
recognition O
have O
been O
isolated O
. O
However O
, O
most O
effector O
CD8+ B-cell_type
T B-cell_type
cells I-cell_type
recovered O
after O
exposure O
to O
Ag O
do O
not O
produce O
sufficient O
IL-2 B-protein
to O
sustain O
growth I-protein
, O
and O
depend O
on O
CD4+ B-cell_type
T I-cell_line
helper I-cell_type
cells I-cell_type
for O
this O
obligate O
growth I-protein
factor I-protein
. B-protein
IL-2 B-protein
expression O
in O
CD4+ B-cell_type
T B-cell_type
cells I-cell_type
is O
primarily O
controlled O
at O
the O
level O
of O
transcription I-DNA
, O
but O
mechanisms O
restricting O
IL-2 B-protein
production O
in O
CD8+ B-cell_type
T B-cell_type
cells I-cell_type
have O
not O
been O
elucidated O
. O
To O
evaluate O
transcriptional O
regulation O
of O
the O
IL-2 B-DNA
gene I-DNA
in O
CD8+ B-cell_type
T B-cell_type
cells I-cell_type
, O
we O
stably O
transfected O
reporter I-DNA
genes I-DNA
into O
Ag O
-specific O
CD8+ B-cell_type
T O
cell O
clones O
. O
CD28+ B-protein
CD8 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
unable O
to O
transcribe O
the O
IL-2 B-DNA
gene I-DNA
in O
response O
to O
antigenic O
stimulation O
had O
a O
block O
in O
transactivation O
of O
the O
-150 O
CD28 B-protein
response O
element I-DNA
( O
CD28RE B-protein
) O
/AP-1 B-DNA
site I-DNA
of O
the O
IL-2 B-DNA
promoter I-DNA
, O
but O
did O
transactivate O
the O
composite O
NFAT/AP-1 B-protein
and O
OCT/AP-1 B-protein
sites I-DNA
, O
and O
a O
consensus O
AP-1 B-protein
motif O
. O
Mutation O
of O
the O
nonconsensus O
-150 B-protein
AP-1 B-protein
site O
to O
a O
consensus O
AP-1 B-protein
site I-DNA
, O
or O
insertion O
of O
a O
CD28RE/AP-1 B-protein
consensus O
site I-DNA
upstream O
of O
the O
native O
-150 B-protein
CD28RE/AP-1 B-DNA
site I-DNA
restored O
transactivation O
of O
the O
altered O
promoter I-DNA
. O
These O
results O
suggest O
that O
the O
defect O
at O
the O
-150 B-DNA
site I-DNA
may O
reflect O
the O
absence O
or O
inactivity O
of O
a O
required O
factor I-protein
rather O
than O
repression O
of O
the O
IL-2 B-DNA
promoter I-DNA
. O
Stem O
cell O
factor I-protein
and O
interleukin-3 B-protein
induce O
stepwise O
generation O
of O
erythroid B-cell_type
precursor B-cell_type
cells I-cell_type
from O
a O
basic O
fibroblast O
growth I-protein
factor I-protein
-dependent O
hematopoietic B-cell_type
stem I-cell_type
cell O
line O
, O
A-6 B-protein
. O
A O
m O
ultipotent O
immature O
myeloid O
cell O
population O
was O
produced O
from O
a O
basic O
fibroblast O
growth I-protein
factor I-protein
( O
bFGF I-DNA
) O
-dependent O
hematopoietic B-cell_type
stem I-cell_type
cell O
line O
, O
A-6 O
, O
when O
cultured O
with O
stem O
cell O
factor I-protein
( O
SCF I-DNA
) O
replacing O
bFGF I-RNA
. O
Those B-cell_type
cells I-cell_type
were O
positive O
for O
stem O
cell O
markers O
, O
c-kit O
and O
CD34 I-protein
, O
and O
a O
myeloid O
cell O
marker O
, O
F4/80 B-protein
. O
Some O
cell O
fractions O
were O
also O
positive O
for O
Mac-1 B-protein
, O
a O
macrophage O
marker O
or O
Gr-1 B-protein
, O
a O
granulocytic O
maker O
, O
but O
negative O
for O
an O
erythroid B-DNA
marker I-protein
TER119 B-protein
. O
They O
also O
showed O
the O
expression O
of O
mRNA I-RNA
for O
the O
myeloid-specific O
PU.1 B-protein
but O
did O
not O
that O
for O
the O
erythroid-specific O
GATA-1 B-protein
. O
Among O
various O
cytokines O
, O
interleukin-3 B-protein
( O
IL-3 B-protein
) O
induced O
erythroid B-DNA
precursor B-cell_type
cells I-cell_type
that O
expressed O
the O
erythroid-specific O
GATA-1 B-protein
and O
beta-major B-protein
globin O
. O
The O
quantitative O
analysis O
showed O
that O
erythroid B-DNA
precursor B-cell_type
cells I-cell_type
were O
newly O
produced O
from O
the O
immature O
myeloid B-cell_type
cells I-cell_type
by O
cultivation O
with O
IL-3 B-protein
. O
SCF O
and O
IL-3 B-protein
induced O
stepwise O
generation O
of O
erythroid B-cell_type
precursor B-cell_type
cells I-cell_type
from O
an O
A-6 B-protein
hematopoietic B-cell_type
stem I-cell_type
cell O
line O
. O
Copyright O
2001 O
Academic O
Press O
. O
Distinct O
BMI-1 O
and O
EZH2 B-protein
expression O
patterns O
in O
thymocytes O
and O
mature O
T B-cell_type
cells I-cell_type
suggest O
a O
role O
for O
Polycomb I-DNA
genes I-DNA
in O
human B-cell_type
T I-cell_line
cell O
differentiation O
. O
BMI-1 O
and O
EZH2 B-protein
Polycomb-group B-protein
( O
PcG I-DNA
) O
proteins I-protein
belong O
to O
two O
distinct O
protein O
complexes O
involved O
in O
the O
regulation O
of O
hematopoiesis O
. O
Using O
unique O
PcG-specific B-protein
antisera O
and O
triple O
immunofluorescence I-protein
, O
we O
found O
that O
mature O
resting O
peripheral B-cell_type
T B-cell_type
cells I-cell_type
expressed O
BMI-1 O
, O
whereas O
dividing O
blasts O
were O
EZH2 B-protein
( O
+ O
) O
. O
By O
contrast O
, O
subcapsular O
immature O
double-negative B-protein
( O
DN I-DNA
) O
( O
CD4 B-protein
( O
- O
) O
/CD8 O
( O
- O
) O
) O
T B-cell_type
cells I-cell_type
in O
the O
thymus O
coexpressed O
BMI-1 O
and O
EZH2 B-protein
or O
were O
BMI-1 O
single O
positive O
. O
Their O
descendants O
, O
double-positive O
( O
DP B-protein
; O
CD4 B-protein
( O
+ O
) O
/CD8 O
( O
+ O
) O
) O
cortical O
thymocytes O
, O
expressed O
EZH2 B-protein
without O
BMI-1 O
. O
Most O
EZH2 B-protein
( O
+ O
) O
DN O
and O
DP B-protein
thymocytes O
were O
dividing O
, O
while O
DN B-protein
BMI-1 O
( O
+ O
) O
/EZH2 B-protein
( O
- O
) O
thymocytes O
were O
resting O
and O
proliferation O
was O
occasionally O
noted O
in O
DN B-protein
BMI-1 O
( O
+ O
) O
/EZH2 B-protein
( O
+ O
) O
cells I-cell_type
. O
Maturation O
of O
DP B-cell_type
cortical O
thymocytes O
to O
single-positive O
( O
CD4 B-protein
( O
+ O
) O
/CD8 O
( O
- O
) O
or O
CD8 B-protein
( O
+ O
) O
/CD4 O
( O
- O
) O
) O
medullar O
thymocytes O
correlated O
with O
decreased O
detectability O
of O
EZH2 B-protein
and O
continued O
relative O
absence O
of O
BMI-1 O
. O
Our O
data O
show O
that O
BMI-1 O
and O
EZH2 B-protein
expression O
in O
mature O
peripheral B-cell_type
T B-cell_type
cells I-cell_type
is O
mutually O
exclusive O
and O
linked O
to O
proliferation O
status O
, O
and O
that O
this O
pattern O
is O
not O
yet O
established O
in O
thymocytes O
of O
the O
cortex O
and O
medulla O
. O
T O
cell O
stage-specific O
PcG O
expression O
profiles O
suggest O
that O
PcG I-DNA
genes I-DNA
contribute O
to O
regulation O
of O
T O
cell O
differentiation O
. O
They O
probably O
reflect O
stabilization O
of O
cell O
type-specific I-DNA
gene I-DNA
expression O
and O
irreversibility O
of O
lineage O
choice O
. O
The O
difference O
in O
PcG O
expression O
between O
medullar O
thymocytes O
and O
mature O
interfollicular O
T B-cell_type
cells I-cell_type
indicates O
that O
additional O
maturation O
processes O
occur O
after O
thymocyte O
transportation O
from O
the O
thymus O
. O
Stepwise O
lineage O
restriction O
of O
progenitors O
in O
lympho-myelopoiesis O
. O
It O
has O
long I-DNA
been O
controversial O
whether O
hematopoiesis O
progresses O
through O
ordered O
stages O
of O
determination O
as O
in O
embryonic B-cell_type
development O
. O
This O
is O
due O
to O
the O
absence O
of O
a O
methodology O
capable O
of O
exactly O
determining O
the O
developmental O
potential O
of O
hematopoietic B-cell_type
stem/progenitor B-cell_type
cells I-cell_type
. O
The O
multilineage O
progenitor O
( O
MLP I-DNA
) O
assay O
enabled O
us O
to O
discriminate O
among O
seven O
types I-cell_type
of O
hematopoietic B-cell_type
progenitors O
, O
which O
are O
multipotent O
progenitor O
p-MTB B-protein
( O
capable O
of O
generating O
myeloid O
, O
T O
and O
B I-DNA
cells I-DNA
) O
, O
bipotent O
progenitors O
p-MT I-DNA
, O
p-MB O
and O
p-TB I-DNA
, O
and O
unipotent O
progenitors O
p-M O
, O
p-T O
and O
p-B O
. O
Among O
these O
seven O
types I-cell_type
, O
the O
p-TB I-DNA
type O
progenitor O
was O
found O
to O
be O
absent O
. O
These O
findings O
indicate O
that O
the O
process O
of O
lineage O
commitment O
proceeds O
through O
an O
ordered O
but O
not O
random O
process O
. O
By O
extending O
the O
area O
of O
investigation O
to O
include O
the O
erythroid O
lineage I-protein
, O
more O
convincing O
evidence O
for O
the O
ordered O
process O
was O
obtained O
. O
Detailed O
and O
exact O
illustration O
of O
the O
process O
of O
hematopoiesis O
will O
provide O
an O
opportunity O
to O
revive O
hematopoiesis O
as O
one O
of O
the O
most O
fascinating O
targets I-cell_line
of O
research O
in O
developmental O
biology O
Epstein-Barr B-protein
Virus O
and O
its O
glycoprotein-350 B-protein
upregulate O
IL-6 B-protein
in O
human B-DNA
B-lymphocytes I-cell_type
via O
CD21 I-protein
, O
involving O
activation O
of O
NF-kappaB O
and O
different O
signaling O
pathways O
. O
Epstein-Barr O
virus O
( O
EBV I-DNA
) O
is O
a O
ubiquitous O
and O
highly O
immunotropic O
gamma O
herpesvirus O
that O
infects O
more O
than O
90 O
% O
of O
humans O
worldwide O
. O
Its O
pathogenicity O
leads O
to O
a O
number O
of O
diseases O
including O
tumors O
that O
result O
from O
EBV O
's O
ability O
to O
readily O
transform O
B-lymphocytes B-protein
and I-DNA
, O
to O
a O
lesser O
extent I-protein
, O
epithelial B-cell_type
cells I-cell_type
. O
EBV O
utilizes O
CD21/CR2 B-protein
as O
its I-DNA
receptor I-protein
on O
B I-DNA
cells O
to O
initiate O
the O
infection O
process O
. O
EBV O
binds O
to O
CR2 B-protein
through O
its O
major O
envelope O
glycoprotein-350 B-protein
( O
gp350 I-DNA
) O
and O
is O
also O
a O
remarkable O
immunomodulating O
agent O
. O
We O
had O
previously O
shown O
that O
EBV O
is O
capable O
of O
modulating O
the O
synthesis O
of O
a O
number O
of O
cytokines O
. O
We O
now O
show O
that O
while O
both O
purified O
recombinant O
gp350 I-protein
( O
rgp350 I-DNA
) O
and O
EBV O
upregulate O
IL-6 I-RNA
mRNA I-RNA
synthesis O
in O
B I-DNA
cells I-cell_line
, O
EBV-induced O
IL-6 B-DNA
gene I-DNA
activation O
occurs O
for O
a O
significantly O
longer O
period O
of O
time O
( O
i.e. I-DNA
12 O
hours O
for O
EBV O
as O
compared O
to O
6 O
hours O
for O
rgp350 B-protein
) O
. O
Moreover O
, O
the O
half-life I-DNA
of O
EBV-induced B-protein
IL-6 I-RNA
mRNA I-RNA
was O
also O
significantly O
longer O
( O
10 O
hours O
) O
than O
that O
of O
mRNA I-RNA
induced O
by O
rgp350 I-protein
( O
about O
6 O
hours O
) O
. O
Both O
EBV O
and O
gp350 I-protein
enhance O
the O
binding O
of O
the O
NF-kappaB B-protein
transcription B-protein
factor I-protein
, O
as O
determined O
by O
band-shift B-DNA
and O
augment O
NF-kappaB O
-mediated O
activation O
of O
a O
CAT O
reporter O
plasmid O
. O
Furthermore O
, O
we O
demonstrate O
that O
while O
the O
activation O
of O
IL-6 B-DNA
gene I-DNA
expression O
by O
gp350 I-protein
is O
mediated O
primarily O
by O
the O
protein O
kinase I-protein
C I-protein
pathway O
, O
EBV O
can O
mediate O
its O
effects O
through O
multiple O
signaling O
pathways O
. O
To O
our O
knowledge O
this O
is O
the O
first O
report O
showing O
that O
the O
binding O
of O
a O
herpesvirus O
envelope O
glycoprotein O
to O
CR2 B-protein
on O
human B-DNA
B I-DNA
cells I-cell_type
results O
in O
the O
activation O
of O
the O
NF-kappaB B-protein
transcription B-protein
factor I-protein
leading O
to O
the O
upregulation O
of O
IL-6 B-DNA
gene I-DNA
expression O
in O
these I-cell_type
lymphocytes I-cell_type
. O
Copyright O
2001 O
Academic O
Press O
. O
Gene- B-DNA
and O
tissue-specificity I-DNA
of O
mutation O
in O
Big O
Blue O
rats O
treated O
with O
the O
hepatocarcinogen O
N-hydroxy-2-acetylaminofluorene B-protein
. O
In O
a O
previous O
study O
, O
we O
found O
that O
treating O
transgenic O
Big O
Blue O
rats O
with O
the O
hepatocarcinogen O
N-hydroxy-2-acetylaminofluorene B-protein
( O
N-OH-AAF I-DNA
) O
produced O
the O
same O
major O
DNA O
adduct O
in O
the O
target I-cell_line
liver O
and O
the O
nontarget O
spleen I-cell_type
lymphocytes I-cell_type
and O
bone B-cell_type
marrow I-cell_line
cells I-cell_line
, O
induced O
lacI O
mutants O
in O
the O
liver O
, O
and O
induced O
much O
lower O
frequencies O
of O
l O
acI O
and O
hprt O
mutants O
in O
spleen I-cell_type
lymphocytes I-cell_type
. O
In O
the O
present O
study O
, O
sequence O
analysis O
was O
conducted O
on O
lacI O
DNA O
and O
hprt O
cDNA I-RNA
from O
the O
mutants O
, O
to O
determine O
the O
mutational O
specificity O
of O
N-OH-AAF B-protein
in O
the O
rat O
. O
All O
the O
mutation O
spectra O
from O
N-OH-AAF-treated O
rats O
differed O
significantly O
from O
corresponding O
mutation O
profiles O
from O
untreated O
animals O
( O
P O
= O
0.02 I-protein
to O
P O
< O
0.0001 B-protein
) O
. O
Although O
there O
were O
similarities O
among O
the O
mutational O
patterns O
derived O
from O
N-OH-AAF-treated O
rats O
( O
e.g. I-DNA
, O
G O
: O
C I-protein
-- O
> O
T I-cell_line
: O
A O
transversion O
was O
the O
most O
common O
mutation O
in O
all O
mutation O
sets O
) O
, O
there O
were O
significant O
differences O
in O
the O
patterns O
of O
basepair O
substitution O
and O
frameshift O
mutation O
between O
the O
liver O
and O
spleen O
lymphocyte I-cell_line
lacI O
mutants O
( O
P O
= O
0.02 B-protein
) O
and O
between O
the O
spleen O
lymphocyte I-cell_line
lacI O
and O
hprt O
mutants O
( O
P O
= O
0.04 B-protein
) O
. O
Also O
, O
multiplex O
PCR O
analysis O
of O
genomic O
DNA O
from O
the O
hprt O
mutants O
indicated O
that O
12 O
% O
of O
mutants O
from O
treated O
rats O
had O
major O
deletions O
in O
the O
hprt O
gene I-DNA
; O
no O
corresponding O
incidence O
of O
large O
deletions O
was O
evident O
among O
lacI O
mutations O
. O
All O
the O
mutation O
profiles O
reflect O
the O
general O
mutational O
specificity O
of O
the O
major O
DNA O
adduct O
formed O
by O
N-OH-AAF B-protein
. O
The O
differences O
between O
N-OH-AAF B-protein
mutation O
in O
the O
endogenous O
gene I-DNA
and O
transgene O
can O
be O
partially O
explained O
by O
the O
structures O
of O
the O
two O
genes I-DNA
. O
The O
tissue-specificity I-DNA
of O
the O
mutation O
spectra O
may O
contribute O
to O
targeting O
tumor O
formation O
to O
the O
liver O
. O
Environ. B-protein
Mol. B-DNA
Mutagen. B-protein
37 O
: O
203-214 O
, O
2001 O
. O
Published O
2001 O
Wiley-Liss O
, O
Inc O
. O
Caspase O
-dependent O
cleavage O
of O
the O
hematopoietic B-cell_type
specific O
adaptor I-protein
protein O
Gads O
alters O
signalling O
from O
the O
T O
cell I-DNA
receptor I-protein
. O
Gads O
is O
a O
SH2 B-protein
and O
SH3 I-protein
domain I-protein
-containing O
, O
hematopoietic-specific O
adaptor I-protein
protein O
that O
functions O
in O
signalling O
from O
the O
T O
cell I-DNA
receptor I-protein
. O
Gads O
acts O
by O
linking O
SLP-76 B-protein
, O
bound O
by O
the O
carboxy-terminal O
Gads O
SH3 I-protein
domain I-protein
, O
to O
tyrosine O
phosphorylated O
LAT O
which O
contains O
binding O
sites O
for O
the O
Gads O
SH2 I-protein
domain I-protein
. O
Gads O
is O
distinguished O
from O
Grb2 O
and O
the O
closely O
related O
Grap O
protein O
by O
the O
presence O
of O
a O
120 O
amino O
acid O
unique O
region O
between O
the O
SH2 I-protein
domain I-protein
and O
the O
carboxy O
terminal I-DNA
SH3 I-protein
domain I-protein
. O
Here O
we O
demonstrate O
that O
the O
unique O
region I-DNA
of O
Gads O
contains O
a O
capase O
cleavage I-DNA
site I-DNA
. O
Induction O
of O
apoptosis O
in I-cell_type
lymphocytes I-cell_type
results O
in O
detectable O
Gads O
cleavage O
by O
60 O
min O
. O
Gads O
cleavage O
is O
blocked O
in O
vivo O
by O
treating B-cell_type
cells I-cell_type
with O
a O
caspase O
3 O
inhibitor O
. O
A O
putative O
caspase O
3 O
cleavage O
site I-DNA
was O
identified O
within O
the O
unique O
region O
and O
mutation O
of O
this O
site I-DNA
prevented O
Gads O
cleavage O
in O
vitro O
, O
and O
in O
vivo O
. O
The O
Gads O
cleavage O
products O
retained O
the O
predicted O
binding O
specificity O
for O
SLP-76 B-protein
and O
LAT O
. O
Expression O
of O
the O
Gads O
cleavage O
products O
in O
Jurkat O
T B-cell_type
cells I-cell_type
inhibited O
NFAT O
activation O
following O
TCR O
cross O
linking O
. O
These O
findings O
indicate O
that O
cleavage O
of O
Gads O
in O
vivo O
could O
function O
to O
alter O
signalling O
downstream O
of O
the O
T O
cell I-DNA
receptor I-protein
by O
disrupting O
cross O
talk O
between O
SLP-76 B-protein
and O
LAT O
. O
Targeting O
of O
p300 O
to O
the O
interleukin-2 B-protein
promoter O
via O
CREB-Rel B-protein
cross-talk B-DNA
during O
mitogen O
and O
oncogenic O
molecular O
signaling O
in O
activated O
T-cells B-protein
. O
In O
this O
report I-protein
, O
we O
explore O
the O
mechanisms O
of O
targeting O
of O
p300 O
to O
the O
interleukin-2 B-protein
( O
IL-2 B-protein
) O
promoter I-DNA
in O
response O
to O
mitogenic O
and O
oncogenic O
molecular O
signals O
. O
Recruitment O
of O
p300 B-cell_type
by O
cAMP-responsive O
element-binding O
protein-Rel O
cross-talk B-DNA
at O
the O
composite O
CD28 B-protein
response O
element I-DNA
( O
CD28RE B-protein
) O
- O
TRE O
element I-DNA
of O
the O
IL-2 B-DNA
promoter I-DNA
is O
essential O
for O
promoter I-DNA
inducibility O
during O
T-cell O
activation O
, O
and O
CD28RE-TRE B-protein
is O
the O
exclusive O
target I-cell_line
of O
the O
human O
T-cell O
lymphotropic O
virus O
type O
I I-protein
oncoprotein O
Tax O
. O
The O
intrinsic O
histone I-protein
acetyltransferase O
activity O
of O
p300 B-cell_type
is O
dispensable O
for O
activation O
of O
the O
IL-2 B-DNA
promoter I-DNA
, O
and O
the O
N-terminal B-protein
743 O
residues O
contain O
the O
minimal O
structural O
requirements O
for O
synergistic O
transactivation O
of O
the O
CD28RE-TRE B-protein
, O
the O
IL-2 B-DNA
promoter I-DNA
, O
and O
endogenous O
IL-2 B-DNA
gene I-DNA
expression O
. O
Mutational O
analysis O
of O
p300 B-cell_type
reveals O
differential O
structural O
requirements O
for O
the O
N-terminal B-protein
p300 I-protein
module O
by O
individual O
cis-elements O
within O
the O
IL-2 B-DNA
promoter I-DNA
. O
These O
findings O
provide O
evidence O
that O
p300 I-protein
assembles O
at O
the O
IL-2 B-DNA
promoter O
to O
form O
an O
enhanceosome-like O
signal O
transduction O
target I-cell_line
that O
is O
centrally O
integrated O
at O
the O
CD28RE-TRE B-DNA
element I-DNA
of O
the O
IL-2 B-DNA
promoter I-DNA
through O
specific O
protein O
module-targeted O
associations O
in O
activated O
T-cells B-protein
. O
Regulation O
of O
cytokine O
production O
in O
T-cell O
responses O
to O
inhalant O
allergen O
: O
GATA-3 B-protein
expression O
distinguishes O
between O
Th1- B-DNA
and O
Th2-polarized B-protein
immunity O
. O
BACKGROUND I-protein
: O
The O
precise O
nature O
of O
allergen-specific B-DNA
cytokine O
responses O
in O
atopics O
versus O
non-atopics I-cell_line
, O
in O
particular O
the O
'Th1 O
polarity O
' O
of O
responses O
in O
non-atopics I-cell_line
, O
remains O
controversial O
. O
This O
is O
due O
in O
part O
to O
the O
relative O
insensitivity O
of O
cytokine O
detection O
systems O
, O
and O
associated O
variations O
in O
kinetics O
of O
cytokine O
production O
and O
catabolism O
in O
in O
vitro O
culture O
systems O
. O
As O
an O
alternative O
to O
cytokine O
measurement O
, O
this O
study O
focuses O
on O
expression O
of O
the O
transcription B-protein
factor I-protein
GATA-3 B-protein
for O
analysis O
of O
allergen-specific B-DNA
Th O
cell O
responses O
. O
METHODS I-protein
: O
Cord O
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
were O
Th1- B-protein
or O
Th2-polarized B-protein
by O
culture O
in O
IL-12- B-protein
or O
IL-4-employing B-DNA
established O
methods O
; O
PBMC O
from O
house O
dust O
mite O
( O
HDM I-DNA
) O
-sensitive O
atopics O
and O
controls O
were O
stimulated O
overnight O
with O
HDM O
; O
cytokine O
production O
was O
measured O
by O
ELISA O
and O
GATA-3 I-RNA
mRNA I-RNA
expression O
by O
PCR O
. O
RESULTS I-protein
: O
Cytokine O
-driven O
Th2 O
polarization O
of O
naive B-cell_type
T B-cell_type
cells I-cell_type
is O
associated O
with O
marked O
upregulation O
of O
GATA-3 B-protein
expression O
, O
whereas O
a O
reciprocal O
expression O
pattern O
accompanies O
differentiation O
towards O
the O
Th1 O
cytokine O
phenotype O
. O
In O
T B-cell_type
cells I-cell_type
from O
HDM O
skin O
prick O
test-positive I-DNA
( O
HDM-SPT+/HDM-IgE+ I-DNA
) O
volunteers O
, O
overnight O
stimulation O
results O
in O
marked O
upregulation O
of O
GATA-3 B-protein
expression O
, O
compared O
to O
an O
equally O
marked O
downregulation O
of O
expression O
in O
T B-cell_type
cells I-cell_type
from O
SPT-/IgE- O
subjects O
. O
In O
subjects O
who O
are O
HDM-SPT+ B-protein
but O
IgE- I-DNA
, O
GATA-3 B-protein
expression O
levels O
remained O
relatively O
stable O
during O
culture O
with O
HDM O
. O
CONCLUSIONS I-protein
: O
Upregulation O
of O
GATA-3 B-protein
expression O
in O
PBMC O
is O
a O
hallmark O
of O
the O
early O
phase O
of O
Th2 B-cell_type
recall O
responses O
to O
specific O
allergen O
in O
atopics O
. O
The O
reciprocal O
expression O
pattern O
observed O
in O
HDM-specific B-protein
recall O
responses O
of O
non-atopics O
provides O
independent O
confirmation O
of O
the O
presence O
of O
underlying O
Th1-like B-protein
immunity O
in O
these O
subjects O
. O
The O
parallel O
findings O
in O
neonatal O
T B-cell_type
cells I-cell_type
suggest O
that O
the O
same O
approach O
may O
be O
utilized O
for O
monitoring O
the O
progress O
of O
allergen-specific B-DNA
Th1/Th2 O
memory O
development O
during O
early O
childhood O
, O
and O
hence O
in O
assessment O
of O
risk O
for O
future O
allergic O
disease O
. O
Copyright O
2001 O
S. B-protein
Karger O
AG I-protein
, O
Basel O
The O
heat O
shock O
response O
reduces O
myelin O
oligodendrocyte O
glycoprotein O
-induced O
experimental O
autoimmune O
encephalomyelitis O
in O
mice O
. O
The O
stress O
response O
( O
SR I-DNA
) O
can O
block O
inflammatory B-DNA
gene I-DNA
expression O
by O
preventing O
activation O
of O
transcription B-protein
factor I-protein
nuclear B-protein
factor-kappa B-DNA
B I-DNA
( O
NF-kappaB I-DNA
) O
. O
As O
inflammatory B-DNA
gene I-DNA
expression O
contributes O
to O
the O
pathogenesis O
of O
demyelinating O
diseases O
, O
we O
tested O
the O
effects O
of O
the O
SR B-protein
on O
the O
progression O
of O
the O
demyelinating O
disease O
experimental O
autoimmune O
encephalomyelitis O
( O
EAE I-DNA
) O
. O
EAE O
was O
actively O
induced O
in O
C57BL/6 B-protein
mice O
using O
an O
encephalitogenic O
myelin O
oligodendrocyte O
glycoprotein O
( O
MOG O
( O
35-55 O
) O
) O
peptide O
. O
Whole O
body O
hyperthermia O
was O
used O
to O
induce O
a O
heat O
shock O
response O
( O
HSR I-DNA
) O
in O
immunized O
mice O
2 O
days O
after O
the O
booster O
MOG I-protein
( O
35-55 O
) O
peptide O
injection O
. O
The O
HSR O
reduced O
the O
incidence O
of O
EAE B-cell_type
by O
70 O
% O
, O
delayed O
disease O
onset O
by O
6 O
days O
, O
and O
attenuated O
disease O
severity O
. O
The O
HSR O
attenuated O
leukocyte O
infiltration O
into O
CNS O
assessed O
by O
quantitation O
of O
perivascular O
infiltrates O
, O
and O
by O
reduced O
staining O
for O
CD4 B-protein
and O
CD25 B-protein
immunopositive O
T-cells B-protein
. O
T-cell O
activation O
, O
assessed O
by O
the O
production O
of O
interferon O
gamma O
( O
IFNgamma I-DNA
) O
in O
response O
to O
MOG O
( O
35-55 O
) O
, O
was O
also O
decreased O
by O
the O
HSR O
. O
The O
HSR O
reduced O
inflammatory B-DNA
gene I-DNA
expression O
in O
the O
brain O
that O
normally O
occurs O
during O
EAE I-protein
, O
including O
the O
early O
increase O
in O
RANTES I-protein
( O
regulated O
on O
activation O
of O
normal O
T-cell O
expressed O
and O
secreted O
) O
expression O
, O
and O
the O
later O
expression O
of O
the O
inducible O
form O
of O
nitric O
oxide O
synthase O
. O
The O
early O
activation O
of O
transcription B-protein
factor I-protein
NF-kappaB B-protein
was O
also O
blocked O
by O
the O
HSR O
. O
The O
finding O
that O
the O
SR B-protein
reduces O
inflammation O
in O
the O
brain O
and O
the O
clinical O
severity O
of O
EAE B-cell_type
opens O
a O
novel O
therapeutic O
approach O
for O
prevention O
of O
autoimmune O
diseases O
. O
In O
vivo O
detection O
of O
intracellular O
signaling O
pathways O
in O
developing O
thymocytes O
. O
Information O
regarding O
the O
intracellular O
signaling O
processes O
that O
occur O
during O
the O
development O
of O
T B-cell_type
cells I-cell_type
has O
largely O
been O
obtained O
with O
the O
use O
of O
transgenic O
mouse B-DNA
models O
, O
which O
although O
providing O
invaluable O
information O
are O
time O
consuming O
and O
costly O
. O
To O
this O
end O
, O
we O
have O
developed O
a O
novel O
system O
that O
facilitates O
the O
in O
vivo O
analysis O
of O
signal O
transduction O
pathways O
during O
T-lymphocyte B-protein
development O
. O
This O
approach O
uses O
reporter-plasmids O
for O
the O
detection O
of O
intracellular O
signals O
mediated O
by O
the O
mitogen-activated B-DNA
protein O
kinase I-protein
or O
cyclic O
AMP-dependent B-protein
protein O
kinase I-protein
. O
Reporter-plasmids O
are O
transfected O
into O
thymocytes O
in O
fetal O
thymic B-cell_line
organ O
culture O
by O
accelerated O
DNA/particle B-protein
bombardment O
( O
gene I-DNA
gun O
) O
, O
and O
the O
activation O
of O
a O
signaling O
pathway O
is O
determined O
in O
the O
form O
of O
a O
standard O
luciferase O
assay O
. O
Importantly O
, O
this O
powerful O
technique O
preserves O
the O
structural O
integrity O
of O
the O
thymus O
, O
and O
will O
provide O
an O
invaluable O
tool O
to O
study O
how O
thymocytes O
respond O
to O
normal O
environmental O
stimuli O
encountered O
during O
differentiation O
within O
the O
thymic B-cell_line
milieu O
. O
Thus O
, O
this O
method O
allows O
for O
the O
monitoring O
of O
signals O
that O
occur O
in O
a O
biological O
time O
frame O
, O
such O
as O
during O
differentiation O
, O
and O
within O
the O
natural O
environment O
of O
differentiating B-cell_type
cells I-cell_type
. O
Core-binding B-protein
factor I-protein
beta O
( O
CBFbeta I-DNA
) O
, O
but O
not O
CBFbeta-smooth O
muscle O
myosin O
heavy O
chain O
, O
rescues O
definitive O
hematopoiesis O
in O
CBFbeta O
-deficient O
embryonic B-cell_type
stem I-cell_type
cells I-cell_type
. O
Core-binding B-protein
factor I-protein
beta O
( O
CBFbeta I-DNA
) O
is O
the O
non-DNA-binding O
subunit O
of O
the O
heterodimeric O
CBFs O
. O
Genes O
encoding O
CBFbeta O
( O
CBFB I-DNA
) O
, O
and O
one O
of O
the O
DNA-binding B-protein
CBFalpha O
subunits O
, O
Runx1 I-cell_line
( O
also O
known O
as O
CBFalpha2 I-cell_line
, O
AML1 I-protein
, O
and O
PEBP2alphaB B-protein
) O
, O
are O
required O
for O
normal O
hematopoiesis O
and O
are O
also O
frequent O
targets I-cell_line
of O
chromosomal O
translocations O
in O
acute O
leukemias O
in O
humans O
. O
Homozygous O
disruption O
of O
either O
the O
Runx1 O
or O
Cbfb B-DNA
gene I-DNA
in O
mice O
results O
in O
embryonic B-cell_type
lethality O
at O
midgestation O
due O
to O
hemorrhaging O
in O
the O
central O
nervous O
system I-protein
, O
and O
severely O
impairs O
fetal O
liver O
hematopoiesis O
. O
Results O
of O
this O
study O
show O
that O
Cbfb-deficient O
mouse B-DNA
embryonic B-cell_type
stem I-cell_type
( O
ES I-DNA
) O
cells I-cell_type
can O
differentiate O
into O
primitive O
erythroid B-DNA
colonies I-protein
in O
vitro O
, O
but O
are O
impaired O
in O
their O
ability O
to O
produce O
definitive O
erythroid I-cell_type
and O
myeloid O
colonies O
, O
mimicking O
the O
in O
vivo O
defect O
. O
Definitive O
hematopoiesis O
is O
restored O
by O
ectopic O
expression O
of O
full-length O
Cbfb O
transgenes O
, O
as O
well O
as O
by O
a O
transgene O
encoding O
only O
the O
heterodimerization I-protein
domain I-protein
of O
CBFbeta O
. O
In O
contrast O
, O
the O
CBFbeta O
- O
smooth O
muscle O
myosin O
heavy O
chain O
( O
SMMHC I-DNA
) O
fusion O
protein O
generated O
by O
the O
inv O
( O
16 O
) O
associated O
with O
acute O
myeloid O
leukemias O
( O
M4Eo I-DNA
) O
can O
not O
rescue O
definitive O
hematopoiesis O
by O
Cbfb-deficient O
ES B-cell_type
cells I-cell_type
. O
Sequences O
responsible O
for O
the O
inability O
of O
CBFbeta O
-SMMHC O
to O
rescue O
definitive O
hematopoiesis O
reside O
in O
the O
SMMHC O
portion O
of O
the O
fusion O
protein O
. O
Results O
also O
show O
that O
the O
CBFbeta-SMMHC B-protein
fusion O
protein O
transdominantly O
inhibits O
definitive O
hematopoiesis O
, O
but O
not O
to O
the O
same O
extent O
as O
homozygous O
loss O
of O
Runx1 B-cell_type
or O
Cbfb O
. O
CBFbeta-SMMHC B-protein
preferentially O
inhibits O
the O
differentiation O
of O
myeloid O
lineage I-cell_type
cells I-cell_line
, O
while O
increasing O
the O
number O
of O
blastlike B-cell_type
cells I-cell_type
in O
culture O
. O
The O
latency O
pattern O
of O
Epstein-Barr O
virus O
infection O
and O
viral O
IL-10 B-protein
expression O
in O
cutaneous O
natural O
killer/T-cell B-protein
lymphomas O
. O
The O
nasal I-DNA
type I-DNA
, O
extranodal O
natural O
killer O
or O
T I-cell_line
( O
NK/T I-DNA
) O
-cell O
lymphoma O
is O
usually O
associated O
with O
latent O
Epstein-Barr O
virus O
( O
EBV I-DNA
) O
infection O
. O
In O
order O
to O
elucidate O
the O
EBV B-DNA
gene I-DNA
expression O
patterns O
in O
vivo O
, O
we O
examined O
eight O
patients O
with O
cutaneous O
EBV-related B-protein
NK/T-cell O
lymphomas O
, O
including O
six O
patients O
with O
a O
NK-cell B-protein
phenotype O
and O
two O
patients O
with O
a O
T-cell O
phenotype O
. O
The O
implication O
of O
EBV B-cell_type
in O
the O
skin O
lesions O
was O
determined O
by O
the O
presence O
of O
EBV-DNA I-protein
, O
EBV-encoded O
nuclear B-protein
RNA I-protein
( O
EBER I-DNA
) O
and O
a O
clonality O
of O
EBV-DNA B-protein
fragments O
containing O
the O
terminal I-DNA
repeats O
. O
Transcripts O
of O
EBV-encoded I-DNA
genes I-DNA
were O
screened O
by O
reverse O
transcription- B-DNA
polymerase O
chain O
reaction O
( O
RT-PCR B-protein
) O
, O
and O
confirmed O
by O
Southern O
blot O
hybridization O
. O
The O
expression O
of O
EBV-related B-protein
antigens O
was O
examined O
by O
immunostaining O
using O
paraffin-embedded B-DNA
tissue O
sections O
and O
cell O
pellets O
of O
EBV-positive O
cell O
lines I-cell_line
. O
Our O
study O
demonstrated O
that O
all O
samples O
from O
the O
patients O
contained O
EBV O
nuclear B-protein
antigen I-protein
( O
EBNA I-DNA
) O
-1 I-RNA
mRNA I-RNA
which O
was O
transcribed O
using O
the O
Q O
promoter I-DNA
, O
whereas O
both O
the O
Q O
promoter I-DNA
and O
another O
upstream O
promoter I-DNA
( O
Cp/Wp I-DNA
) O
were O
used O
in O
EBV-positive O
cell O
lines I-cell_line
, O
B95.8 I-protein
, O
Raji O
and O
Jiyoye O
. O
Latent O
membrane O
protein-1 B-protein
( O
LMP-1 O
) O
mRNA I-RNA
was O
detected O
in O
seven O
of O
eight O
patients O
and O
all O
cell O
lines I-cell_line
, O
whereas O
EBNA-2 I-RNA
transcripts I-RNA
were O
found O
only O
in O
the O
cell O
lines I-cell_line
. O
Immunostaining O
showed O
no O
LMP-1 O
, O
EBNA-2 B-protein
or O
ZEBRA O
antigens O
in O
the O
paraffin-embedded B-DNA
tissue O
sections O
, O
although O
they O
were O
positive O
in O
the O
cell O
line I-cell_type
cells I-cell_type
. O
Latent O
BHRF1 I-RNA
transcripts I-RNA
encoding O
bcl-2 B-protein
homologue O
and O
BCRF1 I-RNA
transcripts I-RNA
encoding O
viral O
interleukin O
( O
vIL I-DNA
) O
-10 O
were O
detected O
in O
one O
and O
two O
of O
eight O
patients O
, O
respectively O
. O
A O
patient O
with O
NK-cell B-protein
lymphoma O
expressing O
both O
transcripts I-RNA
died O
of O
rapid O
progression O
of O
the O
illness O
. O
Our O
results O
indicate O
that O
the O
restricted O
expression O
of O
the O
latency-associated O
EBV I-DNA
genes I-DNA
and O
the O
production O
of O
vIL-10 O
and O
bcl-2 B-protein
homologue O
may O
favour O
tumour O
growth I-protein
, O
evading O
the O
host O
immune O
surveillance O
. O
Copyright O
2001 O
Cancer O
Research O
Campaign O
. O
Oxidized O
alkyl O
phospholipids O
are O
specific O
, O
high O
affinity O
peroxisome O
proliferator-activated B-DNA
receptor I-protein
gamma O
ligands O
and O
agonists O
. O
Synthetic O
high O
affinity O
peroxisome O
proliferator-activated B-DNA
receptor I-protein
( O
PPAR I-DNA
) O
agonists O
are O
known O
, O
but O
biologic O
ligands O
are O
of O
low O
affinity O
. O
Oxidized O
low O
density O
lipoprotein O
( O
oxLDL I-DNA
) O
is O
inflammatory O
and O
signals O
through O
PPARs O
. O
We O
showed I-protein
, O
by O
phospholipase B-protein
A O
( O
1 O
) O
digestion O
, O
that O
PPARgamma O
agonists O
in O
oxLDL I-RNA
arise O
from O
the O
small O
pool O
of O
alkyl O
phosphatidylcholines O
in O
LDL O
. O
We O
identified O
an O
abundant O
oxidatively O
fragmented O
alkyl O
phospholipid O
in O
oxLDL I-DNA
, O
hexadecyl O
azelaoyl O
phosphatidylcholine O
( O
azPC I-DNA
) O
, O
as O
a O
high O
affinity O
ligand O
and O
agonist O
for O
PPARgamma O
. O
[ O
( O
3 O
) O
H O
] O
azPC O
bound O
recombinant O
PPARgamma O
with O
an O
affinity O
( O
K O
( O
d O
) O
( O
( O
app O
) O
) O
approximately O
40 O
nm O
) O
that O
was O
equivalent O
to O
rosiglitazone O
( O
BRL49653 B-protein
) O
, O
and O
competition O
with O
rosiglitazone O
showed O
that O
binding O
occurred O
in O
the O
ligand-binding I-cell_type
pocket O
. O
azPC O
induced O
PPRE O
reporter B-DNA
gene I-DNA
expression O
, O
as O
did O
rosiglitazone O
, O
with O
a O
half-maximal B-DNA
effect O
at O
100 O
nm O
. O
Overexpression O
of O
PPARalpha B-cell_type
or O
PPARgamma O
revealed O
that O
azPC O
was O
a O
specific O
PPARgamma O
agonist O
. O
The O
scavenger I-DNA
receptor I-protein
CD36 B-protein
is O
encoded O
by O
a O
PPRE-responsive B-DNA
gene I-DNA
, O
and O
azPC O
enhanced O
expression O
of O
CD36 B-protein
in O
primary B-cell_line
human I-cell_line
monocytes B-cell_type
. O
We O
found O
that O
anti-CD36 B-protein
inhibited O
azPC O
uptake I-protein
, O
and O
it O
inhibited O
PPRE O
reporter O
induction O
. O
Results O
with O
a O
small O
molecule O
phospholipid O
flippase O
mimetic O
suggest O
azPC O
acts O
intracellularly O
and O
that O
cellular O
azPC O
accumulation O
was O
efficient O
. O
Thus O
, O
certain O
alkyl O
phospholipid O
oxidation O
products O
in O
oxLDL I-RNA
are O
specific O
, O
high O
affinity O
extracellular O
ligands O
and O
agonists O
for O
PPARgamma O
that O
induce O
PPAR-responsive I-DNA
genes I-DNA
Regulation O
of O
the O
human B-DNA
MAT2B B-DNA
gene I-DNA
encoding O
the O
regulatory O
beta O
subunit O
of O
methionine O
adenosyltransferase I-protein
, O
MAT I-protein
II I-protein
. O
Methionine O
adenosyltransferase O
( O
MAT I-DNA
) O
catalyzes O
the O
biosynthesis O
of O
S-adenosylmethionine B-protein
( O
AdoMet I-DNA
) O
, O
a O
key O
molecule O
in O
transmethylation O
reactions O
and O
polyamine O
biosynthesis O
. O
The O
MAT I-protein
II I-protein
isozyme O
consists O
of O
a O
catalytic O
alpha2 I-protein
and O
a O
regulatory O
beta O
subunit O
. O
Down-regulation O
of O
the O
MAT I-protein
II I-protein
beta O
subunit O
expression O
causes O
a O
6-10-fold B-protein
increase O
in O
intracellular O
AdoMet O
levels O
. O
To O
understand O
the O
mechanism O
by O
which O
the O
beta O
subunit O
expression O
is O
regulated O
, O
we O
cloned O
the O
MAT2B B-DNA
gene I-DNA
, O
determined O
its O
organization O
, O
characterized O
its O
5'-flanking O
sequences O
, O
and O
elucidated O
the O
in O
vitro O
and O
in O
vivo O
regulation O
of O
its O
promoter I-DNA
. O
Transcription I-DNA
of O
the O
MAT2B B-DNA
gene I-DNA
initiates O
at O
position O
-203 B-protein
relative O
to O
the O
translation O
start I-DNA
site I-DNA
. O
Promoter O
deletion O
analysis O
defined O
a O
minimal O
promoter I-DNA
between O
positions O
+52 O
and O
+93 O
base O
pairs O
, O
a O
GC-rich B-DNA
region O
. O
Inclusion O
of O
the O
sequences O
between O
-4 O
and O
+52 O
enhanced O
promoter I-DNA
activity O
; O
this O
was O
primarily O
because O
of O
an O
Sp1 O
recognition O
site I-DNA
at O
+9/+15 B-protein
. O
The O
inclusion O
of O
sequences O
up O
to O
position O
-115 B-protein
provided O
full O
activity O
; O
this O
was O
attributed O
to O
a O
TATA O
at O
-32 B-protein
. O
The O
Sp1 O
site I-DNA
at O
position O
+9 O
was O
key O
for O
the O
formation O
of O
protein.DNA B-cell_type
complexes O
. O
Mutation O
of O
both O
the O
Sp1 O
site I-DNA
at O
+9 O
and O
the O
TATA O
at O
-32 B-protein
reduced O
promoter I-DNA
activity O
to O
its O
minimal O
level O
. O
Supershift O
assays O
showed O
no O
effect O
of O
the O
anti-Sp1 B-protein
antibody O
on O
complex I-protein
formation O
, O
whereas O
the O
anti-Sp3 B-protein
antibody O
had O
a O
strong O
effect O
on O
protein.DNA I-protein
complex I-protein
formation O
, O
suggesting O
that O
Sp3 O
is O
one O
of O
the O
main B-protein
factors I-protein
binding O
to O
this O
Sp1 O
site I-DNA
. O
Chromatin O
immunoprecipitation O
assays O
supported O
the O
involvement O
of O
both O
Sp1 O
and O
Sp3 O
in O
complexes O
formed O
on O
the O
MAT2B B-DNA
promoter I-DNA
. O
The O
data O
show O
that O
the O
5'-untranslated O
sequences O
play O
an O
important O
role O
in O
regulating O
the O
MAT2B B-DNA
gene I-DNA
and O
identifies O
the O
Sp1 O
site I-DNA
at O
+9 O
as O
a O
potential O
target I-cell_line
for O
modulating O
MAT2B B-protein
expression O
, O
a O
process O
that O
can O
have O
a O
major O
effect O
on O
intracellular O
AdoMet O
levels O
. O
Molecular O
pathogenesis O
of O
influenza O
A O
virus O
infection O
and O
virus-induced B-protein
regulation O
of O
cytokine B-DNA
gene I-DNA
expression O
. O
Despite O
vaccines O
and O
antiviral O
substances O
influenza O
still O
causes O
significant O
morbidity O
and O
mortality O
world O
wide O
. O
Better O
understanding O
of O
the O
molecular O
mechanisms O
of O
influenza O
virus O
replication O
, O
pathogenesis O
and O
host O
immune O
responses O
is O
required O
for O
the O
development O
of O
more O
efficient O
means O
of O
prevention O
and O
treatment O
of O
influenza O
. O
Influenza O
A O
virus O
, O
which O
replicates O
in O
epithelial B-cell_type
cells I-cell_type
and O
leukocytes O
, O
regulates O
host O
cell O
transcriptional O
and O
translational O
systems O
and O
activates O
, O
as O
well O
as O
downregulates O
apoptotic O
pathways O
. O
Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES I-DNA
, O
MIP-1 O
alpha I-DNA
, O
MCP-1 O
, O
MCP-3 O
, O
and O
IP-10 B-protein
) O
, O
pro-inflammatory I-cell_line
( O
IL-1 B-protein
beta O
, O
IL-6 B-protein
, O
IL-18 O
, O
and O
TNF-alpha B-protein
) O
, O
and O
antiviral O
( O
IFN-alpha/beta I-DNA
) O
cytokines O
. O
Cytokine B-DNA
gene I-DNA
expression O
is O
associated O
with O
the O
activation O
of O
NF-kappa B-protein
B I-protein
, O
AP-1 B-protein
, O
STAT B-protein
and O
IRF O
signal O
transducing O
molecules I-protein
in O
influenza O
A O
virus-infected B-cell_type
cells I-cell_type
. O
In O
addition O
of O
upregulating O
cytokine B-DNA
gene I-DNA
expression O
, O
influenza O
A O
virus O
infection O
activates O
caspase-1 B-protein
enzyme I-protein
, O
which O
is O
involved O
in O
the O
proteolytic O
processing O
of O
proIL-1 B-protein
beta O
and O
proIL-18 B-protein
into O
their O
biologically O
active O
forms O
. O
Influenza O
A O
virus-induced O
IFN-alpha/beta B-protein
is O
essential O
in O
host O
's O
antiviral O
defence O
by O
activating O
the O
expression O
of O
antiviral O
Mx O
, O
PKR O
and O
oligoadenylate O
synthetase I-DNA
genes I-DNA
. O
IFN-alpha/beta B-protein
also O
prolongs O
T O
cell O
survival O
, O
upregulates O
IL-12 B-protein
and O
IL-18 I-DNA
receptor I-DNA
gene I-DNA
expression O
and O
together O
with O
IL-18 B-protein
stimulates O
NK O
and O
T O
cell O
IFN-gamma B-protein
production O
and O
the O
development O
of O
Th1-type B-protein
immune O
response O
. O
Comparison O
of O
hprt O
and O
lacI O
mutant O
frequency O
with O
DNA O
adduct O
formation O
in O
N-hydroxy-2-acetylaminofluorene-treated B-protein
Big O
Blue O
rats O
. O
N-Hydroxy-2-acetylaminofluorene B-protein
( O
N-OH-AAF I-DNA
) O
is O
the O
proximate O
carcinogenic O
metabolite O
of O
the O
powerful O
rat O
liver O
carcinogen O
2-acetylaminofluorene O
. O
In O
this O
study O
, O
transgenic O
Big O
Blue O
( O
R I-DNA
) O
rats O
were O
used O
to O
examine O
the O
relationship O
between O
in O
vivo O
mutagenicity O
and O
DNA O
adduct O
formation O
by O
N-OH-AAF B-protein
in O
the O
target I-cell_line
liver O
compared O
with O
that O
in O
nontarget O
tissues O
. O
Male O
rats O
were O
given O
one O
, O
two O
, O
or O
four O
doses O
of O
25 O
mg O
N-OH-AAF/kg O
body O
weight O
by O
i.p. B-DNA
injection O
at O
4-day B-DNA
intervals O
, O
and O
groups O
of O
treated O
and O
control O
rats O
were O
euthanized O
up O
to O
10 O
weeks O
after O
beginning O
the O
dosing O
. O
Mutant O
frequencies O
were O
measured O
in O
the O
spleen O
lymphocyte I-cell_line
hprt O
gene I-DNA
, O
and O
lacI O
mutant O
frequencies O
were O
determined O
in O
the O
liver O
and O
spleen I-cell_type
lymphocytes I-cell_type
. O
At O
6 O
weeks O
after O
beginning O
the O
dosing I-protein
, O
the O
hprt O
mutant O
frequency O
in O
spleen I-cell_type
lymphocytes I-cell_type
from O
the O
four-dose B-DNA
group O
was O
16.5 B-protein
x O
10 O
( O
-6 B-protein
) O
compared O
with O
3.2 B-protein
x O
10 O
( O
-6 B-protein
) O
in O
control O
animals O
. O
Also O
at O
6 O
weeks O
, O
rats O
given O
one O
, O
two O
, O
or O
four O
doses O
of O
N-OH-AAF B-protein
had O
lacI O
mutant O
frequencies O
in O
the O
liver O
of O
97.6 B-cell_type
, O
155.6 I-cell_line
, O
and O
406.8 B-protein
x O
10 O
( O
-6 B-protein
) O
, O
respectively O
, O
compared O
with O
a O
control O
frequency O
of O
25.7 B-cell_type
x O
10 O
( O
-6 B-protein
) O
; O
rats O
given O
four O
doses O
had O
lacI O
mutant O
frequencies O
in O
spleen I-cell_type
lymphocytes I-cell_type
of O
55.8 B-cell_type
x O
10 O
( O
-6 B-protein
) O
compared O
with O
a O
control O
frequency O
of O
20.4 B-cell_type
x O
10 O
( O
-6 B-protein
) O
. O
Additional O
rats O
were O
evaluated O
for O
DNA O
adduct O
formation O
in O
the O
liver O
, O
spleen I-cell_type
lymphocytes I-cell_type
, O
and O
bone B-cell_type
marrow I-cell_line
by O
( O
32 I-DNA
) O
P-postlabeling O
. O
Adduct O
analysis O
was O
conducted O
1 O
day O
after O
one O
, O
two O
, O
and O
four O
treatments O
with O
N-OH-AAF I-protein
, O
5 O
days O
after O
one O
treatment O
, O
and O
9 O
days O
after O
two O
treatments O
. O
N- B-protein
( O
Deoxyguanosin-8-yl B-protein
) O
-2-aminofluorene O
was O
the O
major O
DNA O
adduct O
identified O
in O
all O
the O
tissues O
examined O
. O
Adduct O
concentrations O
increased O
with O
total O
dose O
to O
maximum O
values O
in O
samples O
taken O
1 O
day O
after O
two O
doses O
, O
and O
remained O
essentially O
the O
same O
after O
four O
doses O
. O
In O
samples O
taken O
after O
four O
doses O
, O
adduct O
levels O
were O
103 O
, O
28 O
, O
and O
7 O
fmol/microg I-DNA
of O
DNA O
in O
liver O
, O
spleen I-cell_type
lymphocytes I-cell_type
, O
and O
bone B-cell_type
marrow I-cell_line
, O
respectively O
. O
The O
results O
indicate O
that O
the O
extent O
of O
both O
DNA O
adduct O
formation O
and O
mutant O
induction O
correlates O
with O
the O
organ O
specificity O
for O
N-OH-AAF B-protein
carcinogenesis O
in O
the O
rat O
. O
Environ. B-protein
Mol. B-DNA
Mutagen. B-protein
37 O
: O
195-202 O
, O
2001 O
. O
Published O
2001 O
Wiley-Liss O
, O
Inc O
. O
Expression O
of O
Mad1 B-cell_type
in O
T B-cell_type
cells I-cell_type
leads O
to O
reduced O
thymic B-cell_line
cellularity O
and O
impaired O
mitogen-induced O
proliferation O
. O
To O
investigate O
Mad1 O
function O
in O
vivo O
, O
transgenic O
mice O
were O
generated O
that O
express O
a O
Mad1 O
transgene O
in O
T O
lineage I-cell_type
cells I-cell_type
under O
the O
control O
of O
the O
proximal O
lck O
promoter I-DNA
. O
Thymus O
size O
in O
lck-Mad1 B-protein
transgenic O
mice O
is O
drastically O
reduced O
although O
representation O
of O
the O
various O
thymocyte O
sub O
populations O
appears O
normal O
. O
To O
investigate O
more O
closely O
any O
effects O
of O
Mad1 B-cell_type
expression O
on O
thymocytes O
, O
we O
examined O
thymic B-cell_line
selection O
using O
MHC I-protein
class I-protein
I-restricted B-protein
H-Y-TCR B-protein
transgenic O
mice O
. O
Mad1 O
expression O
in O
vivo O
reduces O
the O
efficiency O
of O
positive O
selection O
. O
Furthermore O
, O
thymocytes O
and O
splenic O
T B-cell_type
cells I-cell_type
from O
lck-Mad1 B-protein
transgenic O
mice O
display O
a O
profound O
proliferative O
defect O
in O
response O
to O
activation O
with O
either O
PMA/Ionomycin B-cell_type
or O
immobilized O
anti-CD3/CD28 B-protein
antibody O
. O
This O
proliferative O
defect O
is O
not O
reversed O
by O
addition O
of O
exogenous O
IL-2 B-protein
and O
is O
p53-independent B-protein
. O
The O
growth O
inhibition O
caused O
by O
Mad1 O
is O
overcome O
by O
expression O
of O
active O
c-Myc O
. O
Differential O
requirement O
for O
the O
transcription B-protein
factor I-protein
PU.1 B-protein
in O
the O
generation O
of O
natural O
killer B-cell_type
cells I-cell_type
versus O
B I-DNA
and O
T B-cell_type
cells I-cell_type
. O
PU.1 B-protein
is O
a O
member O
of O
the O
Ets O
family O
of O
transcription B-protein
factors I-protein
required O
for O
the O
development O
of O
various O
lymphoid O
and O
myeloid O
cell O
lineages O
, O
but O
its O
role O
in O
natural O
killer O
( O
NK O
) O
cell O
development O
is O
not O
known O
. O
The O
study O
shows O
that O
PU.1 B-protein
is O
expressed O
in O
NK B-cell_type
cells I-cell_type
and O
that O
, O
on O
cell O
transfer O
into O
alymphoid O
Rag2/gammac I-cell_line
( O
-/- O
) O
mice O
, O
hematopoietic B-cell_type
progenitors O
of O
PU.1 B-protein
( O
-/- O
) O
fetal O
liver I-cell_type
cells I-cell_type
could O
generate O
functional O
NK B-cell_type
cells I-cell_type
but O
not O
B I-DNA
or O
T B-cell_type
cells I-cell_type
. O
Nevertheless I-protein
, O
the O
numbers O
of O
bone B-cell_type
marrow I-cell_line
NK O
cell O
precursors I-cell_line
and O
splenic O
mature O
NK B-cell_type
cells I-cell_type
were O
reduced O
compared O
to O
controls O
. O
Moreover O
, O
PU.1 B-protein
( O
-/- O
) O
NK B-cell_type
cells I-cell_type
displayed O
reduced O
expression O
of O
the O
receptors O
for O
stem O
cell O
factor I-protein
and O
interleukin O
( O
IL I-DNA
) O
-7 O
, O
suggesting O
a O
nonredundant O
role O
for O
PU.1 B-protein
in O
regulating O
the O
expression O
of O
these O
cytokine I-DNA
receptor I-DNA
genes I-DNA
during O
NK O
cell O
development O
. O
PU.1 B-protein
( O
-/- O
) O
NK B-cell_type
cells I-cell_type
also O
showed O
defective O
expression O
of O
inhibitory O
and O
activating O
members O
of O
the O
Ly49 O
family O
and O
failed O
to O
proliferate O
in O
response O
to O
IL-2 B-protein
and O
IL-12 B-protein
. O
Thus O
, O
despite O
the O
less O
stringent O
requirement O
for O
PU.1 B-protein
in O
NK O
cell O
development O
compared O
to O
B I-DNA
and O
T B-cell_type
cells I-cell_type
, O
PU.1 B-protein
regulates O
NK O
cell O
differentiation O
and O
homeostasis O
. O
Benzene-extracted O
components O
are O
important O
for O
the O
major O
activity O
of O
diesel O
exhaust O
particles O
: O
effect O
on O
interleukin-8 B-protein
gene I-DNA
expression O
in O
human B-DNA
bronchial I-cell_type
epithelial B-cell_type
cells I-cell_type
. O
Epidemiologic B-cell_type
and O
experimental O
studies O
suggest O
that O
diesel O
exhaust O
particles O
( O
DEPs O
) O
may O
be O
related O
to O
increasing O
respiratory O
mortality O
and O
morbidity O
. O
We O
have O
shown O
that O
DEPs O
augmented O
the O
production O
of O
inflammatory O
cytokines O
by O
human B-DNA
airway I-cell_type
epithelial B-cell_type
cells I-cell_type
in O
vitro O
. O
To O
better O
understand O
the O
mechanisms O
of O
their O
proinflammatory O
activities O
, O
we O
studied O
the O
effects O
of O
several O
components O
extracted O
from O
DEPs O
on O
interleukin O
( O
IL I-DNA
) O
-8 O
expression O
in O
human B-DNA
bronchial I-cell_type
epithelial O
cell O
line O
BEAS-2B B-DNA
and O
normal O
human B-cell_type
airway I-cell_type
epithelial B-cell_type
cells I-cell_type
obtained O
from O
very O
peripheral B-cell_type
airways O
by O
an O
ultrathin O
bronchoscope O
. O
We O
used O
several O
agents O
active O
on O
signal O
transduction O
pathways O
in O
cytokine O
expression O
, O
such O
as O
the O
protein O
kinase I-protein
C I-protein
inhibitor O
staurosporin O
, O
antioxidant O
agents O
including O
N-acetyl B-protein
cysteine O
( O
NAC I-DNA
) O
and O
pyrrolidine O
dithiocarbamate O
( O
PDTC I-DNA
) O
, O
and O
p38 O
mitogen-activated B-DNA
protein O
kinase I-protein
( O
MAPK I-DNA
) O
inhibitor O
SB203580 B-protein
. O
Benzene-extracted O
components O
showed O
effects O
mimicking O
DEPs O
on O
IL-8 B-DNA
gene I-DNA
expression O
, O
release O
of O
several O
cytokines O
( O
IL-8 B-protein
; O
granulocyte O
macrophage O
colony-stimulating B-protein
factor I-protein
; O
and O
regulated O
on O
activation O
, O
normal O
T B-cell_type
cells I-cell_type
expressed O
and O
secreted O
) O
and O
nuclear B-protein
factor I-protein
( O
NF I-DNA
) O
-kappa O
B I-DNA
activation O
. O
We O
also O
found O
that O
NAC I-protein
, O
PDTC I-protein
, O
and O
SB203580 B-protein
suppressed O
the O
activities O
of O
DEPs O
and O
their O
benzene O
extracts O
, O
suggesting O
the O
roles O
of O
oxidants-mediated O
NF-kappa B-protein
B I-protein
activation O
and O
p38MAPK O
pathways O
. O
Finally O
, O
benzo O
[ O
a O
] O
pyrene I-protein
, O
one O
of O
the O
important O
compounds O
included O
in O
the O
benzene O
component O
, O
replicated O
the O
activities O
shown O
by O
DEPs O
. O
The O
nuclear I-DNA
receptor I-protein
PPAR O
gamma O
is O
expressed O
by O
mouse B-DNA
T I-cell_type
lymphocytes I-cell_type
and O
PPAR O
gamma O
agonists O
induce O
apoptosis O
. O
Peroxisome O
proliferator-activated B-DNA
receptor I-protein
( O
PPAR I-DNA
) O
-gamma O
is O
a O
nuclear B-protein
hormone I-DNA
receptor I-protein
that O
serves O
as O
a O
trans O
factor I-protein
to O
regulate O
lipid O
metabolism O
. O
Intense O
interest O
is O
focused O
on O
PPAR-gamma B-DNA
and O
its O
ligands O
owing O
to O
its O
putative O
role O
in O
adipocyte O
differentiation O
. O
Little O
is O
known O
, O
however O
, O
about O
the O
functions O
of O
PPAR-gamma B-protein
in O
the O
immune O
system I-protein
, O
especially O
in O
T I-cell_type
lymphocytes I-cell_type
. O
We O
demonstrate O
that O
both O
naive O
and O
activated O
ovalbumin-specific B-cell_type
T B-cell_type
cells I-cell_type
from O
DO11.10-transgenic B-protein
mice O
express O
PPAR-gamma I-RNA
mRNA I-RNA
and O
protein O
. O
In O
order O
to O
determine O
the O
function O
of O
PPAR-gamma B-RNA
, O
T B-cell_type
cells I-cell_type
were O
stimulated O
with O
phorbol O
12-myristate B-protein
13-acetate B-DNA
and O
ionomycin O
or O
antigen I-protein
and O
antigen-presenting B-cell_type
cells I-cell_type
. O
Simultaneous O
exposure O
to O
PPAR-gamma B-protein
ligands O
( O
e.g. I-DNA
15-deoxy-Delta B-protein
( O
12 I-DNA
, O
14 O
) O
-prostaglandin O
J O
( O
2 O
) O
, O
troglitazone O
) O
showed O
drastic O
inhibition O
of O
proliferation O
and O
significant O
decreases O
in O
cell O
viability O
. O
The O
decrease O
in O
cell O
viability O
was O
due O
to O
apoptosis O
of O
the O
T I-cell_type
lymphocytes I-cell_type
, O
and O
occurred O
only O
when B-cell_type
cells I-cell_type
were O
treated O
with O
PPAR-gamma I-DNA
, O
and O
not O
PPAR-alpha B-protein
agonists O
, O
revealing O
specificity O
of O
this O
response O
for O
PPAR-gamma B-protein
. O
These O
observations O
suggest O
that O
PPAR-gamma B-protein
agonists O
play O
an O
important O
role O
in O
regulating O
T I-cell_line
cell-mediated O
immune O
responses O
by O
inducing O
apoptosis O
. O
T O
cell O
death O
via O
PPAR-gamma B-protein
ligation O
may O
act O
as O
a O
potent O
anti-inflammatory O
signal O
in O
the O
immune O
system I-protein
, O
and O
ligands O
could O
possibly O
be O
used O
to O
control O
disorders O
in O
which O
excessive O
inflammation O
occurs O
. O
Suppression O
of O
lung O
inflammation O
in O
rats O
by O
prevention O
of O
NF-kappaB O
activation O
in O
the O
liver O
. O
Activation O
of O
NF-kappaB O
and O
production O
of O
NF-kappaB O
-dependent O
chemokines O
are O
thought O
to O
be O
involved O
in O
the O
pathogenesis O
of O
neutrophilic O
lung O
inflammation O
. O
Calpain-1 B-protein
inhibitor O
( O
CI-1 B-protein
) O
blocks O
activation O
of O
NF-kappaB O
by O
preventing O
proteolysis O
of O
the O
inhibitory O
protein O
IkappaB-alpha B-protein
by O
the O
ubiquitin/proteasome B-DNA
pathway O
. O
We O
hypothesized O
that O
inhibition O
of O
proteasome O
function O
with O
CI-1 B-protein
would O
block O
NF-kappaB O
activation O
in O
vivo O
after O
intraperitoneal O
( O
i.p. I-DNA
) O
treatment O
with O
bacterial O
lipopolysaccharide I-protein
( O
LPS I-DNA
) O
, O
and O
that O
NF-kappaB O
inhibition O
would O
be O
associated O
with O
suppression O
of O
chemokine B-DNA
gene I-DNA
expression O
and O
attenuation O
of O
neutrophilic O
alveolitis O
. O
We O
treated O
rats O
with O
a O
single O
i.p. B-DNA
injection O
of O
CI-1 B-protein
( O
10 O
mg/kg I-DNA
) O
two O
hours O
prior O
to O
i.p. B-protein
LPS I-protein
( O
7 O
mg/kg I-DNA
) O
. O
Treatment O
with O
Cl-1 B-protein
prevented O
degradation O
of O
IkappaB-alpha O
and O
activation O
of O
NF-kappaB O
in O
the O
liver O
in O
response O
to O
LPS O
; O
however O
, O
Cl-1 B-protein
treatment O
had O
no O
detected O
effect O
on O
NF-kappaB O
activation O
in O
lung O
tissue O
. O
CI-1 B-protein
treatment O
prior O
to O
LPS O
resulted O
in O
40 O
% O
lower O
MIP-2 O
concentration O
in O
lung O
lavage O
fluid O
compared O
to O
rats O
treated O
with O
vehicle O
prior O
to O
LPS O
( O
502 O
+/- O
112 O
pg/ml B-DNA
vs. B-protein
859 O
+/-144 B-protein
pg/ml I-DNA
, O
P O
< O
0.05 B-protein
) O
. O
In O
addition O
, O
CI-1 B-protein
treatment O
substantially O
inhibited O
LPS-induced B-protein
neutrophilic O
alveolitis O
( O
2.7+ I-DNA
/- O
1.2 B-protein
x O
10 O
( O
5 O
) O
vs. B-protein
43.7 B-protein
+/- O
12.2 B-protein
x O
10 O
( O
5 O
) O
lung O
lavage O
neutrophils O
, O
P O
< O
0.01 B-protein
) O
. O
These O
data O
indicate O
that O
NF-kappaB O
inhibition O
in O
the O
liver O
can O
alter O
lung O
inflammation O
induced O
by O
systemic O
LPS O
treatment O
and O
suggest O
that O
a O
liver-lung B-DNA
interaction O
contributes O
to O
the O
inflammatory O
response O
of O
the O
lung O
. O
Notch1 B-protein
regulates O
maturation O
of O
CD4+ O
and O
CD8+ B-protein
thymocytes O
by O
modulating O
TCR O
signal O
strength O
. O
Notch O
signaling O
regulates O
cell O
fate O
decisions O
in O
multiple O
lineages O
. O
We O
demonstrate O
in O
this O
report O
that O
retroviral O
expression O
of O
activated O
Notch1 B-protein
in O
mouse B-DNA
thymocytes O
abrogates O
differentiation O
of O
immature O
CD4+CD8+ B-cell_line
thymocytes O
into O
both O
CD4 B-protein
and O
CD8 B-protein
mature O
single-positive B-cell_type
T B-cell_type
cells I-cell_type
. O
The O
ability O
of O
Notch1 O
to O
inhibit O
T O
cell O
development O
was O
observed O
in O
vitro O
and O
in O
vivo O
with O
both O
normal O
and O
TCR O
transgenic O
thymocytes O
. O
Notch1 B-protein
-mediated O
developmental O
arrest O
was O
dose O
dependent O
and O
was O
associated O
with O
impaired O
thymocyte O
responses O
to O
TCR O
stimulation O
. O
Notch1 B-protein
also O
inhibited O
TCR-mediated B-protein
signaling O
in O
Jurkat O
T B-cell_type
cells I-cell_type
. O
These O
data O
indicate O
that O
constitutively O
active O
Notch1 B-protein
abrogates O
CD4+ B-DNA
and O
CD8+ B-protein
maturation O
by O
interfering O
with O
TCR O
signal O
strength O
and O
provide O
an O
explanation O
for O
the O
physiological O
regulation O
of O
Notch O
expression O
during O
thymocyte O
development O
. O
Expression O
of O
SART3 B-protein
antigen I-protein
and O
induction O
of O
CTLs O
by O
SART3-derived B-protein
peptides O
in O
breast O
cancer O
patients O
. O
We O
recently O
reported O
the O
SART3 B-protein
tumour-rejection O
antigen I-protein
as O
possessing O
tumour O
epitopes I-protein
capable O
of O
inducing O
HLA-class B-protein
I-restricted B-protein
cytotoxic B-cell_type
T I-cell_type
lymphocytes I-cell_type
( O
CTLs O
) O
. O
This O
study O
investigated O
expression O
of O
the O
SART3 B-protein
antigen I-protein
in O
breast O
cancer O
to O
explore O
an O
appropriate O
molecule O
for O
use O
in O
specific O
immunotherapy O
of O
breast O
cancer O
patients O
. O
The O
SART3 B-protein
antigen I-protein
was O
detected O
in O
all O
of O
the O
breast O
cancer O
cell O
lines I-cell_line
tested O
, O
30 O
of O
40 O
( O
75 O
% O
) O
breast O
cancer O
tissue O
samples O
, O
and O
0 O
of O
3 O
non-tumourous O
breast O
tissue O
samples O
. O
SART3 B-protein
derived O
peptides O
at O
positions O
109-118 O
and O
315-323 O
induced O
HLA-A24 B-protein
restricted O
CTLs O
that O
reacted O
to O
breast O
cancer B-cell_type
cells I-cell_type
from O
the O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_line
( O
PBMCs O
) O
of O
breast O
cancer O
patients O
. O
Therefore O
, O
the O
SART3 B-protein
antigen I-protein
and O
its O
peptides O
could O
be O
an O
appropriate O
molecule O
for O
use O
in O
specific O
immunotherapy O
of O
the O
majority O
of O
HLA-A24-positive O
breast O
cancer O
patients O
Autostimulation O
of O
the O
Epstein-Barr O
virus O
BRLF1 B-DNA
promoter I-DNA
is O
mediated O
through O
consensus O
Sp1 O
and O
Sp3 O
binding O
sites O
. O
As O
an O
essential O
step O
in O
the O
lytic O
cascade O
, O
the O
Rta O
homologues O
of O
gammaherpesviruses O
all O
activate O
their O
own O
expression O
. O
Consistent O
with O
this O
biologic O
function O
, O
the O
Epstein-Barr O
virus O
( O
EBV I-DNA
) O
Rta O
protein O
powerfully O
stimulates O
the O
promoter I-DNA
of O
its O
own O
gene I-DNA
, O
Rp O
, O
in O
EBV-positive B-protein
B I-DNA
cells I-cell_type
in O
transient-transfection B-DNA
reporter-based O
assays O
. O
We O
analyzed O
the O
activity O
of O
RpCAT B-cell_type
in O
response O
to O
Rta O
by O
deletional O
and O
site-directed I-DNA
mutagenesis O
. O
Two O
cognate O
Sp1 O
binding O
sites O
located O
at O
-279 B-DNA
and O
-45 B-protein
relative O
to O
the O
transcriptional O
start I-DNA
site I-DNA
proved O
crucial O
for O
Rta-mediated O
activation O
. O
Previously O
described O
binding O
sites O
for O
the O
cellular O
transcription B-protein
factor I-protein
Zif268 B-protein
and O
the O
viral O
transactivator O
ZEBRA O
were O
found O
to O
be O
dispensable O
for O
activation O
of O
RpCAT B-cell_type
by O
Rta O
. O
Gel O
shift O
analysis O
, O
using O
extracts O
of O
B I-DNA
cells I-cell_type
in O
latency O
or O
induced O
into O
the O
lytic O
cycle O
, O
identified O
Sp1 O
and O
Sp3 O
as O
the O
predominant O
cellular O
proteins I-protein
bound O
to O
Rp O
near O
-45 B-protein
. O
During O
the O
lytic O
cycle O
, O
ZEBRA O
bound O
Rp O
near O
the O
Sp1/Sp3 B-DNA
site I-DNA
. O
The O
binding O
of O
Sp1 O
and O
Sp3 O
to O
Rp O
correlated O
with O
the O
reporter O
activities O
in O
the O
mutagenesis O
study O
, O
establishing O
a O
direct O
link O
between O
transcriptional O
activation O
of O
Rp O
by O
Rta O
and O
DNA O
binding O
by O
Sp1 O
and/or I-cell_line
Sp3 O
. O
The O
relative O
abundance O
or O
functional O
state O
of O
the O
cellular O
Sp1 O
and O
Sp3 B-protein
transcription B-protein
factors I-protein
may O
be O
altered O
in O
response O
to O
stimuli O
that O
induce O
the O
BRLF1 B-DNA
promoter I-DNA
and O
thereby O
contribute O
to O
the O
activation O
of O
the O
viral O
lytic O
cycle O
. O
Gene O
transfer O
of O
antisense O
hypoxia O
inducible O
factor-1 I-DNA
alpha I-DNA
enhances I-DNA
the O
therapeutic O
efficacy O
of O
cancer O
immunotherapy O
. O
Solid O
tumors O
meet O
their O
demands O
for O
nascent O
blood I-cell_type
vessels I-cell_type
and O
increased O
glycolysis O
, O
to O
combat O
hypoxia O
, O
by O
activating O
multiple I-DNA
genes I-DNA
involved O
in O
angiogenesis O
and O
glucose O
metabolism O
. O
Hypoxia O
inducible O
factor-1 B-protein
( O
HIF-1 O
) O
is O
a O
constitutively O
expressed O
basic O
helix-loop-helix B-protein
transcription B-protein
factor I-protein
, O
formed O
by O
the O
assembly O
of O
HIF-1alpha B-DNA
and O
HIF-1beta B-protein
( O
Arnt O
) O
, O
that O
is O
stablized O
in O
response O
to O
hypoxia O
, O
and O
rapidly O
degraded O
under O
normoxic O
conditions O
. O
It O
activates O
the O
transcription I-DNA
of O
genes I-DNA
important O
for O
maintaining O
oxygen O
homeostasis O
. O
Here O
, O
we O
demonstrate O
that O
engineered O
down-regulation O
of O
HIF-1alpha B-protein
by O
intratumoral B-DNA
gene I-DNA
transfer O
of O
an O
antisense O
HIF-1alpha B-protein
plasmid O
leads O
to O
the O
down-regulation O
of O
VEGF I-protein
, O
and O
decreased O
tumor O
microvessel O
density O
. O
Antisense O
HIF-1alpha B-protein
monotherapy O
resulted O
in O
the O
complete O
and O
permanent O
rejection O
of O
small O
( O
0.1 B-protein
cm O
in O
diameter O
) O
EL-4 B-protein
tumors O
, O
which O
is O
unusual O
for O
an O
anti-angiogenic O
agent O
where O
transient O
suppression O
of O
tumor O
growth O
is O
the O
norm O
. O
It O
induced O
NK O
cell O
-dependent O
rejection O
of O
tumors O
, O
but O
failed O
to O
stimulate O
systemic O
T O
cell O
-mediated O
anti-tumor B-DNA
immunity O
, O
and O
synergized O
with O
B7-1-mediated B-protein
immunotherapy O
to O
cause O
the O
NK O
cell O
and O
CD8 B-cell_type
T O
cell O
-dependent O
rejection O
of O
larger O
EL-4 B-protein
tumors O
( O
0.4 B-protein
cm O
in O
diameter O
) O
that O
were O
refractory O
to O
monotherapies O
. O
Mice O
cured O
of O
their O
tumors O
by O
combination O
therapy O
resisted O
a O
rechallenge O
with O
parental O
tumor I-cell_type
cells I-cell_line
, O
indicating O
systemic O
antitumor O
immunity O
had O
been O
achieved O
. O
In O
summary O
, O
whilst O
intensive O
investigations O
are O
in O
progress O
to O
target I-cell_line
the O
many O
HIF-1 O
effectors O
, O
the O
results O
herein O
indicate O
that O
blocking O
hypoxia-inducible B-DNA
pathways O
and O
enhancing O
NK-mediated B-protein
antitumor O
immunity O
by O
targeting O
HIF-1 O
itself O
may O
be O
advantageous O
, O
especially O
when O
combined O
with O
cancer O
immunotherapy O
. O
Runx2 O
: O
a O
novel O
oncogenic O
effector O
revealed O
by O
in O
vivo O
complementation O
and O
retroviral O
tagging O
. O
The O
Runx2 I-cell_line
( O
Cbfa1 I-DNA
, O
Pebp2alphaA O
, O
Aml3 O
) O
gene I-DNA
was O
previously O
identified O
as O
a O
frequent O
target I-cell_line
for O
transcriptional O
activation O
by O
proviral O
insertion O
in O
T-cell O
lymphomas O
of O
CD2-MYC B-protein
transgenic O
mice O
. O
We O
have O
recently O
shown O
that O
over-expression O
of O
the O
full-length I-DNA
, O
most O
highly O
expressed O
Runx2 O
isoform O
in O
the O
thymus O
perturbs O
T-cell O
development O
, O
leads O
to O
development O
of O
spontaneous O
lymphomas O
at O
low O
frequency O
and O
is O
strongly O
synergistic O
with O
Myc O
. O
To O
gain O
further O
insight O
into O
the O
relationship O
of O
Runx2 O
to O
other O
lymphomagenic O
pathways O
, O
we O
tested O
the O
effect O
of O
combining O
the O
CD2-Runx2 B-protein
transgene O
either O
with O
a O
Pim1 O
transgene O
( O
E O
( O
mu O
) O
-Pim1 O
) O
or O
with O
the O
p53 O
null O
genotype O
, O
as O
each O
of O
these O
displays O
independent O
synergy O
with O
Myc O
. O
In O
both O
cases O
we O
observed O
synergistic O
tumour O
development O
. O
However O
, O
Runx2 O
appeared O
to O
have O
a O
dominant O
effect O
on O
the O
tumour O
phenotype O
in O
each O
case O
, O
with O
most O
tumours O
conforming O
to O
the O
CD3 B-protein
( O
+ O
) O
, O
CD8 B-protein
( O
+ O
) O
, O
CD4 B-protein
( O
+/- O
) O
phenotype O
seen O
in O
CD2-Runx2 B-protein
mice O
. O
Neonatal O
infection O
of O
CD2-Runx2 B-protein
mice O
with O
Moloney O
murine I-cell_line
leukaemia O
virus O
( O
Moloney O
MLV O
) O
also O
led O
to O
a O
dramatic O
acceleration O
of O
tumour O
onset O
. O
Analysis O
of O
known O
Moloney O
MLV O
target I-cell_line
genes I-DNA
in O
these O
lymphomas O
showed O
a O
high O
frequency O
of O
rearrangement O
at O
c-Myc O
or O
N-Myc B-protein
( O
82 O
% O
) O
, O
and O
a O
significant O
number O
at O
Pim1 O
or O
Pim2 B-protein
( O
23 O
% O
) O
, O
and O
at O
Pal1/Gfi1 I-cell_line
( O
18 O
% O
) O
. O
These O
results O
indicate O
that O
Runx2 O
makes O
a O
distinct O
contribution O
to O
T-cell O
lymphoma O
development O
which O
does O
not O
coincide O
with O
any O
of O
the O
oncogene O
complementation O
groups O
previously O
identified O
by O
retroviral O
tagging O
. O
The O
involvement O
of O
TNF-alpha B-protein
-related O
apoptosis-inducing O
ligand O
in O
the O
enhanced O
cytotoxicity O
of O
IFN-beta B-protein
-stimulated O
human B-DNA
dendritic I-cell_type
cells O
to O
tumor I-cell_type
cells I-cell_type
. O
TNF-alpha B-protein
-related O
apoptosis-inducing O
ligand O
( O
TRAIL I-DNA
) O
is O
characterized O
by O
its O
preferential O
induction O
of O
apoptosis O
of O
tumor B-cell_type
cells I-cell_type
but O
not O
normal O
cells I-cell_type
. O
Dendritic B-cell_type
cells I-cell_line
( O
DCs O
) O
, O
besides O
their O
role O
as O
APCs O
, O
now O
have O
been O
demonstrated O
to O
exert O
cytotoxicity O
or O
cytostasis O
on O
some O
tumor I-cell_type
cells I-cell_type
. O
Here O
, O
we O
report O
that O
both O
human B-DNA
CD34 B-protein
( O
+ O
) O
stem O
cell O
-derived O
DCs O
( O
CD34DCs I-DNA
) O
and O
human B-cell_type
CD14 B-protein
( O
+ O
) O
monocyte O
-derived O
DCs O
( O
MoDCs I-DNA
) O
express O
TRAIL O
and O
exhibit O
cytotoxicity O
to O
some O
types I-cell_type
of O
tumor B-cell_type
cells I-cell_type
partially O
through O
TRAIL O
. O
Moderate O
expression O
of O
TRAIL O
appeared O
on O
CD34DCs O
from O
the O
8th O
day O
of O
culture O
and O
was O
also O
seen O
on O
freshly O
isolated O
monocytes B-cell_type
. O
The O
level O
of O
TRAIL O
expression O
remained O
constant O
until O
DC B-protein
maturation O
. O
TRAIL O
expression O
on O
immature O
CD34DCs O
or O
MoDCs O
was O
greatly O
up-regulated B-DNA
after O
IFN-beta B-protein
stimulation O
. O
Moreover O
, O
IFN-beta B-protein
could O
strikingly O
enhance O
the O
ability O
of O
CD34DCs B-cell_type
or O
MoDCs O
to O
kill O
TRAIL-sensitive B-protein
tumor I-cell_type
cells I-cell_line
, O
but O
LPS O
did O
not O
have O
such O
an O
effect O
. O
The O
up-regulation I-DNA
of O
TRAIL O
on O
IFN-beta B-protein
-stimulated O
DCs O
partially O
contributed O
to O
the O
increased O
cytotoxicity O
of O
DCS B-cell_type
: O
Pretreatment O
of O
TRAIL-sensitive B-protein
tumor I-cell_type
cells I-cell_type
with O
caspase-3 B-protein
inhibitor O
could O
significantly O
increase O
their O
resistance O
to O
the O
cytotoxicity O
of O
IFN-beta B-protein
-stimulated O
DCS O
: O
In O
contrast O
, O
NF-kappaB O
inhibitor O
could O
significantly O
increase O
the O
sensitivity O
of O
tumor B-cell_type
cells O
to O
the O
killing O
by O
nonstimulated O
or O
LPS-stimulated B-protein
DCS O
: O
Our O
studies O
demonstrate O
that O
IFN-beta B-protein
-stimulated O
DCs O
are O
functionally O
cytotoxic O
. O
Thus O
, O
an O
innate O
mechanism O
of O
DC-mediated B-protein
antitumor O
immunity O
might O
exist O
in O
vivo O
in O
which O
DCs O
act O
as O
effectors O
to O
directly O
kill O
tumor I-cell_type
cells I-cell_type
partially O
via O
TRAIL O
. O
Subsequently I-protein
, O
DCs O
act O
as O
APCs O
involved O
in O
the O
uptake I-protein
, O
processing O
, O
and O
presentation O
of O
apoptotic O
tumor O
Ags O
to O
cross-prime O
CD8 B-protein
( O
+ O
) O
CTL B-cell_type
cells I-cell_type
. O
Tumor B-cell_type
cells I-cell_type
regulate O
the O
lytic O
activity O
of O
tumor-specific O
cytotoxic O
t O
lymphocytes I-cell_type
by O
modulating O
the O
inhibitory O
natural O
killer I-DNA
receptor I-protein
function O
. O
Tumor-infiltrating O
p58+ B-cell_type
T B-cell_type
cells I-cell_type
from O
a O
renal O
tumor O
were O
specifically O
expanded O
in O
response O
to O
tumor O
cell O
stimulation O
and O
cloned O
. O
These O
p58+ B-cell_type
T B-cell_type
cells I-cell_type
were O
found O
to O
express O
a O
memory O
phenotype O
and O
corresponded O
to O
clonal O
TCRBV3 B-protein
T-cell O
expansion O
. O
Functionally I-protein
, O
p58 O
( O
+ O
) O
CTLs O
displayed O
a O
low O
lytic O
activity O
for O
HLA-A2 B-protein
tumor O
and O
normal O
cells I-cell_type
. O
However O
, O
this O
lytic O
activity O
was O
significantly O
increased O
after O
blockade O
of O
p58 B-cell_type
with O
specific O
monoclonal B-protein
antibodies I-protein
. O
Interestingly B-cell_type
, O
we O
demonstrated O
that O
stimulation O
by O
tumor I-cell_type
cells I-cell_type
was O
required O
to O
trigger O
the O
inhibitory O
effect O
of O
p58 B-cell_type
on O
the O
lytic O
activity O
of O
antigen-specific O
CTLs O
and O
that O
stimulation O
of O
the O
inhibitory O
function O
of O
p58 B-cell_type
by O
tumor I-cell_type
cells I-cell_type
correlated O
with O
an O
inhibition O
of O
nuclear B-protein
factor-kappaB B-protein
activation O
in O
p58+ O
tumor-specific O
CTLS O
. O
T-cell O
factor-1 B-protein
expression O
during O
human B-DNA
natural I-DNA
killer O
cell O
development O
and O
in O
circulating O
CD56 B-protein
( O
+ O
) O
bright O
natural O
killer B-cell_type
cells I-cell_type
. O
Transcription B-protein
factors I-protein
are O
essential O
to O
govern O
differentiation O
along O
the O
lymphoid O
lineage O
from O
uncommitted O
hematopoietic B-cell_type
stem I-cell_type
cells I-cell_type
. O
Although O
many O
of O
these O
transcription B-protein
factors I-protein
have O
putative O
roles O
based O
on O
murine I-cell_line
knockout O
experiments O
, O
their O
function O
in O
human B-DNA
lymphoid I-DNA
development O
is O
less O
known O
and O
was O
studied O
further O
. O
Transcription B-protein
factor I-protein
expression O
in O
fresh O
and O
cultured O
adult O
human B-DNA
bone I-cell_line
marrow I-cell_line
and O
umbilical O
cord O
blood I-cell_type
progenitors I-cell_type
was O
evaluated O
. O
We O
found O
that O
fresh O
CD34 B-protein
( O
+ O
) O
Lin O
( O
- O
) O
cells I-cell_type
that O
are O
human B-DNA
leukocyte I-cell_type
antigen I-protein
( O
HLA I-DNA
) O
-DR O
( O
- O
) O
or O
CD38 B-protein
( O
- O
) O
constitutively O
express O
GATA-3 B-protein
but O
not O
T-cell O
factor-1 B-protein
( O
TCF-1 O
) O
or O
Id-3 B-protein
. O
Culture O
with O
the O
murine I-cell_line
fetal O
liver O
cell O
line O
AFT024 B-protein
and O
defined O
cytokines O
was O
capable O
of O
inducing O
TCF-1 I-RNA
mRNA I-RNA
. O
However O
, O
no O
T-cell B-DNA
receptor I-DNA
gene I-DNA
rearrangement O
was O
identified O
in O
cultured O
progeny O
. O
Id-3 B-protein
, O
a O
basic O
helix O
loop O
helix O
factor I-protein
with O
dominant O
negative O
function O
for O
T-cell O
differentiation O
transcription B-protein
factors I-protein
, O
also O
was O
upregulated O
and O
may O
explain O
unsuccessful O
T-cell O
maturation O
. O
To O
better O
understand O
the O
developmental O
link O
between O
natural O
killer O
( O
NK O
) O
cells I-cell_type
derived O
from O
progenitors O
, O
we O
studied O
NK O
cell O
subsets O
circulating O
in O
blood I-cell_type
. I-cell_type
CD56 B-protein
( O
+bright I-DNA
) O
, O
but O
not O
CD56 B-protein
( O
+dim I-DNA
) O
, O
NK B-cell_type
cells I-cell_type
constitutively O
express O
TCF-1 O
by O
reverse O
transcriptase O
polymerase O
chain O
reaction O
and O
Western O
blot O
analysis O
. O
The O
TCF-1 O
isoform O
found O
in O
CD56 B-protein
( O
+bright I-DNA
) O
cells I-cell_line
, O
which O
express O
lectin O
but O
not O
immunoglobulin O
class B-protein
I I-protein
recognizing O
inhibitory O
receptors O
, O
was O
identical O
to O
that O
induced O
in O
NK O
cell O
differentiation O
culture O
and O
was O
distinctly O
different O
from O
isoforms O
in O
T B-cell_type
cells I-cell_type
. O
These O
results O
suggest O
that O
TCF-1 O
does O
not O
target I-cell_line
human B-DNA
killer I-cell_type
immunoglobulin I-DNA
receptor I-DNA
genes I-DNA
, O
TCF-1 O
is O
uniquely O
expressed O
in O
circulating O
CD56 B-protein
( O
+bright I-DNA
) O
NK B-cell_type
cells I-cell_line
, O
and O
specific O
TCF-1 O
isoforms O
may O
play O
an O
important O
role O
in O
regulating O
NK O
differentiation O
from O
a O
common O
NK/T-cell O
progenitor O
. O
Transcriptional O
activation O
by O
a O
matrix O
associating O
region-binding I-cell_type
protein O
. O
contextual O
requirements O
for O
the O
function O
of O
bright O
. O
Bright O
( O
B I-DNA
cell O
regulator O
of O
IgH B-protein
transcription I-DNA
) O
is O
a O
B O
cell O
-specific O
, O
matrix O
associating O
region-binding I-cell_type
protein O
that O
transactivates O
gene I-DNA
expression O
from O
the O
IgH O
intronic B-DNA
enhancer I-DNA
( O
E O
mu O
) O
. O
We O
show O
here O
that O
Bright O
has O
multiple O
contextual O
requirements O
to O
function O
as O
a O
transcriptional O
activator O
. O
Bright O
can O
not O
transactivate O
via O
out O
of O
context O
, O
concatenated O
binding O
sites O
. O
Transactivation O
is O
maximal O
on O
integrated O
substrates O
. O
Two O
of O
the O
three O
previously O
identified O
binding O
sites O
in O
E O
mu O
are O
required O
for O
full O
Bright O
transactivation O
. O
The O
Bright O
DNA O
binding O
domain I-protein
defined O
a O
new O
family I-protein
, O
which O
includes O
SWI1 I-protein
, O
a O
component O
of O
the O
SWI.SNF I-protein
complex I-protein
shown O
to O
have O
high O
mobility O
group-like O
DNA O
binding O
characteristics O
. O
Similar O
to O
one O
group O
of O
high O
mobility O
group O
box O
proteins I-protein
, O
Bright O
distorts O
E O
mu O
binding O
site O
-containing O
DNA O
on O
binding O
, O
supporting O
the O
concept O
that O
it O
mediates O
E O
mu O
remodeling O
. O
Transfection O
studies O
further O
implicate O
Bright O
in O
facilitating O
spatially O
separated O
promoter-enhancer B-DNA
interactions O
in O
both O
transient O
and O
stable O
assays O
. O
Finally O
, O
we O
show O
that O
overexpression O
of O
Bright O
leads O
to O
enhanced O
DNase B-protein
I I-protein
sensitivity O
of O
the O
endogenous O
E O
mu O
matrix O
associating O
regions I-protein
. O
These O
data O
further O
suggest O
that O
Bright O
may O
contribute O
to O
increased O
gene I-DNA
expression O
by O
remodeling O
the O
immunoglobulin O
locus O
during O
B O
cell O
development O
. O
Analysis O
of O
BCL-6 O
mutations O
in O
classic O
Hodgkin O
disease O
of O
the O
B- O
and O
T-cell O
type O
. I-DNA
BCL-6 O
is O
essential O
for O
germinal O
center O
formation O
and O
thus O
for O
affinity O
maturation O
of O
immunoglobulin O
( O
Ig O
) O
genes I-DNA
by O
somatic O
mutations O
. O
The O
5'-noncoding B-DNA
region I-DNA
of O
the O
BCL-6 B-DNA
gene I-DNA
is O
even O
a O
target I-cell_line
for O
the O
mutation O
machinery O
. O
Translocations O
of O
the O
BCL-6 B-DNA
gene O
to O
heterologous O
promoters O
and O
mutations O
of O
its O
5'-noncoding B-protein
regulatory O
region O
were O
reported O
to O
be O
potential O
mechanisms O
for O
deregulating O
BCL-6 O
expression O
and O
for O
playing O
a O
role O
in O
the O
genesis O
of O
non-Hodgkin O
lymphoma O
. O
In O
line O
with O
this O
hypothesis O
is O
the O
observation O
that O
B-cell O
lymphoma O
with O
somatic O
mutations O
, O
such O
as O
diffuse O
large O
B-cell O
lymphoma O
and O
follicular O
lymphoma O
, O
also O
carry O
BCL-6 O
mutations O
, O
some O
of O
which O
are O
recurrently O
detectable O
. O
Classic O
Hodgkin O
disease O
( O
cHD I-DNA
) O
is O
also O
derived O
from O
B I-DNA
cells I-cell_type
with O
high O
loads O
of O
somatic O
mutations O
and O
thus O
a O
further O
candidate O
for O
BCL-6 O
mutations O
. O
To O
determine O
the O
presence O
and O
potential O
role O
of O
BCL-6 O
mutations O
in O
cHD I-cell_line
, O
the O
5'-noncoding B-protein
BCL-6 O
proportion O
of O
single O
Hodgkin O
and O
Reed-Sternberg B-protein
( O
HRS I-DNA
) O
cells I-cell_type
from O
6 O
cases O
of O
cHD O
and O
6 O
cases O
of O
HD-derived O
cell O
lines I-cell_line
was O
analyzed O
. O
All O
B-cell-derived B-protein
HD B-protein
cases O
and O
cell O
lines I-cell_line
harbored O
BCL-6 O
mutations O
. O
In O
contrast O
, O
both O
T-cell-derived B-protein
HD B-protein
cases O
and O
cell O
lines I-cell_line
were O
devoid O
of O
BCL-6 O
mutations O
. O
With O
only O
one O
exception O
, O
there O
were O
no O
lymphoma-specific B-DNA
recurrent O
BCL-6 O
mutations O
detected O
, O
and O
BCL-6 O
protein O
was O
absent O
from O
the O
HRS B-cell_type
cells I-cell_type
of O
most O
cases O
. O
In O
conclusion O
, O
( O
1 O
) O
somatic O
BCL-6 O
mutations O
are O
restricted O
to O
cHD O
cases O
of O
B-cell O
origin I-protein
, O
and O
( O
2 O
) O
the O
BCL-6 O
mutations O
represent O
mostly O
irrelevant O
somatic O
base O
substitutions O
without O
consequences O
for O
BCL-6 O
protein O
expression O
and O
the O
pathogenesis O
of O
cHD B-cell_type
. O
Gadd45gamma O
is O
dispensable O
for O
normal O
mouse B-DNA
development O
and O
T-cell O
proliferation O
. O
Gadd45gamma I-cell_line
, O
a O
family O
member O
of O
the O
growth O
arrest O
and O
DNA O
damage-inducible O
gene I-DNA
family O
45 I-cell_line
( O
Gadd45 I-DNA
) O
, O
is O
strongly O
induced O
by O
interleukin-2 B-protein
( O
IL-2 B-protein
) O
in O
peripheral B-cell_type
T B-cell_type
cells I-cell_type
. O
While O
in O
most O
tissues O
all O
Gadd45 B-protein
family O
members O
are O
expressed O
, O
Gadd45gamma O
is O
the O
only O
member O
that O
is O
induced O
by O
IL-2 B-protein
. O
Here O
we O
show O
that O
the O
IL-2 B-protein
-induced O
expression O
of O
Gadd45gamma B-cell_type
is O
dependent O
on O
a O
signaling O
pathway O
mediated O
by O
the O
tyrosine I-protein
kinase I-protein
Jak3 O
and O
the O
transcription B-protein
factors I-protein
Stat5a O
and O
Stat5b I-cell_line
( O
signal O
transducer O
and O
activator O
of O
transcription I-DNA
) O
. O
Previous O
studies O
with O
ectopically O
overexpressed O
Gadd45gamma O
in O
various O
cell O
lines I-cell_line
implicated O
its O
function O
in O
negative O
growth O
control O
. O
To O
analyze O
the O
physiological O
role O
of O
Gadd45gamma B-cell_type
we O
used O
homologous O
recombination O
to O
generate O
mice O
lacking O
Gadd45gamma O
. O
Gadd45gamma O
-deficient O
mice O
develop O
normally O
, O
are O
indistinguishable O
from O
their O
littermates O
, O
and O
are O
fertile O
. O
Furthermore O
, O
hematopoiesis O
in O
mice O
lacking O
Gadd45gamma O
is O
not O
impaired O
and O
Gadd45gamma O
-deficient O
T I-cell_type
lymphocytes I-cell_type
show O
normal O
responses O
to O
IL-2 B-protein
. O
These O
data O
demonstrate O
that O
Gadd45gamma O
is O
not O
essential O
for O
normal O
mouse B-DNA
development O
and O
hematopoiesis O
, O
possibly O
due O
to O
functional O
redundancy O
among O
the O
Gadd45 B-protein
family O
members O
. O
Gadd45gamma O
is O
also O
dispensable O
for O
IL-2 B-protein
-induced O
T-cell O
proliferation O
. O
Decreased O
expression O
of O
c-myc B-DNA
family I-DNA
genes I-DNA
in O
thymuses O
from O
myasthenia O
gravis O
patients O
. O
The O
thymus O
is O
a O
critical O
organ O
for O
the O
elimination O
of O
autoreactive B-cell_type
T B-cell_type
cells I-cell_type
by O
apoptosis O
. O
We O
studied O
the O
expression O
of O
apoptosis-associated I-DNA
genes I-DNA
, O
bcl-xL O
, O
bad O
, O
caspase-3 O
, O
and O
c-myc O
family I-DNA
genes I-DNA
in O
myasthenia O
gravis O
( O
MG I-DNA
) O
thymuses O
. O
We O
observed O
that O
the O
mRNA I-RNA
levels O
of O
myc O
family I-DNA
genes I-DNA
, O
c-myc O
and O
max O
, O
were O
markedly O
reduced O
in O
MG B-protein
thymuses O
. O
These O
results O
indicate O
that O
c-myc B-DNA
-mediated O
signaling O
is O
abnormal O
in O
MG B-protein
thymuses O
. O
The O
levels O
of O
molecules O
whose O
expressions O
are O
associated O
with O
myc O
, O
such O
as O
STAM I-protein
, O
prothymosin-alpha O
, O
and O
NFkappaB O
Immunohistochemical O
detection O
of O
interferon-gamma-producing B-cell_type
cells I-cell_type
in O
dermatophytosis O
. O
Skin O
lesions O
of O
dermatophytosis O
are O
thought O
to O
be O
a O
result O
of O
a O
T O
cell O
-dependent O
inflammatory O
response O
that O
is O
mediated O
by O
various O
cytokines O
. O
We O
examined O
whether O
IFN-gamma-positive B-cell_type
cells I-cell_line
( O
as O
expression O
of O
Th1 B-cell_type
response O
) O
were O
present O
in O
the O
skin O
lesions O
of O
dermatophytosis O
in O
situ O
by O
immunohistochemical O
techniques O
. O
Mixtures O
of O
CD4-positive B-cell_type
T B-cell_type
cells I-cell_type
and O
CD8-positive B-cell_type
T B-cell_type
cells I-cell_type
were O
found O
to O
be O
present O
in O
the O
dermal O
infiltrates O
of O
the O
lesions O
. O
Considerable O
numbers O
of O
CD1a-positive B-cell_type
cells I-cell_type
were O
detected O
in O
the O
upper O
dermis O
and O
epidermis O
. O
A O
marked O
accumulation O
of O
CD68-positive B-cell_type
cells I-cell_type
was O
found O
in O
the O
upper O
dermis O
. O
IFN-gamma-positive B-cell_type
cells I-cell_type
were O
present O
in O
the O
upper O
dermis O
of O
the O
lesions O
. O
The O
pattern O
of O
IFN-gamma B-protein
staining O
appeared O
to O
be O
intracellular O
in O
mononuclear O
lymphoid B-cell_type
cells I-cell_type
. O
The O
staining O
was O
considered O
to O
be O
highly O
specific O
because O
it O
could O
be O
completely O
blocked O
by O
preabsorption O
with O
recombinant O
IFN-gamma B-protein
. O
Our O
data O
support O
the O
hypothesis O
that O
the O
skin O
lesions O
of O
dermatophytosis O
may O
be O
associated O
with O
a O
Th1 O
response O
. O
Th1 O
response O
, O
which O
is O
characterized O
by O
IFN-gamma B-protein
release O
, O
is O
thought O
to O
be O
involved O
in O
the O
host O
defense O
against O
dermatophytes O
and O
to O
reflect O
cutaneous O
reaction O
in O
dermatophytosis O
. O
Regulation O
of O
the O
helix-loop-helix B-protein
proteins I-protein
, O
E2A B-protein
and O
Id3 O
, O
by O
the O
Ras B-protein
- O
ERK O
MAPK O
cascade O
. O
Activation O
of O
mitogen-activated O
protein O
kinase I-protein
( O
MAPK I-DNA
) O
pathways O
leads O
to O
cellular O
differentiation O
and/or I-cell_line
proliferation O
in O
a O
wide O
variety O
of O
cell O
types I-cell_type
, O
including O
developing O
thymocytes O
. O
The O
basic O
helix-loop-helix I-cell_line
( O
bHLH I-DNA
) O
proteins I-protein
E12 O
and O
E47 B-protein
and O
an O
inhibitor O
HLH I-protein
protein I-protein
, O
Id3 O
, O
play O
key O
roles O
in O
thymocyte O
differentiation O
. O
We O
show O
here O
that O
E2A B-protein
DNA O
binding O
is O
lowered O
in O
primary B-cell_line
immature I-cell_line
thymocytes O
consequent O
to O
T O
cell I-DNA
receptor I-protein
( O
TCR I-DNA
) O
-mediated O
ligation O
. O
Whereas O
expression O
of O
E2A I-RNA
mRNA I-RNA
and O
protein O
are O
unaltered O
, O
Id3 I-RNA
transcripts I-RNA
are O
rapidly O
induced O
upon O
signaling O
from O
the O
TCR O
. O
Activation O
of O
Id3 B-protein
transcription O
is O
regulated O
in O
a O
dose-dependent O
manner O
by O
the O
extracellular O
signal-regulated O
kinase I-protein
( O
ERK I-DNA
) O
MAPK O
module O
. O
These O
observations O
directly O
connect O
the O
ERK O
MAPK O
cascade O
and O
HLH B-protein
proteins I-protein
in O
a O
linear O
pathway O
. O
Retinoic O
acid O
up-regulates O
myeloid O
ICAM-3 B-protein
expression O
and O
function O
in O
a O
cell-specific I-DNA
fashion O
-- O
evidence O
for O
retinoid O
signaling O
pathways O
in O
the O
mast O
cell O
lineage I-cell_type
. O
Investigation I-DNA
of O
mast O
cell O
responsiveness O
toward O
retinoic O
acid O
( O
RA I-DNA
) O
revealed O
selective O
promotion O
of O
ICAM-3 B-protein
expression O
in O
the O
human B-DNA
mast O
cell O
line O
HMC-1 O
. O
This O
process O
was O
dose- B-DNA
and O
time-dependent O
and O
detectable O
by O
flow O
cytometry O
, O
Western O
blot O
analysis O
, O
ELISA I-protein
, O
and O
Northern O
blot O
analysis O
. O
ICAM-3 B-protein
modulation O
was O
found O
to O
be O
cell-type B-DNA
dependent O
, O
detectable O
also O
for O
HL-60 B-protein
cells I-cell_type
and O
monocytes B-cell_type
but O
not O
U-937 B-protein
and O
only O
weakly O
for O
KU812 B-protein
cells I-cell_type
. O
Terminally O
differentiated O
skin O
mast B-cell_type
cells I-cell_type
also O
failed O
to O
up-modulate O
their O
ICAM-3 B-protein
, O
suggesting O
the O
requirement O
for O
some O
degree O
of O
immaturity O
for O
the O
process O
. O
RA-mediated B-protein
effects O
on O
ICAM-1 B-protein
expression O
, O
studied O
in O
parallel O
, O
were O
clearly O
distinct O
from O
those O
on O
ICAM-3 B-protein
. O
Investigation I-DNA
of O
retinoid I-DNA
receptor I-protein
expression O
, O
known O
to O
mediate O
intracellular O
RA B-protein
signaling O
, O
revealed O
presence O
of O
RAR I-DNA
alpha I-DNA
, O
RAR O
gamma O
, O
RXR O
beta O
, O
and O
RXR O
gamma I-RNA
transcripts I-RNA
in O
all O
cell O
lines I-cell_line
studied O
, O
and O
HMC-1 B-cell_type
cells I-cell_type
were O
the O
only O
line O
lacking O
RXR I-DNA
alpha I-DNA
. I-RNA
RAR O
beta O
, O
not O
expressed O
at O
baseline O
, O
was O
induced O
by O
RA B-protein
in O
a O
fashion O
obviously O
correlating O
with O
ICAM-3 B-protein
up-regulation B-protein
. O
Increased O
ICAM-3 B-protein
expression O
was O
of O
functional O
significance O
, O
such O
that O
processes O
stimulated O
or O
co-stimulated B-protein
via O
ICAM-3 B-protein
( O
homotypic O
aggregation O
, O
IL-8 B-protein
secretion O
) O
were O
clearly O
enhanced O
upon O
RA B-protein
pretreatment O
, O
suggesting O
that O
RA B-protein
may O
contribute O
via O
hitherto O
unrecognized O
pathways O
to O
immune O
function O
and O
host O
defense O
. O
CD28 B-protein
and O
T O
cell O
co-stimulation O
. O
Over O
the O
last O
decade O
the O
concept O
of O
T O
cell O
co-stimulation O
has O
emerged O
to O
take O
a O
central O
role O
in O
the O
process O
of O
T O
cell O
activation O
. O
However O
, O
the O
exact O
definition O
of O
co-stimulation O
is O
still O
unclear O
. O
In O
this O
review O
, O
we O
re-examine B-DNA
the O
concept O
of O
co-stimulation O
. O
We O
suggest O
that O
while O
co-stimulation O
is O
important O
, O
there O
is O
little O
evidence O
to O
link O
co-stimulation O
with O
T O
cell O
anergy O
. O
We O
then O
suggest O
a O
framework O
for O
studying O
co-stimulation O
. O
Focusing O
on O
recent O
advances O
in O
our O
understanding O
of O
CD28 B-protein
, O
we O
discuss O
four O
areas O
of O
T O
cell O
activation O
where O
co-stimulation O
may O
play O
a O
role O
. O
Regulation O
of O
activator O
protein-1 B-protein
and O
NF-kappa B-protein
B I-protein
in O
CD8+ B-cell_type
T B-cell_type
cells I-cell_type
exposed O
to O
peripheral O
self-antigens I-cell_type
. O
The O
transcriptional O
events O
that O
control O
T O
cell O
tolerance O
to O
peripheral O
self O
Ags O
are O
still O
unknown O
. O
In O
this O
study O
, O
we O
analyzed O
the O
regulation O
of O
AP-1 B-protein
- O
and O
NF-kappa B-protein
B I-protein
-mediated O
transcription O
during O
in O
vivo O
induction O
of O
tolerance O
to O
a O
self O
Ag O
expressed O
exclusively O
on O
hepatocytes O
. O
Naive O
CD8 B-protein
( O
+ O
) O
Desire O
( O
Des O
) O
( O
+ O
) O
T B-cell_type
cells I-cell_type
isolated O
from O
the O
Des O
TCR-transgenic B-protein
mice O
that O
are O
specific O
for O
the O
H-2K B-protein
( O
b O
) O
class B-protein
I I-protein
Ag O
were O
transferred O
into O
Alb-K B-protein
( O
b O
) O
-transgenic O
mice O
that O
express O
the O
H-2K B-protein
( O
b O
) O
Ag O
on O
hepatocytes O
only O
. O
Tolerance O
develops O
in O
these O
mice O
. O
We O
found O
that O
the O
self-reactive I-DNA
CD8 B-protein
( O
+ O
) O
Des O
( O
+ O
) O
T B-cell_type
cells I-cell_type
were O
transiently O
activated O
, O
then O
became O
unresponsive O
and O
were O
further O
deleted O
. O
In O
contrast O
to O
CD8 B-protein
( O
+ O
) O
Des O
( O
+ O
) O
T B-cell_type
cells I-cell_type
activated O
in O
vivo O
with O
APCs O
, O
which O
express O
high O
AP-1 B-protein
and O
high O
NF-kappa B-protein
B I-protein
transcriptional O
activity O
, O
the O
unresponsive O
CD8 B-protein
( O
+ O
) O
Des O
( O
+ O
) O
T B-cell_type
cells I-cell_type
expressed O
no O
AP-1 B-protein
and O
only O
weak O
NF-kappa B-protein
B I-protein
transcriptional O
activity O
. O
The O
differences O
in O
NF-kappa B-protein
B I-protein
transcriptional O
activity O
correlated O
with O
the O
generation O
of O
distinct O
NF-kappa B-protein
B I-protein
complexes O
. O
Indeed O
, O
in O
vivo O
primed O
T B-cell_type
cells I-cell_type
predominantly O
express O
p50/p50 O
and O
p65/p50 O
dimers O
, O
whereas O
these O
p50-containing B-protein
complexes O
are O
barely O
detectable O
in O
tolerant O
T B-cell_type
cells I-cell_type
that O
express O
p65- B-DNA
and O
c-Rel-containing O
complexes O
. O
These O
observations O
suggest O
that O
fine O
regulation O
of O
NF-kappa B-protein
B I-protein
complex I-protein
formation O
may O
determine B-cell_type
T O
cell O
fate O
. O
Transcriptional O
regulation O
in I-cell_type
lymphocytes I-cell_type
. O
Lymphocytes O
have O
been O
used O
to O
investigate O
many O
cellular O
processes O
, O
including O
lineage O
commitment O
, O
differentiation O
, O
proliferation O
and O
apoptosis O
. O
The O
transcription B-protein
factors I-protein
that O
mediate O
these O
processes O
are O
often O
expressed O
broadly O
in O
many O
cell O
types I-cell_type
. O
The O
emerging O
theme O
is O
one O
of O
cell-type-specific O
regulation O
, O
affecting O
not O
only O
the O
functional O
activation O
of O
transcription B-protein
factors I-protein
but O
also O
their O
access O
to O
appropriate O
regions I-protein
of O
DNA O
. O
Existence O
of O
retinoic O
acid-receptor I-DNA
-independent O
retinoid O
X-receptor B-protein
-dependent O
pathway O
in O
myeloid O
cell O
function O
. O
We O
previously O
reported O
that O
ER-27191 B-protein
( O
4- O
[ O
4 O
, O
5 O
, O
7 O
, O
8 O
, O
9 O
, O
10-hexahydro-7 O
, O
7 O
, O
10 O
, O
10-tetramethyl-1- O
( O
3-pyridylmethyl B-protein
) O
anthra O
[ O
1 O
, O
2-b O
] O
pyrrol-3-yl O
] O
benzoic O
acid O
) O
is O
a O
potent O
antagonist O
of O
retinoic O
acid I-DNA
receptor I-protein
( O
RAR I-DNA
) O
, O
and O
ER-35795 B-protein
( O
( O
2E I-DNA
, O
4E O
, O
6E B-protein
) O
-7- O
[ O
1- B-protein
( O
1-methylethyl B-protein
) O
-8-chloro-1 O
, O
2 O
, O
3 O
, O
4-tetrahydroquinolin-6-yl B-protein
] O
-6-fluoro-3-methyl-2 I-cell_line
, O
4 O
, O
6-nonatrienoic O
acid O
) O
is O
a O
novel O
retinoid O
X I-DNA
receptor I-protein
( O
RXR I-DNA
) O
-specific O
agonist O
. O
By O
using O
these O
compounds O
, O
we O
investigated O
whether O
distinct O
RAR O
-dependent O
and O
RXR O
-dependent O
pathways O
operate O
to O
mediate O
the O
diverse O
activities O
of O
retinoids O
, O
particularly O
, O
the O
effects O
of O
the O
RXR O
pathway O
on O
cellular O
function O
. O
ER-27191 B-protein
completely O
antagonized O
HL60 O
cell O
differentiation O
induced O
by O
all-trans-retinoic O
acid O
( O
atRA I-DNA
) O
. O
However O
, O
the O
differentiation O
induced O
by O
the O
ER-35795 B-protein
was O
not O
antagonized O
at O
all O
by O
the O
RAR O
antagonist O
, O
but O
was O
inhibited O
by O
an O
RXR O
homodimer O
antagonist O
( O
LGD100754 I-DNA
, O
( O
2E I-DNA
, O
4E O
, O
6Z B-protein
) O
-7- O
( O
3-n-propoxy-5 I-DNA
, O
6 O
, O
7 O
, O
8-tetrahydro-5 O
, O
5 O
, O
8 O
, O
8-tetramethylnaphthalen-2-yl B-protein
) O
-3-methylocta-2 O
, O
4 O
, O
6-trienoic O
acid O
) O
. O
Its O
agonistic O
action O
on O
RXR/RAR B-protein
heterodimer O
, O
on O
the O
other O
hand O
, O
was O
neutralized O
by O
the O
RAR O
antagonist O
. O
During O
HL60 O
cell O
differentiation O
, O
atRA O
induced O
RARbeta I-RNA
mRNA I-RNA
, O
while O
the O
RXR O
had O
no O
effect O
. O
Interestingly B-cell_type
, O
a O
functional O
RXR O
-pathway O
was O
also O
seen O
in O
lipopolysaccharide-induced B-DNA
inhibition O
of O
mouse B-DNA
splenocyte O
proliferation O
. O
These O
results O
strongly O
suggest O
the O
existence O
of O
a O
pharmacological O
RXR O
-dependent O
pathway O
that O
is O
activated O
by O
a O
ligand O
that O
can O
bind O
to O
RXR O
. O
Targeting O
Src O
homology O
2 O
domain-containing B-protein
tyrosine I-protein
phosphatase O
( O
SHP-1 O
) O
into O
lipid O
rafts O
inhibits O
CD3 B-protein
-induced O
T O
cell O
activation O
. O
To O
study O
the O
mechanism O
by O
which O
protein B-protein
tyrosine I-protein
phosphatases O
( O
PTPs O
) O
regulate O
CD3 B-protein
-induced B-protein
tyrosine I-protein
phosphorylation O
, O
we O
investigated O
the O
distribution O
of O
PTPs O
in O
subdomains O
of O
plasma O
membrane O
. O
We O
report O
here O
that O
the O
bulk O
PTP O
activity O
associated O
with O
T O
cell O
membrane O
is O
present O
outside O
the O
lipid O
rafts O
, O
as O
determined O
by O
sucrose O
density O
gradient O
sedimentation O
. O
In O
Jurkat O
T B-cell_type
cells I-cell_type
, O
approximately O
5 O
-- O
10 O
% O
of O
Src O
homology O
2 O
domain-containing B-protein
tyrosine I-protein
phosphatase O
( O
SHP-1 O
) O
is O
constitutively O
associated O
with O
plasma O
membrane O
, O
and O
nearly O
50 O
% O
of O
SHP-2 O
is O
translocated O
to O
plasma O
membrane O
after O
vanadate O
treatment O
. O
Similar O
to O
transmembrane O
PTP I-protein
, O
CD45 I-protein
, O
the O
membrane-associated B-DNA
populations O
of O
SHP-1 O
and O
SHP-2 O
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling O
molecules I-protein
such O
as O
Lck O
, O
linker O
for O
activation O
of O
T B-cell_type
cells I-cell_type
, O
and O
CD3 B-protein
zeta O
are O
enriched O
. O
We O
further O
demonstrated O
that O
CD3 B-protein
-induced B-protein
tyrosine I-protein
phosphorylation O
of O
these O
substrates O
is O
largely O
restricted O
to O
lipid O
rafts O
, O
unless O
PTPs O
are O
inhibited O
. O
It O
suggests O
that O
a O
restricted O
partition O
of O
PTPs O
among O
membrane O
subdomains O
may O
regulate O
protein B-protein
tyrosine I-protein
phosphorylation O
in O
T O
cell O
membrane O
. O
To O
test O
this O
hypothesis O
, O
we O
targeted O
SHP-1 O
into O
lipid O
rafts O
by O
using O
the O
N-terminal B-protein
region I-DNA
of O
Lck O
( O
residues O
1 O
-- O
14 O
) O
. O
The O
results O
indicate O
that O
the O
expression O
of O
Lck/SHP-1 B-protein
chimera O
inside O
lipid O
rafts O
profoundly O
inhibits O
CD3 B-protein
-induced B-protein
tyrosine I-protein
phosphorylation O
of O
CD3 B-protein
zeta/epsilon I-protein
, O
IL-2 B-protein
generation O
, O
and O
nuclear B-protein
mobilization O
of O
NF-AT B-protein
. O
Collectively I-protein
, O
these O
results O
suggest O
that O
the O
exclusion O
of O
PTPs O
from O
lipid O
rafts O
may O
be O
a O
mechanism O
that O
potentiates O
TCR O
/ O
CD3 B-protein
activation O
An O
instructive O
component O
in O
T I-cell_line
helper O
cell I-DNA
type O
2 O
( O
Th2 B-protein
) O
development O
mediated O
by O
GATA-3 B-protein
. O
Although O
interleukin O
( O
IL I-DNA
) O
-12 O
and O
IL-4 B-protein
polarize O
naive O
CD4 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
toward O
T I-cell_line
helper O
cell I-DNA
type O
1 O
( O
Th1 B-protein
) O
or O
Th2 O
phenotypes O
, O
it O
is O
not O
known O
whether O
cytokines O
instruct O
the O
developmental O
fate O
in O
uncommitted O
progenitors O
or O
select O
for O
outgrowth O
of O
cells I-cell_type
that O
have O
stochastically O
committed O
to O
a O
particular O
fate O
. O
To O
distinguish O
these O
instructive O
and O
selective O
models O
, O
we O
used O
surface I-protein
affinity O
matrix O
technology O
to O
isolate O
committed O
progenitors O
based O
on O
cytokine O
secretion O
phenotype O
and O
developed O
retroviral-based O
tagging O
approaches O
to O
directly O
monitor O
individual O
progenitor O
fate O
decisions O
at O
the O
clonal O
and O
population O
levels O
. O
We O
observe O
IL-4 B-protein
-dependent O
redirection O
of O
phenotype O
in O
cells I-cell_type
that O
have O
already O
committed O
to O
a O
non-IL-4-producing O
fate O
, O
inconsistent O
with O
predictions O
of O
the O
selective O
model O
. O
Further O
, O
retroviral O
tagging O
of O
naive O
progenitors O
with O
the O
Th2-specific B-protein
transcription B-protein
factor I-protein
GATA-3 B-protein
provided O
direct O
evidence O
for O
instructive O
differentiation O
, O
and O
no O
evidence O
for O
the O
selective O
outgrowth O
of O
cells I-cell_type
committed O
to O
either O
the O
Th1 O
or O
Th2 O
fate O
. O
These O
data O
would O
seem O
to O
exclude O
selection O
as O
an O
exclusive O
mechanism O
in O
Th1 O
/ O
Th2 O
differentiation O
, O
and O
support O
an O
instructive O
model O
of O
cytokine-driven O
transcriptional O
programming O
of O
cell O
fate O
decisions O
. O
In O
vitro-activated O
human B-DNA
lupus I-cell_type
T B-cell_type
cells I-cell_type
express O
normal O
estrogen B-protein
receptor I-protein
proteins I-protein
which O
bind O
to O
the O
estrogen O
response O
element I-DNA
. O
We O
have O
shown O
that O
estrogen B-protein
receptor I-protein
( O
ERalpha I-DNA
, O
ERbeta O
) O
transcripts O
are O
expressed O
in O
SLE O
and O
normal O
T B-cell_type
cells I-cell_type
. O
In O
this O
study O
, O
T O
cell O
nuclear B-protein
extracts O
from O
female O
lupus O
patients O
and O
normal O
donors O
were O
tested O
for O
biologically O
active O
ER B-protein
proteins I-protein
capable O
of O
binding O
to O
the O
human B-DNA
estrogen B-protein
response O
element I-DNA
( O
hERE I-DNA
) O
by O
electrophoretic O
mobility O
shift O
assays O
. O
When O
peripheral B-cell_type
blood I-cell_type
T I-cell_type
cells I-cell_type
were O
stimulated O
with O
17beta-estradiol B-protein
( O
E2 B-protein
) O
, O
PMA O
and O
ionomycin O
, O
two O
major O
retarded O
bands O
in O
T O
cell O
nuclear B-protein
extracts O
exhibited O
a O
migration O
pattern O
similar O
to O
slow O
migrating O
protein-ERE O
complexes O
in O
human B-DNA
breast I-cell_type
cancer O
cell O
extracts O
. O
T B-cell_type
cells I-cell_type
cultured O
only O
with O
E2 B-protein
did O
not O
have O
these O
complexes O
. O
The O
formation O
of O
the O
complexes O
was O
inhibited O
by O
competition O
with O
the O
hERE I-RNA
cold O
oligonucleotide O
and O
partially O
with O
anti-ERalpha B-protein
antibodies I-protein
. O
There O
was O
no O
notable O
difference O
in O
the O
migration O
pattern O
of O
ERE-binding B-protein
proteins I-protein
between O
the O
SLE O
and O
normal O
T O
cell O
extracts O
. O
Together O
, O
these O
results O
suggest O
that O
activated O
human B-cell_type
T I-cell_type
cells I-cell_type
, O
whether O
lupus-derived B-protein
or O
normal-derived I-DNA
, O
contain O
biologically O
active O
ERalpha O
proteins I-protein
. O
Other B-protein
factors I-protein
may O
be O
responsible O
for O
differential O
sensitivity O
of O
lupus B-cell_type
T B-cell_type
cells O
to O
estrogen O
. O
Mechanism O
of O
the O
inhibitory O
effect O
of O
protease O
inhibitor O
on O
tumor O
necrosis B-protein
factor I-protein
alpha I-DNA
production I-DNA
of O
monocytes B-cell_type
. O
If O
the O
inflammatory O
response O
becomes O
excessive O
or O
uncontrolled O
by O
some O
stimuli O
, O
inappropriate O
inflammatory O
responses O
occur O
. O
Monocytes O
are O
extremely O
important B-cell_type
cells I-cell_type
for O
regulating O
the O
cytokine O
network O
and O
tumor O
necrosis B-protein
factor I-protein
alpha I-DNA
( O
TNFalpha I-DNA
) O
and O
interleukin- B-protein
( O
IL I-DNA
) O
10 O
, O
which O
are O
mainly O
synthesized O
by O
monocytes B-cell_type
, O
are O
representative O
cytokines O
that O
play O
a O
central O
role O
in O
the O
cytokine O
network O
. O
Protease O
inhibitors O
such O
as O
gabexate O
mesilate O
( O
GM I-DNA
) O
and O
ulinastatin O
( O
UTI I-DNA
) O
have O
been O
shown O
to O
have O
various O
beneficial O
effects O
by O
inhibiting O
the O
activation O
of O
leukocytes O
, O
but O
the O
mechanism O
for O
this O
has O
yet O
to O
be O
fully O
elucidated O
. O
In O
this O
study O
we O
investigated O
the O
mechanism O
of O
the O
inhibitory O
effect O
of O
protease O
inhibitors O
on O
the O
proinflammatory O
cytokine O
production O
of O
lipopolysaccharide- B-DNA
( O
LPS I-DNA
) O
stimulated O
monocytes B-cell_type
. O
LPS-stimulated B-protein
monocytes B-cell_type
were O
treated O
with O
GM B-protein
or O
UTI O
. O
The O
value O
of O
TNFalpha O
and O
IL-10 B-protein
in O
the O
culture O
medium O
of O
monocytes B-cell_type
was O
measured O
and O
each O
mRNA I-RNA
expression O
was O
assayed O
. O
The O
inhibitory O
effect O
of O
protease O
inhibitors O
on O
the O
activity O
of O
intracellular O
signal O
transduction O
pathways O
such O
as O
protein O
kinase I-protein
C I-protein
( O
PKC I-DNA
) O
and O
nuclear B-protein
factor I-protein
kappa B-DNA
B I-DNA
( O
NFkappaB I-DNA
) O
were O
also O
evaluated O
. O
GM B-protein
decreased O
the O
TNFalpha O
production O
of O
LPS-stimulated B-protein
monocytes B-cell_type
as O
shown O
by O
the O
inhibition O
of O
mRNA I-RNA
expression O
and O
increased O
the O
IL-10 B-protein
production O
of O
LPS-stimulated B-protein
monocytes B-cell_type
. O
GM B-protein
also O
suppressed O
the O
NFkappaB O
activity O
of O
LPS-stimulated B-protein
monocytes B-cell_type
. O
UTI O
decreased O
the O
TNFalpha O
production O
of O
LPS-stimulated B-protein
monocytes B-cell_type
, O
but O
did O
not O
inhibit O
the O
TNFalpha I-RNA
mRNA I-RNA
expression O
. O
The O
present O
study O
shows O
that O
the O
inhibitory O
effect O
of O
GM B-cell_type
on O
the O
TNFalpha O
production O
of O
activated O
human O
monocytes B-cell_type
is O
mediated O
by O
the O
suppression O
of O
NFkappaB B-cell_type
activation O
, O
while O
the O
mechanism O
of O
UTI B-cell_type
inhibiting O
TNFalpha O
production O
of O
human B-cell_type
monocytes B-cell_type
may O
be O
due O
to O
the O
inhibition O
of O
either O
the O
translation O
or O
secretion O
of O
TNFalpha O
. O
Homocysteine O
stimulates O
the O
expression O
of O
monocyte O
chemoattractant O
protein-1 B-protein
in O
endothelial B-cell_type
cells I-cell_type
leading O
to O
enhanced O
monocyte O
chemotaxis O
. O
Hyperhomocysteinemia O
has O
been O
identified O
as O
an O
independent O
risk I-protein
factor I-protein
for O
atherosclerosis O
. O
The O
infiltration O
of O
monocytes B-cell_type
into O
the O
arterial O
wall O
is O
one O
of O
the O
key O
events O
during O
atherogenesis O
. O
Monocyte O
chemoattractant O
protein-1 B-protein
( O
MCP-1 O
) O
is O
a O
potent O
chemokine O
that O
stimulates O
the O
migration O
of O
monocytes B-cell_type
into O
the O
intima O
of O
the O
arterial O
wall O
. O
The O
mechanism O
by O
which O
increased O
monocyte O
infiltration O
occurs O
in O
atherosclerotic O
lesions O
in O
patients O
with O
hyperhomocysteinemia O
has O
not O
been O
delineated O
. O
The O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effect O
of O
homocysteine O
on O
MCP-1 O
production O
in O
endothelial B-cell_type
cells I-cell_type
. O
Cells O
were O
incubated O
with O
homocysteine O
. O
The O
secretion O
of O
MCP-1 O
protein O
was O
significantly O
increased O
( O
195 O
% O
as O
compared O
to O
the O
control O
) O
in O
cells I-cell_type
treated O
with O
pathological O
concentrations O
of O
homocysteine O
. O
Such O
effect O
was O
accompanied O
by O
an O
increased O
expression O
of O
MCP-1 I-RNA
mRNA I-RNA
( O
176 O
% O
as O
compared O
to O
the O
control O
) O
in O
endothelial B-cell_type
cells I-cell_type
which O
resulted O
in O
enhanced O
monocyte O
chemotaxis O
. O
The O
p38 O
MAP I-protein
kinase I-protein
as O
well O
as O
other O
members O
of O
the O
p38 O
MAP I-protein
kinase I-protein
pathway O
, O
including O
MKK3 I-protein
, O
MKK6 I-protein
, O
ATF-2 O
and O
Elk-1 B-protein
, O
were O
activated O
in O
homocysteine-treated B-cell_type
cells I-cell_type
. O
Homocysteine-induced B-protein
MCP-1 O
expression O
and O
subsequent O
monocyte O
chemotaxis O
were O
blocked O
by O
a O
p38 O
MAP I-protein
kinase I-protein
inhibitor O
( O
SB203580 B-protein
) O
suggesting O
that O
the O
p38 O
MAP I-protein
kinase I-protein
pathway O
might O
be O
involved O
in O
homocysteine-induced B-DNA
MCP-1 O
expression O
in O
endothelial B-cell_type
cells I-cell_type
. O
In O
contrast O
, O
staurosporine O
, O
a O
protein O
kinase I-protein
C I-protein
inhibitor O
, O
had O
no O
effect O
on O
homocysteine-induced B-DNA
MCP-1 O
expression O
. O
In O
conclusion O
, O
our O
results O
indicate O
that O
homocysteine O
stimulates O
MCP-1 O
expression O
in O
endothelial B-cell_type
cells I-cell_type
leading O
to O
enhanced O
monocyte O
chemotaxis O
. O
Inducible O
resistance O
to O
Fas-mediated O
apoptosis O
in O
B I-DNA
cells I-cell_type
. O
Apoptosis O
produced O
in O
B I-DNA
cells I-cell_type
through O
Fas O
( O
APO-1 O
, O
CD95 B-protein
) O
triggering O
is O
regulated O
by O
signals O
derived O
from O
other O
surface I-protein
receptors O
: O
CD40 B-protein
engagement O
produces O
upregulation O
of O
Fas O
expression O
and O
marked O
susceptibility O
to O
Fas O
-induced O
cell O
death O
, O
whereas O
antigen I-DNA
receptor I-protein
engagement O
, O
or O
IL-4R B-protein
engagement O
, O
inhibits O
Fas O
killing O
and O
in O
so O
doing O
induces O
a O
state O
of O
Fas O
-resistance O
, O
even O
in O
otherwise O
sensitive O
, O
CD40 B-protein
-stimulated O
targets I-cell_line
. O
Surface O
immunoglobulin O
and O
IL-4R B-protein
utilize O
at O
least O
partially O
distinct O
pathways O
to O
produce O
Fas O
-resistance O
that O
differentially O
depend O
on O
PKC O
and O
STAT6 I-protein
, O
respectively O
. O
Further O
, O
surface I-protein
immunoglobulin O
signaling O
for O
inducible O
Fas O
-resistance O
bypasses O
Btk O
, O
requires O
NF-kappaB I-DNA
, O
and O
entails O
new O
macromolecular O
synthesis O
. O
Terminal O
effectors O
of O
B O
cell O
Fas O
-resistance O
include O
the O
known O
anti-apoptotic B-DNA
gene I-DNA
products O
, O
Bcl-xL O
and O
FLIP I-protein
, O
and O
a O
novel O
anti-apoptotic B-DNA
gene I-DNA
that O
encodes O
FAIM I-protein
( O
Fas O
Apoptosis O
Inhibitory O
Molecule O
) O
. O
faim O
was O
identified O
by O
differential O
display O
and O
exists O
in O
two O
alternatively O
spliced O
forms O
; O
faim-S B-protein
is O
broadly O
expressed O
, O
but O
faim-L B-protein
expression O
is O
tissue-specific O
. O
The O
FAIM O
sequence O
is O
highly O
evolu- B-DNA
tionarily O
conserved O
, O
suggesting O
an O
important O
role O
for O
this O
molecule O
throughout O
phylogeny O
. O
Inducible O
resistance O
to O
Fas O
killing O
is O
hypothesized O
to O
protect O
foreign O
antigen-specific B-DNA
B I-DNA
cells I-cell_type
during O
potentially O
hazardous O
interactions O
with O
FasL-bearing B-cell_type
T B-cell_type
cells I-cell_type
, O
whereas O
autoreactive O
B I-DNA
cells I-cell_type
fail O
to O
become O
Fas O
-resistant O
and O
are O
deleted O
via O
Fas O
-dependent O
cytotoxicity O
. O
Inadvertent O
or O
aberrant O
acquisition O
of O
Fas O
-resistance O
may O
permit O
autoreactive O
B I-DNA
cells O
to O
escape O
Fas O
deletion O
, O
and O
malignant I-cell_type
lymphocytes I-cell_type
to O
impede O
anti-tumor B-DNA
immunity O
. O
Stromal O
cell-derived B-protein
factor I-protein
1 O
alpha I-DNA
-induced I-DNA
chemotaxis O
in O
T B-cell_type
cells I-cell_type
is O
mediated O
by O
nitric O
oxide O
signaling O
pathways O
. O
Stromal O
cell-derived B-protein
factor I-protein
1 O
alpha I-DNA
( O
SDF1 I-DNA
alpha I-DNA
) O
and O
its O
cognate O
chemokine I-DNA
receptor I-protein
CXCR4 O
act O
as O
potent O
chemoattractants O
and O
regulate O
trafficking O
and O
homing O
of O
hematopoietic B-cell_type
progenitor I-cell_type
cells I-cell_type
and I-cell_type
lymphocytes I-cell_type
. O
However O
, O
the O
molecular O
mechanisms O
regulating O
SDF1 I-DNA
alpha I-DNA
-driven I-DNA
cell O
migration O
are O
not O
well O
defined O
. O
In O
this O
study O
, O
we O
have O
explored O
the O
roles O
of O
the O
second O
messenger O
NO O
and O
the O
transcription B-protein
factor I-protein
NF-kappa B-protein
B I-protein
in O
SDF1 I-DNA
alpha I-DNA
-induced B-cell_type
T O
cell O
migration O
. O
SDF1 I-DNA
alpha I-DNA
treatment I-DNA
of O
Jurkat B-cell_type
T B-cell_type
cells I-cell_type
increased O
the O
activity O
of O
NO B-cell_type
synthase O
, O
which O
catalyzes O
the O
generation O
of O
NO B-cell_type
. O
We O
observed O
that O
pretreatment O
of O
Jurkat B-cell_type
cells I-cell_type
or O
activated O
PBLs O
with O
several O
NO B-protein
donors O
significantly O
enhanced O
the O
SDF1 I-DNA
alpha I-DNA
-induced I-DNA
migration O
, O
whereas O
various O
inhibitors O
of O
NO B-cell_type
synthase O
markedly O
abrogated O
the O
chemotactic O
response O
in O
a O
concentration-dependent B-DNA
manner O
. O
Furthermore O
, O
we O
observed O
that O
inhibitors O
of O
the O
transcription B-protein
factor I-protein
NF-kappa B-protein
B I-protein
, O
which O
is O
linked O
to O
NO B-protein
signaling O
pathways O
, O
also O
significantly O
blocked O
the O
SDF1 I-DNA
alpha I-DNA
-induced I-DNA
chemotactic O
response O
. O
However O
, O
these O
compounds O
did O
not O
have O
a O
significant O
effect O
on O
SDF1 I-DNA
alpha I-DNA
-induced I-DNA
mitogen-activated B-DNA
protein O
kinase I-protein
activity O
. O
In O
addition O
, O
the O
MAP/Erk I-protein
kinase I-protein
kinase I-protein
inhibitor O
PD98059 B-protein
did O
not O
abrogate O
SDF1 I-DNA
alpha I-DNA
-induced I-DNA
chemotaxis O
. O
AKT I-protein
, O
which O
has O
been O
shown O
to O
mediate O
NO B-protein
production O
, O
was O
also O
phosphorylated O
upon O
SDF1 I-DNA
alpha I-DNA
stimulation I-DNA
. O
These O
studies O
suggest O
that O
NO-related B-protein
signaling O
pathways O
may O
mediate O
SDF1 I-DNA
alpha I-DNA
-induced I-DNA
chemotaxis O
, O
but O
not O
mitogen-activated B-DNA
protein O
kinase I-protein
activation O
. O
The O
lack O
of O
NF-kappa B-protein
B I-protein
transactivation O
and O
PKC O
epsilon O
expression O
in O
CD4 B-protein
( O
+ O
) O
CD8 B-protein
( O
+ O
) O
thymocytes O
correlates O
with O
negative O
selection O
. O
Deletion O
of O
autoreactive O
thymocytes O
at O
the O
DP B-protein
stage O
is O
the O
basis O
for O
tolerance O
to O
thymus-expressed O
self O
antigens O
. O
In O
this O
study O
we O
investigated O
whether O
distinct O
signalling O
pathways O
are O
induced O
in O
DP B-protein
thymocytes O
as O
compared O
to O
mature O
T B-cell_type
cells I-cell_type
upon O
stimulation O
with O
antigen I-protein
. O
Using O
triple O
transgenic O
mice O
expressing O
a O
TCR O
transgene O
, O
dominant O
negative O
ras/Mek B-protein
proteins I-protein
and O
a O
reporter B-DNA
gene I-DNA
construct O
with O
AP-1 B-protein
or O
NF-kappa B-protein
B I-protein
binding I-DNA
sites I-DNA
, O
we O
showed O
a O
complete O
lack O
of O
transcriptional O
activity O
of O
NF-kappa B-protein
B I-protein
but O
not O
AP-1 B-protein
in O
DP B-protein
thymocytes O
, O
whereas O
both O
were O
transcriptionally O
active O
in O
mature O
T B-cell_type
cells I-cell_type
after O
antigenic O
stimulation O
. O
Lack O
of O
NF-kappa B-protein
B I-protein
induction O
correlated O
with O
increased O
death O
in O
response O
to O
antigen I-protein
. O
AP-1 B-protein
induction O
was O
dependent O
on O
the O
integrity O
of O
the O
ras/Mek O
pathway O
indicating O
that O
this O
pathway O
was O
activated O
in O
the O
DP B-protein
thymocytes O
. O
In O
contrast O
, O
we O
found O
a O
complete O
lack O
of O
constitutive O
expression O
of O
the O
epsilon O
isoform O
of O
Protein O
Kinase O
C I-protein
( O
PKC I-DNA
) O
in O
DP B-protein
thymocytes O
, O
although O
it O
was O
present O
in O
mature O
thymocytes O
and O
peripheral B-cell_type
T B-cell_type
cells I-cell_type
. O
Taken O
together O
the O
results O
suggest O
that O
the O
lack O
of O
PKC B-cell_type
epsilon O
in O
DP B-protein
thymocytes O
could O
lead O
to O
the O
absence O
of O
NF-kappa B-protein
B I-protein
activity O
after O
antigenic O
stimulation O
contributing O
to O
negative O
selection O
. O
Cell O
Death O
and O
Differentiation O
( O
2000 I-DNA
) O
7 O
, O
1253 O
- O
1262 O
. O
CD2 B-protein
stimulation O
leads O
to O
the O
delayed O
and O
prolonged O
activation O
of O
STAT1 B-protein
in O
T B-cell_type
cells I-cell_type
but O
not O
NK B-cell_type
cells I-cell_type
. O
OBJECTIVE O
: O
T I-cell_type
lymphocytes I-cell_type
can O
be O
activated O
by O
soluble B-protein
factors I-protein
such O
as O
cytokines O
or O
through O
direct O
cell-cell B-DNA
interactions O
. O
Although O
cytokine O
receptors O
are O
known O
to O
signal O
through O
STAT B-protein
family O
transcription B-protein
factors I-protein
, O
the O
mechanisms O
by O
which O
other O
cell-surface B-DNA
molecules I-protein
, O
such O
as O
CD2 B-protein
, O
transduce O
signals O
is O
unclear O
. O
The O
goal O
of O
this O
study O
was O
to O
determine O
whether O
stimulation O
of O
T B-cell_type
cells I-cell_type
through O
CD2 B-protein
recapitulates O
aspects O
of O
cytokine O
-induced O
T-cell O
activation O
by O
use O
of O
STAT B-protein
transcription B-protein
factors I-protein
. O
MATERIALS O
AND O
METHODS I-protein
: O
T B-cell_type
cells I-cell_type
were O
treated O
with O
anti-CD2 B-protein
antibodies I-protein
or O
cells I-cell_type
bearing O
the O
natural O
CD2 B-protein
ligand O
CD58 I-protein
, O
after O
which O
signaling O
through O
STAT B-protein
transcription B-protein
factors I-protein
was O
assessed O
. O
RESULTS I-protein
: O
Stimulation O
of O
CD2 B-protein
on O
primary B-cell_type
T I-cell_type
lymphocytes I-cell_type
leads O
to O
the O
tyrosine I-protein
phosphorylation O
, O
nuclear O
translocation I-protein
, O
and O
DNA O
binding O
of O
STAT1 B-protein
. O
In O
contrast O
to O
stimulation O
by O
cytokines O
, O
the O
activation O
of O
STAT1 B-protein
in O
response O
to O
CD2 B-protein
ligation O
is O
delayed O
and O
does O
not O
involve O
Jak O
kinases I-protein
. B-protein
Furthermore O
, O
while O
STAT B-protein
phosphorylation O
induced O
by O
cytokines O
is O
generally O
transient O
, O
STAT1 B-protein
phosphorylation O
following O
CD2 B-protein
stimulation O
persists O
for O
a O
period O
of O
days O
. O
Transcription I-DNA
of O
key O
target I-cell_line
genes I-DNA
such O
as O
IRF1 B-protein
and O
c-fos O
proceeds O
with O
delayed O
kinetics O
following O
CD2 B-protein
stimulation O
, O
suggesting O
that O
this O
unique O
pattern O
of O
STAT B-protein
activation O
may O
lead O
to O
a O
distinct O
cellular O
response O
following O
CD2 B-protein
ligation O
. O
This O
pathway O
appears O
to O
be O
restricted O
to O
T B-cell_type
cells I-cell_type
, O
as O
stimulation O
of O
CD2 B-protein
on O
NK B-cell_type
cells I-cell_type
does O
not O
lead O
to O
STAT1 B-protein
activation O
. O
CONCLUSION I-protein
: O
Stimulation O
of O
T B-cell_type
cells I-cell_type
through O
cell-surface B-DNA
molecules I-protein
such O
as O
CD2 B-protein
involves O
activation O
of O
STAT B-protein
transcription B-protein
factors I-protein
, O
thus O
recapitulating O
elements I-DNA
of O
cytokine O
signaling O
. O
NFATc1 I-cell_type
and O
NFATc2 B-protein
together O
control O
both O
T I-cell_line
and O
B O
cell O
activation O
and O
differentiation O
. O
NFAT B-protein
transcription B-protein
factors I-protein
play O
critical O
roles O
in O
gene I-DNA
transcription O
during O
immune O
responses O
. O
To O
investigate O
further O
the O
two O
most O
prominent O
NFAT O
family O
members O
, O
NFATc1 O
and O
NFATc2 I-cell_line
, O
we O
generated O
mice O
bearing O
lymphoid O
systems O
devoid O
of O
both O
. O
Doubly O
deficient B-cell_type
T B-cell_type
cells I-cell_type
displayed O
cell O
surface I-protein
markers O
of O
activation O
yet O
were O
significantly O
deficient O
in O
the O
development O
of O
multiple O
effector O
functions O
, O
including O
Th O
cytokine O
production O
, O
surface I-protein
effector O
molecule O
expression O
, O
and O
cytolytic O
activity O
. O
Nevertheless I-protein
, O
doubly O
deficient O
B I-DNA
cells I-cell_type
were O
hyperactivated O
, O
as O
evidenced O
by O
extremely O
elevated O
serum O
IgG1 B-DNA
and O
IgE I-DNA
, O
as O
well O
as O
plasma O
cell O
expansion O
and O
infiltration O
of O
end O
organs O
. O
Thus O
, O
in O
T B-cell_type
cells I-cell_type
, O
NFATc1 O
and O
NFATc2 B-protein
are O
dispensable O
for O
inflammatory O
reactivity O
but O
are O
required O
for O
effector O
differentiation O
, O
while O
in O
B I-DNA
cells I-cell_line
, O
NFATs O
regulate O
both O
normal O
homeostasis O
and O
differentiation O
. O
Epstein-barr O
virus O
immediate-early O
protein O
BZLF1 B-protein
is O
SUMO-1 B-protein
modified O
and O
disrupts O
promyelocytic O
leukemia O
bodies O
. O
Although O
the O
immediate-early B-protein
proteins I-protein
of O
both O
herpes O
simplex O
virus O
( O
HSV I-DNA
) O
and O
cytomegalovirus O
( O
CMV I-DNA
) O
are O
known O
to O
modify O
promyelocytic O
leukemia O
( O
PML I-DNA
) O
( O
ND10 B-protein
) O
bodies O
in O
the O
nucleus O
of O
the O
host O
cell O
, O
it O
has O
been O
unclear O
whether O
lytic O
infection O
with O
gamma O
herpesviruses O
induces O
a O
similar O
effect O
. O
The O
PML I-protein
protein O
is O
induced O
by O
interferon O
, O
involved O
in O
major O
histocompatibility I-protein
complex I-protein
class B-protein
I I-protein
presentation O
, O
and O
necessary O
for O
certain O
types I-cell_type
of O
apoptosis O
. O
Therefore O
, O
it O
is O
likely O
that O
PML O
bodies O
function O
in O
an O
antiviral O
capacity O
. O
SUMO-1 B-protein
modification O
of O
PML B-cell_type
is O
known O
to O
be O
required O
for O
the O
formation O
of O
PML B-cell_type
bodies O
. O
To O
examine O
whether O
Epstein-Barr O
virus O
( O
EBV I-DNA
) O
lytic O
replication O
interferes O
with O
PML O
bodies O
, O
we O
expressed O
the O
EBV O
immediate-early I-DNA
genes I-DNA
BZLF1 B-protein
( O
Z I-DNA
) O
and O
BRLF1 B-protein
( O
R I-DNA
) O
in O
EBV-positive O
cell O
lines I-cell_line
and O
examined O
PML O
localization O
. O
Both O
Z O
and O
R O
expression O
resulted O
in O
PML O
dispersion O
in O
EBV-positive B-protein
cells I-cell_type
. O
Z O
but O
not O
R O
expression O
is O
sufficient O
to O
disrupt O
PML O
bodies O
in O
EBV-negative O
cell O
lines I-cell_line
. O
We O
show O
that O
dispersion O
of O
PML B-cell_type
bodies O
by O
Z O
requires O
a O
portion O
of O
the O
transcriptional O
activation I-protein
domain I-protein
of O
Z O
but O
not O
the O
DNA-binding B-protein
function O
. O
As O
was O
previously O
reported O
for O
the O
HSV-1 O
ICP0 B-protein
and O
CMV O
IE1 B-protein
proteins I-protein
, O
Z O
reduces O
the O
amount O
of O
SUMO-1-modified B-protein
PML O
. O
We O
also O
found O
that O
Z O
itself O
is O
SUMO-1 B-protein
modified O
( O
through O
amino O
acid O
12 O
) O
and O
that O
Z O
competes O
with O
PML O
for O
limiting O
amounts O
of O
SUMO-1 B-protein
. O
These O
results O
suggest O
that O
disruption O
of O
PML B-cell_type
bodies O
is O
important O
for O
efficient O
lytic O
replication O
of O
EBV B-cell_type
. O
Furthermore O
, O
Z O
may O
potentially O
alter O
the O
function O
of O
a O
variety O
of O
cellular O
proteins I-protein
by O
inhibiting O
SUMO-1 B-protein
modification O
Suppression O
of O
nuclear B-protein
factor-kappaB O
and O
stimulation O
of O
inhibitor O
kappaB I-RNA
by O
troglitazone O
: O
evidence O
for O
an O
anti-inflammatory B-DNA
effect O
and O
a O
potential O
antiatherosclerotic O
effect O
in O
the O
obese O
. O
To O
elucidate O
whether O
troglitazone O
exerts O
an O
antiinflammatory O
effect O
in O
humans O
, O
in O
vivo O
, O
we O
investigated O
the O
suppression O
of O
nuclear B-protein
factor I-protein
kappaB B-protein
( O
NFkappaB I-DNA
) O
in O
mononuclear B-cell_type
cells I-cell_line
( O
MNC I-DNA
) O
by O
this O
drug O
. O
We O
measured O
intranuclear O
NFkappaB I-protein
, O
total O
cellular O
NFkappaB I-protein
, O
inhibitor O
kappaB I-cell_line
( O
IkappaB I-DNA
) O
alpha I-DNA
, O
reactive O
oxygen O
species O
( O
ROS I-DNA
) O
generation O
, O
and O
p47 B-protein
( O
phox O
) O
subunit O
( O
a O
key O
component O
protein O
of O
nicotinamide O
adenine O
dinucleotide O
phosphate O
oxidase O
) O
in O
MNC O
. O
Plasma O
tumor O
necrosis B-protein
factor I-protein
( O
TNF I-DNA
) O
-alpha O
, O
soluble O
intercellular O
adhesion O
molecule-1 B-protein
( O
sICAM-1 B-protein
) O
, O
monocyte O
chemoattractant O
protein-1 B-protein
( O
MCP-1 O
) O
, O
plasminogen O
activator O
inhibitor I-DNA
type O
1 O
( O
PAI-1 O
) O
, O
C-reactive B-protein
protein I-protein
( O
CRP I-DNA
) O
, O
and O
interleukin O
( O
IL I-DNA
) O
-10 O
( O
antiinflammatory O
cytokine O
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory O
transcription B-protein
factor I-protein
NFkappaB B-protein
. O
Seven O
nondiabetic O
obese O
patients O
were O
given O
400 O
mg O
troglitazone O
daily O
for O
4 O
weeks O
. O
Blood O
samples O
were O
collected O
before O
and O
at O
weekly O
intervals O
thereafter O
. O
MNC O
were O
separated O
; O
and O
the O
levels O
of O
intranuclear O
NFkappaB I-protein
, O
total O
cellular O
NFkappaB I-protein
, O
IkappaBalpha I-protein
, O
and O
p47 B-protein
( O
phox O
) O
subunit O
and O
ROS O
generation O
were O
determined O
. O
Plasma O
was O
used O
to O
measure O
insulin O
glucose O
, O
TNFalpha O
, O
sICAM I-DNA
, O
MCP-1 O
, O
PAI-1 O
, O
CRP I-protein
, O
and O
IL-10 B-protein
. O
Plasma O
insulin O
concentrations O
fell O
significantly O
at O
week O
1 O
, O
from O
31.2 B-protein
+/- O
29.1 I-protein
to O
14.2 B-protein
+/- O
11.4 B-protein
mU/L I-protein
( O
P O
< O
0.01 B-protein
) O
and O
remained O
low O
throughout O
4 O
weeks O
. O
Plasma O
glucose O
concentrations O
did O
not O
alter O
significantly O
. O
There O
was O
a O
fall O
in O
intranuclear O
NFkappaB I-protein
, O
total O
cellular O
NFkappaB I-protein
, O
and O
p47 B-protein
( O
phox O
) O
subunit O
, O
with O
an O
increase O
in O
cellular O
IkappaBalpha O
at O
week O
2 O
, O
which O
persisted O
until O
week O
4 O
. O
There O
was O
a O
parallel O
fall O
in O
ROS O
generation O
by O
MNC O
at O
week O
1 O
; O
this O
progressed O
and O
persisted O
until O
week O
4 O
( O
P O
< O
0.001 B-protein
) O
. O
Plasma O
TNF-alpha I-DNA
, O
sICAM-1 O
, O
MCP-1 O
, O
and O
PAI-1 O
concentrations O
fell O
significantly O
at O
week O
4 O
. O
Plasma O
IL-10 B-protein
concentration O
increased O
significantly O
, O
whereas O
plasma O
CRP O
concentrations O
decreased O
. O
We O
conclude O
that O
troglitazone O
has O
an O
antiinflammatory O
action O
that O
may O
contribute O
to O
its O
putative O
antiatherosclerotic O
effects O
. O
Tyrosine O
phosphorylation-dependent B-DNA
activation O
of O
NF-kappa B-protein
B I-protein
. O
Requirement O
for O
p56 O
LCK O
and O
ZAP-70 B-protein
protein B-protein
tyrosine I-protein
kinases I-protein
. B-protein
Phosphorylation O
of O
the O
N-terminal B-protein
domain I-protein
of O
I I-protein
kappa B-DNA
B I-DNA
inhibitory O
subunits O
induces O
activation O
of O
the O
transcription B-protein
factor I-protein
NF-kappa B-protein
B I-protein
. O
Although O
serine O
phosphorylation O
has O
been O
shown O
to O
induce O
ubiquitination O
and O
subsequent O
proteasome-mediated B-DNA
degradation O
of O
I I-protein
kappa B-DNA
B-alpha I-DNA
, O
little O
is O
known O
about O
the O
mechanisms O
that O
lead O
to O
release O
of O
active O
NF-kappa B-protein
B I-protein
in O
T B-cell_type
cells I-cell_type
as O
a O
consequence O
of O
tyrosine I-protein
phosphorylation O
of O
I I-protein
kappa B-DNA
B-alpha B-protein
[ O
Imbert O
, O
V. I-protein
, O
Rupec O
, O
R.A. I-protein
, O
Livolsi O
, O
A. I-protein
, O
Pahl O
, O
H.L. I-protein
, O
Traenckner O
, O
B.M. I-protein
, O
Mueller-Dieckmann O
, O
C. I-protein
, O
Farahifar O
, O
D. I-protein
, O
Rossi O
, O
B. I-protein
, O
Auberger O
, O
P. I-protein
, O
Baeuerle O
, O
P. B-protein
& O
Peyron O
, O
J.F. I-protein
( O
1996 I-DNA
) O
Cell O
86 I-cell_line
, O
787 O
-- O
798 O
] O
. O
The O
involvement O
of O
the O
tyrosine I-protein
kinases I-protein
p56 B-protein
( O
lck O
) O
and O
ZAP-70 B-protein
in O
this O
reaction O
is O
demonstrated O
here O
using O
specific O
pharmacological O
inhibitors O
and O
Jurkat O
mutants O
unable O
to O
express O
these O
kinases I-protein
. B-protein
Although O
the O
inhibitors O
prevented O
both O
pervanadate-induced B-DNA
phosphorylation O
of O
I I-protein
kappa B-DNA
B-alpha B-protein
on O
Tyr42 I-cell_type
and O
NF-kappa B-protein
B I-protein
activation O
, O
we O
observed O
that O
, O
in O
p56 I-cell_line
( O
lck O
) O
-deficient O
Jurkat O
mutants O
, O
NF-kappa B-protein
B I-protein
could O
still O
associate O
with O
I I-protein
kappa B-DNA
B-alpha B-protein
despite O
phosphorylation O
on O
Tyr42 O
. O
Furthermore O
, O
the O
SH2 I-protein
domain I-protein
of O
p56 B-cell_type
( O
lck O
) O
appeared O
to O
be O
required O
for O
pervanadate-induced B-DNA
NF-kappa B-protein
B I-protein
activation O
but O
not O
for O
Tyr42 O
phosphorylation O
. O
These O
results O
show O
that O
p56 I-cell_line
( O
lck O
) O
and O
ZAP-70 B-protein
are O
key O
components O
of O
the O
signaling O
pathway O
that O
leads O
to O
phosphotyrosine-dependent O
NF-kappa B-protein
B I-protein
activation O
in O
T B-cell_type
cells I-cell_type
and O
confirm O
that O
tyrosine I-protein
kinases I-protein
must O
control O
at O
least O
two O
different O
steps O
to O
induce O
activation O
of O
NF-kappa B-protein
B I-protein
. O
Finally O
, O
we O
show O
that O
H O
( O
2 O
) O
O O
( O
2 O
) O
, O
which O
stimulates O
p56 I-cell_line
( O
lck O
) O
and O
ZAP-70 B-protein
in O
T B-cell_type
cells I-cell_type
, O
is O
an O
activator O
of O
NF-kappa B-protein
B I-protein
through O
tyrosine I-protein
phosphorylation O
of O
I I-protein
kappa B-DNA
B-alpha B-protein
. O
Specific O
missense O
mutations O
in O
NEMO O
result O
in O
hyper-IgM O
syndrome O
with O
hypohydrotic O
ectodermal O
dysplasia O
. O
The O
gene I-DNA
that O
encodes O
nuclear B-protein
factor I-protein
kappaB B-protein
( O
NF-kappaB I-DNA
) O
essential O
modulator O
( O
or O
NEMO I-protein
, O
also O
known O
as O
IKKgamma O
) O
is O
required O
for O
activation O
of O
the O
transcription B-protein
factor I-protein
NF-kappaB B-protein
. O
We O
describe O
mutations O
in O
the O
putative O
zinc-finger I-protein
domain I-protein
of O
NEMO O
that O
result O
in O
an O
X-linked B-protein
primary B-cell_line
immunodeficiency I-cell_line
characterized O
by O
hyper-IgM O
syndrome O
and O
hypohydrotic O
ectodermal O
dysplasia O
( O
XHM-ED B-protein
) O
. O
These O
mutations O
prevent O
CD40 B-protein
ligand O
( O
CD40L B-protein
) O
-mediated O
degradation O
of O
inhibitor O
of O
NF-kappaB I-DNA
alpha I-DNA
( O
IkappaB-alpha I-DNA
) O
and O
account O
for O
the O
following O
observations O
: O
B I-DNA
cells I-cell_type
from O
XHM-ED B-protein
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class-switch B-DNA
recombination O
and O
antigen-presenting B-cell_type
cells I-cell_line
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF-kappaB-regulated B-protein
cytokines O
interleukin O
12 O
( O
IL-12 B-protein
) O
or O
tumor O
necrosis B-protein
factor I-protein
alpha I-DNA
( O
TNF-alpha I-DNA
) O
when O
stimulated O
with O
CD40L B-protein
. O
Nevertheless I-protein
, O
innate O
immunity O
is O
preserved O
in O
XHM-ED B-protein
patients O
because O
APCs O
retain O
the O
capacity O
to O
respond O
to O
stimulation O
by O
lipopolysaccharide O
or O
Staphylococcus O
aureus O
Cowan O
's O
antigen I-protein
( O
SAC I-DNA
) O
. O
Overall O
, O
the O
phenotype O
observed O
in O
XHM-ED B-protein
patients O
shows O
that O
the O
putative O
zinc-finger I-protein
domain I-protein
of O
NEMO O
has O
a O
regulatory O
function O
and O
demonstrates O
the O
definite O
requirement O
of O
CD40 B-protein
-mediated O
NF-kappaB O
activation O
for O
B O
cell O
immunoglobulin O
class-switching O
. O
Granulocytic O
differentiation O
of O
human B-cell_type
NB4 B-protein
promyelocytic O
leukemia B-cell_type
cells I-cell_type
induced O
by O
all-trans O
retinoic O
acid O
metabolites I-protein
. O
The O
metabolism O
of O
all-trans B-cell_type
retinoic O
acid O
( O
ATRA I-DNA
) O
has O
been O
reported O
to O
be O
partly O
responsible O
for O
the O
in O
vivo O
resistance O
to O
ATRA O
seen O
in O
the O
treatment O
of O
human B-cell_type
acute I-cell_type
promyelocytic O
leukemia O
( O
APL I-DNA
) O
. O
However O
, O
ATRA O
metabolism O
appears O
to O
be O
involved O
in O
the O
growth O
inhibition O
of O
several O
cancer O
cell O
lines I-cell_line
in O
vitro O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
in O
vitro O
activity O
of O
the O
principal O
metabolites I-protein
of O
ATRA O
[ O
4-hydroxy-retinoic O
acid O
( O
4-OH-RA B-protein
) O
, O
18-hydroxy-retinoic O
acid O
( O
18-OH-RA B-protein
) O
, O
4-oxo-retinoic O
acid O
( O
4-oxo-RA B-protein
) O
, O
and O
5 O
, O
6-epoxy-retinoic O
acid O
( O
5 O
, O
6-epoxy-RA B-protein
) O
] O
in O
NB4 B-protein
, O
a O
human B-DNA
promyelocytic I-DNA
leukemia O
cell O
line O
that O
exhibits O
the O
APL O
diagnostic O
t O
( O
15 O
; O
17 O
) O
chromosomal O
translocation O
and O
expresses O
the O
PML-RAR I-DNA
alpha I-DNA
fusion I-protein
protein O
. O
We O
established O
that O
the O
four O
ATRA O
metabolites I-protein
were O
indeed O
formed O
by O
the O
NB4 B-protein
cells I-cell_type
in O
vitro O
. O
NB4 B-protein
cell O
growth O
was O
inhibited O
( O
69-78 O
% O
at O
120 O
h O
) O
and O
cell O
cycle O
progression O
in O
the O
G1 B-protein
phase O
( O
82-85 O
% O
at O
120 O
h O
) O
was O
blocked O
by O
ATRA O
and O
all O
of O
the O
metabolites I-protein
at O
1 O
microM I-RNA
concentration O
. O
ATRA O
and O
its O
metabolites I-protein
could O
induce O
NB4 B-protein
cells I-cell_type
differentiation O
with O
similar O
activity O
, O
as O
evaluated O
by O
cell O
morphology O
, O
by O
the O
nitroblue O
tetrazolium O
reduction O
test O
( O
82-88 O
% O
at O
120 O
h O
) O
or O
by O
the O
expression O
of O
the O
maturation O
specific O
cell O
surface I-protein
marker O
CD11c O
. O
In O
addition O
, O
nuclear O
body O
reorganization O
to O
macropunctated O
structures O
, O
as O
well O
as O
the O
degradation O
of O
PML-RAR I-DNA
alpha I-DNA
, O
was O
found O
to O
be O
similar O
for O
ATRA O
and O
all O
of O
its O
metabolites I-protein
. O
Comparison O
of O
the O
relative O
potency O
of O
the O
retinoids O
using O
the O
nitroblue O
tetrazolium O
reduction O
test O
showed O
effective O
concentrations O
required O
to O
differentiate O
50 O
% O
of O
cells I-cell_type
in O
72 O
h O
as O
follows O
: O
ATRA I-protein
, O
15.8 B-protein
+/- O
1.7 B-protein
nM I-RNA
; O
4-oxo-RA O
, O
38.3 B-protein
+/- O
1.3 O
nM I-RNA
; O
18-OH-RA B-protein
, O
55.5 B-protein
+/- O
1.8 B-protein
nM I-RNA
; O
4-OH-RA I-protein
, O
79.8 B-protein
+/- O
1.8 B-protein
nM I-RNA
; O
and O
5 O
, O
6-epoxy-RA O
, O
99.5 B-protein
+/- O
1.5 B-protein
nM I-RNA
. O
The O
ATRA O
metabolites I-protein
were O
found O
to O
exert O
their O
differentiation O
effects O
via O
the O
RAR I-DNA
alpha I-DNA
nuclear B-protein
receptors O
, O
because O
the O
RAR O
alpha-specific O
antagonist O
BMS614 B-protein
blocked O
metabolite-induced O
CD11c O
expression O
in O
NB4 B-protein
cells I-cell_type
. O
These O
data O
demonstrate O
that O
the O
principal O
ATRA O
Phase O
1 O
metabolites I-protein
can O
elicit O
leukemia O
cell O
growth O
inhibition O
and O
differentiation O
in O
vitro O
through O
the O
RAR I-DNA
alpha I-DNA
signaling I-DNA
pathway O
, O
and O
they O
suggest O
that O
these O
metabolites I-protein
may O
play O
a O
role O
in O
ATRA O
antileukemic O
activity O
in O
vivo O
. O
Expression O
of O
oestrogen O
and O
progesterone O
receptors O
by O
mast B-cell_type
cells I-cell_type
alone O
, O
but O
not I-cell_type
lymphocytes I-cell_type
, O
macrophages O
or O
other O
immune B-cell_type
cells I-cell_type
in O
human B-DNA
upper I-cell_type
airways O
. O
BACKGROUND I-protein
: O
Nasal O
polyposis O
often O
coexists O
with O
asthma O
in O
airway O
inflammatory O
conditions O
characterised O
by O
the O
infiltration O
of O
a O
range O
of O
immune B-cell_type
cells I-cell_type
. O
A O
potentially O
important O
role O
for O
ovarian O
hormones O
has O
been O
implicated O
in O
airway O
inflammation O
but O
the O
cellular O
target I-cell_line
for O
such O
action O
is O
not O
known O
. O
METHODS I-protein
: O
Expression O
of O
oestrogen O
receptors O
( O
ER B-protein
) O
and O
progesterone O
receptors O
( O
PR I-DNA
) O
was O
examined O
using O
immunohistochemistry O
in O
formalin O
fixed O
nasal O
polyp O
tissues O
from O
47 O
subjects O
. O
The B-cell_type
cells I-cell_type
positive O
for O
ER B-protein
or O
PR B-protein
were O
confirmed O
by O
spatial O
location O
, O
dual O
immunolabelling O
, O
and O
histochemical O
staining O
. O
RESULTS I-protein
: O
Consistent O
with O
the O
known O
features O
of O
nasal O
polyps O
, O
CD4+ B-protein
( O
T O
helper/inducer I-cell_type
) O
, O
CD8+ B-protein
( O
cytotoxic/suppressor I-DNA
) O
, O
CD68+ B-protein
( O
macrophages O
) O
, O
mast B-cell_type
cells I-cell_line
, O
eosinophils O
and O
neutrophils O
were O
all O
clearly O
detected O
by O
their O
relevant O
monoclonal B-protein
antibodies I-protein
or O
appropriate O
histochemical O
staining O
, O
but O
only O
mast B-cell_type
cells I-cell_type
tested O
positive O
for O
ER B-protein
/PR O
labelling O
with O
their O
polyclonal O
and O
monoclonal B-protein
antibodies I-protein
. O
The O
frequencies O
for O
expression O
were O
61.7 B-protein
% O
for O
ER B-protein
positive O
and O
59.6 B-protein
% O
for O
PR B-protein
positive B-cell_type
cells I-cell_type
. O
The O
expression O
of O
ER B-protein
/ O
PR B-protein
was O
independent O
of O
patient O
sex O
and O
age O
but O
was O
highly O
correlated O
with O
the O
numbers O
of O
mast B-cell_type
cells I-cell_line
( O
r O
= O
0.973 I-cell_line
, O
p O
< O
0.001 B-DNA
for O
ER B-protein
; O
r O
= O
0.955 I-cell_line
, O
p O
< O
0.001 B-DNA
for O
PR B-protein
) O
. O
Fewer O
than O
5 O
% O
of O
mast B-cell_type
cells I-cell_type
were O
found O
to O
be O
negative O
for O
ER B-protein
/ O
PR B-protein
expression O
. O
CONCLUSIONS I-protein
: O
Mast B-cell_type
cells I-cell_type
alone O
, O
but O
not I-cell_type
lymphocytes I-cell_type
, O
macrophages O
, O
or O
other O
immune B-cell_type
cells I-cell_line
, O
express O
ER B-protein
/ O
PR B-protein
in O
human B-DNA
upper I-cell_type
airways O
. O
Numerous O
ER/PR B-protein
positive O
mast B-cell_type
cells I-cell_type
exist O
in O
nasal O
polyps O
, O
indicating O
that O
this O
may O
be O
a O
major O
route O
for O
the O
involvement O
of O
sex O
hormones O
in O
airway O
inflammation O
when O
exposed O
to O
the O
higher O
and O
varying O
concentration O
of O
oestrogen O
and O
progesterone O
characteristic O
of O
females O
. O
NF O
kappa B-DNA
b O
signaling O
in O
posthypoxic O
endothelial B-cell_type
cells I-cell_type
: O
relevance O
to O
E-selectin B-protein
expression O
and O
neutrophil O
adhesion O
. O
Our O
previous O
studies O
have O
implicated O
the O
nuclear B-protein
transcription B-protein
factor I-protein
kappa B-DNA
B I-DNA
( O
NF O
kappa B-DNA
B I-DNA
) O
in O
the O
regulation O
of O
adhesion O
molecule O
expression O
in O
endothelial B-cell_type
cells I-cell_type
exposed O
to O
anoxia-reoxygenation B-protein
( O
A/R B-protein
) O
or O
a O
redox O
imbalance O
. O
The O
objectives O
of O
this O
study O
were O
( O
1 O
) O
to O
define O
the O
kinetics O
of O
NF O
kappa B-DNA
B I-DNA
activation O
by O
examining O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
degradation I-DNA
and O
the O
nuclear B-protein
translocation O
of O
p65 B-cell_type
in O
response O
to O
A/R B-protein
or O
redox O
imbalance O
( O
induced O
by O
treatment O
of O
cells I-cell_type
with O
diamide O
and O
buthionine O
sulfoximine O
) O
and O
( O
2 O
) O
to O
determine O
whether O
the O
signal O
for O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
degradation I-DNA
, O
nuclear O
translocation O
of O
p65 B-cell_type
, O
and O
E-selectin B-protein
-mediated O
neutrophil O
adhesion O
is O
related O
to O
the O
activity O
of O
protein B-protein
tyrosine I-protein
kinase I-protein
( O
PTK I-DNA
) O
, O
protein B-protein
tyrosine I-protein
phosphatase O
( O
PTPase I-DNA
) O
and/or O
protein O
kinase I-protein
C I-protein
( O
PKC I-DNA
) O
. O
The O
results O
demonstrate O
that O
both O
A/R O
and O
redox O
imbalance O
led O
to O
I O
kappa B-DNA
B I-DNA
alpha I-DNA
degradation I-DNA
within O
30 O
min O
and O
the O
concomitant O
appearance O
of O
p65 B-cell_type
in O
the O
nucleus O
, O
consistent O
with O
rapid O
cytosolic O
activation O
of O
NF O
kappa B-DNA
B I-DNA
and O
subsequent O
nuclear B-protein
translocation O
of O
the O
activated O
p65 O
subunit O
. O
Inhibition O
of O
PKC B-cell_type
blocked O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
degradation I-DNA
and O
p65 O
translocation O
in O
A/R-challenged I-DNA
, O
but O
not O
redox-altered I-DNA
, O
endothelial B-cell_type
cells I-cell_type
. O
However O
, O
both O
A/R- B-DNA
and O
redox-induced B-protein
NF O
kappa B-DNA
B I-DNA
activation O
was O
blocked O
by O
inhibition O
of O
PTK B-cell_type
. O
Similarly O
, O
A/R-induced O
E-selectin B-protein
expression O
and O
neutrophil-endothelial O
cell O
adhesion O
were O
blocked O
by O
inhibition O
of O
PKC B-cell_type
or O
PTK I-protein
, O
while O
only O
PTK O
inhibited O
the O
redox-induced B-protein
adhesion O
response O
. O
Pretreatment O
of O
cells I-cell_type
with O
N-acetyl B-protein
cysteine O
effectively O
blocked O
A/R- B-protein
or O
redox-induced B-protein
I I-protein
kappa B-DNA
B I-DNA
degradation O
and O
significantly O
attenuated O
the O
respective O
neutrophil O
adhesion O
responses O
. O
Collectively I-protein
, O
these O
findings O
indicate O
that O
A/R-induced O
E-selectin B-protein
expression O
and O
neutrophil-endothelial O
cell O
adhesion O
are O
mediated O
by O
both O
PKC O
and O
PTK I-protein
, O
which O
signal O
rapid O
activation O
of O
NF O
kappa B-DNA
B I-DNA
. O
This O
A/R-induced O
NF O
kappa B-DNA
B I-DNA
signaling O
response O
appears O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
intracellular O
redox O
imbalance O
. O
Copyright O
2001 O
S. B-protein
Karger O
AG I-protein
, O
Basel O
Induction O
of O
apoptosis O
in O
human I-cell_type
lymphocytes I-cell_type
by O
the O
herbicide O
2 O
, O
4-dichlorophenoxyacetic O
acid O
. O
Dimethylammonium O
salt O
of O
2 O
, O
4-dichlorophenoxyacetic O
acid O
( O
DMA-2 O
, O
4-D B-protein
) O
is O
a O
widely O
used O
herbicide O
that O
is O
considered O
moderately O
toxic O
. O
In O
the O
present O
study O
we O
found O
that O
DMA-2 O
, O
4-D B-protein
is O
able O
to O
cause O
apoptosis O
in O
peripheral B-cell_type
blood I-cell_type
lymphocytes I-cell_type
of O
healthy O
individuals O
and O
Jurkat O
T B-cell_type
cells I-cell_type
. O
Apoptosis O
induced O
by O
DMA-2 O
, O
4-D B-protein
was O
dose O
and O
time O
dependent O
, O
independent O
of O
Fas O
, O
TNF I-DNA
receptor I-protein
1 O
or O
the O
aromatic O
hydrocarbon I-DNA
receptor I-protein
, O
and O
involved O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
activation O
of O
caspase-9 B-protein
. O
ZVAD-FMK I-protein
, O
a O
broad-spectrum O
inhibitor O
of O
caspases O
, O
blocked O
DMA-2 O
, O
4-D-induced O
apoptosis O
completely O
. O
While O
an O
inhibitor O
of O
caspase-9 B-protein
, O
as O
well O
as O
caspase-9 B-protein
and O
caspase-3 B-protein
inhibitors O
in O
combination O
, O
strongly O
blocked O
DMA-2 O
, O
4-D-induced O
apoptosis O
, O
an O
inhibitor O
of O
caspase-3 B-protein
had O
a O
moderate O
inhibitory O
effect O
. O
Unlike O
Fas O
-mediated O
apoptosis O
, O
the O
initiator O
caspase O
, O
caspase-8 O
, O
was O
not O
involved O
in O
DMA-2 O
, O
4-D-induced O
apoptosis O
. O
Transfection O
of O
Jurkat B-cell_type
cells I-cell_type
with O
Bcl-2 B-protein
prevented O
DMA-2 O
, O
4-D-induced O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
led O
to O
a O
complete O
blockage O
of O
apoptosis O
. O
Our O
data O
indicate O
that O
DMA-2 O
, O
4-D B-protein
kills O
human I-cell_type
lymphocytes I-cell_type
by O
initiating O
apoptosis O
via O
a O
direct O
effect O
on O
mitochondria O
. O
The O
activation O
of O
caspases O
occurs O
downstream O
of O
mitochondrial O
damage I-protein
, O
and O
the O
dysfunction O
of O
mitochondria O
appears O
to O
be O
sufficient O
for O
triggering O
all O
downstream O
events O
leading O
to O
apoptosis O
. O
Inhibition O
of O
Th1 B-cell_type
differentiation O
by O
IL-6 B-protein
is O
mediated O
by O
SOCS1 B-protein
. O
Interleukin O
6 O
( O
IL-6 B-protein
) O
is O
a O
cytokine O
produced O
by O
immune O
and O
nonimmune B-cell_type
cells I-cell_type
and O
exhibits O
functional O
pleiotropy O
and O
redundancy O
. O
IL-6 B-protein
plays O
an O
important O
role O
in O
the O
differentiation O
of O
several O
cell O
types I-cell_type
. O
Here O
, O
we O
describe O
a O
novel O
function O
of O
IL-6 B-protein
: O
the O
negative O
regulation O
of O
CD4 B-protein
+ O
Th1 O
cell O
differentiation O
. O
While O
IL-6 B-protein
-directed O
CD4 B-protein
+ O
Th2 O
differentiation O
is O
mediated O
by O
IL-4 B-protein
, O
inhibition O
of O
Th1 B-cell_type
differentiation O
by O
IL-6 B-protein
is O
independent O
of O
IL-4 B-protein
. O
IL-6 B-protein
upregulates O
suppressor O
of O
cytokine O
signaling O
1 O
( O
SOCS1 B-protein
) O
expression O
in O
activated O
CD4+ B-cell_type
T B-cell_type
cells I-cell_type
, O
thereby O
interfering O
with O
signal O
transducer O
and O
activator O
of O
transcription O
1 O
( O
STAT1 B-protein
) O
phosphorylation O
induced O
by O
interferon O
gamma O
( O
IFNgamma I-DNA
) O
. O
Inhibition O
of O
IFNgamma O
receptor-mediated B-DNA
signals O
by O
IL-6 B-protein
prevents O
autoregulation O
of O
IFNgamma B-DNA
gene I-DNA
expression O
by O
IFNgamma O
during O
CD4+ B-cell_type
T O
cell O
activation O
, O
thereby O
preventing O
Th1 O
differentiation O
. O
Thus O
, O
IL-6 B-protein
promotes O
CD4 B-protein
+ O
Th2 O
differentiation O
and O
inhibits O
Th1 O
differentiation O
by O
two O
independent O
molecular O
mechanisms O
. O
Interaction O
between O
CCAAT/enhancer O
binding O
protein O
and O
cyclic O
AMP O
response O
element I-DNA
binding O
protein O
1 O
regulates O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
transcription O
in B-RNA
cells I-cell_type
of O
the O
monocyte/macrophage O
lineage O
. O
Recent O
observations O
have O
shown O
two O
CCAAT/enhancer O
binding O
protein O
( O
C/EBP I-DNA
) O
binding O
sites O
to O
be O
critically O
important O
for O
efficient O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
( O
HIV-1 B-protein
) O
replication O
within B-cell_type
cells I-cell_type
of O
the O
monocyte/macrophage O
lineage O
, O
a O
cell I-DNA
type O
likely O
involved O
in O
transport O
of O
the O
virus O
to O
the O
brain O
. O
Additionally I-protein
, O
sequence O
variation O
at O
C/EBP I-DNA
site I-DNA
I I-protein
, O
which O
lies O
immediately O
upstream O
of O
the O
distal O
nuclear B-protein
factor I-protein
kappa B-DNA
B I-DNA
site I-DNA
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating O
transcription B-protein
factor I-protein
( O
ATF I-DNA
) O
/ O
cyclic O
AMP O
response O
element I-DNA
binding O
protein O
( O
CREB I-DNA
) O
, O
has O
been O
shown O
to O
affect O
HIV-1 B-DNA
long I-DNA
terminal I-DNA
repeat I-DNA
( O
LTR I-DNA
) O
activity O
. O
Given O
that O
C/EBP B-protein
proteins I-protein
have O
been O
shown O
to O
interact O
with O
many O
other O
transcription B-protein
factors I-protein
including O
members O
of O
the O
ATF/CREB B-protein
family I-protein
, O
we O
proceeded O
to O
determine O
whether O
an O
adjacent O
ATF/CREB B-protein
binding O
site O
could O
affect O
C/EBP I-protein
protein O
binding O
to O
C/EBP I-DNA
site I-DNA
I I-protein
. O
Electrophoretic O
mobility O
shift O
analyses O
indicated O
that O
selected O
ATF/CREB I-DNA
site I-DNA
variants O
assisted O
in O
the O
recruitment O
of O
C/EBP B-protein
proteins I-protein
to O
an O
adjacent O
, O
naturally O
occurring O
, O
low-affinity O
C/EBP I-DNA
site I-DNA
. O
This O
biophysical O
interaction O
appears O
to O
occur O
via O
at O
least O
two O
mechanisms O
. O
First O
, O
low O
amounts O
of O
CREB-1 B-protein
and O
C/EBP B-protein
appear O
to O
heterodimerize O
and O
bind O
to O
a O
site I-DNA
consisting O
of O
a O
half O
site I-DNA
from O
both O
the O
ATF/CREB I-protein
and O
C/EBP B-protein
binding O
sites O
. O
In O
addition O
, O
CREB-1 B-protein
homodimers O
bind O
to O
the O
ATF/CREB I-DNA
site I-DNA
and O
recruit O
C/EBP B-protein
dimers O
to O
their O
cognate O
weak O
binding O
sites O
. O
This O
interaction O
is O
reciprocal O
, O
since O
C/EBP B-protein
dimer O
binding O
to O
a O
strong O
C/EBP I-DNA
site I-DNA
leads O
to O
enhanced O
CREB-1 B-protein
recruitment O
to O
ATF/CREB B-protein
sites I-DNA
that O
are O
weakly O
bound O
by O
CREB O
. O
Sequence O
variation O
at O
both O
C/EBP I-protein
and O
ATF/CREB I-DNA
sites I-DNA
affects O
the O
molecular O
interactions O
involved O
in O
mediating O
both O
of O
these O
mechanisms O
. O
Most O
importantly O
, O
sequence O
variation O
at O
the O
ATF/CREB B-protein
binding O
site O
affected O
basal O
LTR O
activity O
as O
well O
as O
LTR O
function O
following O
interleukin-6 B-protein
stimulation O
, O
a O
treatment O
that O
leads O
to O
increases O
in O
C/EBP B-protein
activation O
. O
Thus O
, O
HIV-1 O
LTR O
ATF/CREB B-protein
binding O
site O
sequence O
variation O
may O
modulate O
cellular O
signaling O
at O
the O
viral B-DNA
promoter I-DNA
through O
the O
C/EBP B-protein
pathway O
Selective O
inhibition O
of O
interleukin-4 B-protein
gene I-DNA
expression O
in O
human B-cell_type
T I-cell_type
cells I-cell_type
by O
aspirin O
. O
Previous O
studies O
indicated O
that O
aspirin O
( O
acetylsalicylic O
acid O
[ O
ASA O
] O
) O
can O
have O
profound O
immunomodulatory O
effects O
by O
regulating O
cytokine B-DNA
gene I-DNA
expression O
in O
several O
types I-cell_type
of O
cells I-cell_type
. O
This O
study O
is O
the O
first O
in O
which O
concentrations O
of O
ASA B-cell_type
in O
the O
therapeutic O
range O
were O
found O
to O
significantly O
reduce O
interleukin O
( O
IL I-DNA
) O
-4 O
secretion O
and O
RNA O
expression O
in O
freshly O
isolated O
and O
mitogen-primed O
human B-DNA
CD4+ B-cell_type
T B-cell_type
cells I-cell_type
. O
In O
contrast O
, O
ASA O
did O
not O
affect O
IL-13 B-protein
, O
interferon-gamma O
, O
and O
IL-2 B-protein
expression O
. O
ASA O
inhibited O
IL-4 B-protein
, O
but O
not O
IL-2 B-protein
, O
promoter-driven O
chloramphenicol O
acetyltransferase O
expression O
in O
transiently O
transfected O
Jurkat O
T B-cell_type
cells I-cell_type
. O
The O
structurally O
unrelated O
nonsteroidal O
anti-inflammatory B-DNA
drugs O
indomethacin O
and O
flurbiprofen O
did O
not O
affect O
cytokine B-DNA
gene I-DNA
expression O
in O
T B-cell_type
cells I-cell_type
, O
whereas O
the O
weak O
cyclo-oxygenase O
inhibitor O
salicylic O
acid O
was O
at O
least O
as O
effective O
as O
ASA O
in O
inhibiting O
IL-4 B-protein
expression O
and O
promoter I-DNA
activity O
. O
The O
inhibitory O
effect O
of O
ASA B-cell_type
on O
IL-4 B-protein
transcription O
was O
not O
mediated O
by O
decreased O
nuclear B-protein
expression O
of O
the O
known O
salicylate O
target I-cell_line
nuclear B-protein
factor I-protein
( O
NF I-DNA
) O
-kappaB O
and O
was O
accompanied O
by O
reduced O
binding O
of O
an O
inducible B-protein
factor I-protein
to O
an O
IL-4 B-DNA
promoter I-DNA
region O
upstream O
of O
, O
but O
not O
overlapping O
, O
the O
NF I-DNA
of O
activated B-cell_type
T I-cell_line
cells- B-DNA
and O
NF-kappaB-binding O
P1 B-protein
element I-DNA
. O
It O
is O
concluded O
that O
anti-inflammatory B-DNA
salicylates O
, O
by O
means O
of O
a O
previously O
unrecognized O
mechanism O
of O
action O
, O
can O
influence O
the O
nature O
of O
adaptive O
immune O
responses O
by O
selectively O
inhibiting O
the O
expression O
of O
IL-4 B-protein
, O
a O
critical O
effector O
of O
these O
responses O
, O
in O
CD4+ B-cell_type
T B-cell_type
cells I-cell_type
. O
Molecular O
and O
cellular O
mediators O
of O
interleukin-1 B-protein
-dependent O
acute O
inflammatory O
arthritis O
. O
OBJECTIVE O
: O
To O
examine O
the O
molecular O
and O
cellular O
mechanisms O
in O
a O
model O
of O
acute O
inflammatory O
monarticular O
arthritis O
induced O
by O
methylated O
bovine O
serum O
albumin O
( O
mBSA I-DNA
) O
and O
interleukin-1 B-protein
( O
IL-1 B-protein
) O
. O
METHODS I-protein
: O
Mice O
were O
injected O
intraarticularly O
with O
mBSA I-RNA
on O
day O
0 O
and O
subcutaneously O
with O
recombinant O
human B-DNA
IL-1beta I-cell_type
on O
days O
0-2 O
. O
At O
day O
7 O
, O
knee O
joints O
were O
removed O
and O
assessed O
histologically O
. O
Flow O
cytometry O
and O
RNase O
protection O
were O
used O
to O
analyze O
IL-1 B-protein
-dependent O
events O
. O
RESULTS I-protein
: O
C57BL/6 I-protein
( O
B6 B-protein
) O
, O
129/Sv I-cell_line
, O
and O
( O
B6 B-protein
x O
129/ O
Sv O
) O
F1 B-protein
hybrid O
mice O
, O
all O
H-2b B-protein
strains O
, O
were O
susceptible O
to O
mBSA O
/IL-1-induced B-protein
arthritis O
, O
whereas O
C3H/HeJ I-cell_line
( O
H-2k B-protein
) O
mice O
were O
not O
. O
B6 B-protein
mice O
lacking O
T I-cell_line
and O
B I-DNA
cells I-cell_line
( O
RAG1-/- B-protein
) O
or O
major O
histocompatibility I-protein
complex I-protein
( O
MHC I-DNA
) O
class O
II I-protein
antigens I-protein
( O
MHCII-/- I-DNA
) O
, O
and O
B6 B-protein
mice O
treated O
with O
a O
CD4+ B-cell_type
T I-cell_line
cell-depleting O
monoclonal O
antibody O
, O
were O
resistant O
to O
disease O
. O
In O
contrast O
, O
B I-DNA
cell-deficient I-DNA
( O
muMT/ I-DNA
muMT I-DNA
) O
mice O
developed O
arthritis O
at O
an O
incidence O
and O
severity O
similar O
to O
that O
of O
controls O
. O
RelB-deficient B-protein
( O
RelB-/- I-DNA
) O
bone O
marrow I-cell_line
chimeric O
mice O
had O
arthritis O
that O
was O
significantly O
reduced O
in O
incidence O
and O
severity O
. O
In O
B6 B-protein
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL-1-dependent B-DNA
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger O
RNA I-protein
( O
mRNA I-DNA
) O
for O
the O
chemokines O
monocyte O
chemoattractant O
protein O
1 O
, O
macrophage O
inhibitory O
protein O
2 O
( O
MIP-2 O
) O
, O
RANTES I-protein
, O
MIP-1alpha O
, O
and O
MIP-1beta I-DNA
, O
in O
vivo O
and O
in O
vitro O
. O
CONCLUSION I-protein
: O
Arthritis O
induced O
by O
mBSA I-RNA
/ O
IL-1 B-protein
is O
strain O
specific O
and O
dependent O
on O
CD4+ B-cell_type
T I-cell_type
lymphocytes I-cell_type
and O
at O
least O
partially O
on O
RelB I-protein
, O
but O
not O
on O
B I-DNA
lymphocytes I-cell_type
or O
antibody O
. O
IL-1 B-protein
contributes O
to O
leukocyte O
recruitment O
to O
the O
synovium O
and O
directly O
induces O
chemokine O
mRNA I-RNA
production O
by O
synovial B-cell_type
cells I-cell_type
. O
This O
model O
of O
acute O
monarticular O
arthritis O
is O
particularly O
suitable O
for O
further O
investigations O
into O
cell-mediated I-DNA
immunity O
in O
arthritis O
and O
the O
role O
of O
IL-1 B-protein
. O
Positive O
and O
negative O
regulation O
of O
granulopoiesis O
by O
endogenous O
RARalpha O
. O
Acute O
promyelocytic O
leukemia O
( O
APL I-DNA
) O
is O
always O
associated O
with O
chromosomal O
translocations O
that O
disrupt O
the O
retinoic O
acid I-DNA
receptor I-DNA
alpha I-DNA
( O
RARalpha I-DNA
) O
gene I-DNA
. O
Whether O
these O
translocations O
relate O
to O
a O
role O
for O
endogenous O
RARalpha O
in O
normal O
granulopoiesis O
remains O
uncertain O
because O
most O
studies O
addressing O
this O
question O
have O
used O
non-physiological B-DNA
overexpression O
systems O
. O
Granulocyte O
differentiation O
in O
cells I-cell_type
derived O
from O
RARalpha-deficient O
( O
RARalpha I-DNA
( O
-/- O
) O
) O
mice O
was O
studied O
and O
evaluated O
in O
the O
context O
of O
agonist-bound O
and O
ligand-free O
RARalpha O
. O
Our O
results O
demonstrate O
that O
RARalpha O
is O
dispensable O
for O
granulopoiesis O
, O
as O
RARalpha I-cell_line
( O
-/- O
) O
mice O
have O
a O
normal O
granulocyte O
population O
despite O
an O
impaired O
ability O
to O
respond O
to O
retinoids O
. O
However O
, O
although O
it O
is O
not O
absolutely O
required O
, O
RARalpha O
can O
bidirectionally O
modulate O
granulopoiesis O
. O
RARalpha O
stimulates O
differentiation O
in O
response O
to O
exogenous O
retinoic O
acid O
. O
Furthermore O
, O
endogenous O
retinoids O
control O
granulopoiesis O
in O
vivo O
, O
as O
either O
vitamin O
A-deficient B-protein
mice O
or O
animals O
treated O
with O
an O
RAR O
antagonist O
accumulate O
more O
immature O
granulocytes O
in O
their O
bone I-cell_line
marrow I-cell_line
. O
Conversely O
, O
RARalpha O
acts O
to O
limit O
differentiation O
in O
the O
absence O
of O
ligand O
because O
granulocyte O
precursors I-cell_line
from O
RARalpha I-cell_line
( O
-/- O
) O
mice O
differentiate O
earlier O
in O
culture O
. O
Thus O
, O
the O
block O
in O
granulopoiesis O
exerted O
by O
RARalpha O
fusion O
proteins I-protein
expressed O
in O
APL B-cell_type
cells I-cell_type
may O
correspond O
to O
an O
amplification O
of O
a O
normal O
function O
of O
unliganded O
RARalpha O
. O
Expression O
and O
function O
of O
a O
stem O
cell O
promoter I-DNA
for O
the O
murine I-cell_line
CBFalpha2 B-DNA
gene I-DNA
: O
distinct O
roles O
and O
regulation O
in O
natural O
killer O
and O
T O
cell O
development O
. O
The O
Runt O
family O
transcription B-protein
factor I-protein
CBFalpha2 B-protein
( O
AML1 I-DNA
, O
PEBP2alphaB O
, O
or O
Runx1 B-protein
) O
is O
required O
by O
hematopoietic B-cell_type
stem I-cell_type
cells I-cell_type
and O
expressed O
at O
high O
levels O
in O
T-lineage B-protein
cells I-cell_type
. O
In O
human B-cell_type
T I-cell_type
cells I-cell_type
CBFalpha2 O
is O
usually O
transcribed O
from O
a O
different O
promoter I-DNA
( O
distal O
promoter I-DNA
) O
than O
in O
myeloid B-cell_type
cells I-cell_line
( O
proximal O
promoter I-DNA
) O
, O
but O
the O
developmental O
and O
functional O
significance O
of O
this O
promoter I-DNA
switch O
has O
not O
been O
known O
. O
Here O
, O
we O
report O
that O
both O
coding O
and O
noncoding O
sequences O
of O
the O
distal O
5 O
' O
end O
are O
highly O
conserved O
between O
the O
human B-DNA
and I-DNA
the O
murine I-cell_line
genes I-DNA
, O
and O
the O
distal O
promoter I-DNA
is O
responsible O
for O
the O
overwhelming O
majority O
of O
CBFalpha2 B-cell_type
expression O
in O
murine I-cell_line
hematopoietic B-cell_type
stem I-cell_type
cells I-cell_type
as O
well O
as O
in O
T B-cell_type
cells I-cell_type
. O
Distal O
promoter I-DNA
activity O
is O
maintained O
throughout O
T O
cell O
development O
and O
at O
lower O
levels O
in O
B O
cell O
development O
, O
but O
downregulated O
in O
natural O
killer O
cell O
development O
. O
The O
distal O
N-terminal B-protein
isoform O
binds O
to O
functionally O
important O
regulatory I-DNA
sites I-DNA
from O
known O
target I-cell_line
genes I-DNA
with O
two- O
to O
threefold O
higher O
affinity O
than O
the O
proximal O
N-terminal B-protein
isoform O
. O
Neither O
full-length O
isoform O
alters O
growth O
of O
a O
myeloid O
cell O
line O
under O
nondifferentiating O
conditions O
, O
but O
the O
proximal O
isoform O
selectively O
delays O
mitotic O
arrest O
of O
the O
cell O
line O
under O
differentiating O
conditions O
, O
resulting O
in O
the O
generation O
of O
greater O
numbers O
of O
neutrophils O
. O
Constitutive O
PI3-K B-protein
activity O
is O
essential O
for O
proliferation O
, O
but O
not O
survival O
, O
of O
Theileria O
parva-transformed B-DNA
B I-DNA
cells I-cell_type
. O
Theileria O
is O
an O
intracellular O
parasite O
that O
causes O
lymphoproliferative O
disorders O
in O
cattle I-protein
, O
and O
infection O
of O
leucocytes O
induces O
a O
transformed O
phenotype O
similar O
to O
tumour B-cell_type
cells I-cell_line
, O
but O
the O
mechanisms O
by O
which O
the O
parasite O
induces O
this O
phenotype O
are O
not O
understood O
. O
Here O
, O
we O
show O
that O
infected O
B I-DNA
lymphocytes I-cell_type
display O
constitutive O
phosphoinositide O
3-kinase B-protein
( O
PI3-K B-protein
) O
activity O
, O
which O
appears O
to O
be O
necessary O
for O
proliferation O
, O
but O
not O
survival O
. O
Importantly O
, O
we O
demonstrate O
that O
one O
mechanism O
by O
which O
PI3-K B-protein
mediates O
the O
proliferation O
of O
infected O
B I-DNA
lymphocytes I-cell_type
is O
through O
the O
induction O
of O
a O
granulocyte-monocyte B-DNA
colony-stimulating B-protein
factor I-protein
( O
GM-CSF B-protein
) O
-dependent O
autocrine O
loop O
. O
PI3-K B-protein
induction O
of O
GM-CSF B-protein
appears O
to O
be O
at O
the O
transcriptional O
level O
and I-DNA
, O
consistently O
, O
we O
demonstrate O
that O
PI3-K B-protein
is O
also O
involved O
in O
the O
constitutive O
induction O
of O
AP-1 B-protein
and O
NF-kappaB I-DNA
, O
which O
characterizes O
Theileria-infected O
leucocytes O
. O
Taken O
together O
, O
our O
results O
highlight O
a O
novel O
strategy O
exploited O
by O
the O
intracellular O
parasite O
Theileria O
to O
induce O
continued O
proliferation O
of O
its O
host O
leucocyte O
. O
Lymphokine O
dependence O
of O
STAT3 B-protein
activation O
produced O
by O
surface I-protein
immunoglobulin O
cross-linking O
and O
by O
phorbol O
ester O
plus O
calcium O
ionophore O
treatment O
in O
B I-DNA
cells I-cell_type
. O
Stimulation O
of O
B I-DNA
cells I-cell_type
by O
surface I-protein
immunoglobulin O
( O
sIg B-protein
) O
triggering O
, O
or O
through O
the O
mitogenic O
combination O
of O
phorbol O
ester O
and O
calcium O
ionophore O
, O
is O
accompanied O
by O
activation O
of O
STAT B-protein
transcription B-protein
factors I-protein
. O
The O
mechanism O
responsible O
for O
the O
delayed O
nuclear B-protein
accumulation O
of O
phosphorylated O
STAT3 B-protein
was O
examined O
in O
detail I-protein
, O
focusing O
on O
the O
role O
of O
B I-DNA
cell-derived I-DNA
lymphokines O
. O
sIg I-protein
-induced O
activation O
of O
STAT3 B-protein
was O
partially O
inhibited O
in O
B I-DNA
cells I-cell_type
obtained O
from O
IL-6- B-protein
or O
IL-10-deficient B-protein
mice O
, O
and O
was O
partially O
blocked O
by O
neutralizing B-protein
antibodies I-protein
directed O
against O
either O
of O
these O
lymphokines O
. O
sIg I-protein
-induced O
STAT3 B-protein
activation O
was O
completely O
inhibited O
by O
combining O
IL-6- B-DNA
and O
IL-10-specific B-protein
neutralizing B-protein
antibodies I-protein
, O
or O
by O
adding O
individual O
neutralizing B-protein
antibodies I-protein
to O
B I-DNA
cells I-cell_type
obtained O
from O
lymphokine-deficient B-DNA
animals O
. O
In O
contrast O
, O
IL-10 B-protein
alone O
appeared O
to O
account O
for O
STAT3 B-protein
activation O
resulting O
from O
B O
cell O
stimulation O
with O
phorbol O
ester O
and O
calcium O
ionophore O
. O
In O
keeping O
with O
these O
results O
, O
soluble O
IL-6 B-protein
and O
IL-10 B-protein
were O
found O
in O
supernatant O
fluid O
obtained O
from O
stimulated O
B I-DNA
cells I-cell_type
. O
This O
work O
indicates O
that O
a O
lymphokine O
pathway O
is O
responsible O
for O
STAT3 B-protein
activation O
that O
occurs O
late O
after O
B O
cell O
stimulation O
, O
and O
points O
out O
differences O
in O
B O
cell O
activation O
that O
result O
from O
stimulation O
through O
the O
antigen I-DNA
receptor I-protein
and O
through O
pharmacological O
mimicry O
of O
signaling O
mediators O
. O
Transcription B-protein
factor I-protein
AP-4 B-protein
is O
a O
ligand O
for O
immunoglobulin-kappa B-DNA
promoter I-DNA
E-box B-DNA
elements I-DNA
. O
Immunoglobulin O
( O
Ig O
) O
-kappa O
promoters O
from O
humans O
and O
mice O
share O
conserved O
sequences O
. O
The O
octamer O
element I-DNA
is O
common O
to O
all O
Ig O
promoters O
and O
pivotal O
for O
their O
function O
. O
However O
, O
other O
conserved O
sequence O
motifs O
, O
that O
differ O
between O
Ig O
variable B-DNA
gene I-DNA
families O
, O
are O
required O
for O
normal O
promoter I-DNA
function O
. O
These O
conserved O
motifs O
do O
not O
stimulate O
transcription O
in O
the O
absence O
of O
an O
octamer O
. O
One O
example O
is O
an O
E-box I-DNA
of O
the O
E47/E12 I-DNA
type O
( O
5'-CAGCTG-3 B-protein
' O
) O
, O
which O
is O
found O
in O
all O
promoters O
of O
the O
human B-DNA
and I-DNA
murine I-cell_line
Ig-kappa B-DNA
gene I-DNA
subgroups/families I-protein
, O
with O
the O
exception O
of O
subgroups O
II I-protein
and O
VI O
and O
their O
related O
murine I-cell_line
families O
. O
In O
the O
present O
study O
we O
show O
that O
the O
ubiquitously O
expressed O
transcription B-protein
factor I-protein
AP-4 B-protein
, O
and O
not O
E47 I-protein
, O
interacts O
specifically O
with O
the O
kappa B-DNA
promoter I-DNA
E-boxes O
when O
tested O
in O
electrophoretic O
mobility-shift O
assays O
using O
nuclear B-protein
extracts O
derived O
from O
human B-DNA
and I-DNA
murine I-cell_line
B-cell B-cell_line
lines I-cell_line
. O
Furthermore O
, O
AP-4 B-protein
, O
unlike O
E47 I-protein
, O
did O
not O
act O
as O
a O
transactivator O
, O
which O
is O
in O
agreement O
with O
previous O
studies O
on O
intact O
kappa B-DNA
promoters O
, O
showing O
that O
transcription O
is O
absent O
when O
the O
octamer O
element I-DNA
has O
been O
mutated O
. O
Based O
on O
these O
data O
, O
and O
the O
conservation O
of O
the O
5'-CAGCTG-3 B-protein
' O
motif O
among O
human B-DNA
and I-DNA
murine I-cell_line
kappa B-DNA
promoters O
, O
we O
propose O
that O
AP-4 B-protein
is O
the O
major O
ligand O
for O
Ig-kappa B-DNA
promoter I-DNA
E-boxes O
. O
A O
16-mer O
peptide O
( O
RQIKIWFQNRRMKWKK I-DNA
) O
from O
antennapedia O
preferentially O
targets I-cell_line
the O
Class O
I I-protein
pathway O
. O
Translocation I-DNA
of O
antigenic O
peptides O
into O
the O
cytosol O
of O
antigen I-protein
presenting B-cell_type
cells I-cell_type
facilitates O
proteosomal O
processing O
and O
loading O
into O
Class O
I I-protein
molecules I-protein
for O
MHC I-protein
presentation O
on O
the O
cell O
surface I-protein
. O
The O
DNA O
binding O
domain I-protein
of O
the O
Drosophila O
transcription B-protein
factor I-protein
( O
Antennapedia I-DNA
) O
, O
a O
60 O
amino O
acid O
protein I-protein
, O
is O
rapidly O
taken O
up O
by O
cells I-cell_type
and O
has O
been O
fused O
to O
selected O
antigens O
to O
enhance O
their O
immunogenicity O
. O
We O
now O
demonstrate O
that O
a O
16 O
amino O
acid O
peptide O
from O
antennapedia O
can O
facilitate O
the O
cytoplasmic O
uptake O
of O
CTL B-cell_type
epitope O
9-mer B-DNA
peptides O
. O
Synthetic O
peptides O
were O
made O
containing O
the O
16-mer B-protein
antennapedia O
peptide O
linked O
in O
tandem O
to O
the O
ovalbumin O
SIINFEKL O
CTL O
peptide O
. O
The O
peptide O
complex I-protein
was O
shown O
to O
rapidly O
internalise O
into O
APCs O
by O
confocal O
microscopy O
. O
This O
peptide O
induced O
CTL O
in O
C57BL/6 B-protein
mice O
and O
protected O
them O
against O
growth O
of O
an O
ovalbumin O
expressing O
tumour O
cell O
line O
( O
E.G7-OVA B-protein
) O
. O
The O
ability O
of O
the O
hybrid O
peptide O
to O
be O
processed O
and O
presented O
by O
APCs O
was O
similar O
, O
whether O
the O
SIINFEKL O
sequence O
was O
appended O
at O
the O
C-terminus B-protein
or O
N-terminus B-protein
of O
the O
Antennapedia O
peptide O
. O
The O
production O
of O
synthetic O
peptides O
containing O
other O
CTL O
peptide O
epitopes I-protein
may O
be O
useful O
for O
priming O
CTLs O
in O
vitro O
and O
in O
vivo O
Bone O
marrow I-cell_line
cells I-cell_type
promote O
TH2 B-protein
polarization O
and O
inhibit O
virus-specific O
CTL O
generation O
. O
This O
laboratory O
recently O
reported O
that O
human B-DNA
bone I-cell_line
marrow I-cell_line
cells I-cell_line
( O
BMC I-DNA
) O
inhibit O
the O
generation O
of O
virus-specific O
CTL O
in O
culture O
. O
The O
culture O
supernatants O
contained O
increased O
levels O
of O
prostaglandin O
E O
( O
2 O
) O
( O
PGE O
( O
2 O
) O
) O
( O
shown O
to O
favor O
TH2 B-protein
cell O
development O
) O
and O
also O
inhibited O
EBV-CTL B-protein
effector O
cell O
development O
. O
In O
this O
study O
, O
we O
obtained O
PBL O
from O
Epstein-Barr O
virus O
( O
EBV I-DNA
) O
IgG O
antibody O
positive O
kidney O
transplant O
recipients O
( O
R I-DNA
) O
and O
their O
living-related I-cell_type
donors O
( O
LRD I-DNA
) O
one O
year O
after O
renal O
transplantation O
. O
EBV-specific B-protein
CTL O
were O
then O
generated O
in O
vitro O
by O
stimulating O
PBL O
with O
autologous O
EBV-transformed B-protein
B I-DNA
cells I-cell_line
( O
EBV-B B-protein
) O
in O
the O
presence O
or O
absence O
of O
autologous O
BMC O
. O
The O
addition O
of O
BMC O
to O
the O
EBV-CTL B-protein
generation O
cultures I-cell_line
increased O
the O
intracellular O
expression O
in O
CD3+ B-cell_type
cells I-cell_type
of O
IL-4 B-protein
, O
-5 O
, O
-6 O
, O
-10 O
, O
and O
-13 B-protein
. O
These O
CD3+ B-cell_type
cells I-cell_type
also O
expressed O
increased O
levels O
of O
the O
TH2 B-protein
associated I-DNA
receptor I-protein
CCR3 O
. O
Inhibition O
was O
even O
observed O
by O
preparing O
EBV-CTL B-protein
generating O
cultures I-cell_line
in O
trans-wells O
that O
separated O
the O
autologous O
BMC O
from O
the O
PBL O
+ O
EBV-B B-protein
. O
It O
was O
then O
observed O
that O
CD3+ B-cell_type
cells I-cell_type
obtained O
after O
7 O
days O
of O
culture O
in O
the O
presence O
of O
autologous O
BMC O
could O
be O
used O
as O
inhibitors O
of O
EBV-CTL B-protein
generation O
. O
Protein O
Kinase O
A O
( O
PKA I-DNA
) O
, O
a O
cAMP I-RNA
kinase I-protein
that O
is O
involved O
in O
the O
upregulation O
of O
TH2 B-protein
cytokine O
activity O
, O
was O
increased O
in O
EBV-CTL B-protein
cultures I-cell_line
by O
the O
presence O
of O
BMC B-cell_type
. O
Additionally I-protein
, O
IL-4-mediated O
signal O
transduction O
and O
activation O
of O
transcription O
( O
STAT-6 B-protein
) O
phosphorylation O
was O
slightly O
increased O
. O
These O
results O
show O
that O
the O
BMC O
inhibition O
is O
mediated O
by O
soluble B-protein
factors I-protein
( O
cytokines O
) O
and O
that O
cell-cell B-DNA
contact O
in O
this O
autologous O
system O
is O
not O
required O
, O
so O
that O
BMC I-protein
( O
at O
least O
partially O
, O
via O
cytokine O
production O
) O
promote O
TH2 B-protein
polarization O
in O
culture O
. O
Moreover O
, O
TH2 B-protein
cells I-cell_type
induced O
by O
culturing O
with O
autologous O
BMC O
directly O
inhibit O
EBV-CTL B-protein
generation O
, O
and O
TH2 B-protein
associated O
PKA I-protein
, O
CCR3 I-protein
, O
and O
STAT-6 B-protein
phosphorylation O
are O
enhanced O
by O
BMC O
. O
Reduction O
in O
DNA O
binding O
activity O
of O
the O
transcription B-protein
factor I-protein
Pax-5a B-protein
in O
B I-DNA
lymphocytes I-cell_type
of O
aged O
mice O
. O
Aging O
has O
been O
associated O
with O
intrinsic O
changes O
of O
the O
humoral O
immune O
response O
, O
which O
may O
lead O
to O
an O
increased O
occurrence O
of O
autoimmune O
disorders O
and O
pathogenic O
susceptibility O
. O
The O
transcription B-protein
factor I-protein
Pax-5 B-protein
is O
a O
key O
regulator O
of O
B O
cell O
development O
. O
Pax-5a/B B-protein
cell-specific I-DNA
activator O
protein O
and O
an O
alternatively O
spliced O
isoform O
, O
Pax-5d O
, O
may O
have O
opposing O
functions O
in O
transcriptional O
regulation O
due O
to O
the O
lack O
of O
a O
transactivation I-protein
domain I-protein
in O
Pax-5d B-protein
. O
To O
study O
B O
cell O
-specific O
changes O
that O
occur O
during O
the O
aging O
process O
, O
we O
investigated O
expression O
patterns O
of O
Pax-5a O
and O
5d O
in O
mature O
B I-DNA
cells I-DNA
of O
young O
and O
aged O
mice O
. O
RNase O
protection O
assays O
showed O
a O
similar O
transcriptional O
pattern O
for O
both O
age O
groups O
that O
indicates O
that O
aging O
has O
no O
affect O
on O
transcription O
initiation O
or O
alternative O
splicing O
for O
either O
isoform O
. O
In O
contrast O
, O
a O
significant O
reduction O
in O
the O
DNA O
binding O
activity O
of O
Pax-5a B-protein
but O
not O
Pax-5d B-protein
protein O
was O
observed O
in O
aged O
B I-DNA
cells I-cell_type
in O
vitro O
, O
while O
Western O
blot O
analyses O
showed O
that O
similar O
levels O
of O
Pax-5a O
and O
5d B-protein
proteins I-protein
were O
present O
in O
both O
age O
groups O
. O
The O
observed O
decrease O
in O
Pax-5a O
binding O
activity O
correlated O
with O
changes O
in O
expression O
of O
two O
Pax-5 B-protein
target I-cell_line
genes I-DNA
in O
aged O
B I-DNA
cells I-cell_type
. O
Expression O
of O
the O
Ig O
J O
chain O
and O
the O
secreted O
form O
of O
Ig O
mu O
, O
which O
are O
both O
known O
to O
be O
suppressed O
by O
Pax-5a B-protein
in O
mature O
B I-DNA
cells I-cell_line
, O
were O
increased O
in O
B I-DNA
cells I-DNA
of O
aged O
mice O
. O
Together O
, O
our O
studies O
suggest O
that O
changes O
associated O
with O
the O
aging O
phenotype O
cause O
posttranslational O
modification O
( O
s O
) O
of O
Pax-5a B-protein
but O
not O
Pax-5d I-cell_line
, O
which O
may O
lead O
to O
an O
abnormal O
B O
cell O
phenotype O
in O
aged O
mice O
, O
associated O
with O
elevated O
levels O
of O
J O
chain O
, O
and O
secretion O
of O
IgM B-cell_type
NF-kappa B-protein
B/Rel I-protein
participation O
in O
the O
lymphokine-dependent B-DNA
proliferation O
of O
T I-cell_line
lymphoid B-cell_type
cells I-cell_type
. O
Proliferative B-cell_type
responses O
of O
lymphoid B-cell_type
cells O
to O
IL-2 B-protein
and O
IL-4 B-protein
depend O
on O
activation O
of O
the B-cell_type
cells I-cell_line
, O
but O
the O
mechanism O
( O
s O
) O
by O
which O
activation O
enhances O
cellular O
competence O
to O
respond O
to O
cytokines O
is O
not O
fully O
understood O
. O
The O
NF-kappaB/Rel B-protein
family O
represents O
one O
signal O
transduction O
pathway O
induced O
during O
such O
activation O
. O
We O
show O
in O
this O
study O
that O
inhibition O
of O
NF-kappaB O
through O
the O
expression O
of O
an O
IkappaBalpha I-cell_line
( O
inhibitory O
protein O
that O
dissociates O
from O
NF-kappaB B-protein
) O
mutant O
refractory O
to O
signal-induced O
degradation O
( O
IkappaBalpha I-DNA
( O
DeltaN I-DNA
) O
) O
interfered O
with O
the O
acquisition O
of O
competence O
to O
proliferate O
in O
response O
to O
IL-4 B-protein
as O
well O
as O
IL-2 B-protein
. O
Thymocytes O
and O
T B-cell_type
cells I-cell_type
from O
IkappaBalpha I-cell_line
( O
DeltaN I-DNA
) O
transgenic O
mice O
expressed O
normal O
levels O
of O
IL-2R B-RNA
subunits I-protein
. O
However O
, O
transgenic B-cell_type
cells I-cell_type
exhibited O
a O
dramatic O
defect O
in O
Stat5A B-protein
activation O
treatment O
with O
IL-2 B-protein
, O
and O
a O
similar O
defect O
was O
observed O
for O
IL-4 B-protein
-induced O
Stat5 O
. O
In O
contrast O
, O
T I-cell_line
lymphoid B-cell_type
cells I-cell_type
with O
inhibition O
of O
NF-kappaB O
showed O
normal O
insulin I-DNA
receptor I-protein
substrate-2 O
phosphorylation O
and O
only O
a O
modest O
decrease O
in O
Stat6 O
activation O
and O
insulin I-DNA
receptor I-protein
substrate-1 O
phosphorylation O
after O
IL-4 B-protein
stimulation O
. O
These O
results O
indicate O
that O
the O
NF-kappaB/Rel/IkappaBalpha B-protein
system O
can O
regulate O
cytokine I-DNA
receptor I-protein
capacitation O
through O
effects O
on O
the O
induction O
of O
downstream O
signaling O
by O
the O
Stat O
transcription B-protein
factor I-protein
family O
. O
BMS-189453 B-protein
, O
a O
novel O
retinoid I-DNA
receptor I-protein
antagonist O
, O
is O
a O
potent O
testicular O
toxin O
. O
BMS-189453 B-protein
is O
a O
synthetic O
retinoid O
that O
acts O
as O
an O
antagonist O
at O
retinoic O
acid O
receptors O
alpha I-DNA
, O
beta O
, O
and O
gamma O
. O
In O
Sprague O
Dawley O
rats O
at O
daily O
oral O
doses O
of O
15 O
, O
60 O
, O
or O
240 O
mg/kg B-DNA
for O
1 O
month O
, O
BMS-189453 B-protein
produced O
increases O
in O
leukocyte O
counts O
, O
alkaline O
phosphatase O
and O
alanine O
aminotransferase O
levels O
, O
and O
marked O
testicular O
degeneration O
and O
atrophy O
at O
all O
doses O
. O
Significant O
overt O
signs O
of O
toxicity O
and O
deaths O
occurred O
at O
240 O
mg/kg I-DNA
, O
whereas O
body-weight B-DNA
and O
food-consumption O
decreases O
occurred O
at O
60 O
and O
240 O
mg/kg B-DNA
. O
When O
BMS-189453 B-protein
was O
administered O
to O
male O
rats O
at O
daily O
doses O
ranging O
from O
12.5 I-protein
to O
100 O
mg/kg B-DNA
for O
1 O
week O
, O
only O
minimal O
testicular O
changes O
occurred O
at O
all O
doses O
, O
shortly O
after O
the O
dosing O
period O
. O
However O
, O
after O
a O
1-month O
drug-free B-DNA
observation O
period I-protein
, O
marked O
testicular O
atrophy O
was O
evident O
at O
all O
doses O
. O
BMS-189453 B-protein
was O
then O
administered O
at O
doses O
of O
2 O
, O
10 O
, O
or O
50 O
mg/kg O
to O
male O
rats O
for O
1 O
, O
3 O
, O
or O
7 O
consecutive O
days O
. O
Dose- B-DNA
and O
duration-dependent O
testicular O
toxicity O
that O
occurred O
after O
a O
1-month O
observation O
period O
did O
not O
recover O
, O
and O
, O
in O
some O
cases O
, O
was O
more O
severe O
4 O
months O
after O
the O
last O
dose O
. O
In O
rabbits O
administered O
BMS-189453 B-protein
at O
oral O
doses O
of O
2 O
, O
10 O
, O
or O
50 O
mg/kg B-DNA
for O
1 O
week O
, O
testicular O
degeneration O
and O
atrophy O
were O
evident O
in O
the O
high-dose B-DNA
group O
at O
1 O
month O
following O
treatment O
. O
These O
studies O
indicate O
that O
retinoid O
antagonists O
can O
selectively O
produce O
progressive O
and O
prolonged O
testicular O
toxicity O
after O
single O
or O
repeated O
oral O
doses O
that O
are O
otherwise O
well O
tolerated O
. O
Sequential O
involvement O
of O
NFAT O
and O
Egr B-protein
transcription B-protein
factors I-protein
in O
FasL O
regulation O
. O
The O
critical O
function O
of O
NFAT B-protein
proteins I-protein
in O
maintaining O
lymphoid O
homeostasis O
was O
revealed O
in O
mice O
lacking O
both O
NFATp O
and O
NFAT4 B-protein
( O
DKO I-DNA
) O
. O
DKO O
mice O
exhibit O
increased O
lymphoproliferation I-protein
, O
decreased O
activation-induced O
cell O
death O
, O
and O
impaired O
induction O
of O
FasL B-RNA
. O
The O
transcription B-protein
factors I-protein
Egr2 O
and O
Egr3 O
are O
potent O
activators O
of O
FasL B-RNA
expression O
. O
Here O
we O
find O
that O
Egr2 O
and O
Egr3 O
are O
NFAT O
target I-cell_line
genes I-DNA
. O
Activation O
of O
FasL B-RNA
occurs O
via O
the O
NFAT O
-dependent O
induction O
of O
Egr3 B-cell_type
, O
as O
demonstrated O
by O
the O
ability O
of O
exogenously O
provided O
NFATp O
to O
restore O
Egr O
-dependent O
FasL B-DNA
promoter I-DNA
activity O
in O
DKO O
lymph O
node B-cell_type
cells I-cell_type
. O
Further O
, O
Egr3 O
expression O
is O
enriched O
in O
Th1 B-cell_type
cells I-cell_line
, O
suggesting O
a O
molecular O
basis O
for O
the O
known O
preferential O
expression O
of O
FasL B-RNA
in O
the O
Th1 O
versus O
Th2 O
subset O
. O
Mechanisms O
and O
clinical O
relevance O
of O
nongenomic O
glucocorticoid O
actions O
. O
Glucocorticoids O
have O
profound O
anti-inflammatory B-DNA
and O
immunosuppressive O
actions O
when O
used O
therapeutically O
. O
The O
therapeutic O
dose O
is O
quite O
variable O
and O
depends O
on O
the O
disease O
, O
but O
ranges O
from O
very O
low O
to O
extremely O
high O
. O
The O
rationale O
for O
the O
use O
of O
various O
dosage O
regimens O
for O
specific O
clinical O
indications O
is O
the O
existence O
of O
three O
distinct O
, O
therapeutically O
relevant O
effects O
: O
genomic O
, O
specific O
nongenomic O
and O
unspecific O
nongenomic O
. O
Genomic O
effects O
are O
mediated O
by O
cytosolic O
receptors O
that O
alter O
expression O
of O
specific O
genes I-DNA
. O
Specific O
nongenomic O
effects O
occur O
within O
a O
few O
minutes O
and O
are O
mediated O
by O
steroid-selective B-DNA
membrane O
receptors O
. O
Unspecific O
nongenomic O
effects O
occur O
within O
seconds O
, O
but O
only O
at O
high O
glucocorticoid O
dosages O
, O
and O
seem O
to O
result O
from O
direct O
interactions O
with O
biological O
membranes O
. O
For O
unspecific O
nongenomic O
effects O
, O
methylprednisolone O
and O
other O
glucocorticoids O
have O
been O
shown O
to O
inhibit O
cation O
cycling O
across O
the O
plasma O
membrane O
, O
but O
to O
have O
little O
effect O
on O
protein O
synthesis O
. O
Thus O
, O
glucocorticoids O
could O
diminish O
or O
prevent O
the O
acute O
immune O
response O
by O
interfering O
with O
processes O
such O
as O
the O
rise O
in O
intracellular O
Ca2+ O
concentration O
. O
It O
is O
proposed O
that O
the O
additional O
therapeutic O
benefit O
of O
higher O
doses O
is O
obtained O
via O
these O
nongenomic O
effects O
. O
High O
glucose-induced O
intercellular O
adhesion O
molecule-1 B-protein
( O
ICAM-1 B-protein
) O
expression O
through O
an O
osmotic O
effect O
in O
rat O
mesangial B-cell_type
cells I-cell_type
is O
PKC-NF-kappa B-protein
B-dependent B-protein
. O
AIMS/HYPOTHESIS B-protein
: O
Infiltration O
of O
mononuclear B-cell_type
cells I-cell_type
and O
glomerular O
enlargement O
accompanied O
by O
glomerular O
cell O
proliferation O
are O
very O
early O
characteristics O
of O
the O
pathophysiology O
of O
diabetes O
. O
To O
clarify O
the O
mechanism O
of O
early O
diabetic O
nephropathy O
, O
we O
measured O
[ O
3H B-protein
] O
-thymidine O
incorporation O
and O
cell O
numbers O
to O
show O
the O
influence O
of O
a O
high O
ambient O
glucose O
concentration O
and O
the O
osmotic O
effect O
on O
rat O
mesangial O
cell O
proliferation O
. O
We O
also O
measured O
the O
effect O
of O
high O
glucose O
on O
the O
expression O
of O
intercellular O
adhesion O
molecule-1 B-protein
and O
vascular O
adhesion O
molecule-1 B-protein
by O
flow O
cytometry O
and O
semiquantitative O
RT-PCR B-protein
in O
mesangial B-cell_type
cells I-cell_type
and O
the O
adhesion O
of O
leukocytes O
to O
mesangial B-cell_type
cells I-cell_type
. O
METHODS/RESULTS B-protein
: O
Cells O
exposed O
to O
high O
D-glucose B-protein
( O
30 O
mmol/l I-DNA
) O
caused O
an O
increase O
in O
[ O
3H B-protein
] O
-thymidine O
incorporation O
and O
cell O
numbers O
at O
24 O
and O
48 O
h O
and O
normalized O
at O
72 O
h O
( O
p O
< O
0.05 B-protein
) O
, O
whereas O
these O
changes O
were O
not O
found O
in O
high O
mannitol O
( O
30 O
mmol/l I-DNA
) O
, O
IL-1 B-protein
beta O
, O
or O
TNF I-DNA
alpha I-DNA
-stimulated I-RNA
mesangial B-cell_type
cells I-cell_type
. O
Cells O
exposed O
to O
high-glucose B-protein
( O
15 I-DNA
, O
30 O
, O
or O
60 O
mmol/l I-DNA
) O
or O
osmotic O
agents O
( O
L-glucose I-DNA
, O
raffinose O
and O
mannitol O
) O
showed O
that O
intercellular O
adhesion O
molecule-1 B-protein
expression O
began O
to O
increase O
after O
24 O
h O
, O
reached O
its O
maximum O
at O
24 O
and O
48 O
h O
and O
gradually O
decreased O
afterwards O
. O
The O
stimulatory O
effects O
of O
high O
glucose O
and O
high O
mannitol O
on O
mRNA I-RNA
expression O
were O
observed O
as O
early O
as O
6 O
h O
and O
reached O
its O
maximum O
at O
12 O
h O
. O
Up-regulation I-DNA
of O
ICAM-1 B-protein
protein O
and O
mRNA I-RNA
was O
also O
found O
in O
IL-1-beta B-DNA
and O
TNF-alpha B-protein
-stimulated O
mesangial B-cell_type
cells I-cell_type
. O
Neither O
vascular O
adhesion O
molecule-1 B-protein
protein O
nor O
mRNA I-RNA
expression O
was O
, O
however O
, O
affected O
by O
high O
glucose O
and O
high O
mannitol O
. O
Notably O
, O
the O
protein O
kinase I-protein
C I-protein
inhibitors O
calphostin O
C I-protein
and O
staurosporine O
reduced O
high O
glucose- B-DNA
or O
high O
mannitol-induced I-cell_line
intercellular O
adhesion O
molecule-1 I-RNA
mRNA I-RNA
expression O
and O
high O
glucose-induced O
proliferation O
. O
Furthermore O
, O
the O
NF-kappa B-protein
B I-protein
inhibitor O
N-tosyl-L-phenylalanine B-protein
chloromethyl O
ketone O
reduced O
high O
glucose- B-DNA
or O
high O
mannitol-induced I-cell_line
intercellular O
adhesion O
molecule-1 I-RNA
mRNA I-RNA
expression O
and O
high O
glucose-induced O
proliferation O
. O
Results O
showed O
that O
high O
glucose O
( O
15 I-DNA
, O
30 O
mmol/l I-DNA
) O
or O
high O
concentrations O
of O
osmotic O
agents O
remarkably O
increased O
the O
number O
of O
adherent O
leukocytes O
to O
mesangial B-cell_type
cells I-cell_line
( O
p O
< O
0.01 B-protein
) O
compared O
with O
control B-cell_type
cells I-cell_line
( O
5 O
mmol/l I-cell_line
D-glucose B-protein
) O
. O
Functional O
blocking O
of O
intercellular O
adhesion O
molecule-1 B-protein
on O
mesangial B-cell_type
cells I-cell_type
with O
rat O
intercellular O
adhesion O
molecule-1 B-protein
monoclonal O
antibody O
, O
calphostin O
C I-protein
, O
staurosporine O
, O
or O
N-tosyl-L-phenylalanine B-protein
chloromethyl O
ketone O
significantly O
inhibited O
high O
glucose- B-DNA
or O
high O
mannitol-induced I-cell_line
increase O
in O
leukocyte O
adhesion O
( O
p O
< O
< O
0.05 B-protein
) O
. O
CONCLUSION/INTERPRETATION B-protein
: O
These O
results O
suggest O
that O
high O
glucose O
can O
upregulate O
intercellular O
adhesion O
molecule-1 B-protein
protein O
and O
mRNA I-RNA
expression O
but O
not O
vascular O
adhesion O
molecule-1 B-protein
expression O
in O
mesangial B-cell_type
cells I-cell_type
and O
promote O
leukocyte O
adhesion O
through O
up-regulation I-DNA
of O
intercellular O
adhesion O
molecule-1 B-protein
through O
osmotic O
effect O
, O
possibly O
depending O
on O
the O
protein O
kinase I-protein
C I-protein
nuclear O
factor-kappa B-DNA
B I-DNA
( O
PKC O
- O
NF-kappa B-protein
B I-DNA
) O
pathway O
. O
High O
glucose O
itself O
can O
also O
promote O
mesangial O
cell O
proliferation O
through O
the O
PKC-NF-kappa B-DNA
B I-DNA
pathways O
. O
We O
conclude O
that O
hyperglycaemia O
in O
itself O
seems O
to O
be O
an O
important O
factor I-protein
in O
the O
development O
of O
early O
diabetic O
nephropathy O
. O
Combined O
corticosteroid/ B-DNA
granulocyte O
colony-stimulating B-protein
factor I-protein
( O
G-CSF B-protein
) O
therapy O
in O
the O
treatment O
of O
severe O
congenital O
neutropenia O
unresponsive O
to O
G-CSF B-protein
: O
Activated O
glucocorticoid O
receptors O
synergize O
with O
G-CSF B-protein
signals O
. O
More O
than O
90 O
% O
of O
patients O
with O
severe O
congenital O
neutropenia O
( O
SCN I-DNA
) O
respond O
to O
granulocyte O
colony-stimulating B-protein
factor I-protein
( O
G-CSF B-protein
) O
therapy O
. O
The O
basis O
for O
the O
refractory O
state O
in O
the O
remaining O
patients O
is O
unknown O
. O
To O
address O
this O
issue O
, O
we O
studied O
a O
child O
with O
SCN O
who O
was O
totally O
unresponsive O
to O
G-CSF B-protein
and O
had O
a O
novel O
point O
mutation O
in O
the O
extracellular I-protein
domain I-protein
of O
the O
G-CSF B-DNA
receptor I-protein
( O
GCSF-R B-protein
) O
. O
Marrow O
stromal O
support O
of O
granulopoiesis O
was O
evaluated O
by O
plating O
CD34 B-protein
( O
+ O
) O
cells I-cell_type
on O
preformed O
stromal O
layers O
. O
Nonadherent B-cell_type
cells I-cell_type
were O
harvested O
and O
assayed O
in O
clonogenic O
assays O
for O
granulocytic O
colony O
production O
. O
The O
in O
vitro O
effect O
of O
G-CSF B-protein
and O
corticosteroids O
on O
granulopoiesis O
was O
evaluated O
in O
clonogenic O
assays O
of O
marrow I-cell_line
mononuclear B-cell_type
cells I-cell_line
, O
by O
proliferation O
studies O
of O
the O
murine I-cell_line
myeloid O
cell O
line O
32D B-protein
expressing O
the O
patient O
's O
mutated O
G-CSFR I-protein
, O
and O
by O
measuring O
STAT5 B-protein
activation O
in O
nuclear B-protein
extracts O
from O
stimulated B-cell_type
cells I-cell_type
. O
Patient O
's O
stroma O
supported O
granulopoiesis O
derived O
from O
control O
marrow I-cell_line
CD34 B-protein
( O
+ O
) O
cells I-cell_type
in O
a O
normal O
manner O
. O
Normal O
stroma I-protein
, O
however O
, O
failed O
to O
induce O
granulopoiesis O
from O
patient O
's O
CD34 B-protein
( O
+ O
) O
cells I-cell_type
. O
Clonogenic O
assays O
of O
the O
patient O
's O
marrow I-cell_line
mononuclear B-cell_type
cells I-cell_type
incorporating O
either O
G-CSF B-protein
or O
hydrocortisone O
produced O
little O
neutrophil O
growth O
. O
In O
contrast O
, O
inclusion O
of O
both O
G-CSF B-protein
and O
hydrocortisone O
in O
the O
cytokine O
`` O
cocktail O
'' O
markedly O
increased O
the O
neutrophil O
numbers O
. O
Proliferation I-DNA
of O
32D B-cell_type
cells I-cell_type
expressing O
the O
mutated I-DNA
receptor I-protein
and O
STAT5 B-protein
activation O
were O
improved O
by O
a O
combination O
of O
G-CSF B-protein
and O
dexamethasone O
. O
When O
small O
daily O
doses O
of O
oral O
prednisone O
were O
then O
administered O
to O
the O
patient O
with O
conventional O
doses O
of O
subcutaneous O
G-CSF I-DNA
, O
the O
patient O
responded O
with O
increased O
neutrophil O
numbers O
and O
with O
a O
complete O
reversal O
of O
the O
infectious O
problems O
. O
These O
data O
provide O
insight O
into O
SCN O
unresponsive O
to O
standard O
G-CSF B-protein
treatment O
and O
to O
the O
potential O
corrective O
action O
of O
combined O
treatment O
with O
G-CSF B-protein
and O
corticosteroids O
through O
synergistic O
activation O
of O
STAT5 B-protein
. O
Human O
renal O
mesangial B-cell_type
cells I-cell_type
are O
a O
target I-cell_line
for O
the O
anti-inflammatory B-DNA
action O
of O
9-cis O
retinoic O
acid O
. O
Mesangial B-cell_type
cells I-cell_type
play O
an O
active O
role O
in O
the O
inflammatory O
response O
to O
glomerular O
injury O
. O
We O
have O
studied O
in O
cultured O
human B-DNA
mesangial I-cell_type
cells I-cell_line
( O
CHMC I-DNA
) O
several O
effects O
of O
9-cis O
retinoic O
acid O
( O
9-cRA B-protein
) O
, O
an O
activator O
of O
both O
retinoic O
acid O
receptors O
( O
RARs O
) O
and O
retinoid O
X O
receptors O
( O
RXRs O
) O
. O
9-cRA B-protein
inhibited O
foetal O
calf O
serum-induced B-protein
CHMC O
proliferation O
. O
It O
also O
prevented O
CHMC O
death O
induced O
by O
the O
inflammatory O
mediator O
H O
( O
2 O
) O
O O
( O
2 O
) O
. O
This O
preventive O
effect O
was O
not O
due O
to O
any O
increase O
in O
H O
( O
2 O
) O
O O
( O
2 O
) O
catabolism O
and O
it O
persisted O
even O
when O
both O
catalase O
and O
glutathione O
synthesis O
were O
inhibited O
. O
Finally O
, O
9-cRA O
diminished O
monocyte O
adhesion O
to O
FCS-stimulated B-protein
CHMC O
. O
Interestingly B-cell_type
, O
the O
retinoid O
also O
inhibited O
in O
FCS-stimulated B-protein
cells I-cell_type
the O
protein O
expression O
of O
two O
mesangial O
adhesion O
molecules I-protein
, O
fibronectin O
and O
osteopontin O
, O
but O
it O
did O
not O
modify O
the O
protein O
expression O
of O
intercellular O
adhesion O
molecule-1 B-protein
and O
vascular O
adhesion O
molecule-1 B-protein
. O
All O
major O
RARs O
and O
RXRs O
isotypes O
were O
expressed O
in O
CHMC O
regardless O
of O
the O
presence O
or O
absence O
of O
9-cRA B-protein
. O
Transcripts O
to O
RAR-alpha O
, O
RAR-beta O
and O
RXR-alpha B-protein
increased O
after O
incubation O
with O
9-cRA B-protein
whereas O
RXR-gamma B-protein
was O
inhibited O
, O
suggesting O
a O
major O
role O
for O
RARs O
and O
RXRs O
in O
9-cRA-anti-inflammatory B-protein
effects O
. O
9-cRA B-protein
was O
toxic O
only O
at O
50 O
microM I-cell_line
( O
a O
concentration O
50 O
- O
5000 O
times O
higher O
than O
required O
for O
the O
effects O
above O
) O
. O
Cell O
death O
occurred O
by O
apoptosis O
, O
whose O
onset O
was O
associated O
with O
a O
pronounced O
increase O
in O
catalase O
activity O
and O
reduced O
glutathione O
content O
, O
being O
more O
effectively O
induced O
by O
all-trans O
retinoic O
acid O
. O
Modulation O
of O
the O
oxidant/antioxidant B-DNA
balance O
failed O
to O
inhibit O
apoptosis O
. O
We O
conclude O
that O
mesangial B-cell_type
cells I-cell_type
might O
be O
a O
target I-cell_line
for O
the O
treatment O
of O
inflammatory O
glomerulopathies O
with O
9-cRA B-protein
. O
Expression O
of O
mammalian O
defensin I-DNA
genes I-DNA
. O
Antimicrobial B-cell_type
peptides O
are O
a O
prevalent O
mechanism O
of O
host O
defense O
found O
throughout O
nature O
. O
In O
mammals O
, O
defensins O
are O
among O
the O
most O
abundant O
of O
these O
broad-spectrum O
antibiotics O
, O
and O
are O
expressed O
in O
epithelial O
and O
hematopoietic B-cell_type
cells I-cell_type
. O
The O
defensin O
peptides O
are O
especially O
abundant O
in O
neutrophils O
; O
however O
, O
gene I-DNA
expression O
is O
limited O
to O
the O
promyelocyte O
stage O
. O
In O
epithelial B-cell_type
cells I-cell_line
, O
defensin I-DNA
genes I-DNA
are O
found O
as O
both O
constitutively O
expressed O
and O
inducible O
. O
Induction O
has O
been O
observed O
in O
vitro O
by O
stimulation O
with O
bacterial O
lipopolysaccharide O
as O
well O
as O
inflammatory O
mediators O
. O
In O
vivo O
, O
up-regulation I-DNA
of O
several O
defensin I-DNA
genes I-DNA
occurs O
in O
both O
infectious O
and O
inflammatory O
states O
. O
Gene O
regulation O
occurs O
via O
signal O
transduction O
pathways O
common O
to O
other O
innate O
immune O
responses O
, O
utilizing O
transcription B-protein
factors I-protein
such O
as O
nuclear B-protein
factor I-protein
( O
NF I-DNA
) O
-kappaB O
and O
NF B-protein
interleukin-6 B-protein
. O
Together O
, O
the O
data O
suggest O
a O
broad-based O
innate O
host O
defense O
whereby O
potent O
antimicrobial O
peptides O
are O
present O
to O
prevent O
initial O
colonization O
by O
pathogenic O
microorganisms O
. O
In O
addition O
, O
the O
recognition O
of O
bacteria O
coupled O
with O
a O
nascent O
inflammatory O
response O
can O
bolster O
this O
defense O
by O
a O
coordinated O
up-regulation I-DNA
of O
the O
peptides O
. O
Multiple O
signals O
required O
for O
cyclic O
AMP-responsive B-DNA
element I-DNA
binding O
protein O
( O
CREB I-DNA
) O
binding O
protein O
interaction O
induced O
by O
CD3/CD28 B-protein
costimulation O
. O
The O
optimal O
activation O
of O
cAMP-responsive B-DNA
element I-DNA
binding O
protein O
( O
CREB I-DNA
) O
, O
similar O
to O
the O
full O
activation O
of O
T I-cell_type
lymphocytes I-cell_type
, O
requires O
the O
stimulation O
of O
both O
CD3 B-protein
and O
CD28 B-protein
. O
Using O
a O
reporter O
system O
to O
detect O
interaction O
of O
CREB O
and O
CREB-binding B-protein
protein I-protein
( O
CBP I-DNA
) O
, O
in O
this O
study O
we O
found O
that O
CREB O
binds O
to O
CBP O
only O
by O
engagement O
of O
both O
CD3 B-protein
and O
CD28 B-protein
. O
CD3/CD28 B-protein
-promoted O
CREB O
- O
CBP O
interaction O
was O
dependent O
on O
p38 O
mitogen-activated B-DNA
protein O
kinase I-protein
( O
MAPK I-DNA
) O
and O
calcium/calmodulin-dependent B-protein
protein O
kinase I-protein
( O
CaMK I-DNA
) O
IV O
in O
addition O
to O
the O
previously O
identified O
extracellular O
signal-regulated O
kinase I-protein
pathway O
. O
Extracellular B-cell_type
signal-regulated O
kinase I-protein
, O
CaMKIV I-protein
, O
and O
p38 O
MAPK O
were O
also O
the O
kinases I-protein
involved O
in O
CREB O
Ser O
( O
133 O
) O
phosphorylation O
induced O
by O
CD3/CD28 B-protein
. O
A O
reconstitution O
experiment O
illustrated O
that O
optimum O
CREB O
- O
CBP O
interaction O
and O
CREB O
trans-activation O
were O
attained O
when O
these O
three O
kinase I-protein
pathways O
were O
simultaneously O
activated O
in O
T B-cell_type
cells I-cell_type
. O
Our O
results O
demonstrate O
that O
coordinated O
activation O
of O
different O
kinases I-protein
leads O
to O
full O
activation O
of O
CREB O
. O
Notably O
, O
CD28 B-protein
ligation O
activated O
p38 O
MAPK O
and O
CaMKIV I-DNA
, O
the O
kinases I-protein
stimulated O
by O
CD3 B-protein
engagement O
, O
suggesting O
that O
CD28 B-protein
acts O
by O
increasing O
the O
activation O
extent O
of O
p38 B-cell_type
MAPK O
and O
CaMKIV O
. O
These O
results O
support O
the O
model O
of O
a O
minimum O
activation O
threshold O
for O
CREB O
- O
CBP O
interaction O
that O
can O
be O
reached O
only O
when O
both O
CD3 B-protein
and O
CD28 B-protein
are O
stimulated O
. O
The O
murine I-cell_line
IL-2 B-DNA
promoter I-DNA
contains O
distal O
regulatory O
elements I-DNA
responsive O
to O
the O
Ah B-DNA
receptor I-protein
, O
a O
member O
of O
the O
evolutionarily O
conserved O
bHLH-PAS B-protein
transcription B-protein
factor I-protein
family O
. O
Signaling O
through O
the O
TCR O
and O
costimulatory O
signals O
primarily O
control O
transcription I-DNA
of O
the O
IL-2 B-DNA
gene I-DNA
in O
naive O
T B-cell_type
cells I-cell_type
. O
The O
minimal O
promoter I-DNA
necessary O
for O
this O
expression O
lies O
proximal O
, O
between O
-300 B-DNA
and O
the O
transcription O
start I-DNA
site I-DNA
. O
We O
had O
previously O
shown O
that O
activation O
of O
the O
arylhydrocarbon I-DNA
receptor I-protein
( O
AHR I-DNA
) O
, O
a O
member O
of O
the O
bHLH-PAS B-protein
family O
of O
transcription B-protein
factors I-protein
, O
leads O
to O
increased O
mRNA I-RNA
expression O
of O
IL-2 B-protein
in O
murine I-cell_line
fetal O
thymocytes O
. O
The O
AHR O
is O
abundant O
in O
the O
thymus O
and O
may O
play O
a O
role O
for O
the O
development O
of O
the O
immune O
system O
. O
Moreover O
, O
its O
overactivation O
by O
chemicals O
such O
as O
dioxins O
leads O
to O
immunosuppression O
and O
thymic B-cell_line
involution O
. O
Binding O
motifs O
for O
the O
liganded O
AHR O
can O
be O
identified O
in O
the O
distal O
region O
-1300 O
to O
-800 O
of O
the O
mouse B-DNA
IL-2 B-DNA
promoter I-DNA
. O
We O
show O
here O
that O
these O
DNA O
motifs O
, O
the O
so-called B-DNA
dioxin O
response O
elements I-DNA
, O
after O
binding O
to O
the O
liganded O
AHR O
are O
sufficient O
to O
transactivate O
luciferase O
expression O
in O
a O
reporter B-DNA
gene I-DNA
system O
. O
The O
IL-2 B-DNA
gene I-DNA
can O
be O
induced O
by O
the O
AHR O
also O
in O
thymocytes O
in O
vivo O
after O
injection O
of O
2 O
, O
3 O
, O
7 O
, O
8-tetrachlorodibenzo-p-dioxin O
, O
a O
potent O
ligand O
of O
the O
AHR O
. O
The O
AHR O
mediates O
the O
IL-2 B-protein
induction O
as O
shown O
with O
AHR O
-deficient O
mice O
. O
However O
, O
in O
spleen B-cell_type
cells I-cell_type
in O
vitro O
costimulation O
via O
the O
TCR O
is O
necessary O
for O
optimal O
IL-2 B-DNA
gene I-DNA
induction O
. O
Thus O
, O
the O
IL-2 B-DNA
promoter I-DNA
region O
contains O
novel O
distal O
regulatory O
elements I-DNA
that O
can O
be O
addressed O
by O
the O
AHR O
to O
induce O
IL-2 B-protein
and O
can O
cooperate O
with O
the O
proximal B-DNA
promoter I-DNA
Visualization I-DNA
of O
Syk-antigen B-DNA
receptor I-protein
interactions O
using O
green O
fluorescent O
protein O
: O
differential O
roles O
for O
Syk O
and O
Lyn O
in O
the O
regulation O
of B-DNA
receptor I-protein
capping O
and O
internalization O
. O
The O
cross-linking I-DNA
of O
the O
B O
cell O
Ag B-DNA
receptor I-protein
( O
BCR I-DNA
) O
is O
coupled O
to O
the O
stimulation O
of O
multiple O
intracellular O
signal O
transduction O
cascades O
via O
receptor-associated I-DNA
, O
protein B-protein
tyrosine I-protein
kinases I-protein
of O
both O
the O
Src O
and O
Syk O
families O
. O
To O
monitor O
changes O
in O
the O
subcellular O
distribution O
of O
Syk O
in O
B I-DNA
cells I-cell_type
responding O
to O
BCR O
cross-linking I-DNA
, O
we O
expressed O
in O
Syk O
-deficient O
DT40 B-protein
B I-DNA
cells I-cell_type
a O
fusion O
protein O
consisting O
of O
Syk O
coupled O
to O
green O
fluorescent O
protein O
. O
Treatment O
of O
these B-cell_type
cells I-cell_type
with O
anti-IgM B-protein
Abs O
leads O
to O
the O
recruitment O
of O
the O
kinase I-protein
from O
cytoplasmic O
and O
nuclear B-protein
compartments O
to O
the O
site I-DNA
of O
the O
cross-linked B-DNA
receptor I-protein
at O
the O
plasma O
membrane O
. O
The O
Syk-receptor O
complexes O
aggregate O
into O
membrane O
patches O
that O
redistribute O
to O
form O
a O
cap O
at O
one O
pole O
of O
the O
cell O
. O
Syk O
is O
not O
demonstrably O
associated O
with O
the O
internalized I-DNA
receptor I-protein
. O
Catalytically B-cell_type
active O
Syk O
promotes O
and O
stabilizes O
the O
formation O
of O
tightly O
capped O
BCR O
complexes O
at O
the O
plasma O
membrane O
. O
Lyn O
is O
not O
required O
for O
the O
recruitment O
of O
Syk O
to O
the O
cross-linked B-DNA
receptor I-protein
, O
but O
is O
required O
for O
the O
internalization O
of O
the O
clustered O
BCR O
complexes O
. O
In O
the O
absence O
of O
Lyn O
, O
receptor-Syk O
complexes O
at O
the O
plasma O
membrane O
are O
long I-DNA
lived I-DNA
, O
and O
the O
receptor-mediated B-DNA
activation O
of O
the O
NF-AT B-protein
transcription I-protein
factor I-protein
is O
enhanced O
. O
Thus O
, O
Lyn O
appears O
to O
function O
to O
negatively O
regulate O
aspects O
of O
BCR B-cell_type
-dependent O
signaling O
by O
stimulating I-DNA
receptor I-protein
internalization O
and O
down-regulation O
. O
Renal O
interstitial O
fibrosis O
is O
reduced O
in O
angiotensin O
II I-protein
type O
1a I-DNA
receptor I-protein
-deficient O
mice O
. O
Unilateral O
ureteral O
obstruction O
( O
UUO I-DNA
) O
results O
in O
tubulointerstitial O
fibrosis O
of O
the O
affected O
kidney O
by O
stimulating O
the O
renin-angiotensin B-DNA
system O
. O
This O
study O
established O
a O
UUO O
model O
in O
angiotensin O
type O
1a I-DNA
receptor I-protein
( O
AT1a I-DNA
) O
deficient O
( O
mutant O
) O
mice O
to O
elucidate O
the O
role O
of O
angiotensin O
II I-protein
through O
AT1a O
on O
the O
fibrosis O
of O
the O
obstructed O
kidney O
( O
OBK I-DNA
) O
. O
The O
relative O
volume O
of O
the O
tubulointerstitium O
was O
measured O
by O
an O
image O
analyzer O
; O
deposition O
of O
collagen O
types I-cell_type
III O
and O
IV O
and O
monocyte O
/ O
macrophage O
infiltration O
were O
histologically O
examined O
using O
specific O
antibodies I-protein
. O
Also O
determined O
were O
the O
mRNA I-RNA
levels O
of O
transforming O
growth O
factor-beta B-DNA
by O
Northern O
blot O
analysis O
. O
Nuclear O
factor-kappaB B-protein
activity O
was O
assessed O
by O
gel O
shift O
assay O
. O
UUO O
in O
wild O
mice O
resulted O
in O
a O
marked O
expansion O
of O
relative O
volume O
of O
the O
tubulointerstitium I-protein
, O
together O
with O
increased O
deposition O
of O
collagen O
types I-cell_type
III O
and O
IV O
and O
number O
of O
infiltrated O
monocytes B-cell_type
/ O
macrophages O
in O
the O
interstitium O
, O
relative O
to O
sham-operated O
mice O
. O
In O
comparison O
, O
these O
changes O
were O
significantly O
lower O
in O
mutant O
mice O
with O
UUO O
. O
The O
mRNA I-RNA
level O
of O
transforming O
growth O
factor-beta B-DNA
was O
significantly O
higher O
in O
the O
OBK O
of O
wild O
mice O
with O
UUO O
compared O
with O
sham-operated I-DNA
mice O
. O
In O
contrast O
, O
the O
increase O
in O
mRNA I-RNA
level O
in O
the O
OBK O
of O
mutant O
mice O
was O
significantly O
less O
than O
in O
wild O
mice O
. O
Finally O
, O
UUO O
resulted O
in O
activation O
of O
nuclear B-protein
factor-kappaB B-protein
in O
wild O
mice O
but O
was O
inhibited O
in O
the O
OBK O
of O
mutant O
mice O
. O
The O
results O
provide O
direct O
evidence O
that O
angiotensin O
II I-protein
acting O
via O
the O
AT1a O
plays O
a O
pivotal O
role O
in O
the O
development O
of O
tubulointerstitial O
fibrosis O
in O
UUO O
. O
HLA-DQ B-protein
tetramers O
identify O
epitope-specific B-cell_type
T B-cell_type
cells I-cell_type
in O
peripheral B-cell_type
blood I-cell_type
of O
herpes O
simplex O
virus O
type O
2-infected B-DNA
individuals O
: O
direct O
detection O
of O
immunodominant O
antigen-responsive B-cell_type
cells I-cell_type
. O
Ag-specific B-cell_line
CD4+ B-cell_type
T B-cell_type
cells I-cell_type
are O
present O
in O
peripheral B-cell_type
blood I-cell_type
in O
low O
frequency O
, O
where O
they O
undergo O
recruitment O
and O
expansion O
during O
immune O
responses O
and O
in O
the O
pathogenesis O
of O
numerous O
autoimmune O
diseases O
. O
MHC I-protein
tetramers I-protein
, O
which O
constitute O
a O
labeled O
MHC-peptide B-protein
ligand O
suitable O
for O
binding O
to O
the O
Ag-specific B-DNA
receptor I-protein
on O
T B-cell_type
cells I-cell_type
, O
provide O
a O
novel O
approach O
for O
the O
detection O
and O
characterization O
of O
such O
rare B-cell_type
cells I-cell_type
. O
In O
this O
study O
, O
we O
utilized O
this O
technology O
to O
identify O
HLA O
DQ B-protein
-restricted O
Ag-specific B-cell_line
T B-cell_type
cells I-cell_type
in O
the O
peripheral B-cell_type
blood I-cell_type
of O
human B-cell_type
subjects I-cell_type
and O
to O
identify O
immunodominant O
epitopes I-protein
associated O
with O
viral O
infection O
. O
Peptides O
representing O
potential O
epitope O
regions I-protein
of O
the O
VP16 B-protein
protein O
from O
HSV-2 O
were O
loaded O
onto O
recombinant O
DQ0602 B-protein
molecules O
to O
generate O
a O
panel O
of O
Ag-specific B-cell_line
DQ0602 B-protein
tetramers O
. O
VP16 B-protein
Ag O
-specific O
DQ-restricted B-cell_type
T B-cell_type
cells I-cell_type
were O
identified O
and O
expanded O
from O
the O
peripheral B-cell_type
blood I-cell_type
of O
HSV-2-infected B-protein
individuals O
, O
representing O
two O
predominant O
epitope O
specificities O
. O
Although O
the O
VP16 B-protein
369-380 O
peptide O
has O
a O
lower O
binding O
affinity O
for O
DQ0602 B-protein
molecules I-protein
than O
the O
VP16 B-protein
33-52 O
peptide O
, O
T B-cell_type
cells I-cell_type
that O
recognized O
the O
VP16 B-protein
369-380 O
peptide O
occurred O
at O
a O
much O
higher O
frequency O
than O
those O
that O
were O
specific O
for O
the O
VP16 B-protein
33-52 O
peptide O
. O
Down-regulation O
of O
BOB.1/OBF.1 B-cell_type
and O
Oct2 O
in O
classical O
Hodgkin O
disease O
but O
not O
in O
lymphocyte I-cell_line
predominant O
Hodgkin O
disease O
correlates O
with O
immunoglobulin O
transcription O
. I-RNA
In O
contrast O
to O
the O
tumor I-cell_type
cells I-cell_line
( O
L O
& O
H B-cell_type
cells I-cell_type
) O
of O
lymphocyte I-cell_line
predominant O
Hodgkin O
disease O
( O
LPHD I-DNA
) O
, O
Hodgkin O
and O
Reed-Sternberg B-protein
( O
HRS I-DNA
) O
cells O
of O
classical O
Hodgkin O
disease O
( O
cHD I-DNA
) O
are O
unable O
to O
transcribe O
immunoglobulin O
, O
despite O
the O
presence O
of O
rearranged O
immunoglobulin I-DNA
genes I-DNA
. O
Although O
initial O
studies O
have O
suggested O
crippling O
immunoglobulin O
gene I-DNA
mutations O
to O
be O
the O
cause O
of O
absent O
immunoglobulin O
expression O
in O
cHD I-cell_line
, O
recent O
work O
of O
our O
group O
has O
demonstrated O
an O
impaired O
activation O
of O
the O
immunoglobulin O
promoter I-DNA
as O
a O
superior O
mechanism O
. O
As O
immunoglobulin O
transcription O
is O
mainly O
regulated O
by O
the O
B-cell B-protein
transcription B-protein
factors I-protein
Oct2 O
and O
BOB.1/OBF.1 I-protein
, O
we O
analyzed O
35 O
cases O
of O
LPHD I-protein
, O
32 O
cases O
of O
cHD B-cell_type
, O
and O
2 O
Hodgkin O
disease O
cell O
lines I-cell_line
for O
the O
expression O
of O
these O
transcription B-protein
factors I-protein
and O
also O
in O
parallel O
for O
immunoglobulin O
expression O
. O
Our O
results O
demonstrate O
an O
absence O
of O
Oct2 B-cell_type
and/or I-cell_line
BOB.1/OBF.1 B-protein
in O
cHD O
and O
a O
striking O
overexpression O
of O
Oct2 B-cell_type
in O
LPHD O
. O
Immunoglobulin O
expression O
was O
lacking O
in O
cHD I-RNA
but O
present O
in O
LPHD O
. O
Furthermore O
, O
the O
reintroduction O
of O
BOB.1/OBF.1 B-cell_type
and O
Oct2 O
into O
cultured O
HRS B-cell_type
cells I-cell_type
restored O
the O
activity O
of O
cotransduced O
immunoglobulin O
promoter I-DNA
constructs O
. O
Our O
findings O
dismiss O
the O
concept O
that O
the O
different O
immunoglobulin O
expression O
in O
cHD O
and O
LPHD O
is O
due O
to O
disrupting O
mutations O
of O
immunoglobulin O
V I-DNA
genes I-DNA
in O
cHD I-RNA
but O
is O
most O
likely O
due O
to O
a O
down-regulation O
of O
Oct2 B-cell_type
and/or I-cell_line
BOB.1/OBF.1 B-protein
. O
This O
study O
further O
revealed O
Oct2 O
as O
a O
new O
and O
valuable O
marker O
for O
the O
identification O
of O
L O
& O
H B-cell_type
cells I-cell_type
and O
their O
distinction O
from O
HRS B-cell_type
cells I-cell_type
. O
The O
impairment O
of O
immunoglobulin O
transcription O
with O
a O
down-regulated O
synthesis O
of O
Oct2 O
and O
BOB.1/OBF.1 B-protein
is O
the O
first O
established O
general O
recurrent O
defect O
found O
in O
HRS B-cell_type
cells I-cell_type
. O
Constitutive O
expression O
of O
NF-kappa B-protein
B I-protein
is O
a O
characteristic O
feature O
of O
mycosis O
fungoides O
: O
implications O
for O
apoptosis O
resistance O
and O
pathogenesis O
. O
The O
NF-kappa B-protein
B I-protein
family O
of O
transcription B-protein
factors I-protein
is O
an O
important O
regulator O
of O
genes I-DNA
expressed O
during O
inflammatory O
responses O
, O
immunoglobulin O
( O
Ig O
) O
class O
switching O
, O
cellular O
differentiation O
, O
and O
apoptosis O
. O
Recently O
, O
members O
of O
the O
NF-kappaB O
family I-protein
, O
including O
p65 I-cell_line
( O
Rel O
A O
) O
, O
have O
been O
implicated O
in O
promoting O
survival O
of O
various O
hematopoeitic O
neoplasms O
, O
including O
T O
cell O
malignancies O
such O
as O
adult O
T O
cell O
leukemia-lymphoma O
. O
We O
investigated O
the O
expression O
of O
active O
NF-kappa B-protein
B I-protein
p65 I-protein
( O
Rel O
A O
) O
in O
cases O
of O
mycosis O
fungoides O
( O
MF I-DNA
) O
and O
the O
effect O
of O
chemical O
inhibitors O
of O
NF-kappa B-protein
B I-protein
on O
apoptosis O
in O
cutaneous B-cell_type
T O
cell O
lymphoma O
( O
CTCL I-DNA
) O
cell O
lines I-cell_line
. O
Paraffin-embedded O
tissues O
from O
23 O
cutaneous O
lesions O
and O
a O
single O
lymph O
node O
biopsy O
from O
patients O
diagnosed O
with O
MF B-protein
were O
evaluated O
for O
p65 I-cell_line
( O
Rel O
A O
) O
expression O
by O
using O
a O
monoclonal O
mouse B-DNA
antibody O
that O
detects O
the O
activated O
form O
of O
p65 B-cell_type
( O
Rel O
A O
) O
. O
Apoptosis O
after O
treatment O
with O
the O
NF-kappa B-protein
B I-protein
inhibitors O
gliotoxin O
, O
MG132 I-protein
, O
BAY O
11-7082 O
, O
and O
BAY O
11-7085 O
was O
quantitatively O
measured O
in O
the O
CTCL O
cell O
lines I-cell_line
HuT-78 O
and O
HH B-protein
by O
propidium O
iodide O
( O
PI I-DNA
) O
/cell O
cycle O
analysis O
for O
detection O
of O
a O
hypodiploid O
( O
sub-G B-protein
( O
0 O
) O
) O
population O
and O
by O
determination O
of O
increased O
Annexin O
V/7-amino-actinomycin O
D O
( O
7-AAD B-protein
) O
expression O
. O
Nuclear O
extracts O
from O
CTCL B-cell_type
cells I-cell_type
before O
and O
after O
chemical O
inhibition O
were O
analyzed O
for O
NF-kappa B-protein
B I-protein
nuclear O
DNA-binding B-protein
activity O
by O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA I-DNA
) O
with O
quantitative O
densitometry O
. O
Nuclear O
expression O
of O
p65 B-cell_type
( O
Rel O
A O
) O
before O
and O
after O
treatment O
with O
the O
various O
inhibitory O
compounds O
was O
measured O
by O
immunofluorescence O
staining O
in O
each O
CTCL O
cell O
line O
. O
Neoplastic O
T I-cell_type
lymphocytes I-cell_type
from O
22 O
of O
24 O
cases O
of O
MF B-cell_type
showed O
strong O
nuclear O
and O
cytoplasmic O
expression O
of O
active O
p65 I-cell_line
( O
Rel O
A O
) O
. O
Compared O
with O
untreated O
control B-cell_type
cells I-cell_line
, O
a O
marked O
increase O
in O
apoptosis O
, O
a O
significant O
decrease O
in O
NF-kappa B-protein
B I-protein
DNA-binding O
activity O
, O
and O
a O
marked O
decrease O
in O
nuclear B-protein
p65 I-protein
( O
Rel O
A O
) O
expression O
were O
seen O
in O
cells I-cell_type
from O
both O
CTCL O
cell O
lines I-cell_line
after O
chemical O
NF-kappa B-protein
B I-protein
inhibition O
. O
These O
data O
show O
that O
the O
active O
form O
of O
NF-kappa B-protein
B I-protein
p65 I-protein
( O
Rel O
A O
) O
is O
commonly O
expressed O
in O
neoplastic O
T I-cell_type
lymphocytes I-cell_type
in O
patients O
with O
MF B-protein
. O
In O
CTCL O
cell O
lines I-cell_line
, O
the O
significant O
decrease O
in O
nuclear B-protein
NF-kappa B-protein
B I-protein
expression O
and O
the O
marked O
increase O
in O
spontaneous O
apoptosis O
caused O
by O
chemical O
NF-kappa B-protein
B I-protein
inhibition O
suggest O
a O
critical O
role O
for O
NF-kappa B-protein
B I-protein
in O
the O
pathogenesis O
and O
tumor O
cell O
maintenance O
of O
CTCLs O
. O
HUM O
PATHOL I-protein
31 O
: O
1482-1490 O
. O
Human O
T-cell O
leukemia O
virus O
type O
1 O
tax O
protein O
activates O
transcription O
through O
AP-1 B-protein
site I-DNA
by O
inducing O
DNA O
binding O
activity O
in O
T B-cell_type
cells I-cell_type
. O
Human O
T-cell O
leukemia O
virus O
type O
1 O
( O
HTLV-1 B-protein
) O
Tax O
protein O
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B-protein
factor I-protein
AP-1 B-protein
, O
such O
as O
c-Jun I-DNA
, O
JunD I-protein
, O
c-Fos O
, O
and O
Fra-1 B-protein
, O
at O
the O
level O
of O
RNA B-cell_type
expression O
in O
T B-cell_type
cells I-cell_type
. O
We O
examined O
the O
activity O
of O
Tax O
in O
transcription O
through O
AP-1-binding B-protein
sites I-DNA
( O
AP-1 B-protein
site I-DNA
) O
in O
T B-cell_type
cells I-cell_type
. O
Transient O
transfection O
studies O
showed O
that O
Tax O
activated O
the O
expression O
of O
a O
luciferase O
gene I-DNA
regulated O
by O
two O
copies O
of O
an O
AP-1 B-protein
site I-DNA
in O
the O
human B-DNA
Jurkat I-cell_type
T-cell O
line O
. O
Tax O
activates O
the O
expression O
of O
viral O
and O
cellular I-DNA
genes I-DNA
through O
two O
different O
enhancers O
: O
a O
cAMP-responsive B-protein
( O
CRE I-DNA
) O
-like O
element I-DNA
and O
a O
kappaB B-DNA
element I-DNA
. O
Two O
Tax O
mutants O
differentially O
activated O
expression O
of O
these O
two O
elements I-DNA
. O
Tax703 B-protein
preferentially O
activated O
the O
kappaB B-DNA
element I-DNA
but O
not O
the O
CRE-like B-protein
one O
, O
whereas O
TaxM22 B-DNA
showed O
the O
reverse O
. O
In O
addition O
, O
Tax703 O
and O
Tax O
, O
but O
not O
TaxM22 B-DNA
, O
converted O
cell O
growth O
of O
a O
mouse B-DNA
T-cell O
line O
from O
being O
interleukin O
( O
IL I-DNA
) O
-2-dependent O
to O
being O
IL-2-independent B-DNA
. O
Unlike O
the O
wild-type B-DNA
Tax O
, O
Tax703 O
and O
TaxM22 B-protein
only O
weakly O
activated O
the O
AP-1 B-protein
site I-DNA
in O
the O
T-cell O
line O
. O
Thus O
, O
Tax O
seems O
to O
activate O
the O
AP-1 B-protein
site I-DNA
via O
mechanisms O
distinct O
from O
those O
of O
kappaB B-cell_type
or O
CRE-like B-DNA
elements I-DNA
, O
and O
the O
activation O
of O
the O
AP-1 B-protein
site I-DNA
is O
dispensable O
for O
IL-2-independent B-DNA
growth O
of O
CTLL-2 B-protein
. O
Electrophoretic O
mobility O
shift O
assays O
showed O
that O
Tax O
induced O
strong O
binding O
activity O
to O
an O
AP-1 B-protein
site I-DNA
in O
CTLL-2 B-protein
, O
whereas O
Tax703 B-protein
did O
not O
, O
indicating O
that O
the O
induction O
of O
binding O
activity O
to O
the O
AP-1 B-protein
site I-DNA
is O
essential O
for O
the O
transcriptional O
activation O
by O
Tax O
. O
The O
binding O
complex I-protein
induced O
by O
Tax O
in O
CTLL-2 B-protein
contained O
JunD O
and O
Fra-2 B-protein
. O
Other O
AP-1 B-protein
proteins I-protein
were O
undetectable O
. O
Activation O
of O
transcription O
through O
the O
AP-1 B-protein
site I-DNA
in O
Jurkat B-cell_type
cells I-cell_type
by O
JunD O
and/or I-cell_line
Fra-2 B-protein
was O
weak O
. O
c-Jun I-DNA
, O
JunB I-protein
, O
and O
c-Fos O
activation O
was O
greater O
, O
although O
the O
level O
was O
still O
less O
than O
that O
with O
Tax O
. O
Thus O
, O
the O
induction O
of O
AP-1 B-protein
mRNA I-RNA
by O
Tax O
may O
not O
be O
sufficient O
for O
a O
complete O
activation O
of O
AP-1 B-protein
site I-DNA
by O
Tax O
. O
Our O
results O
suggest O
that O
Tax O
activates O
the O
transcription I-DNA
of O
cellular I-DNA
genes I-DNA
with O
AP-1 B-protein
sites I-DNA
by O
inducing O
the O
DNA-binding B-protein
activity O
of O
AP-1 B-protein
proteins I-protein
in O
T B-cell_type
cells I-cell_type
, O
a O
mechanism O
distinct O
from O
those O
of O
CRE-like B-DNA
and O
kappaB O
elements I-DNA
. O
Copyright O
2001 O
Academic O
Press O
. O
Strict O
control O
of O
human B-cell_type
immunodeficiency I-DNA
virus O
type O
1 O
replication O
by O
a O
genetic O
switch O
: O
Tet O
for O
Tat O
. O
Live-attenuated O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
( O
HIV-1 B-protein
) O
variants O
have O
shown O
great O
promise O
as O
AIDS O
vaccines O
, O
but O
continued O
replication O
can O
lead O
to O
the O
selection O
of O
faster-replicating O
variants O
that O
are O
pathogenic O
. O
We O
therefore O
designed O
HIV-1 O
genomes O
that O
replicate O
exclusively O
upon O
addition O
of O
the O
nontoxic O
effector O
doxycycline O
( O
dox O
) O
. O
This O
was O
achieved O
by O
replacement O
of O
the O
viral O
TAR-Tat O
system O
for O
transcriptional O
activation O
by O
the O
Escherichia O
coli-derived B-DNA
Tet O
system O
for O
inducible B-DNA
gene I-DNA
expression O
. O
These O
designer O
`` O
HIV-rtTA B-protein
'' O
viruses O
replicate O
in O
a O
strictly O
dox-dependent B-protein
manner O
both O
in O
a O
T-cell O
line O
and O
in O
primary B-cell_type
blood I-cell_type
cells I-cell_type
, O
and O
the O
rate O
of O
replication O
can O
be O
fine-tuned B-DNA
by O
simple O
variation O
of O
the O
dox O
concentration O
. O
These O
HIV-rtTA B-protein
viruses O
provide O
a O
tool O
to O
perform O
genetics O
, O
e.g. I-protein
, O
selection O
and O
optimization O
experiments O
, O
with O
the O
E. B-protein
coli-derived B-DNA
Tet O
reagents O
in O
a O
eukaryotic O
background O
. O
Furthermore O
, O
such O
viruses O
may O
represent O
improved O
vaccine O
candidates O
because O
their O
replication O
can O
be O
turned O
on O
and O
off O
at O
will O
. O
Synovial O
fluid O
induced O
nuclear B-protein
factor-kappaB B-protein
DNA O
binding O
in O
a O
monocytic B-cell_line
cell O
line O
. O
OBJECTIVE O
: O
To O
determine O
the O
effects O
of O
synovial O
fluids O
( O
SF I-DNA
) O
on O
DNA O
binding O
activity O
of O
transcription B-protein
factor I-protein
nuclear B-protein
factor-kappaB B-protein
( O
NF-kappaB I-DNA
) O
in O
the O
Mono O
Mac O
6 O
monocytic/macrophage O
cell O
line O
as O
a O
model O
for O
the O
interaction O
between O
SF O
and O
synovial O
tissue O
macrophages O
in O
arthritis O
. O
METHODS I-protein
: O
Mono O
Mac O
6 O
cells I-cell_type
were O
incubated O
with O
SF B-protein
from O
the O
knee O
joints O
of O
human B-cell_type
subjects I-cell_type
with O
rheumatoid O
arthritis O
( O
RA I-DNA
) O
, O
undifferentiated O
seronegative O
oligoarthritis O
, O
and O
osteoarthritis O
( O
OA I-DNA
) O
. O
Nuclear O
extracts O
prepared O
from O
the O
Mono O
Mac O
6 O
cells I-cell_type
and O
RA B-protein
synovial O
tissue O
were O
analyzed O
by O
electrophoretic O
mobility O
shift O
analysis O
( O
EMSA I-DNA
) O
for O
NF-kappaB O
DNA O
binding O
proteins I-protein
. O
RESULTS I-protein
: O
Induction O
of O
NF-kappaB O
DNA O
binding O
by O
the O
p65 I-cell_line
( O
RelA I-DNA
) O
/p50 O
heterodimer O
was O
observed O
in O
response O
to O
incubation O
of O
Mono O
Mac O
6 O
cells I-cell_type
with O
SF I-cell_line
( O
20 O
% O
in O
culture O
medium O
) O
from O
5 O
of O
8 O
subjects O
with O
RA I-protein
, O
4 O
of O
5 O
with O
OA I-protein
, O
and O
none O
of O
3 O
with O
undifferentiated O
seronegative O
oligoarthritis O
. O
Incubation O
of O
SF B-cell_type
with O
neutralizing B-protein
antibodies I-protein
against O
tumor O
necrosis O
factor-alpha B-DNA
( O
TNF-alpha I-DNA
) O
, O
but O
not O
antibodies I-protein
against O
interleukin O
6 O
( O
IL-6 B-protein
) O
, O
significantly O
reduced O
the O
induction O
of O
p65/p50 O
binding O
activity O
in O
SF B-protein
from O
subjects O
with O
RA O
and O
OA B-protein
. O
Unexpectedly I-protein
, O
a O
slowly O
migrating O
SF B-protein
inducible O
NF-kappaB O
-binding O
complex I-protein
was O
observed O
in O
EMSA I-DNA
of O
Mono O
Mac O
6 O
cells I-cell_type
after O
incubation O
with O
SF B-protein
from O
5 O
of O
8 O
RA O
and O
2 O
of O
5 O
OA B-protein
subjects O
. O
The O
induction O
of O
this O
complex I-protein
by O
SF B-protein
was O
not O
affected O
by O
neutralization O
of O
TNF-alpha B-protein
or O
IL-6 B-protein
in O
SF I-protein
, O
and O
the O
complex I-protein
was O
not O
inducible O
by O
TNF-alpha I-DNA
, O
IL-1beta O
, O
TNF-alpha O
/ O
IL-1beta O
, O
IL-6 B-protein
, O
platelet O
derived O
growth I-protein
factor I-protein
, O
lipopolysaccharide I-protein
, O
or O
tetradecanoyl O
phorbol O
acetate O
. O
The O
slowly O
migrating O
complex I-protein
could O
not O
be O
supershifted O
with O
antibodies I-protein
against O
NF-kappaB I-DNA
, O
Jun O
, O
or O
the O
transcriptional O
coactivators O
p300 I-protein
or O
CBP O
. O
A O
NF-kappaB-binding O
complex I-protein
with O
similar O
slow O
mobility O
was O
observed O
in O
nuclear B-protein
extracts O
prepared O
from O
fresh O
human B-DNA
RA I-cell_type
synovial O
tissue O
. O
CONCLUSION I-protein
: O
Biological O
activity O
of O
TNF-alpha B-protein
in O
SF B-protein
from O
RA O
and O
OA B-protein
subjects O
is O
capable O
of O
inducing O
p65/p50 O
NF-kappaB O
DNA O
binding O
activity O
in O
macrophages O
. O
A O
property O
of O
SF B-cell_type
that O
is O
independent O
of O
TNF-alpha B-DNA
and O
other O
cytokines O
is O
responsible O
for O
the O
induction O
of O
a O
novel O
slowly O
migrating O
NF-kappaB-binding B-protein
complex I-protein
. O
Soluble O
mediators O
in O
SF I-DNA
of O
subjects O
with O
RA O
and O
OA B-protein
can O
therefore O
modulate O
binding O
of O
nuclear B-protein
proteins I-protein
to O
the O
NF-kappaB O
binding O
site O
in O
macrophages O
and O
may O
play O
a O
role O
in O
inflammatory B-DNA
gene I-DNA
expression O
in O
arthritis O
. O
Peroxisome O
proliferator O
activator O
receptor-gamma O
agonists O
and O
15-deoxy-Delta B-protein
( O
12 I-DNA
, O
14 O
) O
( O
12 I-DNA
, O
14 O
) O
-PGJ O
( O
2 O
) O
induce O
apoptosis O
in O
normal O
and O
malignant O
B-lineage B-protein
cells I-cell_type
. O
The O
research O
described O
herein O
evaluates O
the O
expression O
and O
functional O
significance O
of O
peroxisome O
proliferator O
activator O
receptor-gamma B-protein
( O
PPAR-gamma I-DNA
) O
on O
B-lineage B-protein
cells I-cell_type
. O
Normal O
mouse B-DNA
B I-DNA
cells I-cell_type
and O
a O
variety O
of O
B I-DNA
lymphoma O
cells I-cell_type
reflective O
of O
stages O
of O
B O
cell O
differentiation O
( O
e.g. I-DNA
, O
70Z/3 I-protein
, O
CH31 I-protein
, O
WEHI-231 B-protein
, O
CH12 I-protein
, O
and O
J558 B-protein
) O
express O
PPAR-gamma I-RNA
mRNA I-RNA
and O
, O
by O
Western O
blot O
analysis O
, O
the O
67-kDa B-protein
PPAR-gamma B-protein
protein O
. O
15-Deoxy-Delta B-protein
( O
12 I-DNA
, O
14 O
) O
-PGJ O
( O
2 O
) O
( O
15d-PGJ B-protein
( O
2 O
) O
) O
, O
a O
PPAR-gamma B-protein
agonist O
, O
has O
a O
dose-dependent O
antiproliferative O
and O
cytotoxic O
effect O
on O
normal O
and O
malignant O
B I-DNA
cells I-cell_type
as O
shown O
by O
[ O
( O
3 O
) O
H O
] O
thymidine O
and O
3- O
[ O
4 O
, O
5-dimethylthiazol-2-yl B-protein
] O
-2 O
, O
5-diphenyltetrazolium O
bromide O
assays O
. O
Only O
PPAR-gamma B-protein
agonists O
( O
thiazolidinediones O
) O
, O
and O
not O
PPAR-alpha B-protein
agonists O
, O
mimicked O
the O
effect O
of O
15d-PGJ B-protein
( O
2 O
) O
on O
B-lineage B-protein
cells I-cell_line
, O
indicating O
that O
the O
mechanism O
by O
which O
15d-PGJ B-protein
( O
2 O
) O
negatively O
affects O
B-lineage B-protein
cells I-cell_type
involves O
in O
part O
PPAR-gamma B-protein
. O
The O
mechanism O
by O
which O
PPAR-gamma B-protein
agonists O
induce O
cytotoxicity O
is O
via O
apoptosis O
, O
as O
shown O
by O
annexin O
V O
staining O
and O
as O
confirmed O
by O
DNA O
fragmentation O
detected O
using O
the O
TUNEL O
assay O
. O
Interestingly B-cell_type
, O
addition O
of O
PGF B-cell_type
( O
2alpha I-DNA
) O
, O
which O
was O
not O
known O
to O
affect I-cell_type
lymphocytes I-cell_type
, O
dramatically O
attenuated O
the O
deleterious O
effects O
of O
PPAR-gamma B-protein
agonists O
on O
B I-DNA
lymphomas O
. O
Surprisingly I-protein
, O
15d-PGJ O
( O
2 O
) O
induced O
a O
massive O
increase O
in O
nuclear B-protein
mitogen-activated I-protein
protein O
kinase I-protein
activation O
, O
and O
pretreatment O
with O
PGF I-protein
( O
2alpha I-DNA
) O
blunted O
the O
mitogen-activated B-DNA
protein O
kinase I-protein
activation O
. O
This O
is O
the O
first O
study O
evaluating O
PPAR-gamma B-protein
expression O
and O
its O
significance O
on O
B I-DNA
lymphocytes I-cell_type
. O
PPAR-gamma B-protein
agonists O
may O
serve O
as O
a O
counterbalance O
to O
the O
stimulating O
effects O
of O
other O
PGs O
, O
namely O
PGE I-protein
( O
2 O
) O
, O
which O
promotes O
B O
cell O
differentiation O
. O
Finally O
, O
the O
use O
of O
PGs O
, O
such O
as O
15d-PGJ B-protein
( O
2 O
) O
, O
and O
synthetic O
PPAR-gamma B-protein
agonists O
to O
induce O
apoptosis O
in O
B-lineage B-protein
cells I-cell_type
may O
lead O
to O
the O
development O
of O
novel O
therapies O
for O
fatal O
B I-DNA
lymphomas O
Inhibition O
of O
STAT3 B-protein
signaling O
leads O
to O
apoptosis O
of O
leukemic O
large O
granular I-cell_type
lymphocytes I-cell_type
and O
decreased O
Mcl-1 B-protein
expression O
. O
Large O
granular O
lymphocyte I-cell_line
( O
LGL I-DNA
) O
leukemia O
is O
characterized O
by O
the O
expansion O
of O
antigen-activated B-DNA
cytotoxic B-cell_type
T I-cell_type
lymphocytes I-cell_type
. O
These O
leukemic B-cell_type
cells I-cell_type
are O
resistant O
to O
Fas-mediated O
apoptosis O
despite O
expressing O
high O
levels O
of O
Fas O
. O
We O
found O
that O
leukemic O
LGL O
from O
19 O
patients O
displayed O
high O
levels O
of O
activated O
STAT3 B-protein
. O
Treatment O
of O
leukemic O
LGL O
with O
the O
JAK-selective B-protein
tyrosine I-protein
kinase I-protein
inhibitor O
AG-490 B-protein
induced O
apoptosis O
with O
a O
corresponding O
decrease O
in O
STAT B-protein
-DNA B-DNA
binding O
activity O
. O
Moreover O
, O
using O
an O
antisense O
oligonucleotide O
approach O
to O
diminish O
STAT3 B-protein
expression O
, O
we O
found O
that O
Fas O
sensitivity O
was O
restored O
in O
leukemic O
LGL O
. O
AG-490-induced B-protein
apoptosis O
in O
leukemic O
LGL O
was O
independent O
of O
Bcl-xL B-protein
or O
Bcl-2 B-protein
expression O
. O
However O
, O
we O
found O
that O
the O
Bcl-2-family B-protein
protein O
Mcl-1 B-protein
was O
significantly O
reduced O
by O
AG-490 B-protein
treatment O
. O
Activated O
STAT3 B-protein
was O
shown O
to O
bind O
an O
SIE-related B-DNA
element I-DNA
in O
the O
murine I-cell_line
mcl-1 B-DNA
promoter I-DNA
. O
Using O
a O
luciferase O
reporter O
assay O
, O
we O
demonstrated O
that O
v-src B-DNA
overexpression O
in O
NIH3T3 B-protein
induced O
STAT3 B-protein
-dependent O
transcriptional O
activity O
from O
the O
mcl-1 B-DNA
promoter I-DNA
and O
increased O
endogenous O
Mcl-1 B-protein
protein O
levels O
. O
We O
conclude O
that O
STAT3 B-protein
activation O
contributed O
to O
accumulation O
of O
the O
leukemic O
LGL O
clones O
. O
These O
findings O
suggest O
that O
investigation O
should O
focus O
on O
novel O
strategies O
targeting O
STAT3 B-protein
in O
the O
treatment O
of O
LGL B-cell_type
leukemia O
. O
Decreased O
immediate O
inflammatory B-DNA
gene I-DNA
induction O
in O
activating O
transcription O
factor-2 B-protein
mutant O
mice O
. O
Transcription B-protein
factor I-protein
activating O
transcription B-protein
factor I-protein
( O
ATF I-DNA
) O
-2 O
is O
activated O
by O
inflammatory O
signals O
transduced O
by O
the O
JNK O
and O
p38 O
MAP I-protein
kinase I-protein
pathways O
. O
To O
better O
define O
the O
role O
of O
ATF-2 O
in O
inflammation O
, O
adult O
mice O
expressing O
small O
amounts O
of O
a O
mutant O
ATF-2 O
protein O
were O
challenged O
with O
lipopolysaccharide I-protein
( O
LPS I-DNA
) O
, O
anti-CD3 B-protein
antibody O
or O
virus O
. O
Within O
3 O
h O
of O
challenge O
by O
LPS I-protein
, O
ATF-2 O
mutant O
mice O
had O
decreased O
induction O
of O
the O
adhesion O
molecules I-protein
E-selectin B-protein
, O
P-selectin B-protein
and O
VCAM-1 B-protein
as O
well O
as O
the O
cytokines O
tumor O
necrosis O
factor-alpha I-DNA
, O
IL-1beta O
and O
IL-6 B-protein
compared O
with O
control O
mice O
. O
Stimulation O
of O
T I-cell_type
lymphocytes I-cell_type
by O
anti-CD3 B-protein
antibody O
also O
showed O
less O
induction O
of O
IL-1 B-protein
and O
IL-6 B-protein
in O
ATF-2 O
mutant O
tissues O
. O
ATF-2 O
mutant O
thymocytes O
treated O
with O
anti-CD3 B-protein
antibody O
in O
vitro O
demonstrated O
reduced O
induction O
of O
c-Jun O
, O
JunB I-protein
, O
JunD O
and O
Fra-2 B-protein
. O
However O
, O
similar O
to O
what O
was O
observed O
after O
p38 B-protein
kinase I-protein
inhibition O
in O
normal O
mice O
, O
relative O
ATF-2 O
deficiency O
did O
not O
prevent O
the O
development O
of O
a O
mononuclear O
cell O
infiltrate O
in O
the O
week O
following O
an O
inflammatory O
stimulus O
. O
ATF-2 O
mutant O
mice O
proved O
more O
susceptible O
to O
death O
than O
control O
mice O
from O
LPS O
plus O
D-galactosamine B-protein
injection O
or O
Coxsackievirus O
B3 B-protein
infection O
and O
had O
a O
higher O
incidence O
of O
mononuclear O
pulmonary O
infiltrates O
after O
exposure O
to O
Herpes O
simplex O
virus-1 B-protein
. O
ATF-2 O
is O
essential O
for O
maximal O
immediate O
induction O
of O
adhesion O
molecules I-protein
and O
cytokine I-DNA
genes I-DNA
, O
but O
at O
later O
time O
points O
may O
even O
protect O
against O
overactive O
immune O
responses O
. O
LIGHT I-protein
, O
a O
TNF-like B-protein
molecule O
, O
costimulates O
T O
cell O
proliferation O
and O
is O
required O
for O
dendritic O
cell O
-mediated O
allogeneic O
T O
cell O
response O
. O
LIGHT O
is O
a O
recently O
identified O
member O
of O
the O
TNF O
superfamily O
and O
its O
receptors O
, O
herpesvirus O
entry O
mediator O
and O
lymphotoxin O
beta I-DNA
receptor I-protein
, O
are O
found O
in O
T B-cell_type
cells I-cell_type
and O
stromal B-cell_type
cells I-cell_type
. O
In O
this O
study O
, O
we O
demonstrate O
that O
LIGHT O
is O
selectively O
expressed O
on O
immature O
dendritic B-cell_type
cells I-cell_line
( O
DCs O
) O
generated O
from O
human B-DNA
PBMCs I-cell_type
. O
In O
contrast O
, O
LIGHT O
is O
not O
detectable O
in O
DCs O
either O
freshly O
isolated O
from O
PBMCs O
or O
rendered O
mature O
in O
vitro O
by O
LPS O
treatment O
. O
Blockade O
of O
LIGHT O
by O
its O
soluble O
receptors O
, O
lymphotoxin O
beta O
receptor-Ig O
or O
HVEM-Ig I-DNA
, O
inhibits O
the O
induction O
of O
DC B-cell_type
-mediated O
primary B-cell_line
allogeneic I-cell_line
T O
cell O
response O
. O
Furthermore O
, O
engagement O
of O
LIGHT O
costimulates O
human B-cell_type
T I-cell_line
cell O
proliferation O
, O
amplifies O
the O
NF-kappaB O
signaling O
pathway O
, O
and O
preferentially O
induces O
the O
production O
of O
IFN-gamma B-RNA
, O
but O
not O
IL-4 B-protein
, O
in O
the O
presence O
of O
an O
antigenic O
signal O
. O
Our O
results O
suggest O
that O
LIGHT O
is O
a O
costimulatory O
molecule O
involved O
in O
DC B-protein
-mediated O
cellular O
immune O
responses O
. O
Suppression O
of O
HIV O
type O
1 O
replication O
by O
a O
dominant-negative B-DNA
Ets-1 B-protein
mutant O
. O
Activity O
of O
the O
distal O
region I-DNA
of O
the O
human B-DNA
immunodeficiency I-DNA
virus O
( O
HIV-1 B-protein
) O
long I-DNA
terminal I-DNA
repeat I-DNA
( O
LTR I-DNA
) O
, O
which O
contains O
binding O
sites O
for O
the O
Ets-1 B-protein
and O
USF-1 O
proteins I-protein
, O
is O
integral O
for O
HIV-1 O
replication O
. O
The O
Ets-1 B-protein
and O
USF-1 O
proteins I-protein
play O
a O
critical O
role O
in O
the O
activity O
of O
the O
HIV-1 O
LTR O
distal B-DNA
enhancer B-DNA
region I-DNA
, O
as O
indicated O
by O
the O
potent O
dominant O
negative O
effect O
of O
a O
mutant O
Ets-1 B-protein
lacking O
trans-activation O
domains O
on O
the O
transcriptional O
activity O
of O
the O
LTR O
. O
To O
determine O
the O
biological O
relevance O
of O
the O
Ets-1 B-protein
and O
USF-1 O
proteins I-protein
in O
HIV-1 O
replication O
, O
we O
examined O
the O
effect O
of O
expression O
of O
the O
dominant-negative B-DNA
mutant O
of O
Ets-1 B-protein
( O
dnEts-1 B-protein
) O
on O
HIV-1 O
infection O
of O
T B-cell_type
cells I-cell_type
. O
We O
demonstrated O
that O
expression O
of O
dnEts B-cell_type
markedly O
suppressed O
HIV-1 O
infection O
of O
a O
T O
cell O
line O
. O
This O
finding O
indicates O
that O
formation O
of O
a O
transcriptionaly O
active O
USF-1/Ets-1 B-protein
complex I-protein
is O
important O
in O
the O
productive O
infection O
of O
cells I-cell_type
by O
HIV-1 O
, O
and O
suggests O
that O
inhibition O
of O
the O
interaction O
between O
USF-1 O
and O
Ets-1 B-protein
with O
the O
HIV-1 O
LTR O
may O
provide O
a O
new O
target I-cell_line
for O
anti-HIV-1 B-DNA
gene I-DNA
therapy O
. O
Human O
eosinophils O
constitutively O
express O
nuclear B-protein
factor I-protein
of O
activated B-cell_type
T B-cell_type
cells I-cell_type
p O
and O
c O
. O
BACKGROUND I-protein
: O
Eosinophils O
are O
now O
known O
to O
produce O
a O
variety O
of O
proinflammatory O
cytokines O
, O
although O
the O
molecular B-protein
factors I-protein
that O
regulate O
their O
production O
are O
poorly O
understood O
. O
The O
expression O
of O
almost O
all O
of O
the O
cytokines O
produced O
by O
eosinophils O
, O
including O
the O
proallergic O
cytokine O
IL-4 B-protein
, O
is O
now O
known O
to O
be O
regulated O
at O
the O
level O
of O
transcription O
by O
members O
of O
the O
nuclear B-protein
factor I-protein
of O
activated B-cell_type
T B-cell_type
cells I-cell_type
( O
NFAT I-DNA
) O
family O
of O
transcription B-protein
factors I-protein
. O
OBJECTIVE O
: O
We O
sought O
to O
characterize O
the O
expression O
of O
different O
NFAT B-protein
proteins I-protein
in O
resting O
and O
activated O
eosinophils O
. O
METHODS I-protein
: O
Nuclear O
and O
whole O
cell O
extracts O
were O
obtained O
from O
both O
peripheral B-cell_type
blood I-cell_type
eosinophils I-cell_type
and O
those O
obtained O
from O
bronchoalveolar O
lavage O
fluid O
of O
asthmatic O
subjects O
after O
endobronchial O
allergen O
challenge O
. O
NFAT O
expression O
was O
determined O
by O
using O
immunoprecipitation O
and O
Western O
blot O
analysis O
, O
DNA-binding O
assays O
, O
and O
RT-PCR B-protein
analysis O
of O
eosinophil O
mRNA I-RNA
. O
RESULTS I-protein
: O
Both O
peripheral B-cell_type
blood I-cell_type
and I-cell_type
bronchoalveolar O
lavage O
fluid O
eosinophils O
expressed O
NFATp O
and O
NFATc O
protein O
. O
Unlike O
activated B-cell_type
T B-cell_type
cells I-cell_type
, O
which O
express O
multiple O
NFATc O
isoforms O
, O
eosinophils O
preferentially O
express O
the O
approximately O
85-kd B-DNA
isoform O
. O
In O
addition O
, O
eosinophils O
were O
found O
to O
constitutively O
express O
NFATc I-RNA
mRNA I-RNA
. O
A O
brief O
incubation O
with O
the O
T I-cell_line
( O
H I-DNA
) O
2 O
cytokines O
IL-4 B-protein
and O
IL-5 B-protein
was O
sufficient O
to O
induce O
the O
nuclear B-protein
translocation O
of O
NFATc O
. O
Eosinophil O
nuclear B-protein
extracts O
contain O
multiple B-protein
factors I-protein
that O
can O
specifically O
recognize O
the O
IL-4 B-DNA
promoter I-DNA
P1 B-protein
NFAT I-DNA
site I-DNA
in O
DNA-binding B-protein
assays O
, O
including O
NFATp O
. O
CONCLUSION I-protein
: O
NFATp O
and O
NFATc O
can O
regulate O
the O
expression O
of O
cytokines O
and O
other I-DNA
genes I-DNA
in O
eosinophils O
but O
appear O
to O
be O
regulated O
by O
a O
novel O
signal O
transduction O
mechanism O
in O
these I-cell_type
cells I-cell_type
. O
BLyS O
BINDS O
TO B-protein
B I-DNA
CELLS O
WITH O
HIGH O
AFFINITY O
AND O
INDUCES I-protein
ACTIVATION I-protein
OF B-protein
THE O
TRANSCRIPTION I-protein
FACTORS I-protein
NF-kappaB O
AND O
ELF-1 O
. O
B I-DNA
lymphocyte I-cell_line
stimulator O
( O
BLyS I-DNA
) O
is O
a O
novel O
member O
of O
the O
TNF O
family O
of O
proteins I-protein
expressed O
by O
myeloid B-cell_type
cells I-cell_type
as O
membrane-bound O
and O
soluble O
forms O
. O
BLyS O
was O
shown O
to O
act O
specifically O
on O
B I-DNA
cells I-cell_line
, O
inducing O
proliferation O
and O
immunoglobulin O
production O
both O
in O
vitro O
and O
in O
vivo O
. O
The O
present O
study O
was O
undertaken O
to O
characterize O
binding O
of O
radiolabeled O
BLyS O
to O
its O
cognate I-DNA
receptor I-protein
on O
human B-DNA
B I-DNA
lymphocytes I-cell_type
and O
examine O
intracellular O
events O
initiated O
by O
BLyS O
binding O
. O
Similar O
to O
other O
TNF O
family O
members O
, O
BLyS O
is O
present O
in O
solution O
as O
a O
homotrimer O
as O
determined O
by O
gel O
filtration O
chromatography O
and O
light O
scattering O
analysis O
. O
BLyS O
binding O
to O
B I-DNA
cells I-cell_type
is O
specific O
as O
other O
TNF O
family O
members O
tested O
did O
not O
compete O
for O
( O
125 O
) O
I- O
BLyS O
binding O
. O
Analysis O
of O
equilibrium O
binding O
of O
( O
125 O
) O
I-labeled O
BLyS O
to O
purified O
human B-DNA
tonsillar I-cell_type
B I-DNA
cells I-cell_type
demonstrated O
saturable O
binding O
. O
Scatchard O
analysis O
of O
the O
binding O
data O
revealed O
a O
single O
class O
of O
high-affinity O
binding O
on O
human B-DNA
B I-DNA
cells I-cell_type
with O
approximately O
2600 O
binding O
sites O
per O
cell O
and O
an O
apparent O
dissociation O
constant O
( O
K O
( O
D I-DNA
) O
) O
of O
about O
0.1 B-protein
nM I-RNA
. O
In O
addition O
we O
report O
that O
BLyS O
binding O
to O
B I-DNA
cells I-cell_type
results O
in O
the O
activation O
of O
NF-kappaB O
and O
the O
Ets O
family O
transcription B-protein
factor I-protein
, O
ELF-1 O
, O
and O
in O
the O
induction O
of O
mRNA I-RNA
for O
Polo-like O
kinase I-protein
( O
PLK I-DNA
) O
. O
Copyright O
2001 O
Academic O
Press O
. O
Design O
and O
use O
of O
an O
inducibly O
activated O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
Nef O
to O
study O
immune O
modulation O
. O
The O
Nef O
protein O
of O
the O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
( O
HIV-1 B-protein
) O
has O
been O
shown O
to O
enhance O
the O
infectivity O
of O
virus O
particles O
, O
downmodulate O
cell O
surface I-protein
proteins I-protein
, O
and O
associate O
with O
many O
intracellular O
proteins I-protein
that O
are O
thought O
to O
facilitate O
HIV O
infection O
. O
One O
of O
the O
challenges O
in O
defining O
the O
molecular O
events O
regulated O
by O
Nef O
has O
been O
obtaining O
good O
expression O
of O
Nef O
protein O
in O
T B-cell_type
cells I-cell_type
. O
This O
has O
been O
attributed O
to O
effects O
of O
Nef O
on O
cell O
proliferation O
and O
apoptosis O
. O
We O
have O
designed O
a O
Nef O
protein O
that O
is O
readily O
expressed O
in O
T-cell B-cell_line
lines I-cell_line
and O
whose O
function O
is O
inducibly O
activated O
. O
It O
is O
composed O
of O
a O
fusion O
between O
full-length O
Nef O
and O
the O
estrogen B-protein
receptor I-protein
hormone-binding O
domain I-protein
( O
Nef-ER I-DNA
) O
. O
The O
Nef-ER B-protein
is O
kept O
in O
an O
inactive O
state O
due O
to O
steric O
hindrance O
, O
and O
addition O
of O
the O
membrane-permeable O
drug O
4-hydroxytamoxifen O
( O
4-HT B-protein
) O
, O
which O
binds O
to O
the O
ER I-protein
domain I-protein
, O
leads O
to O
inducible O
activation O
of O
Nef-ER B-protein
within B-cell_type
cells I-cell_type
. O
We O
demonstrate O
that O
Nef-ER B-protein
inducibly O
associates O
with O
the O
62-kDa B-protein
Ser/Thr I-protein
kinase I-protein
and O
is O
localized O
to O
specific O
membrane O
microdomains O
( O
lipid O
rafts O
) O
only O
after O
activation O
. O
Using O
this O
inducible O
Nef O
, O
we O
also O
compared O
the O
specific O
requirements O
for O
CD4 B-protein
and O
HLA-A2 B-protein
downmodulation O
in O
a O
SupT1 B-DNA
T-cell O
line O
. O
Half-maximal O
downmodulation O
of O
cell O
surface I-protein
CD4 B-protein
required O
very O
little O
active O
Nef-ER O
and O
occurred O
as O
early O
as O
4 O
h O
after O
addition O
of O
4-HT B-protein
. O
In O
contrast O
, O
50 O
% O
downmodulation O
of O
HLA-A2 B-protein
by O
Nef O
required O
16 O
to O
24 O
h O
and O
about O
50- O
to O
100-fold-greater O
concentrations O
of O
4-HT B-protein
. O
These O
data O
suggest O
that O
HLA-A2 B-protein
downmodulation O
may O
require O
certain O
threshold O
levels O
of O
active O
Nef O
. O
The O
differential O
timing O
of O
CD4 B-protein
and O
HLA-A2 B-protein
downmodulation O
may O
have O
implications O
for O
HIV O
pathogenesis O
and O
immune O
evasion O
. O
Regulation O
of O
chemokine O
mRNA I-RNA
expression O
in O
a O
rat O
model O
of O
vanadium-induced I-cell_line
pulmonary O
inflammation O
. O
Environmental B-cell_type
and O
occupational O
exposure O
to O
vanadium O
dusts O
results O
in O
toxic O
effects O
mainly O
confined O
to O
the O
respiratory O
system O
. O
Using O
a O
rat O
model O
of O
acute O
lung O
inflammation O
induced O
by O
intratracheal O
instillation O
of O
sodium O
metavanadate O
( O
NaVO3 I-DNA
) O
at O
the O
dose O
of O
200 O
microg O
V/kg I-protein
, O
we O
investigated O
the O
relationship O
between O
the O
cytologic O
characterization O
of O
pulmonary O
inflammation O
and O
the O
expression O
of O
chemokine O
mRNA I-RNA
. O
Significant O
polymorphonuclear O
leukocyte O
( O
PMN I-DNA
) O
influx O
( O
P O
< O
0.01 B-protein
) O
into O
the O
lung O
was O
noted O
4 O
h O
after O
NaVO3 B-DNA
instillation O
, O
whereas O
alveolar O
macrophages O
( O
AMs O
) O
in O
bronchoalveolar O
lavage O
( O
BAL I-DNA
) O
cells I-cell_type
appeared O
to O
decrease O
significantly O
. O
In O
contrast O
, O
neither O
PMNs O
nor O
AMs O
changed O
substantially O
1 O
h O
after O
NaVO3 B-DNA
instillation O
. O
By O
Northern O
analysis O
, O
macrophage O
inflammatory O
protein I-protein
( O
MIP I-DNA
) O
-2 I-RNA
mRNA I-RNA
in O
BAL B-cell_type
cells I-cell_type
increased O
markedly O
1 O
h O
after O
NaVO3 B-DNA
instillation O
and O
reduced O
a O
little O
bit O
at O
4 O
h O
, O
whereas O
MIP-1alpha I-RNA
mRNA I-RNA
in O
BAL B-cell_type
cells I-cell_type
was O
expressed O
relatively O
high O
1 O
h O
after O
NaVO3 B-DNA
instillation O
, O
although O
a O
basal O
expression O
was O
detected O
in O
control O
group O
, O
and O
returned O
rapidly O
nearly O
to O
control O
level O
at O
4 O
h O
. O
Since O
MIP-2 O
is O
a O
potent O
PMN O
chemoattractant O
and O
MIP-1alpha B-protein
is O
a O
potent O
macrophage/monocyte B-DNA
chemoattractant O
has O
been O
well O
known O
. O
The O
facts O
that O
PMN O
influx O
was O
preceded O
by O
increased O
MIP-2 I-RNA
mRNA I-RNA
expression O
, O
suggesting O
that O
MIP-2 O
is O
involved O
in O
the O
development O
of O
NaVO3-induced B-protein
pulmonary O
inflammation O
, O
whereas O
increased O
MIP-1alpha I-RNA
mRNA I-RNA
expression O
was O
followed O
by O
decreased O
AMs O
in O
BAL B-cell_type
cells I-cell_line
, O
suggesting O
AMs O
might O
be O
activated O
by O
MIP-1alpha O
, O
adherent O
to O
the O
lining O
surface I-protein
of O
the O
airways O
and O
then O
resistant O
to O
be O
washed O
out O
. O
To O
delineate O
the O
mechanisms O
of O
transcriptional O
activation O
, O
we O
recently O
cloned O
the O
5'-flanking B-DNA
region I-DNA
of O
the O
MIP-2 B-DNA
gene I-DNA
. O
The O
promotor O
region O
contains O
consensus O
binding O
sites O
for O
transcription B-protein
factor I-protein
nuclear B-protein
factor I-protein
kappaB B-protein
( O
NF-kappaB I-DNA
) O
and O
activator O
protein-1 B-protein
( O
AP-1 B-protein
) O
. O
Using O
electrophoretic O
mobility O
shift O
assay O
, O
increased O
nuclear B-protein
NF-kappaB I-DNA
, O
not O
AP-1 B-protein
, O
binding O
activity O
was O
detected O
1 O
h O
after O
NaVO3 B-DNA
instillation O
, O
which O
correlated O
with O
the O
induction O
of O
MIP-2 I-RNA
mRNA I-RNA
. O
p65 I-cell_line
( O
Rel O
A O
) O
and O
p50 O
protein O
appears O
to O
be O
involved O
in O
MIP-2 O
NF-kappaB O
binding O
. O
Taken O
together O
, O
our O
studies O
suggest O
that O
MIP-2 O
is O
an O
important O
mediator O
of O
NaVO3-induced B-protein
pulmonary O
inflammation O
in O
the O
rat O
model O
. O
In O
addition O
, O
elevated O
MIP-2 I-RNA
mRNA I-RNA
levels O
are O
accompanied O
by O
increased O
NF-kappaB O
binding O
activity O
in O
BAL B-cell_type
cells I-cell_line
, O
suggesting O
possible O
MIP-2 O
transcriptional O
regulation O
through O
NF-kappaB O
. O
Activation O
of O
signal O
transduction O
and O
apoptosis O
in O
healthy O
lymphomonocytes O
exposed O
to O
bystander O
HIV-1-infected B-protein
cells I-cell_type
. O
Persistent O
activation O
of O
the O
immune O
system O
is O
one O
of O
the O
hallmarks O
of O
HIV-1 O
infection O
. O
In O
this O
study O
we O
analysed O
the O
induction O
of O
factors I-protein
involved O
in O
cytokine O
signal O
transduction O
, O
such O
as O
STAT B-protein
1 O
proteins I-protein
and O
IRF-1 I-RNA
mRNA I-RNA
, O
in O
normal O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_line
( O
PBMC I-DNA
) O
exposed O
to O
HIV-infected B-protein
cells I-cell_line
, O
and O
the O
induction O
of O
apoptosis O
. O
Western O
blot O
analyses O
and O
reverse O
transcriptase-polymerase B-DNA
chain O
reaction O
results O
indicate O
that O
both B-cell_type
cells I-cell_type
infected O
with O
a O
X4 B-protein
strain O
and I-DNA
cells I-cell_type
infected O
with O
a O
R5 B-protein
strain O
are O
able O
to O
increase O
intracellular O
levels O
of O
STAT B-protein
1alpha I-protein
and O
beta O
proteins I-protein
as O
well O
as O
IRF-1 I-RNA
mRNA I-RNA
. O
This O
effect O
was O
prevented O
by O
neutralizing B-protein
antibodies I-protein
against O
interferon-alpha I-cell_line
( O
IFN-alpha I-DNA
) O
. O
HIV-1-infected B-protein
cells I-cell_type
dose-dependently O
induced O
apoptotic O
commitment O
in O
normal O
PBMC I-protein
, O
as O
revealed O
by O
DNA O
fragmentation O
analysis O
, O
but O
this O
was O
not O
accompanied O
by O
an O
increase O
of O
caspase-3 B-protein
activity O
, O
even O
if O
a O
slight O
up-regulation I-DNA
of O
IL-1beta-converting B-protein
enzyme O
mRNA I-RNA
was O
detected O
. O
Apoptosis O
induction O
could O
be O
abrogated O
mainly O
by O
antibodies I-protein
against O
tumour O
necrosis O
factor-alpha B-DNA
( O
TNF-alpha I-DNA
) O
and O
, O
to O
a O
lesser O
extent I-protein
, O
by O
antibodies I-protein
against O
IFN-gamma B-protein
. O
All O
these O
findings O
suggest O
that O
uninfected O
PBMC O
can O
undergo O
activation O
of O
signal O
transduction O
and O
apoptosis O
after O
exposure O
to O
bystander O
HIV-infected B-protein
cells I-cell_line
, O
subsequent O
to O
the O
induction O
of O
cytokines O
such O
as O
IFNs O
and O
TNF-alpha B-protein
. O
The O
physical O
association O
of O
protein O
kinase I-protein
C I-protein
theta O
with O
a O
lipid O
raft-associated O
inhibitor O
of O
kappa B-DNA
B I-protein
factor I-protein
kinase I-protein
( O
IKK I-DNA
) O
complex I-protein
plays O
a O
role O
in O
the O
activation O
of O
the O
NF-kappa B-protein
B I-protein
cascade O
by O
TCR O
and O
CD28 B-protein
. O
We O
investigated O
the O
role O
of O
protein O
kinase I-protein
C I-protein
theta O
( O
PKCtheta I-DNA
) O
in O
the O
activation O
of O
the O
NF-kappaB O
cascade O
in O
primary B-cell_line
human I-cell_line
CD4 B-protein
( O
+ O
) O
lymphocytes I-cell_type
. O
Among O
six O
or O
so O
PKC O
isoforms O
expressed O
in O
T B-cell_type
cells I-cell_type
, O
only O
PKCtheta O
participates O
in O
the O
assembly O
of O
the O
supramolecular O
activation O
clusters O
at O
the O
contact O
site I-DNA
of O
the O
TCR O
with O
Ag O
. O
Signaling O
via O
both O
the O
TCR O
and O
CD28 B-protein
is O
required O
for O
optimal O
activation O
of O
the O
multisubunit O
IkappaB I-protein
kinase I-protein
( O
IKK I-DNA
) O
complex I-protein
in O
primary B-cell_line
human I-cell_line
T I-cell_type
lymphocytes I-cell_type
; O
this O
activation O
could O
be O
inhibited O
by O
a O
Ca O
( O
2+ O
) O
-independent O
PKC O
isoform O
inhibitor O
, O
rottlerin O
. O
Moreover O
, O
endogenous O
PKCtheta O
physically O
associates O
with O
activated O
IKK O
complexes O
in O
CD3/CD28-costimulated O
primary B-cell_line
CD4 I-cell_line
( O
+ O
) O
T B-cell_type
cells I-cell_type
. O
The O
same O
set O
of O
stimuli O
also O
induced O
relocation O
of O
endogenous O
PKCtheta O
and O
IKKs O
to O
a O
GM1 B-protein
ganglioside-enriched I-DNA
, O
detergent-insoluble O
membrane O
compartment O
in O
primary B-cell_type
T I-cell_line
cells I-cell_type
. O
IKKs O
recruited O
to O
these O
lipid O
rafts O
were O
capable O
of O
phosphorylating O
a O
recombinant O
IkappaBalpha O
sustrate O
. O
Confocal O
microscopy O
further O
demonstrated O
that O
exogenously O
expressed O
PKCtheta O
and O
IKKss O
colocalize O
in O
the O
membrane O
of O
CD3/CD28-costimulated O
Jurkat O
T B-cell_type
cells I-cell_type
. O
Constitutively O
active O
but O
not O
kinase-inactive O
PKCtheta O
activated O
IKKbeta O
in O
Jurkat O
T B-cell_type
cells I-cell_type
. O
Expression O
of O
dominant-active O
PKCtheta O
also O
had O
stimulatory O
effects O
on O
the O
CD28 B-protein
response O
element I-DNA
of O
the O
IL-2 B-DNA
promoter I-DNA
. O
Taken O
together O
, O
these O
data O
show O
that O
the O
activation O
of O
PKCtheta O
by O
the O
TCR O
and O
CD28 B-protein
plays O
an O
important O
role O
in O
the O
assembly O
and O
activation O
of O
IKK B-cell_type
complexes O
in O
the O
T O
cell O
membrane O
T-cell O
-mediated O
regulation O
of O
osteoclastogenesis O
by O
signalling O
cross-talk B-DNA
between O
RANKL O
and O
IFN-gamma B-protein
. O
Bone O
resorption O
is O
regulated O
by O
the O
immune O
system I-protein
, O
where O
T-cell O
expression O
of O
RANKL B-cell_type
( O
receptor I-DNA
activator O
of O
nuclear B-protein
factor I-protein
( O
NF I-DNA
) O
-kappaB O
ligand O
) O
, O
a O
member O
of O
the O
tumour-necrosis B-protein
factor I-protein
family O
that O
is O
essential O
for O
osteoclastogenesis I-protein
, O
may O
contribute O
to O
pathological O
conditions O
, O
such O
as O
autoimmune O
arthritis O
. O
However O
, O
whether O
activated B-cell_type
T B-cell_type
cells I-cell_type
maintain O
bone I-cell_line
homeostasis O
by O
counterbalancing O
the O
action O
of O
RANKL O
remains O
unknown O
. O
Here O
we O
show O
that O
T-cell O
production O
of O
interferon O
( O
IFN I-DNA
) O
-gamma O
strongly O
suppresses O
osteoclastogenesis O
by O
interfering O
with O
the O
RANKL O
-RANK B-protein
signalling O
pathway O
. O
IFN-gamma B-protein
induces O
rapid O
degradation O
of O
the O
RANK O
adapter O
protein I-protein
, O
TRAF6 B-protein
( O
tumour O
necrosis B-protein
factor I-protein
receptor-associated B-protein
factor I-protein
6 O
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL O
-induced O
activation O
of O
the O
transcription B-protein
factor I-protein
NF-kappaB O
and O
JNK O
. O
This O
inhibition O
of O
osteoclastogenesis O
is O
rescued O
by O
overexpressing O
TRAF6 B-protein
in O
precursor B-cell_type
cells I-cell_line
, O
which O
indicates O
that O
TRAF6 B-protein
is O
the O
target I-cell_line
critical O
for O
the O
IFN-gamma B-protein
action O
. O
Furthermore O
, O
we O
provide O
evidence O
that O
the O
accelerated O
degradation O
of O
TRAF6 B-protein
requires O
both O
its O
ubiquitination O
, O
which O
is O
initiated O
by O
RANKL I-protein
, O
and O
IFN-gamma B-protein
-induced O
activation O
of O
the O
ubiquitin-proteasome B-DNA
system O
. O
Our O
study O
shows O
that O
there O
is O
cross-talk B-DNA
between O
the O
tumour O
necrosis B-protein
factor I-protein
and O
IFN O
families O
of O
cytokines O
, O
through O
which O
IFN-gamma B-protein
provides O
a O
negative O
link O
between O
T-cell O
activation O
and O
bone B-cell_type
resorption O
. O
Our O
results O
may O
offer O
a O
therapeutic O
approach O
to O
treat O
the O
inflammation-induced B-DNA
tissue O
breakdown O
. O
Stromal-derived B-protein
factor I-protein
1 O
and O
thrombopoietin O
regulate O
distinct O
aspects O
of O
human B-cell_type
megakaryopoiesis I-cell_type
. O
The O
role O
of O
the O
chemokine O
binding O
stromal-derived O
factor I-protein
1 O
( O
SDF-1 O
) O
in O
normal O
human B-cell_type
megakaryopoiesis I-cell_type
at O
the O
cellular O
and O
molecular O
levels O
and O
its O
comparison O
with O
that O
of O
thrombopoietin O
( O
TPO I-DNA
) O
have O
not O
been O
determined O
. O
In O
this O
study O
it O
was O
found O
that O
SDF-1 O
, O
unlike O
TPO I-protein
, O
does O
not O
stimulate O
alpha I-DNA
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cell O
proliferation O
or O
differentiation O
or O
have O
an O
antiapoptotic O
effect O
. O
However O
, O
it O
does O
induce O
chemotaxis O
, O
trans-Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase O
9 O
( O
MMP-9 O
) O
and O
vascular O
endothelial O
growth I-protein
factor I-protein
( O
VEGF I-DNA
) O
by O
these I-cell_type
cells I-cell_line
, O
and O
both O
SDF-1 O
and O
TPO O
increase O
the O
adhesion O
of O
alpha I-DNA
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen O
and O
vitronectin O
. O
Investigating B-cell_type
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF-1 O
and O
TPO O
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation/activation I-protein
( O
mitogen-activated O
protein O
kinase I-protein
[ O
MAPK O
] O
p42/44 I-cell_line
, O
MAPK O
p38 I-protein
, O
and O
AKT O
[ O
protein O
kinase I-protein
B I-DNA
] O
) O
and O
some O
that O
were O
distinct O
for O
TPO I-protein
( O
eg O
, O
JAK-STAT B-protein
) O
and O
for O
SDF-1 O
( O
eg O
, O
NF-kappa B-protein
B I-DNA
) O
. O
It O
was O
also O
found O
that O
though O
inhibition O
of O
phosphatidyl-inositol O
3-kinase B-protein
( O
PI-3K B-protein
) O
by O
LY294002 B-protein
in O
alpha I-DNA
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells I-cell_type
induced O
apoptosis O
and O
inhibited O
chemotaxis O
adhesion O
and O
the O
secretion O
of O
MMP-9 O
and O
VEGF I-protein
, O
the O
inhibition O
of O
MAPK O
p42/44 I-cell_line
( O
by O
the O
MEK O
inhibitor O
U0126 B-protein
) O
had O
no O
effect O
on O
the O
survival O
, O
proliferation O
, O
and O
migration O
of O
these B-cell_type
cells I-cell_type
. O
Hence O
, O
it O
is O
suggested O
that O
the O
proliferative O
effect O
of O
TPO B-cell_type
is O
more O
related O
to O
activation O
of O
the O
JAK-STAT B-protein
pathway O
( O
unique O
to O
TPO O
) O
, O
and O
the O
PI-3K-AKT B-protein
axis O
is O
differentially O
involved O
in O
TPO- B-DNA
and O
SDF-1-dependent B-protein
signaling O
. O
Accordingly O
, O
PI-3K B-protein
is O
involved O
in O
TPO O
-mediated O
inhibition O
of O
apoptosis O
, O
TPO- O
and O
SDF-1-regulated B-protein
adhesion O
to O
fibrinogen O
and O
vitronectin O
, O
and O
SDF-1 O
-mediated O
migration O
. O
This O
study O
expands O
the O
understanding O
of O
the O
role O
of O
SDF-1 O
and O
TPO O
in O
normal O
human B-cell_type
megakaryopoiesis I-cell_type
and O
indicates O
the O
molecular O
basis O
of O
the O
observed O
differences O
in O
cellular O
responses O
. O
( O
Blood. I-DNA
2000 O
; O
96 O
: O
4142-4151 O
) O
Adhesion O
of O
immature O
and O
mature O
T B-cell_type
cells I-cell_type
induces O
in O
human B-DNA
thymic B-cell_line
epithelial B-cell_type
cells I-cell_line
( O
TEC I-DNA
) O
activation O
of O
IL-6 B-DNA
gene I-DNA
trascription O
factors I-protein
( O
NF-kappaB I-DNA
and O
NF-IL6 B-protein
) O
and O
IL-6 B-protein
gene I-DNA
expression O
: O
role O
of O
alpha3beta1 O
and O
alpha6beta4 O
integrins O
. O
T O
cell O
precursors I-cell_line
homed O
to O
thymus O
develop O
in O
close O
contact O
with O
stromal B-cell_type
cells I-cell_type
. O
Among O
them O
, O
thymic B-cell_line
epithelial B-cell_type
cells I-cell_line
( O
TEC I-DNA
) O
are O
known O
to O
exert O
dominant O
roles O
in O
their O
survival O
and O
functional O
shaping O
. O
Key O
molecules I-protein
mediating O
TEC O
/ O
thymocytes O
interactions O
include O
cytokines O
and O
growth B-protein
factors I-protein
secreted O
by O
the O
two O
cell O
types I-cell_type
and O
adhesion O
receptors O
mediating O
cell O
contact O
. O
Signaling O
events O
triggered O
in O
thymocytes O
by O
adhesion O
to O
epithelial O
cells I-cell_type
have O
been O
extensively O
investigated O
, O
whereas O
little O
is O
known O
on O
the O
opposite O
phenomenon O
. O
We O
have O
previously O
investigated O
this O
issue O
in O
a O
co-culture B-DNA
system O
composed O
of O
TEC B-cell_type
cultures I-cell_line
derived O
from O
human O
normal O
thymus O
and O
heterologous O
thymocytes O
. O
We O
demonstrated O
that O
thymocytes O
adhere O
to O
TEC O
involving O
beta1 I-protein
and O
beta4 O
integrins O
and O
induce O
the O
clustering O
of O
alpha3beta1 O
and O
alpha6beta4 O
heterodimers O
at O
the O
TEC O
surface I-protein
. O
In O
addition O
thymocyte O
adhesion O
was O
followed O
by O
activation O
of O
NF-kappaB O
and O
NF-IL6 B-protein
gene I-DNA
transcription B-protein
factors I-protein
and O
enhanced O
IL-6 B-protein
production O
. O
The O
two O
latter O
phenomena O
were O
reproduced O
by O
the O
cross-linking I-DNA
of O
the O
alpha3 I-protein
, O
alpha6 I-protein
, O
beta1 O
and O
beta4 O
integrins O
, O
thus O
implying O
that O
the O
alpha3beta1 O
and O
alpha6beta4 O
heterodimers O
can O
signal O
during O
thymocyte O
adhesion O
. O
We O
have O
extended O
our O
previous O
work O
investigating O
in O
the O
same O
experimental O
setting O
the O
inducing O
activity O
of O
non O
stimulated O
or O
activated O
policlonal O
or O
clonal O
mature O
T B-cell_type
cells I-cell_type
as O
representative O
of O
the O
more O
mature O
thymocyte O
subset O
. O
We O
found O
that O
adhesion O
of O
unstimulated B-cell_type
T O
cell O
i O
) O
involved O
beta1 I-protein
, O
but O
not O
beta4 I-protein
integrin O
functions O
at O
the O
surface I-protein
ii O
) O
induced O
the O
clustering O
of O
alpha3beta1 B-cell_type
, O
but O
not O
alpha2beta1 O
heterodimers O
at O
the O
TEC O
surface I-protein
and O
iii O
) O
up-regulated O
the O
nuclear B-protein
binding O
activity O
of O
NF-kappaB B-protein
transcription B-protein
factor I-protein
and O
the O
IL-6 B-protein
secretion O
. O
We O
propose O
that O
alpha3beta1 O
and O
alpha6beta4 O
heterodimers O
are O
induced O
to O
cluster O
at O
the O
TEC O
surface I-protein
recognizing O
yet O
unknown O
cellular O
ligands O
differentially O
expressed O
during O
T O
cell O
development O
. O
Identification O
and O
characterization O
of O
SKAT-2 B-protein
, O
a O
novel O
Th2-specific B-protein
zinc O
finger O
gene I-DNA
. O
We O
have O
identified O
a O
novel O
Kruppel-type O
zinc O
finger O
( O
ZF I-DNA
) O
gene I-DNA
, O
SKAT-2 B-protein
, O
which O
is O
selectively O
expressed O
by O
murine I-cell_line
Th2 B-cell_type
cells I-cell_type
. O
The O
protein O
encoded O
by O
this O
gene I-DNA
has O
14 O
C2H2-type B-protein
ZF B-protein
tandemly O
arrayed O
at O
its O
C I-protein
terminus O
and O
N-terminal B-protein
SCAN O
box O
and O
KRAB O
domains O
. O
SKAT-2 B-protein
is O
tissue O
restricted O
in O
expression O
at O
the O
RNA O
level O
, O
detectable O
only O
in O
brain O
and O
at O
low O
levels O
in O
kidney O
and O
spleen O
and O
few O
hematopoietic B-cell_type
cell O
lines I-cell_line
. O
By O
in O
situ O
hybridization O
, O
SKAT-2 B-protein
expression O
was O
found O
to O
peak O
in O
antigen-stimulated O
CD4 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
after O
2-3 O
days O
of O
culture O
under O
Th2 O
but O
not O
Th1 O
biasing O
conditions O
. O
This O
pattern O
of O
expression O
closely O
mirrored O
that O
of O
GATA-3 B-protein
in O
the O
same B-cell_type
cells I-cell_type
. O
In O
transient O
transfection O
experiments O
in O
phorbol O
12-myristate B-protein
13-acetate/ionomycin-stimulated B-protein
EL4 B-protein
cells I-cell_line
, O
SKAT-2 B-protein
was O
found O
to O
up-regulate O
the O
activity O
of O
the O
IL-4 B-protein
but O
not O
the O
IL-5 B-DNA
promoter I-DNA
, O
contrasting O
with O
the O
ability O
of O
GATA-3 B-protein
to O
activate O
both O
promoters O
. O
This O
result O
was O
confirmed O
using O
clones O
of O
EL4 B-cell_type
cells I-cell_type
stably O
expressing O
an O
inducible O
form O
of O
SKAT-2 B-protein
, O
thus O
SKAT-2 B-protein
is O
a O
novel O
Th2-specific B-DNA
gene I-DNA
that O
may O
play O
a O
role O
in O
selective O
regulation O
of O
cytokine I-DNA
genes I-DNA
in O
T B-cell_type
cells I-cell_type
. O
hsp70 I-protein
interacting O
protein O
Hip O
does O
not O
affect O
glucocorticoid I-DNA
receptor I-protein
folding O
by O
the O
hsp90-based O
chaperone O
machinery O
except O
to O
oppose O
the O
effect O
of O
BAG-1 O
. O
Reticulocyte O
lysate O
contains O
a O
chaperone O
system O
that O
assembles O
glucocorticoid I-DNA
receptor I-protein
( O
GR I-DNA
) O
.hsp90 B-protein
heterocomplexes O
. O
Using O
purified O
proteins I-protein
, O
we O
have O
prepared O
a O
five-protein B-DNA
heterocomplex O
assembly O
system O
consisting O
of O
two O
proteins I-protein
essential O
for O
heterocomplex O
assembly- B-DNA
hsp90 I-protein
and O
hsp70 O
-and O
three O
proteins I-protein
that O
act O
as O
co-chaperones O
to O
enhance O
assembly- B-DNA
Hop O
, O
hsp40 I-protein
, O
p23 O
[ O
Morishima O
, O
Y. I-protein
, O
Kanelakis O
, O
K. B-protein
C. I-protein
, O
Silverstein O
, O
A. B-protein
M. I-protein
, O
Dittmar O
, O
K. B-protein
D. I-protein
, O
Estrada O
, O
L. I-protein
, O
and O
Pratt O
, O
W. B-protein
B. I-cell_line
( O
2000 I-DNA
) O
J. B-protein
Biol. B-DNA
Chem. B-DNA
275 O
, O
6894-6900 O
] O
. O
The O
hsp70 I-protein
co-chaperone B-DNA
Hip O
has O
been O
recovered O
in O
receptor.hsp90 B-protein
heterocomplexes O
at O
an O
intermediate O
stage O
of O
assembly O
in O
reticulocyte O
lysate I-protein
, O
and O
Hip O
is O
also O
thought O
to O
be O
an O
intrinsic O
component O
of O
the O
assembly O
machinery O
. O
Here O
we O
show O
that O
immunodepletion O
of O
Hip O
from O
reticulocyte O
lysate O
or O
addition O
of O
high O
levels O
of O
Hip O
to O
the O
purified O
five-protein B-DNA
system O
does O
not O
affect O
GR.hsp90 B-protein
heterocomplex O
assembly O
or O
the O
activation O
of O
steroid O
binding O
activity O
that O
occurs O
with O
assembly O
. O
Despite O
the O
fact O
that O
Hip O
does O
not O
affect O
assembly O
, O
it O
is O
recovered O
in O
GR.hsp90 B-protein
heterocomplexes O
assembled O
by O
both O
systems O
. O
In O
the O
five-protein B-DNA
system I-protein
, O
Hip O
prevents O
inhibition O
of O
assembly O
by O
the O
hsp70 I-protein
co-chaperone B-DNA
BAG-1 O
, O
and O
cotransfection O
of O
Hip O
with O
BAG-1 O
opposes O
BAG-1 O
reduction O
of O
steroid O
binding O
activity O
in O
COS B-cell_line
cells I-cell_type
. O
We O
conclude O
that O
Hip O
is O
not O
a O
component O
of O
the O
assembly O
machinery O
but O
that O
it O
could O
play O
a O
regulatory O
role O
in O
opposition O
to O
BAG-1 O
. O
Cutting O
edge O
: O
STAT6-deficient B-protein
mice O
have O
enhanced O
tumor O
immunity O
to O
primary B-cell_line
and O
metastatic O
mammary O
carcinoma O
. O
STAT4 B-protein
and O
STAT6 B-protein
are O
essential O
for O
the O
development O
of O
CD4 B-protein
( O
+ O
) O
Th1 O
and O
Th2 O
development O
, O
respectively O
. O
Tumor O
immunologists O
have O
hypothesized O
that O
Th1 B-cell_type
cells I-cell_type
are O
critical O
in O
tumor O
immunity O
because O
they O
facilitate O
differentiation O
of O
CD8 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
, O
which O
are O
potent O
anti-tumor B-DNA
effectors O
. O
We O
have O
used O
STAT4 B-protein
( O
-/- O
) O
and O
STAT6 B-protein
( O
-/- O
) O
mice O
to O
test O
this O
hypothesis O
. O
BALB/c I-cell_type
and O
knockout O
mice O
were O
challenged O
in O
the O
mammary O
gland O
with O
the O
highly O
malignant O
and O
spontaneously O
metastatic O
BALB/c-derived B-protein
4T1 B-protein
mammary O
carcinoma O
. O
Primary O
tumor O
growth O
and O
metastatic O
disease O
are O
reduced O
in O
STAT6 B-protein
( O
-/- O
) O
mice O
relative O
to O
BALB/c O
and O
STAT4 B-protein
( O
-/- O
) O
mice O
. O
Ab O
depletions O
demonstrate O
that O
the O
effect O
is O
mediated O
by O
CD8 B-protein
( O
+ O
) O
T B-cell_type
cells I-cell_type
, O
and O
immunized O
STAT6 B-protein
( O
-/- O
) O
mice O
have O
higher O
levels O
of O
4T1-specific B-protein
CTL O
than O
BALB/c B-protein
or O
STAT4 B-protein
( O
-/- O
) O
mice O
. O
Surprisingly I-protein
, O
Th1 O
or O
Th2 B-cell_type
cells I-cell_type
are O
not O
involved O
, O
because O
CD4 B-protein
depletion O
does O
not O
diminish O
the O
anti-tumor B-DNA
effect O
. O
Therefore O
, O
deletion O
of O
the O
STAT6 B-DNA
gene I-DNA
facilitates O
development O
of O
potent O
anti-tumor B-DNA
immunity O
via O
a O
CD4 B-protein
( O
+ O
) O
-independent O
pathway O
. O
Activation O
of O
oncogenic O
transcription B-protein
factor I-protein
AP-1 B-protein
in O
T B-cell_type
cells I-cell_type
infected O
with O
human B-cell_type
T I-cell_line
cell O
leukemia O
virus O
type O
1 O
. O
Human O
T O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV-1 B-protein
) O
Tax O
protein O
transforms O
primary B-cell_line
human I-cell_line
T I-cell_type
cells I-cell_type
in O
vitro O
. O
We O
previously O
showed O
that O
Tax O
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B-protein
factor I-protein
AP-1 B-protein
such O
as O
c-Jun I-DNA
, O
JunD I-protein
, O
c-Fos O
, O
and O
Fra-1 B-protein
at O
the O
mRNA I-RNA
level O
in O
T B-cell_type
cells I-cell_type
. O
In O
this O
study O
, O
we O
have O
examined O
the O
ability O
of O
Tax O
to O
activate O
transcription O
through O
the O
AP-1-binding B-DNA
site I-DNA
( O
AP-1 B-protein
site I-DNA
) O
. O
A O
transient O
transfection O
study O
showed O
that O
Tax O
can O
activate O
transcription O
through O
the O
AP-1-binding B-DNA
site I-DNA
in O
a O
human B-cell_type
T I-cell_line
cell O
line O
, O
whereas O
any O
combination O
of O
AP-1 B-protein
proteins I-protein
did O
so O
much O
less O
than O
Tax O
, O
indicating O
that O
the O
activation O
of O
the O
AP-1 B-protein
site I-DNA
by O
Tax O
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP-1 B-protein
mRNA I-RNA
. O
Fresh O
peripheral B-cell_type
blood I-cell_type
leukemia I-cell_type
cells I-cell_type
of O
all O
surveyed O
ATL O
patients O
displayed O
constitutive O
AP-1 B-protein
DNA-binding B-protein
activity O
, O
whereas O
no O
normal O
individuals O
did O
. O
However O
, O
the O
HTLV-1 B-protein
genes I-DNA
, O
including O
tax O
, O
are O
not O
significantly O
expressed O
in O
fresh O
leukemia B-cell_type
cells I-cell_type
from O
ATL O
patients O
. O
Our O
present O
results O
suggest O
that O
activation O
of O
AP-1 B-protein
occurs O
through O
Tax-dependent O
and O
-independent O
mechanisms O
in O
HTLV-1-infected O
T B-cell_type
cells I-cell_type
, O
which O
may O
play O
some O
roles O
in O
dysregulated O
phenotypes O
of O
HTLV-1-infected B-cell_type
cells I-cell_type
. O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6'-pentachlorobiphenyl O
induces O
apoptosis O
in O
human O
monocytic B-cell_line
cells I-cell_type
. O
Polychlorinatedbiphenyls I-cell_line
( O
PCBs O
) O
are O
a O
group O
of O
persistent O
and O
widely O
dispersed O
environmental O
pollutants O
, O
some O
of O
which O
may O
be O
immunotoxic O
. O
In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
PCBs O
on O
immune O
system O
by O
assessing O
apoptotic O
cell O
death O
in O
human O
monocytic B-cell_line
U937 B-protein
cells I-cell_type
. O
Among O
the O
various O
congeners O
tested I-protein
, O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6'-pentachlorobiphenyl B-protein
( O
PeCB I-DNA
) O
, O
a O
highly O
ortho-substituted B-DNA
congener O
, O
specifically O
induced O
DNA O
fragmentation O
, O
a O
hallmark O
of O
apoptosis O
, O
while O
the O
other O
examined O
di- O
, O
tri- O
, O
tetra- B-DNA
, O
and O
pentachlorobiphenyls O
did O
not O
. O
To O
further O
study O
the O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6'-PeCB-induced O
cell O
death O
, O
various O
features O
of O
apoptosis O
were O
examined O
. O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6'-PeCB O
caused O
a O
decrease O
in O
cell O
viability O
and O
induced O
cellular O
morphologic O
features O
characteristic O
of O
apoptosis O
such O
as O
chromatin O
aggregation O
and O
apoptotic O
bodies O
. O
In O
addition O
, O
caspase-3 O
, O
an O
executioner O
of O
apoptosis O
, O
was O
activated O
and O
its O
substrate O
, O
poly O
( O
ADP-ribose I-DNA
) O
polymerase O
( O
PARP I-DNA
) O
, O
was O
cleaved O
during O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6'-PeCB-induced O
apoptosis O
. O
In O
contrast O
, O
3 O
, O
3 O
' O
, O
4 O
, O
4 O
' O
, O
5-PeCB O
, O
a O
congener O
of O
coplanar O
structure O
, O
as O
well O
as O
2 O
, O
3 O
, O
7 O
, O
8-TCDD B-protein
did O
not O
induce O
apoptosis O
in O
these O
human O
monocytic B-cell_line
cells I-cell_line
, O
although O
they O
potently O
induced O
CYP O
1A1 B-protein
in O
human B-DNA
hepatoma I-DNA
Hep O
G2 B-protein
cells I-cell_type
. O
Taken O
together O
, O
the O
data O
indicate O
that O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6'-PeCB O
induces O
apoptosis O
in O
human O
monocytic B-cell_line
cells I-cell_type
through O
a O
mechanism O
that O
is O
independent O
of O
the O
arylhydrocarbon I-DNA
receptor I-protein
. O
This O
suggests O
a O
possibly O
separate O
mechanism O
by O
which O
PCBs O
cause O
immunosuppression O
. O
Effects O
of O
deregulated O
Raf O
activation O
on O
integrin O
, O
cytokine-receptor O
expression O
and O
the O
induction O
of O
apoptosis O
in O
hematopoietic B-cell_type
cells I-cell_type
. O
The O
effects O
of O
deregulated O
Raf O
activation O
on O
the O
growth O
and O
differentiation O
of O
hematopoietic B-cell_type
cells I-cell_type
were O
investigated O
. O
The O
cytokine-dependent O
murine I-cell_line
myeloid O
FDC-P1 B-protein
and O
human B-cell_type
erythroleukemic I-cell_type
TF-1 O
cell O
lines I-cell_line
were O
transformed O
to O
grow O
in O
response O
to O
deregulated O
Raf O
expression O
in O
the O
absence O
of O
exogenous O
cytokines O
. O
The O
conditionally O
active O
Raf B-protein
proteins I-protein
were O
regulated O
by O
beta-estradiol O
as O
cDNAs I-protein
containing O
the O
Raf O
catalytic O
, O
but O
lacking O
negative-regulatory B-DNA
domains O
, O
were O
ligated O
to O
the O
hormone O
binding I-protein
domain I-protein
of O
the O
estrogen B-protein
receptor I-protein
( O
deltaRaf I-DNA
: O
ER B-protein
) O
. O
Continuous O
deltaRaf I-protein
expression O
prevented O
apoptosis O
in O
the O
absence O
of O
exogenous O
cytokines O
and O
altered O
the O
morphology O
of O
the O
FD/deltaRaf O
: O
ER B-protein
cells I-cell_type
as O
they O
grew O
in O
large O
aggregated O
masses O
( O
> O
100 B-cell_type
cells I-cell_type
) O
whereas O
the O
parental O
cytokine-dependent O
FDC-P1 B-protein
cells I-cell_type
grew O
in O
smaller O
grape-like B-DNA
clusters O
( O
< O
10 B-DNA
cells I-cell_type
) O
. O
FD/deltaRaf-1 B-protein
: O
ER B-protein
cells I-cell_type
growing O
in O
response O
to O
Raf O
activation O
displayed O
decreased O
levels O
of O
the O
Mac-2 B-protein
and O
Mac-3 B-protein
molecules I-protein
on O
their O
cell O
surface I-protein
. O
In O
contrast O
, O
when O
these I-cell_type
cells I-cell_type
were O
cultured O
in O
IL-3 B-protein
, O
higher O
levels O
of O
these O
adhesion O
molecules I-protein
were O
detected O
. O
Expression O
of O
activated O
Raf O
oncoproteins O
also O
abrogated O
cytokine O
dependency O
and O
prevented O
apoptosis O
of O
TF-1 B-protein
cells I-cell_type
. O
Moreover O
, O
the O
differentiation O
status O
of O
these O
Raf-responsive B-protein
cells I-cell_type
was O
more O
immature O
upon O
Raf O
activation O
as O
culture O
with O
the O
differentiation-inducing B-DNA
agent O
phorbol O
12 O
myristate O
13-acetate B-protein
( O
PMA I-DNA
) O
and O
beta-estradiol O
resulted O
in O
decreased O
levels O
of O
the O
CD11b I-cell_type
and O
CD18 B-protein
integrin O
molecules I-protein
on O
the O
cell O
surface I-protein
. O
In O
contrast O
when O
the O
Raf-responsive B-protein
cells I-cell_type
were O
induced O
to O
differentiate O
with O
PMA O
and O
GM-CSF I-DNA
, O
in O
the O
absence O
of O
deltaRaf B-cell_type
: O
ER B-protein
activation O
, O
increased O
levels O
of O
the O
CD11b I-cell_type
and O
CD18 B-protein
molecules I-protein
were O
detected O
. O
Retinoic O
acid O
( O
RA I-DNA
) O
inhibited O
3H-thymidine B-protein
incorporation O
in O
response O
to O
GM-CSF B-protein
. O
Interestingly B-cell_type
, O
Raf O
activation O
counterbalanced O
the O
inhibition O
of O
DNA O
synthesis O
caused O
by O
RA B-protein
but O
not O
PMA O
. O
Thus O
deregulated O
Raf O
expression O
can O
alter O
cytokine O
dependency O
, O
integrin O
expression O
and O
the O
stage O
of O
differentiation O
. O
These O
Raf-responsive O
cell O
lines I-cell_line
will O
be O
useful O
in O
elucidating O
the O
roles O
of O
the O
MAP I-protein
kinase I-protein
cascade O
on O
hematopoietic B-cell_type
cell O
differentiation O
and O
malignant O
transformation O
Cyclic O
AMP O
activates O
p38 O
mitogen-activated B-DNA
protein O
kinase I-protein
in O
Th2 B-cell_type
cells I-cell_type
: O
phosphorylation O
of O
GATA-3 B-protein
and O
stimulation O
of O
Th2 B-cell_type
cytokine B-DNA
gene I-DNA
expression O
. O
cAMP I-RNA
is O
an O
important O
second O
messenger O
with O
immunomodulatory O
properties O
. O
Elevation O
of O
intracellular O
cAMP I-RNA
in O
T B-cell_type
cells I-cell_type
, O
induced O
by O
agents O
such O
as O
IL-1alpha B-protein
or O
PGs O
, O
inhibits O
T O
cell O
activation O
. O
In O
effector O
T B-cell_type
cells I-cell_type
, O
an O
increase O
in O
the O
level O
of O
intracellular O
cAMP I-RNA
inhibits O
cytokine O
production O
in O
Th1 B-cell_type
cells I-cell_type
but O
stimulates O
cytokine O
production O
in O
Th2 B-cell_type
cells I-cell_type
. O
Here O
we O
report O
that O
cAMP-induced B-protein
effects O
in O
Th2 B-cell_type
cells I-cell_type
occur O
independently O
of O
the O
protein O
kinase I-protein
A O
pathway O
, O
which O
is O
the O
major O
mediator O
of O
cAMP-induced B-protein
signaling O
events O
in O
most O
cell O
types I-cell_type
. O
Instead O
, O
cAMP I-RNA
stimulates O
activation O
of O
p38 B-cell_type
mitogen-activated B-DNA
protein O
kinase I-protein
in O
Th2 B-cell_type
cells I-cell_type
. O
This O
appears O
to O
be O
a O
Th2 O
-selective O
event O
because O
cAMP I-RNA
barely O
increased O
p38 O
phosphorylation O
in O
Th1 B-cell_type
cells I-cell_type
. O
We O
show O
that O
in O
Th2 B-cell_type
cells I-cell_line
, O
cAMP I-RNA
promotes O
the O
production O
of O
both O
IL-5 B-protein
and O
IL-13 B-protein
, O
which O
play O
distinct O
but O
critical O
roles O
in O
asthma O
pathogenesis O
. O
Our O
data O
also O
show O
that O
cAMP I-RNA
causes O
increased O
phosphorylation O
of O
the O
transcription B-protein
factor I-protein
GATA-3 B-protein
, O
which O
we O
have O
shown O
is O
a O
critical O
regulator O
of O
Th2 B-cell_type
cytokine B-DNA
gene I-DNA
expression O
and I-DNA
, O
in O
turn O
, O
of O
airway O
inflammation O
in O
mice O
. O
Thus O
, O
Th2 O
-specific O
GATA-3 B-protein
expression O
and O
p38 O
mitogen-activated B-DNA
protein O
kinase I-protein
activation O
together O
provide O
a O
molecular O
basis O
for O
the O
differential O
effects O
of O
cAMP I-RNA
in O
the O
two O
T I-cell_line
helper O
cell O
subsets O
. O
Characterization O
of O
IL-4 B-protein
and O
IL-13 B-protein
signals O
dependent O
on O
the O
human B-DNA
IL-13 I-DNA
receptor I-DNA
alpha I-DNA
chain I-DNA
1 O
: O
redundancy O
of O
requirement O
of O
tyrosine I-protein
residue O
for O
STAT3 B-protein
activation O
. O
IL-4 B-protein
and O
IL-13 B-protein
are O
pleiotropic O
cytokines O
whose O
biological O
activities O
overlap O
with O
each O
other O
. O
IL-13 B-DNA
receptor I-DNA
alpha I-DNA
chain I-DNA
1 O
( O
IL-13R I-DNA
alpha I-DNA
1 O
) O
is O
necessary O
for O
binding O
to O
IL-13 B-protein
, O
and O
the O
heterodimer O
composed O
of O
IL-13R B-protein
alpha I-DNA
1 O
and O
IL-4R I-DNA
alpha I-DNA
chain I-DNA
transduces O
IL-13 B-protein
and O
IL-4 B-protein
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular I-protein
domain I-protein
of O
IL-13R B-protein
alpha I-DNA
1 O
is O
not O
fully O
understood O
. O
In O
this O
study O
, O
we O
constructed O
wild O
and O
mutated O
types I-cell_type
of O
human B-cell_type
IL-13R I-DNA
alpha I-DNA
1 O
, O
and O
analyzed O
IL-4 B-protein
and O
IL-13 B-protein
signals O
using O
an O
IL-13R B-protein
alpha I-DNA
1 O
-transfected O
human B-DNA
B I-DNA
cell O
line O
. O
Expression O
of O
IL-13R B-protein
alpha I-DNA
1 O
evoked O
STAT3 B-protein
activation O
by O
IL-4 B-protein
and O
IL-13 B-protein
, O
and O
in O
stimulated O
human B-DNA
B I-DNA
cells I-cell_line
, O
on O
which O
IL-13R B-protein
alpha I-DNA
1 O
was O
highly O
expressed O
, O
IL-4 B-protein
and O
IL-13 B-protein
induced O
STAT3 B-protein
activation O
. O
Replacement O
of O
the O
two O
tyrosine I-protein
residues O
completely O
abolished O
STAT3 B-protein
activation O
, O
although O
replacing O
either O
tyrosine I-protein
residue O
alone O
retained O
it O
. O
Furthermore O
, O
we O
found O
that O
the O
Box1 B-DNA
region O
and O
the O
C-terminal B-protein
tail O
of O
IL-13R B-protein
alpha I-DNA
1 O
were O
critical O
for O
binding O
to O
Tyk2 O
, O
and O
activation O
of O
Jak1 B-cell_type
, O
Tyk2 O
, O
the O
insulin I-DNA
receptor I-protein
substrate-1 O
and O
STAT6 B-protein
respectively O
. O
These O
results O
suggest O
that O
STAT3 B-protein
activation O
is O
involved O
with O
IL-4 B-protein
and O
IL-13 B-protein
signals O
in O
human B-DNA
B I-DNA
cells I-cell_type
along O
with O
the O
activation O
of O
STAT6 I-protein
, O
and O
that O
there O
is O
a O
unique O
sequence O
in O
IL-13R B-protein
alpha I-DNA
1 O
to O
activate O
STAT3 B-protein
. O
Functional O
uncoupling O
of O
the O
Janus O
kinase I-protein
3-Stat5 O
pathway O
in O
malignant O
growth O
of O
human B-cell_type
T I-cell_line
cell O
leukemia O
virus O
type O
1-transformed O
human B-cell_type
T I-cell_type
cells I-cell_type
. O
Human O
T O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV-1 B-protein
) O
transforms O
cytokine O
-dependent O
T I-cell_type
lymphocytes I-cell_type
and O
causes O
adult O
T O
cell O
leukemia O
. O
Janus B-protein
tyrosine I-protein
kinase I-protein
( O
Jak O
) O
3 O
and O
transcription B-protein
factors I-protein
Stat5a O
and O
Stat5b B-protein
are O
essential O
for O
the O
proliferation O
of O
normal O
T B-cell_type
cells I-cell_type
and O
are O
constitutively O
hyperactivated O
in O
both O
HTLV-1-transformed O
human B-cell_type
T I-cell_line
cell O
lines I-cell_line
and O
lymphocytes I-cell_type
isolated O
from O
HTLV-1-infected B-protein
patients O
; O
therefore O
, O
a O
critical O
role O
for O
the O
Jak3-Stat5 B-protein
pathway O
in O
the O
progression O
of O
this O
disease O
has O
been O
postulated O
. O
We O
recently O
reported O
that O
tyrphostin O
AG-490 B-protein
selectively O
blocked O
IL-2 B-protein
activation O
of O
Jak3/Stat5 O
and O
growth O
of O
murine I-cell_line
T O
cell O
lines I-cell_line
. O
Here O
we O
demonstrate O
that O
disruption O
of O
Jak3/Stat5a/b B-cell_type
signaling O
with O
AG-490 B-protein
( O
50 O
& O
mgr O
; O
M O
) O
blocked O
the O
proliferation O
of O
primary B-cell_line
human I-cell_line
T I-cell_type
lymphocytes I-cell_type
, O
but O
paradoxically O
failed O
to O
inhibit O
the O
proliferation O
of O
HTLV-1-transformed O
human B-cell_type
T I-cell_line
cell O
lines I-cell_line
, O
HuT-102 O
and O
MT-2 B-protein
. O
Structural O
homologues O
of O
AG-490 B-protein
also O
inhibited O
the O
proliferation O
of O
primary B-cell_line
human I-cell_line
T I-cell_type
cells I-cell_type
, O
but O
not O
HTLV-1-infected B-protein
cells I-cell_type
. O
Disruption O
of O
constitutive O
Jak3/Stat5 O
activation O
by O
AG-490 B-protein
was O
demonstrated O
by O
inhibition O
of O
1 O
) O
tyrosine O
phosphorylation O
of O
Jak3 B-cell_type
, O
Stat5a I-cell_line
( O
Tyr O
( O
694 O
) O
) O
, O
and O
Stat5b I-cell_line
( O
Tyr O
( O
699 O
) O
) O
; O
2 O
) O
serine O
phosphorylation O
of O
Stat5a I-cell_line
( O
Ser O
( O
726 O
) O
) O
as O
determined O
by O
a O
novel O
phosphospecific O
Ab O
; O
and O
3 O
) O
Stat5a/b O
DNA O
binding O
to O
the O
Stat5-responsive O
beta-casein B-DNA
promoter I-DNA
. O
In O
contrast O
, O
AG-490 B-protein
had O
no O
effect O
on O
DNA O
binding O
by O
p50/p65 O
components O
of O
NF-kappaB B-RNA
, O
a O
transcription B-protein
factor I-protein
activated O
by O
the O
HTLV-1-encoded B-protein
phosphoprotein O
, O
Tax O
. O
Collectively I-protein
, O
these O
data O
suggest O
that O
the O
Jak3-Stat5 B-protein
pathway O
in O
HTLV-1-transformed B-cell_type
T B-cell_type
cells I-cell_type
has O
become O
functionally O
redundant O
for O
proliferation O
. O
Reversal O
of O
this O
functional O
uncoupling O
may O
be O
required O
before O
Jak3/Stat5 O
inhibitors O
will O
be O
useful O
in O
the O
treatment O
of O
this O
malignancy O
. O
The O
Epstein-Barr O
virus O
promoter I-DNA
initiating O
B-cell O
transformation O
is O
activated O
by O
RFX O
proteins I-protein
and O
the O
B-cell-specific O
activator O
protein O
BSAP/Pax5 O
. O
Epstein-Barr O
virus O
( O
EBV I-DNA
) O
-induced O
B-cell O
growth O
transformation O
, O
a O
central O
feature O
of O
the O
virus O
' O
strategy O
for O
colonizing O
the O
human B-DNA
B-cell I-cell_type
system I-protein
, O
requires O
full O
virus O
latent B-DNA
gene I-DNA
expression O
and O
is O
initiated O
by O
transcription O
from O
the O
viral B-DNA
promoter I-DNA
Wp O
. O
Interestingly B-cell_type
, O
when O
EBV O
accesses O
other O
cell O
types I-cell_type
, O
this O
growth-transforming B-DNA
program O
is O
not O
activated O
. O
The O
present O
work O
focuses O
on O
a O
region I-DNA
of O
Wp O
which O
in O
reporter O
assays O
confers O
B-cell O
-specific O
activity O
. O
Bandshift O
studies O
indicate O
that O
this O
region O
contains O
three O
factor I-protein
binding O
sites I-DNA
, O
termed O
sites I-DNA
B I-DNA
, O
C I-protein
, O
and O
D I-DNA
, O
in O
addition O
to O
a O
previously O
characterized O
CREB I-DNA
site I-DNA
. O
Here O
we O
show O
that O
site I-DNA
C I-protein
binds O
members O
of O
the O
ubiquitously O
expressed O
RFX O
family O
of O
proteins I-protein
, O
notably O
RFX1 I-protein
, O
RFX3 I-protein
, O
and O
the O
associated O
factor I-protein
MIBP1 B-protein
, O
whereas O
sites I-DNA
B I-DNA
and O
D O
both O
bind O
the O
B-cell-specific O
activator O
protein O
BSAP/Pax5 O
. O
In O
reporter O
assays O
with O
mutant O
Wp O
constructs O
, O
the O
loss O
of O
factor I-protein
binding O
to O
any O
one O
of O
these O
sites I-DNA
severely O
impaired B-DNA
promoter I-DNA
activity O
in O
B I-DNA
cells I-cell_line
, O
while O
the O
wild-type B-DNA
promoter I-DNA
could O
be O
activated O
in O
non-B B-cell_line
cells I-cell_type
by O
ectopic O
BSAP O
expression O
. O
We O
suggest O
that O
Wp O
regulation O
by O
BSAP O
helps O
to O
ensure O
the O
B-cell O
specificity O
of O
EBV B-cell_type
's O
growth-transforming B-DNA
function O
. O
Activation O
of O
the O
Lck B-protein
tyrosine I-protein
protein I-protein
kinase I-protein
by O
the O
Herpesvirus O
saimiri O
tip O
protein O
involves O
two O
binding O
interactions O
. O
The O
Tip O
protein O
of O
Herpesvirus O
saimiri O
strain O
484C B-protein
binds O
to O
and O
activates O
the O
Lck B-protein
tyrosine I-protein
protein I-protein
kinase I-protein
. O
Two O
sequences O
in O
the O
Tip O
protein O
were O
previously O
shown O
to O
be O
involved O
in O
binding O
to O
Lck O
. O
A O
proline-rich B-DNA
region I-DNA
, O
residues O
132-141 O
, O
binds O
to O
the O
SH3 I-protein
domain I-protein
of O
the O
Lck O
protein O
. O
We O
show O
here O
that O
the O
other O
Lck-binding I-protein
domain I-protein
, O
residues O
104-113 O
, O
binds O
to O
the O
carboxyl-terminal B-DNA
half O
of O
Lck O
and O
that O
this O
binding O
does O
not O
require O
the O
Lck O
SH3 I-protein
domain I-protein
. O
Mutated O
Tip O
containing O
only O
one O
functional O
Lck-binding I-protein
domain I-protein
can O
bind O
stably O
to O
Lck O
, O
although O
not O
as O
strongly O
as O
wild-type B-DNA
Tip O
. O
Interaction O
of O
Tip O
with O
Lck O
through O
either O
Lck-binding I-protein
domain I-protein
increases O
the O
activity O
of O
Lck O
in O
vivo O
. O
Simultaneous O
binding O
of O
both O
domains O
is O
required O
for O
maximal O
activation O
of O
Lck O
. O
The O
transient O
expression O
of O
Tip O
in O
T B-cell_type
cells I-cell_type
was O
found O
to O
stimulate O
both O
Stat3 O
-dependent O
and O
NF-AT B-protein
-dependent O
transcription O
. I-RNA
Mutant O
forms O
of O
Tip O
lacking O
one O
or O
the O
other O
of O
the O
two O
Lck-binding B-protein
domains O
retained O
the O
ability O
to O
stimulate O
Stat3 O
-dependent B-protein
transcription O
. I-RNA
Tip O
lacking O
the O
proline-rich B-DNA
Lck-binding I-protein
domain I-protein
exhibited O
almost O
wild-type B-DNA
activity O
in O
this O
assay O
. O
In O
contrast O
, O
ablation O
of O
either O
Lck-binding I-protein
domain I-protein
abolished O
the O
ability O
of O
Tip O
to O
stimulate O
NF-AT B-protein
-dependent O
transcription O
. I-RNA
Full O
biological O
activity O
of O
Tip O
, O
therefore O
, O
appears O
to O
require O
both O
Lck-binding B-protein
domains O
. O
Accumulation O
of O
RXR I-DNA
alpha I-DNA
during I-DNA
activation O
of O
cycling O
human B-cell_type
T I-cell_type
lymphocytes I-cell_type
: O
modulation O
of O
RXRE O
transactivation O
function O
by O
mitogen-activated B-DNA
protein O
kinase I-protein
pathways O
. O
We O
have O
previously O
reported O
that O
the O
activation O
of O
resting O
human B-DNA
immature I-DNA
peripheral B-cell_type
blood I-cell_type
T I-cell_line
( O
PBT I-DNA
) O
lymphocytes I-cell_type
is O
associated O
with O
the O
loss O
of O
retinoid O
X I-DNA
receptor I-DNA
alpha I-DNA
( O
RXRalpha I-DNA
) O
expression O
. O
In O
the O
present O
study O
, O
we O
have O
demonstrated O
that O
, O
unlike O
resting B-cell_type
cells I-cell_line
, O
activation O
of O
cycling O
human B-DNA
mature I-cell_type
PBT I-cell_type
lymphocytes I-cell_type
, O
and O
T I-cell_line
lymphocyte I-cell_line
leukemia O
cell O
lines I-cell_line
is O
accompanied O
by O
the O
accumulation O
of O
RXRalpha I-RNA
mRNA I-RNA
and O
protein O
. O
Interestingly B-cell_type
, O
cyclosporin O
A O
further O
augmented O
RXRalpha O
expression O
, O
indicating O
the O
involvement O
of O
calcineurin O
pathways O
in O
the O
process O
. O
9-cis O
retinoic O
acid O
inhibited O
the O
accumulation O
, O
suggesting O
that O
retinoids O
can O
regulate O
the O
synthesis O
of O
their O
own O
receptors O
during O
T O
cell O
activation O
. O
Transfection O
analysis O
in O
Jurkat B-cell_type
cells I-cell_line
, O
using O
RXRE-dependent B-protein
reporter O
assays O
, O
showed O
that O
RXRalpha O
accumulated O
during O
T O
cell O
activation O
was O
transcriptionally O
inactive O
. O
To O
investigate O
the O
mechanism O
of O
such O
inhibition O
, O
the O
role O
of O
two O
mitogen-activated B-DNA
protein O
kinase I-protein
pathways O
, O
c-Jun O
N-terminal B-protein
kinase I-protein
( O
JNK I-DNA
) O
and O
extracellular O
signal-regulated O
kinase I-protein
( O
ERK I-DNA
) O
, O
in O
modulating O
RXRE-dependent B-protein
transcription I-DNA
, O
was O
explored O
. O
The O
expression O
of O
constitutively O
active O
MAP/ERK B-protein
kinase I-protein
kinase I-protein
1 O
( O
MEKK1 B-protein
) O
inhibited O
RXRE-dependent B-protein
transcription I-DNA
, O
whereas O
dominant O
negative O
MEKK1 B-protein
increased O
the O
transcription I-DNA
, O
indicating O
the O
involvement O
of O
JNK B-cell_type
signaling O
pathways O
in O
the O
process O
. O
In O
contrast O
, O
expression O
of O
constitutively O
active O
MEK1 I-protein
, O
which O
activates O
ERK O
pathway O
, O
enhanced O
RXRE-dependent B-protein
activation O
. O
When O
both O
were O
activated O
simultaneously O
, O
JNK O
pathway O
was O
dominant O
over O
ERK O
pathway O
and O
resulted O
in O
inhibition O
of O
RXRE-mediated B-protein
transcription O
. I-RNA
These O
data O
demonstrate O
a O
dual O
regulatory O
control O
of O
RXRalpha O
expression O
during O
the O
activation O
of O
resting O
and O
cycling O
T I-cell_type
lymphocytes I-cell_type
and O
indicate O
a O
dynamic O
balance O
between O
JNK O
and O
ERK O
pathways O
in O
modulating O
RXRE-mediated B-protein
transactivation O
. O
The O
proteasome O
regulates O
receptor-mediated B-DNA
endocytosis O
of O
interleukin-2 B-protein
. O
Recent O
studies O
have O
increasingly O
implicated O
the O
proteasome O
in O
the O
regulation O
of O
cell O
surface I-protein
receptors O
. O
In O
the O
present O
study O
, O
we O
investigated O
the O
role O
of O
the O
proteasome O
for O
ligand-dependent O
endocytosis O
and O
degradation O
of O
the O
interleukin-2 B-protein
( O
IL-2 B-protein
) O
-interleukin-2 B-DNA
receptor I-protein
( O
IL-2R B-protein
) O
complex I-protein
. O
Proteasome O
inhibitors O
impaired O
internalization O
of O
IL-2.IL-2R B-protein
and O
prevented O
the O
lysosomal O
degradation O
of O
this O
cytokine O
. O
Based O
on O
time-course O
studies O
, O
proteasome O
activity O
is O
primarily O
required O
after O
initial O
endocytosis O
of O
the O
IL-2.IL-2R B-protein
. O
Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL-2 B-protein
internalized O
by O
IL-2R B-DNA
that O
were O
comprised O
of O
cytoplasmic O
tailless O
beta- B-DNA
or O
gamma O
c-subunits I-cell_line
, O
suggesting O
that O
the O
target I-cell_line
protein O
for O
the O
proteasome O
is O
independent O
of O
either O
the O
cytoplasmic O
tail O
of O
the O
IL-2R B-DNA
beta- B-DNA
or O
gamma O
c-subunits O
and O
their O
associated O
signaling O
components O
. O
Therefore O
, O
a O
functional O
proteasome O
is O
required O
for O
optimal O
endocytosis O
of O
the O
IL-2R/ligand B-protein
complex I-protein
and O
is O
essential O
for O
the O
subsequent O
lysosomal O
degradation O
of O
IL-2 B-protein
, O
possibly O
by O
regulating O
trafficking O
to O
the O
lysosome O
. O
Functional O
characterization O
of O
the O
two O
alternative O
promoters O
of O
human B-cell_type
p45 I-cell_type
NF-E2 B-DNA
gene I-DNA
. O
OBJECTIVE O
: O
The O
transcription B-protein
factor I-protein
NF-E2 B-protein
, O
a O
heterodimeric O
protein I-protein
complex I-protein
composed O
of O
p45 O
and O
small O
Maf O
family O
proteins I-protein
, O
is O
considered O
crucial O
for O
the O
proper O
differentiation O
of O
erythrocytes B-cell_type
and O
megakaryocytes O
in O
vivo O
. O
We O
report O
the O
results O
of O
studies O
aimed O
at O
understanding O
the O
regulatory O
mechanisms O
controlling O
p45 B-DNA
gene I-DNA
expression O
in O
erythroid I-cell_type
cells I-cell_type
. O
MATERIALS O
AND O
METHODS I-protein
: O
Human O
p45 O
mRNAs I-protein
have O
two O
alternative O
isoforms O
, O
aNF-E2 O
and O
fNF-E2 O
, O
and O
these O
isoforms O
are O
transcribed O
from O
the O
alternative O
promoters O
. O
We O
investigated O
lineage-specific O
expression O
of O
both O
isomers O
in O
human O
erythroid I-cell_type
and O
megakaryocytic B-cell_type
cells I-cell_type
by O
reverse O
transcriptase O
polymerase O
chain O
reaction O
or O
Northern O
blot O
analysis O
. O
For O
functional O
characterization O
of O
both O
promoters O
, O
plasmids O
in O
which O
reporter I-DNA
genes I-DNA
were O
placed O
under O
the O
control O
of O
a O
series O
of O
truncated O
or O
mutated O
promoter I-DNA
fragments O
were O
transfected O
to O
human O
hematopoietic B-cell_type
cell O
lines I-cell_line
. O
RESULTS I-protein
: O
When O
CD34 B-protein
( O
+ O
) O
cells I-cell_type
isolated O
from O
human B-DNA
cord I-DNA
blood I-cell_type
were I-cell_type
induced O
to O
unilineage O
erythroid B-DNA
or O
megakaryocytic O
differentiation O
in O
liquid O
suspension O
culture O
, O
both O
transcripts I-RNA
, O
although O
barely O
detected O
at O
day O
0 O
, O
were O
induced O
in O
both O
erythroid I-cell_type
and O
megakaryocytic O
cultures I-cell_line
. O
fNF-E2 I-RNA
mRNA I-RNA
was O
found O
to O
be O
more O
abundant O
in O
erythroid I-cell_type
cells I-cell_type
than O
megakaryocytic B-cell_type
cells I-cell_type
at O
day O
7 O
of O
culture O
. O
Although O
both O
isomers O
were O
expressed O
in O
human B-DNA
erythroid-megakaryocytic I-cell_type
cell O
lines I-cell_line
, O
megakaryocytic O
maturation O
with O
loss O
of O
erythroid B-cell_type
phenotype O
induced O
by O
phorbol O
12-myristate B-protein
13-acetate B-protein
( O
PMA I-DNA
) O
resulted O
in O
exclusive O
downregulation O
of O
fNF-E2 O
, O
suggesting O
that O
fNF-E2 B-DNA
promoter I-DNA
is O
more O
erythroid B-DNA
specific O
. O
Functional O
analysis O
of O
fNF-E2 B-DNA
promoter I-DNA
showed O
that O
the O
promoter I-DNA
is O
active O
only O
in O
erythroid-megakaryocytic B-cell_type
cells I-cell_type
and O
that O
the O
double O
GATA O
sit O
e O
in O
the O
proximal O
region O
is O
necessary O
for O
its O
efficient O
activity O
. O
CONCLUSION I-protein
: O
These O
results O
suggest O
that O
GATA B-protein
proteins I-protein
, O
which O
govern O
the O
differentiation O
of O
erythroid O
lineage I-cell_type
cells I-cell_line
, O
are O
required O
for O
full O
promoter I-DNA
activity O
of O
the O
p45 B-DNA
gene I-DNA
. O
Transcriptional O
activation O
of O
heme O
oxygenase-1 O
and O
its O
functional O
significance O
in O
acetaminophen-induced O
hepatitis O
and O
hepatocellular O
injury O
in O
the O
rat O
. O
BACKGROUND/AIM B-protein
: O
Glutathione O
depletion O
contributes O
to O
acetaminophen O
hepatotoxicity O
and O
is O
known O
to O
induce O
the O
oxidative O
stress O
reactant O
heme O
oxygenase-1 B-protein
. O
The O
metabolites I-protein
of O
the O
heme O
oxygenase O
pathway O
, O
biliverdin O
, O
carbon O
monoxide O
, O
and O
iron O
may O
modulate O
acetaminophen O
toxicity O
. O
The O
aim O
of O
this O
study O
was O
to O
assess O
cell-type B-DNA
specific O
expression O
of O
heme O
oxygenase-1 O
and O
its O
impact O
on O
liver O
injury O
and O
microcirculatory O
disturbances O
in O
a O
model O
of O
acetaminophen-induced O
hepatitis O
. O
METHODS I-protein
: O
Gene O
expression O
of O
heme O
oxygenase-1 B-protein
was O
studied O
by O
Northern- O
and O
Western O
analysis O
as O
well O
as O
immunohistochemistry O
. O
The O
time O
course O
of O
heme O
oxygenase-1 O
and O
-2 O
, O
cytokine-induced I-cell_line
neutrophil O
chemoattractant-1 I-DNA
, O
and O
intercellular O
adhesion O
molecule-1 B-protein
was O
studied O
by O
Northern O
analysis O
. O
DNA-binding B-protein
activity O
of O
nuclear B-protein
factor-kappaB B-protein
was O
determined O
by O
electrophoretic O
mobility O
shift O
assay O
. O
Sinusoidal O
perfusion O
and O
leukocyte-endothelial O
interactions O
were O
assessed O
by O
intravital O
microscopy O
. O
RESULTS I-protein
: O
Acetaminophen B-cell_type
caused O
a O
moderate O
sinusoidal O
perfusion O
failure O
( O
-15 O
% O
) O
and O
infiltration O
of O
neutrophils O
along O
with O
activation O
of O
nuclear B-protein
factor-kappaB O
and O
intercellular O
adhesion O
molecule-1 B-protein
and O
cytokine-induced I-cell_line
neutrophil O
chemoattractant-1 B-protein
mRNAs I-protein
. O
Induction O
of O
heme O
oxygenase-1 I-RNA
mRNA I-RNA
and O
protein O
( O
approximately O
30-fold B-protein
) O
in O
hepatocytes O
and O
non-parenchymal B-protein
cells I-cell_type
paralleled O
the O
inflammatory O
response O
. O
Blockade O
of O
heme O
oxygenase O
activity O
with O
tin-protoporphyrin-IX O
abrogated O
acetaminophen-induced O
hepatic O
neutrophil O
accumulation O
and O
nuclear B-protein
factor-kappaB B-protein
activation O
, O
but O
failed O
to O
affect O
sinusoidal O
perfusion O
and O
liver O
injury O
. O
CONCLUSIONS I-protein
: O
The O
inflammatory O
response O
associated O
with O
acetaminophen O
hepatotoxicity O
is O
modulated O
by O
the O
parallel O
induction O
of O
the O
heme O
oxygenase-1 B-DNA
gene I-DNA
. O
However O
, O
heme O
oxygenase-1 B-protein
has O
no O
permissive O
effect O
on O
sinusoidal O
perfusion O
and O
does O
not O
affect O
liver O
injury O
in O
this O
model O
. O
These O
data O
argue O
against O
a O
central O
role O
of O
nuclear B-protein
factor-kappaB B-protein
activation O
and O
neutrophil O
infiltration O
as O
perpetuating B-protein
factors I-protein
of O
liver O
injury O
in O
acetaminophen O
toxicity O
. O
Tumor O
necrosis O
factor-alpha B-DNA
-induced O
proliferation O
requires O
synthesis O
of O
granulocyte-macrophage B-DNA
colony-stimulating B-protein
factor I-protein
. B-protein
OBJECTIVE O
: O
Tumor O
necrosis O
factor- I-DNA
alpha I-DNA
( O
TNF-alpha I-DNA
) O
induces O
a O
variety O
of O
cellular O
responses O
, O
some O
of O
them O
being O
at O
least O
seemingly O
contradictory O
. O
Thus O
, O
we O
set O
out O
to O
find O
differences O
in O
the O
modes O
of O
proliferative O
and O
apoptotic O
responses O
to O
TNF- I-DNA
alpha I-DNA
. I-RNA
MATERIALS O
AND O
METHODS I-protein
: O
We O
screened O
a O
panel O
of O
acute O
myeloid O
leukemia-derived O
cell O
lines I-cell_line
for O
TNF- I-DNA
alpha I-DNA
-responsiveness B-protein
. O
In O
two O
lines I-cell_line
( O
OCI-AML-1 I-DNA
, O
OCI-AML-11 B-protein
) O
, O
TNF- I-DNA
alpha I-DNA
acted I-DNA
as O
an O
apoptotic O
agent O
; O
in O
others O
( O
HU-3 B-protein
, O
M-07e O
, O
TF-1 B-protein
) O
, O
it O
had O
the O
opposite O
effect O
, O
preventing O
apoptosis O
and O
inducing O
proliferation O
. O
Direct O
and O
indirect O
signaling O
mechanisms O
, O
including O
NF-kappaB O
activation O
and O
cytokine O
synthesis O
, O
were O
analyzed O
. O
RESULTS I-protein
: O
All O
cell O
lines I-cell_line
tested O
expressed O
TNF- I-DNA
alpha I-DNA
receptors B-protein
I I-protein
and O
II I-protein
and O
responded O
to O
TNF- I-DNA
alpha I-DNA
by O
upregulation O
of O
intercellular O
adhesion O
molecule-1 B-protein
. O
In O
contrast O
to O
granulocyte-macrophage O
colony-stimulating B-protein
factor I-protein
( O
GM-CSF B-protein
) O
, O
TNF- I-DNA
alpha I-DNA
did I-DNA
not O
activate O
the O
MAP I-protein
kinase I-protein
and O
p70S6 B-protein
kinase I-protein
pathways O
. O
Nevertheless I-protein
, O
inhibitors O
of O
these O
pathways O
clearly O
reduced O
the O
TNF-alpha B-protein
-induced O
cell O
growth O
, O
indicating O
that O
TNF- B-protein
alpha-proliferative B-cell_type
cells I-cell_type
produced O
a O
growth I-protein
factor I-protein
that O
induced O
proliferation O
upon O
stimulation O
of O
the O
above O
pathways O
. O
Anti-GM-CSF B-protein
antibodies I-protein
inhibited O
the O
TNF-alpha B-protein
-induced O
growth I-protein
, O
suggesting O
the O
presence O
of O
an O
autocrine O
loop O
for O
cell O
proliferation O
mediated O
by O
GM-CSF B-protein
. O
Supporting O
this O
notion I-protein
, O
TNF-alpha O
-induced O
upregulation O
of O
GM-CSF I-RNA
mRNA I-RNA
levels O
and O
protein O
secretion O
in O
the O
TNF-alpha B-protein
-proliferative O
, O
but O
not O
in O
the O
TNF-alpha-apoptotic O
cell O
lines I-cell_line
. O
CONCLUSION I-protein
: O
These O
data O
identify O
GM-CSF B-protein
synthesis O
as O
an O
early O
and O
essential O
step O
in O
TNF- B-protein
alpha-induced B-protein
proliferation O
. O
We O
show O
for O
the O
first O
time O
that O
TNF-alpha-treated O
cell O
lines I-cell_line
producing O
no O
or O
only O
minimal O
amounts O
of O
GM-CSF B-protein
demonstrate O
an O
apoptotic O
phenotype O
, O
while O
cell O
lines I-cell_line
with O
high O
GM-CSF B-protein
expression O
rates O
can O
escape O
from O
growth O
arrest O
or O
even O
apoptosis O
. O
In O
this O
context O
, O
we O
discuss O
arguments O
pointing O
at O
NF-kappaB O
as O
regulator O
of O
GM-CSF B-protein
synthesis O
and O
thus O
indirectly O
as O
regulator O
for O
the O
escape O
of O
TNF-alpha B-protein
-induced O
apoptosis O
Glucocorticoid I-DNA
receptor I-protein
content O
of O
T I-cell_type
lymphocytes I-cell_type
: O
evidence O
for O
heterogeneity O
. O
Glucocorticoid O
receptors O
were O
measured O
in O
T I-cell_type
lymphocytes I-cell_type
that O
were O
isolated O
from O
peripheral B-cell_type
blood I-cell_type
by O
either O
nylon O
wool O
filtration O
or O
E-rosette B-protein
sedimentation O
. O
T B-cell_type
cells I-cell_type
isolated O
by O
nylon O
wool O
filtration O
specifically O
bind O
6.7 B-protein
+/- O
0.2 B-protein
fmol O
of O
dexamethasone O
per O
million B-cell_type
cells I-cell_line
( O
equivalent O
to O
4000 O
+/- O
200 O
receptors O
per O
cell O
) O
, O
whereas O
T B-cell_type
cells I-cell_type
isolated O
by O
E-rosette B-protein
sedimentation O
bind O
12.0 B-protein
+/- O
0.7 B-protein
fmol O
of O
dexamethasone O
per O
million B-cell_type
cells I-cell_line
( O
equivalent O
to O
7200 O
+/- O
400 O
receptors O
per O
cell O
) O
. O
This O
difference O
in O
the O
amount O
of O
dexamethasone O
bound O
by O
the O
two O
T O
cell O
preparations O
was O
significant O
( O
p O
less O
than O
.001 B-protein
) O
and O
was O
present O
immediately O
after O
cell O
isolation O
. O
The O
binding O
affinities O
of O
the O
different O
T O
cell O
preparations O
for O
dexamethasone O
were O
similar O
. O
T B-cell_type
cells I-cell_type
that O
are O
isolated O
by O
a O
combination O
of O
nylon O
wool O
filtration O
followed O
by O
E-rosette B-protein
sedimentation O
bind O
the O
same O
amount O
of O
dexamethasone O
as O
T B-cell_type
cells I-cell_type
isolated O
by O
nylon O
wool O
filtration O
alone O
. O
T B-cell_type
cells I-cell_type
isolated O
by O
a O
combination O
of O
E-rosette B-protein
sedimentation O
following O
by O
nylon O
wool O
filtration O
bind O
less O
dexamethasone O
than O
do O
T B-cell_type
cells I-cell_type
isolated O
by O
E-rosette B-protein
sedimentation O
alone O
. O
These O
findings O
suggest O
that O
T B-cell_type
cells I-cell_type
are O
heterogeneous O
with O
respect O
to O
their O
quantity O
of O
glucocorticoid O
receptors O
. O
Isolation O
of O
T B-cell_type
cells I-cell_type
by O
E-rosette B-protein
sedimentation O
enriches O
for O
T B-cell_type
cells I-cell_type
that O
have O
a O
greater O
number O
of O
glucocorticoid O
receptors O
, O
and O
isolation O
of O
T B-cell_type
cells I-cell_type
by O
nylon O
wool O
filtration O
enriches O
for O
T B-cell_type
cells I-cell_type
that O
have O
a O
lesser O
number O
of O
glucocorticoid O
receptors O
. O
Glucocorticoid O
receptors O
and O
glucocorticoid O
sensitivity O
of O
human B-cell_type
leukemic I-cell_type
cells I-cell_type
. O
We O
have O
established O
optimal O
conditions O
for O
the O
measurement O
of O
glucocorticoid O
receptors O
( O
GR I-DNA
) O
in O
human B-DNA
white I-cell_type
cells I-cell_type
using O
a O
whole-cell B-DNA
binding O
assay O
with O
[ O
3H B-protein
] O
dexamethasone O
as O
the O
ligand I-protein
, O
and O
the O
subsequent O
determination O
of O
the O
GR B-protein
content O
in O
normal O
human I-cell_type
lymphocytes I-cell_type
and O
in O
leukemic B-cell_type
cells I-cell_type
of O
patients O
with O
various O
forms O
of O
acute O
and O
chronic O
leukemia O
. O
A O
number O
of O
leukemia O
cell O
lines I-cell_line
in O
continuous O
culture O
were O
also O
subjected O
to O
the O
GR B-protein
assay O
, O
and O
the O
results O
were O
correlated O
with O
the O
sensitivity O
of O
these O
cell O
lines O
to O
glucocorticoid O
steroids O
in O
vitro O
. O
The O
GR B-protein
content O
of O
normal O
human I-cell_type
lymphocytes I-cell_type
amounted O
to O
4 O
, O
850 O
+/- O
1 O
, O
340 O
( O
mean O
+/- O
SD B-protein
) O
receptors/cell O
. O
The O
mean O
equilibrium O
dissociation O
constant O
( O
KD I-DNA
) O
of O
the O
interaction O
of O
[ O
3H B-protein
] O
dexamethasone O
with O
the O
GR B-protein
was O
1.2 B-protein
x O
10 O
( O
-8 B-protein
) O
M O
. O
Steroidal O
compounds O
with O
a O
known O
glucocorticoid O
potency O
effectively O
competed O
for O
the O
binding O
, O
whereas O
steroids O
devoid O
of O
glucocorticoid O
activity O
( O
e.g. I-DNA
estradiol-17 B-protein
beta O
and O
testosterone O
) O
were O
ineffective O
. O
The O
GR B-protein
content O
of O
the O
blast I-cell_type
cells I-cell_type
obtained O
from O
eight O
patients O
suffering O
from O
acute O
leukemia O
and O
four O
patients O
with O
a O
blast O
crisis O
of O
chronic O
myelocytic O
leukemia O
was O
found O
to O
be O
highly O
variable O
( O
3 O
, O
230-29 O
, O
900 O
receptors/cell I-DNA
) O
, O
while O
the I-cell_type
lymphocytes I-cell_type
of O
six O
patients O
with O
chronic O
lymphatic O
leukemia O
contained O
a O
rather O
stable O
GR B-protein
content O
( O
2 O
, O
930-5 O
, O
120 O
receptors/cell I-DNA
) O
, O
which O
was O
comparable O
with O
that O
of O
normal I-cell_type
lymphocytes I-cell_type
. O
GR B-protein
was O
identified O
in O
all O
the O
12 O
malignant O
continuous O
white O
cell O
lines I-cell_line
studied O
. O
Large B-cell_type
cells I-cell_type
contained O
more O
GR B-protein
than O
the O
smaller O
ones O
. O
There O
was O
no O
apparent O
correlation O
between O
the O
GR B-protein
concentration O
and O
the O
sensitivity O
of O
the B-cell_type
cells I-cell_type
in O
vitro O
to O
glucocorticoids O
as O
judged O
by O
[ O
3H B-protein
] O
thymidine O
incorporation O
studies O
. O
Distribution O
of O
the O
surface I-protein
markers O
in O
the O
leukemic O
cell O
lines I-cell_line
did O
not O
relate O
to O
the O
GR B-protein
concentration O
. O
We O
conclude O
that O
the O
presence O
of O
GR B-cell_type
is O
probably O
a O
universal O
feature O
of O
the O
leukemic B-cell_type
cells I-cell_line
, O
and O
, O
from O
a O
clinical O
standpoint O
, O
probably O
does O
not O
alone O
imply O
steroid O
responsiveness O
. O
Evidence O
for O
a O
steroid I-DNA
receptor I-protein
in O
rheumatoid O
synovial O
tissue B-cell_type
cells I-cell_type
. O
One O
mechanism O
by O
which O
glucocorticoids O
could O
exert O
their O
anti-inflammatory B-DNA
action O
is O
via O
rapidly O
saturable O
, O
stereo-specific O
cytoplasmic O
protein O
receptors O
. O
This O
report O
is O
of O
an O
investigation O
into O
such O
a O
possibility O
in O
synovial B-cell_type
cells I-cell_type
. O
Synovium O
, O
obtained O
from O
knee O
joints O
of O
rheumatoid O
patients O
undergoing O
surgery O
, O
was O
incubated O
with O
clostridiopeptidase O
A O
and O
trypsin-EDTA O
to O
obtain O
cell O
suspensions O
. O
These O
, O
together O
with O
cells I-cell_type
obtained O
from O
synovial O
fluid O
aspirated O
from O
patients O
with O
rheumatoid O
arthritis O
, O
were O
identified O
by O
electron O
microscopy O
. O
Duplicate O
samples O
of O
these O
cell O
suspensions O
were O
incubated O
with O
increasing O
concentrations O
of O
H3Dexamethasone B-cell_type
( O
1 O
x O
10 O
( O
-10 B-protein
) O
M-1 B-protein
x O
10 O
( O
-9 B-protein
) O
M O
) O
for O
30 O
minutes O
at O
37 O
degrees O
C I-protein
. O
Analysis O
of O
the O
proportion O
of O
steroid O
bound O
to O
whole I-cell_type
cells I-cell_type
showed O
evidence O
for O
specific O
, O
rapidly O
saturable O
, O
receptors O
in O
the B-cell_type
cells I-cell_type
obtained O
from O
synovial O
tissue I-protein
, O
but O
this O
was O
not O
found O
in O
synovial O
fluid I-cell_type
cells I-cell_type
. O
Electron O
micrographs O
showed O
that B-cell_type
cells I-cell_type
obtained O
from O
synovial O
tissue O
consisted O
of O
synovial O
fibroblast O
- O
and O
macrophage-types I-DNA
, O
lymphocytes I-cell_type
, O
monocytes B-cell_type
and O
macrophages O
. O
Polymorphonuclear O
leucocytes O
appeared O
to O
be O
absent O
. O
However O
, O
in O
synovial O
fluid O
cell I-DNA
type O
polymorphonuclear I-DNA
leucocytes O
were O
the O
predominant O
cell I-DNA
type O
. I-DNA
We O
concluded O
from O
this O
, O
that O
one O
or O
more O
of O
the O
cell O
types I-cell_type
present O
in O
synovial O
tissue O
contain O
a O
specific O
steroid I-DNA
receptor I-protein
, O
but O
that O
this O
is O
lacking O
in O
synovial O
fluid O
polymorphonuclear O
leucocytes O
. O
Clinical O
implications O
of O
glucocorticoid O
receptors O
in O
human B-DNA
leukemia I-DNA
. O
Glucorticoid O
receptors O
were O
studied O
in O
various O
populations O
of O
normal O
human B-cell_type
peripheral B-cell_type
blood I-cell_type
lymphocytes I-cell_type
and O
leukemic O
lymphoblasts O
. O
Normal I-cell_type
lymphocytes I-cell_type
contain O
low O
levels O
of O
glucocorticoid I-DNA
receptor I-protein
( O
approximately I-DNA
2 O
, O
500 O
sites/cell I-DNA
) O
which O
are O
identical O
in O
T- O
and O
non-T-fractions O
. O
Phytohemagglutinin O
treatment O
increases O
levels O
about O
3-fold B-protein
. O
Leukemic O
lymphoblasts O
contain O
larger O
numbers O
of B-DNA
receptor I-DNA
sites I-DNA
. O
Presence O
of B-DNA
receptor I-protein
is O
correlated O
with O
in O
vitro O
sensitivitiy O
to O
glucocorticoids O
and O
in O
vivo O
response O
to O
therapy O
. O
Quantity O
of B-DNA
receptor I-protein
is O
also O
correlated O
with O
complete O
remission O
duration O
independently O
of O
leukemic O
cell I-DNA
type O
( O
T O
or O
null O
) O
, O
initial O
WBC I-protein
, O
or O
age O
of O
patient O
. O
Quantitative O
determination O
of O
glucocorticoid I-DNA
receptor I-protein
levels O
in O
acute O
lymphoblastic O
leukemia O
may O
be O
of O
value O
both O
as O
an O
independent O
prognostic O
variable O
and O
in O
suggesting O
which O
patients O
should O
receive O
glucocorticoid O
therapy O
. O
Functional O
and O
physical O
interaction O
of O
protein-tyrosine O
kinases I-protein
Fyn O
and O
Csk O
in O
the O
T-cell O
signaling O
system O
. O
The O
Src-like O
protein-tyrosine B-protein
kinase I-protein
Fyn O
is O
associated O
with O
T-cell O
antigen I-DNA
receptor I-protein
. O
Transient O
expression O
of O
actively O
mutated O
Fyn O
, O
having O
Phe-528 B-protein
instead O
of O
Tyr-528 B-protein
or O
Thr-338 B-protein
instead O
of O
Ile-338 B-protein
, O
in O
Jurkat O
T-cells B-protein
stimulated O
the O
serum O
response O
element I-DNA
( O
SRE I-DNA
) O
, O
12-O-tetradecanoyl-phorbol-13-acetate O
response O
element I-DNA
, O
cyclic O
AMP O
response O
element I-DNA
, O
and O
c-fos O
promoter I-DNA
. O
The O
stimulation O
of O
SRE B-cell_type
was O
particularly O
prominent O
not O
only O
with O
active O
Fyn O
but O
also O
with O
normal O
( O
wild-type I-DNA
) O
Fyn O
. O
SRE O
was O
also O
stimulated O
by O
both O
normal O
and O
active O
Lck O
. O
Furthermore O
, O
normal O
and O
active O
Fyn O
stimulated O
transcription O
from O
the O
IL-2 B-DNA
gene I-DNA
promoter I-DNA
when O
transfected B-cell_line
cells I-cell_type
were O
stimulated O
by O
concanavalin O
A O
plus O
12-O-tetradecanoylphorbol-13-acetate B-protein
. O
Under O
the O
same O
conditions O
, O
Lck O
did O
not O
stimulate O
IL-2 B-DNA
promoter I-DNA
unless O
it O
was O
activated O
by O
mutation O
. O
Interestingly B-cell_type
, O
a O
mutant O
Fyn O
, O
which O
has O
deletions O
within O
the O
SH2 B-protein
region O
and O
so O
is O
able O
to O
transform O
chicken O
embryo O
fibroblasts O
, O
did O
not O
stimulate O
either O
the O
c-fos O
or O
IL-2 B-DNA
promoter I-DNA
, O
suggesting O
the O
importance O
of O
this O
region O
in O
T-cell O
signaling O
. O
Csk O
, O
which O
phosphorylates B-protein
tyrosine I-protein
residues O
in O
the O
negative O
regulatory I-DNA
sites I-DNA
of O
Src O
family O
kinases I-protein
, O
down-regulated O
Fyn- O
and O
Lck-mediated O
stimulation O
of O
the O
serum O
response O
element I-DNA
and O
Fyn-mediated O
enhancement O
of O
IL-2 B-DNA
promoter I-DNA
activity O
. O
These O
data O
suggest O
that O
Fyn O
and O
Lck O
, O
whose O
activities O
are O
regulated O
by O
Csk O
, O
are O
involved O
in O
different O
phases O
of O
T-cell O
activation O
. O
A O
novel O
NF-kappa B-protein
B I-protein
complex I-protein
containing O
p65 O
homodimers O
: O
implications O
for O
transcriptional O
control O
at O
the O
level O
of O
subunit O
dimerization O
. O
The O
predominant O
inducible O
form O
of O
the O
NF-kappa B-protein
B I-protein
transcription I-DNA
factor I-protein
is O
a O
heteromeric O
complex I-protein
containing O
two O
Rel-related B-protein
DNA-binding B-protein
subunits O
, O
termed O
p65 O
and O
p50 O
. O
Prior O
transfection O
studies O
have O
shown O
that O
when O
these O
p65 O
and O
p50 O
subunits O
are O
expressed O
independently O
as O
stable O
homodimers O
, O
p65 O
stimulates O
kappa B-DNA
B-directed B-protein
transcription I-DNA
, O
whereas O
p50 O
functions O
as O
a O
kappa B-DNA
B-specific B-protein
repressor O
. O
While O
authentic O
p50 O
homodimers O
( O
previously O
termed O
KBF1 B-protein
) O
have O
been O
detected O
in O
nuclear B-protein
extracts O
from O
nontransfected B-cell_type
cells I-cell_line
, O
experimental O
evidence O
supporting O
the O
existence O
of O
p65 B-cell_type
homodimers O
in O
vivo O
was O
lacking O
. O
We O
now O
provide O
direct O
biochemical O
evidence O
for O
the O
presence O
of O
an O
endogenous O
pool O
of O
inducible O
p65 O
homodimers O
in O
intact O
human B-cell_type
T I-cell_type
cells I-cell_type
. O
As O
with O
the O
prototypical O
NF-kappa B-protein
B I-protein
p50-p65 O
heterodimer O
, O
this O
novel O
p65 O
homodimeric O
form O
of O
NF-kappa B-protein
B I-protein
is O
functionally O
sequestered O
in O
the O
cytoplasm O
but O
rapidly O
appears O
in O
the O
nuclear B-protein
compartment O
following O
cellular O
stimulation O
. O
Site-directed B-protein
mutagenesis O
studies O
indicate O
that O
the O
homodimerization O
function O
of O
p65 B-cell_type
is O
dependent O
upon O
the O
presence O
of O
cysteine O
216 O
and O
a O
conserved O
recognition O
motif O
for O
protein O
kinase I-protein
A O
( O
RRPS O
; O
amino O
acids O
273 O
to O
276 O
) O
, O
both O
of O
which O
reside O
within O
a O
91-amino-acid B-protein
segment I-DNA
of O
the O
Rel O
homology I-protein
domain I-protein
that O
mediates O
self-association O
. O
In O
contrast O
, O
mutations O
at O
these O
two O
sites I-DNA
do O
not O
affect O
heterodimerization O
of O
p65 B-cell_type
with O
p50 O
or O
its O
functional O
interaction O
with O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
. I-RNA
These O
later O
findings O
indicate O
that O
neither O
homo- B-DNA
nor O
heterodimer O
formation O
is O
an O
absolute O
prerequisite O
for O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
recognition I-DNA
of O
p65 B-cell_type
. O
Taken O
together O
with O
prior O
in O
vivo O
transcription O
studies I-protein
, O
these O
results O
suggest O
that O
the O
biological O
activities O
of O
p65 O
and O
p50 O
homodimers O
are O
independently O
regulated O
, O
thereby O
providing O
an O
integrated O
and O
flexible O
control O
mechanism O
for O
the O
rapid O
activation O
and O
repression O
of O
NF-kappa B-protein
B I-protein
/ O
Rel O
-directed B-DNA
gene I-DNA
expression O
. O
Carrier O
determination O
for O
X-linked B-protein
agammaglobulinemia O
using O
X O
inactivation O
analysis O
of O
purified O
B I-DNA
cells I-cell_type
. O
We O
report O
the O
development O
of O
a O
relatively O
quick O
and O
simple O
method O
for O
the O
assessment O
of O
X O
inactivation O
status O
for O
carrier O
determination O
in O
families O
affected O
by O
X-linked B-protein
agammaglobulinemia I-protein
( O
XLA I-DNA
) O
. O
This O
method O
utilises O
an O
immunomagnetic O
separation O
technique O
for O
B O
cell O
purification O
and O
a O
polymerase O
chain O
reaction O
( O
PCR I-DNA
) O
based O
assay O
for O
the O
determination O
of O
methylation O
status O
at O
the O
androgen I-DNA
receptor I-protein
( O
AR I-DNA
) O
gene I-DNA
locus O
to O
assess O
whether O
X O
inactivation O
is O
random O
or O
non-random B-DNA
at O
this O
locus O
. O
We O
report O
the O
results O
we O
have O
obtained O
using O
this O
assay O
to O
investigate O
females O
known O
to O
be O
carriers O
of O
various O
X-linked B-protein
immunodeficiency O
disorders O
. O
In O
addition O
, O
we O
investigated O
four O
females O
from O
different O
families O
affected O
by O
XLA I-protein
, O
two O
of O
whom O
were O
of O
unknown O
carrier O
status O
, O
and O
we O
discuss O
the O
results O
obtained O
with O
this O
and O
other O
X-inactivation B-protein
assays O
. O
A O
similar O
assay O
has O
recently O
been O
described O
by O
Allen O
et O
al. I-cell_line
( O
1992 I-DNA
) O
and O
applied O
to O
members O
of O
one O
family O
affected O
by O
XLA O
. O
Effects O
of O
IL-4 B-protein
and O
Fc O
gamma I-DNA
receptor I-protein
II I-protein
engagement O
on O
Egr-1 B-protein
expression O
during O
stimulation O
of O
B I-DNA
lymphocytes I-cell_type
by O
membrane O
immunoglobulin O
crosslinking O
. O
Egr-1 B-protein
is O
an O
immediate O
early B-DNA
gene I-DNA
that O
is O
rapidly O
upregulated O
in O
response O
to O
mitogenic O
signals O
induced O
by O
antigen I-DNA
receptor I-protein
crosslinking O
on O
murine I-cell_line
B I-DNA
lymphocytes I-cell_type
. O
It O
has O
been O
shown O
that O
levels O
of O
Egr-1 B-protein
expression O
are O
closely O
correlated O
with O
B O
cell O
proliferation O
in O
several O
models O
of O
B O
cell O
activation O
and O
tolerance O
. O
We O
compared O
the O
expression O
of O
Egr-1 B-protein
during O
B O
cell O
stimulation O
with O
Fab'2 I-cell_type
and O
IgG O
anti-immunoglobulin B-DNA
( O
anti-Ig I-DNA
) O
, O
since O
it O
is O
known O
that O
Fab'2 B-protein
anti-Ig O
is O
mitogenic O
while O
IgG O
anti-Ig O
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B O
cell O
Fc O
gamma O
RII O
to O
membrane O
Ig O
. O
While O
mitogenic O
doses O
of O
Fab'2 B-protein
anti-Ig O
induce O
large O
and O
rapid O
increases O
in O
Egr-1 B-protein
expression O
, O
IgG O
anti-Ig O
results O
in O
smaller O
increases O
in O
Egr-1 I-RNA
mRNA I-RNA
, O
comparable O
to O
that O
seen O
with O
submitogenic O
concentrations O
of O
Fab'2 B-protein
anti-Ig O
. O
However O
, O
the O
correlation O
between O
Egr-1 B-protein
expression O
and O
B O
cell O
proliferation O
breaks O
down O
when O
IL-4 B-protein
is O
added O
as O
a O
co-mitogen O
to O
induce O
B O
cell O
proliferation O
with O
IgG O
anti-Ig O
or O
submitogenic O
concentrations O
of O
Fab'2 B-protein
anti-Ig O
. O
No O
corresponding O
increases O
in O
Egr-1 I-RNA
mRNA I-RNA
levels O
are O
observed O
when O
IL-4 B-protein
is O
added O
. O
Therefore O
, O
IL-4 B-protein
overcomes O
Fc O
receptor-mediated B-DNA
inhibition O
of O
B O
cell O
proliferation O
without O
affecting O
inhibition O
of O
Egr-1 I-RNA
mRNA I-RNA
induction O
, O
as O
demonstrated O
earlier O
for O
c-myc I-RNA
mRNA I-RNA
in O
this O
system O
. O
Identification O
of O
a O
novel O
cyclosporin-sensitive B-DNA
element I-DNA
in O
the O
human B-DNA
tumor I-cell_type
necrosis B-protein
factor I-protein
alpha I-DNA
gene I-DNA
promoter I-DNA
. O
Tumor O
necrosis B-protein
factor I-protein
alpha I-DNA
( O
TNF-alpha I-DNA
) O
, O
a O
cytokine O
with O
pleiotropic O
biological O
effects O
, O
is O
produced O
by O
a O
variety O
of O
cell O
types I-cell_type
in O
response O
to O
induction O
by O
diverse O
stimuli O
. O
In O
this O
paper O
, O
TNF-alpha I-RNA
mRNA I-RNA
is O
shown O
to O
be O
highly O
induced O
in O
a O
murine I-cell_line
T O
cell O
clone O
by O
stimulation O
with O
T O
cell I-DNA
receptor I-protein
( O
TCR I-DNA
) O
ligands O
or O
by O
calcium O
ionophores O
alone O
. O
Induction O
is O
rapid O
, O
does O
not O
require O
de O
novo O
protein O
synthesis O
, O
and O
is O
completely O
blocked O
by O
the O
immunosuppressant O
cyclosporin O
A O
( O
CsA I-DNA
) O
. O
We O
have O
identified O
a O
human B-DNA
TNF-alpha B-DNA
promoter I-DNA
element I-DNA
, O
kappa O
3 O
, O
which O
plays O
a O
key O
role O
in O
the O
calcium-mediated O
inducibility O
and O
CsA O
sensitivity O
of O
the O
gene I-DNA
. O
In O
electrophoretic O
mobility O
shift O
assays O
, O
an O
oligonucleotide O
containing O
kappa B-DNA
3 O
forms O
two O
DNA O
protein O
complexes O
with O
proteins I-protein
that O
are O
present O
in O
extracts O
from O
unstimulated B-cell_type
T B-cell_type
cells I-cell_type
. O
These O
complexes O
appear O
in O
nuclear B-protein
extracts O
only O
after O
T O
cell O
stimulation O
. O
Induction O
of O
the O
inducible O
nuclear B-protein
complexes O
is O
rapid O
, O
independent O
of O
protein O
synthesis O
, O
and O
blocked O
by O
CsA I-cell_line
, O
and O
thus O
, O
exactly O
parallels O
the O
induction O
of O
TNF-alpha I-RNA
mRNA I-RNA
by O
TCR O
ligands O
or O
by O
calcium O
ionophore O
. O
Our O
studies O
indicate O
that O
the O
kappa B-DNA
3 O
binding O
factor O
resembles O
the O
preexisting O
component O
of O
nuclear B-protein
factor I-protein
of O
activated B-cell_type
T B-cell_type
cells I-cell_type
. O
Thus O
, O
the O
TNF-alpha B-DNA
gene I-DNA
is O
an O
immediate O
early B-DNA
gene I-DNA
in O
activated B-cell_type
T B-cell_type
cells I-cell_type
and O
provides O
a O
new O
model O
system O
in O
which O
to O
study O
CsA-sensitive B-DNA
gene I-DNA
induction O
in O
activated B-cell_type
T B-cell_type
cells I-cell_type
. O
Differences O
in O
expression O
of O
transcription B-protein
factor I-protein
AP-1 B-protein
in O
human B-DNA
promyelocytic I-DNA
HL-60 B-protein
cells I-cell_type
during O
differentiation O
towards O
macrophages O
versus O
granulocytes O
. O
Commitment O
of O
HL-60 B-protein
cells O
to O
macrophage O
or O
granulocytic O
differentiation O
was O
achieved O
by O
incubation O
with O
4 O
beta-phorbol B-DNA
12-myristate B-protein
13-acetate B-protein
( O
PMA I-DNA
) O
for O
30-60 O
min O
or O
with O
dimethyl O
sulphoxide O
( O
DMSO I-DNA
) O
for O
24 O
h O
respectively O
. O
The O
commitment O
stage O
towards O
PMA-induced B-protein
macrophage O
differentiation O
was O
associated O
with O
increases O
in O
jun O
B I-DNA
and O
c-fos I-RNA
mRNA I-RNA
levels O
, O
as O
well O
as O
with O
an O
increase O
in O
the O
binding O
activity O
of O
transcription B-protein
factor I-protein
AP-1 B-protein
. O
Nevertheless I-protein
, O
gel O
retardation O
analysis O
indicated O
that O
the O
AP-1 B-protein
activity O
detected O
in O
untreated B-cell_type
cells I-cell_type
was O
drastically O
reduced O
during O
the O
commitment O
stage O
of O
DMSO-induced B-DNA
HL-60 B-protein
differentiation O
towards O
granulocytes O
. O
When O
HL-60 B-protein
cells I-cell_type
were O
treated O
with O
sodium O
butyrate O
, O
which O
induced O
monocytic B-cell_line
differentiation O
, O
a O
remarkable O
increase O
in O
AP-1 B-protein
binding O
activity O
was O
detected O
. O
Treatment O
of O
HL-60 B-protein
cells I-cell_type
with O
1 O
alpha I-DNA
, O
25-dihydroxyvitamin O
D3 I-protein
, O
another O
monocytic B-cell_line
differentiation O
agent O
, O
induced O
a O
weak O
, O
but O
appreciable O
, O
increase O
in O
AP-1 B-protein
activity O
. O
Furthermore O
, O
addition O
of O
sodium O
butyrate O
or O
1 O
alpha I-DNA
, O
25-dihydroxyvitamin O
D3 O
to O
HL-60 B-protein
cells I-cell_type
induced O
the O
expression O
of O
c-fos O
, O
c-jun O
, O
jun O
B I-DNA
and O
jun O
D O
proto-oncogenes O
. O
In O
contrast O
, O
when O
HL-60 B-protein
cells I-cell_type
were O
treated O
with O
retinoic O
acid O
, O
a O
granulocytic O
differentiation O
inducer O
, O
no O
enhanced O
AP-1 B-protein
binding O
activity O
was O
observed O
, O
and O
only O
a O
weak O
increase O
in O
jun O
D I-RNA
mRNA I-RNA
level O
was O
detected O
. O
These O
data O
indicate O
that O
formation O
of O
AP-1 B-protein
is O
not O
required O
for O
the O
induction O
of O
HL-60 B-protein
differentiation O
towards O
granulocytes O
, O
whereas O
induction O
of O
monocytic B-cell_line
differentiation O
is O
correlated O
with O
an O
increase O
in O
AP-1 B-protein
activity O
. O
The O
differential O
expression O
of O
AP-1 B-protein
activity O
may O
be O
critical O
in O
the O
differentiation O
of O
HL-60 B-protein
cells I-cell_type
towards O
monocytic B-cell_line
or O
granulocytic O
lineages O
Glucocorticoid O
receptors O
and O
sensitivity O
in O
leukemias O
. O
In O
an O
attempt O
to O
investigate O
the O
utility O
of O
glucocorticoid I-DNA
receptor I-protein
determination O
to O
predict O
clinical O
responsiveness O
in O
human B-DNA
leukemias I-cell_type
we O
have O
studied O
glucocorticoid O
receptors O
in O
the O
leukemic B-cell_type
cells I-cell_type
from O
46 O
patients O
and O
in O
the I-cell_type
lymphocytes I-cell_type
from O
18 O
normal O
donors O
. O
In O
the O
normal I-cell_type
lymphocytes I-cell_type
there O
were O
3 O
, O
875 O
( O
Median O
) O
specific O
binding O
sites O
per O
cell O
. O
The O
blasts O
from O
17 O
patients O
with O
ANLL O
had O
on O
average O
higher O
levels O
of O
binding O
sites O
per O
cell O
( O
Median O
= O
7 O
, O
250 O
, O
range O
: O
0 O
to O
15 O
, O
295 O
) O
than O
the O
other O
leukemias O
. O
Of O
the O
15 O
patients O
with O
CLL I-protein
, O
six O
had O
received O
glucocorticoid O
treatment O
for O
3 O
to O
5 O
years O
. O
Their I-cell_type
lymphocytes I-cell_type
had O
lower O
number O
of O
receptors O
( O
Median O
= O
2 O
, O
000 O
) O
than O
the O
other O
cases O
which O
were O
newly O
diagnosed O
( O
Median O
= O
4 O
, O
500 O
) O
. O
Four O
patients O
had O
ALL/AUL I-protein
, O
three O
patients O
had O
blast O
crisis O
as O
terminal I-DNA
phase O
of O
CML I-protein
, O
and O
seven O
had O
leukemic O
Non-Hodgkin O
lymphomas O
( O
Median O
= O
3 O
, O
500 O
sites/cell I-DNA
) O
. O
In O
24 O
patients O
we O
have O
also O
studied O
the O
in O
vitro O
sensitivity O
of O
the O
leukemic B-cell_type
cells O
to O
dexamethasone O
. O
There O
was O
no O
marked O
correlation O
between O
glucocorticoid I-DNA
receptor I-protein
levels O
and O
in O
vitro O
sensitivity O
. O
An O
attempt O
to O
correlate I-DNA
receptor I-protein
levels O
with O
clinical O
responsiveness O
demonstrated O
that O
glucocorticoid I-DNA
receptor I-protein
determination O
might O
be O
of O
value O
in O
patients O
with O
lymphoid O
malignancies O
but O
probably O
not O
in O
patients O
with O
other O
leukemias O
. O
'Activation-labile O
' O
glucocorticoid-receptor B-DNA
complexes O
of O
a O
steroid-resistant B-DNA
variant O
of O
CEM-C7 B-protein
human B-DNA
lymphoid I-cell_type
cells I-cell_type
. O
For O
cytoplasmic O
glucocorticoid-receptor B-DNA
complexes O
to O
enter O
and O
accumulate O
in O
the O
nucleus O
a O
temperature-dependent O
event O
, O
'activation O
' O
is O
required O
. O
Activation O
can O
be O
achieved O
in O
vitro O
by O
increased O
ionic O
strength O
, O
dilution O
or O
gel O
filtration O
and O
is O
manifested O
by O
an O
increased O
affinity O
of O
steroid-receptor O
complex I-protein
for O
DNA O
and O
an O
altered O
elution O
profile O
from O
ion-exchange B-DNA
resins O
. O
Munck O
and O
Foley O
have O
shown O
that O
activated O
complexes O
isolated O
from O
thymocytes O
elute O
from O
DEAE-cellulose B-protein
in O
a O
manner O
identical O
to O
complexes O
activated O
in O
vitro O
. O
We O
report O
here O
that O
DEAE-cellulose B-protein
chromatography O
of O
steroid-receptor O
complexes O
from O
CEM-C7 I-protein
, O
a O
cloned O
human B-DNA
leukaemic I-cell_type
T-cell O
line O
sensitive O
to O
the O
cytolytic O
action O
of O
glucocorticoids O
, O
and O
its O
steroid-resistant B-DNA
subclone O
4R4 B-protein
demonstrated O
that O
steroid O
receptors O
of O
clone O
4R4 B-protein
can O
not O
form O
stable O
activated O
complexes O
. O
This O
defines O
a O
new O
defect O
in B-DNA
receptor I-protein
action O
, O
activation O
lability O
( O
r+act1 I-DNA
) O
, O
which O
is O
unlike O
either O
the O
r- B-DNA
, O
r+nt- O
, O
or O
r+nti B-DNA
phenotypes O
previously O
described O
for O
mouse B-DNA
lymphoid O
variants O
. O
Granulocytes O
in O
the O
endometrium O
of O
post-partum O
women O
. O
Endometrial O
samples O
of O
women O
at O
various O
stages O
of O
gonadal O
activity O
after O
parturition O
were O
examined O
for O
the O
presence O
and O
numbers O
of O
endometrial O
granulocytes O
. O
Although O
samples O
at O
all O
the O
stages O
contained O
significant O
numbers O
of O
the O
granulocytes O
( O
i.e. I-DNA
greater O
than O
7/high-power B-protein
field O
) O
, O
the O
100 O
% O
values O
for O
late-proliferative B-DNA
and O
adaptation O
hyperplasia O
were O
significantly O
higher O
than O
the O
values O
for O
the O
resting O
( O
81.8 I-DNA
% O
) O
, O
early O
( O
82.4 I-DNA
% O
) O
and O
mid- B-protein
( O
87.9 I-DNA
% O
) O
proliferative O
and O
secretory O
( O
83.3 I-DNA
% O
) O
phases O
. O
We O
suggest O
that O
this O
correlates O
with O
the O
suggestion O
that O
the O
granulocytes O
constitute O
a O
receptor I-protein
system O
for O
oestrogens O
. O
Interaction O
of O
glucocorticoids O
with O
macrophages O
. O
Identification O
of O
glucocorticoid O
receptors O
in O
monocytes B-cell_type
and O
macrophages O
. O
Glucocorticoid O
binding O
was O
measured O
in O
resident O
and O
thioglycollate-elicited B-protein
mouse B-DNA
peritoneal O
macrophages O
, O
rabbit O
alveolar O
macrophages O
, O
and O
human B-cell_type
monocytes B-cell_type
. O
Two O
assays O
of O
binding O
were O
used O
-- O
an O
assay O
with O
intact B-DNA
cells I-cell_type
in O
suspension O
or O
monolayers O
, O
and O
an O
assay O
of O
cytosol O
and O
nuclear B-protein
forms O
of O
glucocorticoid O
receptors O
. O
The O
mononuclear O
phagocytes O
contained O
approximately O
equal O
to O
4 O
-- O
10 O
X O
10 O
( O
3 O
) O
high O
affinity I-DNA
receptor I-DNA
sites I-DNA
per O
cell O
, O
with O
dissociation O
constants O
of O
approximately O
equal O
to O
2 O
-- O
8 O
nM I-RNA
dexamethasone O
. O
The O
binding O
to O
the O
saturable I-DNA
sites I-DNA
was O
specific O
for O
steroids O
with O
glucocorticoid O
or O
antiglucocorticoid O
activity O
. O
Cortisol O
, O
corticosterone O
, O
and O
progesterone O
competed O
with O
dexamethasone O
for O
binding O
, O
whereas O
estradiol O
, O
dihydrotestosterone I-protein
, O
and O
11-epicortisol B-protein
competed O
very O
little O
. O
Binding O
of O
dexamethasone O
to O
cytosol O
and O
nuclear B-protein
forms O
of O
the I-DNA
receptor I-protein
complex I-protein
and O
temperature-sensitive O
translocation O
of O
cytosol O
forms O
to O
nuclear B-protein
forms O
were O
shown O
. O
At O
37 O
degrees O
C I-protein
the O
predominant O
form O
of O
the O
hormone-receptor O
complex I-protein
was O
nuclear B-protein
. O
These O
results O
demonstrate O
that O
corticosteroids O
interact O
with O
macrophages O
at O
physiological O
concentrations O
. O
Nitric O
oxide O
signaling O
: O
a O
possible O
role O
for O
G O
proteins I-protein
. O
We O
have O
previously O
reported O
various O
inductive O
effects O
of O
nitric O
oxide O
on O
human B-DNA
PBMC I-DNA
. O
We O
describe O
a O
novel O
and O
potentially O
important O
mechanism O
of O
nitric O
oxide O
signaling-through B-DNA
direct O
activation O
of O
guanine O
nucleotide-binding B-protein
proteins I-protein
( O
G O
proteins I-protein
) O
. O
We O
have O
found O
that O
nitric O
oxide O
treatment O
of O
membranes O
isolated O
from O
fresh O
human B-DNA
PBMC I-DNA
enhances O
the O
ability O
of O
these O
membranes O
to O
hydrolyze O
[ O
gamma-32P B-protein
] O
GTP O
and O
bind O
[ O
gamma-35S B-protein
] O
GTP O
. O
In O
addition O
, O
treatment O
of O
whole B-cell_type
cells I-cell_type
with O
nitric O
oxide O
yielded O
membranes O
with O
enhanced O
GTPase O
activity O
. O
Furthermore O
, O
the O
GTPase O
activity O
of O
pure O
, O
recombinant O
Gs O
alpha I-DNA
, O
Gi O
alpha I-DNA
1 O
, O
and O
p21ras B-protein
was O
greatly O
enhanced O
by O
nitric O
oxide O
. O
In O
support O
of O
the O
existence O
of O
this O
pathway O
in O
whole I-cell_type
cells I-cell_line
, O
we O
found O
that O
the O
G O
protein O
inhibitor O
, O
GDP-beta-S O
, O
blocked O
NF-kappa B-protein
B I-protein
translocation O
induced O
by O
nitric O
oxide O
or O
LPS O
in O
permeabilized B-cell_type
cells I-cell_type
. O
In O
addition O
, O
nitric O
oxide O
greatly O
reduced O
the O
pertussis O
toxin-mediated O
ADP-ribosylation I-DNA
of O
45- O
and O
41-kDa B-protein
proteins I-protein
in O
membranes O
of O
these B-cell_type
cells I-cell_type
. O
Because O
G O
proteins I-protein
play O
a O
central O
role O
in O
many O
diverse O
signaling O
systems O
, O
activation O
by O
an O
endogenous O
and O
inducible O
oxidant O
may O
represent O
a O
novel O
signaling O
pathway O
. O
The O
granulocyte-macrophage B-DNA
colony-stimulating B-protein
factor I-protein
promoter I-DNA
cis-acting B-DNA
element I-DNA
CLE0 B-protein
mediates O
induction O
signals O
in O
T B-cell_type
cells I-cell_type
and O
is O
recognized O
by O
factors I-protein
related O
to O
AP1 B-protein
and O
NFAT O
. O
Expression O
of O
the O
granulocyte-macrophage B-DNA
colony-stimulating B-protein
factor I-protein
( O
GM-CSF B-protein
) O
gene I-DNA
in O
T B-cell_type
cells I-cell_type
is O
activated O
by O
the O
combination O
of O
phorbol O
ester O
( O
phorbol O
myristate O
acetate O
) O
and O
calcium O
ionophore O
( O
A23187 B-protein
) O
, O
which O
mimic O
antigen I-protein
stimulation O
through O
the O
T-cell B-DNA
receptor I-protein
. O
We O
have O
previously O
shown O
that O
a O
fragment O
containing O
bp O
-95 O
to O
+27 O
of O
the O
mouse B-DNA
GM-CSF B-DNA
promoter I-DNA
can O
confer O
inducibility O
to O
reporter I-DNA
genes I-DNA
in O
the O
human B-DNA
Jurkat I-cell_type
T-cell O
line O
. O
Here O
we O
use O
an O
in O
vitro O
transcription O
system O
to O
demonstrate O
that O
a O
cis-acting B-DNA
element I-DNA
( O
positions O
-54 O
to O
-40 B-protein
) O
, O
referred O
to O
as O
CLE0 I-protein
, O
is O
a O
target I-cell_line
for O
the O
induction O
signals O
. O
We O
observed O
induction O
with O
templates O
containing O
intact O
CLE0 B-protein
but O
not O
with O
templates O
with O
deleted O
or O
mutated O
CLE0 B-protein
. O
We O
also O
observed O
that O
two O
distinct O
signals O
were O
required O
for O
the O
stimulation O
through O
CLE0 I-protein
, O
since O
only O
extracts O
from B-cell_type
cells I-cell_type
treated O
with O
both O
phorbol O
myristate O
acetate O
and O
A23187 B-protein
supported O
optimal O
induction O
. O
Stimulation O
probably O
was O
mediated O
by O
CLE0-binding B-protein
proteins I-protein
because O
depletion O
of O
these O
proteins I-protein
specifically O
reduced O
GM-CSF B-protein
transcription O
. I-RNA
One O
of O
the O
binding O
factors O
possessed O
biochemical O
and O
immunological O
features O
identical O
to O
those O
of O
the O
transcription B-protein
factor I-protein
AP1 B-protein
. O
Another I-protein
factor I-protein
resembled O
the O
T-cell-specific B-protein
factor I-protein
NFAT O
. O
The O
characteristics O
of O
these O
two O
factors I-protein
are O
consistent O
with O
their O
involvement O
in O
GM-CSF B-protein
induction O
. O
The O
presence O
of O
CLE0-like B-protein
elements I-DNA
in O
the O
promoters O
of O
interleukin-3 B-protein
( O
IL-3 B-protein
) O
, O
IL-4 B-protein
, O
IL-5 B-protein
, O
GM-CSF I-protein
, O
and O
NFAT I-DNA
sites I-DNA
in O
the O
IL-2 B-DNA
promoter I-DNA
suggests O
that O
the O
factors I-protein
we O
detected O
, O
or O
related O
factors I-protein
that O
recognize O
these O
sites I-DNA
, O
may O
account O
for O
the O
coordinate O
induction O
of O
these O
genes I-DNA
during O
T-cell O
activation O
. O
Identification O
and O
characterization O
of O
an O
Alu-containing O
, O
T-cell-specific B-DNA
enhancer I-DNA
located O
in O
the O
last O
intron O
of O
the O
human B-DNA
CD8 I-DNA
alpha I-DNA
gene I-DNA
. O
Expression O
of O
the O
human B-DNA
CD8 I-DNA
alpha I-DNA
gene I-DNA
is O
restricted O
to O
cells I-cell_type
of O
the O
lymphoid O
lineage I-cell_type
and O
developmentally O
regulated O
during O
thymopoiesis O
. O
As O
an O
initial O
step O
towards O
understanding O
the O
molecular O
basis O
for O
tissue-specific O
expression O
of O
this O
gene I-DNA
, O
we O
surveyed O
the O
surrounding O
chromatin O
structure O
for O
potential O
cis-acting B-DNA
regulatory O
regions I-protein
by O
DNase B-protein
I I-protein
hypersensitivity O
mapping O
and O
found O
four O
hypersensitive O
sites I-DNA
, O
three O
of O
which O
were O
T O
cell O
restricted O
. O
By O
using O
a O
reporter-based O
expression O
approach O
, O
a O
T-cell-specific B-DNA
enhancer I-DNA
was O
identified O
by O
its O
close O
association O
with O
a O
prominent O
T-cell-restricted O
hypersensitive O
sites I-DNA
in O
the O
last O
intron O
of O
the O
CD8 B-protein
alpha I-DNA
gene I-DNA
. O
Deletion O
studies O
demonstrated O
that O
the O
minimal B-DNA
enhancer I-DNA
is O
adjacent O
to O
a O
negative O
regulatory O
element I-DNA
. O
DNA O
sequence O
analysis O
of O
the O
minimal B-DNA
enhancer I-DNA
revealed O
a O
striking O
cluster O
of O
consensus O
binding O
sites O
for O
Ets-1 B-protein
, O
TCF-1 O
, O
CRE I-protein
, O
GATA-3 B-protein
, O
LyF-1 O
, O
and O
bHLH B-protein
proteins I-protein
which O
were O
verified O
by O
electrophoretic O
mobility O
shift O
assays O
. O
In O
addition O
, O
the O
5 O
' O
end O
of O
the O
enhancer I-DNA
was O
composed O
of O
an O
Alu O
repeat O
which O
contained O
the O
GATA-3 B-protein
, O
bHLH I-protein
, O
and O
LyF-1 O
binding O
sites O
. O
Site-directed B-protein
mutation O
of O
the O
Ets-1 B-protein
and O
GATA-3 B-protein
sites I-DNA
dramatically O
reduced O
enhancer I-DNA
activity O
. O
The O
functional O
importance O
of O
the O
other O
binding O
sites O
only O
became O
apparent O
when O
combinations O
of O
mutations O
were O
analyzed O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
the O
human B-DNA
CD8 I-DNA
alpha I-DNA
gene I-DNA
is O
regulated O
by O
the O
interaction O
of O
multiple O
T-cell O
nuclear B-protein
proteins I-protein
with O
a O
transcriptional O
enhancer I-DNA
located O
in O
the O
last O
intron O
of O
the O
gene I-DNA
. O
Comparison O
of O
the O
CD8 B-protein
alpha I-DNA
enhancer I-DNA
with O
other O
recently O
identified O
T-cell-specific O
regulatory O
elements I-DNA
suggests O
that O
a O
common O
set O
of O
transcription B-protein
factors I-protein
regulates O
several O
T-cell O
genes I-DNA
. O
Molecular O
regulation O
of O
the O
human B-DNA
IL-3 B-DNA
gene I-DNA
: O
inducible B-cell_type
T I-cell_line
cell-restricted O
expression O
requires O
intact O
AP-1 B-protein
and O
Elf-1 B-protein
nuclear B-protein
protein O
binding O
sites O
. O
Interleukin O
3 O
( O
IL-3 B-protein
) O
is O
a O
hematopoietic B-cell_type
stem-cell O
growth O
and O
differentiation B-protein
factor I-protein
that O
is O
expressed O
solely O
in O
activated B-cell_type
T I-cell_line
and O
NK B-cell_type
cells I-cell_type
. O
Studies O
to O
date O
have O
identified O
elements I-DNA
5 O
' O
to O
the O
IL-3 B-protein
coding O
sequences O
that O
regulate O
its O
transcription I-DNA
, O
but O
the O
sequences O
that O
confer O
T I-cell_line
cell-specific I-DNA
expression O
remain O
to O
be O
clearly O
defined O
. O
We O
have O
now O
identified O
DNA O
sequences O
that O
are O
required O
for O
T I-cell_line
cell-restricted O
IL-3 B-DNA
gene I-DNA
transcription O
. I-RNA
A O
series O
of O
transient O
transfections O
performed O
with O
human B-DNA
IL-3-chloramphenicol I-cell_type
acetyltransferase O
( O
CAT I-DNA
) O
reporter O
plasmids O
in O
T I-cell_line
and O
non-T B-cell_type
cells I-cell_type
revealed O
that O
a O
plasmid O
containing O
319 O
bp O
of O
5 O
' O
flanking O
sequences O
was O
active O
exclusively O
in O
T B-cell_type
cells I-cell_type
. O
Deletion O
analysis O
revealed O
that O
T O
cell O
specificity O
was O
conferred O
by O
a O
49-bp B-DNA
fragment O
( O
bp O
-319 O
to O
-270 B-protein
) O
that O
included O
a O
potential O
binding O
site O
for O
AP-1 B-protein
transcription B-protein
factors I-protein
6 O
bp O
upstream O
of O
a O
binding O
site O
for O
Elf-1 B-protein
, O
a O
member O
of O
the O
Ets O
family O
of O
transcription B-protein
factors I-protein
. O
DNaseI O
footprint O
and O
electrophoretic O
mobility O
shift O
assay O
analyses O
performed O
with O
MLA-144 B-protein
T O
cell O
nuclear B-protein
extracts O
demonstrated O
that O
this O
49-bp B-DNA
region O
contains O
a O
nuclear B-protein
protein O
binding O
region O
that O
includes O
consensus O
AP-1 B-protein
and O
Elf-1 B-protein
binding O
sites O
. O
In O
addition O
, O
extracts O
prepared O
from O
purified O
human B-cell_type
T I-cell_type
cells I-cell_type
contained O
proteins I-protein
that O
bound O
to O
synthetic O
oligonucleotides O
corresponding O
to O
the O
AP-1 B-protein
and O
Elf-1 B-protein
binding O
sites O
. O
In O
vitro-transcribed B-DNA
and O
-translated O
Elf-1 B-protein
protein O
bound O
specifically O
to O
the O
Elf-1 B-DNA
site I-DNA
, O
and O
Elf-1 B-protein
antisera O
competed O
and O
super O
shifted O
nuclear B-protein
protein O
complexes O
present O
in O
MLA-144 B-protein
nuclear B-protein
extracts O
. O
Moreover O
, O
addition O
of O
anti-Jun B-protein
family O
antiserum O
in O
electrophoretic O
mobility O
shift O
assay O
reactions O
completely O
blocked O
formation O
of O
the O
AP-1-related B-protein
complexes O
. O
Transient O
transfection O
studies O
in O
MLA-144 B-protein
T B-cell_type
cells I-cell_type
revealed O
that O
constructs O
containing O
mutations O
in O
the O
AP-1 B-protein
site I-DNA
almost O
completely O
abolished O
CAT O
activity O
while O
mutation O
of O
the O
Elf-1 B-DNA
site I-DNA
or O
the O
NF-IL-3 B-DNA
site I-DNA
, O
a O
previously O
described O
nuclear B-protein
protein O
binding O
site O
( O
bp. I-DNA
-155 O
to O
-148 B-protein
) O
in O
the O
IL-3 B-DNA
promoter I-DNA
, O
reduced O
CAT O
activity O
to O
< O
25 O
% O
of O
the O
activity O
given O
by O
wild-type B-DNA
constructs O
. O
We O
conclude O
that O
expression O
of O
the O
human B-DNA
IL-3 B-DNA
gene I-DNA
requires O
the O
AP-1 B-protein
and O
Elf-1 B-protein
binding O
sites O
; O
however O
, O
unlike O
other O
previously O
characterized O
cytokine I-DNA
genes I-DNA
such O
as O
IL-2 B-protein
, O
the O
AP-1 B-protein
and O
Elf-1 B-protein
factors I-protein
can O
bind O
independently O
in O
the O
IL-3 B-DNA
gene I-DNA
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O
Combination O
IL-2 B-protein
and O
IL-4 B-protein
reduces O
glucocorticoid O
receptor-binding I-cell_line
affinity O
and O
T O
cell O
response O
to O
glucocorticoids O
. O
The O
mechanisms O
contributing O
to O
persistent O
T O
cell O
activation O
and O
poor O
response O
to O
glucocorticoids O
in O
chronic O
inflammatory O
illnesses O
such O
as O
steroid O
resistant O
( O
SR I-DNA
) O
asthma O
are O
poorly O
defined O
. O
We O
examined O
the O
possibility O
that O
certain O
cytokines O
, O
specifically O
IL-2 B-protein
and O
IL-4 B-protein
, O
could O
affect O
T O
cell O
response O
to O
glucocorticoids O
. O
A O
[ O
3H B-protein
] O
dexamethasone O
radioligand-binding B-DNA
assay O
was O
used O
to O
measure O
the O
number O
of O
glucocorticoid O
receptors O
( O
GR I-DNA
) O
and O
dissociation O
constant O
( O
Kd O
) O
in O
PBMC O
from O
normal O
donors O
and O
patients O
with O
SR B-protein
asthma I-protein
, O
cultured O
in O
the O
absence O
and O
presence O
of O
these O
cytokines O
. O
PBMC O
from O
normal O
donors O
incubated O
for O
48 O
h O
in O
the O
presence O
of O
combination O
IL-2 B-protein
+ O
IL-4 B-protein
had O
nuclear B-protein
GR I-protein
with O
significantly O
reduced O
binding O
affinity O
( O
GR B-protein
Kd O
= O
36.1 B-protein
+/- O
1.63 B-protein
nM I-cell_line
, O
mean O
+/- O
SEM O
; O
p O
= O
0.0001 B-protein
) O
as O
compared O
with O
PBMC O
incubated O
with O
medium O
alone O
( O
GR B-protein
Kd O
= O
6.74 B-protein
+/- O
0.46 B-protein
nM O
) O
. O
The O
cytosolic O
GR B-protein
Kd O
remained O
unchanged O
. O
However O
, O
when O
PBMC O
were O
incubated O
with O
IL-2 B-protein
alone O
or O
IL-4 B-protein
alone O
, O
no O
change O
in O
GR-binding B-protein
affinity O
was O
observed O
. O
Furthermore O
, O
when O
T B-cell_type
cells I-cell_type
and O
non-T B-cell_type
cells I-cell_type
were O
individually O
stimulated O
with O
combination O
IL-2 B-protein
+ O
IL-4 B-protein
, O
a O
significant O
reduction O
in O
GR-binding B-protein
affinity O
was O
observed O
only O
in O
the O
T O
cell O
population O
( O
p O
= O
0.0001 B-protein
) O
. O
The O
IL-2 B-protein
+ O
IL-4-induced B-protein
alteration O
in O
PBMC O
GR B-protein
Kd O
was O
associated O
with O
an O
increase O
in O
GR B-protein
number O
( O
8348 I-DNA
+/- O
964 O
vs O
1710 O
+/- O
228 O
sites/cell B-DNA
; O
p O
= O
0.0003 B-protein
) O
. O
More O
importantly O
, O
the O
alteration O
in O
PBMC O
GR-binding B-protein
affinity O
with O
IL-2 B-protein
+ O
IL-4 B-protein
was O
associated O
with O
a O
functional O
change O
in O
T O
cell O
response O
to O
methylprednisolone O
MPN I-protein
, O
i.e. I-protein
, O
a O
reduced O
inhibitory O
effect O
of O
MPN B-cell_type
on O
PMA/ionomycin-induced O
T O
cell O
proliferation O
. O
These O
effects O
of O
IL-2 B-protein
+ O
IL-4 B-protein
on O
PBMC O
GR B-protein
affinity O
and O
response O
to O
MPN O
were O
blocked O
by O
co-incubation B-protein
with O
IFN-gamma B-protein
. O
Freshly O
isolated O
PBMC O
from O
four O
patients O
with O
SR B-protein
asthma O
had O
a O
significantly O
reduced O
GR-binding B-protein
affinity O
( O
Kd O
= O
40.0 B-protein
+/- O
2.68 B-protein
nM I-RNA
; O
p O
= O
0.0001 B-protein
) O
when O
compared O
with O
seven O
normal O
subjects O
( O
7.15 I-DNA
+/- O
0.41 B-protein
nM O
) O
. O
The O
altered O
PBMC O
GR O
binding O
from O
patients O
with O
SR B-protein
asthma O
reversed O
to O
normal O
when O
incubated O
with O
medium O
alone O
, O
but O
was O
sustained O
with O
IL-2 B-protein
+ O
IL-4 B-protein
. O
These O
observations O
suggest O
that O
with O
persistent O
inflammation O
certain O
cytokines O
may O
contribute O
to O
an O
impaired O
response O
to O
glucocorticoids O
. O
Furthermore O
, O
the O
effects O
of O
IL-2 B-protein
and O
IL-4 B-protein
were O
blocked O
by O
IFN-gamma B-protein
. O
Characterization O
of O
the O
human B-DNA
CD4 B-protein
gene I-DNA
promoter I-DNA
: O
transcription O
from O
the O
CD4 B-protein
gene I-DNA
core O
promoter I-DNA
is O
tissue-specific O
and O
is O
activated O
by O
Ets O
proteins I-protein
. O
We O
analyzed O
the O
5 O
' O
transcription O
control O
sequences O
of O
the O
human B-DNA
CD4 B-protein
gene I-DNA
. O
We O
located O
the O
transcription O
initiation I-DNA
site I-DNA
and O
showed O
that O
the O
CD4 B-protein
core O
promoter I-DNA
( O
positions O
-40 O
to O
+16 B-protein
) O
lacks O
a O
classical O
`` O
TATA O
'' O
or O
initiator O
positioning O
consensus O
sequence O
but O
directs O
precise O
and O
efficient O
transcription O
when O
coupled O
to O
the O
ubiquitously O
active O
simian O
virus O
40 B-DNA
enhancer I-DNA
. O
The O
transcriptional O
activity O
of O
the O
CD4 B-protein
gene I-DNA
promoter I-DNA
correlated O
with O
CD4 B-protein
expression O
in O
various O
cell O
types I-cell_type
. O
Interestingly B-cell_type
, O
the O
CD4 B-protein
core O
promoter I-DNA
also O
displayed O
a O
tissue-specific O
transcriptional O
activity O
. O
Within O
this O
fragment O
, O
three O
nucleic O
acid O
sequences O
are O
completely O
conserved O
in O
the O
murine I-cell_line
CD4 B-protein
gene I-DNA
. O
One O
of O
these O
sequences O
contains O
a O
perfect O
ETS O
consensus O
sequence O
. O
Another O
ETS O
consensus O
sequence O
is O
located O
1060 O
nt O
upstream O
. O
Electrophoretic-mobility-shift B-protein
assays O
showed O
that O
the O
core O
promoter I-DNA
ETS O
motif O
binds O
an O
Ets-related B-protein
protein O
specifically O
expressed O
at O
high O
levels O
in O
CD4+ B-cell_type
cells I-cell_type
. O
Moreover O
, O
in O
CD4- B-protein
cells I-cell_line
, O
overexpression O
of O
Ets-1 B-protein
or O
Ets-2 B-protein
efficiently O
and O
specifically O
activated O
transcription O
from O
the O
CD4 B-protein
promoter I-DNA
and O
core O
promoter I-DNA
. O
These O
data O
indicate O
that O
Ets B-protein
transcription B-protein
factors I-protein
play O
a O
central O
role O
in O
controlling O
CD4 B-protein
gene I-DNA
expression O
, O
by O
binding O
to O
both O
a O
classical O
remote O
site I-DNA
and O
an O
unusual O
proximal O
activator O
sequence O
Glucocorticoid I-DNA
receptor I-protein
activation O
and O
inactivation O
in O
c O
ultured O
human I-cell_type
lymphocytes I-cell_type
. O
Although O
glucocorticoids O
are O
not O
cytolytic O
for O
and O
do O
not O
inhibit O
the O
growth O
of O
the O
IM-9 B-protein
line O
of O
cultured O
human B-DNA
lymphoblasts I-DNA
, O
these O
cells I-cell_type
have O
a O
high O
steroid-binding O
capacity O
. O
We O
have O
used O
IM-9 B-protein
cells I-cell_type
in O
order O
to O
examine O
whether O
unoccupied O
glucocorticoid O
receptors O
are O
inactivated O
and O
activated O
in O
intact B-DNA
cells I-cell_type
. O
when O
IM-9 B-protein
cells I-cell_type
are O
incubated O
in O
glucose-free B-DNA
medium O
in O
a O
nitrogen O
atmosphere O
, O
both O
their O
ability O
to O
bind O
triamcinolone O
acetonide O
and O
their O
ATP O
levels O
decline O
and I-DNA
, O
when O
glucose O
and O
oxygen O
are O
reintroduced O
, O
ATP O
levels O
and I-DNA
receptor I-protein
activity O
return O
. O
The O
specific O
glucocorticoid-binding B-DNA
activity O
of O
cytosol O
prepared O
from B-cell_type
cells I-cell_type
exposed O
to O
various O
degrees O
of O
energy O
limitation O
is O
directly O
correlated O
with O
the O
ATP O
content O
. O
Receptor O
activation O
in O
intact B-DNA
cells I-cell_type
is O
rapid O
and O
independent O
of O
protein O
synthesis O
. O
Cytosol O
prepared O
from O
inactivated B-cell_type
cells I-cell_type
can O
not O
be O
activated O
by O
addition O
of O
ATP B-cell_type
. O
The O
inactivation O
of O
glucocorticoid O
receptors O
that O
occurs O
when O
cytosol O
from O
normal O
IM-9 B-protein
cells I-cell_type
is O
incubated O
at O
25 O
degrees O
C I-protein
is O
inhibited O
by O
molybdate O
, O
vanadate O
, O
fluoride O
, O
ATP I-protein
, O
and O
several O
other O
nucleotides O
. O
The O
experiments O
with O
intact O
human B-DNA
lymphoblasts I-cell_type
suggest O
that O
assays O
of O
specific O
glucocorticoid-binding B-DNA
capacity O
do O
not O
necessarily O
reflect O
the O
cellular O
content O
of B-DNA
receptor I-protein
protein O
. O
Glucocorticoids O
and I-cell_type
lymphocytes I-cell_type
. O
II I-protein
. O
Cell O
cycle-dependent O
changes O
in O
glucocorticoid I-DNA
receptor I-protein
content O
. O
To O
study O
variations O
in O
glucocorticoid I-DNA
receptor I-protein
levels O
during O
the O
cell O
cycle O
, O
we O
have O
separated O
mitogen-stimulated O
human O
peripheral I-cell_type
lymphocytes I-cell_type
and O
rat O
lymph O
node B-cell_type
cells I-cell_type
by O
unit O
gravity O
sedimentation O
and O
measured O
glucocorticoid O
binding O
in O
the O
resultant O
fractions O
. O
By O
morphologic O
criteria O
and O
thymidine O
incorporation O
, O
the O
fractions O
were O
separated O
into O
populations O
of O
G0 B-protein
and O
G1 B-protein
phase O
and O
S O
and O
post-S B-protein
phase O
cells I-cell_type
. O
A O
2- O
to O
3-fold O
increase O
in O
glucocorticoid I-DNA
receptor I-DNA
sites I-DNA
per O
cell O
, O
for O
cells I-cell_type
in O
the O
S O
and O
post-S B-protein
phase O
over O
those O
in O
G0 I-protein
and O
G1 I-protein
, O
was O
observed O
with O
both O
nonstimulated O
rat O
lymph O
node O
cell O
suspensions O
and O
concanavalin O
A-stimulated O
human O
peripheral I-cell_type
lymphocytes I-cell_type
. O
These O
observations O
together O
with O
those O
from O
other O
studies O
indicate O
that O
formation O
of O
new O
glucocorticoid O
receptors O
near O
the O
S O
phase O
may O
be O
a O
general O
phenomenon O
in O
proliferating B-cell_type
cells I-cell_type
. O
We O
propose O
that O
this O
increase O
in O
glucocorticoid O
receptors O
during O
the O
cell O
cycle O
may O
explain O
the O
increase O
in O
glucocorticoid O
receptors O
in O
mitogen-stimulated I-cell_type
lymphocytes I-cell_type
. O
The O
leukocyte O
migration O
inhibition O
response O
to O
certain O
breast O
cancer-related I-cell_type
antigens O
( O
MCF-7 O
and O
MuMTV I-DNA
) O
: O
their O
potential O
as O
discriminants O
. O
Certain O
oncogenic O
viruses O
have O
been O
implicated O
in O
human B-DNA
breast I-cell_type
cancer I-protein
, O
including O
the O
murine I-cell_line
mammary O
tumor O
virus O
( O
MuMTV I-DNA
) O
and O
the O
Mason-Pfizer B-protein
monkey O
virus O
( O
MPMV I-DNA
) O
. O
We O
have O
used O
the O
leukocyte O
migration O
inhibition O
( O
LMI I-DNA
) O
response O
to O
assay O
the O
response O
to O
several O
potential O
breast O
cancer-related I-cell_type
antigens O
, O
including O
MuMTV I-DNA
, O
MPMV I-protein
, O
and O
a O
breast O
cancer O
cultured O
cell O
line O
, O
MCF-7 O
, O
in O
96 O
breast O
cancer O
patients O
, O
in O
32 O
women O
with O
benign O
breast O
disease O
, O
and O
in O
67 O
normal O
women O
. O
The O
lowest O
tenth O
percentile O
of O
control O
( O
LMI I-DNA
) O
responses O
was O
used O
as O
the O
cutoff O
point O
to O
designate O
responders O
. O
Breast O
cancer O
patients O
showed O
significant O
responses O
to O
MuMTV I-cell_line
( O
49 O
% O
and O
to O
MCF-7 O
( O
50 O
% O
) O
, O
but O
not O
to O
MPMV I-protein
( O
29 O
% O
) O
. O
In O
a O
paired-antigen I-cell_type
study O
using O
MuMTV I-cell_type
and O
MCF-7 O
, O
75 O
% O
of O
the O
breast O
cancer O
patients O
responded O
, O
versus O
18 O
% O
of O
the O
normal O
women O
( O
P O
less O
than O
0.0050 B-protein
) O
. O
The O
potential O
for O
this O
assay O
to O
distinguish O
`` O
normal O
'' O
from O
`` O
breast O
cancer O
'' O
was O
analyzed O
using O
a O
migration O
index O
derived O
from O
discriminant O
analysis O
. O
The O
ability O
of O
the O
assay O
to O
discriminate O
`` O
normal O
'' O
from O
`` O
cancer O
'' O
was O
significant O
( O
P O
less O
than O
0.001 B-protein
) O
and O
showed O
a O
sensitivity O
of O
detecting O
`` O
cancer O
'' O
of O
75 O
% O
. O
The O
overall O
responses O
to O
MuMTV O
and O
MCF-7 O
were O
analyzed O
with O
reference O
to O
certain O
prognostic O
factors I-protein
, O
but O
showed O
no O
relation O
to O
age O
, O
menstrual O
status O
, O
estrogen B-protein
receptor I-protein
status O
, O
or O
stage O
of O
disease O
. O
The O
above O
reactions O
suggest O
that O
a O
large O
proportion O
of O
breast O
cancer O
patients O
exhibit O
presensitization O
to O
antigenfs O
found O
in O
MuMTV I-cell_type
and O
MCF-7 O
, O
which O
may O
be O
cross-reactive O
with O
antigens O
in O
the O
primary B-cell_line
cancer I-cell_line
. O
These O
responses O
appear O
to O
be O
independent O
of O
major O
prognostic O
variables O
. O
Further O
refinement O
of O
this O
assay O
may O
yield O
one O
which O
is O
more O
highly O
discriminating O
for O
breast O
cancer O
. O
Chronic O
lymphatic O
leukaemia O
: O
cellular O
effects O
of O
glucocorticoids O
in O
vitro O
. O
Glucocorticoid I-DNA
receptor I-protein
levels O
and O
steroid O
induced O
inhibition O
of O
nucleic O
acid O
precursors I-cell_line
have O
been O
examined O
in I-cell_type
lymphocytes I-cell_type
from O
27 O
patients O
at O
different O
stages O
of O
chronic O
lymphatic O
leukaemia O
. O
No O
correlation O
can O
be O
found O
between O
the O
level O
of O
glucocorticoid O
receptors O
and O
the O
stage O
of O
the O
disease O
. O
On O
the O
other O
hand O
, O
a O
significant O
difference O
( O
P O
less O
than O
0.02 B-protein
) O
was O
found O
between O
stage O
O O
and O
stage O
III/IV B-protein
patients O
, O
in O
terms O
of O
the O
in O
vitro O
effect O
of O
dexamethasone O
on O
[ O
3H B-protein
] O
uridine O
incorporation O
. O
Pyrrolidine O
dithiocarbamate O
inhibits O
NF-kappa B-protein
B I-protein
mobilization O
and O
TNF O
production O
in O
human O
monocytes B-cell_type
. O
The O
human B-DNA
TNF I-cell_type
promoter I-DNA
contains O
four O
potential O
nuclear B-protein
factor-kappa B-DNA
B I-DNA
( O
NF-kappa B-protein
B I-DNA
) O
-binding I-DNA
sites I-DNA
, O
with O
the O
strongest O
binding O
seen O
for O
the O
-605 B-protein
motif O
. O
Nuclear O
extracts O
from O
unstimulated B-cell_type
cells I-cell_type
of O
the O
human O
monocytic B-cell_line
cell O
line O
, O
Mono O
Mac O
6 O
, O
contain O
one O
specific O
binding O
protein O
( O
complex I-protein
II I-protein
) O
, O
consistent O
with O
a O
constitutive O
p50 O
homodimer O
. O
Stimulation O
of O
Mono O
Mac O
6 O
cells I-cell_type
with O
LPS O
will O
increase O
complex I-protein
II I-protein
and O
will O
strongly O
induce O
a O
second O
specific O
complex I-protein
( O
complex I-protein
I I-protein
) O
, O
which O
represents O
the O
p50/65 B-protein
heterodimer O
. O
Treatment O
of O
Mono O
Mac O
6 O
cells I-cell_type
with O
pyrrolidine-dithiocarbamate B-DNA
( O
PDTC I-DNA
) O
at O
300 O
microM I-RNA
will O
block O
the O
LPS-induced B-protein
complex I-protein
I I-protein
almost O
completely O
and O
will O
reduce O
complex I-protein
II I-protein
to O
the O
constitutive O
level O
. O
Binding O
activity O
of O
other O
nuclear B-protein
factors I-protein
that O
recognize O
the O
SP-1 B-protein
and O
c/EBP O
motifs O
of O
the O
human B-DNA
TNF I-cell_type
promoter I-DNA
is O
not O
affected O
by O
such O
treatment O
. O
Northern O
blot O
analysis O
demonstrates O
that O
PDTC O
treatment O
will O
strongly O
reduce O
LPS-induced B-protein
TNF I-RNA
transcripts I-RNA
. O
Secreted O
TNF I-protein
protein O
as O
detected O
in O
the O
Wehi O
164S/ActD O
bioassay O
and O
in O
a O
sandwich O
immunoassay O
was O
similarly O
reduced O
by O
PDTC O
. O
Kinetic O
analyses O
show O
that O
after O
LPS O
stimulation O
, O
NF-kappa B-protein
B I-protein
will O
peak O
at O
1 O
h O
, O
TNF O
transcript O
prevalence O
at O
2 O
h O
, O
and O
TNF I-protein
protein O
at O
4 O
h O
. O
PDTC O
did O
not O
shift O
this O
response O
to O
LPS O
to O
a O
later O
time O
, O
but O
suppressed O
NF-kappa B-protein
B I-protein
mobilization I-DNA
, O
TNF I-RNA
transcripts I-RNA
, O
and O
TNF I-protein
protein O
over O
the O
entire O
8-h O
observation O
period O
. O
Analysis O
of O
freshly O
isolated O
, O
LPS-stimulated B-protein
blood I-cell_type
monocytes I-cell_type
showed O
a O
similar O
blockade O
of O
NF-kappa B-protein
B I-protein
. O
Furthermore O
, O
in O
these O
primary B-cell_line
cells I-cell_line
, O
induction O
of O
TNF I-RNA
transcripts I-RNA
, O
as O
determined O
by O
Northern O
blot O
analysis O
and O
by O
quantitative O
polymerase O
chain O
reaction O
, O
was O
prevented O
by O
PDTC O
as O
was O
TNF I-protein
protein O
production O
. O
These O
data O
show O
that O
dithiocarbamates O
can O
profoundly O
affect O
cytokine O
expression O
and O
suggest O
that O
NF-kappa B-protein
B I-protein
is O
involved O
in O
LPS-induced B-protein
TNF B-DNA
gene I-DNA
expression O
in O
human O
monocytes B-cell_type
. O
Comparing O
regions I-protein
of O
the O
Epstein-Barr O
virus O
ZEBRA I-protein
protein O
which O
function O
as O
transcriptional O
activating O
sequences O
in O
Saccharomyces B-cell_type
cerevisiae O
and O
in O
B I-DNA
cells I-cell_type
. O
The O
ZEBRA I-protein
protein O
activates O
expression O
of O
Epstein-Barr O
virus O
early-lytic-cycle I-DNA
genes I-DNA
in O
human B-DNA
B I-DNA
lymphocytes I-cell_type
. O
Here O
it O
is O
shown O
that O
ZEBRA O
also O
behaves O
as O
a O
sequence-specific O
transcriptional O
activator O
in O
Saccharomyces B-cell_type
cerevisiae O
. O
Deletional O
mutagenesis O
defined O
three O
regions I-protein
of O
ZEBRA O
that O
participate O
in O
activation O
in O
S. B-protein
cerevisiae O
. O
These O
regions I-protein
are O
designated O
YI I-cell_line
( O
amino O
acids O
[ O
aa O
] O
1 O
to O
25 O
) O
, O
YII O
( O
aa O
51 O
to O
102 O
) O
, O
and O
YIII I-protein
( O
aa O
228 O
to O
245 O
) O
. O
Two O
of O
the O
three O
regions I-protein
of O
the O
native O
ZEBRA I-protein
protein O
act O
together O
to O
mediate O
activation O
when O
assayed O
on O
ZEBRA O
binding O
sites O
. O
However O
, O
when O
fused O
to O
the O
DNA O
binding O
domain I-protein
of O
GAL B-cell_type
4 O
and O
assayed O
on O
GAL4 B-protein
binding O
sites I-DNA
, O
regions I-protein
YII O
and O
YIII O
were O
each O
sufficient O
to O
confer O
activation O
in O
S. B-protein
cerevisiae O
. O
Regions O
of O
ZEBRA O
which O
affected O
activation O
in O
S. B-protein
cerevisiae O
were O
also O
required O
in O
human B-DNA
B I-DNA
lymphocytes I-cell_type
. O
The O
amino-terminal B-DNA
region I-DNA
of O
ZEBRA B-cell_type
( O
aa O
1 O
to O
98 O
) O
was O
required O
for O
activation O
both O
in O
S. B-protein
cerevisiae O
and O
in O
human B-DNA
B I-DNA
cells I-cell_type
; O
deletion O
of O
the O
carboxy-terminal O
18 O
aa O
also O
significantly O
reduced O
activation O
in O
both O
cell O
types I-cell_type
. O
Thus O
, O
the O
behavior O
of O
ZEBRA O
in O
human B-DNA
B I-DNA
cells I-cell_type
and O
S. B-protein
cerevisiae O
suggests O
that O
the O
protein O
contains O
universal O
activation O
motifs O
that O
interact O
with O
conserved O
components O
of O
the O
transcription O
machinery O
. O
However O
, O
certain O
deletion O
mutants O
of O
ZEBRA O
containing O
mutations O
in O
the O
N-terminal B-protein
region O
exhibited O
discordant O
behaviors O
in O
S. B-protein
cerevisiae O
and O
in O
B I-DNA
cells I-cell_type
. O
For O
example O
, O
deletion O
of O
ZEBRA O
aa O
26 O
to O
51 O
impaired O
activation O
to O
a O
great O
extent O
in O
B I-DNA
cells I-cell_type
but O
had O
little O
or O
no O
effect O
in O
S. B-protein
cerevisiae O
. O
The O
discordant O
mutants O
may O
reflect O
interactions O
with O
a O
variable I-protein
domain I-protein
of O
a O
conserved O
component O
or O
unique O
interactions O
with O
specialized O
components O
of O
the O
basal O
transcription O
apparatus O
in O
different B-cell_type
cells I-cell_type
. O
Functional O
interaction O
of O
the O
v-Rel B-DNA
and O
c-Rel O
oncoproteins O
with O
the O
TATA-binding B-DNA
protein O
and O
association O
with O
transcription B-protein
factor I-protein
IIB O
. O
Rel O
family O
proteins I-protein
regulate O
the O
expression O
of O
genes I-DNA
linked O
to O
kappa B-DNA
B-binding B-protein
motifs O
. O
Little O
is O
known O
, O
however O
, O
of O
the O
mechanism O
by O
which O
they O
enhance O
transcription O
. I-RNA
We O
have O
investigated O
the O
ability O
of O
the O
v-Rel B-DNA
and O
c-Rel O
oncoproteins O
to O
interact O
with O
components O
of O
the O
basal O
transcription O
machinery O
. O
Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation I-protein
domain I-protein
mapping O
to O
the O
unique O
C I-protein
terminus O
of O
chicken O
c-Rel B-DNA
and O
the O
F9 B-protein
cell-specific I-DNA
activation O
region O
common O
to O
both O
v-Rel B-DNA
and O
c-Rel O
interact O
with O
the O
TATA-binding B-DNA
protein I-protein
( O
TBP I-DNA
) O
and O
transcription B-protein
factor I-protein
IIB B-protein
( O
TFIIB I-DNA
) O
in O
vitro O
and O
in O
vivo O
. O
We O
also O
demonstrate O
that O
TPB O
interaction O
with O
Rel O
activation O
regions I-protein
leads O
to O
synergistic O
activation O
of O
transcription I-DNA
of O
a O
kappa B-DNA
B-linked B-protein
reporter B-DNA
gene I-DNA
. O
Combined O
with O
the O
observation O
that O
the O
mouse B-DNA
c-Rel B-DNA
and O
human B-cell_type
RelA I-cell_type
proteins I-protein
also O
interact O
with O
TBP O
and O
TFIIB O
in O
vitro O
, O
these O
results O
suggest O
that O
association O
with O
basal O
transcription B-protein
factors I-protein
is O
important O
for O
the O
transcriptional O
activities O
of O
Rel O
family O
proteins I-protein
. O
p21ras B-protein
and O
calcineurin O
synergize O
to O
regulate O
the O
nuclear B-protein
factor I-protein
of O
activated B-cell_type
T B-cell_type
cells I-cell_type
. O
In O
T I-cell_type
lymphocytes I-cell_type
, O
triggering O
of O
the O
T O
cell I-DNA
receptor I-protein
( O
TCR I-DNA
) O
induces O
several O
signaling O
cascades O
which O
ultimately O
synergize O
to O
induce O
the O
activity O
of O
the O
nuclear B-protein
factor I-protein
of O
activated B-cell_type
T B-cell_type
cells I-cell_type
( O
NFAT I-DNA
) O
, O
a O
DNA O
binding O
complex I-protein
critical O
to O
the O
inducibility O
and O
T O
cell O
specificity O
of O
the O
T O
cell O
growth I-protein
factor I-protein
interleukin O
2 O
. O
One O
immediate O
consequence O
of O
T O
cell O
activation O
via O
the O
TCR O
is O
an O
increase O
in O
cytosolic O
calcium O
. O
Calcium O
signals O
are O
important O
for O
NFAT O
induction O
, O
and O
recent O
studies O
have O
identified O
calcineurin O
, O
a O
calcium-calmodulin O
dependent O
serine-threonine O
phosphatase O
, O
as O
a O
prominent O
component O
of O
the O
calcium O
signaling O
pathway O
in O
T B-cell_type
cells I-cell_type
. O
A O
second O
important O
molecule O
in O
TCR O
signal O
transduction O
is O
the O
guanine O
nucleotide O
binding O
protein O
, O
p21ras I-cell_line
, O
which O
is O
coupled O
to O
the O
TCR O
by O
a O
protein B-protein
tyrosine I-protein
kinase I-protein
dependent O
mechanism O
. O
The O
experiments O
presented O
here O
show O
that O
expression O
by O
transfection O
of O
mutationally O
activated O
calcineurin O
or O
activated O
p21ras B-protein
alone O
is O
insufficient O
for O
NFAT O
transactivation O
. O
However O
, O
coexpression O
of O
the O
activated O
calcineurin O
with O
activated O
p21ras B-protein
could O
mimic O
TCR O
signals O
in O
NFAT O
induction O
. O
These O
data O
identify O
calcineurin O
and O
p21ras B-protein
as O
cooperative O
partners O
in O
T O
cell O
activation O
. O
Expression O
of O
the O
chicken O
GATA I-protein
factor I-protein
family O
during O
early O
erythroid B-DNA
development O
and O
differentiation O
. O
The O
DNA O
motif O
WGATAR I-protein
has O
been O
identified O
within O
transcriptional O
regulatory O
domains O
of O
globin O
and O
other O
erythroid-specific I-DNA
genes I-DNA
and O
the O
activator O
proteins I-protein
that O
bind O
to O
this O
regulatory O
element I-DNA
, O
the O
GATA B-protein
factors I-protein
, O
belong O
to O
a O
multi-gene B-DNA
family O
that O
is O
expressed O
in O
chicken O
erythroid I-cell_type
cells I-cell_type
. O
Here O
we O
show O
that O
, O
as O
in O
chickens O
, O
multiple O
members O
of O
the O
GATA I-protein
factor I-protein
family O
are O
expressed O
in O
human B-DNA
and I-DNA
murine I-cell_line
erythroid I-cell_type
cells I-cell_type
. O
During O
the O
early O
stages O
of O
chicken O
embryogenesis O
( O
well O
before O
blood I-cell_type
island I-cell_type
formation O
) O
, O
each O
of O
the O
GATA O
family O
members O
is O
transcribed O
with O
a O
unique O
temporal O
and O
spatial O
pattern O
. O
In O
the O
primitive O
erythroid O
lineage I-protein
, O
transcription I-DNA
of O
the O
embryonic B-cell_type
epsilon-globin B-DNA
gene I-DNA
parallels O
GATA-1 B-protein
expression O
while O
the O
switch O
to O
beta-globin I-DNA
transcription O
in O
definitive O
erythroid I-cell_type
cells I-cell_type
is O
directly O
preceded O
by O
a O
pronounced O
increase O
in O
GATA-3 B-protein
accumulation O
. O
The O
timing O
and O
pattern O
of O
expression O
of O
these O
different O
mRNAs I-protein
during O
avian O
erythroid B-DNA
development O
and O
differentiation O
suggests O
that O
temporally O
regulated O
changes O
in O
GATA I-protein
factor I-protein
expression O
are O
required O
for O
vertebrate O
hematopoiesis O
. O
Molecular O
regulation O
of O
human B-cell_type
interleukin I-cell_type
2 O
and O
T-cell O
function O
by O
interleukin O
4 O
. O
Distinct O
functional O
T-cell O
subsets O
, O
differing O
in O
the O
patterns O
of O
lymphokines O
produced O
, O
regulate O
cell-mediated I-DNA
and O
humoral O
immune O
responses O
. O
The O
two O
major O
types I-cell_type
and O
their O
principal O
products O
, O
interleukin O
4 O
and O
interferon O
gamma O
( O
IL-4 B-protein
and O
IFN-gamma B-protein
) O
, O
are O
reciprocally O
negatively O
interactive O
. O
To O
analyze O
the O
molecular O
mechanism O
of O
IL-4-mediated B-protein
suppression O
of O
cell-mediated B-cell_type
immunity O
we O
studied O
its O
effects O
on O
expression O
of O
interleukin O
2 O
( O
IL-2 B-protein
) O
and O
IFN-gamma B-protein
. O
IL-4 B-protein
pretreatment O
of O
Jurkat B-cell_type
cells I-cell_type
prior O
to O
stimulation O
resulted O
in O
a O
decrease O
in O
transcription I-DNA
of O
the O
IL2 B-protein
gene I-DNA
. O
IL-4 B-protein
suppressed O
IL-2 B-protein
and O
IFN-gamma I-RNA
mRNA I-RNA
levels O
in O
primary B-cell_line
human I-cell_line
T I-cell_type
cells I-cell_type
, O
and O
addition O
of O
anti-CD28 B-protein
antibodies I-protein
relieved O
this O
suppression O
. O
Using O
enhancer-reporter B-DNA
constructs O
, O
IL-4 B-protein
specifically O
down-regulated O
the O
NFIL-2B B-DNA
element I-DNA
. O
Electrophoretic O
mobility O
shift O
assays O
using O
a O
DNA O
oligomer O
containing O
the O
NFIL-2B B-DNA
binding O
site O
indicated O
that O
IL-4 B-protein
inhibited O
the O
NFIL-2B B-protein
complex I-protein
and O
that O
the O
NFIL-2B B-protein
DNA O
binding O
factor O
is O
distinct O
from O
AP- B-protein
1 O
. O
These O
results O
suggest O
that O
IL-4 B-protein
may O
regulate O
development O
and O
function O
of O
T-cell O
subsets O
involved O
in O
cell-mediated I-DNA
immunity O
in O
part O
by O
inhibiting O
factors I-protein
required O
for O
transcription I-DNA
of O
the O
IL2 B-protein
gene I-DNA
Immunochemical O
differences O
between O
glucocorticoid O
receptors O
from O
corticoid-sensitive B-DNA
and O
-resistant O
malignant I-cell_type
lymphocytes I-cell_type
. O
We O
have O
explored O
the O
possibility O
of O
using O
antibodies I-protein
against O
purified O
rat O
liver O
glucocorticoid O
receptors O
to O
study O
the O
immunochemical O
properties O
of O
glucocorticoid O
receptors O
from O
murine I-cell_line
and O
human B-cell_type
malignant I-cell_type
lymphocytes I-cell_type
. O
For O
this O
purpose O
, O
purified O
immune O
immunoglobulin O
G O
was O
covalently O
linked O
to O
Sepharose O
CL-4B B-protein
. O
We O
then O
examined O
the O
ability O
of O
the O
affinity O
gel O
to O
recognize O
cytosolic O
[ O
3H B-protein
] O
triamcinolone O
acetonide-receptor O
complexes O
from O
the O
corticoid-sensitive B-DNA
( O
CS I-DNA
) O
and O
-resistant O
strains O
of O
mouse B-DNA
lymphoma O
P1798 I-protein
, O
from O
CS I-cell_type
lymphocytes I-cell_type
of O
patients O
with O
chronic O
lymphatic O
leukemia O
, O
and O
from O
a O
CS B-protein
clone O
of O
human B-cell_type
leukemic I-DNA
lymphoblasts O
in O
tissue O
culture O
( O
CH6 B-protein
) O
. O
Mouse B-DNA
thymus O
was O
used O
as O
a O
source O
of O
glucocorticoid I-DNA
receptor I-protein
from O
normal O
CS I-cell_type
lymphocytes I-cell_type
. O
Whereas O
the O
immunoaffinity O
column O
retained O
70 O
to O
84 O
% O
of O
the O
58- O
to O
62-A B-protein
( O
Stokes O
radius O
) O
[ O
3H B-protein
] O
triamcinolone O
acetonide-receptor O
complexes O
characteristic O
of O
the O
CS B-protein
mouse B-DNA
and O
human I-cell_type
lymphocytes I-cell_type
, O
it O
failed O
to O
recognize O
the O
27- O
to O
28-A B-protein
( O
Stokes O
radius O
) O
glucocorticoid I-DNA
receptor I-protein
present O
in O
corticoid-resistant B-DNA
mouse B-DNA
lymphoma O
P1798 B-protein
cells I-cell_type
. O
Therefore O
, O
under O
appropriate O
experimental O
conditions O
, O
it O
was O
possible O
to O
demonstrate O
cross-reactivity O
between O
the O
antiserum O
against O
rat O
liver O
glucocorticoid I-DNA
receptor I-protein
and O
the O
58- O
to O
62-A B-protein
( O
Stokes O
radius O
) O
glucocorticoid I-DNA
receptor I-protein
from O
species O
as O
diverse O
as O
mouse B-DNA
and O
humans O
. O
Heterogeneity I-DNA
of O
the O
in O
vitro O
responses O
to O
glucocorticoids O
in O
acute O
leukemia O
. O
In O
leukocyte O
population O
freshly O
isolated O
from O
the O
blood I-cell_type
of O
26 O
patients O
with O
acute O
leukemia O
, O
we O
have O
measured O
several O
parameters O
including O
glucocorticoid O
receptors O
, O
nucleoside O
incorporation O
, O
percentage O
of O
cells I-cell_type
in O
S O
phase O
, O
and O
steroid-induced O
cell O
lysis O
. O
In O
addition O
, O
in O
some O
cases O
, O
the O
short-term O
response O
to O
steroid O
therapy O
was O
determined O
. O
Although O
, O
in O
all O
the O
patients O
studied O
, O
leukocytes O
were O
found O
to O
contain O
glucocorticoid O
receptors O
, O
we O
failed O
to O
demonstrate O
any O
correlation O
between O
the O
level O
of O
binding O
sites O
and O
the O
in O
vitro O
or O
in O
vivo O
response O
to O
glucocorticoids O
. O
This O
absence O
of O
correlation O
could O
be O
in O
part O
explained O
by O
the O
marked O
heterogeneity O
of O
the O
steroid O
response O
demonstrated O
in O
leukocyte O
subpopulations O
. O
It O
appears O
, O
however O
, O
that O
the O
degree O
of O
steroid O
action O
in O
vitro O
as O
well O
as O
the O
extent O
of O
spontaneous O
and O
dexamethasone-induced O
cell O
death O
may O
be O
related O
to O
the O
number O
of O
cells I-cell_type
in O
the O
S O
phase O
of O
the O
cell O
cycle O
. O
Glucocorticoid O
receptors O
in O
cytosol O
and O
nuclear B-protein
extract O
of O
human B-cell_type
leukocytes I-cell_type
. O
Cortisol O
binding O
by O
cytosol O
and O
0.4 B-protein
M O
KCl O
extract O
of O
the O
nuclear B-protein
fraction O
of O
human B-cell_type
leukocytes I-cell_type
were O
studied O
by O
gel O
chromatography O
and O
ion O
exchange O
filtration O
on O
DEAE O
cellulose O
. O
The O
cytoplasmic O
cortisol O
binding O
protein O
has O
a O
molecular O
weight O
95 O
000 O
and O
the O
soluble O
nuclear B-protein
binding O
protein O
50 O
000 O
. O
The O
absence O
of O
the O
uptake O
of O
radioactive O
cortisol O
by O
isolated O
nuclei O
and O
the O
apparent O
requirement O
of O
the O
cytosol O
for O
glucocorticoid O
specific O
binding O
in O
nuclear I-DNA
receptor I-protein
sites I-DNA
was O
observed O
. O
The O
association O
constant O
characterising O
the O
binding O
of O
cortisol O
to O
cytosol O
was O
KA B-protein
= O
3.5 B-protein
. O
10 O
( O
9 O
) O
l/mol O
. O
Corticosteroid-induced B-protein
lymphopenia O
, O
immunosuppression O
, O
and O
body O
defense O
. O
The O
apparent O
paradox O
of O
heightened O
adrenal O
corticosteroid O
levels O
associated O
with O
reduction O
in O
the O
competence O
of O
the O
body O
's O
defensive O
apparatus O
to O
cope O
with O
exposure O
to O
new O
microbial O
antigens O
is O
considered O
. O
The O
question O
is O
asked O
how O
this O
lowered O
defensive O
capability O
, O
which O
occurs O
in O
the O
face O
of O
a O
threat O
to O
body O
integrity O
, O
is O
consistent O
with O
Cannon O
's O
principals O
of O
the O
`` O
wisdom O
of O
the O
body. B-DNA
'' O
The O
suggestion O
is O
offered O
that O
the O
immunologic O
response O
to O
self-antigens O
exposed O
by O
disease O
or O
trauma O
may O
be O
suppressed O
by O
corticosteroid O
to O
offset O
the O
likelihood O
of O
autoimmune O
attack O
. O
Protein B-protein
tyrosine I-protein
kinase I-protein
activation O
is O
required O
for O
lipopolysaccharide O
induction O
of O
cytokines O
in O
human B-cell_type
blood I-cell_type
monocytes I-cell_type
. O
Bacterial O
LPS O
induce O
production O
of O
cytokines O
such O
as O
IL-1 B-protein
, O
IL-6 B-protein
, O
and O
TNF O
in O
mononuclear O
phagocytes O
, O
and O
this O
represents O
a O
central O
component O
in O
the O
pathogenesis O
of O
septic O
shock O
syndrome O
. O
However O
, O
the O
mechanisms O
by O
which O
LPS O
activates O
these I-cell_type
cells O
to O
express O
cytokines O
are O
not O
completely O
characterized O
. O
The O
present O
study O
addressed O
the O
role O
of O
different O
protein I-protein
kinases I-protein
in O
the O
LPS O
induction O
of O
cytokines O
. O
It O
is O
shown O
that O
LPS O
induced O
a O
12- O
to O
16-fold O
increase O
in O
IL-1 B-protein
beta O
, O
IL-6 B-protein
, O
and O
TNF-alpha I-RNA
mRNA I-RNA
levels O
, O
and O
this O
was O
completely O
or O
more O
than O
80 O
% O
blocked O
by O
the O
protein B-protein
tyrosine I-protein
kinase I-protein
specific O
inhibitors O
herbimycin O
A O
and O
genistein O
at O
the O
concentrations O
of O
1.7 B-cell_type
and O
37 O
microM I-protein
, O
respectively O
. O
Protein O
kinase I-protein
C I-protein
inhibition O
by O
staurosporine O
reduced O
LPS O
induction O
of O
TNF-alpha B-RNA
, O
whereas O
it O
had O
no O
effects O
on O
IL-6 B-protein
and O
IL-1 B-protein
beta O
. O
Inhibition O
of O
protein O
kinase I-protein
A O
by O
H89 B-protein
reduced O
IL-6 I-RNA
mRNA I-RNA
levels O
but O
did O
not O
detectably O
change O
IL-1 B-protein
beta O
or O
TNF-alpha I-RNA
mRNA I-RNA
levels O
. O
In O
contrast O
, O
LPS O
did O
not O
increase O
leukemia O
inhibitory O
factor I-protein
mRNA I-RNA
, O
which O
was O
constitutively O
expressed O
and O
not O
significantly O
reduced O
by O
these O
inhibitors O
. O
In O
addition O
to O
cytokine O
mRNA I-RNA
levels O
, O
LPS-induced O
IL-6 B-protein
protein O
synthesis O
and O
IL-6 B-protein
bioactivity O
were O
also O
reduced O
to O
baseline O
levels O
by O
the O
PTK O
inhibitors O
herbimycin O
A O
and O
genistein O
. O
Both O
PTK O
inhibitors O
also O
reduced O
the O
LPS O
activation O
of O
nuclear B-protein
factor-kappa B-DNA
B I-DNA
( O
NF-kappa B-protein
B I-DNA
) O
, O
which O
is O
a O
transcription B-protein
factor I-protein
involved O
in O
the O
expression O
of O
cytokine I-DNA
genes I-DNA
such O
as O
IL-6 B-protein
and O
TNF-alpha B-protein
. O
The O
activation O
of O
NF-kappa B-protein
B I-protein
was O
also O
reduced O
by O
H89 I-protein
, O
whereas O
staurosporine O
had O
no O
effect O
on O
this O
response O
. O
In O
summary O
, O
these O
findings O
suggest O
that O
protein O
kinase I-protein
C I-protein
and O
protein O
kinase I-protein
A O
appear O
to O
have O
selective O
effects O
in O
the O
LPS O
induction O
of O
cytokines O
, O
whereas O
PTK O
is O
required O
for O
LPS O
induction O
of O
a O
broad O
spectrum O
of O
cytokines O
and O
NF-kappa B-protein
B I-protein
activation O
in O
monocytes B-cell_type
. O
In O
vivo O
control O
of O
NF-kappa B-protein
B I-protein
activation O
by O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
. I-RNA
The O
transcription B-protein
factor I-protein
NF-kappa B-protein
B I-protein
is O
stored O
in O
the O
cytoplasm O
in O
complexes O
with O
the O
inhibitor O
protein O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
. I-RNA
It O
has O
been O
shown O
in O
vitro O
that O
dissociation O
of O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
from I-DNA
these O
complexes O
results O
in O
active O
NF-kappa B-protein
B I-protein
. O
In O
this O
report O
we O
show O
that O
lipopolysaccharide I-protein
( O
LPS I-DNA
) O
-induced O
activation O
of O
B I-DNA
or O
pre-B B-cell_line
cells I-cell_type
results O
in O
loss O
of O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
from I-DNA
NF-kappa B-protein
B I-protein
complexes O
in O
vivo O
. O
Many O
liberated O
NF-kappa B-protein
B I-protein
dimers O
reached O
the O
nucleus O
, O
where O
increased O
c-rel I-DNA
, O
p65 O
and O
p50 O
were O
detected O
by O
immunoblotting O
and O
by O
DNA O
binding O
assays O
. O
Some O
liberated O
dimers O
were O
retained O
in O
the O
cytoplasm O
, O
however O
, O
through O
binding O
to O
newly O
synthesized O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
, O
a O
finding O
which O
strongly O
suggests O
( O
i O
) O
that O
the O
LPS-induced O
signal O
causes O
dissociation O
of O
complexes O
rather O
than O
preventing O
their O
association O
and O
( O
ii O
) O
that O
dissociation O
results O
from O
modification O
of O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
and I-DNA
not O
of O
c-rel B-DNA
or O
p65 O
. O
No O
effect O
of O
LPS B-cell_type
treatment O
was O
detected O
on O
p105 I-protein
or O
p100 I-protein
, O
which O
also O
retain O
rel O
family O
members O
in O
the O
cytoplasm O
. O
Quite O
unexpectedly O
, O
we O
also O
found O
that O
in O
unstimulated B-cell_type
cells I-cell_type
there O
is O
a O
constant O
ongoing O
process O
of O
degradation O
and O
replacement O
of O
complexed O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
. I-RNA
We O
propose O
that O
this O
turnover O
results O
in O
the O
low O
level O
of O
active O
NF-kappa B-protein
B I-protein
presumably O
necessary O
even O
in O
the O
unstimulated O
cell O
, O
and O
that O
the O
high O
rate O
of O
synthesis O
of O
I I-protein
kappa B-DNA
B I-DNA
alpha I-DNA
provides I-DNA
the O
ability O
to O
turn O
off O
NF-kappa B-protein
B I-protein
activity O
rapidly O
as O
soon O
as O
the O
activating O
signal O
ceases O
. O
Identification O
of O
a O
killer O
cell-specific I-DNA
regulatory O
element I-DNA
of O
the O
mouse B-DNA
perforin B-DNA
gene I-DNA
: O
an O
Ets-binding B-protein
site-homologous O
motif O
that O
interacts O
with O
Ets-related B-protein
proteins I-protein
. O
The O
gene I-DNA
encoding O
the O
cytolytic O
protein O
perforin O
is O
selectively O
expressed O
by O
activated O
killer I-cell_type
lymphocytes I-cell_type
. O
To O
understand O
the O
mechanisms O
underlying O
the O
cell-type-specific O
expression O
of O
this O
gene I-DNA
, O
we O
have O
characterized O
the O
regulatory O
functions O
and O
the O
DNA-protein B-protein
interactions O
of O
the O
5'-flanking B-DNA
region I-DNA
of O
the O
mouse B-DNA
perforin B-DNA
gene I-DNA
( O
Pfp O
) O
. O
A O
region O
extending O
from O
residues O
+62 O
through O
-141 O
, O
which O
possesses O
the O
essential B-DNA
promoter I-DNA
activity O
, O
and O
regions I-protein
further O
upstream O
, O
which O
are O
able O
to O
either O
enhance O
or O
suppress O
gene I-DNA
expression O
, O
were O
identified O
. O
The O
region O
between O
residues O
-411 B-DNA
and O
-566 B-protein
was O
chosen O
for O
further O
characterization O
, O
since O
it O
contains O
an O
enhancer-like B-protein
activity O
. O
We O
have O
identified O
a O
32-mer O
sequence O
( O
residues O
-491 O
to O
-522 B-protein
) O
which O
appeared O
to O
be O
capable O
of O
enhancing B-DNA
gene I-DNA
expression O
in O
a O
killer O
cell-specific I-DNA
manner O
. O
Within O
this O
segment I-DNA
, O
a O
9-mer B-DNA
motif O
( O
5'-ACAGGAAGT-3 B-protein
' O
, O
residues O
-505 O
to O
-497 O
; O
designated O
NF-P B-protein
motif O
) O
, O
which O
is O
highly O
homologous O
to O
the O
Ets O
proto-oncoprotein-binding I-DNA
site I-DNA
, O
was O
found O
to O
interact O
with O
two O
proteins I-protein
, O
NF-P1 O
and O
NF-P2 B-protein
. O
NF-P2 B-protein
appears O
to O
be O
induced O
by O
reagents O
known O
to O
up-regulate O
the O
perforin O
message O
level O
and O
is O
present O
exclusively O
in O
killer B-cell_type
cells I-cell_type
. O
Electrophoretic O
mobility O
shift O
assay O
and O
UV B-protein
cross-linking B-protein
experiments O
revealed O
that O
NF-P1 B-DNA
and O
NF-P2 B-protein
may O
possess O
common O
DNA-binding B-protein
subunits O
. O
However O
, O
the O
larger O
native O
molecular O
mass O
of O
NF-P1 B-protein
suggests O
that O
NF-P1 B-protein
contains O
an O
additional O
non-DNA-binding O
subunit O
( O
s O
) O
. O
In O
view O
of O
the O
homology O
between O
the O
NF-P B-protein
motif O
and O
other O
Ets O
proto-oncoprotein-binding I-DNA
sites I-DNA
, O
it O
is O
postulated O
that O
NF-P1 B-DNA
and O
NF-P2 B-protein
belong O
to O
the O
Ets O
protein O
family O
. O
Results O
obtained O
from O
the O
binding O
competition O
assay O
, O
nevertheless O
, O
suggest O
that O
NF-P1 B-DNA
and O
NF-P2 B-protein
are O
related O
to O
but O
distinct O
from O
Ets O
proteins I-protein
, O
e.g. I-protein
, O
Ets-1 O
, O
Ets-2 O
, O
and O
NF-AT/Elf-1 O
, O
known O
to O
be O
expressed O
in O
T B-cell_type
cells I-cell_type
. O
The O
role O
of O
NF-kappa B-protein
B1 I-protein
( O
p50/p105 I-DNA
) O
gene I-DNA
expression O
in O
activation O
of O
human B-cell_type
blood I-cell_type
T-lymphocytes I-cell_type
via O
CD2 B-protein
and O
CD28 B-protein
adhesion O
molecules I-protein
. O
Stimulation O
of O
primary B-cell_line
human I-cell_line
T-lymphocytes I-cell_type
via O
CD2 B-protein
and O
CD28 B-protein
adhesion O
molecules I-protein
induces O
a O
long-lasting B-DNA
proliferation O
( O
> O
3 O
weeks O
) O
. O
This O
potent O
activation O
does O
not O
require O
accessory B-cell_type
cells I-cell_line
, O
such O
as O
monocytes B-cell_type
, O
but O
depends O
on O
persistent O
interleukin O
2 O
( O
IL-2 B-protein
) O
secretion O
and O
receptivity O
, O
which O
is O
associated O
with O
high O
and O
prolonged O
expression O
of O
the O
inducible O
CD25/IL-2 B-DNA
receptor I-DNA
alpha I-DNA
( I-DNA
IL-2R I-DNA
alpha I-DNA
) O
chain O
gene I-DNA
. O
The O
transcription B-protein
factor I-protein
NF-kappa B-protein
B I-protein
participates O
in O
the O
regulation O
of O
both O
IL-2 B-protein
and I-DNA
IL-2R I-DNA
alpha I-DNA
genes I-DNA
, O
as O
well O
as O
multiple O
cellular I-DNA
genes I-DNA
involved O
in O
T-cell O
proliferation O
. O
To O
evaluate O
the O
role O
of O
NF-kappa B-protein
B I-protein
in O
human O
peripheral B-cell_type
blood I-cell_type
T-lymphocytes I-cell_type
, O
we O
previously O
analyzed O
the O
activation O
of O
NF-kappa B-protein
B-related B-protein
complexes O
in O
response O
to O
CD2+CD28 B-protein
costimulation O
. O
We O
demonstrated O
a O
long-term B-DNA
induction O
of O
p50/p65 B-cell_type
heterodimer O
, O
a O
putative O
p65/c-Rel B-protein
heterodimer O
, O
and O
a O
constitutive O
nuclear B-protein
expression O
of O
KBF1/p50 B-cell_type
homodimers O
. O
As O
the O
role O
of O
p50 B-cell_type
remains O
unclear O
, O
we O
focused O
our O
present O
study O
on O
NF-kappa B-protein
B1 I-protein
( O
p50/p105 I-DNA
) O
gene I-DNA
regulation O
. O
Using O
electrophoretic O
mobility O
shift O
assays O
and O
Western O
and O
Northern O
blot O
analyses O
, O
we O
studied O
NF-kappa B-protein
B1 B-DNA
gene I-DNA
expression O
during O
T-cell O
stimulation O
via O
CD2+CD28 B-protein
. O
We O
observed O
a O
transient O
4- O
to O
5-fold O
increase O
of O
NF-kappa B-protein
B1 B-DNA
gene I-DNA
expression O
at O
both O
the O
mRNA I-RNA
and O
protein O
levels O
, O
lasting O
for O
at O
least O
24 O
h O
. O
p50 O
DNA-binding B-protein
activity O
apparently O
stays O
highly O
controlled O
when O
p105 I-protein
expression O
is O
enhanced O
by O
a O
physiological O
stimulus O
of O
peripheral B-cell_type
blood I-cell_type
T-cells I-cell_type
. O
Partial O
inhibition O
of O
p50 O
and O
p105 O
expression O
by O
NF-kappa B-protein
B1 I-protein
antisense O
oligonucleotides O
significantly O
reduced O
T-cell O
proliferation O
and O
CD25/IL-2R I-DNA
alpha O
cell I-cell_type
surface I-protein
expression O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
Vitamin O
D I-DNA
receptor I-protein
quantitation O
in O
human B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
in O
health O
and O
disease O
. O
Vitamin O
D I-DNA
receptor I-protein
( O
VDR I-DNA
) O
concentration O
was O
quantitated O
in O
human O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_line
( O
PBMC I-DNA
) O
from O
patients O
with O
absorptive O
hypercalciuria O
( O
AH I-DNA
) O
and O
patients O
with O
high O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
due O
to O
acquired O
or O
transient O
disease O
states O
and O
the O
results O
compared O
to O
those O
in O
normal O
subjects O
. O
VDR O
concentration O
in O
resting B-cell_type
cells I-cell_type
was O
not O
different O
between O
the O
three O
groups O
and O
represented O
constitutive I-DNA
receptor I-protein
expression O
of O
monocytes B-cell_type
. O
Following O
activation O
with O
phytohemagglutinin I-protein
, O
patients O
with O
hypercalcitriolemia O
demonstrated O
significantly O
greater O
VDR O
concentrations O
. O
Patients O
with O
AH B-protein
demonstrated O
a O
normal O
value O
for O
the O
group O
, O
but O
6 O
patients O
had O
significantly O
greater O
concentrations O
of O
VDR B-cell_type
despite O
normal O
plasma O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
in O
four O
of O
the O
patients O
. O
Proliferation B-cell_type
, O
as O
assessed O
from O
[ O
3H B-protein
] O
thymidine O
incorporation O
was O
inversely O
correlated O
with O
serum O
1 O
, O
25 O
( O
OH I-DNA
) O
2D3 O
and O
was O
significant O
( O
R O
= O
-0.299 I-cell_line
, O
p O
= O
0.048 B-protein
) O
. O
Taken O
together O
, O
the O
results O
suggest O
that O
PBMC O
provide O
a O
useful O
system O
for O
studying O
VDR O
status O
in O
transient O
or O
acquired O
states O
of O
hypercalcitriolemia B-RNA
. O
Furthermore O
, O
the O
studies O
in O
patients O
with O
absorptive O
hypercalciuria O
disclosed O
it O
to O
be O
a O
heterogeneous O
disorder O
, O
characterized O
by O
both O
vitamin O
D-dependent B-DNA
and O
D-independent B-protein
forms O
of B-DNA
receptor I-protein
up-regulation I-DNA
. O
Reactive O
oxygen O
intermediates O
activate O
NF-kappa B-protein
B I-protein
in O
a O
tyrosine I-protein
kinase-dependent O
mechanism O
and O
in O
combination O
with O
vanadate O
activate O
the O
p56lck B-protein
and O
p59fyn B-protein
tyrosine I-protein
kinases I-protein
in O
human I-cell_type
lymphocytes I-cell_type
. O
We O
have O
previously O
observed O
that O
ionizing O
radiation O
induces O
tyrosine I-protein
phosphorylation O
in O
human B-DNA
B-lymphocyte I-cell_type
precursors I-cell_line
by O
stimulation O
of O
unidentified B-protein
tyrosine I-protein
kinases I-protein
and O
this O
phosphorylation O
is O
substantially O
augmented O
by O
vanadate O
. O
Ionizing O
radiation O
generates O
reactive O
oxygen O
intermediates O
( O
ROI O
) O
. O
Because O
H2O2 B-protein
is O
a O
potent O
ROI O
generator O
that O
readily O
crosses O
the O
plasma O
membrane O
, O
we O
used O
H2O2 O
to O
examine O
the O
effects O
of O
ROI O
on O
signal O
transduction O
. O
We O
now O
provide O
evidence O
that O
the O
tyrosine I-protein
kinase I-protein
inhibitor O
herbimycin O
A O
and O
the O
free O
radical O
scavenger O
N-acetyl-cysteine O
inhibit O
both O
radiation-induced B-DNA
and O
H2O2-induced B-protein
activation O
of O
NF-kappa B-protein
B I-protein
, O
indicating O
that O
activation O
triggered O
by O
ROI O
is O
dependent O
on O
tyrosine I-protein
kinase I-protein
activity O
. O
H2O2 B-protein
was O
found O
to O
stimulate O
Ins-1 B-protein
, O
4 O
, O
5-P3 B-protein
production O
in O
a O
tyrosine I-protein
kinase-dependent O
manner O
and O
to O
induce O
calcium O
signals O
that O
were O
greatly O
augmented O
by O
vanadate O
. O
The O
synergistic O
induction O
of O
tyrosine I-protein
phosphorylation O
by O
H2O2 B-protein
plus O
vanadate O
included O
physiologically O
relevant O
proteins I-protein
such O
as O
PLC O
gamma O
1 O
. O
Although O
treatment O
of O
cells I-cell_type
with O
H2O2 B-protein
alone O
did O
not O
affect O
the O
activity O
of O
src O
family O
kinases I-protein
, O
treatment O
with O
H2O2 B-protein
plus O
vanadate O
led O
to O
activation O
of O
the O
p56lck B-protein
and O
p59fyn B-protein
tyrosine I-protein
kinases I-protein
. B-protein
The O
combined O
inhibition O
of O
phosphatases O
and O
activation O
of O
kinases I-protein
provides O
a O
potent O
mechanism O
for O
the O
synergistic O
effects O
of O
H2O2 B-protein
plus O
vanadate O
. O
Induction O
of O
tyrosine I-protein
phosphorylation O
by O
ROI O
may O
thus O
lead O
to O
many O
of O
the O
pleiotropic O
effects O
of O
ROI O
in O
lymphoid B-cell_type
cells I-cell_line
, O
including O
downstream O
activation O
of O
PLC B-cell_type
gamma O
1 O
and O
NF-kappa B-protein
B I-protein
Influence O
of O
sex O
hormone O
binding O
globulin O
and O
serum O
albumin O
on O
the O
conversion O
of O
androstenedione O
to O
testosterone O
by O
human B-DNA
erythrocytes B-cell_type
. O
The O
influence O
of O
human B-cell_type
serum I-cell_type
albumin O
and O
sex O
hormone O
binding O
globulin O
( O
SHBG I-DNA
) O
on O
the O
enzymic O
conversion O
of O
androstenedione O
to O
testosterone O
in O
human B-DNA
erythrocytes B-cell_type
was O
investigated O
in O
vitro O
. O
Total O
plasma O
and O
albumin O
delayed O
the O
conversion O
rate O
of O
androstenedione O
, O
while O
SHBG O
increased O
it O
markedly O
. O
The O
effect O
of O
SHBG O
was O
largely O
abolished O
by O
heating O
to O
60 O
degrees O
C I-protein
for O
1 O
h O
and O
by O
saturating O
its O
binding O
sites O
by O
DHT O
. O
The O
effect O
of O
both O
proteins I-protein
was O
found O
to O
be O
related O
to O
their O
concentration O
. O
It O
appears O
that O
the O
binding O
sites I-DNA
of O
albumin O
provide O
a O
mechanism O
for O
retarding O
androstenedione O
uptake O
by O
the O
erythrocytes B-cell_type
and O
that O
the O
high O
binding O
affinity O
of O
SHBG O
for O
testosterone O
facilitates O
the O
diffusion O
of O
this O
steroid O
out O
of O
the O
cell O
and O
thus O
, O
displaces O
the O
chemical O
equilibrium O
within O
the O
cell O
. O
Glucocorticoids O
and I-cell_type
lymphocytes I-cell_type
. O
I I-protein
. O
Increased O
glucocorticoid I-DNA
receptor I-protein
levels O
in O
antigen-stimulated I-cell_type
lymphocytes I-cell_type
. O
Recently O
a O
2- O
to O
3-fold O
increase O
in O
the O
number O
of O
glucocorticoid O
receptors O
in O
human O
peripheral I-cell_type
lymphocytes I-cell_type
has O
been O
noted O
after O
in O
vitro O
mitogen O
stimulation O
. O
Here O
, O
we O
extend O
these O
observations O
to O
in O
vivo O
immunization O
. O
After O
unilateral O
immunization O
of O
adrenalectomized O
male O
rats O
, O
a O
50 O
% O
increase O
in O
glucocorticoid I-DNA
receptor I-DNA
sites I-DNA
per O
cell O
, O
determined O
by O
binding O
of O
dexamethasone O
, O
was O
observed O
in O
cell O
suspensions O
of O
homolateral O
lymph O
nodes O
over O
those O
from O
the O
contralateral O
nonimmunized O
side O
of O
the O
same O
animal O
. O
The O
association O
constant O
for O
dexamethasone O
was O
similar O
in O
both O
groups O
, O
as O
was O
the O
stereospecificity O
for O
various O
steroids O
, O
the O
time O
course O
of O
cytoplasmic O
and O
nuclear B-protein
association O
, O
and O
cytoplasmic-to-nuclear B-protein
translocation O
. O
Despite O
a O
50 O
% O
increase O
in O
the O
number O
of O
glucocorticoid I-DNA
receptor I-DNA
sites I-DNA
per O
cell O
, O
the O
cells I-cell_type
from O
the O
homolateral O
and O
controlateral O
lymph O
nodes O
were O
equally O
sensitive O
to O
the O
inhibitory O
effects O
of O
dexamethasone O
, O
as O
determined O
by O
measurements O
of O
the O
incorporation O
of O
radiolabeled O
precursors I-cell_line
of O
protein I-protein
, O
RNA I-protein
, O
and O
DNA O
, O
or O
measurements O
of O
in O
vitro O
cell O
survival O
. O
Glucocorticoid O
receptors O
and O
actions O
in O
rat O
thymocytes O
and O
immunologically O
stimulated O
human O
peripheral I-cell_type
lymphocytes I-cell_type
. O
After O
reviewing O
briefly O
our O
earlier O
studies O
on O
glucocorticoid O
receptors O
and O
mechanisms O
in O
thymus B-cell_type
cells I-cell_line
, O
we O
have O
outlined O
results O
from O
the O
following O
two O
areas O
of O
current O
interest O
in O
our O
laboratories O
: O
the O
`` O
life-cycle B-DNA
'' O
of O
glucocorticoid O
receptors O
and O
complexes O
in O
thymus B-cell_type
cells I-cell_line
, O
and O
the O
levels O
of O
glucocorticoid O
receptors O
and O
sensitivity O
in O
immunologically O
stimulated O
human O
peripheral I-cell_type
lymphocytes I-cell_type
. O
Several O
of O
our O
results O
on O
energetics O
and O
kinetics O
of O
hormone O
binding O
to O
glucocorticoid O
receptors O
in O
rat O
thymus B-cell_type
cells I-cell_type
seem O
to O
require O
extension O
of O
the O
simplest O
model O
of O
hormone-receptor O
transformations O
in O
intact B-DNA
cells I-cell_type
. O
ATP-depletion B-protein
experiments O
suggest O
the O
existence O
of O
a O
nonbinding O
form O
of O
the I-DNA
receptor I-protein
; O
`` O
chase O
'' O
experiments O
suggest O
reaction O
of O
hormone O
directly O
with O
nuclear-bound I-DNA
receptor I-protein
; O
experiments O
on O
depletion O
and O
replenishment I-DNA
of O
cytoplasmic B-DNA
receptor I-protein
using O
cortisol O
and O
dexamethasone O
suggest O
the O
existence O
of O
at O
least O
two O
subpopulations O
of O
nuclear-bound B-cell_type
hormone-receptor O
complex I-protein
. O
We O
have O
found O
that O
mitogen O
or O
immunologic O
stimulation O
of O
human B-cell_type
peripheral I-cell_type
lymphocytes I-cell_type
in O
culture O
leads O
within O
24 O
h O
or O
so O
to O
a O
striking O
increase O
in O
the O
number O
of O
glucocorticoid I-DNA
receptor I-DNA
sites I-DNA
per O
cell O
. O
We O
believe O
this O
increase O
may O
be O
due O
to O
partial O
synchronization O
of O
the O
cell O
population O
in O
a O
phase O
of O
the O
cell O
cycle O
in O
which I-DNA
receptor I-protein
content O
is O
high O
. O
Contrary O
to O
the O
widely O
held O
view O
that O
mitogen-stimulated B-cell_type
cells I-cell_type
become O
insensitive O
to O
glucocorticoids O
, O
our O
experiments O
show O
that O
with O
respect O
to O
inhibition O
of O
thymidine O
and O
uridine O
incorporation O
and O
glucose O
uptake I-protein
, O
the O
cells I-cell_type
are O
highly O
sensitive O
to O
dexamethasone O
at O
24 I-cell_line
, O
48 O
, O
and O
72 O
h O
after O
stimulation O
with O
concanavalin O
A O
. O
Nuclear O
glucocorticoid O
binding O
in O
chronic O
lymphatic O
leukemia I-cell_type
lymphocytes I-cell_type
. O
A O
reliable O
procedure O
is O
described O
for O
isolating O
3H-triamcinolone O
acetonide O
( O
3H-TA B-protein
) O
receptor I-protein
complexes O
from O
purified O
chronic O
lymphatic O
leukemia O
( O
CLL I-DNA
) O
lymphocyte I-cell_line
nuclei I-protein
, O
based O
on O
the O
use O
of O
carbobenzoxy-L-phenylalanine B-protein
( O
CBZ-L-phe I-DNA
) O
to O
prevent O
breakdown O
of O
hormone-receptor O
complexes O
during O
extraction O
of O
nuclei O
with O
0.6M B-protein
KCl O
. O
Using O
this O
method I-protein
, O
specific O
nuclear B-protein
glucocorticoid O
binding O
was O
demonstrated O
in O
14/14 O
patients O
with O
untreated O
CLL O
. O
No O
correlation O
was O
found O
between O
levels O
of O
nuclear-associated B-cell_type
3H-TA B-DNA
and O
peripheral B-cell_type
white O
blood O
cell I-cell_type
count O
or O
rosetting O
ability O
of O
circulating I-cell_type
lymphocytes I-cell_type
. O
Multiple O
closely-linked O
NFAT/octamer B-DNA
and O
HMG B-protein
I I-protein
( O
Y I-DNA
) O
binding O
sites O
are O
part O
of O
the O
interleukin-4 B-protein
promoter I-DNA
. O
We O
show O
here O
that O
the O
immediate O
upstream O
region O
( O
from O
position O
-12 O
to O
-270 B-protein
) O
of O
the O
murine I-cell_line
interleukin O
4 O
( O
Il-4 B-protein
) O
gene I-DNA
harbors O
a O
strong O
cell-type B-DNA
specific O
transcriptional O
enhancer I-DNA
. O
In O
T I-cell_line
lymphoma O
cells I-cell_line
, O
the O
activity O
of O
the O
Il-4 B-protein
promoter/enhancer B-DNA
is O
stimulated O
by O
phorbol O
esters O
, O
Ca++ O
ionophores O
and O
agonists O
of O
protein O
kinase I-protein
A O
and O
inhibited O
by O
low O
doses O
of O
the O
immunosuppressant O
cyclosporin O
A O
. O
The O
Il-4 B-protein
promoter/enhancer B-DNA
is O
transcriptionally O
inactive O
in O
B I-DNA
lymphoma O
cells I-cell_type
and O
HeLa B-cell_type
cells I-cell_type
. O
DNase B-protein
I I-protein
footprint O
protection O
experiments O
revealed O
six O
sites I-DNA
of O
the O
Il-4 B-protein
promoter/enhancer O
to O
be O
bound O
by O
nuclear B-protein
proteins I-protein
from O
lymphoid O
and O
myeloid B-cell_type
cells I-cell_type
. O
Among O
them O
are O
four O
purine O
boxes O
which O
have O
been O
described O
to O
be O
important O
sequence O
motifs O
of O
the O
Il-2 B-DNA
promoter I-DNA
. O
They O
contain O
the O
motif O
GGAAA O
and O
are O
recognized O
by O
the O
inducible O
and O
cyclosporin O
A-sensitive B-protein
transcription B-protein
factor I-protein
NFAT-1 B-protein
. O
Three O
of O
the O
Il-4 B-protein
NFAT-1 B-protein
sites I-DNA
are O
closely O
linked O
to O
weak O
binding O
sites I-DNA
of O
Octamer B-protein
factors I-protein
. O
Several O
purine O
boxes O
and O
an O
AT-rich B-protein
protein-binding B-DNA
site I-DNA
of O
the O
Il-4 B-DNA
promoter I-DNA
are O
also O
recognized O
by O
the O
high O
mobility O
group O
protein O
HMG B-protein
I I-protein
( O
Y I-DNA
) O
. O
Whereas O
the O
binding O
of O
NFAT-1 B-protein
and O
Octamer B-protein
factors I-protein
enhance O
the O
activity O
of O
the O
Il-4 B-DNA
promoter I-DNA
, O
the O
binding O
of O
HMG B-protein
I I-protein
( O
Y I-DNA
) O
suppresses O
its O
activity O
and I-DNA
, O
therefore O
, O
appears O
to O
be O
involved O
in O
the O
suppression O
of O
Il-4 B-protein
transcription O
in O
resting O
T I-cell_type
lymphocytes I-cell_type
. O
Reversibility I-DNA
of O
the O
differentiated O
state O
in O
somatic B-cell_type
cells I-cell_type
. O
Analysis O
of O
de O
novo O
gene I-DNA
activation O
in O
multinucleated O
heterokaryons O
has O
shown O
that O
the O
differentiated O
state O
, O
although O
stable O
, O
is O
not O
irreversible O
, O
and O
can O
be O
reprogrammed O
in O
the O
presence O
of O
appropriate O
combinations O
of O
trans-acting B-cell_type
regulatory O
molecules I-protein
. O
These O
properties O
have O
been O
exploited O
to O
design O
strategies O
for O
identifying O
novel O
regulators O
of O
cellular O
differentiation O
. O
Phosphatidylcholine O
hydrolysis O
activates O
NF-kappa B-protein
B I-protein
and O
increases O
human B-DNA
immunodeficiency I-DNA
virus O
replication O
in O
human O
monocytes I-cell_type
and O
T I-cell_type
lymphocytes I-cell_type
. O
We O
have O
tested O
whether O
breakdown O
of O
phosphatidylcholine B-RNA
( O
PC I-DNA
) O
initiated O
by O
exogenous O
addition O
of O
a O
PC-specific B-protein
phospholipase B-protein
C I-protein
( O
PC-PLC B-protein
) O
from O
Bacillus O
cereus O
or O
by O
endogenous O
overexpression O
of O
PC-PLC B-protein
induces O
functional O
activation O
of O
NF-kappa B-protein
B I-protein
and O
increases O
human B-DNA
immunodeficiency I-DNA
virus O
( O
HIV O
) O
enhancer I-DNA
activity O
. O
PC-PLC-activated O
hydrolysis O
of O
PC B-cell_type
was O
found O
to O
induce O
bona O
fide O
p50/p65 O
NF-kappa B-protein
B I-protein
binding O
activity O
in O
three O
different O
cell O
lines I-cell_line
of O
human B-cell_type
or O
murine I-cell_line
origin O
. O
No O
significant O
changes O
in O
the O
turnover O
of O
other O
cellular O
phospholipids O
were O
detected O
in O
PC-PLC-treated B-protein
cells I-cell_type
. O
Induction O
of O
NF-kappa B-protein
B I-protein
by O
PC-PLC B-protein
did O
not O
depend O
on O
de O
novo O
synthesis O
of O
proteins I-protein
or O
autocrine O
secretion O
of O
either O
tumor O
necrosis B-protein
factor I-protein
or O
interleukin O
1 O
. O
In O
human O
monocytic B-cell_line
and O
lymphoblastoid O
T-cell B-cell_line
lines I-cell_line
, O
induction O
of O
NF-kappa B-protein
B I-protein
by O
PC-PLC B-protein
resulted O
in O
clear O
induction O
of O
luciferase O
expression O
vectors O
placed O
under O
the O
control O
of O
synthetic O
kappa B-DNA
B I-DNA
enhancers O
or O
wild I-DNA
type I-DNA
, O
but O
not O
kappa B-DNA
B-mutated I-DNA
, O
HIV O
long I-DNA
terminal I-DNA
repeat I-DNA
constructs O
. O
HIV O
replication O
was O
increased O
by O
PC-PLC B-protein
in O
chronically O
infected O
monocytes B-cell_type
and O
T I-cell_type
lymphocytes I-cell_type
. O
NF-kappa B-protein
B I-protein
activation O
promoted O
by O
addition O
of O
exogenous O
PC-PLC B-protein
correlated O
with O
an O
intense O
production O
of O
diacylglycerol O
. O
However O
, O
addition O
of O
a O
phosphatidylinositol-specific B-DNA
PLC O
from O
B.cereus B-protein
also O
induced O
diacylglycerol O
but O
did O
not O
activate O
kappa B-DNA
B I-DNA
enhancer-directed O
vectors O
. O
PC-PLC-induced O
NF-kappa B-protein
B I-protein
activation O
could O
not O
be O
blocked O
by O
a O
specific O
inhibitor O
of O
phorbol O
ester-inducible O
protein I-protein
kinases I-protein
C I-protein
. O
These O
results O
indicate O
that O
a O
cellular O
transduction O
pathway O
, O
dependent O
on O
specific O
PC B-protein
breakdown O
, O
is O
functional O
in O
T I-cell_type
lymphocytes I-cell_type
and O
monocytes B-cell_type
and O
may O
be O
used O
by O
various O
transmembrane O
receptors O
to O
activate O
HIV O
transcription O
through O
NF-kappa B-protein
B-dependent B-protein
induction O
of O
the O
HIV O
enhancer I-DNA
. O
Novel O
mechanism O
for O
inhibition O
of O
human B-cell_type
T I-cell_type
cells I-cell_type
by O
glucocorticoids O
. O
Glucocorticoids O
inhibit O
signal O
transduction O
through O
IL-2 B-DNA
receptor I-protein
. O
Interaction O
of O
IL-2 B-protein
with O
its O
high O
affinity O
membrane I-DNA
receptor I-protein
complex I-protein
( O
IL-2R B-protein
) O
present O
on O
activated B-cell_type
T I-cell_type
lymphocytes I-cell_type
induces O
cell O
proliferation O
and O
mediates O
effector O
functions O
. O
Glucocorticoids O
inhibit O
IL-2 B-protein
production O
by O
inhibiting O
TCR-mediated O
signal O
transduction O
. O
We O
asked O
whether O
they O
also O
inhibit O
the O
action O
of O
IL-2 B-protein
by O
inhibiting O
signal O
transduction O
through O
IL-2R B-DNA
. I-RNA
Human O
peripheral B-cell_type
blood I-cell_type
T I-cell_type
cells I-cell_type
, O
stimulated O
with O
PMA O
for O
48 O
h O
( O
PMA O
blasts O
) O
, O
were O
incubated O
with O
IL-2 B-protein
in O
the O
presence O
of O
incremental O
dosages O
of O
dexamethasone O
( O
Dex O
; O
10 O
( O
-5 B-protein
) O
-10 O
( O
-9 B-protein
) O
M O
) O
. O
Dex O
inhibited O
the O
IL-2-dependent B-DNA
proliferation O
of O
PMA B-cell_type
blasts O
in O
a O
dose-dependent O
fashion O
( O
IC50 I-DNA
, O
5 O
x O
10 O
( O
-8 B-protein
) O
M O
) O
. O
Cell O
surface I-protein
expression O
of O
IL-2R B-RNA
alpha- B-DNA
and O
beta-chains O
as O
determined O
by O
immunofluorescence O
analysis O
was O
not O
affected O
by O
Dex O
. O
In O
addition O
, O
Scatchard O
plot O
analysis O
of O
125I-labeled O
IL-2 B-protein
showed O
that O
Dex O
did O
not O
affect O
the O
binding O
of O
IL-2 B-protein
, O
thus O
suggesting O
that O
inhibition O
is O
due O
to O
a O
postreceptor O
effect O
. O
Inhibition O
of O
T O
cell O
proliferation O
by O
Dex O
was O
associated O
with O
decreased O
IL-2-dependent B-protein
tyrosine I-protein
phosphorylation O
of O
several O
intracellular O
proteins I-protein
and O
decreased O
phosphorylation O
of O
the O
retinoblastoma O
gene I-DNA
product O
Rb O
, O
a O
protein O
essential O
for O
controlling O
the O
progression O
of O
cells I-cell_type
through O
the O
cell O
cycle O
. O
IL-2-dependent B-DNA
IL-2R B-DNA
alpha I-protein
expression O
in O
PMA O
blasts O
and O
NF-kB O
induction O
in O
resting O
human B-cell_type
T I-cell_type
cells I-cell_type
were O
also O
inhibited O
by O
Dex O
. O
These O
results O
demonstrate O
that O
glucocorticoids O
inhibit O
preactivated B-cell_type
T B-cell_type
cells I-cell_type
by O
down-regulating O
signal O
transduction O
through O
IL-2R B-DNA
. I-RNA
Chronic O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
infection O
stimulates O
distinct O
NF-kappa B-protein
B/rel I-protein
DNA O
binding O
activities O
in O
myelomonoblastic B-cell_type
cells I-cell_type
. O
The O
relationship O
between O
human B-DNA
immunodeficiency I-DNA
virus O
type O
1 O
( O
HIV-1 B-protein
) O
infection O
and O
the O
induction O
of O
NF-kappa B-protein
B I-protein
binding O
activity O
was O
examined O
in O
a O
myeloid O
cell O
model O
of O
HIV-1 O
infection O
derived O
from O
the O
PLB-985 O
cell O
line O
. O
Chronic O
infection O
of O
PLB-985 B-protein
cells I-cell_type
led O
to O
increased O
monocyte-specific O
surface I-protein
marker O
expression O
, O
increased O
c-fms B-DNA
gene I-DNA
transcription I-DNA
, O
and O
morphological O
alterations O
consistent O
with O
differentiation O
along O
the O
monocytic B-cell_line
pathway O
. O
PLB-IIIB B-protein
cells I-cell_type
displayed O
a O
constitutive O
NF-kappa B-protein
B-like O
binding O
activity O
that O
was O
distinct O
from O
that O
induced O
by O
tumor O
necrosis B-protein
factor I-protein
alpha I-DNA
or B-RNA
phorbol O
12-myristate B-protein
13-acetate B-DNA
treatment O
of O
the O
parental O
PLB-985 O
cell O
line O
. O
This O
unique O
DNA O
binding O
activity O
consisted O
of O
proteins I-protein
of O
70 O
, O
90 O
, O
and O
100 O
kDa I-protein
with O
a O
high O
degree O
of O
binding O
specificity O
for O
the O
NF-kappa B-protein
B I-DNA
site I-DNA
within O
the O
PRDII I-protein
domain I-protein
of O
beta O
interferon O
. O
In O
this O
report I-protein
, O
we O
characterize O
the O
nature O
of O
these O
proteins I-protein
and O
demonstrate O
that O
binding O
of O
these O
proteins I-protein
is O
also O
induced O
following O
Sendai O
paramyxovirus O
infection O
. O
The O
70-kDa B-protein
protein O
corresponds O
to O
the O
NF-kappa B-protein
B I-protein
RelA I-protein
( O
p65 B-protein
) O
subunit O
, O
which O
is O
activated O
in O
response O
to O
an O
acute O
paramyxovirus O
infection O
or O
a O
chronic O
HIV-1 O
infection O
. O
Virus O
infection O
does O
not O
appear O
to O
alter O
the O
amount O
of O
RelA B-RNA
( O
p65 B-protein
) O
or O
NFKB1 B-protein
( O
p50 B-protein
) O
but O
rather O
affects O
the O
capacity O
of O
I I-protein
kappa B-DNA
B I-DNA
alpha O
to O
sequester O
RelA I-protein
( O
p65 B-protein
) O
, O
therefore O
leading O
to O
constitutive O
levels O
of O
RelA O
DNA O
binding O
activity O
and O
to O
increased O
levels O
of O
NF-kappa B-protein
B-dependent B-DNA
gene I-DNA
activity O
. O
The O
virally O
induced O
90- O
to O
100-kDa B-protein
proteins I-protein
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII I-protein
domain I-protein
and O
an O
AT-rich O
sequence O
but O
do O
not O
cross-react O
with O
NF-kappa B-protein
B I-protein
subunit-specific I-DNA
antisera O
directed O
against O
NFKB1 B-protein
( O
p105 O
or O
p50 B-protein
) O
, O
NFKB2 B-protein
( O
p100 O
or O
p52 B-protein
) O
, O
RelA O
( O
p65 B-protein
) O
, O
or O
c-rel B-DNA
. O
DNA O
binding O
of O
the O
90- O
to O
100-kDa B-protein
proteins I-protein
was O
not O
inhibited O
by O
recombinant O
I I-protein
kappa B-DNA
B I-DNA
alpha/MAD-3 O
and O
was O
resistant O
to O
tryptic O
digestion O
, O
suggesting O
that O
these O
proteins I-protein
may O
not O
be O
NF-kappa B-protein
B I-protein
related O
. O
Transient O
cotransfection O
experiments O
demonstrated O
that O
RelA O
and O
NFKB1 B-protein
expression O
maximally O
stimulated O
HIV-1 O
LTR- O
and O
NF-kappa B-protein
B-dependent B-protein
reporter I-DNA
genes I-DNA
; O
differences O
in O
NF-kappa B-protein
B-like O
binding O
activity O
were O
also O
reflected O
in O
higher O
constitutive O
levels O
of O
NF-kappa B-protein
B-regulated B-DNA
gene I-DNA
expression O
in O
HIV-1-infected B-protein
myeloid B-cell_type
cells I-cell_type
. O
Presence O
of O
estrogen-binding I-cell_line
sites I-DNA
on O
macrophage-like O
synoviocytes O
and O
CD8+ I-protein
, O
CD29+ I-protein
, O
CD45RO+ B-cell_type
T I-cell_type
lymphocytes I-cell_type
in O
normal O
and O
rheumatoid O
synovium O
. O
OBJECTIVE O
. O
To O
study O
the O
presence O
of O
estrogen-binding I-cell_line
sites I-DNA
( O
EBS I-DNA
) O
in O
the O
synovial O
tissues O
of O
male O
and O
female O
patients O
with O
rheumatoid O
arthritis O
( O
RA I-DNA
) O
and O
in O
age- B-DNA
and O
sex-matched O
healthy O
controls O
. O
METHODS I-protein
. O
Both I-DNA
type O
1 O
( O
high O
affinity O
, O
low O
binding O
capacity O
) O
and I-DNA
type O
2 O
( O
reduced O
affinity O
, O
higher O
binding O
capacity O
) O
EBS O
were O
investigated O
in O
both O
soluble O
and O
nuclear B-protein
fractions O
of O
homogenized O
synovial O
tissue O
samples O
by O
a O
dextran-coated O
charcoal O
method O
. O
To O
determine O
what I-DNA
type I-DNA
of O
synovial O
cell O
was O
positive O
for O
EBS I-protein
, O
cryosections O
of O
synovial O
tissues O
were O
immunostained O
with O
a O
specific O
monoclonal O
anti-estrogen I-DNA
receptor I-protein
antibody O
( O
anti-ER O
MAb O
) O
using O
both O
immunofluorescence O
and O
immunoperoxidase O
techniques O
. O
Double O
immunostaining O
with O
the O
anti-ER O
MAb O
and O
with O
specific O
MAb O
to O
detect O
different O
macrophage O
antigens O
( O
Ber-MAC3 I-DNA
, O
MAC387 I-protein
, O
CD68 B-protein
) O
and O
CD8+ B-cell_type
T O
cell O
subsets O
( O
CD29+ I-DNA
, O
CD45RO+ O
and O
CD29- B-protein
, O
CD45RO- B-protein
) O
was O
performed O
. O
RESULTS I-protein
. O
Higher O
affinity O
EBS O
were O
found O
mostly O
in O
nuclear O
cell O
fractions O
of O
either O
RA B-protein
or O
control O
synovial O
tissues O
( O
28 I-DNA
of O
the O
33 O
) O
. O
These O
EBS O
were O
present O
to O
a O
lesser O
extent O
in O
soluble O
cell O
fractions O
( O
11 O
of O
the O
33 O
) O
. O
Immunostaining O
showed O
the O
estrogen O
receptor-positive B-DNA
cells O
to O
be O
the O
macrophage-like O
synoviocytes O
and O
the O
CD8+ I-protein
, O
CD29+ B-cell_type
T B-cell_type
cells I-cell_type
both O
in O
RA O
and O
in O
control O
synovial O
tissues O
. O
Higher O
nuclear B-protein
content O
of O
EBS B-cell_type
was O
consistent O
with O
more O
intense O
nuclear B-protein
staining O
of O
synoviocytes O
and O
T B-cell_type
cells I-cell_type
. O
CONCLUSION I-protein
. O
It O
is O
conceivable O
that O
the O
immunomodulatory O
activity O
exerted O
by O
estrogens O
is O
at O
least O
partly O
mediated O
through O
their O
interaction O
with O
EBS O
that O
are O
present O
on O
macrophage-like O
synoviocytes O
, O
functioning O
as O
antigen-processing B-DNA
and O
antigen-presenting B-cell_type
cells I-cell_line
, O
and O
on O
antigen-experienced B-DNA
( O
memory O
) O
CD8+ B-cell_type
T I-cell_type
lymphocytes I-cell_type
( O
CD29+ I-DNA
, O
CD45RO+ O
